0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	medroxyprogesterone	_	_	O
6	acetate	_	_	O
7	(	_	_	O
8	MPA	_	_	O
9	)	_	_	O
10	on	_	_	O
11	appetite	_	_	O
12	,	_	_	O
13	weight	_	_	O
14	,	_	_	O
15	and	_	_	O
16	quality	_	_	O
17	of	_	_	O
18	life	_	_	O
19	(	_	_	O
20	QL	_	_	O
21	)	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	advanced	_	_	O
26	-	_	_	O
27	stage	_	_	O
28	,	_	_	O
29	incurable	_	_	O
30	,	_	_	O
31	non	_	_	O
32	-	_	_	O
33	hormone	_	_	O
34	-	_	_	O
35	sensitive	_	_	O
36	cancer	_	_	O
37	.	_	_	O

38	Two	_	_	O
39	hundred	_	_	O
40	six	_	_	O
41	eligible	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	randomized	_	_	O
45	between	_	_	O
46	double	_	_	O
47	-	_	_	O
48	blind	_	_	O
49	MPA	_	_	O
50	500	_	_	O
51	mg	_	_	O
52	twice	_	_	O
53	daily	_	_	O
54	or	_	_	O
55	placebo	_	_	O
56	.	_	_	O

57	Appetite	_	_	O
58	(	_	_	O
59	0	_	_	O
60	to	_	_	O
61	10	_	_	O
62	numerical	_	_	O
63	rating	_	_	O
64	scale	_	_	O
65	)	_	_	O
66	,	_	_	O
67	weight	_	_	O
68	,	_	_	O
69	and	_	_	O
70	QL	_	_	O
71	(	_	_	O
72	European	_	_	O
73	Organization	_	_	O
74	for	_	_	O
75	Research	_	_	O
76	and	_	_	O
77	Treatment	_	_	O
78	of	_	_	O
79	Cancer	_	_	O
80	Quality	_	_	O
81	of	_	_	O
82	Life	_	_	O
83	Questionnaire	_	_	O
84	[	_	_	O
85	EORTC	_	_	O
86	-	_	_	O
87	QLQ	_	_	O
88	-	_	_	O
89	C30	_	_	O
90	]	_	_	O
91	)	_	_	O
92	were	_	_	O
93	assessed	_	_	O
94	before	_	_	O
95	the	_	_	O
96	start	_	_	O
97	of	_	_	O
98	treatment	_	_	O
99	(	_	_	O
100	t	_	_	O
101	=	_	_	O
102	0	_	_	O
103	)	_	_	O
104	,	_	_	O
105	and	_	_	O
106	6	_	_	O
107	weeks	_	_	O
108	(	_	_	O
109	t	_	_	O
110	=	_	_	O
111	6	_	_	O
112	)	_	_	O
113	and	_	_	O
114	12	_	_	O
115	weeks	_	_	O
116	(	_	_	O
117	t	_	_	O
118	=	_	_	O
119	12	_	_	O
120	)	_	_	O
121	thereafter	_	_	O
122	.	_	_	O

123	One	_	_	O
124	hundred	_	_	O
125	thirty	_	_	O
126	-	_	_	O
127	four	_	_	O
128	patients	_	_	O
129	(	_	_	O
130	68	_	_	O
131	MPA	_	_	O
132	and	_	_	O
133	66	_	_	O
134	placebo	_	_	O
135	)	_	_	O
136	were	_	_	O
137	assessable	_	_	O
138	at	_	_	O
139	t	_	_	O
140	=	_	_	O
141	6	_	_	O
142	and	_	_	O
143	99	_	_	O
144	patients	_	_	O
145	(	_	_	O
146	53	_	_	O
147	MPA	_	_	O
148	and	_	_	O
149	46	_	_	O
150	placebo	_	_	O
151	)	_	_	O
152	at	_	_	O
153	t	_	_	O
154	=	_	_	O
155	12	_	_	O
156	.	_	_	O

157	A	_	_	B-Premise
158	beneficial	_	_	I-Premise
159	effect	_	_	I-Premise
160	of	_	_	I-Premise
161	MPA	_	_	I-Premise
162	on	_	_	I-Premise
163	appetite	_	_	I-Premise
164	was	_	_	I-Premise
165	observed	_	_	I-Premise
166	after	_	_	I-Premise
167	both	_	_	I-Premise
168	6	_	_	I-Premise
169	weeks	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=	_	_	I-Premise
173	.	_	_	I-Premise

174	008	_	_	I-Premise
175	)	_	_	I-Premise
176	and	_	_	I-Premise
177	12	_	_	I-Premise
178	weeks	_	_	I-Premise
179	(	_	_	I-Premise
180	P	_	_	I-Premise
181	=	_	_	I-Premise
182	.	_	_	I-Premise

183	01	_	_	I-Premise
184	)	_	_	I-Premise
185	of	_	_	I-Premise
186	treatment	_	_	I-Premise
187	.	_	_	I-Premise

188	After	_	_	B-Premise
189	12	_	_	I-Premise
190	weeks	_	_	I-Premise
191	,	_	_	I-Premise
192	a	_	_	I-Premise
193	mean	_	_	I-Premise
194	weight	_	_	I-Premise
195	gain	_	_	I-Premise
196	of	_	_	I-Premise
197	0	_	_	I-Premise
198	.	_	_	I-Premise

199	6	_	_	I-Premise
200	+	_	_	I-Premise
201	/	_	_	I-Premise
202	-	_	_	I-Premise
203	4	_	_	I-Premise
204	.	_	_	I-Premise

205	4	_	_	I-Premise
206	kg	_	_	I-Premise
207	was	_	_	I-Premise
208	seen	_	_	I-Premise
209	in	_	_	I-Premise
210	the	_	_	I-Premise
211	MPA	_	_	I-Premise
212	,	_	_	I-Premise
213	versus	_	_	I-Premise
214	an	_	_	I-Premise
215	ongoing	_	_	I-Premise
216	mean	_	_	I-Premise
217	weight	_	_	I-Premise
218	loss	_	_	I-Premise
219	of	_	_	I-Premise
220	1	_	_	I-Premise
221	.	_	_	I-Premise

222	4	_	_	I-Premise
223	+	_	_	I-Premise
224	/	_	_	I-Premise
225	-	_	_	I-Premise
226	4	_	_	I-Premise
227	.	_	_	I-Premise

228	6	_	_	I-Premise
229	kg	_	_	I-Premise
230	in	_	_	I-Premise
231	the	_	_	I-Premise
232	placebo	_	_	I-Premise
233	group	_	_	I-Premise
234	.	_	_	I-Premise

235	This	_	_	B-Premise
236	difference	_	_	I-Premise
237	of	_	_	I-Premise
238	2	_	_	I-Premise
239	.	_	_	I-Premise

240	0	_	_	I-Premise
241	kg	_	_	I-Premise
242	was	_	_	I-Premise
243	statistically	_	_	I-Premise
244	significant	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.	_	_	I-Premise

249	04	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	During	_	_	B-Premise
253	the	_	_	I-Premise
254	study	_	_	I-Premise
255	,	_	_	I-Premise
256	several	_	_	I-Premise
257	areas	_	_	I-Premise
258	of	_	_	I-Premise
259	QL	_	_	I-Premise
260	deteriorated	_	_	I-Premise
261	in	_	_	I-Premise
262	the	_	_	I-Premise
263	total	_	_	I-Premise
264	group	_	_	I-Premise
265	of	_	_	I-Premise
266	patients	_	_	I-Premise
267	.	_	_	I-Premise

268	With	_	_	B-Claim
269	the	_	_	I-Claim
270	exception	_	_	I-Claim
271	of	_	_	I-Claim
272	an	_	_	I-Claim
273	improvement	_	_	I-Claim
274	in	_	_	I-Claim
275	appetite	_	_	I-Claim
276	and	_	_	I-Claim
277	possible	_	_	I-Claim
278	also	_	_	I-Claim
279	a	_	_	I-Claim
280	reduction	_	_	I-Claim
281	in	_	_	I-Claim
282	nausea	_	_	I-Claim
283	and	_	_	I-Claim
284	vomiting	_	_	I-Claim
285	,	_	_	I-Claim
286	no	_	_	I-Claim
287	measurable	_	_	I-Claim
288	beneficial	_	_	I-Claim
289	effects	_	_	I-Claim
290	of	_	_	I-Claim
291	MPA	_	_	I-Claim
292	on	_	_	I-Claim
293	QL	_	_	I-Claim
294	could	_	_	I-Claim
295	be	_	_	I-Claim
296	demonstrated	_	_	I-Claim
297	.	_	_	I-Claim

298	The	_	_	B-Premise
299	side	_	_	I-Premise
300	effects	_	_	I-Premise
301	profile	_	_	I-Premise
302	of	_	_	I-Premise
303	MPA	_	_	I-Premise
304	was	_	_	I-Premise
305	favorable	_	_	I-Premise
306	:	_	_	I-Premise
307	only	_	_	I-Premise
308	a	_	_	I-Premise
309	trend	_	_	I-Premise
310	toward	_	_	I-Premise
311	an	_	_	I-Premise
312	increase	_	_	I-Premise
313	in	_	_	I-Premise
314	(	_	_	I-Premise
315	usually	_	_	I-Premise
316	mild	_	_	I-Premise
317	)	_	_	I-Premise
318	peripheral	_	_	I-Premise
319	edema	_	_	I-Premise
320	was	_	_	I-Premise
321	observed	_	_	I-Premise
322	.	_	_	I-Premise

323	In	_	_	B-Claim
324	weight	_	_	I-Claim
325	-	_	_	I-Claim
326	losing	_	_	I-Claim
327	,	_	_	I-Claim
328	advanced	_	_	I-Claim
329	-	_	_	I-Claim
330	stage	_	_	I-Claim
331	non	_	_	I-Claim
332	-	_	_	I-Claim
333	hormone	_	_	I-Claim
334	-	_	_	I-Claim
335	sensitive	_	_	I-Claim
336	cancer	_	_	I-Claim
337	patients	_	_	I-Claim
338	,	_	_	I-Claim
339	MPA	_	_	I-Claim
340	exhibits	_	_	I-Claim
341	a	_	_	I-Claim
342	mild	_	_	I-Claim
343	side	_	_	I-Claim
344	effects	_	_	I-Claim
345	profile	_	_	I-Claim
346	,	_	_	I-Claim
347	has	_	_	I-Claim
348	a	_	_	I-Claim
349	beneficial	_	_	I-Claim
350	effect	_	_	I-Claim
351	on	_	_	I-Claim
352	appetite	_	_	I-Claim
353	,	_	_	I-Claim
354	and	_	_	I-Claim
355	may	_	_	I-Claim
356	prevent	_	_	I-Claim
357	further	_	_	I-Claim
358	weight	_	_	I-Claim
359	loss	_	_	I-Claim
360	.	_	_	I-Claim

361	However	_	_	B-Claim
362	,	_	_	I-Claim
363	general	_	_	I-Claim
364	QL	_	_	I-Claim
365	in	_	_	I-Claim
366	the	_	_	I-Claim
367	present	_	_	I-Claim
368	study	_	_	I-Claim
369	was	_	_	I-Claim
370	not	_	_	I-Claim
371	measurably	_	_	I-Claim
372	influenced	_	_	I-Claim
373	by	_	_	I-Claim
374	MPA	_	_	I-Claim
375	treatment	_	_	I-Claim
376	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	health	_	_	O
4	-	_	_	O
5	related	_	_	O
6	quality	_	_	O
7	of	_	_	O
8	life	_	_	O
9	in	_	_	O
10	patients	_	_	O
11	with	_	_	O
12	narrow	_	_	O
13	gastric	_	_	O
14	tube	_	_	O
15	and	_	_	O
16	whole	_	_	O
17	stomach	_	_	O
18	reconstructions	_	_	O
19	after	_	_	O
20	oncologic	_	_	O
21	esophagectomy	_	_	O
22	.	_	_	O

23	In	_	_	O
24	a	_	_	O
25	prospective	_	_	O
26	randomized	_	_	O
27	single	_	_	O
28	-	_	_	O
29	center	_	_	O
30	study	_	_	O
31	from	_	_	O
32	2007	_	_	O
33	to	_	_	O
34	2008	_	_	O
35	,	_	_	O
36	104	_	_	O
37	patients	_	_	O
38	underwent	_	_	O
39	esophagectomy	_	_	O
40	for	_	_	O
41	cancer	_	_	O
42	.	_	_	O

43	To	_	_	O
44	assess	_	_	O
45	health	_	_	O
46	-	_	_	O
47	related	_	_	O
48	quality	_	_	O
49	of	_	_	O
50	life	_	_	O
51	,	_	_	O
52	the	_	_	O
53	questionnaire	_	_	O
54	(	_	_	O
55	European	_	_	O
56	Organization	_	_	O
57	for	_	_	O
58	Research	_	_	O
59	and	_	_	O
60	Treatment	_	_	O
61	of	_	_	O
62	Cancer	_	_	O
63	Quality	_	_	O
64	of	_	_	O
65	Life	_	_	O
66	Questionnaire	_	_	O
67	Core	_	_	O
68	30	_	_	O
69	and	_	_	O
70	the	_	_	O
71	Oesophagus	_	_	O
72	-	_	_	O
73	Specific	_	_	O
74	Quality	_	_	O
75	of	_	_	O
76	Life	_	_	O
77	Questionnaire	_	_	O
78	18	_	_	O
79	)	_	_	O
80	was	_	_	O
81	administered	_	_	O
82	at	_	_	O
83	3	_	_	O
84	weeks	_	_	O
85	,	_	_	O
86	6	_	_	O
87	months	_	_	O
88	,	_	_	O
89	1	_	_	O
90	year	_	_	O
91	,	_	_	O
92	and	_	_	O
93	2	_	_	O
94	years	_	_	O
95	after	_	_	O
96	surgery	_	_	O
97	.	_	_	O

98	The	_	_	B-Premise
99	perioperative	_	_	I-Premise
100	complication	_	_	I-Premise
101	rate	_	_	I-Premise
102	was	_	_	I-Premise
103	26	_	_	I-Premise
104	.	_	_	I-Premise

105	9	_	_	I-Premise
106	%	_	_	I-Premise
107	in	_	_	I-Premise
108	narrow	_	_	I-Premise
109	gastric	_	_	I-Premise
110	tube	_	_	I-Premise
111	group	_	_	I-Premise
112	and	_	_	I-Premise
113	48	_	_	I-Premise
114	.	_	_	I-Premise

115	1	_	_	I-Premise
116	%	_	_	I-Premise
117	in	_	_	I-Premise
118	whole	_	_	I-Premise
119	stomach	_	_	I-Premise
120	group	_	_	I-Premise
121	(	_	_	I-Premise
122	P	_	_	I-Premise
123	=	_	_	I-Premise
124	0	_	_	I-Premise
125	.	_	_	I-Premise

126	31	_	_	I-Premise
127	)	_	_	I-Premise
128	.	_	_	I-Premise

129	At	_	_	B-Premise
130	the	_	_	I-Premise
131	time	_	_	I-Premise
132	of	_	_	I-Premise
133	3	_	_	I-Premise
134	weeks	_	_	I-Premise
135	after	_	_	I-Premise
136	surgery	_	_	I-Premise
137	,	_	_	I-Premise
138	the	_	_	I-Premise
139	reflux	_	_	I-Premise
140	and	_	_	I-Premise
141	dyspnea	_	_	I-Premise
142	scores	_	_	I-Premise
143	were	_	_	I-Premise
144	higher	_	_	I-Premise
145	in	_	_	I-Premise
146	whole	_	_	I-Premise
147	stomach	_	_	I-Premise
148	group	_	_	I-Premise
149	than	_	_	I-Premise
150	in	_	_	I-Premise
151	narrow	_	_	I-Premise
152	gastric	_	_	I-Premise
153	tube	_	_	I-Premise
154	group	_	_	I-Premise
155	,	_	_	I-Premise
156	which	_	_	I-Premise
157	meant	_	_	I-Premise
158	that	_	_	I-Premise
159	the	_	_	I-Premise
160	patients	_	_	I-Premise
161	in	_	_	I-Premise
162	whole	_	_	I-Premise
163	stomach	_	_	I-Premise
164	group	_	_	I-Premise
165	suffered	_	_	I-Premise
166	more	_	_	I-Premise
167	severe	_	_	I-Premise
168	problem	_	_	I-Premise
169	.	_	_	I-Premise

170	At	_	_	B-Premise
171	the	_	_	I-Premise
172	time	_	_	I-Premise
173	of	_	_	I-Premise
174	6	_	_	I-Premise
175	months	_	_	I-Premise
176	and	_	_	I-Premise
177	1	_	_	I-Premise
178	year	_	_	I-Premise
179	after	_	_	I-Premise
180	surgery	_	_	I-Premise
181	,	_	_	I-Premise
182	the	_	_	I-Premise
183	reflux	_	_	I-Premise
184	scores	_	_	I-Premise
185	were	_	_	I-Premise
186	lower	_	_	I-Premise
187	in	_	_	I-Premise
188	narrow	_	_	I-Premise
189	gastric	_	_	I-Premise
190	tube	_	_	I-Premise
191	group	_	_	I-Premise
192	than	_	_	I-Premise
193	in	_	_	I-Premise
194	whole	_	_	I-Premise
195	stomach	_	_	I-Premise
196	group	_	_	I-Premise
197	,	_	_	I-Premise
198	which	_	_	I-Premise
199	revealed	_	_	I-Premise
200	that	_	_	I-Premise
201	there	_	_	I-Premise
202	were	_	_	I-Premise
203	less	_	_	I-Premise
204	problems	_	_	I-Premise
205	of	_	_	I-Premise
206	reflux	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	patients	_	_	I-Premise
210	of	_	_	I-Premise
211	narrow	_	_	I-Premise
212	gastric	_	_	I-Premise
213	tube	_	_	I-Premise
214	group	_	_	I-Premise
215	;	_	_	I-Premise
216	meanwhile	_	_	O
217	,	_	_	O
218	the	_	_	B-Premise
219	score	_	_	I-Premise
220	of	_	_	I-Premise
221	physical	_	_	I-Premise
222	function	_	_	I-Premise
223	scale	_	_	I-Premise
224	in	_	_	I-Premise
225	narrow	_	_	I-Premise
226	gastric	_	_	I-Premise
227	tube	_	_	I-Premise
228	group	_	_	I-Premise
229	was	_	_	I-Premise
230	higher	_	_	I-Premise
231	conversely	_	_	I-Premise
232	,	_	_	I-Premise
233	which	_	_	I-Premise
234	suggested	_	_	I-Premise
235	that	_	_	I-Premise
236	the	_	_	I-Premise
237	patients	_	_	I-Premise
238	gain	_	_	I-Premise
239	a	_	_	I-Premise
240	better	_	_	I-Premise
241	status	_	_	I-Premise
242	in	_	_	I-Premise
243	physical	_	_	I-Premise
244	function	_	_	I-Premise
245	.	_	_	I-Premise

246	Nausea	_	_	B-Premise
247	and	_	_	I-Premise
248	vomiting	_	_	I-Premise
249	is	_	_	I-Premise
250	the	_	_	I-Premise
251	only	_	_	I-Premise
252	notable	_	_	I-Premise
253	symptom	_	_	I-Premise
254	that	_	_	I-Premise
255	was	_	_	I-Premise
256	worse	_	_	I-Premise
257	in	_	_	I-Premise
258	whole	_	_	I-Premise
259	stomach	_	_	I-Premise
260	group	_	_	I-Premise
261	at	_	_	I-Premise
262	the	_	_	I-Premise
263	time	_	_	I-Premise
264	of	_	_	I-Premise
265	2	_	_	I-Premise
266	years	_	_	I-Premise
267	after	_	_	I-Premise
268	surgery	_	_	I-Premise
269	,	_	_	I-Premise
270	which	_	_	O
271	suggested	_	_	O
272	that	_	_	O
273	patients	_	_	B-Claim
274	in	_	_	I-Claim
275	whole	_	_	I-Claim
276	stomach	_	_	I-Claim
277	group	_	_	I-Claim
278	suffered	_	_	I-Claim
279	more	_	_	I-Claim
280	severe	_	_	I-Claim
281	nausea	_	_	I-Claim
282	and	_	_	I-Claim
283	vomiting	_	_	I-Claim
284	.	_	_	I-Claim

285	Narrow	_	_	B-Claim
286	gastric	_	_	I-Claim
287	tube	_	_	I-Claim
288	reconstruction	_	_	I-Claim
289	may	_	_	I-Claim
290	be	_	_	I-Claim
291	a	_	_	I-Claim
292	good	_	_	I-Claim
293	alternative	_	_	I-Claim
294	choice	_	_	I-Claim
295	for	_	_	I-Claim
296	patients	_	_	I-Claim
297	undergoing	_	_	I-Claim
298	oncologic	_	_	I-Claim
299	esophagectomy	_	_	I-Claim
300	in	_	_	I-Claim
301	view	_	_	I-Claim
302	of	_	_	I-Claim
303	better	_	_	I-Claim
304	health	_	_	I-Claim
305	-	_	_	I-Claim
306	related	_	_	I-Claim
307	quality	_	_	I-Claim
308	of	_	_	I-Claim
309	life	_	_	I-Claim
310	after	_	_	I-Claim
311	the	_	_	I-Claim
312	surgery	_	_	I-Claim
313	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	two	_	_	O
3	cisplatin	_	_	O
4	based	_	_	O
5	chemotherapy	_	_	O
6	schedules	_	_	O
7	in	_	_	O
8	patients	_	_	O
9	with	_	_	O
10	advanced	_	_	O
11	non	_	_	O
12	-	_	_	O
13	small	_	_	O
14	-	_	_	O
15	cell	_	_	O
16	lung	_	_	O
17	cancer	_	_	O
18	(	_	_	O
19	NSCLC	_	_	O
20	)	_	_	O
21	.	_	_	O

22	A	_	_	O
23	total	_	_	O
24	of	_	_	O
25	332	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	advanced	_	_	O
29	NSCLC	_	_	O
30	were	_	_	O
31	randomized	_	_	O
32	to	_	_	O
33	receive	_	_	O
34	cisplatin	_	_	O
35	80	_	_	O
36	mg	_	_	O
37	/	_	_	O
38	m2	_	_	O
39	on	_	_	O
40	day	_	_	O
41	1	_	_	O
42	either	_	_	O
43	in	_	_	O
44	combination	_	_	O
45	with	_	_	O
46	teniposide	_	_	O
47	100	_	_	O
48	mg	_	_	O
49	/	_	_	O
50	m2	_	_	O
51	on	_	_	O
52	days	_	_	O
53	1	_	_	O
54	,	_	_	O
55	3	_	_	O
56	,	_	_	O
57	and	_	_	O
58	5	_	_	O
59	(	_	_	O
60	arm	_	_	O
61	A	_	_	O
62	)	_	_	O
63	or	_	_	O
64	paclitaxel	_	_	O
65	175	_	_	O
66	mg	_	_	O
67	/	_	_	O
68	m2	_	_	O
69	by	_	_	O
70	3	_	_	O
71	-	_	_	O
72	hour	_	_	O
73	infusion	_	_	O
74	on	_	_	O
75	day	_	_	O
76	1	_	_	O
77	(	_	_	O
78	arm	_	_	O
79	B	_	_	O
80	)	_	_	O
81	;	_	_	O
82	cycles	_	_	O
83	were	_	_	O
84	repeated	_	_	O
85	every	_	_	O
86	3	_	_	O
87	weeks	_	_	O
88	.	_	_	O

89	Fifteen	_	_	O
90	patients	_	_	O
91	were	_	_	O
92	ineligible	_	_	O
93	;	_	_	O
94	patient	_	_	O
95	characteristics	_	_	O
96	were	_	_	O
97	well	_	_	O
98	balanced	_	_	O
99	between	_	_	O
100	the	_	_	O
101	two	_	_	O
102	arms	_	_	O
103	:	_	_	O
104	71	_	_	O
105	%	_	_	O
106	were	_	_	O
107	male	_	_	O
108	,	_	_	O
109	71	_	_	O
110	%	_	_	O
111	had	_	_	O
112	less	_	_	O
113	than	_	_	O
114	5	_	_	O
115	%	_	_	O
116	weight	_	_	O
117	loss	_	_	O
118	,	_	_	O
119	89	_	_	O
120	%	_	_	O
121	had	_	_	O
122	a	_	_	O
123	World	_	_	O
124	Health	_	_	O
125	Organization	_	_	O
126	(	_	_	O
127	WHO	_	_	O
128	)	_	_	O
129	performance	_	_	O
130	status	_	_	O
131	of	_	_	O
132	0	_	_	O
133	to	_	_	O
134	1	_	_	O
135	,	_	_	O
136	51	_	_	O
137	%	_	_	O
138	had	_	_	O
139	adenocarcinoma	_	_	O
140	,	_	_	O
141	and	_	_	O
142	61	_	_	O
143	%	_	_	O
144	had	_	_	O
145	stage	_	_	O
146	IV	_	_	O
147	disease	_	_	O
148	.	_	_	O

149	Hematologic	_	_	B-Premise
150	toxicity	_	_	I-Premise
151	was	_	_	I-Premise
152	significantly	_	_	I-Premise
153	more	_	_	I-Premise
154	severe	_	_	I-Premise
155	in	_	_	I-Premise
156	arm	_	_	I-Premise
157	A	_	_	I-Premise
158	(	_	_	I-Premise
159	leukopenia	_	_	I-Premise
160	,	_	_	I-Premise
161	neutropenia	_	_	I-Premise
162	,	_	_	I-Premise
163	and	_	_	I-Premise
164	thrombocytopenia	_	_	I-Premise
165	grade	_	_	I-Premise
166	3	_	_	I-Premise
167	or	_	_	I-Premise
168	4	_	_	I-Premise
169	:	_	_	I-Premise
170	66	_	_	I-Premise
171	%	_	_	I-Premise
172	v	_	_	I-Premise
173	19	_	_	I-Premise
174	%	_	_	I-Premise
175	,	_	_	I-Premise
176	83	_	_	I-Premise
177	%	_	_	I-Premise
178	v	_	_	I-Premise
179	55	_	_	I-Premise
180	%	_	_	I-Premise
181	,	_	_	I-Premise
182	36	_	_	I-Premise
183	%	_	_	I-Premise
184	v	_	_	I-Premise
185	2	_	_	I-Premise
186	%	_	_	I-Premise
187	in	_	_	I-Premise
188	arms	_	_	I-Premise
189	A	_	_	I-Premise
190	and	_	_	I-Premise
191	B	_	_	I-Premise
192	,	_	_	I-Premise
193	respectively	_	_	I-Premise
194	)	_	_	I-Premise
195	,	_	_	I-Premise
196	which	_	_	I-Premise
197	resulted	_	_	I-Premise
198	in	_	_	I-Premise
199	more	_	_	I-Premise
200	febrile	_	_	I-Premise
201	neutropenia	_	_	I-Premise
202	(	_	_	I-Premise
203	27	_	_	I-Premise
204	%	_	_	I-Premise
205	v	_	_	I-Premise
206	3	_	_	I-Premise
207	%	_	_	I-Premise
208	in	_	_	I-Premise
209	arms	_	_	I-Premise
210	A	_	_	I-Premise
211	and	_	_	I-Premise
212	B	_	_	I-Premise
213	,	_	_	I-Premise
214	respectively	_	_	I-Premise
215	)	_	_	I-Premise
216	,	_	_	I-Premise
217	dose	_	_	I-Premise
218	reductions	_	_	I-Premise
219	,	_	_	I-Premise
220	and	_	_	I-Premise
221	treatment	_	_	I-Premise
222	delays	_	_	I-Premise
223	.	_	_	I-Premise

224	There	_	_	B-Premise
225	were	_	_	I-Premise
226	a	_	_	I-Premise
227	total	_	_	I-Premise
228	of	_	_	I-Premise
229	nine	_	_	I-Premise
230	toxic	_	_	I-Premise
231	deaths	_	_	I-Premise
232	,	_	_	I-Premise
233	six	_	_	I-Premise
234	due	_	_	I-Premise
235	to	_	_	I-Premise
236	neutropenic	_	_	I-Premise
237	sepsis	_	_	I-Premise
238	:	_	_	I-Premise
239	five	_	_	I-Premise
240	in	_	_	I-Premise
241	arm	_	_	I-Premise
242	A	_	_	I-Premise
243	and	_	_	I-Premise
244	one	_	_	I-Premise
245	in	_	_	I-Premise
246	arm	_	_	I-Premise
247	B	_	_	I-Premise
248	.	_	_	I-Premise

249	In	_	_	B-Premise
250	contrast	_	_	I-Premise
251	,	_	_	I-Premise
252	arthralgia	_	_	I-Premise
253	/	_	_	I-Premise
254	myalgia	_	_	I-Premise
255	(	_	_	I-Premise
256	grade	_	_	I-Premise
257	2	_	_	I-Premise
258	or	_	_	I-Premise
259	3	_	_	I-Premise
260	,	_	_	I-Premise
261	4	_	_	I-Premise
262	%	_	_	I-Premise
263	v	_	_	I-Premise
264	17	_	_	I-Premise
265	%	_	_	I-Premise
266	)	_	_	I-Premise
267	,	_	_	I-Premise
268	peripheral	_	_	I-Premise
269	neurotoxicity	_	_	I-Premise
270	(	_	_	I-Premise
271	grade	_	_	I-Premise
272	2	_	_	I-Premise
273	or	_	_	I-Premise
274	3	_	_	I-Premise
275	,	_	_	I-Premise
276	6	_	_	I-Premise
277	%	_	_	I-Premise
278	v	_	_	I-Premise
279	29	_	_	I-Premise
280	%	_	_	I-Premise
281	)	_	_	I-Premise
282	,	_	_	I-Premise
283	and	_	_	I-Premise
284	hypersensitivity	_	_	I-Premise
285	reactions	_	_	I-Premise
286	(	_	_	I-Premise
287	1	_	_	I-Premise
288	%	_	_	I-Premise
289	v	_	_	I-Premise
290	7	_	_	I-Premise
291	%	_	_	I-Premise
292	,	_	_	I-Premise
293	all	_	_	I-Premise
294	grades	_	_	I-Premise
295	)	_	_	I-Premise
296	were	_	_	I-Premise
297	significantly	_	_	I-Premise
298	more	_	_	I-Premise
299	frequent	_	_	I-Premise
300	in	_	_	I-Premise
301	arm	_	_	I-Premise
302	B	_	_	I-Premise
303	.	_	_	I-Premise

304	The	_	_	B-Claim
305	frequency	_	_	I-Claim
306	and	_	_	I-Claim
307	severity	_	_	I-Claim
308	of	_	_	I-Claim
309	other	_	_	I-Claim
310	toxicities	_	_	I-Claim
311	were	_	_	I-Claim
312	comparable	_	_	I-Claim
313	between	_	_	I-Claim
314	the	_	_	I-Claim
315	two	_	_	I-Claim
316	arms	_	_	I-Claim
317	.	_	_	I-Claim

318	Responses	_	_	B-Premise
319	were	_	_	I-Premise
320	one	_	_	I-Premise
321	complete	_	_	I-Premise
322	and	_	_	I-Premise
323	44	_	_	I-Premise
324	partial	_	_	I-Premise
325	on	_	_	I-Premise
326	arm	_	_	I-Premise
327	A	_	_	I-Premise
328	(	_	_	I-Premise
329	28	_	_	I-Premise
330	%	_	_	I-Premise
331	)	_	_	I-Premise
332	and	_	_	I-Premise
333	two	_	_	I-Premise
334	complete	_	_	I-Premise
335	and	_	_	I-Premise
336	61	_	_	I-Premise
337	partial	_	_	I-Premise
338	(	_	_	I-Premise
339	41	_	_	I-Premise
340	%	_	_	I-Premise
341	)	_	_	I-Premise
342	on	_	_	I-Premise
343	arm	_	_	I-Premise
344	B	_	_	I-Premise
345	(	_	_	I-Premise
346	P	_	_	I-Premise
347	=	_	_	I-Premise
348	.	_	_	I-Premise

349	018	_	_	I-Premise
350	)	_	_	I-Premise
351	.	_	_	I-Premise

352	There	_	_	B-Premise
353	was	_	_	I-Premise
354	no	_	_	I-Premise
355	significant	_	_	I-Premise
356	difference	_	_	I-Premise
357	in	_	_	I-Premise
358	survival	_	_	I-Premise
359	,	_	_	I-Premise
360	with	_	_	I-Premise
361	median	_	_	I-Premise
362	and	_	_	I-Premise
363	1	_	_	I-Premise
364	-	_	_	I-Premise
365	year	_	_	I-Premise
366	survivals	_	_	I-Premise
367	9	_	_	I-Premise
368	.	_	_	I-Premise

369	9	_	_	I-Premise
370	versus	_	_	I-Premise
371	9	_	_	I-Premise
372	.	_	_	I-Premise

373	7	_	_	I-Premise
374	months	_	_	I-Premise
375	and	_	_	I-Premise
376	41	_	_	I-Premise
377	%	_	_	I-Premise
378	versus	_	_	I-Premise
379	43	_	_	I-Premise
380	%	_	_	I-Premise
381	,	_	_	I-Premise
382	respectively	_	_	I-Premise
383	in	_	_	I-Premise
384	arm	_	_	I-Premise
385	A	_	_	I-Premise
386	and	_	_	I-Premise
387	B	_	_	I-Premise
388	.	_	_	I-Premise

389	Progression	_	_	B-Premise
390	-	_	_	I-Premise
391	free	_	_	I-Premise
392	survival	_	_	I-Premise
393	was	_	_	I-Premise
394	4	_	_	I-Premise
395	.	_	_	I-Premise

396	9	_	_	I-Premise
397	and	_	_	I-Premise
398	5	_	_	I-Premise
399	.	_	_	I-Premise

400	4	_	_	I-Premise
401	months	_	_	I-Premise
402	in	_	_	I-Premise
403	arm	_	_	I-Premise
404	A	_	_	I-Premise
405	and	_	_	I-Premise
406	B	_	_	I-Premise
407	,	_	_	I-Premise
408	respectively	_	_	I-Premise
409	.	_	_	I-Premise

410	Selected	_	_	O
411	centers	_	_	O
412	participated	_	_	O
413	in	_	_	O
414	a	_	_	O
415	quality	_	_	O
416	-	_	_	O
417	of	_	_	O
418	-	_	_	O
419	life	_	_	O
420	(	_	_	O
421	QoL	_	_	O
422	)	_	_	O
423	assessment	_	_	O
424	,	_	_	O
425	which	_	_	O
426	was	_	_	O
427	performed	_	_	O
428	by	_	_	O
429	the	_	_	O
430	European	_	_	O
431	Organization	_	_	O
432	for	_	_	O
433	Research	_	_	O
434	and	_	_	O
435	Treatment	_	_	O
436	of	_	_	O
437	Cancer	_	_	O
438	(	_	_	O
439	EORTC	_	_	O
440	)	_	_	O
441	QLQ	_	_	O
442	-	_	_	O
443	C30	_	_	O
444	and	_	_	O
445	LC	_	_	O
446	-	_	_	O
447	13	_	_	O
448	administered	_	_	O
449	at	_	_	O
450	baseline	_	_	O
451	and	_	_	O
452	every	_	_	O
453	6	_	_	O
454	weeks	_	_	O
455	thereafter	_	_	O
456	.	_	_	O

457	Arm	_	_	B-Premise
458	B	_	_	I-Premise
459	achieved	_	_	I-Premise
460	a	_	_	I-Premise
461	better	_	_	I-Premise
462	score	_	_	I-Premise
463	at	_	_	I-Premise
464	week	_	_	I-Premise
465	6	_	_	I-Premise
466	for	_	_	I-Premise
467	emotional	_	_	I-Premise
468	,	_	_	I-Premise
469	cognitive	_	_	I-Premise
470	and	_	_	I-Premise
471	social	_	_	I-Premise
472	functioning	_	_	I-Premise
473	,	_	_	I-Premise
474	global	_	_	I-Premise
475	health	_	_	I-Premise
476	status	_	_	I-Premise
477	,	_	_	I-Premise
478	fatigue	_	_	I-Premise
479	,	_	_	I-Premise
480	and	_	_	I-Premise
481	appetite	_	_	I-Premise
482	loss	_	_	I-Premise
483	,	_	_	I-Premise
484	which	_	_	I-Premise
485	was	_	_	I-Premise
486	lost	_	_	I-Premise
487	at	_	_	I-Premise
488	12	_	_	I-Premise
489	weeks	_	_	I-Premise
490	.	_	_	I-Premise

491	In	_	_	B-Claim
492	conclusion	_	_	I-Claim
493	,	_	_	I-Claim
494	arm	_	_	I-Claim
495	B	_	_	I-Claim
496	appears	_	_	I-Claim
497	superior	_	_	I-Claim
498	to	_	_	I-Claim
499	arm	_	_	I-Claim
500	A	_	_	I-Claim
501	with	_	_	I-Claim
502	regard	_	_	I-Claim
503	to	_	_	I-Claim
504	response	_	_	I-Claim
505	rate	_	_	I-Claim
506	,	_	_	I-Claim
507	side	_	_	I-Claim
508	effects	_	_	I-Claim
509	,	_	_	I-Claim
510	and	_	_	I-Claim
511	QoL	_	_	I-Claim
512	.	_	_	I-Claim

513	Although	_	_	B-Claim
514	survival	_	_	I-Claim
515	was	_	_	I-Claim
516	not	_	_	I-Claim
517	improved	_	_	I-Claim
518	,	_	_	I-Claim
519	arm	_	_	B-Claim
520	B	_	_	I-Claim
521	offers	_	_	I-Claim
522	a	_	_	I-Claim
523	better	_	_	I-Claim
524	palliation	_	_	I-Claim
525	for	_	_	I-Claim
526	advanced	_	_	I-Claim
527	NSCLC	_	_	I-Claim
528	patients	_	_	I-Claim
529	than	_	_	I-Claim
530	arm	_	_	I-Claim
531	A	_	_	I-Claim
532	.	_	_	I-Claim


0	Delirium	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	serious	_	_	I-Claim
4	and	_	_	I-Claim
5	common	_	_	I-Claim
6	postoperative	_	_	I-Claim
7	complication	_	_	I-Claim
8	,	_	_	O
9	especially	_	_	O
10	in	_	_	O
11	frail	_	_	O
12	elderly	_	_	O
13	patients	_	_	O
14	.	_	_	O

15	The	_	_	O
16	aim	_	_	O
17	of	_	_	O
18	this	_	_	O
19	study	_	_	O
20	was	_	_	O
21	to	_	_	O
22	evaluate	_	_	O
23	the	_	_	O
24	effect	_	_	O
25	of	_	_	O
26	a	_	_	O
27	geriatric	_	_	O
28	liaison	_	_	O
29	intervention	_	_	O
30	in	_	_	O
31	comparison	_	_	O
32	with	_	_	O
33	standard	_	_	O
34	care	_	_	O
35	on	_	_	O
36	the	_	_	O
37	incidence	_	_	O
38	of	_	_	O
39	postoperative	_	_	O
40	delirium	_	_	O
41	in	_	_	O
42	frail	_	_	O
43	elderly	_	_	O
44	cancer	_	_	O
45	patients	_	_	O
46	treated	_	_	O
47	with	_	_	O
48	an	_	_	O
49	elective	_	_	O
50	surgical	_	_	O
51	procedure	_	_	O
52	for	_	_	O
53	a	_	_	O
54	solid	_	_	O
55	tumour	_	_	O
56	.	_	_	O

57	Patients	_	_	O
58	over	_	_	O
59	65	_	_	O
60	years	_	_	O
61	of	_	_	O
62	age	_	_	O
63	who	_	_	O
64	were	_	_	O
65	undergoing	_	_	O
66	elective	_	_	O
67	surgery	_	_	O
68	for	_	_	O
69	a	_	_	O
70	solid	_	_	O
71	tumour	_	_	O
72	were	_	_	O
73	recruited	_	_	O
74	to	_	_	O
75	a	_	_	O
76	multicentre	_	_	O
77	,	_	_	O
78	prospective	_	_	O
79	,	_	_	O
80	randomized	_	_	O
81	,	_	_	O
82	controlled	_	_	O
83	trial	_	_	O
84	.	_	_	O

85	The	_	_	O
86	patients	_	_	O
87	were	_	_	O
88	randomized	_	_	O
89	to	_	_	O
90	standard	_	_	O
91	treatment	_	_	O
92	versus	_	_	O
93	a	_	_	O
94	geriatric	_	_	O
95	liaison	_	_	O
96	intervention	_	_	O
97	.	_	_	O

98	The	_	_	O
99	intervention	_	_	O
100	consisted	_	_	O
101	of	_	_	O
102	a	_	_	O
103	preoperative	_	_	O
104	geriatric	_	_	O
105	consultation	_	_	O
106	,	_	_	O
107	an	_	_	O
108	individual	_	_	O
109	treatment	_	_	O
110	plan	_	_	O
111	targeted	_	_	O
112	at	_	_	O
113	risk	_	_	O
114	factors	_	_	O
115	for	_	_	O
116	delirium	_	_	O
117	,	_	_	O
118	daily	_	_	O
119	visits	_	_	O
120	by	_	_	O
121	a	_	_	O
122	geriatric	_	_	O
123	nurse	_	_	O
124	during	_	_	O
125	the	_	_	O
126	hospital	_	_	O
127	stay	_	_	O
128	and	_	_	O
129	advice	_	_	O
130	on	_	_	O
131	managing	_	_	O
132	any	_	_	O
133	problems	_	_	O
134	encountered	_	_	O
135	.	_	_	O

136	The	_	_	O
137	primary	_	_	O
138	outcome	_	_	O
139	was	_	_	O
140	the	_	_	O
141	incidence	_	_	O
142	of	_	_	O
143	postoperative	_	_	O
144	delirium	_	_	O
145	.	_	_	O

146	The	_	_	O
147	secondary	_	_	O
148	outcome	_	_	O
149	measures	_	_	O
150	were	_	_	O
151	the	_	_	O
152	severity	_	_	O
153	of	_	_	O
154	delirium	_	_	O
155	,	_	_	O
156	length	_	_	O
157	of	_	_	O
158	hospital	_	_	O
159	stay	_	_	O
160	,	_	_	O
161	complications	_	_	O
162	,	_	_	O
163	mortality	_	_	O
164	,	_	_	O
165	care	_	_	O
166	dependency	_	_	O
167	,	_	_	O
168	quality	_	_	O
169	of	_	_	O
170	life	_	_	O
171	,	_	_	O
172	return	_	_	O
173	to	_	_	O
174	an	_	_	O
175	independent	_	_	O
176	preoperative	_	_	O
177	living	_	_	O
178	situation	_	_	O
179	and	_	_	O
180	additional	_	_	O
181	care	_	_	O
182	at	_	_	O
183	home	_	_	O
184	.	_	_	O

185	In	_	_	O
186	total	_	_	O
187	,	_	_	O
188	the	_	_	O
189	data	_	_	O
190	of	_	_	O
191	260	_	_	O
192	patients	_	_	O
193	were	_	_	O
194	analysed	_	_	O
195	.	_	_	O

196	Delirium	_	_	B-Premise
197	occurred	_	_	I-Premise
198	in	_	_	I-Premise
199	31	_	_	I-Premise
200	patients	_	_	I-Premise
201	(	_	_	I-Premise
202	11	_	_	I-Premise
203	.	_	_	I-Premise

204	9	_	_	I-Premise
205	%	_	_	I-Premise
206	)	_	_	I-Premise
207	,	_	_	I-Premise
208	and	_	_	I-Premise
209	there	_	_	I-Premise
210	was	_	_	I-Premise
211	no	_	_	I-Premise
212	significant	_	_	I-Premise
213	difference	_	_	I-Premise
214	between	_	_	I-Premise
215	the	_	_	I-Premise
216	incidence	_	_	I-Premise
217	of	_	_	I-Premise
218	delirium	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	intervention	_	_	I-Premise
222	group	_	_	I-Premise
223	and	_	_	I-Premise
224	the	_	_	I-Premise
225	usual	_	_	I-Premise
226	-	_	_	I-Premise
227	care	_	_	I-Premise
228	group	_	_	I-Premise
229	(	_	_	I-Premise
230	9	_	_	I-Premise
231	.	_	_	I-Premise

232	4	_	_	I-Premise
233	%	_	_	I-Premise
234	vs	_	_	I-Premise
235	.	_	_	I-Premise

236	14	_	_	I-Premise
237	.	_	_	I-Premise

238	3	_	_	I-Premise
239	%	_	_	I-Premise
240	,	_	_	I-Premise
241	OR	_	_	I-Premise
242	:	_	_	I-Premise
243	0	_	_	I-Premise
244	.	_	_	I-Premise

245	63	_	_	I-Premise
246	,	_	_	I-Premise
247	95	_	_	I-Premise
248	%	_	_	I-Premise
249	CI	_	_	I-Premise
250	:	_	_	I-Premise
251	0	_	_	I-Premise
252	.	_	_	I-Premise

253	29	_	_	I-Premise
254	-	_	_	I-Premise
255	1	_	_	I-Premise
256	.	_	_	I-Premise

257	35	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Within	_	_	B-Claim
261	this	_	_	I-Claim
262	study	_	_	I-Claim
263	,	_	_	I-Claim
264	a	_	_	I-Claim
265	geriatric	_	_	I-Claim
266	liaison	_	_	I-Claim
267	intervention	_	_	I-Claim
268	based	_	_	I-Claim
269	on	_	_	I-Claim
270	frailty	_	_	I-Claim
271	for	_	_	I-Claim
272	the	_	_	I-Claim
273	prevention	_	_	I-Claim
274	of	_	_	I-Claim
275	postoperative	_	_	I-Claim
276	delirium	_	_	I-Claim
277	in	_	_	I-Claim
278	frail	_	_	I-Claim
279	elderly	_	_	I-Claim
280	cancer	_	_	I-Claim
281	patients	_	_	I-Claim
282	undergoing	_	_	I-Claim
283	elective	_	_	I-Claim
284	surgery	_	_	I-Claim
285	for	_	_	I-Claim
286	a	_	_	I-Claim
287	solid	_	_	I-Claim
288	tumour	_	_	I-Claim
289	has	_	_	I-Claim
290	not	_	_	I-Claim
291	proven	_	_	I-Claim
292	to	_	_	I-Claim
293	be	_	_	I-Claim
294	effective	_	_	I-Claim
295	.	_	_	I-Claim


0	Tivozanib	_	_	B-Claim
1	is	_	_	I-Claim
2	a	_	_	I-Claim
3	potent	_	_	I-Claim
4	and	_	_	I-Claim
5	selective	_	_	I-Claim
6	tyrosine	_	_	I-Claim
7	kinase	_	_	I-Claim
8	inhibitor	_	_	I-Claim
9	of	_	_	I-Claim
10	vascular	_	_	I-Claim
11	endothelial	_	_	I-Claim
12	growth	_	_	I-Claim
13	factor	_	_	I-Claim
14	receptor	_	_	I-Claim
15	1	_	_	I-Claim
16	(	_	_	I-Claim
17	VEGFR1	_	_	I-Claim
18	)	_	_	I-Claim
19	,	_	_	I-Claim
20	-	_	_	I-Claim
21	2	_	_	I-Claim
22	,	_	_	I-Claim
23	and	_	_	I-Claim
24	-	_	_	I-Claim
25	3	_	_	I-Claim
26	.	_	_	I-Claim

27	This	_	_	O
28	phase	_	_	O
29	III	_	_	O
30	trial	_	_	O
31	compared	_	_	O
32	tivozanib	_	_	O
33	with	_	_	O
34	sorafenib	_	_	O
35	as	_	_	O
36	initial	_	_	O
37	targeted	_	_	O
38	therapy	_	_	O
39	in	_	_	O
40	patients	_	_	O
41	with	_	_	O
42	metastatic	_	_	O
43	renal	_	_	O
44	cell	_	_	O
45	carcinoma	_	_	O
46	(	_	_	O
47	RCC	_	_	O
48	)	_	_	O
49	.	_	_	O

50	Patients	_	_	O
51	with	_	_	O
52	metastatic	_	_	O
53	RCC	_	_	O
54	,	_	_	O
55	with	_	_	O
56	a	_	_	O
57	clear	_	_	O
58	cell	_	_	O
59	component	_	_	O
60	,	_	_	O
61	prior	_	_	O
62	nephrectomy	_	_	O
63	,	_	_	O
64	measurable	_	_	O
65	disease	_	_	O
66	,	_	_	O
67	and	_	_	O
68	0	_	_	O
69	or	_	_	O
70	1	_	_	O
71	prior	_	_	O
72	therapies	_	_	O
73	for	_	_	O
74	metastatic	_	_	O
75	RCC	_	_	O
76	were	_	_	O
77	randomly	_	_	O
78	assigned	_	_	O
79	to	_	_	O
80	tivozanib	_	_	O
81	or	_	_	O
82	sorafenib	_	_	O
83	.	_	_	O

84	Prior	_	_	O
85	VEGF	_	_	O
86	-	_	_	O
87	targeted	_	_	O
88	therapy	_	_	O
89	and	_	_	O
90	mammalian	_	_	O
91	target	_	_	O
92	of	_	_	O
93	rapamycin	_	_	O
94	inhibitor	_	_	O
95	were	_	_	O
96	not	_	_	O
97	permitted	_	_	O
98	.	_	_	O

99	The	_	_	O
100	primary	_	_	O
101	end	_	_	O
102	point	_	_	O
103	was	_	_	O
104	progression	_	_	O
105	-	_	_	O
106	free	_	_	O
107	survival	_	_	O
108	(	_	_	O
109	PFS	_	_	O
110	)	_	_	O
111	by	_	_	O
112	independent	_	_	O
113	review	_	_	O
114	.	_	_	O

115	A	_	_	O
116	total	_	_	O
117	of	_	_	O
118	517	_	_	O
119	patients	_	_	O
120	were	_	_	O
121	randomly	_	_	O
122	assigned	_	_	O
123	to	_	_	O
124	tivozanib	_	_	O
125	(	_	_	O
126	n	_	_	O
127	=	_	_	O
128	260	_	_	O
129	)	_	_	O
130	or	_	_	O
131	sorafenib	_	_	O
132	(	_	_	O
133	n	_	_	O
134	=	_	_	O
135	257	_	_	O
136	)	_	_	O
137	.	_	_	O

138	PFS	_	_	B-Premise
139	was	_	_	I-Premise
140	longer	_	_	I-Premise
141	with	_	_	I-Premise
142	tivozanib	_	_	I-Premise
143	than	_	_	I-Premise
144	with	_	_	I-Premise
145	sorafenib	_	_	I-Premise
146	in	_	_	I-Premise
147	the	_	_	I-Premise
148	overall	_	_	I-Premise
149	population	_	_	I-Premise
150	(	_	_	I-Premise
151	median	_	_	I-Premise
152	,	_	_	I-Premise
153	11	_	_	I-Premise
154	.	_	_	I-Premise

155	9	_	_	I-Premise
156	v	_	_	I-Premise
157	9	_	_	I-Premise
158	.	_	_	I-Premise

159	1	_	_	I-Premise
160	months	_	_	I-Premise
161	;	_	_	I-Premise
162	hazard	_	_	I-Premise
163	ratio	_	_	I-Premise
164	[	_	_	I-Premise
165	HR	_	_	I-Premise
166	]	_	_	I-Premise
167	,	_	_	I-Premise
168	0	_	_	I-Premise
169	.	_	_	I-Premise

170	797	_	_	I-Premise
171	;	_	_	I-Premise
172	95	_	_	I-Premise
173	%	_	_	I-Premise
174	CI	_	_	I-Premise
175	,	_	_	I-Premise
176	0	_	_	I-Premise
177	.	_	_	I-Premise

178	639	_	_	I-Premise
179	to	_	_	I-Premise
180	0	_	_	I-Premise
181	.	_	_	I-Premise

182	993	_	_	I-Premise
183	;	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.	_	_	I-Premise

187	042	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	One	_	_	O
191	hundred	_	_	O
192	fifty	_	_	O
193	-	_	_	O
194	six	_	_	O
195	patients	_	_	O
196	(	_	_	O
197	61	_	_	O
198	%	_	_	O
199	)	_	_	O
200	who	_	_	O
201	progressed	_	_	O
202	on	_	_	O
203	sorafenib	_	_	O
204	crossed	_	_	O
205	over	_	_	O
206	to	_	_	O
207	receive	_	_	O
208	tivozanib	_	_	O
209	.	_	_	O

210	The	_	_	B-Premise
211	final	_	_	I-Premise
212	overall	_	_	I-Premise
213	survival	_	_	I-Premise
214	(	_	_	I-Premise
215	OS	_	_	I-Premise
216	)	_	_	I-Premise
217	analysis	_	_	I-Premise
218	showed	_	_	I-Premise
219	a	_	_	I-Premise
220	trend	_	_	I-Premise
221	toward	_	_	I-Premise
222	longer	_	_	I-Premise
223	survival	_	_	I-Premise
224	on	_	_	I-Premise
225	the	_	_	I-Premise
226	sorafenib	_	_	I-Premise
227	arm	_	_	I-Premise
228	than	_	_	I-Premise
229	on	_	_	I-Premise
230	the	_	_	I-Premise
231	tivozanib	_	_	I-Premise
232	arm	_	_	I-Premise
233	(	_	_	I-Premise
234	median	_	_	I-Premise
235	,	_	_	I-Premise
236	29	_	_	I-Premise
237	.	_	_	I-Premise

238	3	_	_	I-Premise
239	v	_	_	I-Premise
240	28	_	_	I-Premise
241	.	_	_	I-Premise

242	8	_	_	I-Premise
243	months	_	_	I-Premise
244	;	_	_	I-Premise
245	HR	_	_	I-Premise
246	,	_	_	I-Premise
247	1	_	_	I-Premise
248	.	_	_	I-Premise

249	245	_	_	I-Premise
250	;	_	_	I-Premise
251	95	_	_	I-Premise
252	%	_	_	I-Premise
253	CI	_	_	I-Premise
254	,	_	_	I-Premise
255	0	_	_	I-Premise
256	.	_	_	I-Premise

257	954	_	_	I-Premise
258	to	_	_	I-Premise
259	1	_	_	I-Premise
260	.	_	_	I-Premise

261	624	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	.	_	_	I-Premise

266	105	_	_	I-Premise
267	)	_	_	I-Premise
268	.	_	_	I-Premise

269	Adverse	_	_	B-Premise
270	events	_	_	I-Premise
271	(	_	_	I-Premise
272	AEs	_	_	I-Premise
273	)	_	_	I-Premise
274	more	_	_	I-Premise
275	common	_	_	I-Premise
276	with	_	_	I-Premise
277	tivozanib	_	_	I-Premise
278	than	_	_	I-Premise
279	with	_	_	I-Premise
280	sorafenib	_	_	I-Premise
281	were	_	_	I-Premise
282	hypertension	_	_	I-Premise
283	(	_	_	I-Premise
284	44	_	_	I-Premise
285	%	_	_	I-Premise
286	v	_	_	I-Premise
287	34	_	_	I-Premise
288	%	_	_	I-Premise
289	)	_	_	I-Premise
290	and	_	_	I-Premise
291	dysphonia	_	_	I-Premise
292	(	_	_	I-Premise
293	21	_	_	I-Premise
294	%	_	_	I-Premise
295	v	_	_	I-Premise
296	5	_	_	I-Premise
297	%	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	AEs	_	_	B-Premise
301	more	_	_	I-Premise
302	common	_	_	I-Premise
303	with	_	_	I-Premise
304	sorafenib	_	_	I-Premise
305	than	_	_	I-Premise
306	with	_	_	I-Premise
307	tivozanib	_	_	I-Premise
308	were	_	_	I-Premise
309	hand	_	_	I-Premise
310	-	_	_	I-Premise
311	foot	_	_	I-Premise
312	skin	_	_	I-Premise
313	reaction	_	_	I-Premise
314	(	_	_	I-Premise
315	54	_	_	I-Premise
316	%	_	_	I-Premise
317	v	_	_	I-Premise
318	14	_	_	I-Premise
319	%	_	_	I-Premise
320	)	_	_	I-Premise
321	and	_	_	I-Premise
322	diarrhea	_	_	I-Premise
323	(	_	_	I-Premise
324	33	_	_	I-Premise
325	%	_	_	I-Premise
326	v	_	_	I-Premise
327	23	_	_	I-Premise
328	%	_	_	I-Premise
329	)	_	_	I-Premise
330	.	_	_	I-Premise

331	Tivozanib	_	_	B-Claim
332	demonstrated	_	_	I-Claim
333	improved	_	_	I-Claim
334	PFS	_	_	I-Claim
335	,	_	_	I-Claim
336	but	_	_	I-Claim
337	not	_	_	I-Claim
338	OS	_	_	I-Claim
339	,	_	_	I-Claim
340	and	_	_	I-Claim
341	a	_	_	I-Claim
342	differentiated	_	_	I-Claim
343	safety	_	_	I-Claim
344	profile	_	_	I-Claim
345	,	_	_	I-Claim
346	compared	_	_	I-Claim
347	with	_	_	I-Claim
348	sorafenib	_	_	I-Claim
349	,	_	_	I-Claim
350	as	_	_	I-Claim
351	initial	_	_	I-Claim
352	targeted	_	_	I-Claim
353	therapy	_	_	I-Claim
354	for	_	_	I-Claim
355	metastatic	_	_	I-Claim
356	RCC	_	_	I-Claim
357	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	few	_	_	O
3	reports	_	_	O
4	about	_	_	O
5	the	_	_	O
6	course	_	_	O
7	of	_	_	O
8	vestibular	_	_	O
9	schwannoma	_	_	O
10	(	_	_	O
11	VS	_	_	O
12	)	_	_	O
13	patients	_	_	O
14	following	_	_	O
15	gamma	_	_	O
16	knife	_	_	O
17	radiosurgery	_	_	O
18	(	_	_	O
19	GKRS	_	_	O
20	)	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	the	_	_	O
24	course	_	_	O
25	following	_	_	O
26	conservative	_	_	O
27	management	_	_	O
28	(	_	_	O
29	CM	_	_	O
30	)	_	_	O
31	.	_	_	O

32	In	_	_	O
33	this	_	_	O
34	study	_	_	O
35	,	_	_	O
36	we	_	_	O
37	present	_	_	O
38	prospectively	_	_	O
39	collected	_	_	O
40	data	_	_	O
41	of	_	_	O
42	237	_	_	O
43	patients	_	_	O
44	with	_	_	O
45	unilateral	_	_	O
46	VS	_	_	O
47	extending	_	_	O
48	outside	_	_	O
49	the	_	_	O
50	internal	_	_	O
51	acoustic	_	_	O
52	canal	_	_	O
53	who	_	_	O
54	received	_	_	O
55	either	_	_	O
56	GKRS	_	_	O
57	(	_	_	O
58	113	_	_	O
59	)	_	_	O
60	or	_	_	O
61	CM	_	_	O
62	(	_	_	O
63	124	_	_	O
64	)	_	_	O
65	.	_	_	O

66	The	_	_	O
67	aim	_	_	O
68	was	_	_	O
69	to	_	_	O
70	measure	_	_	O
71	the	_	_	O
72	effect	_	_	O
73	of	_	_	O
74	GKRS	_	_	O
75	compared	_	_	O
76	with	_	_	O
77	the	_	_	O
78	natural	_	_	O
79	course	_	_	O
80	on	_	_	O
81	tumor	_	_	O
82	growth	_	_	O
83	rate	_	_	O
84	and	_	_	O
85	hearing	_	_	O
86	loss	_	_	O
87	.	_	_	O

88	Secondary	_	_	O
89	end	_	_	O
90	points	_	_	O
91	were	_	_	O
92	postinclusion	_	_	O
93	additional	_	_	O
94	treatment	_	_	O
95	,	_	_	O
96	quality	_	_	O
97	of	_	_	O
98	life	_	_	O
99	(	_	_	O
100	QoL	_	_	O
101	)	_	_	O
102	,	_	_	O
103	and	_	_	O
104	symptom	_	_	O
105	development	_	_	O
106	.	_	_	O

107	The	_	_	O
108	patients	_	_	O
109	underwent	_	_	O
110	magnetic	_	_	O
111	resonance	_	_	O
112	imaging	_	_	O
113	scans	_	_	O
114	,	_	_	O
115	clinical	_	_	O
116	examination	_	_	O
117	,	_	_	O
118	and	_	_	O
119	QoL	_	_	O
120	assessment	_	_	O
121	by	_	_	O
122	SF	_	_	O
123	-	_	_	O
124	36	_	_	O
125	questionnaire	_	_	O
126	.	_	_	O

127	Statistics	_	_	O
128	were	_	_	O
129	performed	_	_	O
130	by	_	_	O
131	using	_	_	O
132	Spearman	_	_	O
133	correlation	_	_	O
134	coefficient	_	_	O
135	,	_	_	O
136	Kaplan	_	_	O
137	-	_	_	O
138	Meier	_	_	O
139	plot	_	_	O
140	,	_	_	O
141	Poisson	_	_	O
142	regression	_	_	O
143	model	_	_	O
144	,	_	_	O
145	mixed	_	_	O
146	linear	_	_	O
147	regression	_	_	O
148	models	_	_	O
149	,	_	_	O
150	and	_	_	O
151	mixed	_	_	O
152	logistic	_	_	O
153	regression	_	_	O
154	models	_	_	O
155	.	_	_	O

156	Mean	_	_	O
157	follow	_	_	O
158	-	_	_	O
159	up	_	_	O
160	time	_	_	O
161	was	_	_	O
162	55	_	_	O
163	.	_	_	O

164	0	_	_	O
165	months	_	_	O
166	(	_	_	O
167	26	_	_	O
168	.	_	_	O

169	1	_	_	O
170	standard	_	_	O
171	deviation	_	_	O
172	,	_	_	O
173	range	_	_	O
174	10	_	_	O
175	-	_	_	O
176	132	_	_	O
177	)	_	_	O
178	.	_	_	O

179	Thirteen	_	_	O
180	patients	_	_	O
181	were	_	_	O
182	lost	_	_	O
183	to	_	_	O
184	follow	_	_	O
185	-	_	_	O
186	up	_	_	O
187	.	_	_	O

188	Serviceable	_	_	B-Premise
189	hearing	_	_	I-Premise
190	was	_	_	I-Premise
191	lost	_	_	I-Premise
192	in	_	_	I-Premise
193	54	_	_	I-Premise
194	of	_	_	I-Premise
195	71	_	_	I-Premise
196	(	_	_	I-Premise
197	76	_	_	I-Premise
198	%	_	_	I-Premise
199	)	_	_	I-Premise
200	(	_	_	I-Premise
201	CM	_	_	I-Premise
202	)	_	_	I-Premise
203	and	_	_	I-Premise
204	34	_	_	I-Premise
205	of	_	_	I-Premise
206	53	_	_	I-Premise
207	(	_	_	I-Premise
208	64	_	_	I-Premise
209	%	_	_	I-Premise
210	)	_	_	I-Premise
211	(	_	_	I-Premise
212	GKRS	_	_	I-Premise
213	)	_	_	I-Premise
214	patients	_	_	I-Premise
215	during	_	_	I-Premise
216	the	_	_	I-Premise
217	study	_	_	I-Premise
218	period	_	_	I-Premise
219	(	_	_	I-Premise
220	not	_	_	I-Premise
221	significant	_	_	I-Premise
222	,	_	_	I-Premise
223	log	_	_	I-Premise
224	-	_	_	I-Premise
225	rank	_	_	I-Premise
226	test	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	There	_	_	B-Premise
230	was	_	_	I-Premise
231	a	_	_	I-Premise
232	significant	_	_	I-Premise
233	reduction	_	_	I-Premise
234	in	_	_	I-Premise
235	tumor	_	_	I-Premise
236	volume	_	_	I-Premise
237	over	_	_	I-Premise
238	time	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	GKRS	_	_	I-Premise
242	group	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Premise
245	need	_	_	I-Premise
246	for	_	_	I-Premise
247	treatment	_	_	I-Premise
248	following	_	_	I-Premise
249	initial	_	_	I-Premise
250	GKRS	_	_	I-Premise
251	or	_	_	I-Premise
252	CM	_	_	I-Premise
253	differed	_	_	I-Premise
254	at	_	_	I-Premise
255	highly	_	_	I-Premise
256	significant	_	_	I-Premise
257	levels	_	_	I-Premise
258	(	_	_	I-Premise
259	log	_	_	I-Premise
260	-	_	_	I-Premise
261	rank	_	_	I-Premise
262	test	_	_	I-Premise
263	,	_	_	I-Premise
264	P	_	_	I-Premise
265	<	_	_	I-Premise
266	.	_	_	I-Premise

267	001	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	Symptom	_	_	B-Premise
271	and	_	_	I-Premise
272	QoL	_	_	I-Premise
273	development	_	_	I-Premise
274	did	_	_	I-Premise
275	not	_	_	I-Premise
276	differ	_	_	I-Premise
277	significantly	_	_	I-Premise
278	between	_	_	I-Premise
279	the	_	_	I-Premise
280	groups	_	_	I-Premise
281	.	_	_	I-Premise

282	In	_	_	B-Claim
283	VS	_	_	I-Claim
284	patients	_	_	I-Claim
285	,	_	_	I-Claim
286	GKRS	_	_	I-Claim
287	reduces	_	_	I-Claim
288	the	_	_	I-Claim
289	tumor	_	_	I-Claim
290	growth	_	_	I-Claim
291	rate	_	_	I-Claim
292	and	_	_	I-Claim
293	thereby	_	_	I-Claim
294	the	_	_	I-Claim
295	incidence	_	_	I-Claim
296	rate	_	_	I-Claim
297	of	_	_	I-Claim
298	new	_	_	I-Claim
299	treatment	_	_	I-Claim
300	about	_	_	I-Claim
301	tenfold	_	_	I-Claim
302	.	_	_	I-Claim

303	Hearing	_	_	B-Claim
304	is	_	_	I-Claim
305	lost	_	_	I-Claim
306	at	_	_	I-Claim
307	similar	_	_	I-Claim
308	rates	_	_	I-Claim
309	in	_	_	I-Claim
310	both	_	_	I-Claim
311	groups	_	_	I-Claim
312	.	_	_	I-Claim

313	Symptoms	_	_	B-Claim
314	and	_	_	I-Claim
315	QoL	_	_	I-Claim
316	seem	_	_	I-Claim
317	not	_	_	I-Claim
318	to	_	_	I-Claim
319	be	_	_	I-Claim
320	significantly	_	_	I-Claim
321	affected	_	_	I-Claim
322	by	_	_	I-Claim
323	GKRS	_	_	I-Claim
324	.	_	_	I-Claim


0	The	_	_	O
1	CO	_	_	O
2	.	_	_	O

3	20	_	_	O
4	trial	_	_	O
5	randomized	_	_	O
6	patients	_	_	O
7	with	_	_	O
8	K	_	_	O
9	-	_	_	O
10	RAS	_	_	O
11	wild	_	_	O
12	-	_	_	O
13	type	_	_	O
14	,	_	_	O
15	chemotherapy	_	_	O
16	-	_	_	O
17	refractory	_	_	O
18	,	_	_	O
19	metastatic	_	_	O
20	colorectal	_	_	O
21	cancer	_	_	O
22	to	_	_	O
23	receive	_	_	O
24	cetuximab	_	_	O
25	(	_	_	O
26	CET	_	_	O
27	)	_	_	O
28	plus	_	_	O
29	brivanib	_	_	O
30	alaninate	_	_	O
31	(	_	_	O
32	BRIV	_	_	O
33	)	_	_	O
34	or	_	_	O
35	CET	_	_	O
36	plus	_	_	O
37	placebo	_	_	O
38	(	_	_	O
39	CET	_	_	O
40	/	_	_	O
41	placebo	_	_	O
42	)	_	_	O
43	.	_	_	O

44	Quality	_	_	O
45	of	_	_	O
46	life	_	_	O
47	(	_	_	O
48	QoL	_	_	O
49	)	_	_	O
50	was	_	_	O
51	assessed	_	_	O
52	using	_	_	O
53	the	_	_	O
54	European	_	_	O
55	Organization	_	_	O
56	for	_	_	O
57	Research	_	_	O
58	and	_	_	O
59	Treatment	_	_	O
60	of	_	_	O
61	Cancer	_	_	O
62	Quality	_	_	O
63	of	_	_	O
64	Life	_	_	O
65	Questionnaire	_	_	O
66	C30	_	_	O
67	at	_	_	O
68	baseline	_	_	O
69	and	_	_	O
70	at	_	_	O
71	2	_	_	O
72	,	_	_	O
73	4	_	_	O
74	,	_	_	O
75	6	_	_	O
76	,	_	_	O
77	8	_	_	O
78	,	_	_	O
79	12	_	_	O
80	,	_	_	O
81	16	_	_	O
82	,	_	_	O
83	and	_	_	O
84	24	_	_	O
85	weeks	_	_	O
86	until	_	_	O
87	disease	_	_	O
88	progression	_	_	O
89	.	_	_	O

90	Predefined	_	_	O
91	coprimary	_	_	O
92	QoL	_	_	O
93	endpoints	_	_	O
94	were	_	_	O
95	time	_	_	O
96	to	_	_	O
97	deterioration	_	_	O
98	(	_	_	O
99	first	_	_	O
100	worsening	_	_	O
101	from	_	_	O
102	baseline	_	_	O
103	of	_	_	O
104	≥	_	_	O
105	10	_	_	O
106	points	_	_	O
107	)	_	_	O
108	on	_	_	O
109	the	_	_	O
110	Physical	_	_	O
111	Function	_	_	O
112	(	_	_	O
113	PF	_	_	O
114	)	_	_	O
115	and	_	_	O
116	Global	_	_	O
117	(	_	_	O
118	GHS	_	_	O
119	)	_	_	O
120	scales	_	_	O
121	.	_	_	O

122	Of	_	_	O
123	750	_	_	O
124	randomized	_	_	O
125	patients	_	_	O
126	,	_	_	O
127	721	_	_	O
128	(	_	_	O
129	358	_	_	O
130	of	_	_	O
131	whom	_	_	O
132	received	_	_	O
133	CET	_	_	O
134	/	_	_	O
135	BRIV	_	_	O
136	)	_	_	O
137	were	_	_	O
138	assessable	_	_	O
139	for	_	_	O
140	QoL	_	_	O
141	.	_	_	O

142	QoL	_	_	O
143	compliance	_	_	O
144	and	_	_	O
145	baseline	_	_	O
146	PF	_	_	O
147	and	_	_	O
148	GHS	_	_	O
149	scores	_	_	O
150	did	_	_	O
151	not	_	_	O
152	differ	_	_	O
153	by	_	_	O
154	treatment	_	_	O
155	arm	_	_	O
156	.	_	_	O

157	The	_	_	B-Premise
158	median	_	_	I-Premise
159	time	_	_	I-Premise
160	to	_	_	I-Premise
161	deterioration	_	_	I-Premise
162	was	_	_	I-Premise
163	1	_	_	I-Premise
164	.	_	_	I-Premise

165	6	_	_	I-Premise
166	months	_	_	I-Premise
167	versus	_	_	I-Premise
168	1	_	_	I-Premise
169	.	_	_	I-Premise

170	1	_	_	I-Premise
171	months	_	_	I-Premise
172	for	_	_	I-Premise
173	GHS	_	_	I-Premise
174	(	_	_	I-Premise
175	P	_	_	I-Premise
176	=	_	_	I-Premise
177	.	_	_	I-Premise

178	02	_	_	I-Premise
179	)	_	_	I-Premise
180	and	_	_	I-Premise
181	5	_	_	I-Premise
182	.	_	_	I-Premise

183	6	_	_	I-Premise
184	months	_	_	I-Premise
185	versus	_	_	I-Premise
186	1	_	_	I-Premise
187	.	_	_	I-Premise

188	7	_	_	I-Premise
189	months	_	_	I-Premise
190	for	_	_	I-Premise
191	PF	_	_	I-Premise
192	(	_	_	I-Premise
193	P	_	_	I-Premise
194	<	_	_	I-Premise
195	.	_	_	I-Premise

196	0001	_	_	I-Premise
197	)	_	_	I-Premise
198	favoring	_	_	I-Premise
199	CET	_	_	I-Premise
200	/	_	_	I-Premise
201	placebo	_	_	I-Premise
202	.	_	_	I-Premise

203	Secondary	_	_	B-Premise
204	analysis	_	_	I-Premise
205	favored	_	_	I-Premise
206	CET	_	_	I-Premise
207	/	_	_	I-Premise
208	placebo	_	_	I-Premise
209	for	_	_	I-Premise
210	QOL	_	_	I-Premise
211	response	_	_	I-Premise
212	on	_	_	I-Premise
213	the	_	_	I-Premise
214	PF	_	_	I-Premise
215	,	_	_	I-Premise
216	Cognitive	_	_	I-Premise
217	Function	_	_	I-Premise
218	,	_	_	I-Premise
219	Fatigue	_	_	I-Premise
220	,	_	_	I-Premise
221	Nausea	_	_	I-Premise
222	,	_	_	I-Premise
223	Appetite	_	_	I-Premise
224	,	_	_	I-Premise
225	and	_	_	I-Premise
226	Diarrhea	_	_	I-Premise
227	scales	_	_	I-Premise
228	.	_	_	I-Premise

229	A	_	_	B-Premise
230	greater	_	_	I-Premise
231	percentage	_	_	I-Premise
232	of	_	_	I-Premise
233	patients	_	_	I-Premise
234	on	_	_	I-Premise
235	the	_	_	I-Premise
236	CET	_	_	I-Premise
237	/	_	_	I-Premise
238	BRIV	_	_	I-Premise
239	arm	_	_	I-Premise
240	had	_	_	I-Premise
241	PF	_	_	I-Premise
242	worsening	_	_	I-Premise
243	at	_	_	I-Premise
244	6	_	_	I-Premise
245	weeks	_	_	I-Premise
246	(	_	_	I-Premise
247	31	_	_	I-Premise
248	%	_	_	I-Premise
249	vs	_	_	I-Premise
250	17	_	_	I-Premise
251	%	_	_	I-Premise
252	)	_	_	I-Premise
253	.	_	_	I-Premise

254	Clinical	_	_	B-Premise
255	adverse	_	_	I-Premise
256	events	_	_	I-Premise
257	of	_	_	I-Premise
258	≥	_	_	I-Premise
259	grade	_	_	I-Premise
260	3	_	_	I-Premise
261	were	_	_	I-Premise
262	more	_	_	I-Premise
263	common	_	_	I-Premise
264	with	_	_	I-Premise
265	CET	_	_	I-Premise
266	/	_	_	I-Premise
267	BRIV	_	_	I-Premise
268	than	_	_	I-Premise
269	with	_	_	I-Premise
270	CET	_	_	I-Premise
271	/	_	_	I-Premise
272	placebo	_	_	I-Premise
273	,	_	_	I-Premise
274	including	_	_	I-Premise
275	fatigue	_	_	I-Premise
276	(	_	_	I-Premise
277	25	_	_	I-Premise
278	%	_	_	I-Premise
279	vs	_	_	I-Premise
280	11	_	_	I-Premise
281	%	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	hypertension	_	_	I-Premise
285	,	_	_	I-Premise
286	rash	_	_	I-Premise
287	,	_	_	I-Premise
288	diarrhea	_	_	I-Premise
289	,	_	_	I-Premise
290	abdominal	_	_	I-Premise
291	pain	_	_	I-Premise
292	,	_	_	I-Premise
293	dehydration	_	_	I-Premise
294	,	_	_	I-Premise
295	and	_	_	I-Premise
296	anorexia	_	_	I-Premise
297	.	_	_	I-Premise

298	Compared	_	_	B-Claim
299	with	_	_	I-Claim
300	CET	_	_	I-Claim
301	/	_	_	I-Claim
302	placebo	_	_	I-Claim
303	,	_	_	I-Claim
304	the	_	_	I-Claim
305	combination	_	_	I-Claim
306	of	_	_	I-Claim
307	CET	_	_	I-Claim
308	/	_	_	I-Claim
309	BRIV	_	_	I-Claim
310	worsened	_	_	I-Claim
311	time	_	_	I-Claim
312	to	_	_	I-Claim
313	QoL	_	_	I-Claim
314	deterioration	_	_	I-Claim
315	for	_	_	I-Claim
316	patients	_	_	I-Claim
317	with	_	_	I-Claim
318	K	_	_	I-Claim
319	-	_	_	I-Claim
320	RAS	_	_	I-Claim
321	wild	_	_	I-Claim
322	-	_	_	I-Claim
323	type	_	_	I-Claim
324	,	_	_	I-Claim
325	chemotherapy	_	_	I-Claim
326	-	_	_	I-Claim
327	refractory	_	_	I-Claim
328	,	_	_	I-Claim
329	metastatic	_	_	I-Claim
330	colorectal	_	_	I-Claim
331	cancer	_	_	I-Claim
332	on	_	_	I-Claim
333	the	_	_	I-Claim
334	PF	_	_	I-Claim
335	and	_	_	I-Claim
336	GHS	_	_	I-Claim
337	scales	_	_	I-Claim
338	of	_	_	I-Claim
339	European	_	_	I-Claim
340	Organization	_	_	I-Claim
341	for	_	_	I-Claim
342	Research	_	_	I-Claim
343	and	_	_	I-Claim
344	Treatment	_	_	I-Claim
345	of	_	_	I-Claim
346	Cancer	_	_	I-Claim
347	Quality	_	_	I-Claim
348	of	_	_	I-Claim
349	Life	_	_	I-Claim
350	Questionnaire	_	_	I-Claim
351	C30	_	_	I-Claim
352	.	_	_	I-Claim

353	This	_	_	B-Claim
354	result	_	_	I-Claim
355	may	_	_	I-Claim
356	be	_	_	I-Claim
357	due	_	_	I-Claim
358	to	_	_	I-Claim
359	higher	_	_	I-Claim
360	rates	_	_	I-Claim
361	of	_	_	I-Claim
362	fatigue	_	_	I-Claim
363	and	_	_	I-Claim
364	gastrointestinal	_	_	I-Claim
365	adverse	_	_	I-Claim
366	events	_	_	I-Claim
367	.	_	_	I-Claim


0	In	_	_	O
1	an	_	_	O
2	international	_	_	O
3	,	_	_	O
4	randomized	_	_	O
5	phase	_	_	O
6	III	_	_	O
7	trial	_	_	O
8	,	_	_	O
9	sunitinib	_	_	O
10	demonstrated	_	_	O
11	statistically	_	_	O
12	significant	_	_	O
13	efficacy	_	_	O
14	over	_	_	O
15	interferon	_	_	O
16	alfa	_	_	O
17	(	_	_	O
18	IFN	_	_	O
19	-	_	_	O
20	alpha	_	_	O
21	)	_	_	O
22	as	_	_	O
23	first	_	_	O
24	-	_	_	O
25	line	_	_	O
26	therapy	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	metastatic	_	_	O
31	renal	_	_	O
32	cell	_	_	O
33	carcinoma	_	_	O
34	(	_	_	O
35	mRCC	_	_	O
36	)	_	_	O
37	(	_	_	O
38	progression	_	_	O
39	-	_	_	O
40	free	_	_	O
41	survival	_	_	O
42	time	_	_	O
43	,	_	_	O
44	11	_	_	O
45	v	_	_	O
46	5	_	_	O
47	months	_	_	O
48	,	_	_	O
49	respectively	_	_	O
50	;	_	_	O
51	P	_	_	O
52	<	_	_	O
53	.	_	_	O

54	001	_	_	O
55	;	_	_	O
56	objective	_	_	O
57	response	_	_	O
58	rate	_	_	O
59	,	_	_	O
60	31	_	_	O
61	%	_	_	O
62	v	_	_	O
63	6	_	_	O
64	%	_	_	O
65	,	_	_	O
66	respectively	_	_	O
67	;	_	_	O
68	P	_	_	O
69	<	_	_	O
70	.	_	_	O

71	001	_	_	O
72	)	_	_	O
73	.	_	_	O

74	We	_	_	O
75	report	_	_	O
76	health	_	_	O
77	-	_	_	O
78	related	_	_	O
79	quality	_	_	O
80	-	_	_	O
81	of	_	_	O
82	-	_	_	O
83	life	_	_	O
84	(	_	_	O
85	QOL	_	_	O
86	)	_	_	O
87	results	_	_	O
88	from	_	_	O
89	this	_	_	O
90	trial	_	_	O
91	.	_	_	O

92	Seven	_	_	O
93	hundred	_	_	O
94	fifty	_	_	O
95	mRCC	_	_	O
96	patients	_	_	O
97	were	_	_	O
98	randomly	_	_	O
99	assigned	_	_	O
100	to	_	_	O
101	sunitinib	_	_	O
102	(	_	_	O
103	6	_	_	O
104	-	_	_	O
105	week	_	_	O
106	cycles	_	_	O
107	:	_	_	O
108	50	_	_	O
109	mg	_	_	O
110	orally	_	_	O
111	once	_	_	O
112	daily	_	_	O
113	for	_	_	O
114	4	_	_	O
115	weeks	_	_	O
116	,	_	_	O
117	followed	_	_	O
118	by	_	_	O
119	2	_	_	O
120	weeks	_	_	O
121	off	_	_	O
122	)	_	_	O
123	or	_	_	O
124	IFN	_	_	O
125	-	_	_	O
126	alpha	_	_	O
127	(	_	_	O
128	9	_	_	O
129	million	_	_	O
130	units	_	_	O
131	subcutaneous	_	_	O
132	injections	_	_	O
133	,	_	_	O
134	three	_	_	O
135	times	_	_	O
136	weekly	_	_	O
137	)	_	_	O
138	.	_	_	O

139	QOL	_	_	O
140	measures	_	_	O
141	included	_	_	O
142	the	_	_	O
143	Functional	_	_	O
144	Assessment	_	_	O
145	of	_	_	O
146	Cancer	_	_	O
147	Therapy	_	_	O
148	-	_	_	O
149	General	_	_	O
150	(	_	_	O
151	FACT	_	_	O
152	-	_	_	O
153	G	_	_	O
154	)	_	_	O
155	,	_	_	O
156	the	_	_	O
157	FACT	_	_	O
158	-	_	_	O
159	Kidney	_	_	O
160	Symptom	_	_	O
161	Index	_	_	O
162	-	_	_	O
163	15	_	_	O
164	item	_	_	O
165	(	_	_	O
166	FKSI	_	_	O
167	-	_	_	O
168	15	_	_	O
169	)	_	_	O
170	,	_	_	O
171	and	_	_	O
172	the	_	_	O
173	EuroQoL	_	_	O
174	-	_	_	O
175	5D	_	_	O
176	'	_	_	O
177	s	_	_	O
178	utility	_	_	O
179	score	_	_	O
180	(	_	_	O
181	EQ	_	_	O
182	-	_	_	O
183	5D	_	_	O
184	Index	_	_	O
185	)	_	_	O
186	and	_	_	O
187	its	_	_	O
188	visual	_	_	O
189	analog	_	_	O
190	scale	_	_	O
191	(	_	_	O
192	EQ	_	_	O
193	-	_	_	O
194	VAS	_	_	O
195	)	_	_	O
196	.	_	_	O

197	The	_	_	O
198	primary	_	_	O
199	QOL	_	_	O
200	end	_	_	O
201	point	_	_	O
202	was	_	_	O
203	the	_	_	O
204	FKSI	_	_	O
205	Disease	_	_	O
206	-	_	_	O
207	Related	_	_	O
208	Symptoms	_	_	O
209	(	_	_	O
210	FKSI	_	_	O
211	-	_	_	O
212	DRS	_	_	O
213	)	_	_	O
214	subscale	_	_	O
215	.	_	_	O

216	Higher	_	_	O
217	scores	_	_	O
218	indicated	_	_	O
219	better	_	_	O
220	outcomes	_	_	O
221	(	_	_	O
222	better	_	_	O
223	QOL	_	_	O
224	or	_	_	O
225	fewer	_	_	O
226	symptoms	_	_	O
227	)	_	_	O
228	.	_	_	O

229	Data	_	_	O
230	were	_	_	O
231	analyzed	_	_	O
232	for	_	_	O
233	the	_	_	O
234	intent	_	_	O
235	-	_	_	O
236	to	_	_	O
237	-	_	_	O
238	treat	_	_	O
239	population	_	_	O
240	using	_	_	O
241	mixed	_	_	O
242	-	_	_	O
243	effects	_	_	O
244	models	_	_	O
245	,	_	_	O
246	supplemented	_	_	O
247	with	_	_	O
248	pattern	_	_	O
249	-	_	_	O
250	mixture	_	_	O
251	models	_	_	O
252	.	_	_	O

253	Patients	_	_	B-Premise
254	receiving	_	_	I-Premise
255	sunitinib	_	_	I-Premise
256	reported	_	_	I-Premise
257	higher	_	_	I-Premise
258	FKSI	_	_	I-Premise
259	-	_	_	I-Premise
260	15	_	_	I-Premise
261	and	_	_	I-Premise
262	FKSI	_	_	I-Premise
263	-	_	_	I-Premise
264	DRS	_	_	I-Premise
265	scores	_	_	I-Premise
266	at	_	_	I-Premise
267	each	_	_	I-Premise
268	cycle	_	_	I-Premise
269	than	_	_	I-Premise
270	those	_	_	I-Premise
271	receiving	_	_	I-Premise
272	IFN	_	_	I-Premise
273	-	_	_	I-Premise
274	alpha	_	_	I-Premise
275	,	_	_	I-Premise
276	with	_	_	I-Premise
277	a	_	_	I-Premise
278	significant	_	_	I-Premise
279	difference	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	overall	_	_	I-Premise
283	least	_	_	I-Premise
284	squares	_	_	I-Premise
285	means	_	_	I-Premise
286	(	_	_	I-Premise
287	3	_	_	I-Premise
288	.	_	_	I-Premise

289	27	_	_	I-Premise
290	and	_	_	I-Premise
291	1	_	_	I-Premise
292	.	_	_	I-Premise

293	98	_	_	I-Premise
294	,	_	_	I-Premise
295	respectively	_	_	I-Premise
296	;	_	_	I-Premise
297	P	_	_	I-Premise
298	<	_	_	I-Premise
299	.	_	_	I-Premise

300	0001	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	Similarly	_	_	O
304	,	_	_	O
305	differences	_	_	B-Premise
306	in	_	_	I-Premise
307	least	_	_	I-Premise
308	squares	_	_	I-Premise
309	means	_	_	I-Premise
310	for	_	_	I-Premise
311	FACT	_	_	I-Premise
312	-	_	_	I-Premise
313	G	_	_	I-Premise
314	(	_	_	I-Premise
315	and	_	_	I-Premise
316	all	_	_	I-Premise
317	subscales	_	_	I-Premise
318	)	_	_	I-Premise
319	,	_	_	I-Premise
320	EQ	_	_	I-Premise
321	-	_	_	I-Premise
322	5D	_	_	I-Premise
323	Index	_	_	I-Premise
324	,	_	_	I-Premise
325	and	_	_	I-Premise
326	EQ	_	_	I-Premise
327	-	_	_	I-Premise
328	VAS	_	_	I-Premise
329	were	_	_	I-Premise
330	all	_	_	I-Premise
331	significantly	_	_	I-Premise
332	favorable	_	_	I-Premise
333	for	_	_	I-Premise
334	sunitinib	_	_	I-Premise
335	(	_	_	I-Premise
336	P	_	_	I-Premise
337	<	_	_	I-Premise
338	.	_	_	I-Premise

339	01	_	_	I-Premise
340	)	_	_	I-Premise
341	.	_	_	I-Premise

342	Per	_	_	O
343	pre	_	_	O
344	-	_	_	O
345	established	_	_	O
346	thresholds	_	_	O
347	,	_	_	O
348	between	_	_	O
349	-	_	_	O
350	treatment	_	_	O
351	differences	_	_	O
352	in	_	_	O
353	the	_	_	O
354	mean	_	_	O
355	scores	_	_	O
356	were	_	_	O
357	clinically	_	_	O
358	meaningful	_	_	O
359	after	_	_	O
360	cycle	_	_	O
361	4	_	_	O
362	for	_	_	O
363	FKSI	_	_	O
364	-	_	_	O
365	DRS	_	_	O
366	and	_	_	O
367	at	_	_	O
368	all	_	_	O
369	assessments	_	_	O
370	for	_	_	O
371	FKSI	_	_	O
372	-	_	_	O
373	15	_	_	O
374	,	_	_	O
375	FACT	_	_	O
376	-	_	_	O
377	G	_	_	O
378	,	_	_	O
379	and	_	_	O
380	the	_	_	O
381	FACT	_	_	O
382	-	_	_	O
383	G	_	_	O
384	functional	_	_	O
385	well	_	_	O
386	-	_	_	O
387	being	_	_	O
388	subscale	_	_	O
389	.	_	_	O

390	Sunitinib	_	_	B-Claim
391	provides	_	_	I-Claim
392	superior	_	_	I-Claim
393	QOL	_	_	I-Claim
394	compared	_	_	I-Claim
395	with	_	_	I-Claim
396	IFN	_	_	I-Claim
397	-	_	_	I-Claim
398	alpha	_	_	I-Claim
399	in	_	_	I-Claim
400	mRCC	_	_	I-Claim
401	patients	_	_	I-Claim
402	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	recombinant	_	_	O
6	human	_	_	O
7	erythropoietin	_	_	O
8	(	_	_	O
9	epoetin	_	_	O
10	beta	_	_	O
11	)	_	_	O
12	on	_	_	O
13	anemia	_	_	O
14	,	_	_	O
15	transfusion	_	_	O
16	need	_	_	O
17	,	_	_	O
18	and	_	_	O
19	quality	_	_	O
20	of	_	_	O
21	life	_	_	O
22	(	_	_	O
23	QOL	_	_	O
24	)	_	_	O
25	in	_	_	O
26	severely	_	_	O
27	anemic	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	low	_	_	O
31	-	_	_	O
32	grade	_	_	O
33	non	_	_	O
34	-	_	_	O
35	Hodgkin	_	_	O
36	'	_	_	O
37	s	_	_	O
38	lymphoma	_	_	O
39	(	_	_	O
40	NHL	_	_	O
41	)	_	_	O
42	,	_	_	O
43	chronic	_	_	O
44	lymphocytic	_	_	O
45	leukemia	_	_	O
46	(	_	_	O
47	CLL	_	_	O
48	)	_	_	O
49	,	_	_	O
50	or	_	_	O
51	multiple	_	_	O
52	myeloma	_	_	O
53	(	_	_	O
54	MM	_	_	O
55	)	_	_	O
56	.	_	_	O

57	Transfusion	_	_	O
58	-	_	_	O
59	dependent	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	NHL	_	_	O
63	(	_	_	O
64	n	_	_	O
65	=	_	_	O
66	106	_	_	O
67	)	_	_	O
68	,	_	_	O
69	CLL	_	_	O
70	(	_	_	O
71	n	_	_	O
72	=	_	_	O
73	126	_	_	O
74	)	_	_	O
75	,	_	_	O
76	or	_	_	O
77	MM	_	_	O
78	(	_	_	O
79	n	_	_	O
80	=	_	_	O
81	117	_	_	O
82	)	_	_	O
83	and	_	_	O
84	a	_	_	O
85	low	_	_	O
86	serum	_	_	O
87	erythropoietin	_	_	O
88	concentration	_	_	O
89	were	_	_	O
90	randomized	_	_	O
91	to	_	_	O
92	receive	_	_	O
93	epoetin	_	_	O
94	beta	_	_	O
95	150	_	_	O
96	IU	_	_	O
97	/	_	_	O
98	kg	_	_	O
99	or	_	_	O
100	placebo	_	_	O
101	subcutaneously	_	_	O
102	three	_	_	O
103	times	_	_	O
104	a	_	_	O
105	week	_	_	O
106	for	_	_	O
107	16	_	_	O
108	weeks	_	_	O
109	.	_	_	O

110	Primary	_	_	O
111	efficacy	_	_	O
112	criteria	_	_	O
113	were	_	_	O
114	transfusion	_	_	O
115	-	_	_	O
116	free	_	_	O
117	and	_	_	O
118	transfusion	_	_	O
119	-	_	_	O
120	and	_	_	O
121	severe	_	_	O
122	anemia	_	_	O
123	-	_	_	O
124	free	_	_	O
125	survival	_	_	O
126	(	_	_	O
127	hemoglobin	_	_	O
128	[	_	_	O
129	Hb	_	_	O
130	]	_	_	O
131	>	_	_	O
132	8	_	_	O
133	.	_	_	O

134	5	_	_	O
135	g	_	_	O
136	/	_	_	O
137	dL	_	_	O
138	)	_	_	O
139	between	_	_	O
140	weeks	_	_	O
141	5	_	_	O
142	to	_	_	O
143	16	_	_	O
144	.	_	_	O

145	Response	_	_	O
146	was	_	_	O
147	defined	_	_	O
148	as	_	_	O
149	an	_	_	O
150	increase	_	_	O
151	in	_	_	O
152	Hb	_	_	O
153	>	_	_	O
154	or	_	_	O
155	=	_	_	O
156	2	_	_	O
157	g	_	_	O
158	/	_	_	O
159	dL	_	_	O
160	with	_	_	O
161	elimination	_	_	O
162	of	_	_	O
163	transfusion	_	_	O
164	need	_	_	O
165	.	_	_	O

166	QOL	_	_	O
167	was	_	_	O
168	assessed	_	_	O
169	by	_	_	O
170	the	_	_	O
171	Functional	_	_	O
172	Assessment	_	_	O
173	of	_	_	O
174	Cancer	_	_	O
175	Therapy	_	_	O
176	scale	_	_	O
177	.	_	_	O

178	Transfusion	_	_	B-Premise
179	-	_	_	I-Premise
180	free	_	_	I-Premise
181	(	_	_	I-Premise
182	P	_	_	I-Premise
183	=	_	_	I-Premise
184	.	_	_	I-Premise

185	0012	_	_	I-Premise
186	)	_	_	I-Premise
187	survival	_	_	I-Premise
188	and	_	_	I-Premise
189	transfusion	_	_	I-Premise
190	-	_	_	I-Premise
191	and	_	_	I-Premise
192	severe	_	_	I-Premise
193	anemia	_	_	I-Premise
194	-	_	_	I-Premise
195	free	_	_	I-Premise
196	survival	_	_	I-Premise
197	(	_	_	I-Premise
198	P	_	_	I-Premise
199	=	_	_	I-Premise
200	.	_	_	I-Premise

201	0001	_	_	I-Premise
202	)	_	_	I-Premise
203	were	_	_	I-Premise
204	significantly	_	_	I-Premise
205	greater	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	epoetin	_	_	I-Premise
209	beta	_	_	I-Premise
210	group	_	_	I-Premise
211	versus	_	_	I-Premise
212	placebo	_	_	I-Premise
213	(	_	_	I-Premise
214	Wald	_	_	I-Premise
215	chi	_	_	I-Premise
216	(	_	_	I-Premise
217	2	_	_	I-Premise
218	)	_	_	I-Premise
219	test	_	_	I-Premise
220	)	_	_	I-Premise
221	,	_	_	I-Premise
222	giving	_	_	I-Premise
223	a	_	_	I-Premise
224	relative	_	_	I-Premise
225	risk	_	_	I-Premise
226	reduction	_	_	I-Premise
227	of	_	_	I-Premise
228	43	_	_	I-Premise
229	%	_	_	I-Premise
230	and	_	_	I-Premise
231	51	_	_	I-Premise
232	%	_	_	I-Premise
233	,	_	_	I-Premise
234	respectively	_	_	I-Premise
235	.	_	_	I-Premise

236	The	_	_	B-Premise
237	response	_	_	I-Premise
238	rate	_	_	I-Premise
239	was	_	_	I-Premise
240	67	_	_	I-Premise
241	%	_	_	I-Premise
242	and	_	_	I-Premise
243	27	_	_	I-Premise
244	%	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	epoetin	_	_	I-Premise
248	beta	_	_	I-Premise
249	versus	_	_	I-Premise
250	the	_	_	I-Premise
251	placebo	_	_	I-Premise
252	group	_	_	I-Premise
253	,	_	_	I-Premise
254	respectively	_	_	I-Premise
255	(	_	_	I-Premise
256	P	_	_	I-Premise
257	<	_	_	I-Premise
258	.	_	_	I-Premise

259	0001	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	After	_	_	B-Premise
263	12	_	_	I-Premise
264	and	_	_	I-Premise
265	16	_	_	I-Premise
266	weeks	_	_	I-Premise
267	of	_	_	I-Premise
268	treatment	_	_	I-Premise
269	,	_	_	I-Premise
270	QOL	_	_	I-Premise
271	significantly	_	_	I-Premise
272	improved	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	epoetin	_	_	I-Premise
276	beta	_	_	I-Premise
277	group	_	_	I-Premise
278	compared	_	_	I-Premise
279	with	_	_	I-Premise
280	placebo	_	_	I-Premise
281	(	_	_	I-Premise
282	P	_	_	I-Premise
283	<	_	_	I-Premise
284	.	_	_	I-Premise

285	05	_	_	I-Premise
286	)	_	_	I-Premise
287	;	_	_	I-Premise
288	this	_	_	B-Premise
289	improvement	_	_	I-Premise
290	correlated	_	_	I-Premise
291	with	_	_	I-Premise
292	an	_	_	I-Premise
293	increase	_	_	I-Premise
294	in	_	_	I-Premise
295	Hb	_	_	I-Premise
296	concentration	_	_	I-Premise
297	(	_	_	I-Premise
298	>	_	_	I-Premise
299	or	_	_	I-Premise
300	=	_	_	I-Premise
301	2	_	_	I-Premise
302	g	_	_	I-Premise
303	/	_	_	I-Premise
304	dL	_	_	I-Premise
305	)	_	_	I-Premise
306	.	_	_	I-Premise

307	A	_	_	O
308	target	_	_	O
309	Hb	_	_	O
310	that	_	_	O
311	could	_	_	O
312	be	_	_	O
313	generally	_	_	O
314	recommended	_	_	O
315	could	_	_	O
316	not	_	_	O
317	be	_	_	O
318	identified	_	_	O
319	.	_	_	O

320	Many	_	_	B-Claim
321	severely	_	_	I-Claim
322	anemic	_	_	I-Claim
323	and	_	_	I-Claim
324	transfusion	_	_	I-Claim
325	-	_	_	I-Claim
326	dependent	_	_	I-Claim
327	patients	_	_	I-Claim
328	with	_	_	I-Claim
329	advanced	_	_	I-Claim
330	MM	_	_	I-Claim
331	,	_	_	I-Claim
332	NHL	_	_	I-Claim
333	,	_	_	I-Claim
334	and	_	_	I-Claim
335	CLL	_	_	I-Claim
336	and	_	_	I-Claim
337	a	_	_	I-Claim
338	low	_	_	I-Claim
339	performance	_	_	I-Claim
340	status	_	_	I-Claim
341	benefited	_	_	I-Claim
342	from	_	_	I-Claim
343	epoetin	_	_	I-Claim
344	therapy	_	_	I-Claim
345	,	_	_	I-Claim
346	with	_	_	I-Claim
347	elimination	_	_	I-Claim
348	of	_	_	I-Claim
349	severe	_	_	I-Claim
350	anemia	_	_	I-Claim
351	and	_	_	I-Claim
352	transfusion	_	_	I-Claim
353	need	_	_	I-Claim
354	,	_	_	I-Claim
355	and	_	_	I-Claim
356	improvement	_	_	I-Claim
357	in	_	_	I-Claim
358	QOL	_	_	I-Claim
359	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	oral	_	_	O
8	bexarotene	_	_	O
9	(	_	_	O
10	Targretin	_	_	O
11	capsules	_	_	O
12	;	_	_	O
13	Ligand	_	_	O
14	Pharmaceuticals	_	_	O
15	Incorporated	_	_	O
16	,	_	_	O
17	San	_	_	O
18	Diego	_	_	O
19	,	_	_	O
20	Calif	_	_	O
21	)	_	_	O
22	.	_	_	O

23	The	_	_	O
24	effects	_	_	O
25	of	_	_	O
26	2	_	_	O
27	randomized	_	_	O
28	doses	_	_	O
29	of	_	_	O
30	6	_	_	O
31	.	_	_	O

32	5	_	_	O
33	mg	_	_	O
34	/	_	_	O
35	m	_	_	O
36	(	_	_	O
37	2	_	_	O
38	)	_	_	O
39	per	_	_	O
40	day	_	_	O
41	(	_	_	O
42	with	_	_	O
43	crossover	_	_	O
44	for	_	_	O
45	progression	_	_	O
46	)	_	_	O
47	vs	_	_	O
48	650	_	_	O
49	mg	_	_	O
50	/	_	_	O
51	m	_	_	O
52	(	_	_	O
53	2	_	_	O
54	)	_	_	O
55	per	_	_	O
56	day	_	_	O
57	(	_	_	O
58	later	_	_	O
59	modified	_	_	O
60	to	_	_	O
61	300	_	_	O
62	mg	_	_	O
63	/	_	_	O
64	m	_	_	O
65	(	_	_	O
66	2	_	_	O
67	)	_	_	O
68	per	_	_	O
69	day	_	_	O
70	)	_	_	O
71	were	_	_	O
72	evaluated	_	_	O
73	in	_	_	O
74	an	_	_	O
75	open	_	_	O
76	-	_	_	O
77	label	_	_	O
78	,	_	_	O
79	multicenter	_	_	O
80	,	_	_	O
81	phase	_	_	O
82	2	_	_	O
83	and	_	_	O
84	3	_	_	O
85	study	_	_	O
86	conducted	_	_	O
87	between	_	_	O
88	February	_	_	O
89	1997	_	_	O
90	and	_	_	O
91	November	_	_	O
92	1998	_	_	O
93	.	_	_	O

94	Eighteen	_	_	O
95	international	_	_	O
96	cutaneous	_	_	O
97	T	_	_	O
98	-	_	_	O
99	cell	_	_	O
100	lymphoma	_	_	O
101	clinics	_	_	O
102	at	_	_	O
103	academic	_	_	O
104	referral	_	_	O
105	centers	_	_	O
106	.	_	_	O

107	Fifty	_	_	O
108	-	_	_	O
109	eight	_	_	O
110	patients	_	_	O
111	with	_	_	O
112	biopsy	_	_	O
113	-	_	_	O
114	proven	_	_	O
115	stage	_	_	O
116	IA	_	_	O
117	through	_	_	O
118	IIA	_	_	O
119	cutaneous	_	_	O
120	T	_	_	O
121	-	_	_	O
122	cell	_	_	O
123	lymphoma	_	_	O
124	that	_	_	O
125	was	_	_	O
126	refractory	_	_	O
127	to	_	_	O
128	(	_	_	O
129	or	_	_	O
130	patients	_	_	O
131	were	_	_	O
132	intolerant	_	_	O
133	of	_	_	O
134	)	_	_	O
135	treatment	_	_	O
136	or	_	_	O
137	had	_	_	O
138	reached	_	_	O
139	at	_	_	O
140	least	_	_	O
141	a	_	_	O
142	6	_	_	O
143	-	_	_	O
144	month	_	_	O
145	response	_	_	O
146	plateau	_	_	O
147	under	_	_	O
148	at	_	_	O
149	least	_	_	O
150	2	_	_	O
151	forms	_	_	O
152	of	_	_	O
153	prior	_	_	O
154	therapy	_	_	O
155	(	_	_	O
156	median	_	_	O
157	of	_	_	O
158	3	_	_	O
159	.	_	_	O

160	5	_	_	O
161	prior	_	_	O
162	therapies	_	_	O
163	)	_	_	O
164	.	_	_	O

165	Bexarotene	_	_	O
166	(	_	_	O
167	Targretin	_	_	O
168	capsules	_	_	O
169	)	_	_	O
170	administered	_	_	O
171	once	_	_	O
172	daily	_	_	O
173	with	_	_	O
174	meal	_	_	O
175	for	_	_	O
176	16	_	_	O
177	weeks	_	_	O
178	or	_	_	O
179	longer	_	_	O
180	.	_	_	O

181	Primary	_	_	O
182	end	_	_	O
183	point	_	_	O
184	classification	_	_	O
185	of	_	_	O
186	overall	_	_	O
187	response	_	_	O
188	rate	_	_	O
189	of	_	_	O
190	complete	_	_	O
191	and	_	_	O
192	partial	_	_	O
193	remissions	_	_	O
194	determined	_	_	O
195	by	_	_	O
196	either	_	_	O
197	the	_	_	O
198	Physician	_	_	O
199	'	_	_	O
200	s	_	_	O
201	Global	_	_	O
202	Assessment	_	_	O
203	of	_	_	O
204	Clinical	_	_	O
205	Condition	_	_	O
206	or	_	_	O
207	the	_	_	O
208	objective	_	_	O
209	Composite	_	_	O
210	Assessment	_	_	O
211	of	_	_	O
212	Index	_	_	O
213	Lesion	_	_	O
214	Severity	_	_	O
215	.	_	_	O

216	Body	_	_	O
217	surface	_	_	O
218	area	_	_	O
219	,	_	_	O
220	time	_	_	O
221	to	_	_	O
222	response	_	_	O
223	,	_	_	O
224	duration	_	_	O
225	of	_	_	O
226	disease	_	_	O
227	control	_	_	O
228	,	_	_	O
229	time	_	_	O
230	to	_	_	O
231	disease	_	_	O
232	progression	_	_	O
233	,	_	_	O
234	individual	_	_	O
235	index	_	_	O
236	lesion	_	_	O
237	signs	_	_	O
238	and	_	_	O
239	symptoms	_	_	O
240	,	_	_	O
241	and	_	_	O
242	quality	_	_	O
243	of	_	_	O
244	life	_	_	O
245	parameters	_	_	O
246	were	_	_	O
247	secondary	_	_	O
248	outcomes	_	_	O
249	.	_	_	O

250	Responses	_	_	B-Premise
251	(	_	_	I-Premise
252	>	_	_	I-Premise
253	or	_	_	I-Premise
254	=	_	_	I-Premise
255	50	_	_	I-Premise
256	%	_	_	I-Premise
257	improvement	_	_	I-Premise
258	)	_	_	I-Premise
259	were	_	_	I-Premise
260	seen	_	_	I-Premise
261	in	_	_	I-Premise
262	3	_	_	I-Premise
263	(	_	_	I-Premise
264	20	_	_	I-Premise
265	%	_	_	I-Premise
266	)	_	_	I-Premise
267	of	_	_	I-Premise
268	15	_	_	I-Premise
269	patients	_	_	I-Premise
270	with	_	_	I-Premise
271	an	_	_	I-Premise
272	initial	_	_	I-Premise
273	dose	_	_	I-Premise
274	at	_	_	I-Premise
275	6	_	_	I-Premise
276	.	_	_	I-Premise

277	5	_	_	I-Premise
278	mg	_	_	I-Premise
279	/	_	_	I-Premise
280	m	_	_	I-Premise
281	(	_	_	I-Premise
282	2	_	_	I-Premise
283	)	_	_	I-Premise
284	per	_	_	I-Premise
285	day	_	_	I-Premise
286	(	_	_	I-Premise
287	95	_	_	I-Premise
288	%	_	_	I-Premise
289	confidence	_	_	I-Premise
290	interval	_	_	I-Premise
291	[	_	_	I-Premise
292	CI	_	_	I-Premise
293	]	_	_	I-Premise
294	,	_	_	I-Premise
295	0	_	_	I-Premise
296	%	_	_	I-Premise
297	-	_	_	I-Premise
298	40	_	_	I-Premise
299	%	_	_	I-Premise
300	)	_	_	I-Premise
301	,	_	_	I-Premise
302	15	_	_	I-Premise
303	(	_	_	I-Premise
304	54	_	_	I-Premise
305	%	_	_	I-Premise
306	)	_	_	I-Premise
307	of	_	_	I-Premise
308	28	_	_	I-Premise
309	patients	_	_	I-Premise
310	at	_	_	I-Premise
311	300	_	_	I-Premise
312	mg	_	_	I-Premise
313	/	_	_	I-Premise
314	m	_	_	I-Premise
315	(	_	_	I-Premise
316	2	_	_	I-Premise
317	)	_	_	I-Premise
318	per	_	_	I-Premise
319	day	_	_	I-Premise
320	(	_	_	I-Premise
321	95	_	_	I-Premise
322	%	_	_	I-Premise
323	CI	_	_	I-Premise
324	,	_	_	I-Premise
325	35	_	_	I-Premise
326	%	_	_	I-Premise
327	-	_	_	I-Premise
328	72	_	_	I-Premise
329	%	_	_	I-Premise
330	)	_	_	I-Premise
331	,	_	_	I-Premise
332	and	_	_	I-Premise
333	10	_	_	I-Premise
334	(	_	_	I-Premise
335	67	_	_	I-Premise
336	%	_	_	I-Premise
337	)	_	_	I-Premise
338	of	_	_	I-Premise
339	15	_	_	I-Premise
340	patients	_	_	I-Premise
341	at	_	_	I-Premise
342	above	_	_	I-Premise
343	300	_	_	I-Premise
344	mg	_	_	I-Premise
345	/	_	_	I-Premise
346	m	_	_	I-Premise
347	(	_	_	I-Premise
348	2	_	_	I-Premise
349	)	_	_	I-Premise
350	per	_	_	I-Premise
351	day	_	_	I-Premise
352	(	_	_	I-Premise
353	95	_	_	I-Premise
354	%	_	_	I-Premise
355	CI	_	_	I-Premise
356	,	_	_	I-Premise
357	43	_	_	I-Premise
358	%	_	_	I-Premise
359	-	_	_	I-Premise
360	91	_	_	I-Premise
361	%	_	_	I-Premise
362	)	_	_	I-Premise
363	.	_	_	I-Premise

364	The	_	_	B-Premise
365	rate	_	_	I-Premise
366	of	_	_	I-Premise
367	progressive	_	_	I-Premise
368	disease	_	_	I-Premise
369	was	_	_	I-Premise
370	47	_	_	I-Premise
371	%	_	_	I-Premise
372	,	_	_	I-Premise
373	21	_	_	I-Premise
374	%	_	_	I-Premise
375	,	_	_	I-Premise
376	and	_	_	I-Premise
377	13	_	_	I-Premise
378	%	_	_	I-Premise
379	at	_	_	I-Premise
380	the	_	_	I-Premise
381	same	_	_	I-Premise
382	dose	_	_	I-Premise
383	levels	_	_	I-Premise
384	,	_	_	I-Premise
385	respectively	_	_	I-Premise
386	.	_	_	I-Premise

387	Eight	_	_	B-Premise
388	(	_	_	I-Premise
389	73	_	_	I-Premise
390	%	_	_	I-Premise
391	)	_	_	I-Premise
392	of	_	_	I-Premise
393	11	_	_	I-Premise
394	patients	_	_	I-Premise
395	crossing	_	_	I-Premise
396	over	_	_	I-Premise
397	from	_	_	I-Premise
398	6	_	_	I-Premise
399	.	_	_	I-Premise

400	5	_	_	I-Premise
401	mg	_	_	I-Premise
402	/	_	_	I-Premise
403	m	_	_	I-Premise
404	(	_	_	I-Premise
405	2	_	_	I-Premise
406	)	_	_	I-Premise
407	per	_	_	I-Premise
408	day	_	_	I-Premise
409	to	_	_	I-Premise
410	higher	_	_	I-Premise
411	doses	_	_	I-Premise
412	subsequently	_	_	I-Premise
413	responded	_	_	I-Premise
414	.	_	_	I-Premise

415	The	_	_	B-Premise
416	median	_	_	I-Premise
417	duration	_	_	I-Premise
418	of	_	_	I-Premise
419	response	_	_	I-Premise
420	from	_	_	I-Premise
421	start	_	_	I-Premise
422	of	_	_	I-Premise
423	therapy	_	_	I-Premise
424	could	_	_	I-Premise
425	not	_	_	I-Premise
426	be	_	_	I-Premise
427	estimated	_	_	I-Premise
428	for	_	_	I-Premise
429	the	_	_	I-Premise
430	15	_	_	I-Premise
431	patients	_	_	I-Premise
432	at	_	_	I-Premise
433	300	_	_	I-Premise
434	mg	_	_	I-Premise
435	/	_	_	I-Premise
436	m	_	_	I-Premise
437	(	_	_	I-Premise
438	2	_	_	I-Premise
439	)	_	_	I-Premise
440	per	_	_	I-Premise
441	day	_	_	I-Premise
442	owing	_	_	I-Premise
443	to	_	_	I-Premise
444	low	_	_	I-Premise
445	relapse	_	_	I-Premise
446	rates	_	_	I-Premise
447	in	_	_	I-Premise
448	2	_	_	I-Premise
449	patients	_	_	I-Premise
450	(	_	_	I-Premise
451	13	_	_	I-Premise
452	%	_	_	I-Premise
453	)	_	_	I-Premise
454	;	_	_	I-Premise
455	at	_	_	I-Premise
456	higher	_	_	I-Premise
457	doses	_	_	I-Premise
458	it	_	_	I-Premise
459	was	_	_	I-Premise
460	516	_	_	I-Premise
461	days	_	_	I-Premise
462	.	_	_	I-Premise

463	The	_	_	B-Premise
464	following	_	_	I-Premise
465	drug	_	_	I-Premise
466	-	_	_	I-Premise
467	related	_	_	I-Premise
468	adverse	_	_	I-Premise
469	effects	_	_	I-Premise
470	were	_	_	I-Premise
471	reversible	_	_	I-Premise
472	and	_	_	I-Premise
473	treatable	_	_	I-Premise
474	:	_	_	I-Premise
475	hypertriglyceridemia	_	_	I-Premise
476	(	_	_	I-Premise
477	46	_	_	I-Premise
478	patients	_	_	I-Premise
479	[	_	_	I-Premise
480	79	_	_	I-Premise
481	%	_	_	I-Premise
482	]	_	_	I-Premise
483	)	_	_	I-Premise
484	,	_	_	I-Premise
485	hypercholesterolemia	_	_	I-Premise
486	(	_	_	I-Premise
487	28	_	_	I-Premise
488	patients	_	_	I-Premise
489	[	_	_	I-Premise
490	48	_	_	I-Premise
491	%	_	_	I-Premise
492	]	_	_	I-Premise
493	)	_	_	I-Premise
494	,	_	_	I-Premise
495	headache	_	_	I-Premise
496	(	_	_	I-Premise
497	27	_	_	I-Premise
498	patients	_	_	I-Premise
499	[	_	_	I-Premise
500	47	_	_	I-Premise
501	%	_	_	I-Premise
502	]	_	_	I-Premise
503	)	_	_	I-Premise
504	,	_	_	I-Premise
505	central	_	_	I-Premise
506	hypothyroidism	_	_	I-Premise
507	(	_	_	I-Premise
508	23	_	_	I-Premise
509	patients	_	_	I-Premise
510	[	_	_	I-Premise
511	40	_	_	I-Premise
512	%	_	_	I-Premise
513	]	_	_	I-Premise
514	)	_	_	I-Premise
515	,	_	_	I-Premise
516	asthenia	_	_	I-Premise
517	(	_	_	I-Premise
518	21	_	_	I-Premise
519	patients	_	_	I-Premise
520	[	_	_	I-Premise
521	36	_	_	I-Premise
522	%	_	_	I-Premise
523	]	_	_	I-Premise
524	)	_	_	I-Premise
525	,	_	_	I-Premise
526	and	_	_	I-Premise
527	leukopenia	_	_	I-Premise
528	(	_	_	I-Premise
529	16	_	_	I-Premise
530	patients	_	_	I-Premise
531	[	_	_	I-Premise
532	28	_	_	I-Premise
533	%	_	_	I-Premise
534	]	_	_	I-Premise
535	)	_	_	I-Premise
536	.	_	_	I-Premise

537	No	_	_	B-Premise
538	cases	_	_	I-Premise
539	of	_	_	I-Premise
540	drug	_	_	I-Premise
541	-	_	_	I-Premise
542	related	_	_	I-Premise
543	neutropenic	_	_	I-Premise
544	fever	_	_	I-Premise
545	,	_	_	I-Premise
546	sepsis	_	_	I-Premise
547	,	_	_	I-Premise
548	or	_	_	I-Premise
549	death	_	_	I-Premise
550	occurred	_	_	I-Premise
551	.	_	_	I-Premise

552	Pancreatitis	_	_	B-Premise
553	occurred	_	_	I-Premise
554	in	_	_	I-Premise
555	3	_	_	I-Premise
556	patients	_	_	I-Premise
557	with	_	_	I-Premise
558	triglyceride	_	_	I-Premise
559	levels	_	_	I-Premise
560	higher	_	_	I-Premise
561	than	_	_	I-Premise
562	14	_	_	I-Premise
563	.	_	_	I-Premise

564	69	_	_	I-Premise
565	mmol	_	_	I-Premise
566	/	_	_	I-Premise
567	L	_	_	I-Premise
568	(	_	_	I-Premise
569	1300	_	_	I-Premise
570	mg	_	_	I-Premise
571	/	_	_	I-Premise
572	dL	_	_	I-Premise
573	)	_	_	I-Premise
574	,	_	_	I-Premise
575	all	_	_	I-Premise
576	of	_	_	I-Premise
577	whom	_	_	I-Premise
578	were	_	_	I-Premise
579	taking	_	_	I-Premise
580	300	_	_	I-Premise
581	mg	_	_	I-Premise
582	/	_	_	I-Premise
583	m	_	_	I-Premise
584	(	_	_	I-Premise
585	2	_	_	I-Premise
586	)	_	_	I-Premise
587	or	_	_	I-Premise
588	more	_	_	I-Premise
589	of	_	_	I-Premise
590	oral	_	_	I-Premise
591	bexarotene	_	_	I-Premise
592	per	_	_	I-Premise
593	day	_	_	I-Premise
594	.	_	_	I-Premise

595	Bexarotene	_	_	B-Claim
596	(	_	_	I-Claim
597	Targretin	_	_	I-Claim
598	capsules	_	_	I-Claim
599	)	_	_	I-Claim
600	(	_	_	I-Claim
601	the	_	_	I-Claim
602	first	_	_	I-Claim
603	retinoid	_	_	I-Claim
604	X	_	_	I-Claim
605	receptor	_	_	I-Claim
606	-	_	_	I-Claim
607	selective	_	_	I-Claim
608	rexinoid	_	_	I-Claim
609	)	_	_	I-Claim
610	was	_	_	I-Claim
611	well	_	_	I-Claim
612	tolerated	_	_	I-Claim
613	and	_	_	I-Claim
614	effective	_	_	I-Claim
615	as	_	_	I-Claim
616	an	_	_	I-Claim
617	oral	_	_	I-Claim
618	treatment	_	_	I-Claim
619	for	_	_	I-Claim
620	15	_	_	I-Claim
621	(	_	_	I-Claim
622	54	_	_	I-Claim
623	%	_	_	I-Claim
624	)	_	_	I-Claim
625	of	_	_	I-Claim
626	28	_	_	I-Claim
627	patients	_	_	I-Claim
628	with	_	_	I-Claim
629	refractory	_	_	I-Claim
630	or	_	_	I-Claim
631	persistent	_	_	I-Claim
632	early	_	_	I-Claim
633	-	_	_	I-Claim
634	stage	_	_	I-Claim
635	cutaneous	_	_	I-Claim
636	T	_	_	I-Claim
637	-	_	_	I-Claim
638	cell	_	_	I-Claim
639	lymphoma	_	_	I-Claim
640	at	_	_	I-Claim
641	doses	_	_	I-Claim
642	of	_	_	I-Claim
643	300	_	_	I-Claim
644	mg	_	_	I-Claim
645	/	_	_	I-Claim
646	m	_	_	I-Claim
647	(	_	_	I-Claim
648	2	_	_	I-Claim
649	)	_	_	I-Claim
650	per	_	_	I-Claim
651	day	_	_	I-Claim
652	.	_	_	I-Claim

653	Hypertriglyceridemia	_	_	B-Claim
654	and	_	_	I-Claim
655	hypothyroidism	_	_	I-Claim
656	require	_	_	I-Claim
657	monitoring	_	_	I-Claim
658	but	_	_	I-Claim
659	are	_	_	I-Claim
660	reversible	_	_	I-Claim
661	and	_	_	I-Claim
662	manageable	_	_	I-Claim
663	with	_	_	I-Claim
664	concomitant	_	_	I-Claim
665	medication	_	_	I-Claim
666	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	sought	_	_	O
3	to	_	_	O
4	continue	_	_	O
5	research	_	_	O
6	on	_	_	O
7	psychosocial	_	_	O
8	interventions	_	_	O
9	for	_	_	O
10	patients	_	_	O
11	being	_	_	O
12	treated	_	_	O
13	with	_	_	O
14	radiation	_	_	O
15	therapy	_	_	O
16	across	_	_	O
17	multiple	_	_	O
18	centers	_	_	O
19	and	_	_	O
20	to	_	_	O
21	replicate	_	_	O
22	positive	_	_	O
23	findings	_	_	O
24	of	_	_	O
25	a	_	_	O
26	single	_	_	O
27	-	_	_	O
28	center	_	_	O
29	study	_	_	O
30	of	_	_	O
31	patients	_	_	O
32	being	_	_	O
33	treated	_	_	O
34	with	_	_	O
35	chemotherapy	_	_	O
36	.	_	_	O

37	The	_	_	O
38	primary	_	_	O
39	objective	_	_	O
40	of	_	_	O
41	this	_	_	O
42	study	_	_	O
43	was	_	_	O
44	to	_	_	O
45	determine	_	_	O
46	if	_	_	O
47	a	_	_	O
48	stress	_	_	O
49	management	_	_	O
50	intervention	_	_	O
51	was	_	_	O
52	effective	_	_	O
53	in	_	_	O
54	improving	_	_	O
55	quality	_	_	O
56	of	_	_	O
57	life	_	_	O
58	and	_	_	O
59	decreasing	_	_	O
60	psychological	_	_	O
61	distress	_	_	O
62	in	_	_	O
63	patients	_	_	O
64	undergoing	_	_	O
65	radiotherapy	_	_	O
66	for	_	_	O
67	cancer	_	_	O
68	.	_	_	O

69	A	_	_	O
70	total	_	_	O
71	of	_	_	O
72	310	_	_	O
73	patients	_	_	O
74	about	_	_	O
75	to	_	_	O
76	begin	_	_	O
77	radiotherapy	_	_	O
78	treatment	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	receive	_	_	O
84	usual	_	_	O
85	care	_	_	O
86	only	_	_	O
87	or	_	_	O
88	self	_	_	O
89	-	_	_	O
90	administered	_	_	O
91	stress	_	_	O
92	management	_	_	O
93	training	_	_	O
94	.	_	_	O

95	Quality	_	_	O
96	-	_	_	O
97	of	_	_	O
98	-	_	_	O
99	life	_	_	O
100	assessments	_	_	O
101	occurred	_	_	O
102	at	_	_	O
103	baseline	_	_	O
104	and	_	_	O
105	for	_	_	O
106	3	_	_	O
107	weeks	_	_	O
108	after	_	_	O
109	the	_	_	O
110	beginning	_	_	O
111	of	_	_	O
112	radiotherapy	_	_	O
113	treatment	_	_	O
114	.	_	_	O

115	Overall	_	_	B-Premise
116	,	_	_	I-Premise
117	patients	_	_	I-Premise
118	assigned	_	_	I-Premise
119	to	_	_	I-Premise
120	receive	_	_	I-Premise
121	stress	_	_	I-Premise
122	management	_	_	I-Premise
123	training	_	_	I-Premise
124	did	_	_	I-Premise
125	not	_	_	I-Premise
126	report	_	_	I-Premise
127	significantly	_	_	I-Premise
128	less	_	_	I-Premise
129	psychological	_	_	I-Premise
130	distress	_	_	I-Premise
131	on	_	_	I-Premise
132	the	_	_	I-Premise
133	Medical	_	_	I-Premise
134	Outcomes	_	_	I-Premise
135	Study	_	_	I-Premise
136	36	_	_	I-Premise
137	-	_	_	I-Premise
138	Item	_	_	I-Premise
139	Short	_	_	I-Premise
140	Form	_	_	I-Premise
141	(	_	_	I-Premise
142	SF	_	_	I-Premise
143	-	_	_	I-Premise
144	36	_	_	I-Premise
145	)	_	_	I-Premise
146	Mental	_	_	I-Premise
147	Component	_	_	I-Premise
148	Summary	_	_	I-Premise
149	Scale	_	_	I-Premise
150	than	_	_	I-Premise
151	did	_	_	I-Premise
152	those	_	_	I-Premise
153	assigned	_	_	I-Premise
154	to	_	_	I-Premise
155	usual	_	_	I-Premise
156	care	_	_	I-Premise
157	.	_	_	I-Premise

158	When	_	_	O
159	divided	_	_	O
160	into	_	_	O
161	subgroups	_	_	O
162	based	_	_	O
163	on	_	_	O
164	the	_	_	O
165	SF	_	_	O
166	-	_	_	O
167	36	_	_	O
168	Mental	_	_	O
169	Component	_	_	O
170	Summary	_	_	O
171	Scale	_	_	O
172	scores	_	_	O
173	immediately	_	_	O
174	after	_	_	O
175	their	_	_	O
176	first	_	_	O
177	radiotherapy	_	_	O
178	treatment	_	_	O
179	,	_	_	O
180	patients	_	_	B-Premise
181	with	_	_	I-Premise
182	above	_	_	I-Premise
183	-	_	_	I-Premise
184	average	_	_	I-Premise
185	levels	_	_	I-Premise
186	of	_	_	I-Premise
187	psychological	_	_	I-Premise
188	distress	_	_	I-Premise
189	(	_	_	I-Premise
190	scores	_	_	I-Premise
191	<	_	_	I-Premise
192	or	_	_	I-Premise
193	=	_	_	I-Premise
194	50	_	_	I-Premise
195	)	_	_	I-Premise
196	who	_	_	I-Premise
197	were	_	_	I-Premise
198	randomly	_	_	I-Premise
199	assigned	_	_	I-Premise
200	to	_	_	I-Premise
201	the	_	_	I-Premise
202	intervention	_	_	I-Premise
203	condition	_	_	I-Premise
204	reported	_	_	I-Premise
205	significant	_	_	I-Premise
206	improvement	_	_	I-Premise
207	in	_	_	I-Premise
208	their	_	_	I-Premise
209	distress	_	_	I-Premise
210	compared	_	_	I-Premise
211	with	_	_	I-Premise
212	those	_	_	I-Premise
213	assigned	_	_	I-Premise
214	to	_	_	I-Premise
215	usual	_	_	I-Premise
216	care	_	_	I-Premise
217	only	_	_	I-Premise
218	on	_	_	I-Premise
219	the	_	_	I-Premise
220	SF	_	_	I-Premise
221	-	_	_	I-Premise
222	36	_	_	I-Premise
223	Mental	_	_	I-Premise
224	Health	_	_	I-Premise
225	Subscale	_	_	I-Premise
226	and	_	_	I-Premise
227	the	_	_	I-Premise
228	Center	_	_	I-Premise
229	for	_	_	I-Premise
230	Epidemiologic	_	_	I-Premise
231	Studies	_	_	I-Premise
232	Depression	_	_	I-Premise
233	Scale	_	_	I-Premise
234	.	_	_	I-Premise

235	This	_	_	B-Claim
236	study	_	_	I-Claim
237	found	_	_	I-Claim
238	that	_	_	I-Claim
239	self	_	_	I-Claim
240	-	_	_	I-Claim
241	administered	_	_	I-Claim
242	stress	_	_	I-Claim
243	management	_	_	I-Claim
244	training	_	_	I-Claim
245	is	_	_	I-Claim
246	effective	_	_	I-Claim
247	only	_	_	I-Claim
248	in	_	_	I-Claim
249	those	_	_	I-Claim
250	radiotherapy	_	_	I-Claim
251	patients	_	_	I-Claim
252	with	_	_	I-Claim
253	initially	_	_	I-Claim
254	higher	_	_	I-Claim
255	levels	_	_	I-Claim
256	of	_	_	I-Claim
257	psychological	_	_	I-Claim
258	distress	_	_	I-Claim
259	.	_	_	I-Claim

260	Additional	_	_	B-Claim
261	research	_	_	I-Claim
262	should	_	_	I-Claim
263	examine	_	_	I-Claim
264	the	_	_	I-Claim
265	benefits	_	_	I-Claim
266	of	_	_	I-Claim
267	stress	_	_	I-Claim
268	management	_	_	I-Claim
269	training	_	_	I-Claim
270	targeted	_	_	I-Claim
271	specifically	_	_	I-Claim
272	to	_	_	I-Claim
273	patients	_	_	I-Claim
274	experiencing	_	_	I-Claim
275	heightened	_	_	I-Claim
276	distress	_	_	I-Claim
277	.	_	_	I-Claim


0	Exercise	_	_	O
1	improves	_	_	O
2	physical	_	_	O
3	functioning	_	_	O
4	and	_	_	O
5	symptom	_	_	O
6	management	_	_	O
7	during	_	_	O
8	breast	_	_	O
9	cancer	_	_	O
10	chemotherapy	_	_	O
11	,	_	_	O
12	but	_	_	O
13	the	_	_	O
14	effects	_	_	O
15	of	_	_	O
16	different	_	_	O
17	doses	_	_	O
18	and	_	_	O
19	types	_	_	O
20	of	_	_	O
21	exercise	_	_	O
22	are	_	_	O
23	unknown	_	_	O
24	.	_	_	O

25	A	_	_	O
26	multicenter	_	_	O
27	trial	_	_	O
28	in	_	_	O
29	Canada	_	_	O
30	randomized	_	_	O
31	301	_	_	O
32	breast	_	_	O
33	cancer	_	_	O
34	patients	_	_	O
35	to	_	_	O
36	thrice	_	_	O
37	-	_	_	O
38	weekly	_	_	O
39	supervised	_	_	O
40	exercise	_	_	O
41	during	_	_	O
42	chemotherapy	_	_	O
43	consisting	_	_	O
44	of	_	_	O
45	either	_	_	O
46	a	_	_	O
47	standard	_	_	O
48	dose	_	_	O
49	of	_	_	O
50	25	_	_	O
51	to	_	_	O
52	30	_	_	O
53	minutes	_	_	O
54	of	_	_	O
55	aerobic	_	_	O
56	exercise	_	_	O
57	(	_	_	O
58	STAN	_	_	O
59	;	_	_	O
60	n	_	_	O
61	=	_	_	O
62	96	_	_	O
63	)	_	_	O
64	,	_	_	O
65	a	_	_	O
66	higher	_	_	O
67	dose	_	_	O
68	of	_	_	O
69	50	_	_	O
70	to	_	_	O
71	60	_	_	O
72	minutes	_	_	O
73	of	_	_	O
74	aerobic	_	_	O
75	exercise	_	_	O
76	(	_	_	O
77	HIGH	_	_	O
78	;	_	_	O
79	n	_	_	O
80	=	_	_	O
81	101	_	_	O
82	)	_	_	O
83	,	_	_	O
84	or	_	_	O
85	a	_	_	O
86	combined	_	_	O
87	dose	_	_	O
88	of	_	_	O
89	50	_	_	O
90	to	_	_	O
91	60	_	_	O
92	minutes	_	_	O
93	of	_	_	O
94	aerobic	_	_	O
95	and	_	_	O
96	resistance	_	_	O
97	exercise	_	_	O
98	(	_	_	O
99	COMB	_	_	O
100	;	_	_	O
101	n	_	_	O
102	=	_	_	O
103	104	_	_	O
104	)	_	_	O
105	.	_	_	O

106	The	_	_	O
107	primary	_	_	O
108	endpoint	_	_	O
109	was	_	_	O
110	physical	_	_	O
111	functioning	_	_	O
112	assessed	_	_	O
113	by	_	_	O
114	the	_	_	O
115	Medical	_	_	O
116	Outcomes	_	_	O
117	Survey	_	_	O
118	-	_	_	O
119	Short	_	_	O
120	Form	_	_	O
121	(	_	_	O
122	SF	_	_	O
123	)	_	_	O
124	-	_	_	O
125	36	_	_	O
126	.	_	_	O

127	Secondary	_	_	O
128	endpoints	_	_	O
129	were	_	_	O
130	other	_	_	O
131	physical	_	_	O
132	functioning	_	_	O
133	scales	_	_	O
134	,	_	_	O
135	symptoms	_	_	O
136	,	_	_	O
137	fitness	_	_	O
138	,	_	_	O
139	and	_	_	O
140	chemotherapy	_	_	O
141	completion	_	_	O
142	.	_	_	O

143	All	_	_	O
144	statistical	_	_	O
145	tests	_	_	O
146	were	_	_	O
147	linear	_	_	O
148	mixed	_	_	O
149	model	_	_	O
150	analyses	_	_	O
151	,	_	_	O
152	and	_	_	O
153	the	_	_	O
154	P	_	_	O
155	values	_	_	O
156	were	_	_	O
157	two	_	_	O
158	-	_	_	O
159	sided	_	_	O
160	.	_	_	O

161	Follow	_	_	O
162	-	_	_	O
163	up	_	_	O
164	assessment	_	_	O
165	of	_	_	O
166	patient	_	_	O
167	-	_	_	O
168	reported	_	_	O
169	outcomes	_	_	O
170	was	_	_	O
171	99	_	_	O
172	.	_	_	O

173	0	_	_	O
174	%	_	_	O
175	.	_	_	O

176	Adjusted	_	_	B-Premise
177	linear	_	_	I-Premise
178	mixed	_	_	I-Premise
179	-	_	_	I-Premise
180	model	_	_	I-Premise
181	analyses	_	_	I-Premise
182	showed	_	_	I-Premise
183	that	_	_	I-Premise
184	neither	_	_	I-Premise
185	HIGH	_	_	I-Premise
186	(	_	_	I-Premise
187	+	_	_	I-Premise
188	0	_	_	I-Premise
189	.	_	_	I-Premise

190	8	_	_	I-Premise
191	;	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	confidence	_	_	I-Premise
195	interval	_	_	I-Premise
196	[	_	_	I-Premise
197	CI	_	_	I-Premise
198	]	_	_	I-Premise
199	=	_	_	I-Premise
200	-	_	_	I-Premise
201	0	_	_	I-Premise
202	.	_	_	I-Premise

203	8	_	_	I-Premise
204	to	_	_	I-Premise
205	2	_	_	I-Premise
206	.	_	_	I-Premise

207	4	_	_	I-Premise
208	;	_	_	I-Premise
209	P	_	_	I-Premise
210	=	_	_	I-Premise
211	.	_	_	I-Premise

212	30	_	_	I-Premise
213	)	_	_	I-Premise
214	nor	_	_	I-Premise
215	COMB	_	_	I-Premise
216	(	_	_	I-Premise
217	+	_	_	I-Premise
218	0	_	_	I-Premise
219	.	_	_	I-Premise

220	5	_	_	I-Premise
221	;	_	_	I-Premise
222	95	_	_	I-Premise
223	%	_	_	I-Premise
224	CI	_	_	I-Premise
225	=	_	_	I-Premise
226	-	_	_	I-Premise
227	1	_	_	I-Premise
228	.	_	_	I-Premise

229	1	_	_	I-Premise
230	to	_	_	I-Premise
231	2	_	_	I-Premise
232	.	_	_	I-Premise

233	1	_	_	I-Premise
234	;	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	.	_	_	I-Premise

238	52	_	_	I-Premise
239	]	_	_	I-Premise
240	were	_	_	I-Premise
241	superior	_	_	I-Premise
242	to	_	_	I-Premise
243	STAN	_	_	I-Premise
244	for	_	_	I-Premise
245	the	_	_	I-Premise
246	primary	_	_	I-Premise
247	outcome	_	_	I-Premise
248	.	_	_	I-Premise

249	In	_	_	B-Premise
250	secondary	_	_	I-Premise
251	analyses	_	_	I-Premise
252	not	_	_	I-Premise
253	adjusted	_	_	I-Premise
254	for	_	_	I-Premise
255	multiple	_	_	I-Premise
256	comparisons	_	_	I-Premise
257	,	_	_	I-Premise
258	HIGH	_	_	I-Premise
259	was	_	_	I-Premise
260	superior	_	_	I-Premise
261	to	_	_	I-Premise
262	STAN	_	_	I-Premise
263	for	_	_	I-Premise
264	the	_	_	I-Premise
265	SF	_	_	I-Premise
266	-	_	_	I-Premise
267	36	_	_	I-Premise
268	physical	_	_	I-Premise
269	component	_	_	I-Premise
270	summary	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	=	_	_	I-Premise
274	.	_	_	I-Premise

275	04	_	_	I-Premise
276	)	_	_	I-Premise
277	,	_	_	I-Premise
278	SF	_	_	I-Premise
279	-	_	_	I-Premise
280	36	_	_	I-Premise
281	bodily	_	_	I-Premise
282	pain	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	=	_	_	I-Premise
286	.	_	_	I-Premise

287	02	_	_	I-Premise
288	)	_	_	I-Premise
289	,	_	_	I-Premise
290	and	_	_	I-Premise
291	endocrine	_	_	I-Premise
292	symptoms	_	_	I-Premise
293	(	_	_	I-Premise
294	P	_	_	I-Premise
295	=	_	_	I-Premise
296	.	_	_	I-Premise

297	02	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	COMB	_	_	B-Premise
301	was	_	_	I-Premise
302	superior	_	_	I-Premise
303	to	_	_	I-Premise
304	STAN	_	_	I-Premise
305	for	_	_	I-Premise
306	endocrine	_	_	I-Premise
307	symptoms	_	_	I-Premise
308	(	_	_	I-Premise
309	P	_	_	I-Premise
310	=	_	_	I-Premise
311	.	_	_	I-Premise

312	009	_	_	I-Premise
313	)	_	_	I-Premise
314	and	_	_	I-Premise
315	superior	_	_	I-Premise
316	to	_	_	I-Premise
317	STAN	_	_	I-Premise
318	(	_	_	I-Premise
319	P	_	_	I-Premise
320	<	_	_	I-Premise
321	.	_	_	I-Premise

322	001	_	_	I-Premise
323	)	_	_	I-Premise
324	and	_	_	I-Premise
325	HIGH	_	_	I-Premise
326	(	_	_	I-Premise
327	P	_	_	I-Premise
328	<	_	_	I-Premise
329	.	_	_	I-Premise

330	001	_	_	I-Premise
331	)	_	_	I-Premise
332	for	_	_	I-Premise
333	muscular	_	_	I-Premise
334	strength	_	_	I-Premise
335	.	_	_	I-Premise

336	HIGH	_	_	B-Premise
337	was	_	_	I-Premise
338	superior	_	_	I-Premise
339	to	_	_	I-Premise
340	COMB	_	_	I-Premise
341	for	_	_	I-Premise
342	the	_	_	I-Premise
343	SF	_	_	I-Premise
344	-	_	_	I-Premise
345	36	_	_	I-Premise
346	bodily	_	_	I-Premise
347	pain	_	_	I-Premise
348	(	_	_	I-Premise
349	P	_	_	I-Premise
350	=	_	_	I-Premise
351	.	_	_	I-Premise

352	04	_	_	I-Premise
353	)	_	_	I-Premise
354	and	_	_	I-Premise
355	aerobic	_	_	I-Premise
356	fitness	_	_	I-Premise
357	(	_	_	I-Premise
358	P	_	_	I-Premise
359	=	_	_	I-Premise
360	.	_	_	I-Premise

361	03	_	_	I-Premise
362	)	_	_	I-Premise
363	.	_	_	I-Premise

364	No	_	_	B-Premise
365	differences	_	_	I-Premise
366	emerged	_	_	I-Premise
367	for	_	_	I-Premise
368	body	_	_	I-Premise
369	composition	_	_	I-Premise
370	or	_	_	I-Premise
371	chemotherapy	_	_	I-Premise
372	completion	_	_	I-Premise
373	.	_	_	I-Premise

374	A	_	_	B-Claim
375	higher	_	_	I-Claim
376	volume	_	_	I-Claim
377	of	_	_	I-Claim
378	aerobic	_	_	I-Claim
379	or	_	_	I-Claim
380	combined	_	_	I-Claim
381	exercise	_	_	I-Claim
382	is	_	_	I-Claim
383	achievable	_	_	I-Claim
384	and	_	_	I-Claim
385	safe	_	_	I-Claim
386	during	_	_	I-Claim
387	breast	_	_	I-Claim
388	cancer	_	_	I-Claim
389	chemotherapy	_	_	I-Claim
390	and	_	_	I-Claim
391	may	_	_	I-Claim
392	manage	_	_	I-Claim
393	declines	_	_	I-Claim
394	in	_	_	I-Claim
395	physical	_	_	I-Claim
396	functioning	_	_	I-Claim
397	and	_	_	I-Claim
398	worsening	_	_	I-Claim
399	symptoms	_	_	I-Claim
400	better	_	_	I-Claim
401	than	_	_	I-Claim
402	standard	_	_	I-Claim
403	volumes	_	_	I-Claim
404	.	_	_	I-Claim


0	Patients	_	_	O
1	undergoing	_	_	O
2	gastrectomy	_	_	O
3	because	_	_	O
4	of	_	_	O
5	stomach	_	_	O
6	cancer	_	_	O
7	often	_	_	O
8	face	_	_	O
9	weight	_	_	O
10	loss	_	_	O
11	in	_	_	O
12	the	_	_	O
13	perioperational	_	_	O
14	period	_	_	O
15	,	_	_	O
16	which	_	_	O
17	can	_	_	O
18	lead	_	_	O
19	to	_	_	O
20	malnutrition	_	_	O
21	and	_	_	O
22	negative	_	_	O
23	treatment	_	_	O
24	outcomes	_	_	O
25	.	_	_	O

26	The	_	_	O
27	purpose	_	_	O
28	of	_	_	O
29	this	_	_	O
30	study	_	_	O
31	was	_	_	O
32	to	_	_	O
33	develop	_	_	O
34	a	_	_	O
35	patient	_	_	O
36	participation	_	_	O
37	-	_	_	O
38	based	_	_	O
39	dietary	_	_	O
40	intervention	_	_	O
41	(	_	_	O
42	PPDI	_	_	O
43	)	_	_	O
44	and	_	_	O
45	evaluate	_	_	O
46	its	_	_	O
47	effects	_	_	O
48	on	_	_	O
49	patient	_	_	O
50	outcomes	_	_	O
51	.	_	_	O

52	This	_	_	O
53	was	_	_	O
54	a	_	_	O
55	prospective	_	_	O
56	,	_	_	O
57	randomized	_	_	O
58	controlled	_	_	O
59	trial	_	_	O
60	in	_	_	O
61	which	_	_	O
62	the	_	_	O
63	patients	_	_	O
64	were	_	_	O
65	recruited	_	_	O
66	in	_	_	O
67	a	_	_	O
68	cancer	_	_	O
69	center	_	_	O
70	in	_	_	O
71	South	_	_	O
72	Korea	_	_	O
73	.	_	_	O

74	The	_	_	O
75	participants	_	_	O
76	(	_	_	O
77	N	_	_	O
78	=	_	_	O
79	56	_	_	O
80	)	_	_	O
81	,	_	_	O
82	who	_	_	O
83	underwent	_	_	O
84	gastrectomy	_	_	O
85	with	_	_	O
86	stomach	_	_	O
87	cancer	_	_	O
88	stage	_	_	O
89	I	_	_	O
90	to	_	_	O
91	III	_	_	O
92	,	_	_	O
93	were	_	_	O
94	randomly	_	_	O
95	assigned	_	_	O
96	into	_	_	O
97	either	_	_	O
98	the	_	_	O
99	experimental	_	_	O
100	or	_	_	O
101	the	_	_	O
102	control	_	_	O
103	group	_	_	O
104	.	_	_	O

105	The	_	_	O
106	PPDI	_	_	O
107	,	_	_	O
108	which	_	_	O
109	was	_	_	O
110	given	_	_	O
111	on	_	_	O
112	the	_	_	O
113	day	_	_	O
114	before	_	_	O
115	the	_	_	O
116	hospital	_	_	O
117	discharge	_	_	O
118	,	_	_	O
119	comprised	_	_	O
120	2	_	_	O
121	face	_	_	O
122	-	_	_	O
123	to	_	_	O
124	-	_	_	O
125	face	_	_	O
126	and	_	_	O
127	2	_	_	O
128	telephone	_	_	O
129	interventions	_	_	O
130	.	_	_	O

131	The	_	_	O
132	outcome	_	_	O
133	variables	_	_	O
134	included	_	_	O
135	body	_	_	O
136	weight	_	_	O
137	,	_	_	O
138	body	_	_	O
139	mass	_	_	O
140	index	_	_	O
141	,	_	_	O
142	muscle	_	_	O
143	mass	_	_	O
144	,	_	_	O
145	the	_	_	O
146	Patient	_	_	O
147	-	_	_	O
148	Generated	_	_	O
149	Subjective	_	_	O
150	Global	_	_	O
151	Assessment	_	_	O
152	,	_	_	O
153	Dietary	_	_	O
154	Symptom	_	_	O
155	Scale	_	_	O
156	,	_	_	O
157	Functional	_	_	O
158	Assessment	_	_	O
159	Cancer	_	_	O
160	Therapy	_	_	O
161	-	_	_	O
162	General	_	_	O
163	,	_	_	O
164	Karnofsky	_	_	O
165	Performance	_	_	O
166	Status	_	_	O
167	,	_	_	O
168	Adherence	_	_	O
169	to	_	_	O
170	Dietary	_	_	O
171	Guidelines	_	_	O
172	Scale	_	_	O
173	,	_	_	O
174	Scale	_	_	O
175	of	_	_	O
176	Dietary	_	_	O
177	Knowledge	_	_	O
178	,	_	_	O
179	Patient	_	_	O
180	Satisfaction	_	_	O
181	Scale	_	_	O
182	,	_	_	O
183	and	_	_	O
184	a	_	_	O
185	3	_	_	O
186	-	_	_	O
187	day	_	_	O
188	food	_	_	O
189	diary	_	_	O
190	.	_	_	O

191	Participants	_	_	B-Premise
192	in	_	_	I-Premise
193	the	_	_	I-Premise
194	PPDI	_	_	I-Premise
195	intervention	_	_	I-Premise
196	demonstrated	_	_	I-Premise
197	significant	_	_	I-Premise
198	(	_	_	I-Premise
199	P	_	_	I-Premise
200	<	_	_	I-Premise
201	.	_	_	I-Premise

202	05	_	_	I-Premise
203	)	_	_	I-Premise
204	reductions	_	_	I-Premise
205	in	_	_	I-Premise
206	adverse	_	_	I-Premise
207	dietary	_	_	I-Premise
208	symptoms	_	_	I-Premise
209	and	_	_	I-Premise
210	significant	_	_	I-Premise
211	improvements	_	_	I-Premise
212	(	_	_	I-Premise
213	P	_	_	I-Premise
214	<	_	_	I-Premise
215	.	_	_	I-Premise

216	05	_	_	I-Premise
217	)	_	_	I-Premise
218	in	_	_	I-Premise
219	functional	_	_	I-Premise
220	status	_	_	I-Premise
221	,	_	_	I-Premise
222	performance	_	_	I-Premise
223	status	_	_	I-Premise
224	,	_	_	I-Premise
225	dietary	_	_	I-Premise
226	intake	_	_	I-Premise
227	,	_	_	I-Premise
228	adherence	_	_	I-Premise
229	to	_	_	I-Premise
230	dietary	_	_	I-Premise
231	guidelines	_	_	I-Premise
232	,	_	_	I-Premise
233	dietary	_	_	I-Premise
234	knowledge	_	_	I-Premise
235	,	_	_	I-Premise
236	and	_	_	I-Premise
237	satisfaction	_	_	I-Premise
238	with	_	_	I-Premise
239	the	_	_	I-Premise
240	intervention	_	_	I-Premise
241	as	_	_	I-Premise
242	compared	_	_	I-Premise
243	with	_	_	I-Premise
244	the	_	_	I-Premise
245	control	_	_	I-Premise
246	group	_	_	I-Premise
247	over	_	_	I-Premise
248	time	_	_	I-Premise
249	.	_	_	I-Premise

250	The	_	_	B-Claim
251	PPDI	_	_	I-Claim
252	was	_	_	I-Claim
253	an	_	_	I-Claim
254	effective	_	_	I-Claim
255	dietary	_	_	I-Claim
256	intervention	_	_	I-Claim
257	for	_	_	I-Claim
258	patients	_	_	I-Claim
259	undergoing	_	_	I-Claim
260	a	_	_	I-Claim
261	gastrectomy	_	_	I-Claim
262	for	_	_	I-Claim
263	gastric	_	_	I-Claim
264	cancer	_	_	I-Claim
265	and	_	_	I-Claim
266	deserves	_	_	I-Claim
267	additional	_	_	I-Claim
268	study	_	_	I-Claim
269	in	_	_	I-Claim
270	other	_	_	I-Claim
271	populations	_	_	I-Claim
272	of	_	_	I-Claim
273	patients	_	_	I-Claim
274	.	_	_	I-Claim

275	Incorporating	_	_	B-Claim
276	patients	_	_	I-Claim
277	'	_	_	I-Claim
278	perspectives	_	_	I-Claim
279	into	_	_	I-Claim
280	a	_	_	I-Claim
281	dietary	_	_	I-Claim
282	intervention	_	_	I-Claim
283	after	_	_	I-Claim
284	gastrectomy	_	_	I-Claim
285	for	_	_	I-Claim
286	gastric	_	_	I-Claim
287	cancer	_	_	I-Claim
288	may	_	_	I-Claim
289	contribute	_	_	I-Claim
290	to	_	_	I-Claim
291	improved	_	_	I-Claim
292	patient	_	_	I-Claim
293	outcomes	_	_	I-Claim
294	and	_	_	I-Claim
295	quality	_	_	I-Claim
296	care	_	_	I-Claim
297	.	_	_	I-Claim


0	Fatigue	_	_	B-Claim
1	has	_	_	I-Claim
2	a	_	_	I-Claim
3	significant	_	_	I-Claim
4	impact	_	_	I-Claim
5	on	_	_	I-Claim
6	the	_	_	I-Claim
7	quality	_	_	I-Claim
8	of	_	_	I-Claim
9	life	_	_	I-Claim
10	(	_	_	I-Claim
11	QOL	_	_	I-Claim
12	)	_	_	I-Claim
13	of	_	_	I-Claim
14	cancer	_	_	I-Claim
15	patients	_	_	I-Claim
16	.	_	_	I-Claim

17	Recent	_	_	B-Claim
18	research	_	_	I-Claim
19	has	_	_	I-Claim
20	suggested	_	_	I-Claim
21	that	_	_	I-Claim
22	physical	_	_	I-Claim
23	activity	_	_	I-Claim
24	can	_	_	I-Claim
25	reduce	_	_	I-Claim
26	fatigue	_	_	I-Claim
27	in	_	_	I-Claim
28	patients	_	_	I-Claim
29	receiving	_	_	I-Claim
30	active	_	_	I-Claim
31	cancer	_	_	I-Claim
32	treatment	_	_	I-Claim
33	.	_	_	I-Claim

34	In	_	_	O
35	this	_	_	O
36	project	_	_	O
37	,	_	_	O
38	we	_	_	O
39	examined	_	_	O
40	the	_	_	O
41	impact	_	_	O
42	that	_	_	O
43	participation	_	_	O
44	in	_	_	O
45	a	_	_	O
46	randomized	_	_	O
47	controlled	_	_	O
48	trial	_	_	O
49	of	_	_	O
50	a	_	_	O
51	multidisciplinary	_	_	O
52	intervention	_	_	O
53	designed	_	_	O
54	to	_	_	O
55	impact	_	_	O
56	overall	_	_	O
57	QOL	_	_	O
58	had	_	_	O
59	on	_	_	O
60	fatigue	_	_	O
61	for	_	_	O
62	advanced	_	_	O
63	cancer	_	_	O
64	patients	_	_	O
65	actively	_	_	O
66	receiving	_	_	O
67	treatment	_	_	O
68	.	_	_	O

69	Patients	_	_	O
70	with	_	_	O
71	newly	_	_	O
72	diagnosed	_	_	O
73	cancer	_	_	O
74	were	_	_	O
75	randomly	_	_	O
76	assigned	_	_	O
77	to	_	_	O
78	an	_	_	O
79	8	_	_	O
80	-	_	_	O
81	session	_	_	O
82	structured	_	_	O
83	multidisciplinary	_	_	O
84	intervention	_	_	O
85	or	_	_	O
86	a	_	_	O
87	standard	_	_	O
88	-	_	_	O
89	care	_	_	O
90	arm	_	_	O
91	at	_	_	O
92	the	_	_	O
93	beginning	_	_	O
94	of	_	_	O
95	their	_	_	O
96	course	_	_	O
97	of	_	_	O
98	radiotherapy	_	_	O
99	(	_	_	O
100	RT	_	_	O
101	)	_	_	O
102	designed	_	_	O
103	to	_	_	O
104	impact	_	_	O
105	QOL	_	_	O
106	.	_	_	O

107	Ninety	_	_	O
108	-	_	_	O
109	minute	_	_	O
110	sessions	_	_	O
111	were	_	_	O
112	led	_	_	O
113	by	_	_	O
114	either	_	_	O
115	a	_	_	O
116	psychiatrist	_	_	O
117	or	_	_	O
118	psychologist	_	_	O
119	,	_	_	O
120	collaborating	_	_	O
121	with	_	_	O
122	a	_	_	O
123	nurse	_	_	O
124	,	_	_	O
125	physical	_	_	O
126	therapist	_	_	O
127	,	_	_	O
128	chaplain	_	_	O
129	,	_	_	O
130	or	_	_	O
131	social	_	_	O
132	worker	_	_	O
133	,	_	_	O
134	depending	_	_	O
135	on	_	_	O
136	the	_	_	O
137	session	_	_	O
138	'	_	_	O
139	s	_	_	O
140	theme	_	_	O
141	.	_	_	O

142	The	_	_	O
143	fatigue	_	_	O
144	assessments	_	_	O
145	used	_	_	O
146	in	_	_	O
147	this	_	_	O
148	trial	_	_	O
149	included	_	_	O
150	the	_	_	O
151	Linear	_	_	O
152	Analogue	_	_	O
153	Self	_	_	O
154	Assessment	_	_	O
155	(	_	_	O
156	LASA	_	_	O
157	)	_	_	O
158	,	_	_	O
159	the	_	_	O
160	Profile	_	_	O
161	of	_	_	O
162	Mood	_	_	O
163	States	_	_	O
164	(	_	_	O
165	POMS	_	_	O
166	)	_	_	O
167	,	_	_	O
168	Spielberger	_	_	O
169	'	_	_	O
170	s	_	_	O
171	State	_	_	O
172	-	_	_	O
173	Trait	_	_	O
174	Anxiety	_	_	O
175	Inventory	_	_	O
176	(	_	_	O
177	STAI	_	_	O
178	)	_	_	O
179	,	_	_	O
180	and	_	_	O
181	the	_	_	O
182	Symptom	_	_	O
183	Distress	_	_	O
184	Scale	_	_	O
185	(	_	_	O
186	SDS	_	_	O
187	)	_	_	O
188	.	_	_	O

189	There	_	_	O
190	were	_	_	O
191	115	_	_	O
192	participants	_	_	O
193	enrolled	_	_	O
194	and	_	_	O
195	the	_	_	O
196	2	_	_	O
197	randomization	_	_	O
198	arms	_	_	O
199	were	_	_	O
200	well	_	_	O
201	balanced	_	_	O
202	in	_	_	O
203	terms	_	_	O
204	of	_	_	O
205	baseline	_	_	O
206	characteristics	_	_	O
207	and	_	_	O
208	treatment	_	_	O
209	received	_	_	O
210	except	_	_	O
211	for	_	_	O
212	increased	_	_	O
213	commuting	_	_	O
214	distance	_	_	O
215	for	_	_	O
216	the	_	_	O
217	patients	_	_	O
218	in	_	_	O
219	the	_	_	O
220	intervention	_	_	O
221	arm	_	_	O
222	(	_	_	O
223	P	_	_	O
224	=	_	_	O
225	0	_	_	O
226	.	_	_	O

227	042	_	_	O
228	)	_	_	O
229	.	_	_	O

230	Most	_	_	B-Premise
231	of	_	_	I-Premise
232	scores	_	_	I-Premise
233	indicated	_	_	I-Premise
234	less	_	_	I-Premise
235	fatigue	_	_	I-Premise
236	(	_	_	I-Premise
237	higher	_	_	I-Premise
238	score	_	_	I-Premise
239	)	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	standard	_	_	I-Premise
243	treatment	_	_	I-Premise
244	group	_	_	I-Premise
245	,	_	_	I-Premise
246	but	_	_	B-Premise
247	there	_	_	I-Premise
248	were	_	_	I-Premise
249	no	_	_	I-Premise
250	statistically	_	_	I-Premise
251	significant	_	_	I-Premise
252	differences	_	_	I-Premise
253	found	_	_	I-Premise
254	at	_	_	I-Premise
255	baseline	_	_	I-Premise
256	and	_	_	I-Premise
257	weeks	_	_	I-Premise
258	4	_	_	I-Premise
259	,	_	_	I-Premise
260	8	_	_	I-Premise
261	,	_	_	I-Premise
262	and	_	_	I-Premise
263	27	_	_	I-Premise
264	except	_	_	I-Premise
265	for	_	_	I-Premise
266	SDS	_	_	I-Premise
267	at	_	_	I-Premise
268	week	_	_	I-Premise
269	8	_	_	I-Premise
270	(	_	_	I-Premise
271	P	_	_	I-Premise
272	=	_	_	I-Premise
273	0	_	_	I-Premise
274	.	_	_	I-Premise

275	018	_	_	I-Premise
276	)	_	_	I-Premise
277	with	_	_	I-Premise
278	less	_	_	I-Premise
279	patients	_	_	I-Premise
280	reporting	_	_	I-Premise
281	significant	_	_	I-Premise
282	fatigue	_	_	I-Premise
283	in	_	_	I-Premise
284	the	_	_	I-Premise
285	standard	_	_	I-Premise
286	treatment	_	_	I-Premise
287	arm	_	_	I-Premise
288	.	_	_	I-Premise

289	For	_	_	B-Premise
290	the	_	_	I-Premise
291	entire	_	_	I-Premise
292	participant	_	_	I-Premise
293	population	_	_	I-Premise
294	,	_	_	I-Premise
295	fatigue	_	_	I-Premise
296	levels	_	_	I-Premise
297	initially	_	_	I-Premise
298	worsened	_	_	I-Premise
299	with	_	_	I-Premise
300	radiotherapy	_	_	I-Premise
301	,	_	_	I-Premise
302	stabilized	_	_	I-Premise
303	at	_	_	I-Premise
304	week	_	_	I-Premise
305	8	_	_	I-Premise
306	,	_	_	I-Premise
307	and	_	_	I-Premise
308	returned	_	_	I-Premise
309	to	_	_	I-Premise
310	baseline	_	_	I-Premise
311	by	_	_	I-Premise
312	week	_	_	I-Premise
313	27	_	_	I-Premise
314	.	_	_	I-Premise

315	Disease	_	_	B-Premise
316	site	_	_	I-Premise
317	,	_	_	I-Premise
318	chemotherapy	_	_	I-Premise
319	use	_	_	I-Premise
320	,	_	_	I-Premise
321	and	_	_	I-Premise
322	radiotherapy	_	_	I-Premise
323	dose	_	_	I-Premise
324	did	_	_	I-Premise
325	not	_	_	I-Premise
326	have	_	_	I-Premise
327	a	_	_	I-Premise
328	significant	_	_	I-Premise
329	impact	_	_	I-Premise
330	on	_	_	I-Premise
331	fatigue	_	_	I-Premise
332	levels	_	_	I-Premise
333	.	_	_	I-Premise

334	Radiotherapy	_	_	B-Premise
335	initially	_	_	I-Premise
336	caused	_	_	I-Premise
337	a	_	_	I-Premise
338	worsening	_	_	I-Premise
339	of	_	_	I-Premise
340	fatigue	_	_	I-Premise
341	but	_	_	I-Premise
342	with	_	_	I-Premise
343	time	_	_	I-Premise
344	fatigue	_	_	I-Premise
345	levels	_	_	I-Premise
346	returned	_	_	I-Premise
347	to	_	_	I-Premise
348	baseline	_	_	I-Premise
349	.	_	_	O

350	Clinically	_	_	B-Claim
351	,	_	_	I-Claim
352	this	_	_	I-Claim
353	structured	_	_	I-Claim
354	multidisciplinary	_	_	I-Claim
355	intervention	_	_	I-Claim
356	had	_	_	I-Claim
357	no	_	_	I-Claim
358	impact	_	_	I-Claim
359	on	_	_	I-Claim
360	fatigue	_	_	I-Claim
361	,	_	_	I-Claim
362	and	_	_	O
363	there	_	_	B-Claim
364	was	_	_	I-Claim
365	the	_	_	I-Claim
366	suggestion	_	_	I-Claim
367	the	_	_	I-Claim
368	multiple	_	_	I-Claim
369	sessions	_	_	I-Claim
370	may	_	_	I-Claim
371	have	_	_	I-Claim
372	contributed	_	_	I-Claim
373	to	_	_	I-Claim
374	worse	_	_	I-Claim
375	fatigue	_	_	I-Claim
376	during	_	_	I-Claim
377	active	_	_	I-Claim
378	cancer	_	_	I-Claim
379	treatment	_	_	I-Claim
380	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	if	_	_	O
3	raising	_	_	O
4	baseline	_	_	O
5	and	_	_	O
6	maintaining	_	_	O
7	hemoglobin	_	_	O
8	(	_	_	O
9	Hb	_	_	O
10	)	_	_	O
11	levels	_	_	O
12	with	_	_	O
13	red	_	_	O
14	blood	_	_	O
15	cell	_	_	O
16	(	_	_	O
17	RBC	_	_	O
18	)	_	_	O
19	transfusion	_	_	O
20	could	_	_	O
21	improve	_	_	O
22	the	_	_	O
23	outcomes	_	_	O
24	of	_	_	O
25	chemotherapy	_	_	O
26	for	_	_	O
27	advanced	_	_	O
28	gastric	_	_	O
29	cancer	_	_	O
30	(	_	_	O
31	AGC	_	_	O
32	)	_	_	O
33	.	_	_	O

34	Patients	_	_	O
35	were	_	_	O
36	randomized	_	_	O
37	to	_	_	O
38	receive	_	_	O
39	RBC	_	_	O
40	transfusion	_	_	O
41	to	_	_	O
42	maintain	_	_	O
43	their	_	_	O
44	Hb	_	_	O
45	levels	_	_	O
46	>	_	_	O
47	or	_	_	O
48	=	_	_	O
49	10	_	_	O
50	g	_	_	O
51	/	_	_	O
52	dl	_	_	O
53	(	_	_	O
54	arm	_	_	O
55	1	_	_	O
56	)	_	_	O
57	or	_	_	O
58	>	_	_	O
59	or	_	_	O
60	=	_	_	O
61	12	_	_	O
62	(	_	_	O
63	arm	_	_	O
64	2	_	_	O
65	)	_	_	O
66	before	_	_	O
67	the	_	_	O
68	start	_	_	O
69	of	_	_	O
70	their	_	_	O
71	5	_	_	O
72	-	_	_	O
73	fluorouracil	_	_	O
74	-	_	_	O
75	based	_	_	O
76	first	_	_	O
77	-	_	_	O
78	line	_	_	O
79	chemotherapy	_	_	O
80	.	_	_	O

81	Objective	_	_	O
82	response	_	_	O
83	,	_	_	O
84	KPS	_	_	O
85	and	_	_	O
86	quality	_	_	O
87	of	_	_	O
88	life	_	_	O
89	(	_	_	O
90	QOL	_	_	O
91	)	_	_	O
92	data	_	_	O
93	were	_	_	O
94	measured	_	_	O
95	.	_	_	O

96	For	_	_	O
97	87	_	_	O
98	patients	_	_	O
99	enrolled	_	_	O
100	,	_	_	O
101	mean	_	_	O
102	baseline	_	_	O
103	Hb	_	_	O
104	was	_	_	O
105	10	_	_	O
106	.	_	_	O

107	1	_	_	O
108	g	_	_	O
109	/	_	_	O
110	dl	_	_	O
111	,	_	_	O
112	and	_	_	O
113	54	_	_	O
114	patients	_	_	O
115	received	_	_	O
116	RBC	_	_	O
117	prior	_	_	O
118	to	_	_	O
119	chemotherapy	_	_	O
120	initiation	_	_	O
121	.	_	_	O

122	Despite	_	_	O
123	transfusion	_	_	O
124	,	_	_	O
125	we	_	_	O
126	failed	_	_	O
127	to	_	_	O
128	maintain	_	_	O
129	the	_	_	O
130	Hb	_	_	O
131	level	_	_	O
132	above	_	_	O
133	the	_	_	O
134	predefined	_	_	O
135	target	_	_	O
136	range	_	_	O
137	.	_	_	O

138	Eighteen	_	_	B-Premise
139	patients	_	_	I-Premise
140	experienced	_	_	I-Premise
141	brief	_	_	I-Premise
142	and	_	_	I-Premise
143	reversible	_	_	I-Premise
144	adverse	_	_	I-Premise
145	events	_	_	I-Premise
146	during	_	_	I-Premise
147	transfusion	_	_	I-Premise
148	,	_	_	I-Premise
149	including	_	_	I-Premise
150	two	_	_	I-Premise
151	patients	_	_	I-Premise
152	with	_	_	I-Premise
153	acute	_	_	I-Premise
154	pulmonary	_	_	I-Premise
155	edema	_	_	I-Premise
156	.	_	_	I-Premise

157	KPS	_	_	B-Premise
158	was	_	_	I-Premise
159	improved	_	_	I-Premise
160	from	_	_	I-Premise
161	baseline	_	_	I-Premise
162	to	_	_	I-Premise
163	post	_	_	I-Premise
164	-	_	_	I-Premise
165	chemotherapy	_	_	I-Premise
166	in	_	_	I-Premise
167	both	_	_	I-Premise
168	arms	_	_	I-Premise
169	.	_	_	I-Premise

170	QOL	_	_	B-Premise
171	data	_	_	I-Premise
172	showed	_	_	I-Premise
173	improvement	_	_	I-Premise
174	in	_	_	I-Premise
175	some	_	_	I-Premise
176	symptom	_	_	I-Premise
177	scores	_	_	I-Premise
178	,	_	_	I-Premise
179	but	_	_	B-Premise
180	there	_	_	I-Premise
181	was	_	_	I-Premise
182	no	_	_	I-Premise
183	difference	_	_	I-Premise
184	in	_	_	I-Premise
185	the	_	_	I-Premise
186	QOL	_	_	I-Premise
187	scores	_	_	I-Premise
188	between	_	_	I-Premise
189	the	_	_	I-Premise
190	two	_	_	I-Premise
191	arms	_	_	I-Premise
192	at	_	_	I-Premise
193	baseline	_	_	I-Premise
194	and	_	_	I-Premise
195	all	_	_	I-Premise
196	four	_	_	I-Premise
197	cycles	_	_	I-Premise
198	of	_	_	I-Premise
199	treatment	_	_	I-Premise
200	.	_	_	I-Premise

201	Similar	_	_	B-Premise
202	response	_	_	I-Premise
203	rates	_	_	I-Premise
204	were	_	_	I-Premise
205	observed	_	_	I-Premise
206	in	_	_	I-Premise
207	both	_	_	I-Premise
208	arms	_	_	I-Premise
209	(	_	_	I-Premise
210	arm	_	_	I-Premise
211	1	_	_	I-Premise
212	,	_	_	I-Premise
213	30	_	_	I-Premise
214	%	_	_	I-Premise
215	;	_	_	I-Premise
216	arm	_	_	I-Premise
217	2	_	_	I-Premise
218	,	_	_	I-Premise
219	35	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	Both	_	_	B-Premise
224	arms	_	_	I-Premise
225	showed	_	_	I-Premise
226	similar	_	_	I-Premise
227	chemotherapy	_	_	I-Premise
228	duration	_	_	I-Premise
229	(	_	_	I-Premise
230	3	_	_	I-Premise
231	.	_	_	I-Premise

232	8	_	_	I-Premise
233	and	_	_	I-Premise
234	4	_	_	I-Premise
235	.	_	_	I-Premise

236	1	_	_	I-Premise
237	months	_	_	I-Premise
238	,	_	_	I-Premise
239	respectively	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	progression	_	_	I-Premise
243	-	_	_	I-Premise
244	free	_	_	I-Premise
245	survival	_	_	I-Premise
246	(	_	_	I-Premise
247	4	_	_	I-Premise
248	.	_	_	I-Premise

249	0	_	_	I-Premise
250	and	_	_	I-Premise
251	4	_	_	I-Premise
252	.	_	_	I-Premise

253	1	_	_	I-Premise
254	months	_	_	I-Premise
255	)	_	_	I-Premise
256	and	_	_	I-Premise
257	overall	_	_	I-Premise
258	survival	_	_	I-Premise
259	(	_	_	I-Premise
260	9	_	_	I-Premise
261	.	_	_	I-Premise

262	9	_	_	I-Premise
263	and	_	_	I-Premise
264	9	_	_	I-Premise
265	.	_	_	I-Premise

266	3	_	_	I-Premise
267	months	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	Red	_	_	B-Claim
271	blood	_	_	I-Claim
272	cell	_	_	I-Claim
273	transfusion	_	_	I-Claim
274	achieving	_	_	I-Claim
275	Hb	_	_	I-Claim
276	level	_	_	I-Claim
277	above	_	_	I-Claim
278	10	_	_	I-Claim
279	g	_	_	I-Claim
280	/	_	_	I-Claim
281	dl	_	_	I-Claim
282	might	_	_	I-Claim
283	contribute	_	_	I-Claim
284	to	_	_	I-Claim
285	the	_	_	I-Claim
286	improvement	_	_	I-Claim
287	of	_	_	I-Claim
288	the	_	_	I-Claim
289	KPS	_	_	I-Claim
290	and	_	_	I-Claim
291	QOL	_	_	I-Claim
292	seen	_	_	I-Claim
293	in	_	_	I-Claim
294	patients	_	_	I-Claim
295	with	_	_	I-Claim
296	AGC	_	_	I-Claim
297	.	_	_	I-Claim

298	The	_	_	B-Claim
299	observation	_	_	I-Claim
300	of	_	_	I-Claim
301	equivalent	_	_	I-Claim
302	outcomes	_	_	I-Claim
303	at	_	_	I-Claim
304	the	_	_	I-Claim
305	two	_	_	I-Claim
306	target	_	_	I-Claim
307	Hb	_	_	I-Claim
308	levels	_	_	I-Claim
309	supports	_	_	I-Claim
310	the	_	_	I-Claim
311	feasibility	_	_	I-Claim
312	of	_	_	I-Claim
313	anemia	_	_	I-Claim
314	correction	_	_	I-Claim
315	to	_	_	I-Claim
316	Hb	_	_	I-Claim
317	10	_	_	I-Claim
318	g	_	_	I-Claim
319	/	_	_	I-Claim
320	dl	_	_	I-Claim
321	,	_	_	I-Claim
322	which	_	_	I-Claim
323	merits	_	_	I-Claim
324	further	_	_	I-Claim
325	evaluation	_	_	I-Claim
326	.	_	_	O


0	Advice	_	_	B-Claim
1	to	_	_	I-Claim
2	rest	_	_	I-Claim
3	and	_	_	I-Claim
4	take	_	_	I-Claim
5	things	_	_	I-Claim
6	easy	_	_	I-Claim
7	if	_	_	I-Claim
8	patients	_	_	I-Claim
9	become	_	_	I-Claim
10	fatigued	_	_	I-Claim
11	during	_	_	I-Claim
12	radiotherapy	_	_	I-Claim
13	may	_	_	I-Claim
14	be	_	_	I-Claim
15	detrimental	_	_	I-Claim
16	.	_	_	I-Claim

17	Aerobic	_	_	B-Premise
18	walking	_	_	I-Premise
19	improves	_	_	I-Premise
20	physical	_	_	I-Premise
21	functioning	_	_	I-Premise
22	and	_	_	I-Premise
23	has	_	_	I-Premise
24	been	_	_	I-Premise
25	an	_	_	I-Premise
26	intervention	_	_	I-Premise
27	for	_	_	I-Premise
28	chemotherapy	_	_	I-Premise
29	-	_	_	I-Premise
30	related	_	_	I-Premise
31	fatigue	_	_	I-Premise
32	.	_	_	I-Premise

33	A	_	_	O
34	prospective	_	_	O
35	,	_	_	O
36	randomized	_	_	O
37	,	_	_	O
38	controlled	_	_	O
39	trial	_	_	O
40	was	_	_	O
41	performed	_	_	O
42	to	_	_	O
43	determine	_	_	O
44	whether	_	_	O
45	aerobic	_	_	O
46	exercise	_	_	O
47	would	_	_	O
48	reduce	_	_	O
49	the	_	_	O
50	incidence	_	_	O
51	of	_	_	O
52	fatigue	_	_	O
53	and	_	_	O
54	prevent	_	_	O
55	deterioration	_	_	O
56	in	_	_	O
57	physical	_	_	O
58	functioning	_	_	O
59	during	_	_	O
60	radiotherapy	_	_	O
61	for	_	_	O
62	localized	_	_	O
63	prostate	_	_	O
64	carcinoma	_	_	O
65	.	_	_	O

66	Sixty	_	_	O
67	-	_	_	O
68	six	_	_	O
69	men	_	_	O
70	were	_	_	O
71	randomized	_	_	O
72	before	_	_	O
73	they	_	_	O
74	received	_	_	O
75	radical	_	_	O
76	radiotherapy	_	_	O
77	for	_	_	O
78	localized	_	_	O
79	prostate	_	_	O
80	carcinoma	_	_	O
81	,	_	_	O
82	with	_	_	O
83	33	_	_	O
84	men	_	_	O
85	randomized	_	_	O
86	to	_	_	O
87	an	_	_	O
88	exercise	_	_	O
89	group	_	_	O
90	and	_	_	O
91	33	_	_	O
92	men	_	_	O
93	randomized	_	_	O
94	to	_	_	O
95	a	_	_	O
96	control	_	_	O
97	group	_	_	O
98	.	_	_	O

99	Outcome	_	_	O
100	measures	_	_	O
101	were	_	_	O
102	fatigue	_	_	O
103	and	_	_	O
104	distance	_	_	O
105	walked	_	_	O
106	in	_	_	O
107	a	_	_	O
108	modified	_	_	O
109	shuttle	_	_	O
110	test	_	_	O
111	before	_	_	O
112	and	_	_	O
113	after	_	_	O
114	radiotherapy	_	_	O
115	.	_	_	O

116	There	_	_	B-Premise
117	were	_	_	I-Premise
118	no	_	_	I-Premise
119	significant	_	_	I-Premise
120	between	_	_	I-Premise
121	group	_	_	I-Premise
122	differences	_	_	I-Premise
123	noted	_	_	I-Premise
124	with	_	_	I-Premise
125	regard	_	_	I-Premise
126	to	_	_	I-Premise
127	fatigue	_	_	I-Premise
128	scores	_	_	I-Premise
129	at	_	_	I-Premise
130	baseline	_	_	I-Premise
131	(	_	_	I-Premise
132	P	_	_	I-Premise
133	=	_	_	I-Premise
134	0	_	_	I-Premise
135	.	_	_	I-Premise

136	55	_	_	I-Premise
137	)	_	_	I-Premise
138	or	_	_	I-Premise
139	after	_	_	I-Premise
140	4	_	_	I-Premise
141	weeks	_	_	I-Premise
142	of	_	_	I-Premise
143	radiotherapy	_	_	I-Premise
144	(	_	_	I-Premise
145	P	_	_	I-Premise
146	=	_	_	I-Premise
147	0	_	_	I-Premise
148	.	_	_	I-Premise

149	18	_	_	I-Premise
150	)	_	_	I-Premise
151	.	_	_	I-Premise

152	Men	_	_	B-Premise
153	in	_	_	I-Premise
154	the	_	_	I-Premise
155	control	_	_	I-Premise
156	group	_	_	I-Premise
157	had	_	_	I-Premise
158	significant	_	_	I-Premise
159	increases	_	_	I-Premise
160	in	_	_	I-Premise
161	fatigue	_	_	I-Premise
162	scores	_	_	I-Premise
163	from	_	_	I-Premise
164	baseline	_	_	I-Premise
165	to	_	_	I-Premise
166	the	_	_	I-Premise
167	end	_	_	I-Premise
168	of	_	_	I-Premise
169	radiotherapy	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	=	_	_	I-Premise
173	0	_	_	I-Premise
174	.	_	_	I-Premise

175	013	_	_	I-Premise
176	)	_	_	I-Premise
177	,	_	_	I-Premise
178	with	_	_	I-Premise
179	no	_	_	I-Premise
180	significant	_	_	I-Premise
181	increases	_	_	I-Premise
182	observed	_	_	I-Premise
183	in	_	_	I-Premise
184	the	_	_	I-Premise
185	exercise	_	_	I-Premise
186	group	_	_	I-Premise
187	(	_	_	I-Premise
188	P	_	_	I-Premise
189	=	_	_	I-Premise
190	0	_	_	I-Premise
191	.	_	_	I-Premise

192	203	_	_	I-Premise
193	)	_	_	I-Premise
194	.	_	_	I-Premise

195	A	_	_	B-Premise
196	nonsignificant	_	_	I-Premise
197	reduction	_	_	I-Premise
198	(	_	_	I-Premise
199	2	_	_	I-Premise
200	.	_	_	I-Premise

201	4	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	in	_	_	I-Premise
205	shuttle	_	_	I-Premise
206	test	_	_	I-Premise
207	distance	_	_	I-Premise
208	at	_	_	I-Premise
209	the	_	_	I-Premise
210	end	_	_	I-Premise
211	of	_	_	I-Premise
212	radiotherapy	_	_	I-Premise
213	was	_	_	I-Premise
214	observed	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	control	_	_	I-Premise
218	group	_	_	I-Premise
219	;	_	_	I-Premise
220	however	_	_	I-Premise
221	,	_	_	I-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	exercise	_	_	I-Premise
225	group	_	_	I-Premise
226	,	_	_	I-Premise
227	there	_	_	I-Premise
228	was	_	_	I-Premise
229	a	_	_	I-Premise
230	significant	_	_	I-Premise
231	increase	_	_	I-Premise
232	(	_	_	I-Premise
233	13	_	_	I-Premise
234	.	_	_	I-Premise

235	2	_	_	I-Premise
236	%	_	_	I-Premise
237	)	_	_	I-Premise
238	in	_	_	I-Premise
239	distance	_	_	I-Premise
240	walked	_	_	I-Premise
241	(	_	_	I-Premise
242	P	_	_	I-Premise
243	=	_	_	I-Premise
244	0	_	_	I-Premise
245	.	_	_	I-Premise

246	0003	_	_	I-Premise
247	)	_	_	I-Premise
248	.	_	_	I-Premise

249	Men	_	_	B-Premise
250	who	_	_	I-Premise
251	followed	_	_	I-Premise
252	advice	_	_	I-Premise
253	to	_	_	I-Premise
254	rest	_	_	I-Premise
255	and	_	_	I-Premise
256	take	_	_	I-Premise
257	things	_	_	I-Premise
258	easy	_	_	I-Premise
259	if	_	_	I-Premise
260	they	_	_	I-Premise
261	became	_	_	I-Premise
262	fatigued	_	_	I-Premise
263	demonstrated	_	_	I-Premise
264	a	_	_	I-Premise
265	slight	_	_	I-Premise
266	deterioration	_	_	I-Premise
267	in	_	_	I-Premise
268	physical	_	_	I-Premise
269	functioning	_	_	I-Premise
270	and	_	_	I-Premise
271	a	_	_	I-Premise
272	significant	_	_	I-Premise
273	increase	_	_	I-Premise
274	in	_	_	I-Premise
275	fatigue	_	_	I-Premise
276	at	_	_	I-Premise
277	the	_	_	I-Premise
278	end	_	_	I-Premise
279	of	_	_	I-Premise
280	radiotherapy	_	_	I-Premise
281	.	_	_	I-Premise

282	Home	_	_	B-Claim
283	-	_	_	I-Claim
284	based	_	_	I-Claim
285	,	_	_	I-Claim
286	moderate	_	_	I-Claim
287	-	_	_	I-Claim
288	intensity	_	_	I-Claim
289	walking	_	_	I-Claim
290	produced	_	_	I-Claim
291	a	_	_	I-Claim
292	significant	_	_	I-Claim
293	improvement	_	_	I-Claim
294	in	_	_	I-Claim
295	physical	_	_	I-Claim
296	functioning	_	_	I-Claim
297	with	_	_	I-Claim
298	no	_	_	I-Claim
299	significant	_	_	I-Claim
300	increase	_	_	I-Claim
301	in	_	_	I-Claim
302	fatigue	_	_	I-Claim
303	.	_	_	I-Claim

304	Improved	_	_	B-Claim
305	physical	_	_	I-Claim
306	functioning	_	_	I-Claim
307	may	_	_	I-Claim
308	be	_	_	I-Claim
309	necessary	_	_	I-Claim
310	to	_	_	I-Claim
311	combat	_	_	I-Claim
312	radiation	_	_	I-Claim
313	fatigue	_	_	I-Claim
314	.	_	_	I-Claim


0	Research	_	_	O
1	suggests	_	_	O
2	that	_	_	O
3	cancer	_	_	O
4	rehabilitation	_	_	O
5	reduces	_	_	O
6	fatigue	_	_	O
7	in	_	_	O
8	survivors	_	_	O
9	of	_	_	O
10	cancer	_	_	O
11	.	_	_	O

12	To	_	_	O
13	date	_	_	O
14	,	_	_	O
15	it	_	_	O
16	is	_	_	O
17	unclear	_	_	O
18	what	_	_	O
19	type	_	_	O
20	of	_	_	O
21	rehabilitation	_	_	O
22	is	_	_	O
23	most	_	_	O
24	beneficial	_	_	O
25	.	_	_	O

26	This	_	_	O
27	randomized	_	_	O
28	controlled	_	_	O
29	trial	_	_	O
30	compared	_	_	O
31	the	_	_	O
32	effect	_	_	O
33	on	_	_	O
34	cancer	_	_	O
35	-	_	_	O
36	related	_	_	O
37	fatigue	_	_	O
38	of	_	_	O
39	physical	_	_	O
40	training	_	_	O
41	combined	_	_	O
42	with	_	_	O
43	cognitive	_	_	O
44	behavioral	_	_	O
45	therapy	_	_	O
46	with	_	_	O
47	physical	_	_	O
48	training	_	_	O
49	alone	_	_	O
50	and	_	_	O
51	with	_	_	O
52	no	_	_	O
53	intervention	_	_	O
54	.	_	_	O

55	In	_	_	O
56	this	_	_	O
57	multicenter	_	_	O
58	randomized	_	_	O
59	controlled	_	_	O
60	trial	_	_	O
61	,	_	_	O
62	147	_	_	O
63	survivors	_	_	O
64	of	_	_	O
65	cancer	_	_	O
66	were	_	_	O
67	randomly	_	_	O
68	assigned	_	_	O
69	to	_	_	O
70	a	_	_	O
71	group	_	_	O
72	that	_	_	O
73	received	_	_	O
74	physical	_	_	O
75	training	_	_	O
76	combined	_	_	O
77	with	_	_	O
78	cognitive	_	_	O
79	-	_	_	O
80	behavioral	_	_	O
81	therapy	_	_	O
82	(	_	_	O
83	PT	_	_	O
84	+	_	_	O
85	CBT	_	_	O
86	group	_	_	O
87	,	_	_	O
88	n	_	_	O
89	=	_	_	O
90	76	_	_	O
91	)	_	_	O
92	or	_	_	O
93	to	_	_	O
94	a	_	_	O
95	group	_	_	O
96	that	_	_	O
97	received	_	_	O
98	physical	_	_	O
99	training	_	_	O
100	alone	_	_	O
101	(	_	_	O
102	PT	_	_	O
103	group	_	_	O
104	,	_	_	O
105	n	_	_	O
106	=	_	_	O
107	71	_	_	O
108	)	_	_	O
109	.	_	_	O

110	In	_	_	O
111	addition	_	_	O
112	,	_	_	O
113	a	_	_	O
114	nonintervention	_	_	O
115	control	_	_	O
116	group	_	_	O
117	(	_	_	O
118	WLC	_	_	O
119	group	_	_	O
120	)	_	_	O
121	consisting	_	_	O
122	of	_	_	O
123	62	_	_	O
124	survivors	_	_	O
125	of	_	_	O
126	cancer	_	_	O
127	who	_	_	O
128	were	_	_	O
129	on	_	_	O
130	the	_	_	O
131	waiting	_	_	O
132	lists	_	_	O
133	of	_	_	O
134	rehabilitation	_	_	O
135	centers	_	_	O
136	elsewhere	_	_	O
137	was	_	_	O
138	included	_	_	O
139	.	_	_	O

140	The	_	_	O
141	study	_	_	O
142	was	_	_	O
143	conducted	_	_	O
144	at	_	_	O
145	4	_	_	O
146	rehabilitation	_	_	O
147	centers	_	_	O
148	in	_	_	O
149	the	_	_	O
150	Netherlands	_	_	O
151	.	_	_	O

152	All	_	_	O
153	patients	_	_	O
154	were	_	_	O
155	survivors	_	_	O
156	of	_	_	O
157	cancer	_	_	O
158	.	_	_	O

159	Physical	_	_	O
160	training	_	_	O
161	consisting	_	_	O
162	of	_	_	O
163	2	_	_	O
164	hours	_	_	O
165	of	_	_	O
166	individual	_	_	O
167	training	_	_	O
168	and	_	_	O
169	group	_	_	O
170	sports	_	_	O
171	took	_	_	O
172	place	_	_	O
173	twice	_	_	O
174	weekly	_	_	O
175	,	_	_	O
176	and	_	_	O
177	cognitive	_	_	O
178	-	_	_	O
179	behavioral	_	_	O
180	therapy	_	_	O
181	took	_	_	O
182	place	_	_	O
183	once	_	_	O
184	weekly	_	_	O
185	for	_	_	O
186	2	_	_	O
187	hours	_	_	O
188	.	_	_	O

189	Fatigue	_	_	O
190	was	_	_	O
191	assessed	_	_	O
192	with	_	_	O
193	the	_	_	O
194	Multidimensional	_	_	O
195	Fatigue	_	_	O
196	Inventory	_	_	O
197	before	_	_	O
198	and	_	_	O
199	immediately	_	_	O
200	after	_	_	O
201	intervention	_	_	O
202	(	_	_	O
203	12	_	_	O
204	weeks	_	_	O
205	after	_	_	O
206	enrollment	_	_	O
207	)	_	_	O
208	.	_	_	O

209	The	_	_	O
210	WLC	_	_	O
211	group	_	_	O
212	completed	_	_	O
213	questionnaires	_	_	O
214	at	_	_	O
215	the	_	_	O
216	same	_	_	O
217	time	_	_	O
218	points	_	_	O
219	.	_	_	O

220	Baseline	_	_	O
221	fatigue	_	_	O
222	did	_	_	O
223	not	_	_	O
224	differ	_	_	O
225	significantly	_	_	O
226	among	_	_	O
227	the	_	_	O
228	3	_	_	O
229	groups	_	_	O
230	.	_	_	O

231	Over	_	_	B-Premise
232	time	_	_	I-Premise
233	,	_	_	I-Premise
234	levels	_	_	I-Premise
235	of	_	_	I-Premise
236	fatigue	_	_	I-Premise
237	significantly	_	_	I-Premise
238	decreased	_	_	I-Premise
239	in	_	_	I-Premise
240	all	_	_	I-Premise
241	domains	_	_	I-Premise
242	in	_	_	I-Premise
243	all	_	_	I-Premise
244	groups	_	_	I-Premise
245	,	_	_	I-Premise
246	except	_	_	B-Premise
247	in	_	_	I-Premise
248	mental	_	_	I-Premise
249	fatigue	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	WLC	_	_	I-Premise
253	group	_	_	I-Premise
254	.	_	_	I-Premise

255	Analyses	_	_	B-Premise
256	of	_	_	I-Premise
257	variance	_	_	I-Premise
258	of	_	_	I-Premise
259	postintervention	_	_	I-Premise
260	fatigue	_	_	I-Premise
261	showed	_	_	I-Premise
262	statistically	_	_	I-Premise
263	significant	_	_	I-Premise
264	group	_	_	I-Premise
265	effects	_	_	I-Premise
266	on	_	_	I-Premise
267	general	_	_	I-Premise
268	fatigue	_	_	I-Premise
269	,	_	_	I-Premise
270	on	_	_	I-Premise
271	physical	_	_	I-Premise
272	and	_	_	I-Premise
273	mental	_	_	I-Premise
274	fatigue	_	_	I-Premise
275	,	_	_	I-Premise
276	and	_	_	I-Premise
277	on	_	_	I-Premise
278	reduced	_	_	I-Premise
279	activation	_	_	I-Premise
280	but	_	_	I-Premise
281	not	_	_	I-Premise
282	on	_	_	I-Premise
283	reduced	_	_	I-Premise
284	motivation	_	_	I-Premise
285	.	_	_	I-Premise

286	Compared	_	_	B-Premise
287	with	_	_	I-Premise
288	the	_	_	I-Premise
289	WLC	_	_	I-Premise
290	group	_	_	I-Premise
291	,	_	_	I-Premise
292	the	_	_	I-Premise
293	PT	_	_	I-Premise
294	group	_	_	I-Premise
295	reported	_	_	I-Premise
296	significantly	_	_	I-Premise
297	greater	_	_	I-Premise
298	decline	_	_	I-Premise
299	in	_	_	I-Premise
300	4	_	_	I-Premise
301	domains	_	_	I-Premise
302	of	_	_	I-Premise
303	fatigue	_	_	I-Premise
304	,	_	_	I-Premise
305	whereas	_	_	I-Premise
306	the	_	_	I-Premise
307	PT	_	_	I-Premise
308	+	_	_	I-Premise
309	CBT	_	_	I-Premise
310	group	_	_	I-Premise
311	reported	_	_	I-Premise
312	significantly	_	_	I-Premise
313	greater	_	_	I-Premise
314	decline	_	_	I-Premise
315	in	_	_	I-Premise
316	physical	_	_	I-Premise
317	fatigue	_	_	I-Premise
318	only	_	_	I-Premise
319	.	_	_	I-Premise

320	No	_	_	B-Premise
321	significant	_	_	I-Premise
322	differences	_	_	I-Premise
323	in	_	_	I-Premise
324	decline	_	_	I-Premise
325	in	_	_	I-Premise
326	fatigue	_	_	I-Premise
327	were	_	_	I-Premise
328	found	_	_	I-Premise
329	between	_	_	I-Premise
330	the	_	_	I-Premise
331	PT	_	_	I-Premise
332	+	_	_	I-Premise
333	CBT	_	_	I-Premise
334	and	_	_	I-Premise
335	PT	_	_	I-Premise
336	groups	_	_	I-Premise
337	.	_	_	I-Premise

338	Physical	_	_	B-Premise
339	training	_	_	I-Premise
340	combined	_	_	I-Premise
341	with	_	_	I-Premise
342	cognitive	_	_	I-Premise
343	-	_	_	I-Premise
344	behavioral	_	_	I-Premise
345	therapy	_	_	I-Premise
346	and	_	_	I-Premise
347	physical	_	_	I-Premise
348	training	_	_	I-Premise
349	alone	_	_	I-Premise
350	had	_	_	I-Premise
351	significant	_	_	I-Premise
352	and	_	_	I-Premise
353	beneficial	_	_	I-Premise
354	effects	_	_	I-Premise
355	on	_	_	I-Premise
356	fatigue	_	_	I-Premise
357	compared	_	_	I-Premise
358	with	_	_	I-Premise
359	no	_	_	I-Premise
360	intervention	_	_	I-Premise
361	.	_	_	I-Premise

362	Physical	_	_	B-Claim
363	training	_	_	I-Claim
364	was	_	_	I-Claim
365	equally	_	_	I-Claim
366	effective	_	_	I-Claim
367	as	_	_	I-Claim
368	or	_	_	I-Claim
369	more	_	_	I-Claim
370	effective	_	_	I-Claim
371	than	_	_	I-Claim
372	physical	_	_	I-Claim
373	training	_	_	I-Claim
374	combined	_	_	I-Claim
375	with	_	_	I-Claim
376	cognitive	_	_	I-Claim
377	-	_	_	I-Claim
378	behavioral	_	_	I-Claim
379	therapy	_	_	I-Claim
380	in	_	_	I-Claim
381	reducing	_	_	I-Claim
382	cancer	_	_	I-Claim
383	-	_	_	I-Claim
384	related	_	_	I-Claim
385	fatigue	_	_	I-Claim
386	,	_	_	I-Claim
387	suggesting	_	_	O
388	that	_	_	O
389	cognitive	_	_	B-Claim
390	-	_	_	I-Claim
391	behavioral	_	_	I-Claim
392	therapy	_	_	I-Claim
393	did	_	_	I-Claim
394	not	_	_	I-Claim
395	have	_	_	I-Claim
396	additional	_	_	I-Claim
397	beneficial	_	_	I-Claim
398	effects	_	_	I-Claim
399	beyond	_	_	I-Claim
400	the	_	_	I-Claim
401	benefits	_	_	I-Claim
402	of	_	_	I-Claim
403	physical	_	_	I-Claim
404	training	_	_	I-Claim
405	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	docetaxel	_	_	O
4	plus	_	_	O
5	platinum	_	_	O
6	regimens	_	_	O
7	improve	_	_	O
8	survival	_	_	O
9	and	_	_	O
10	affect	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	(	_	_	O
15	QoL	_	_	O
16	)	_	_	O
17	in	_	_	O
18	advanced	_	_	O
19	non	_	_	O
20	-	_	_	O
21	small	_	_	O
22	-	_	_	O
23	cell	_	_	O
24	lung	_	_	O
25	cancer	_	_	O
26	(	_	_	O
27	NSCLC	_	_	O
28	)	_	_	O
29	compared	_	_	O
30	with	_	_	O
31	vinorelbine	_	_	O
32	plus	_	_	O
33	cisplatin	_	_	O
34	as	_	_	O
35	first	_	_	O
36	-	_	_	O
37	line	_	_	O
38	chemotherapy	_	_	O
39	.	_	_	O

40	Patients	_	_	O
41	(	_	_	O
42	n	_	_	O
43	=	_	_	O
44	1	_	_	O
45	,	_	_	O
46	218	_	_	O
47	)	_	_	O
48	with	_	_	O
49	stage	_	_	O
50	IIIB	_	_	O
51	to	_	_	O
52	IV	_	_	O
53	NSCLC	_	_	O
54	were	_	_	O
55	randomly	_	_	O
56	assigned	_	_	O
57	to	_	_	O
58	receive	_	_	O
59	docetaxel	_	_	O
60	75	_	_	O
61	mg	_	_	O
62	/	_	_	O
63	m2	_	_	O
64	and	_	_	O
65	cisplatin	_	_	O
66	75	_	_	O
67	mg	_	_	O
68	/	_	_	O
69	m2	_	_	O
70	every	_	_	O
71	3	_	_	O
72	weeks	_	_	O
73	(	_	_	O
74	DC	_	_	O
75	)	_	_	O
76	;	_	_	O
77	docetaxel	_	_	O
78	75	_	_	O
79	mg	_	_	O
80	/	_	_	O
81	m2	_	_	O
82	and	_	_	O
83	carboplatin	_	_	O
84	area	_	_	O
85	under	_	_	O
86	the	_	_	O
87	curve	_	_	O
88	of	_	_	O
89	6	_	_	O
90	mg	_	_	O
91	/	_	_	O
92	mL	_	_	O
93	*	_	_	O
94	min	_	_	O
95	every	_	_	O
96	3	_	_	O
97	weeks	_	_	O
98	(	_	_	O
99	DCb	_	_	O
100	)	_	_	O
101	;	_	_	O
102	or	_	_	O
103	vinorelbine	_	_	O
104	25	_	_	O
105	mg	_	_	O
106	/	_	_	O
107	m2	_	_	O
108	/	_	_	O
109	wk	_	_	O
110	and	_	_	O
111	cisplatin	_	_	O
112	100	_	_	O
113	mg	_	_	O
114	/	_	_	O
115	m2	_	_	O
116	every	_	_	O
117	4	_	_	O
118	weeks	_	_	O
119	(	_	_	O
120	VC	_	_	O
121	)	_	_	O
122	.	_	_	O

123	Patients	_	_	B-Premise
124	treated	_	_	I-Premise
125	with	_	_	I-Premise
126	DC	_	_	I-Premise
127	had	_	_	I-Premise
128	a	_	_	I-Premise
129	median	_	_	I-Premise
130	survival	_	_	I-Premise
131	of	_	_	I-Premise
132	11	_	_	I-Premise
133	.	_	_	I-Premise

134	3	_	_	I-Premise
135	v	_	_	I-Premise
136	10	_	_	I-Premise
137	.	_	_	I-Premise

138	1	_	_	I-Premise
139	months	_	_	I-Premise
140	for	_	_	I-Premise
141	VC	_	_	I-Premise
142	-	_	_	I-Premise
143	treated	_	_	I-Premise
144	patients	_	_	I-Premise
145	(	_	_	I-Premise
146	P	_	_	I-Premise
147	=	_	_	I-Premise
148	.	_	_	I-Premise

149	044	_	_	I-Premise
150	;	_	_	I-Premise
151	hazard	_	_	I-Premise
152	ratio	_	_	I-Premise
153	,	_	_	I-Premise
154	1	_	_	I-Premise
155	.	_	_	I-Premise

156	183	_	_	I-Premise
157	[	_	_	I-Premise
158	97	_	_	I-Premise
159	.	_	_	I-Premise

160	2	_	_	I-Premise
161	%	_	_	I-Premise
162	confidence	_	_	I-Premise
163	interval	_	_	I-Premise
164	,	_	_	I-Premise
165	0	_	_	I-Premise
166	.	_	_	I-Premise

167	989	_	_	I-Premise
168	to	_	_	I-Premise
169	1	_	_	I-Premise
170	.	_	_	I-Premise

171	416	_	_	I-Premise
172	]	_	_	I-Premise
173	)	_	_	I-Premise
174	.	_	_	I-Premise

175	The	_	_	B-Premise
176	2	_	_	I-Premise
177	-	_	_	I-Premise
178	year	_	_	I-Premise
179	survival	_	_	I-Premise
180	rate	_	_	I-Premise
181	was	_	_	I-Premise
182	21	_	_	I-Premise
183	%	_	_	I-Premise
184	for	_	_	I-Premise
185	DC	_	_	I-Premise
186	-	_	_	I-Premise
187	treated	_	_	I-Premise
188	patients	_	_	I-Premise
189	and	_	_	I-Premise
190	14	_	_	I-Premise
191	%	_	_	I-Premise
192	for	_	_	I-Premise
193	VC	_	_	I-Premise
194	-	_	_	I-Premise
195	treated	_	_	I-Premise
196	patients	_	_	I-Premise
197	.	_	_	I-Premise

198	Overall	_	_	B-Premise
199	response	_	_	I-Premise
200	rate	_	_	I-Premise
201	was	_	_	I-Premise
202	31	_	_	I-Premise
203	.	_	_	I-Premise

204	6	_	_	I-Premise
205	%	_	_	I-Premise
206	for	_	_	I-Premise
207	DC	_	_	I-Premise
208	-	_	_	I-Premise
209	treated	_	_	I-Premise
210	patients	_	_	I-Premise
211	v	_	_	I-Premise
212	24	_	_	I-Premise
213	.	_	_	I-Premise

214	5	_	_	I-Premise
215	%	_	_	I-Premise
216	for	_	_	I-Premise
217	VC	_	_	I-Premise
218	-	_	_	I-Premise
219	treated	_	_	I-Premise
220	patients	_	_	I-Premise
221	(	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	.	_	_	I-Premise

225	029	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Median	_	_	B-Premise
229	survival	_	_	I-Premise
230	(	_	_	I-Premise
231	9	_	_	I-Premise
232	.	_	_	I-Premise

233	4	_	_	I-Premise
234	v	_	_	I-Premise
235	9	_	_	I-Premise
236	.	_	_	I-Premise

237	9	_	_	I-Premise
238	months	_	_	I-Premise
239	[	_	_	I-Premise
240	for	_	_	I-Premise
241	VC	_	_	I-Premise
242	]	_	_	I-Premise
243	;	_	_	I-Premise
244	P	_	_	I-Premise
245	=	_	_	I-Premise
246	.	_	_	I-Premise

247	657	_	_	I-Premise
248	;	_	_	I-Premise
249	hazard	_	_	I-Premise
250	ratio	_	_	I-Premise
251	,	_	_	I-Premise
252	1	_	_	I-Premise
253	.	_	_	I-Premise

254	048	_	_	I-Premise
255	[	_	_	I-Premise
256	97	_	_	I-Premise
257	.	_	_	I-Premise

258	2	_	_	I-Premise
259	confidence	_	_	I-Premise
260	interval	_	_	I-Premise
261	,	_	_	I-Premise
262	0	_	_	I-Premise
263	.	_	_	I-Premise

264	877	_	_	I-Premise
265	to	_	_	I-Premise
266	1	_	_	I-Premise
267	.	_	_	I-Premise

268	253	_	_	I-Premise
269	]	_	_	I-Premise
270	)	_	_	I-Premise
271	and	_	_	I-Premise
272	response	_	_	I-Premise
273	(	_	_	I-Premise
274	23	_	_	I-Premise
275	.	_	_	I-Premise

276	9	_	_	I-Premise
277	%	_	_	I-Premise
278	)	_	_	I-Premise
279	with	_	_	I-Premise
280	DCb	_	_	I-Premise
281	were	_	_	I-Premise
282	similar	_	_	I-Premise
283	to	_	_	I-Premise
284	those	_	_	I-Premise
285	results	_	_	I-Premise
286	for	_	_	I-Premise
287	VC	_	_	I-Premise
288	.	_	_	I-Premise

289	Neutropenia	_	_	B-Premise
290	,	_	_	I-Premise
291	thrombocytopenia	_	_	I-Premise
292	,	_	_	I-Premise
293	infection	_	_	I-Premise
294	,	_	_	I-Premise
295	and	_	_	I-Premise
296	febrile	_	_	I-Premise
297	neutropenia	_	_	I-Premise
298	were	_	_	I-Premise
299	similar	_	_	I-Premise
300	with	_	_	I-Premise
301	all	_	_	I-Premise
302	three	_	_	I-Premise
303	regimens	_	_	I-Premise
304	.	_	_	I-Premise

305	Grade	_	_	B-Premise
306	3	_	_	I-Premise
307	to	_	_	I-Premise
308	4	_	_	I-Premise
309	anemia	_	_	I-Premise
310	,	_	_	I-Premise
311	nausea	_	_	I-Premise
312	,	_	_	I-Premise
313	and	_	_	I-Premise
314	vomiting	_	_	I-Premise
315	were	_	_	I-Premise
316	more	_	_	I-Premise
317	common	_	_	I-Premise
318	(	_	_	I-Premise
319	P	_	_	I-Premise
320	<	_	_	I-Premise
321	.	_	_	I-Premise

322	01	_	_	I-Premise
323	)	_	_	I-Premise
324	with	_	_	I-Premise
325	VC	_	_	I-Premise
326	than	_	_	I-Premise
327	with	_	_	I-Premise
328	DC	_	_	I-Premise
329	or	_	_	I-Premise
330	DCb	_	_	I-Premise
331	.	_	_	I-Premise

332	Patients	_	_	B-Premise
333	treated	_	_	I-Premise
334	with	_	_	I-Premise
335	either	_	_	I-Premise
336	docetaxel	_	_	I-Premise
337	regimen	_	_	I-Premise
338	had	_	_	I-Premise
339	consistently	_	_	I-Premise
340	improved	_	_	I-Premise
341	QoL	_	_	I-Premise
342	compared	_	_	I-Premise
343	with	_	_	I-Premise
344	VC	_	_	I-Premise
345	-	_	_	I-Premise
346	treated	_	_	I-Premise
347	patients	_	_	I-Premise
348	,	_	_	I-Premise
349	who	_	_	I-Premise
350	experienced	_	_	I-Premise
351	deterioration	_	_	I-Premise
352	in	_	_	I-Premise
353	QoL	_	_	I-Premise
354	.	_	_	I-Premise

355	DC	_	_	B-Claim
356	resulted	_	_	I-Claim
357	in	_	_	I-Claim
358	a	_	_	I-Claim
359	more	_	_	I-Claim
360	favorable	_	_	I-Claim
361	overall	_	_	I-Claim
362	response	_	_	I-Claim
363	and	_	_	I-Claim
364	survival	_	_	I-Claim
365	rate	_	_	I-Claim
366	than	_	_	I-Claim
367	VC	_	_	I-Claim
368	.	_	_	I-Claim

369	Both	_	_	B-Claim
370	DC	_	_	I-Claim
371	and	_	_	I-Claim
372	DCb	_	_	I-Claim
373	were	_	_	I-Claim
374	better	_	_	I-Claim
375	tolerated	_	_	I-Claim
376	and	_	_	I-Claim
377	provided	_	_	I-Claim
378	patients	_	_	I-Claim
379	with	_	_	I-Claim
380	consistently	_	_	I-Claim
381	improved	_	_	I-Claim
382	QoL	_	_	I-Claim
383	compared	_	_	I-Claim
384	with	_	_	I-Claim
385	VC	_	_	I-Claim
386	.	_	_	I-Claim

387	These	_	_	B-Claim
388	findings	_	_	I-Claim
389	demonstrate	_	_	I-Claim
390	that	_	_	I-Claim
391	a	_	_	I-Claim
392	docetaxel	_	_	I-Claim
393	plus	_	_	I-Claim
394	platinum	_	_	I-Claim
395	combination	_	_	I-Claim
396	is	_	_	I-Claim
397	an	_	_	I-Claim
398	effective	_	_	I-Claim
399	treatment	_	_	I-Claim
400	option	_	_	I-Claim
401	with	_	_	I-Claim
402	a	_	_	I-Claim
403	favorable	_	_	I-Claim
404	therapeutic	_	_	I-Claim
405	index	_	_	I-Claim
406	for	_	_	I-Claim
407	first	_	_	I-Claim
408	-	_	_	I-Claim
409	line	_	_	I-Claim
410	treatment	_	_	I-Claim
411	of	_	_	I-Claim
412	advanced	_	_	I-Claim
413	or	_	_	I-Claim
414	metastatic	_	_	I-Claim
415	NSCLC	_	_	I-Claim
416	.	_	_	I-Claim


0	Cutaneous	_	_	B-Claim
1	T	_	_	I-Claim
2	-	_	_	I-Claim
3	cell	_	_	I-Claim
4	lymphoma	_	_	I-Claim
5	(	_	_	I-Claim
6	CTCL	_	_	I-Claim
7	)	_	_	I-Claim
8	can	_	_	I-Claim
9	be	_	_	I-Claim
10	associated	_	_	I-Claim
11	with	_	_	I-Claim
12	painful	_	_	I-Claim
13	,	_	_	I-Claim
14	pruritic	_	_	I-Claim
15	,	_	_	I-Claim
16	disfiguring	_	_	I-Claim
17	lesions	_	_	I-Claim
18	.	_	_	I-Claim

19	As	_	_	O
20	part	_	_	O
21	of	_	_	O
22	a	_	_	O
23	multicenter	_	_	O
24	,	_	_	O
25	randomized	_	_	O
26	phase	_	_	O
27	III	_	_	O
28	trial	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	heavily	_	_	O
33	pretreated	_	_	O
34	advanced	_	_	O
35	and	_	_	O
36	/	_	_	O
37	or	_	_	O
38	recurrent	_	_	O
39	CTCL	_	_	O
40	,	_	_	O
41	the	_	_	O
42	effects	_	_	O
43	of	_	_	O
44	an	_	_	O
45	interleukin	_	_	O
46	-	_	_	O
47	2	_	_	O
48	receptor	_	_	O
49	-	_	_	O
50	targeted	_	_	O
51	fusion	_	_	O
52	protein	_	_	O
53	,	_	_	O
54	denileukin	_	_	O
55	diftitox	_	_	O
56	(	_	_	O
57	DAB389IL	_	_	O
58	-	_	_	O
59	2	_	_	O
60	,	_	_	O
61	ONTAK	_	_	O
62	)	_	_	O
63	,	_	_	O
64	on	_	_	O
65	patient	_	_	O
66	-	_	_	O
67	rated	_	_	O
68	overall	_	_	O
69	quality	_	_	O
70	of	_	_	O
71	life	_	_	O
72	(	_	_	O
73	QOL	_	_	O
74	)	_	_	O
75	,	_	_	O
76	skin	_	_	O
77	appearance	_	_	O
78	,	_	_	O
79	and	_	_	O
80	pruritus	_	_	O
81	severity	_	_	O
82	were	_	_	O
83	evaluated	_	_	O
84	.	_	_	O

85	A	_	_	O
86	total	_	_	O
87	of	_	_	O
88	71	_	_	O
89	patients	_	_	O
90	with	_	_	O
91	stage	_	_	O
92	IB	_	_	O
93	-	_	_	O
94	IVA	_	_	O
95	CTCL	_	_	O
96	received	_	_	O
97	intravenous	_	_	O
98	denileukin	_	_	O
99	diftitox	_	_	O
100	9	_	_	O
101	microg	_	_	O
102	/	_	_	O
103	kg	_	_	O
104	/	_	_	O
105	day	_	_	O
106	or	_	_	O
107	18	_	_	O
108	microg	_	_	O
109	/	_	_	O
110	kg	_	_	O
111	/	_	_	O
112	day	_	_	O
113	over	_	_	O
114	15	_	_	O
115	-	_	_	O
116	60	_	_	O
117	minutes	_	_	O
118	for	_	_	O
119	5	_	_	O
120	consecutive	_	_	O
121	days	_	_	O
122	on	_	_	O
123	an	_	_	O
124	outpatient	_	_	O
125	basis	_	_	O
126	;	_	_	O
127	cycles	_	_	O
128	were	_	_	O
129	planned	_	_	O
130	for	_	_	O
131	every	_	_	O
132	21	_	_	O
133	days	_	_	O
134	for	_	_	O
135	a	_	_	O
136	total	_	_	O
137	of	_	_	O
138	8	_	_	O
139	cycles	_	_	O
140	over	_	_	O
141	6	_	_	O
142	months	_	_	O
143	.	_	_	O

144	Prior	_	_	O
145	to	_	_	O
146	each	_	_	O
147	treatment	_	_	O
148	cycle	_	_	O
149	,	_	_	O
150	patients	_	_	O
151	were	_	_	O
152	evaluated	_	_	O
153	for	_	_	O
154	disease	_	_	O
155	response	_	_	O
156	and	_	_	O
157	were	_	_	O
158	asked	_	_	O
159	to	_	_	O
160	self	_	_	O
161	-	_	_	O
162	rate	_	_	O
163	their	_	_	O
164	overall	_	_	O
165	QOL	_	_	O
166	via	_	_	O
167	the	_	_	O
168	Functional	_	_	O
169	Assessment	_	_	O
170	of	_	_	O
171	Cancer	_	_	O
172	Therapy	_	_	O
173	-	_	_	O
174	General	_	_	O
175	(	_	_	O
176	FACT	_	_	O
177	-	_	_	O
178	G	_	_	O
179	)	_	_	O
180	questionnaire	_	_	O
181	,	_	_	O
182	skin	_	_	O
183	appearance	_	_	O
184	(	_	_	O
185	7	_	_	O
186	-	_	_	O
187	point	_	_	O
188	scale	_	_	O
189	)	_	_	O
190	,	_	_	O
191	and	_	_	O
192	pruritus	_	_	O
193	severity	_	_	O
194	(	_	_	O
195	10	_	_	O
196	-	_	_	O
197	cm	_	_	O
198	visual	_	_	O
199	analogue	_	_	O
200	scale	_	_	O
201	)	_	_	O
202	.	_	_	O

203	Composite	_	_	B-Premise
204	FACT	_	_	I-Premise
205	-	_	_	I-Premise
206	G	_	_	I-Premise
207	and	_	_	I-Premise
208	most	_	_	I-Premise
209	individual	_	_	I-Premise
210	subscale	_	_	I-Premise
211	scores	_	_	I-Premise
212	(	_	_	I-Premise
213	physical	_	_	I-Premise
214	,	_	_	I-Premise
215	social	_	_	I-Premise
216	/	_	_	I-Premise
217	family	_	_	I-Premise
218	,	_	_	I-Premise
219	emotional	_	_	I-Premise
220	,	_	_	I-Premise
221	and	_	_	I-Premise
222	functional	_	_	I-Premise
223	well	_	_	I-Premise
224	being	_	_	I-Premise
225	)	_	_	I-Premise
226	in	_	_	I-Premise
227	documented	_	_	I-Premise
228	responders	_	_	I-Premise
229	(	_	_	I-Premise
230	n	_	_	I-Premise
231	=	_	_	I-Premise
232	21	_	_	I-Premise
233	)	_	_	I-Premise
234	gradually	_	_	I-Premise
235	increased	_	_	I-Premise
236	during	_	_	I-Premise
237	the	_	_	I-Premise
238	study	_	_	I-Premise
239	period	_	_	I-Premise
240	,	_	_	I-Premise
241	generally	_	_	I-Premise
242	reaching	_	_	I-Premise
243	statistical	_	_	I-Premise
244	significance	_	_	I-Premise
245	(	_	_	I-Premise
246	P	_	_	I-Premise
247	<	_	_	I-Premise
248	0	_	_	I-Premise
249	.	_	_	I-Premise

250	05	_	_	I-Premise
251	)	_	_	I-Premise
252	by	_	_	I-Premise
253	cycle	_	_	I-Premise
254	3	_	_	I-Premise
255	,	_	_	I-Premise
256	and	_	_	I-Premise
257	were	_	_	I-Premise
258	significantly	_	_	I-Premise
259	(	_	_	I-Premise
260	P	_	_	I-Premise
261	<	_	_	I-Premise
262	or	_	_	I-Premise
263	=	_	_	I-Premise
264	0	_	_	I-Premise
265	.	_	_	I-Premise

266	041	_	_	I-Premise
267	)	_	_	I-Premise
268	higher	_	_	I-Premise
269	than	_	_	I-Premise
270	the	_	_	I-Premise
271	scores	_	_	I-Premise
272	of	_	_	I-Premise
273	nonresponders	_	_	I-Premise
274	at	_	_	I-Premise
275	endpoint	_	_	I-Premise
276	.	_	_	I-Premise

277	Additionally	_	_	B-Premise
278	for	_	_	I-Premise
279	responders	_	_	I-Premise
280	,	_	_	I-Premise
281	assessments	_	_	I-Premise
282	of	_	_	I-Premise
283	skin	_	_	I-Premise
284	severity	_	_	I-Premise
285	and	_	_	I-Premise
286	pruritus	_	_	I-Premise
287	severity	_	_	I-Premise
288	showed	_	_	I-Premise
289	significant	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	<	_	_	I-Premise
293	or	_	_	I-Premise
294	=	_	_	I-Premise
295	0	_	_	I-Premise
296	.	_	_	I-Premise

297	05	_	_	I-Premise
298	)	_	_	I-Premise
299	improvements	_	_	I-Premise
300	at	_	_	I-Premise
301	study	_	_	I-Premise
302	endpoint	_	_	I-Premise
303	compared	_	_	I-Premise
304	with	_	_	I-Premise
305	baseline	_	_	I-Premise
306	.	_	_	I-Premise

307	Adverse	_	_	B-Premise
308	transfusion	_	_	I-Premise
309	-	_	_	I-Premise
310	related	_	_	I-Premise
311	events	_	_	I-Premise
312	(	_	_	I-Premise
313	eg	_	_	I-Premise
314	,	_	_	I-Premise
315	hypersensitivity	_	_	I-Premise
316	reactions	_	_	I-Premise
317	,	_	_	I-Premise
318	flu	_	_	I-Premise
319	-	_	_	I-Premise
320	like	_	_	I-Premise
321	syndrome	_	_	I-Premise
322	)	_	_	I-Premise
323	were	_	_	I-Premise
324	common	_	_	I-Premise
325	during	_	_	I-Premise
326	cycles	_	_	I-Premise
327	1	_	_	I-Premise
328	and	_	_	I-Premise
329	2	_	_	I-Premise
330	,	_	_	I-Premise
331	and	_	_	I-Premise
332	vascular	_	_	I-Premise
333	-	_	_	I-Premise
334	leak	_	_	I-Premise
335	syndrome	_	_	I-Premise
336	occurred	_	_	I-Premise
337	in	_	_	I-Premise
338	25	_	_	I-Premise
339	%	_	_	I-Premise
340	of	_	_	I-Premise
341	patients	_	_	I-Premise
342	.	_	_	I-Premise

343	Denileukin	_	_	B-Claim
344	diftitox	_	_	I-Claim
345	was	_	_	I-Claim
346	not	_	_	I-Claim
347	associated	_	_	I-Claim
348	with	_	_	I-Claim
349	any	_	_	I-Claim
350	clinically	_	_	I-Claim
351	significant	_	_	I-Claim
352	myelosuppression	_	_	I-Claim
353	.	_	_	I-Claim

354	Heavily	_	_	B-Claim
355	pretreated	_	_	I-Claim
356	patients	_	_	I-Claim
357	with	_	_	I-Claim
358	advanced	_	_	I-Claim
359	and	_	_	I-Claim
360	/	_	_	I-Claim
361	or	_	_	I-Claim
362	recurrent	_	_	I-Claim
363	CTCL	_	_	I-Claim
364	who	_	_	I-Claim
365	responded	_	_	I-Claim
366	to	_	_	I-Claim
367	denileukin	_	_	I-Claim
368	diftitox	_	_	I-Claim
369	therapy	_	_	I-Claim
370	showed	_	_	I-Claim
371	significant	_	_	I-Claim
372	improvements	_	_	I-Claim
373	in	_	_	I-Claim
374	self	_	_	I-Claim
375	-	_	_	I-Claim
376	rated	_	_	I-Claim
377	overall	_	_	I-Claim
378	QOL	_	_	I-Claim
379	,	_	_	I-Claim
380	skin	_	_	I-Claim
381	appearance	_	_	I-Claim
382	,	_	_	I-Claim
383	and	_	_	I-Claim
384	pruritus	_	_	I-Claim
385	severity	_	_	I-Claim
386	.	_	_	I-Claim


0	The	_	_	O
1	objective	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	(	_	_	O
13	QoL	_	_	O
14	)	_	_	O
15	of	_	_	O
16	ovarian	_	_	O
17	cancer	_	_	O
18	patients	_	_	O
19	treated	_	_	O
20	with	_	_	O
21	paclitaxel	_	_	O
22	/	_	_	O
23	carboplatin	_	_	O
24	(	_	_	O
25	TC	_	_	O
26	)	_	_	O
27	versus	_	_	O
28	paclitaxel	_	_	O
29	/	_	_	O
30	cisplatin	_	_	O
31	(	_	_	O
32	PT	_	_	O
33	)	_	_	O
34	and	_	_	O
35	to	_	_	O
36	determine	_	_	O
37	the	_	_	O
38	impact	_	_	O
39	of	_	_	O
40	treatment	_	_	O
41	toxicity	_	_	O
42	on	_	_	O
43	the	_	_	O
44	various	_	_	O
45	QoL	_	_	O
46	domains	_	_	O
47	.	_	_	O

48	In	_	_	O
49	this	_	_	O
50	phase	_	_	O
51	III	_	_	O
52	trial	_	_	O
53	,	_	_	O
54	798	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	ovarian	_	_	O
58	cancer	_	_	O
59	stages	_	_	O
60	IIB	_	_	O
61	-	_	_	O
62	IV	_	_	O
63	were	_	_	O
64	randomly	_	_	O
65	assigned	_	_	O
66	to	_	_	O
67	receive	_	_	O
68	TC	_	_	O
69	or	_	_	O
70	PT	_	_	O
71	.	_	_	O

72	The	_	_	O
73	primary	_	_	O
74	end	_	_	O
75	point	_	_	O
76	was	_	_	O
77	progression	_	_	O
78	-	_	_	O
79	free	_	_	O
80	survival	_	_	O
81	;	_	_	O
82	secondary	_	_	O
83	end	_	_	O
84	points	_	_	O
85	included	_	_	O
86	toxicity	_	_	O
87	,	_	_	O
88	QoL	_	_	O
89	,	_	_	O
90	and	_	_	O
91	response	_	_	O
92	to	_	_	O
93	treatment	_	_	O
94	.	_	_	O

95	Patients	_	_	O
96	completed	_	_	O
97	the	_	_	O
98	European	_	_	O
99	Organisation	_	_	O
100	for	_	_	O
101	Research	_	_	O
102	and	_	_	O
103	Treatment	_	_	O
104	of	_	_	O
105	Cancer	_	_	O
106	QLQ	_	_	O
107	-	_	_	O
108	C30	_	_	O
109	before	_	_	O
110	treatment	_	_	O
111	,	_	_	O
112	within	_	_	O
113	3	_	_	O
114	days	_	_	O
115	before	_	_	O
116	the	_	_	O
117	second	_	_	O
118	and	_	_	O
119	the	_	_	O
120	fourth	_	_	O
121	chemotherapy	_	_	O
122	cycle	_	_	O
123	,	_	_	O
124	and	_	_	O
125	3	_	_	O
126	weeks	_	_	O
127	after	_	_	O
128	completion	_	_	O
129	of	_	_	O
130	chemotherapy	_	_	O
131	.	_	_	O

132	Previously	_	_	O
133	reported	_	_	O
134	data	_	_	O
135	showed	_	_	O
136	that	_	_	O
137	patients	_	_	O
138	undergoing	_	_	O
139	TC	_	_	O
140	or	_	_	O
141	PT	_	_	O
142	did	_	_	O
143	not	_	_	O
144	differ	_	_	O
145	in	_	_	O
146	progression	_	_	O
147	-	_	_	O
148	free	_	_	O
149	survival	_	_	O
150	and	_	_	O
151	overall	_	_	O
152	survival	_	_	O
153	.	_	_	O

154	However	_	_	O
155	,	_	_	O
156	the	_	_	O
157	TC	_	_	O
158	arm	_	_	O
159	was	_	_	O
160	superior	_	_	O
161	,	_	_	O
162	indicating	_	_	O
163	a	_	_	O
164	better	_	_	O
165	overall	_	_	O
166	QoL	_	_	O
167	compared	_	_	O
168	with	_	_	O
169	the	_	_	O
170	PT	_	_	O
171	arm	_	_	O
172	.	_	_	O

173	Controlling	_	_	O
174	for	_	_	O
175	toxicity	_	_	O
176	and	_	_	O
177	age	_	_	O
178	,	_	_	O
179	a	_	_	O
180	significant	_	_	O
181	treatment	_	_	O
182	by	_	_	O
183	assessment	_	_	O
184	time	_	_	O
185	interaction	_	_	O
186	was	_	_	O
187	found	_	_	O
188	for	_	_	O
189	four	_	_	O
190	QoL	_	_	O
191	functioning	_	_	O
192	scales	_	_	O
193	and	_	_	O
194	three	_	_	O
195	symptoms	_	_	O
196	scales	_	_	O
197	.	_	_	O

198	Patients	_	_	B-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	TC	_	_	I-Premise
202	arm	_	_	I-Premise
203	showed	_	_	I-Premise
204	better	_	_	I-Premise
205	means	_	_	I-Premise
206	scores	_	_	I-Premise
207	after	_	_	I-Premise
208	treatment	_	_	I-Premise
209	on	_	_	I-Premise
210	overall	_	_	I-Premise
211	QoL	_	_	I-Premise
212	(	_	_	I-Premise
213	P	_	_	I-Premise
214	=	_	_	I-Premise
215	.	_	_	I-Premise

216	012	_	_	I-Premise
217	)	_	_	I-Premise
218	,	_	_	I-Premise
219	physical	_	_	I-Premise
220	functioning	_	_	I-Premise
221	(	_	_	I-Premise
222	P	_	_	I-Premise
223	=	_	_	I-Premise
224	.	_	_	I-Premise

225	012	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	role	_	_	I-Premise
229	functioning	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	.	_	_	I-Premise

234	005	_	_	I-Premise
235	)	_	_	I-Premise
236	,	_	_	I-Premise
237	and	_	_	I-Premise
238	cognitive	_	_	I-Premise
239	functioning	_	_	I-Premise
240	(	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	.	_	_	I-Premise

244	024	_	_	I-Premise
245	)	_	_	I-Premise
246	,	_	_	I-Premise
247	compared	_	_	I-Premise
248	with	_	_	I-Premise
249	the	_	_	I-Premise
250	PT	_	_	I-Premise
251	arm	_	_	I-Premise
252	.	_	_	I-Premise

253	Concerning	_	_	B-Premise
254	symptom	_	_	I-Premise
255	experience	_	_	I-Premise
256	,	_	_	I-Premise
257	patients	_	_	I-Premise
258	undergoing	_	_	I-Premise
259	TC	_	_	I-Premise
260	showed	_	_	I-Premise
261	less	_	_	I-Premise
262	nausea	_	_	I-Premise
263	and	_	_	I-Premise
264	vomiting	_	_	I-Premise
265	(	_	_	I-Premise
266	P	_	_	I-Premise
267	<	_	_	I-Premise
268	.	_	_	I-Premise

269	001	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	less	_	_	I-Premise
273	appetite	_	_	I-Premise
274	loss	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	<	_	_	I-Premise
278	.	_	_	I-Premise

279	001	_	_	I-Premise
280	)	_	_	I-Premise
281	,	_	_	I-Premise
282	and	_	_	I-Premise
283	less	_	_	I-Premise
284	fatigue	_	_	I-Premise
285	(	_	_	I-Premise
286	P	_	_	I-Premise
287	=	_	_	I-Premise
288	.	_	_	I-Premise

289	033	_	_	I-Premise
290	)	_	_	I-Premise
291	after	_	_	I-Premise
292	completion	_	_	I-Premise
293	of	_	_	I-Premise
294	treatment	_	_	I-Premise
295	compared	_	_	I-Premise
296	with	_	_	I-Premise
297	patients	_	_	I-Premise
298	undergoing	_	_	I-Premise
299	PT	_	_	I-Premise
300	.	_	_	I-Premise

301	The	_	_	B-Claim
302	TC	_	_	I-Claim
303	regimen	_	_	I-Claim
304	achieved	_	_	I-Claim
305	better	_	_	I-Claim
306	QoL	_	_	I-Claim
307	outcomes	_	_	I-Claim
308	compared	_	_	I-Claim
309	with	_	_	I-Claim
310	the	_	_	I-Claim
311	PT	_	_	I-Claim
312	regimen	_	_	I-Claim
313	.	_	_	I-Claim

314	Thus	_	_	B-Claim
315	,	_	_	I-Claim
316	clinicians	_	_	I-Claim
317	may	_	_	I-Claim
318	consider	_	_	I-Claim
319	replacing	_	_	I-Claim
320	cisplatin	_	_	I-Claim
321	with	_	_	I-Claim
322	carboplatin	_	_	I-Claim
323	when	_	_	I-Claim
324	treating	_	_	I-Claim
325	ovarian	_	_	I-Claim
326	cancer	_	_	I-Claim
327	patients	_	_	I-Claim
328	with	_	_	I-Claim
329	chemotherapy	_	_	I-Claim
330	.	_	_	I-Claim


0	Research	_	_	B-Claim
1	suggests	_	_	I-Claim
2	that	_	_	I-Claim
3	stress	_	_	I-Claim
4	-	_	_	I-Claim
5	reduction	_	_	I-Claim
6	programs	_	_	I-Claim
7	tailored	_	_	I-Claim
8	to	_	_	I-Claim
9	the	_	_	I-Claim
10	cancer	_	_	I-Claim
11	setting	_	_	I-Claim
12	help	_	_	I-Claim
13	patients	_	_	I-Claim
14	cope	_	_	I-Claim
15	with	_	_	I-Claim
16	the	_	_	I-Claim
17	effects	_	_	I-Claim
18	of	_	_	I-Claim
19	treatment	_	_	I-Claim
20	and	_	_	I-Claim
21	improve	_	_	I-Claim
22	their	_	_	I-Claim
23	quality	_	_	I-Claim
24	of	_	_	I-Claim
25	life	_	_	I-Claim
26	.	_	_	I-Claim

27	Yoga	_	_	O
28	,	_	_	O
29	an	_	_	O
30	ancient	_	_	O
31	Eastern	_	_	O
32	science	_	_	O
33	,	_	_	O
34	incorporates	_	_	O
35	stress	_	_	O
36	-	_	_	O
37	reduction	_	_	O
38	techniques	_	_	O
39	that	_	_	O
40	include	_	_	O
41	regulated	_	_	O
42	breathing	_	_	O
43	,	_	_	O
44	visual	_	_	O
45	imagery	_	_	O
46	,	_	_	O
47	and	_	_	O
48	meditation	_	_	O
49	as	_	_	O
50	well	_	_	O
51	as	_	_	O
52	various	_	_	O
53	postures	_	_	O
54	.	_	_	O

55	The	_	_	O
56	authors	_	_	O
57	examined	_	_	O
58	the	_	_	O
59	effects	_	_	O
60	of	_	_	O
61	the	_	_	O
62	Tibetan	_	_	O
63	yoga	_	_	O
64	(	_	_	O
65	TY	_	_	O
66	)	_	_	O
67	practices	_	_	O
68	of	_	_	O
69	Tsa	_	_	O
70	lung	_	_	O
71	and	_	_	O
72	Trul	_	_	O
73	khor	_	_	O
74	,	_	_	O
75	which	_	_	O
76	incorporate	_	_	O
77	controlled	_	_	O
78	breathing	_	_	O
79	and	_	_	O
80	visualization	_	_	O
81	,	_	_	O
82	mindfulness	_	_	O
83	techniques	_	_	O
84	,	_	_	O
85	and	_	_	O
86	low	_	_	O
87	-	_	_	O
88	impact	_	_	O
89	postures	_	_	O
90	in	_	_	O
91	patients	_	_	O
92	with	_	_	O
93	lymphoma	_	_	O
94	.	_	_	O

95	Thirty	_	_	O
96	-	_	_	O
97	nine	_	_	O
98	patients	_	_	O
99	with	_	_	O
100	lymphoma	_	_	O
101	who	_	_	O
102	were	_	_	O
103	undergoing	_	_	O
104	treatment	_	_	O
105	or	_	_	O
106	who	_	_	O
107	had	_	_	O
108	concluded	_	_	O
109	treatment	_	_	O
110	within	_	_	O
111	the	_	_	O
112	past	_	_	O
113	12	_	_	O
114	months	_	_	O
115	were	_	_	O
116	assigned	_	_	O
117	to	_	_	O
118	a	_	_	O
119	TY	_	_	O
120	group	_	_	O
121	or	_	_	O
122	to	_	_	O
123	a	_	_	O
124	wait	_	_	O
125	-	_	_	O
126	list	_	_	O
127	control	_	_	O
128	group	_	_	O
129	.	_	_	O

130	Patients	_	_	O
131	in	_	_	O
132	the	_	_	O
133	TY	_	_	O
134	group	_	_	O
135	participated	_	_	O
136	in	_	_	O
137	7	_	_	O
138	weekly	_	_	O
139	yoga	_	_	O
140	sessions	_	_	O
141	,	_	_	O
142	and	_	_	O
143	patients	_	_	O
144	in	_	_	O
145	the	_	_	O
146	wait	_	_	O
147	-	_	_	O
148	list	_	_	O
149	control	_	_	O
150	group	_	_	O
151	were	_	_	O
152	free	_	_	O
153	to	_	_	O
154	participate	_	_	O
155	in	_	_	O
156	the	_	_	O
157	TY	_	_	O
158	program	_	_	O
159	after	_	_	O
160	the	_	_	O
161	3	_	_	O
162	-	_	_	O
163	month	_	_	O
164	follow	_	_	O
165	-	_	_	O
166	up	_	_	O
167	assessment	_	_	O
168	.	_	_	O

169	Eighty	_	_	O
170	nine	_	_	O
171	percent	_	_	O
172	of	_	_	O
173	TY	_	_	O
174	participants	_	_	O
175	completed	_	_	O
176	at	_	_	O
177	least	_	_	O
178	2	_	_	O
179	-	_	_	O
180	3	_	_	O
181	three	_	_	O
182	yoga	_	_	O
183	sessions	_	_	O
184	,	_	_	O
185	and	_	_	O
186	58	_	_	O
187	%	_	_	O
188	completed	_	_	O
189	at	_	_	O
190	least	_	_	O
191	5	_	_	O
192	sessions	_	_	O
193	.	_	_	O

194	Patients	_	_	B-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	TY	_	_	I-Premise
198	group	_	_	I-Premise
199	reported	_	_	I-Premise
200	significantly	_	_	I-Premise
201	lower	_	_	I-Premise
202	sleep	_	_	I-Premise
203	disturbance	_	_	I-Premise
204	scores	_	_	I-Premise
205	during	_	_	I-Premise
206	follow	_	_	I-Premise
207	-	_	_	I-Premise
208	up	_	_	I-Premise
209	compared	_	_	I-Premise
210	with	_	_	I-Premise
211	patients	_	_	I-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	wait	_	_	I-Premise
215	-	_	_	I-Premise
216	list	_	_	I-Premise
217	control	_	_	I-Premise
218	group	_	_	I-Premise
219	(	_	_	I-Premise
220	5	_	_	I-Premise
221	.	_	_	I-Premise

222	8	_	_	I-Premise
223	vs	_	_	I-Premise
224	.	_	_	I-Premise

225	8	_	_	I-Premise
226	.	_	_	I-Premise

227	1	_	_	I-Premise
228	;	_	_	I-Premise
229	P	_	_	I-Premise
230	<	_	_	I-Premise
231	0	_	_	I-Premise
232	.	_	_	I-Premise

233	004	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	This	_	_	B-Premise
237	included	_	_	I-Premise
238	better	_	_	I-Premise
239	subjective	_	_	I-Premise
240	sleep	_	_	I-Premise
241	quality	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	0	_	_	I-Premise
246	.	_	_	I-Premise

247	02	_	_	I-Premise
248	)	_	_	I-Premise
249	,	_	_	I-Premise
250	faster	_	_	I-Premise
251	sleep	_	_	I-Premise
252	latency	_	_	I-Premise
253	(	_	_	I-Premise
254	P	_	_	I-Premise
255	<	_	_	I-Premise
256	0	_	_	I-Premise
257	.	_	_	I-Premise

258	01	_	_	I-Premise
259	)	_	_	I-Premise
260	,	_	_	I-Premise
261	longer	_	_	I-Premise
262	sleep	_	_	I-Premise
263	duration	_	_	I-Premise
264	(	_	_	I-Premise
265	P	_	_	I-Premise
266	<	_	_	I-Premise
267	0	_	_	I-Premise
268	.	_	_	I-Premise

269	03	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	and	_	_	I-Premise
273	less	_	_	I-Premise
274	use	_	_	I-Premise
275	of	_	_	I-Premise
276	sleep	_	_	I-Premise
277	medications	_	_	I-Premise
278	(	_	_	I-Premise
279	P	_	_	I-Premise
280	<	_	_	I-Premise
281	0	_	_	I-Premise
282	.	_	_	I-Premise

283	02	_	_	I-Premise
284	)	_	_	I-Premise
285	.	_	_	I-Premise

286	There	_	_	B-Premise
287	were	_	_	I-Premise
288	no	_	_	I-Premise
289	significant	_	_	I-Premise
290	differences	_	_	I-Premise
291	between	_	_	I-Premise
292	groups	_	_	I-Premise
293	in	_	_	I-Premise
294	terms	_	_	I-Premise
295	of	_	_	I-Premise
296	intrusion	_	_	I-Premise
297	or	_	_	I-Premise
298	avoidance	_	_	I-Premise
299	,	_	_	I-Premise
300	state	_	_	I-Premise
301	anxiety	_	_	I-Premise
302	,	_	_	I-Premise
303	depression	_	_	I-Premise
304	,	_	_	I-Premise
305	or	_	_	I-Premise
306	fatigue	_	_	I-Premise
307	.	_	_	I-Premise

308	The	_	_	B-Claim
309	participation	_	_	I-Claim
310	rates	_	_	I-Claim
311	suggested	_	_	I-Claim
312	that	_	_	I-Claim
313	a	_	_	I-Claim
314	TY	_	_	I-Claim
315	program	_	_	I-Claim
316	is	_	_	I-Claim
317	feasible	_	_	I-Claim
318	for	_	_	I-Claim
319	patients	_	_	I-Claim
320	with	_	_	I-Claim
321	cancer	_	_	I-Claim
322	and	_	_	I-Claim
323	that	_	_	I-Claim
324	such	_	_	I-Claim
325	a	_	_	I-Claim
326	program	_	_	I-Claim
327	significantly	_	_	I-Claim
328	improves	_	_	I-Claim
329	sleep	_	_	I-Claim
330	-	_	_	I-Claim
331	related	_	_	I-Claim
332	outcomes	_	_	I-Claim
333	.	_	_	I-Claim

334	However	_	_	B-Premise
335	,	_	_	I-Premise
336	there	_	_	I-Premise
337	were	_	_	I-Premise
338	no	_	_	I-Premise
339	significant	_	_	I-Premise
340	differences	_	_	I-Premise
341	between	_	_	I-Premise
342	groups	_	_	I-Premise
343	for	_	_	I-Premise
344	the	_	_	I-Premise
345	other	_	_	I-Premise
346	outcomes	_	_	I-Premise
347	.	_	_	I-Premise


0	We	_	_	O
1	analyzed	_	_	O
2	the	_	_	O
3	long	_	_	O
4	-	_	_	O
5	term	_	_	O
6	survival	_	_	O
7	of	_	_	O
8	children	_	_	O
9	under	_	_	O
10	6	_	_	O
11	years	_	_	O
12	of	_	_	O
13	age	_	_	O
14	(	_	_	O
15	<	_	_	O
16	6	_	_	O
17	years	_	_	O
18	)	_	_	O
19	enrolled	_	_	O
20	upon	_	_	O
21	the	_	_	O
22	Children	_	_	O
23	'	_	_	O
24	s	_	_	O
25	Cancer	_	_	O
26	Group	_	_	O
27	(	_	_	O
28	CCG	_	_	O
29	)	_	_	O
30	-	_	_	O
31	945	_	_	O
32	high	_	_	O
33	-	_	_	O
34	grade	_	_	O
35	glioma	_	_	O
36	(	_	_	O
37	HGG	_	_	O
38	)	_	_	O
39	study	_	_	O
40	to	_	_	O
41	determine	_	_	O
42	the	_	_	O
43	impact	_	_	O
44	of	_	_	O
45	intrinsic	_	_	O
46	biological	_	_	O
47	characteristics	_	_	O
48	as	_	_	O
49	well	_	_	O
50	as	_	_	O
51	treatment	_	_	O
52	upon	_	_	O
53	both	_	_	O
54	survival	_	_	O
55	and	_	_	O
56	quality	_	_	O
57	of	_	_	O
58	life	_	_	O
59	(	_	_	O
60	QOL	_	_	O
61	)	_	_	O
62	in	_	_	O
63	this	_	_	O
64	younger	_	_	O
65	age	_	_	O
66	population	_	_	O
67	.	_	_	O

68	Analyses	_	_	O
69	were	_	_	O
70	undertaken	_	_	O
71	on	_	_	O
72	patients	_	_	O
73	<	_	_	O
74	6	_	_	O
75	years	_	_	O
76	with	_	_	O
77	institutionally	_	_	O
78	diagnosed	_	_	O
79	HGG	_	_	O
80	enrolled	_	_	O
81	on	_	_	O
82	the	_	_	O
83	CCG	_	_	O
84	-	_	_	O
85	945	_	_	O
86	trial	_	_	O
87	.	_	_	O

88	Comparisons	_	_	O
89	of	_	_	O
90	survival	_	_	O
91	were	_	_	O
92	performed	_	_	O
93	for	_	_	O
94	patients	_	_	O
95	<	_	_	O
96	3	_	_	O
97	years	_	_	O
98	of	_	_	O
99	age	_	_	O
100	(	_	_	O
101	<	_	_	O
102	3	_	_	O
103	years	_	_	O
104	)	_	_	O
105	(	_	_	O
106	treated	_	_	O
107	with	_	_	O
108	intent	_	_	O
109	to	_	_	O
110	avoid	_	_	O
111	irradiation	_	_	O
112	)	_	_	O
113	versus	_	_	O
114	those	_	_	O
115	between	_	_	O
116	3	_	_	O
117	and	_	_	O
118	6	_	_	O
119	years	_	_	O
120	of	_	_	O
121	age	_	_	O
122	(	_	_	O
123	3	_	_	O
124	-	_	_	O
125	6	_	_	O
126	years	_	_	O
127	)	_	_	O
128	(	_	_	O
129	treated	_	_	O
130	with	_	_	O
131	irradiation	_	_	O
132	and	_	_	O
133	chemotherapy	_	_	O
134	)	_	_	O
135	at	_	_	O
136	diagnosis	_	_	O
137	.	_	_	O

138	Discordance	_	_	O
139	between	_	_	O
140	the	_	_	O
141	institutional	_	_	O
142	diagnoses	_	_	O
143	of	_	_	O
144	HGG	_	_	O
145	and	_	_	O
146	consensus	_	_	O
147	-	_	_	O
148	reviewed	_	_	O
149	diagnoses	_	_	O
150	led	_	_	O
151	us	_	_	O
152	to	_	_	O
153	perform	_	_	O
154	further	_	_	O
155	survival	_	_	O
156	analyses	_	_	O
157	for	_	_	O
158	both	_	_	O
159	groups	_	_	O
160	.	_	_	O

161	We	_	_	O
162	compared	_	_	O
163	the	_	_	O
164	two	_	_	O
165	groups	_	_	O
166	of	_	_	O
167	patients	_	_	O
168	for	_	_	O
169	biological	_	_	O
170	markers	_	_	O
171	,	_	_	O
172	and	_	_	O
173	evaluated	_	_	O
174	the	_	_	O
175	neuropsychological	_	_	O
176	and	_	_	O
177	QOL	_	_	O
178	outcomes	_	_	O
179	of	_	_	O
180	long	_	_	O
181	-	_	_	O
182	term	_	_	O
183	survivors	_	_	O
184	.	_	_	O

185	Patients	_	_	B-Premise
186	<	_	_	I-Premise
187	3	_	_	I-Premise
188	years	_	_	I-Premise
189	(	_	_	I-Premise
190	n	_	_	I-Premise
191	=	_	_	I-Premise
192	49	_	_	I-Premise
193	,	_	_	I-Premise
194	19	_	_	I-Premise
195	.	_	_	I-Premise

196	5	_	_	I-Premise
197	%	_	_	I-Premise
198	of	_	_	I-Premise
199	all	_	_	I-Premise
200	enrolled	_	_	I-Premise
201	patients	_	_	I-Premise
202	)	_	_	I-Premise
203	at	_	_	I-Premise
204	diagnosis	_	_	I-Premise
205	had	_	_	I-Premise
206	a	_	_	I-Premise
207	10	_	_	I-Premise
208	-	_	_	I-Premise
209	year	_	_	I-Premise
210	EFS	_	_	I-Premise
211	and	_	_	I-Premise
212	OS	_	_	I-Premise
213	of	_	_	I-Premise
214	29	_	_	I-Premise
215	±	_	_	I-Premise
216	6	_	_	I-Premise
217	.	_	_	I-Premise

218	5	_	_	I-Premise
219	%	_	_	I-Premise
220	and	_	_	I-Premise
221	37	_	_	I-Premise
222	.	_	_	I-Premise

223	5	_	_	I-Premise
224	±	_	_	I-Premise
225	7	_	_	I-Premise
226	%	_	_	I-Premise
227	,	_	_	I-Premise
228	respectively	_	_	I-Premise
229	,	_	_	I-Premise
230	while	_	_	I-Premise
231	for	_	_	I-Premise
232	patients	_	_	I-Premise
233	3	_	_	I-Premise
234	-	_	_	I-Premise
235	6	_	_	I-Premise
236	years	_	_	I-Premise
237	(	_	_	I-Premise
238	n	_	_	I-Premise
239	=	_	_	I-Premise
240	34	_	_	I-Premise
241	,	_	_	I-Premise
242	13	_	_	I-Premise
243	.	_	_	I-Premise

244	5	_	_	I-Premise
245	%	_	_	I-Premise
246	of	_	_	I-Premise
247	all	_	_	I-Premise
248	enrolled	_	_	I-Premise
249	patients	_	_	I-Premise
250	)	_	_	I-Premise
251	10	_	_	I-Premise
252	-	_	_	I-Premise
253	year	_	_	I-Premise
254	EFS	_	_	I-Premise
255	and	_	_	I-Premise
256	OS	_	_	I-Premise
257	were	_	_	I-Premise
258	35	_	_	I-Premise
259	±	_	_	I-Premise
260	8	_	_	I-Premise
261	%	_	_	I-Premise
262	and	_	_	I-Premise
263	36	_	_	I-Premise
264	±	_	_	I-Premise
265	8	_	_	I-Premise
266	%	_	_	I-Premise
267	,	_	_	I-Premise
268	respectively	_	_	I-Premise
269	.	_	_	I-Premise

270	Molecular	_	_	B-Premise
271	marker	_	_	I-Premise
272	analysis	_	_	I-Premise
273	showed	_	_	I-Premise
274	that	_	_	I-Premise
275	a	_	_	I-Premise
276	smaller	_	_	I-Premise
277	proportion	_	_	I-Premise
278	of	_	_	I-Premise
279	patients	_	_	I-Premise
280	<	_	_	I-Premise
281	3	_	_	I-Premise
282	years	_	_	I-Premise
283	harbored	_	_	I-Premise
284	TP53	_	_	I-Premise
285	mutations	_	_	I-Premise
286	(	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	0	_	_	I-Premise
290	.	_	_	I-Premise

291	05	_	_	I-Premise
292	)	_	_	I-Premise
293	.	_	_	I-Premise

294	Analysis	_	_	B-Premise
295	of	_	_	I-Premise
296	QOL	_	_	I-Premise
297	outcomes	_	_	I-Premise
298	with	_	_	I-Premise
299	a	_	_	I-Premise
300	median	_	_	I-Premise
301	length	_	_	I-Premise
302	of	_	_	I-Premise
303	follow	_	_	I-Premise
304	-	_	_	I-Premise
305	up	_	_	I-Premise
306	of	_	_	I-Premise
307	15	_	_	I-Premise
308	.	_	_	I-Premise

309	1	_	_	I-Premise
310	years	_	_	I-Premise
311	(	_	_	I-Premise
312	9	_	_	I-Premise
313	.	_	_	I-Premise

314	5	_	_	I-Premise
315	-	_	_	I-Premise
316	19	_	_	I-Premise
317	.	_	_	I-Premise

318	2	_	_	I-Premise
319	)	_	_	I-Premise
320	showed	_	_	I-Premise
321	comparable	_	_	I-Premise
322	results	_	_	I-Premise
323	.	_	_	I-Premise

324	QOL	_	_	B-Claim
325	and	_	_	I-Claim
326	survival	_	_	I-Claim
327	data	_	_	I-Claim
328	were	_	_	I-Claim
329	similar	_	_	I-Claim
330	for	_	_	I-Claim
331	the	_	_	I-Claim
332	two	_	_	I-Claim
333	groups	_	_	I-Claim
334	.	_	_	I-Claim

335	A	_	_	B-Claim
336	larger	_	_	I-Claim
337	prospective	_	_	I-Claim
338	study	_	_	I-Claim
339	is	_	_	I-Claim
340	justified	_	_	I-Claim
341	to	_	_	I-Claim
342	study	_	_	I-Claim
343	the	_	_	I-Claim
344	efficacy	_	_	I-Claim
345	of	_	_	I-Claim
346	chemotherapy	_	_	I-Claim
347	only	_	_	I-Claim
348	regimens	_	_	I-Claim
349	in	_	_	I-Claim
350	younger	_	_	I-Claim
351	children	_	_	I-Claim
352	.	_	_	I-Claim


0	Quality	_	_	O
1	of	_	_	O
2	life	_	_	O
3	is	_	_	O
4	an	_	_	O
5	important	_	_	O
6	outcome	_	_	O
7	measure	_	_	O
8	in	_	_	O
9	the	_	_	O
10	care	_	_	O
11	of	_	_	O
12	patients	_	_	O
13	with	_	_	O
14	cancer	_	_	O
15	.	_	_	O

16	We	_	_	O
17	developed	_	_	O
18	a	_	_	O
19	new	_	_	O
20	scoring	_	_	O
21	system	_	_	O
22	specifically	_	_	O
23	for	_	_	O
24	the	_	_	O
25	evaluation	_	_	O
26	of	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	upper	_	_	O
30	gastrointestinal	_	_	O
31	cancer	_	_	O
32	and	_	_	O
33	postoperative	_	_	O
34	gastrointestinal	_	_	O
35	dysfunction	_	_	O
36	.	_	_	O

37	This	_	_	O
38	study	_	_	O
39	was	_	_	O
40	undertaken	_	_	O
41	to	_	_	O
42	evaluate	_	_	O
43	the	_	_	O
44	scoring	_	_	O
45	system	_	_	O
46	'	_	_	O
47	s	_	_	O
48	validity	_	_	O
49	in	_	_	O
50	comparing	_	_	O
51	outcomes	_	_	O
52	after	_	_	O
53	gastric	_	_	O
54	resection	_	_	O
55	.	_	_	O

56	Patients	_	_	O
57	with	_	_	O
58	gastric	_	_	O
59	cancer	_	_	O
60	,	_	_	O
61	3	_	_	O
62	months	_	_	O
63	to	_	_	O
64	3	_	_	O
65	years	_	_	O
66	postoperatively	_	_	O
67	,	_	_	O
68	were	_	_	O
69	surveyed	_	_	O
70	using	_	_	O
71	the	_	_	O
72	survey	_	_	O
73	instrument	_	_	O
74	.	_	_	O

75	Postoperative	_	_	O
76	dysfunction	_	_	O
77	scores	_	_	O
78	and	_	_	O
79	the	_	_	O
80	status	_	_	O
81	of	_	_	O
82	resuming	_	_	O
83	activities	_	_	O
84	of	_	_	O
85	daily	_	_	O
86	living	_	_	O
87	were	_	_	O
88	compared	_	_	O
89	with	_	_	O
90	the	_	_	O
91	surgical	_	_	O
92	procedure	_	_	O
93	performed	_	_	O
94	by	_	_	O
95	analysis	_	_	O
96	of	_	_	O
97	variance	_	_	O
98	and	_	_	O
99	multiple	_	_	O
100	-	_	_	O
101	comparison	_	_	O
102	techniques	_	_	O
103	.	_	_	O

104	Of	_	_	O
105	211	_	_	O
106	patients	_	_	O
107	surveyed	_	_	O
108	,	_	_	O
109	165	_	_	O
110	(	_	_	O
111	119	_	_	O
112	men	_	_	O
113	,	_	_	O
114	46	_	_	O
115	women	_	_	O
116	;	_	_	O
117	mean	_	_	O
118	age	_	_	O
119	,	_	_	O
120	65	_	_	O
121	.	_	_	O

122	1	_	_	O
123	±	_	_	O
124	10	_	_	O
125	.	_	_	O

126	5	_	_	O
127	years	_	_	O
128	)	_	_	O
129	responded	_	_	O
130	.	_	_	O

131	Procedures	_	_	O
132	included	_	_	O
133	distal	_	_	O
134	gastrectomy	_	_	O
135	in	_	_	O
136	100	_	_	O
137	,	_	_	O
138	total	_	_	O
139	gastrectomy	_	_	O
140	in	_	_	O
141	57	_	_	O
142	,	_	_	O
143	and	_	_	O
144	pylorus	_	_	O
145	-	_	_	O
146	preserving	_	_	O
147	gastrectomy	_	_	O
148	in	_	_	O
149	8	_	_	O
150	.	_	_	O

151	The	_	_	O
152	overall	_	_	O
153	dysfunction	_	_	O
154	score	_	_	O
155	was	_	_	O
156	61	_	_	O
157	.	_	_	O

158	8	_	_	O
159	±	_	_	O
160	15	_	_	O
161	.	_	_	O

162	5	_	_	O
163	.	_	_	O

164	The	_	_	B-Premise
165	dysfunction	_	_	I-Premise
166	score	_	_	I-Premise
167	was	_	_	I-Premise
168	58	_	_	I-Premise
169	.	_	_	I-Premise

170	9	_	_	I-Premise
171	±	_	_	I-Premise
172	15	_	_	I-Premise
173	.	_	_	I-Premise

174	0	_	_	I-Premise
175	after	_	_	I-Premise
176	distal	_	_	I-Premise
177	gastrectomy	_	_	I-Premise
178	,	_	_	I-Premise
179	66	_	_	I-Premise
180	.	_	_	I-Premise

181	8	_	_	I-Premise
182	±	_	_	I-Premise
183	14	_	_	I-Premise
184	.	_	_	I-Premise

185	1	_	_	I-Premise
186	after	_	_	I-Premise
187	total	_	_	I-Premise
188	gastrectomy	_	_	I-Premise
189	,	_	_	I-Premise
190	and	_	_	I-Premise
191	62	_	_	I-Premise
192	.	_	_	I-Premise

193	4	_	_	I-Premise
194	±	_	_	I-Premise
195	21	_	_	I-Premise
196	.	_	_	I-Premise

197	6	_	_	I-Premise
198	after	_	_	I-Premise
199	pylorus	_	_	I-Premise
200	-	_	_	I-Premise
201	preserving	_	_	I-Premise
202	gastrectomy	_	_	I-Premise
203	.	_	_	I-Premise

204	These	_	_	B-Premise
205	values	_	_	I-Premise
206	differed	_	_	I-Premise
207	significantly	_	_	I-Premise
208	among	_	_	I-Premise
209	the	_	_	I-Premise
210	groups	_	_	I-Premise
211	(	_	_	I-Premise
212	P	_	_	I-Premise
213	=	_	_	I-Premise
214	.	_	_	I-Premise

215	007	_	_	I-Premise
216	)	_	_	I-Premise
217	.	_	_	I-Premise

218	Dysfunction	_	_	B-Premise
219	scores	_	_	I-Premise
220	according	_	_	I-Premise
221	to	_	_	I-Premise
222	postoperative	_	_	I-Premise
223	activity	_	_	I-Premise
224	status	_	_	I-Premise
225	were	_	_	I-Premise
226	49	_	_	I-Premise
227	.	_	_	I-Premise

228	1	_	_	I-Premise
229	±	_	_	I-Premise
230	15	_	_	I-Premise
231	.	_	_	I-Premise

232	6	_	_	I-Premise
233	in	_	_	I-Premise
234	71	_	_	I-Premise
235	patients	_	_	I-Premise
236	who	_	_	I-Premise
237	resumed	_	_	I-Premise
238	their	_	_	I-Premise
239	activities	_	_	I-Premise
240	,	_	_	I-Premise
241	56	_	_	I-Premise
242	.	_	_	I-Premise

243	9	_	_	I-Premise
244	±	_	_	I-Premise
245	15	_	_	I-Premise
246	.	_	_	I-Premise

247	7	_	_	I-Premise
248	in	_	_	I-Premise
249	39	_	_	I-Premise
250	patients	_	_	I-Premise
251	with	_	_	I-Premise
252	reduced	_	_	I-Premise
253	activities	_	_	I-Premise
254	,	_	_	I-Premise
255	57	_	_	I-Premise
256	.	_	_	I-Premise

257	3	_	_	I-Premise
258	±	_	_	I-Premise
259	8	_	_	I-Premise
260	.	_	_	I-Premise

261	8	_	_	I-Premise
262	in	_	_	I-Premise
263	15	_	_	I-Premise
264	patients	_	_	I-Premise
265	with	_	_	I-Premise
266	minimal	_	_	I-Premise
267	activities	_	_	I-Premise
268	,	_	_	I-Premise
269	and	_	_	I-Premise
270	63	_	_	I-Premise
271	.	_	_	I-Premise

272	3	_	_	I-Premise
273	±	_	_	I-Premise
274	11	_	_	I-Premise
275	.	_	_	I-Premise

276	8	_	_	I-Premise
277	(	_	_	I-Premise
278	P	_	_	I-Premise
279	<	_	_	I-Premise
280	.	_	_	I-Premise

281	05	_	_	I-Premise
282	)	_	_	I-Premise
283	in	_	_	I-Premise
284	16	_	_	I-Premise
285	patients	_	_	I-Premise
286	who	_	_	I-Premise
287	did	_	_	I-Premise
288	not	_	_	I-Premise
289	resume	_	_	I-Premise
290	activities	_	_	I-Premise
291	because	_	_	I-Premise
292	of	_	_	I-Premise
293	poor	_	_	I-Premise
294	physical	_	_	I-Premise
295	condition	_	_	I-Premise
296	.	_	_	I-Premise

297	This	_	_	B-Claim
298	scoring	_	_	I-Claim
299	system	_	_	I-Claim
300	for	_	_	I-Claim
301	postoperative	_	_	I-Claim
302	gastrointestinal	_	_	I-Claim
303	dysfunction	_	_	I-Claim
304	provides	_	_	I-Claim
305	an	_	_	I-Claim
306	objective	_	_	I-Claim
307	measure	_	_	I-Claim
308	of	_	_	I-Claim
309	dysfunction	_	_	I-Claim
310	related	_	_	I-Claim
311	to	_	_	I-Claim
312	specific	_	_	I-Claim
313	surgical	_	_	I-Claim
314	procedures	_	_	I-Claim
315	and	_	_	I-Claim
316	correlates	_	_	I-Claim
317	with	_	_	I-Claim
318	activities	_	_	I-Claim
319	of	_	_	I-Claim
320	daily	_	_	I-Claim
321	living	_	_	I-Claim
322	in	_	_	I-Claim
323	the	_	_	I-Claim
324	postoperative	_	_	I-Claim
325	period	_	_	I-Claim
326	.	_	_	I-Claim


0	In	_	_	O
1	a	_	_	O
2	phase	_	_	O
3	3	_	_	O
4	trial	_	_	O
5	comparing	_	_	O
6	the	_	_	O
7	efficacy	_	_	O
8	and	_	_	O
9	safety	_	_	O
10	of	_	_	O
11	axitinib	_	_	O
12	versus	_	_	O
13	sorafenib	_	_	O
14	as	_	_	O
15	second	_	_	O
16	-	_	_	O
17	line	_	_	O
18	treatment	_	_	O
19	for	_	_	O
20	metastatic	_	_	O
21	renal	_	_	O
22	cell	_	_	O
23	carcinoma	_	_	O
24	,	_	_	O
25	patients	_	_	O
26	given	_	_	O
27	axitinib	_	_	O
28	had	_	_	O
29	a	_	_	O
30	longer	_	_	O
31	progression	_	_	O
32	-	_	_	O
33	free	_	_	O
34	survival	_	_	O
35	(	_	_	O
36	PFS	_	_	O
37	)	_	_	O
38	.	_	_	O

39	Here	_	_	O
40	,	_	_	O
41	we	_	_	O
42	report	_	_	O
43	overall	_	_	O
44	survival	_	_	O
45	and	_	_	O
46	updated	_	_	O
47	efficacy	_	_	O
48	,	_	_	O
49	quality	_	_	O
50	of	_	_	O
51	life	_	_	O
52	,	_	_	O
53	and	_	_	O
54	safety	_	_	O
55	results	_	_	O
56	.	_	_	O

57	Eligible	_	_	O
58	patients	_	_	O
59	had	_	_	O
60	clear	_	_	O
61	cell	_	_	O
62	metastatic	_	_	O
63	renal	_	_	O
64	cell	_	_	O
65	carcinoma	_	_	O
66	,	_	_	O
67	progressive	_	_	O
68	disease	_	_	O
69	after	_	_	O
70	one	_	_	O
71	approved	_	_	O
72	systemic	_	_	O
73	treatment	_	_	O
74	,	_	_	O
75	and	_	_	O
76	an	_	_	O
77	Eastern	_	_	O
78	Cooperative	_	_	O
79	Oncology	_	_	O
80	Group	_	_	O
81	performance	_	_	O
82	status	_	_	O
83	(	_	_	O
84	ECOG	_	_	O
85	PS	_	_	O
86	)	_	_	O
87	of	_	_	O
88	0	_	_	O
89	-	_	_	O
90	1	_	_	O
91	.	_	_	O

92	723	_	_	O
93	patients	_	_	O
94	were	_	_	O
95	stratified	_	_	O
96	by	_	_	O
97	ECOG	_	_	O
98	PS	_	_	O
99	and	_	_	O
100	previous	_	_	O
101	treatment	_	_	O
102	and	_	_	O
103	randomly	_	_	O
104	allocated	_	_	O
105	(	_	_	O
106	1	_	_	O
107	:	_	_	O
108	1	_	_	O
109	)	_	_	O
110	to	_	_	O
111	receive	_	_	O
112	axitinib	_	_	O
113	(	_	_	O
114	5	_	_	O
115	mg	_	_	O
116	twice	_	_	O
117	daily	_	_	O
118	;	_	_	O
119	n	_	_	O
120	=	_	_	O
121	361	_	_	O
122	)	_	_	O
123	or	_	_	O
124	sorafenib	_	_	O
125	(	_	_	O
126	400	_	_	O
127	mg	_	_	O
128	twice	_	_	O
129	daily	_	_	O
130	;	_	_	O
131	n	_	_	O
132	=	_	_	O
133	362	_	_	O
134	)	_	_	O
135	.	_	_	O

136	The	_	_	O
137	primary	_	_	O
138	endpoint	_	_	O
139	was	_	_	O
140	PFS	_	_	O
141	assessed	_	_	O
142	by	_	_	O
143	a	_	_	O
144	masked	_	_	O
145	,	_	_	O
146	independent	_	_	O
147	radiology	_	_	O
148	review	_	_	O
149	committee	_	_	O
150	.	_	_	O

151	We	_	_	O
152	assessed	_	_	O
153	patient	_	_	O
154	-	_	_	O
155	reported	_	_	O
156	outcomes	_	_	O
157	using	_	_	O
158	validated	_	_	O
159	questionnaires	_	_	O
160	.	_	_	O

161	Baseline	_	_	O
162	characteristics	_	_	O
163	and	_	_	O
164	development	_	_	O
165	of	_	_	O
166	hypertension	_	_	O
167	on	_	_	O
168	treatment	_	_	O
169	were	_	_	O
170	studied	_	_	O
171	as	_	_	O
172	prognostic	_	_	O
173	factors	_	_	O
174	.	_	_	O

175	Efficacy	_	_	O
176	was	_	_	O
177	assessed	_	_	O
178	in	_	_	O
179	the	_	_	O
180	intention	_	_	O
181	-	_	_	O
182	to	_	_	O
183	-	_	_	O
184	treat	_	_	O
185	population	_	_	O
186	,	_	_	O
187	and	_	_	O
188	safety	_	_	O
189	was	_	_	O
190	assessed	_	_	O
191	in	_	_	O
192	patients	_	_	O
193	who	_	_	O
194	received	_	_	O
195	at	_	_	O
196	least	_	_	O
197	one	_	_	O
198	dose	_	_	O
199	of	_	_	O
200	the	_	_	O
201	study	_	_	O
202	drug	_	_	O
203	.	_	_	O

204	Median	_	_	B-Premise
205	overall	_	_	I-Premise
206	survival	_	_	I-Premise
207	was	_	_	I-Premise
208	20	_	_	I-Premise
209	.	_	_	I-Premise

210	1	_	_	I-Premise
211	months	_	_	I-Premise
212	(	_	_	I-Premise
213	95	_	_	I-Premise
214	%	_	_	I-Premise
215	CI	_	_	I-Premise
216	16	_	_	I-Premise
217	.	_	_	I-Premise

218	7	_	_	I-Premise
219	-	_	_	I-Premise
220	23	_	_	I-Premise
221	.	_	_	I-Premise

222	4	_	_	I-Premise
223	)	_	_	I-Premise
224	with	_	_	I-Premise
225	axitinib	_	_	I-Premise
226	and	_	_	I-Premise
227	19	_	_	I-Premise
228	.	_	_	I-Premise

229	2	_	_	I-Premise
230	months	_	_	I-Premise
231	(	_	_	I-Premise
232	17	_	_	I-Premise
233	.	_	_	I-Premise

234	5	_	_	I-Premise
235	-	_	_	I-Premise
236	22	_	_	I-Premise
237	.	_	_	I-Premise

238	3	_	_	I-Premise
239	)	_	_	I-Premise
240	with	_	_	I-Premise
241	sorafenib	_	_	I-Premise
242	(	_	_	I-Premise
243	hazard	_	_	I-Premise
244	ratio	_	_	I-Premise
245	[	_	_	I-Premise
246	HR	_	_	I-Premise
247	]	_	_	I-Premise
248	0	_	_	I-Premise
249	.	_	_	I-Premise

250	969	_	_	I-Premise
251	,	_	_	I-Premise
252	95	_	_	I-Premise
253	%	_	_	I-Premise
254	CI	_	_	I-Premise
255	0	_	_	I-Premise
256	.	_	_	I-Premise

257	800	_	_	I-Premise
258	-	_	_	I-Premise
259	1	_	_	I-Premise
260	.	_	_	I-Premise

261	174	_	_	I-Premise
262	;	_	_	I-Premise
263	one	_	_	I-Premise
264	-	_	_	I-Premise
265	sided	_	_	I-Premise
266	p	_	_	I-Premise
267	=	_	_	I-Premise
268	0	_	_	I-Premise
269	.	_	_	I-Premise

270	3744	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Median	_	_	B-Premise
274	investigator	_	_	I-Premise
275	-	_	_	I-Premise
276	assessed	_	_	I-Premise
277	PFS	_	_	I-Premise
278	was	_	_	I-Premise
279	8	_	_	I-Premise
280	.	_	_	I-Premise

281	3	_	_	I-Premise
282	months	_	_	I-Premise
283	(	_	_	I-Premise
284	95	_	_	I-Premise
285	%	_	_	I-Premise
286	CI	_	_	I-Premise
287	6	_	_	I-Premise
288	.	_	_	I-Premise

289	7	_	_	I-Premise
290	-	_	_	I-Premise
291	9	_	_	I-Premise
292	.	_	_	I-Premise

293	2	_	_	I-Premise
294	)	_	_	I-Premise
295	with	_	_	I-Premise
296	axitinib	_	_	I-Premise
297	and	_	_	I-Premise
298	5	_	_	I-Premise
299	·	_	_	I-Premise
300	7	_	_	I-Premise
301	months	_	_	I-Premise
302	(	_	_	I-Premise
303	4	_	_	I-Premise
304	.	_	_	I-Premise

305	7	_	_	I-Premise
306	-	_	_	I-Premise
307	6	_	_	I-Premise
308	.	_	_	I-Premise

309	5	_	_	I-Premise
310	)	_	_	I-Premise
311	with	_	_	I-Premise
312	sorafenib	_	_	I-Premise
313	(	_	_	I-Premise
314	HR	_	_	I-Premise
315	0	_	_	I-Premise
316	.	_	_	I-Premise

317	656	_	_	I-Premise
318	,	_	_	I-Premise
319	95	_	_	I-Premise
320	%	_	_	I-Premise
321	CI	_	_	I-Premise
322	0	_	_	I-Premise
323	.	_	_	I-Premise

324	552	_	_	I-Premise
325	-	_	_	I-Premise
326	0	_	_	I-Premise
327	.	_	_	I-Premise

328	779	_	_	I-Premise
329	;	_	_	I-Premise
330	one	_	_	I-Premise
331	-	_	_	I-Premise
332	sided	_	_	I-Premise
333	p	_	_	I-Premise
334	<	_	_	I-Premise
335	0	_	_	I-Premise
336	.	_	_	I-Premise

337	0001	_	_	I-Premise
338	)	_	_	I-Premise
339	.	_	_	I-Premise

340	Patient	_	_	B-Premise
341	-	_	_	I-Premise
342	reported	_	_	I-Premise
343	outcomes	_	_	I-Premise
344	scores	_	_	I-Premise
345	were	_	_	I-Premise
346	similar	_	_	I-Premise
347	in	_	_	I-Premise
348	the	_	_	I-Premise
349	treatment	_	_	I-Premise
350	groups	_	_	I-Premise
351	at	_	_	I-Premise
352	baseline	_	_	I-Premise
353	,	_	_	I-Premise
354	were	_	_	I-Premise
355	maintained	_	_	I-Premise
356	during	_	_	I-Premise
357	treatment	_	_	I-Premise
358	,	_	_	I-Premise
359	but	_	_	B-Premise
360	decreased	_	_	I-Premise
361	at	_	_	I-Premise
362	end	_	_	I-Premise
363	-	_	_	I-Premise
364	of	_	_	I-Premise
365	-	_	_	I-Premise
366	treatment	_	_	I-Premise
367	.	_	_	I-Premise

368	Common	_	_	B-Premise
369	grade	_	_	I-Premise
370	3	_	_	I-Premise
371	or	_	_	I-Premise
372	higher	_	_	I-Premise
373	treatment	_	_	I-Premise
374	-	_	_	I-Premise
375	related	_	_	I-Premise
376	adverse	_	_	I-Premise
377	events	_	_	I-Premise
378	were	_	_	I-Premise
379	hypertension	_	_	I-Premise
380	(	_	_	I-Premise
381	60	_	_	I-Premise
382	[	_	_	I-Premise
383	17	_	_	I-Premise
384	%	_	_	I-Premise
385	]	_	_	I-Premise
386	)	_	_	I-Premise
387	,	_	_	I-Premise
388	diarrhoea	_	_	I-Premise
389	(	_	_	I-Premise
390	40	_	_	I-Premise
391	[	_	_	I-Premise
392	11	_	_	I-Premise
393	%	_	_	I-Premise
394	]	_	_	I-Premise
395	)	_	_	I-Premise
396	,	_	_	I-Premise
397	and	_	_	I-Premise
398	fatigue	_	_	I-Premise
399	(	_	_	I-Premise
400	37	_	_	I-Premise
401	[	_	_	I-Premise
402	10	_	_	I-Premise
403	%	_	_	I-Premise
404	]	_	_	I-Premise
405	)	_	_	I-Premise
406	in	_	_	I-Premise
407	359	_	_	I-Premise
408	axitinib	_	_	I-Premise
409	-	_	_	I-Premise
410	treated	_	_	I-Premise
411	patients	_	_	I-Premise
412	and	_	_	I-Premise
413	hand	_	_	I-Premise
414	-	_	_	I-Premise
415	foot	_	_	I-Premise
416	syndrome	_	_	I-Premise
417	(	_	_	I-Premise
418	61	_	_	I-Premise
419	[	_	_	I-Premise
420	17	_	_	I-Premise
421	%	_	_	I-Premise
422	]	_	_	I-Premise
423	)	_	_	I-Premise
424	,	_	_	I-Premise
425	hypertension	_	_	I-Premise
426	(	_	_	I-Premise
427	43	_	_	I-Premise
428	[	_	_	I-Premise
429	12	_	_	I-Premise
430	%	_	_	I-Premise
431	]	_	_	I-Premise
432	)	_	_	I-Premise
433	,	_	_	I-Premise
434	and	_	_	I-Premise
435	diarrhoea	_	_	I-Premise
436	(	_	_	I-Premise
437	27	_	_	I-Premise
438	[	_	_	I-Premise
439	8	_	_	I-Premise
440	%	_	_	I-Premise
441	]	_	_	I-Premise
442	)	_	_	I-Premise
443	in	_	_	I-Premise
444	355	_	_	I-Premise
445	sorafenib	_	_	I-Premise
446	-	_	_	I-Premise
447	treated	_	_	I-Premise
448	patients	_	_	I-Premise
449	.	_	_	I-Premise

450	In	_	_	B-Premise
451	a	_	_	I-Premise
452	post	_	_	I-Premise
453	-	_	_	I-Premise
454	hoc	_	_	I-Premise
455	12	_	_	I-Premise
456	-	_	_	I-Premise
457	week	_	_	I-Premise
458	landmark	_	_	I-Premise
459	analysis	_	_	I-Premise
460	,	_	_	I-Premise
461	median	_	_	I-Premise
462	overall	_	_	I-Premise
463	survival	_	_	I-Premise
464	was	_	_	I-Premise
465	longer	_	_	I-Premise
466	in	_	_	I-Premise
467	patients	_	_	I-Premise
468	with	_	_	I-Premise
469	a	_	_	I-Premise
470	diastolic	_	_	I-Premise
471	blood	_	_	I-Premise
472	pressure	_	_	I-Premise
473	of	_	_	I-Premise
474	90	_	_	I-Premise
475	mm	_	_	I-Premise
476	Hg	_	_	I-Premise
477	or	_	_	I-Premise
478	greater	_	_	I-Premise
479	than	_	_	I-Premise
480	in	_	_	I-Premise
481	those	_	_	I-Premise
482	with	_	_	I-Premise
483	a	_	_	I-Premise
484	diastolic	_	_	I-Premise
485	blood	_	_	I-Premise
486	pressure	_	_	I-Premise
487	of	_	_	I-Premise
488	less	_	_	I-Premise
489	than	_	_	I-Premise
490	90	_	_	I-Premise
491	mm	_	_	I-Premise
492	Hg	_	_	I-Premise
493	:	_	_	I-Premise
494	20	_	_	I-Premise
495	.	_	_	I-Premise

496	7	_	_	I-Premise
497	months	_	_	I-Premise
498	(	_	_	I-Premise
499	95	_	_	I-Premise
500	%	_	_	I-Premise
501	CI	_	_	I-Premise
502	18	_	_	I-Premise
503	.	_	_	I-Premise

504	4	_	_	I-Premise
505	-	_	_	I-Premise
506	24	_	_	I-Premise
507	.	_	_	I-Premise

508	6	_	_	I-Premise
509	)	_	_	I-Premise
510	versus	_	_	I-Premise
511	12	_	_	I-Premise
512	.	_	_	I-Premise

513	9	_	_	I-Premise
514	months	_	_	I-Premise
515	(	_	_	I-Premise
516	10	_	_	I-Premise
517	.	_	_	I-Premise

518	1	_	_	I-Premise
519	-	_	_	I-Premise
520	20	_	_	I-Premise
521	.	_	_	I-Premise

522	4	_	_	I-Premise
523	)	_	_	I-Premise
524	in	_	_	I-Premise
525	the	_	_	I-Premise
526	axitinib	_	_	I-Premise
527	group	_	_	I-Premise
528	(	_	_	I-Premise
529	p	_	_	I-Premise
530	=	_	_	I-Premise
531	0	_	_	I-Premise
532	.	_	_	I-Premise

533	0116	_	_	I-Premise
534	)	_	_	I-Premise
535	,	_	_	I-Premise
536	and	_	_	I-Premise
537	20	_	_	I-Premise
538	.	_	_	I-Premise

539	2	_	_	I-Premise
540	months	_	_	I-Premise
541	(	_	_	I-Premise
542	17	_	_	I-Premise
543	.	_	_	I-Premise

544	1	_	_	I-Premise
545	-	_	_	I-Premise
546	32	_	_	I-Premise
547	.	_	_	I-Premise

548	0	_	_	I-Premise
549	)	_	_	I-Premise
550	versus	_	_	I-Premise
551	14	_	_	I-Premise
552	.	_	_	I-Premise

553	8	_	_	I-Premise
554	months	_	_	I-Premise
555	(	_	_	I-Premise
556	12	_	_	I-Premise
557	.	_	_	I-Premise

558	0	_	_	I-Premise
559	-	_	_	I-Premise
560	17	_	_	I-Premise
561	.	_	_	I-Premise

562	7	_	_	I-Premise
563	)	_	_	I-Premise
564	in	_	_	I-Premise
565	the	_	_	I-Premise
566	sorafenib	_	_	I-Premise
567	group	_	_	I-Premise
568	(	_	_	I-Premise
569	one	_	_	I-Premise
570	-	_	_	I-Premise
571	sided	_	_	I-Premise
572	p	_	_	I-Premise
573	=	_	_	I-Premise
574	0	_	_	I-Premise
575	.	_	_	I-Premise

576	0020	_	_	I-Premise
577	)	_	_	I-Premise
578	.	_	_	I-Premise

579	Although	_	_	O
580	overall	_	_	B-Claim
581	survival	_	_	I-Claim
582	,	_	_	I-Claim
583	a	_	_	I-Claim
584	secondary	_	_	I-Claim
585	endpoint	_	_	I-Claim
586	for	_	_	I-Claim
587	the	_	_	I-Claim
588	study	_	_	I-Claim
589	,	_	_	I-Claim
590	did	_	_	I-Claim
591	not	_	_	I-Claim
592	differ	_	_	I-Claim
593	between	_	_	I-Claim
594	the	_	_	I-Claim
595	two	_	_	I-Claim
596	groups	_	_	I-Claim
597	,	_	_	I-Claim
598	investigator	_	_	B-Claim
599	-	_	_	I-Claim
600	assessed	_	_	I-Claim
601	PFS	_	_	I-Claim
602	remained	_	_	I-Claim
603	longer	_	_	I-Claim
604	in	_	_	I-Claim
605	the	_	_	I-Claim
606	axitinib	_	_	I-Claim
607	group	_	_	I-Claim
608	compared	_	_	I-Claim
609	with	_	_	I-Claim
610	the	_	_	I-Claim
611	sorafenib	_	_	I-Claim
612	group	_	_	I-Claim
613	.	_	_	I-Claim

614	These	_	_	B-Claim
615	results	_	_	I-Claim
616	establish	_	_	I-Claim
617	axitinib	_	_	I-Claim
618	as	_	_	I-Claim
619	a	_	_	I-Claim
620	second	_	_	I-Claim
621	-	_	_	I-Claim
622	line	_	_	I-Claim
623	treatment	_	_	I-Claim
624	option	_	_	I-Claim
625	for	_	_	I-Claim
626	patients	_	_	I-Claim
627	with	_	_	I-Claim
628	metastatic	_	_	I-Claim
629	renal	_	_	I-Claim
630	cell	_	_	I-Claim
631	carcinoma	_	_	I-Claim
632	.	_	_	I-Claim


0	Shoulder	_	_	O
1	pain	_	_	O
2	and	_	_	O
3	disability	_	_	O
4	are	_	_	O
5	well	_	_	O
6	recognized	_	_	O
7	complications	_	_	O
8	associated	_	_	O
9	with	_	_	O
10	surgery	_	_	O
11	for	_	_	O
12	head	_	_	O
13	and	_	_	O
14	neck	_	_	O
15	cancer	_	_	O
16	.	_	_	O

17	This	_	_	O
18	study	_	_	O
19	was	_	_	O
20	designed	_	_	O
21	to	_	_	O
22	examine	_	_	O
23	the	_	_	O
24	effects	_	_	O
25	of	_	_	O
26	progressive	_	_	O
27	resistance	_	_	O
28	exercise	_	_	O
29	training	_	_	O
30	(	_	_	O
31	PRET	_	_	O
32	)	_	_	O
33	on	_	_	O
34	upper	_	_	O
35	extremity	_	_	O
36	pain	_	_	O
37	and	_	_	O
38	dysfunction	_	_	O
39	in	_	_	O
40	postsurgical	_	_	O
41	head	_	_	O
42	and	_	_	O
43	neck	_	_	O
44	cancer	_	_	O
45	survivors	_	_	O
46	.	_	_	O

47	Fifty	_	_	O
48	-	_	_	O
49	two	_	_	O
50	head	_	_	O
51	and	_	_	O
52	neck	_	_	O
53	cancer	_	_	O
54	survivors	_	_	O
55	were	_	_	O
56	assigned	_	_	O
57	randomly	_	_	O
58	to	_	_	O
59	PRET	_	_	O
60	(	_	_	O
61	n	_	_	O
62	=	_	_	O
63	27	_	_	O
64	)	_	_	O
65	or	_	_	O
66	a	_	_	O
67	standardized	_	_	O
68	therapeutic	_	_	O
69	exercise	_	_	O
70	protocol	_	_	O
71	(	_	_	O
72	TP	_	_	O
73	)	_	_	O
74	(	_	_	O
75	n	_	_	O
76	=	_	_	O
77	25	_	_	O
78	)	_	_	O
79	for	_	_	O
80	12	_	_	O
81	weeks	_	_	O
82	.	_	_	O

83	The	_	_	O
84	primary	_	_	O
85	endpoint	_	_	O
86	was	_	_	O
87	change	_	_	O
88	in	_	_	O
89	patient	_	_	O
90	-	_	_	O
91	rated	_	_	O
92	shoulder	_	_	O
93	pain	_	_	O
94	and	_	_	O
95	disability	_	_	O
96	from	_	_	O
97	baseline	_	_	O
98	to	_	_	O
99	postintervention	_	_	O
100	.	_	_	O

101	Secondary	_	_	O
102	endpoints	_	_	O
103	were	_	_	O
104	upper	_	_	O
105	extremity	_	_	O
106	strength	_	_	O
107	and	_	_	O
108	endurance	_	_	O
109	,	_	_	O
110	range	_	_	O
111	of	_	_	O
112	motion	_	_	O
113	,	_	_	O
114	fatigue	_	_	O
115	,	_	_	O
116	and	_	_	O
117	quality	_	_	O
118	of	_	_	O
119	life	_	_	O
120	.	_	_	O

121	Follow	_	_	O
122	-	_	_	O
123	up	_	_	O
124	assessment	_	_	O
125	for	_	_	O
126	the	_	_	O
127	primary	_	_	O
128	outcome	_	_	O
129	was	_	_	O
130	92	_	_	O
131	%	_	_	O
132	,	_	_	O
133	and	_	_	O
134	adherence	_	_	O
135	to	_	_	O
136	the	_	_	O
137	supervised	_	_	O
138	PRET	_	_	O
139	and	_	_	O
140	TP	_	_	O
141	programs	_	_	O
142	were	_	_	O
143	95	_	_	O
144	%	_	_	O
145	and	_	_	O
146	87	_	_	O
147	%	_	_	O
148	,	_	_	O
149	respectively	_	_	O
150	.	_	_	O

151	On	_	_	B-Premise
152	the	_	_	I-Premise
153	basis	_	_	I-Premise
154	of	_	_	I-Premise
155	intention	_	_	I-Premise
156	-	_	_	I-Premise
157	to	_	_	I-Premise
158	-	_	_	I-Premise
159	treat	_	_	I-Premise
160	analyses	_	_	I-Premise
161	,	_	_	I-Premise
162	PRET	_	_	I-Premise
163	was	_	_	I-Premise
164	superior	_	_	I-Premise
165	to	_	_	I-Premise
166	TP	_	_	I-Premise
167	for	_	_	I-Premise
168	improving	_	_	I-Premise
169	shoulder	_	_	I-Premise
170	pain	_	_	I-Premise
171	and	_	_	I-Premise
172	disability	_	_	I-Premise
173	(	_	_	I-Premise
174	-	_	_	I-Premise
175	9	_	_	I-Premise
176	.	_	_	I-Premise

177	6	_	_	I-Premise
178	;	_	_	I-Premise
179	95	_	_	I-Premise
180	%	_	_	I-Premise
181	confidence	_	_	I-Premise
182	interval	_	_	I-Premise
183	[	_	_	I-Premise
184	95	_	_	I-Premise
185	%	_	_	I-Premise
186	CI	_	_	I-Premise
187	]	_	_	I-Premise
188	,	_	_	I-Premise
189	-	_	_	I-Premise
190	16	_	_	I-Premise
191	.	_	_	I-Premise

192	4	_	_	I-Premise
193	to	_	_	I-Premise
194	-	_	_	I-Premise
195	4	_	_	I-Premise
196	.	_	_	I-Premise

197	5	_	_	I-Premise
198	;	_	_	I-Premise
199	P	_	_	I-Premise
200	=	_	_	I-Premise
201	.	_	_	I-Premise

202	001	_	_	I-Premise
203	)	_	_	I-Premise
204	,	_	_	I-Premise
205	upper	_	_	I-Premise
206	extremity	_	_	I-Premise
207	strength	_	_	I-Premise
208	(	_	_	I-Premise
209	+	_	_	I-Premise
210	10	_	_	I-Premise
211	.	_	_	I-Premise

212	8	_	_	I-Premise
213	kg	_	_	I-Premise
214	;	_	_	I-Premise
215	95	_	_	I-Premise
216	%	_	_	I-Premise
217	CI	_	_	I-Premise
218	,	_	_	I-Premise
219	5	_	_	I-Premise
220	.	_	_	I-Premise

221	4	_	_	I-Premise
222	-	_	_	I-Premise
223	16	_	_	I-Premise
224	.	_	_	I-Premise

225	2	_	_	I-Premise
226	kg	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	<	_	_	I-Premise
230	.	_	_	I-Premise

231	001	_	_	I-Premise
232	)	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	upper	_	_	I-Premise
236	extremity	_	_	I-Premise
237	endurance	_	_	I-Premise
238	(	_	_	I-Premise
239	+	_	_	I-Premise
240	194	_	_	I-Premise
241	repetitions	_	_	I-Premise
242	x	_	_	I-Premise
243	kg	_	_	I-Premise
244	;	_	_	I-Premise
245	95	_	_	I-Premise
246	%	_	_	I-Premise
247	CI	_	_	I-Premise
248	,	_	_	I-Premise
249	10	_	_	I-Premise
250	-	_	_	I-Premise
251	378	_	_	I-Premise
252	repetitions	_	_	I-Premise
253	x	_	_	I-Premise
254	kg	_	_	I-Premise
255	;	_	_	I-Premise
256	P	_	_	I-Premise
257	=	_	_	I-Premise
258	.	_	_	I-Premise

259	039	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Changes	_	_	B-Premise
263	in	_	_	I-Premise
264	neck	_	_	I-Premise
265	dissection	_	_	I-Premise
266	impairment	_	_	I-Premise
267	,	_	_	I-Premise
268	fatigue	_	_	I-Premise
269	,	_	_	I-Premise
270	and	_	_	I-Premise
271	quality	_	_	I-Premise
272	of	_	_	I-Premise
273	life	_	_	I-Premise
274	favored	_	_	I-Premise
275	the	_	_	I-Premise
276	PRET	_	_	I-Premise
277	group	_	_	I-Premise
278	but	_	_	B-Premise
279	did	_	_	I-Premise
280	not	_	_	I-Premise
281	reach	_	_	I-Premise
282	statistical	_	_	I-Premise
283	significance	_	_	I-Premise
284	.	_	_	I-Premise

285	The	_	_	B-Premise
286	PRET	_	_	I-Premise
287	program	_	_	I-Premise
288	significantly	_	_	I-Premise
289	reduced	_	_	I-Premise
290	shoulder	_	_	I-Premise
291	pain	_	_	I-Premise
292	and	_	_	I-Premise
293	disability	_	_	I-Premise
294	and	_	_	I-Premise
295	improved	_	_	I-Premise
296	upper	_	_	I-Premise
297	extremity	_	_	I-Premise
298	muscular	_	_	I-Premise
299	strength	_	_	I-Premise
300	and	_	_	I-Premise
301	endurance	_	_	I-Premise
302	in	_	_	I-Premise
303	head	_	_	I-Premise
304	and	_	_	I-Premise
305	neck	_	_	I-Premise
306	cancer	_	_	I-Premise
307	survivors	_	_	I-Premise
308	who	_	_	I-Premise
309	had	_	_	I-Premise
310	shoulder	_	_	I-Premise
311	dysfunction	_	_	I-Premise
312	because	_	_	I-Premise
313	of	_	_	I-Premise
314	spinal	_	_	I-Premise
315	accessory	_	_	I-Premise
316	nerve	_	_	I-Premise
317	damage	_	_	I-Premise
318	.	_	_	I-Premise

319	Clinicians	_	_	B-Claim
320	should	_	_	I-Claim
321	consider	_	_	I-Claim
322	the	_	_	I-Claim
323	addition	_	_	I-Claim
324	of	_	_	I-Claim
325	PRET	_	_	I-Claim
326	in	_	_	I-Claim
327	the	_	_	I-Claim
328	rehabilitation	_	_	I-Claim
329	of	_	_	I-Claim
330	postsurgical	_	_	I-Claim
331	head	_	_	I-Claim
332	and	_	_	I-Claim
333	neck	_	_	I-Claim
334	cancer	_	_	I-Claim
335	survivors	_	_	I-Claim
336	.	_	_	I-Claim


0	The	_	_	O
1	efficacy	_	_	O
2	of	_	_	O
3	a	_	_	O
4	home	_	_	O
5	-	_	_	O
6	based	_	_	O
7	physical	_	_	O
8	activity	_	_	O
9	(	_	_	O
10	PA	_	_	O
11	)	_	_	O
12	intervention	_	_	O
13	for	_	_	O
14	colorectal	_	_	O
15	cancer	_	_	O
16	patients	_	_	O
17	versus	_	_	O
18	contact	_	_	O
19	control	_	_	O
20	was	_	_	O
21	evaluated	_	_	O
22	in	_	_	O
23	a	_	_	O
24	randomized	_	_	O
25	controlled	_	_	O
26	trial	_	_	O
27	.	_	_	O

28	Forty	_	_	O
29	-	_	_	O
30	six	_	_	O
31	patients	_	_	O
32	(	_	_	O
33	mean	_	_	O
34	age	_	_	O
35	=	_	_	O
36	57	_	_	O
37	.	_	_	O

38	3	_	_	O
39	years	_	_	O
40	[	_	_	O
41	SD	_	_	O
42	=	_	_	O
43	9	_	_	O
44	.	_	_	O

45	7	_	_	O
46	]	_	_	O
47	,	_	_	O
48	57	_	_	O
49	%	_	_	O
50	female	_	_	O
51	,	_	_	O
52	mean	_	_	O
53	=	_	_	O
54	2	_	_	O
55	.	_	_	O

56	99	_	_	O
57	years	_	_	O
58	post	_	_	O
59	-	_	_	O
60	diagnosis	_	_	O
61	[	_	_	O
62	SD	_	_	O
63	=	_	_	O
64	1	_	_	O
65	.	_	_	O

66	64	_	_	O
67	]	_	_	O
68	)	_	_	O
69	who	_	_	O
70	had	_	_	O
71	completed	_	_	O
72	treatment	_	_	O
73	for	_	_	O
74	stages	_	_	O
75	1	_	_	O
76	-	_	_	O
77	3	_	_	O
78	colorectal	_	_	O
79	cancer	_	_	O
80	were	_	_	O
81	randomized	_	_	O
82	to	_	_	O
83	telephone	_	_	O
84	counseling	_	_	O
85	to	_	_	O
86	support	_	_	O
87	PA	_	_	O
88	(	_	_	O
89	PA	_	_	O
90	group	_	_	O
91	,	_	_	O
92	n	_	_	O
93	=	_	_	O
94	20	_	_	O
95	)	_	_	O
96	or	_	_	O
97	contact	_	_	O
98	control	_	_	O
99	(	_	_	O
100	control	_	_	O
101	group	_	_	O
102	,	_	_	O
103	n	_	_	O
104	=	_	_	O
105	26	_	_	O
106	)	_	_	O
107	.	_	_	O

108	PA	_	_	O
109	group	_	_	O
110	participants	_	_	O
111	received	_	_	O
112	3	_	_	O
113	months	_	_	O
114	of	_	_	O
115	PA	_	_	O
116	counseling	_	_	O
117	(	_	_	O
118	based	_	_	O
119	on	_	_	O
120	the	_	_	O
121	transtheoretical	_	_	O
122	model	_	_	O
123	and	_	_	O
124	the	_	_	O
125	social	_	_	O
126	cognitive	_	_	O
127	theory	_	_	O
128	)	_	_	O
129	delivered	_	_	O
130	via	_	_	O
131	telephone	_	_	O
132	,	_	_	O
133	as	_	_	O
134	well	_	_	O
135	as	_	_	O
136	weekly	_	_	O
137	PA	_	_	O
138	tip	_	_	O
139	sheets	_	_	O
140	.	_	_	O

141	Assessments	_	_	O
142	of	_	_	O
143	PA	_	_	O
144	(	_	_	O
145	Seven	_	_	O
146	-	_	_	O
147	day	_	_	O
148	Physical	_	_	O
149	Activity	_	_	O
150	Recall	_	_	O
151	[	_	_	O
152	7	_	_	O
153	-	_	_	O
154	day	_	_	O
155	PAR	_	_	O
156	]	_	_	O
157	and	_	_	O
158	Community	_	_	O
159	Healthy	_	_	O
160	Activities	_	_	O
161	Model	_	_	O
162	Program	_	_	O
163	for	_	_	O
164	Seniors	_	_	O
165	[	_	_	O
166	CHAMPS	_	_	O
167	]	_	_	O
168	)	_	_	O
169	,	_	_	O
170	submaximal	_	_	O
171	aerobic	_	_	O
172	fitness	_	_	O
173	(	_	_	O
174	Treadwalk	_	_	O
175	test	_	_	O
176	)	_	_	O
177	,	_	_	O
178	motivational	_	_	O
179	readiness	_	_	O
180	for	_	_	O
181	PA	_	_	O
182	,	_	_	O
183	and	_	_	O
184	psychosocial	_	_	O
185	outcomes	_	_	O
186	were	_	_	O
187	conducted	_	_	O
188	at	_	_	O
189	baseline	_	_	O
190	,	_	_	O
191	3	_	_	O
192	,	_	_	O
193	6	_	_	O
194	,	_	_	O
195	and	_	_	O
196	12	_	_	O
197	months	_	_	O
198	post	_	_	O
199	-	_	_	O
200	baseline	_	_	O
201	.	_	_	O

202	Objective	_	_	O
203	accelerometer	_	_	O
204	data	_	_	O
205	were	_	_	O
206	collected	_	_	O
207	at	_	_	O
208	the	_	_	O
209	same	_	_	O
210	time	_	_	O
211	points	_	_	O
212	.	_	_	O

213	The	_	_	B-Premise
214	PA	_	_	I-Premise
215	group	_	_	I-Premise
216	reported	_	_	I-Premise
217	significant	_	_	I-Premise
218	increases	_	_	I-Premise
219	in	_	_	I-Premise
220	minutes	_	_	I-Premise
221	of	_	_	I-Premise
222	PA	_	_	I-Premise
223	at	_	_	I-Premise
224	3	_	_	I-Premise
225	months	_	_	I-Premise
226	(	_	_	I-Premise
227	7	_	_	I-Premise
228	-	_	_	I-Premise
229	day	_	_	I-Premise
230	PAR	_	_	I-Premise
231	)	_	_	I-Premise
232	and	_	_	I-Premise
233	caloric	_	_	I-Premise
234	expenditure	_	_	I-Premise
235	(	_	_	I-Premise
236	CHAMPS	_	_	I-Premise
237	)	_	_	I-Premise
238	compared	_	_	I-Premise
239	with	_	_	I-Premise
240	the	_	_	I-Premise
241	control	_	_	I-Premise
242	group	_	_	I-Premise
243	,	_	_	I-Premise
244	but	_	_	B-Premise
245	the	_	_	I-Premise
246	group	_	_	I-Premise
247	differences	_	_	I-Premise
248	were	_	_	I-Premise
249	attenuated	_	_	I-Premise
250	over	_	_	I-Premise
251	time	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	B-Premise
254	PA	_	_	I-Premise
255	group	_	_	I-Premise
256	showed	_	_	I-Premise
257	significant	_	_	I-Premise
258	improvements	_	_	I-Premise
259	in	_	_	I-Premise
260	fitness	_	_	I-Premise
261	at	_	_	I-Premise
262	3	_	_	I-Premise
263	,	_	_	I-Premise
264	6	_	_	I-Premise
265	,	_	_	I-Premise
266	and	_	_	I-Premise
267	12	_	_	I-Premise
268	months	_	_	I-Premise
269	versus	_	_	I-Premise
270	the	_	_	I-Premise
271	control	_	_	I-Premise
272	group	_	_	I-Premise
273	.	_	_	I-Premise

274	Improvements	_	_	B-Premise
275	in	_	_	I-Premise
276	motivational	_	_	I-Premise
277	readiness	_	_	I-Premise
278	for	_	_	I-Premise
279	PA	_	_	I-Premise
280	were	_	_	I-Premise
281	reported	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	PA	_	_	I-Premise
285	group	_	_	I-Premise
286	only	_	_	I-Premise
287	at	_	_	I-Premise
288	3	_	_	I-Premise
289	months	_	_	I-Premise
290	.	_	_	I-Premise

291	No	_	_	B-Premise
292	significant	_	_	I-Premise
293	group	_	_	I-Premise
294	differences	_	_	I-Premise
295	were	_	_	I-Premise
296	found	_	_	I-Premise
297	for	_	_	I-Premise
298	fatigue	_	_	I-Premise
299	,	_	_	I-Premise
300	self	_	_	I-Premise
301	-	_	_	I-Premise
302	reported	_	_	I-Premise
303	physical	_	_	I-Premise
304	functioning	_	_	I-Premise
305	,	_	_	I-Premise
306	and	_	_	I-Premise
307	quality	_	_	I-Premise
308	of	_	_	I-Premise
309	life	_	_	I-Premise
310	at	_	_	I-Premise
311	3	_	_	I-Premise
312	,	_	_	I-Premise
313	6	_	_	I-Premise
314	,	_	_	I-Premise
315	and	_	_	I-Premise
316	12	_	_	I-Premise
317	months	_	_	I-Premise
318	.	_	_	I-Premise

319	A	_	_	B-Claim
320	home	_	_	I-Claim
321	-	_	_	I-Claim
322	based	_	_	I-Claim
323	intervention	_	_	I-Claim
324	improved	_	_	I-Claim
325	survivors	_	_	I-Claim
326	'	_	_	I-Claim
327	PA	_	_	I-Claim
328	and	_	_	I-Claim
329	motivational	_	_	I-Claim
330	readiness	_	_	I-Claim
331	at	_	_	I-Claim
332	3	_	_	I-Claim
333	months	_	_	I-Claim
334	and	_	_	I-Claim
335	increased	_	_	I-Claim
336	submaximal	_	_	I-Claim
337	aerobic	_	_	I-Claim
338	fitness	_	_	I-Claim
339	at	_	_	I-Claim
340	3	_	_	I-Claim
341	,	_	_	I-Claim
342	6	_	_	I-Claim
343	,	_	_	I-Claim
344	and	_	_	I-Claim
345	12	_	_	I-Claim
346	months	_	_	I-Claim
347	.	_	_	I-Claim


0	Persistent	_	_	O
1	insomnia	_	_	O
2	is	_	_	O
3	a	_	_	O
4	common	_	_	O
5	complaint	_	_	O
6	in	_	_	O
7	cancer	_	_	O
8	survivors	_	_	O
9	,	_	_	O
10	but	_	_	O
11	is	_	_	O
12	seldom	_	_	O
13	satisfactorily	_	_	O
14	addressed	_	_	O
15	.	_	_	O

16	The	_	_	O
17	adaptation	_	_	O
18	to	_	_	O
19	cancer	_	_	O
20	care	_	_	O
21	of	_	_	O
22	a	_	_	O
23	validated	_	_	O
24	,	_	_	O
25	cost	_	_	O
26	-	_	_	O
27	effective	_	_	O
28	intervention	_	_	O
29	may	_	_	O
30	offer	_	_	O
31	a	_	_	O
32	practicable	_	_	O
33	solution	_	_	O
34	.	_	_	O

35	The	_	_	O
36	aim	_	_	O
37	of	_	_	O
38	this	_	_	O
39	study	_	_	O
40	was	_	_	O
41	to	_	_	O
42	investigate	_	_	O
43	the	_	_	O
44	clinical	_	_	O
45	effectiveness	_	_	O
46	of	_	_	O
47	protocol	_	_	O
48	-	_	_	O
49	driven	_	_	O
50	cognitive	_	_	O
51	behavior	_	_	O
52	therapy	_	_	O
53	(	_	_	O
54	CBT	_	_	O
55	)	_	_	O
56	for	_	_	O
57	insomnia	_	_	O
58	,	_	_	O
59	delivered	_	_	O
60	by	_	_	O
61	oncology	_	_	O
62	nurses	_	_	O
63	.	_	_	O

64	Randomized	_	_	O
65	,	_	_	O
66	controlled	_	_	O
67	,	_	_	O
68	pragmatic	_	_	O
69	,	_	_	O
70	two	_	_	O
71	-	_	_	O
72	center	_	_	O
73	trial	_	_	O
74	of	_	_	O
75	CBT	_	_	O
76	versus	_	_	O
77	treatment	_	_	O
78	as	_	_	O
79	usual	_	_	O
80	(	_	_	O
81	TAU	_	_	O
82	)	_	_	O
83	in	_	_	O
84	150	_	_	O
85	patients	_	_	O
86	(	_	_	O
87	103	_	_	O
88	females	_	_	O
89	;	_	_	O
90	mean	_	_	O
91	age	_	_	O
92	,	_	_	O
93	61	_	_	O
94	years	_	_	O
95	.	_	_	O

96	)	_	_	O
97	who	_	_	O
98	had	_	_	O
99	completed	_	_	O
100	active	_	_	O
101	therapy	_	_	O
102	for	_	_	O
103	breast	_	_	O
104	,	_	_	O
105	prostate	_	_	O
106	,	_	_	O
107	colorectal	_	_	O
108	,	_	_	O
109	or	_	_	O
110	gynecological	_	_	O
111	cancer	_	_	O
112	.	_	_	O

113	The	_	_	O
114	study	_	_	O
115	conformed	_	_	O
116	to	_	_	O
117	CONSORT	_	_	O
118	guidelines	_	_	O
119	.	_	_	O

120	Primary	_	_	O
121	outcomes	_	_	O
122	were	_	_	O
123	sleep	_	_	O
124	diary	_	_	O
125	measures	_	_	O
126	at	_	_	O
127	baseline	_	_	O
128	,	_	_	O
129	post	_	_	O
130	-	_	_	O
131	treatment	_	_	O
132	,	_	_	O
133	and	_	_	O
134	6	_	_	O
135	-	_	_	O
136	month	_	_	O
137	follow	_	_	O
138	-	_	_	O
139	up	_	_	O
140	.	_	_	O

141	Actigraphic	_	_	O
142	sleep	_	_	O
143	,	_	_	O
144	health	_	_	O
145	-	_	_	O
146	related	_	_	O
147	quality	_	_	O
148	of	_	_	O
149	life	_	_	O
150	(	_	_	O
151	QOL	_	_	O
152	)	_	_	O
153	,	_	_	O
154	psychopathology	_	_	O
155	,	_	_	O
156	and	_	_	O
157	fatigue	_	_	O
158	were	_	_	O
159	secondary	_	_	O
160	measures	_	_	O
161	.	_	_	O

162	CBT	_	_	O
163	comprised	_	_	O
164	five	_	_	O
165	,	_	_	O
166	small	_	_	O
167	group	_	_	O
168	sessions	_	_	O
169	across	_	_	O
170	consecutive	_	_	O
171	weeks	_	_	O
172	,	_	_	O
173	after	_	_	O
174	a	_	_	O
175	manualized	_	_	O
176	protocol	_	_	O
177	.	_	_	O

178	TAU	_	_	O
179	represented	_	_	O
180	normal	_	_	O
181	clinical	_	_	O
182	practice	_	_	O
183	;	_	_	O
184	the	_	_	O
185	appropriate	_	_	O
186	control	_	_	O
187	for	_	_	O
188	a	_	_	O
189	clinical	_	_	O
190	effectiveness	_	_	O
191	study	_	_	O
192	.	_	_	O

193	CBT	_	_	B-Premise
194	was	_	_	I-Premise
195	associated	_	_	I-Premise
196	with	_	_	I-Premise
197	mean	_	_	I-Premise
198	reductions	_	_	I-Premise
199	in	_	_	I-Premise
200	wakefulness	_	_	I-Premise
201	of	_	_	I-Premise
202	55	_	_	I-Premise
203	minutes	_	_	I-Premise
204	per	_	_	I-Premise
205	night	_	_	I-Premise
206	compared	_	_	I-Premise
207	with	_	_	I-Premise
208	no	_	_	I-Premise
209	change	_	_	I-Premise
210	in	_	_	I-Premise
211	TAU	_	_	I-Premise
212	.	_	_	I-Premise

213	These	_	_	O
214	outcomes	_	_	O
215	were	_	_	O
216	sustained	_	_	O
217	6	_	_	O
218	months	_	_	O
219	after	_	_	O
220	treatment	_	_	O
221	.	_	_	O

222	Standardized	_	_	B-Premise
223	relative	_	_	I-Premise
224	effect	_	_	I-Premise
225	sizes	_	_	I-Premise
226	were	_	_	I-Premise
227	large	_	_	I-Premise
228	for	_	_	I-Premise
229	complaints	_	_	I-Premise
230	of	_	_	I-Premise
231	difficulty	_	_	I-Premise
232	initiating	_	_	I-Premise
233	sleep	_	_	I-Premise
234	,	_	_	I-Premise
235	waking	_	_	I-Premise
236	from	_	_	I-Premise
237	sleep	_	_	I-Premise
238	during	_	_	I-Premise
239	the	_	_	I-Premise
240	night	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	for	_	_	I-Premise
244	sleep	_	_	I-Premise
245	efficiency	_	_	I-Premise
246	(	_	_	I-Premise
247	percentage	_	_	I-Premise
248	of	_	_	I-Premise
249	time	_	_	I-Premise
250	in	_	_	I-Premise
251	bed	_	_	I-Premise
252	spent	_	_	I-Premise
253	asleep	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	CBT	_	_	B-Premise
257	was	_	_	I-Premise
258	associated	_	_	I-Premise
259	with	_	_	I-Premise
260	moderate	_	_	I-Premise
261	to	_	_	I-Premise
262	large	_	_	I-Premise
263	effect	_	_	I-Premise
264	sizes	_	_	I-Premise
265	for	_	_	I-Premise
266	five	_	_	I-Premise
267	of	_	_	I-Premise
268	seven	_	_	I-Premise
269	QOL	_	_	I-Premise
270	outcomes	_	_	I-Premise
271	,	_	_	I-Premise
272	including	_	_	I-Premise
273	significant	_	_	I-Premise
274	reduction	_	_	I-Premise
275	in	_	_	I-Premise
276	daytime	_	_	I-Premise
277	fatigue	_	_	I-Premise
278	.	_	_	I-Premise

279	There	_	_	B-Premise
280	was	_	_	I-Premise
281	no	_	_	I-Premise
282	significant	_	_	I-Premise
283	interaction	_	_	I-Premise
284	effect	_	_	I-Premise
285	between	_	_	I-Premise
286	any	_	_	I-Premise
287	of	_	_	I-Premise
288	these	_	_	I-Premise
289	outcomes	_	_	I-Premise
290	and	_	_	I-Premise
291	baseline	_	_	I-Premise
292	demographic	_	_	I-Premise
293	,	_	_	I-Premise
294	clinical	_	_	I-Premise
295	,	_	_	I-Premise
296	or	_	_	I-Premise
297	sleep	_	_	I-Premise
298	characteristics	_	_	I-Premise
299	.	_	_	I-Premise

300	CBT	_	_	B-Claim
301	for	_	_	I-Claim
302	insomnia	_	_	I-Claim
303	may	_	_	I-Claim
304	be	_	_	I-Claim
305	both	_	_	I-Claim
306	clinically	_	_	I-Claim
307	effective	_	_	I-Claim
308	and	_	_	I-Claim
309	feasible	_	_	I-Claim
310	to	_	_	I-Claim
311	deliver	_	_	I-Claim
312	in	_	_	I-Claim
313	real	_	_	I-Claim
314	world	_	_	I-Claim
315	practice	_	_	I-Claim
316	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	uterine	_	_	O
4	artery	_	_	O
5	embolization	_	_	O
6	(	_	_	O
7	UAE	_	_	O
8	)	_	_	O
9	is	_	_	O
10	a	_	_	O
11	cost	_	_	O
12	-	_	_	O
13	effective	_	_	O
14	alternative	_	_	O
15	to	_	_	O
16	hysterectomy	_	_	O
17	for	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	symptomatic	_	_	O
21	uterine	_	_	O
22	fibroids	_	_	O
23	,	_	_	O
24	the	_	_	O
25	authors	_	_	O
26	performed	_	_	O
27	an	_	_	O
28	economic	_	_	O
29	evaluation	_	_	O
30	alongside	_	_	O
31	the	_	_	O
32	multicenter	_	_	O
33	randomized	_	_	O
34	EMMY	_	_	O
35	(	_	_	O
36	EMbolization	_	_	O
37	versus	_	_	O
38	hysterectoMY	_	_	O
39	)	_	_	O
40	trial	_	_	O
41	.	_	_	O

42	Between	_	_	O
43	February	_	_	O
44	2002	_	_	O
45	and	_	_	O
46	February	_	_	O
47	2004	_	_	O
48	,	_	_	O
49	177	_	_	O
50	patients	_	_	O
51	were	_	_	O
52	randomized	_	_	O
53	to	_	_	O
54	undergo	_	_	O
55	UAE	_	_	O
56	(	_	_	O
57	n	_	_	O
58	=	_	_	O
59	88	_	_	O
60	)	_	_	O
61	or	_	_	O
62	hysterectomy	_	_	O
63	(	_	_	O
64	n	_	_	O
65	=	_	_	O
66	89	_	_	O
67	)	_	_	O
68	and	_	_	O
69	followed	_	_	O
70	up	_	_	O
71	until	_	_	O
72	24	_	_	O
73	months	_	_	O
74	after	_	_	O
75	initial	_	_	O
76	treatment	_	_	O
77	allocation	_	_	O
78	.	_	_	O

79	Conditional	_	_	O
80	on	_	_	O
81	the	_	_	O
82	equivalence	_	_	O
83	of	_	_	O
84	clinical	_	_	O
85	outcome	_	_	O
86	,	_	_	O
87	a	_	_	O
88	cost	_	_	O
89	minimization	_	_	O
90	analysis	_	_	O
91	was	_	_	O
92	performed	_	_	O
93	according	_	_	O
94	to	_	_	O
95	the	_	_	O
96	intention	_	_	O
97	to	_	_	O
98	treat	_	_	O
99	principle	_	_	O
100	.	_	_	O

101	Costs	_	_	O
102	included	_	_	O
103	health	_	_	O
104	care	_	_	O
105	costs	_	_	O
106	inside	_	_	O
107	and	_	_	O
108	outside	_	_	O
109	the	_	_	O
110	hospital	_	_	O
111	as	_	_	O
112	well	_	_	O
113	as	_	_	O
114	costs	_	_	O
115	related	_	_	O
116	to	_	_	O
117	absence	_	_	O
118	from	_	_	O
119	work	_	_	O
120	(	_	_	O
121	societal	_	_	O
122	perspective	_	_	O
123	)	_	_	O
124	.	_	_	O

125	Cumulative	_	_	O
126	standardized	_	_	O
127	costs	_	_	O
128	were	_	_	O
129	estimated	_	_	O
130	as	_	_	O
131	volumes	_	_	O
132	multiplied	_	_	O
133	with	_	_	O
134	prices	_	_	O
135	.	_	_	O

136	The	_	_	O
137	nonparametric	_	_	O
138	bootstrap	_	_	O
139	method	_	_	O
140	was	_	_	O
141	used	_	_	O
142	to	_	_	O
143	quantify	_	_	O
144	differences	_	_	O
145	in	_	_	O
146	mean	_	_	O
147	(	_	_	O
148	95	_	_	O
149	%	_	_	O
150	confidence	_	_	O
151	interval	_	_	O
152	[	_	_	O
153	CI	_	_	O
154	]	_	_	O
155	)	_	_	O
156	costs	_	_	O
157	between	_	_	O
158	the	_	_	O
159	strategies	_	_	O
160	.	_	_	O

161	In	_	_	O
162	total	_	_	O
163	,	_	_	O
164	81	_	_	O
165	patients	_	_	O
166	underwent	_	_	O
167	UAE	_	_	O
168	and	_	_	O
169	75	_	_	O
170	underwent	_	_	O
171	hysterectomy	_	_	O
172	.	_	_	O

173	In	_	_	O
174	the	_	_	O
175	UAE	_	_	O
176	group	_	_	O
177	,	_	_	O
178	19	_	_	O
179	patients	_	_	O
180	(	_	_	O
181	23	_	_	O
182	%	_	_	O
183	)	_	_	O
184	underwent	_	_	O
185	secondary	_	_	O
186	hysterectomies	_	_	O
187	.	_	_	O

188	The	_	_	B-Premise
189	mean	_	_	I-Premise
190	total	_	_	I-Premise
191	costs	_	_	I-Premise
192	per	_	_	I-Premise
193	patient	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	UAE	_	_	I-Premise
197	group	_	_	I-Premise
198	were	_	_	I-Premise
199	significantly	_	_	I-Premise
200	lower	_	_	I-Premise
201	than	_	_	I-Premise
202	those	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	hysterectomy	_	_	I-Premise
206	group	_	_	I-Premise
207	(	_	_	I-Premise
208	$	_	_	I-Premise
209	11	_	_	I-Premise
210	,	_	_	I-Premise
211	626	_	_	I-Premise
212	vs	_	_	I-Premise
213	$	_	_	I-Premise
214	18	_	_	I-Premise
215	,	_	_	I-Premise
216	563	_	_	I-Premise
217	;	_	_	I-Premise
218	mean	_	_	I-Premise
219	difference	_	_	I-Premise
220	,	_	_	I-Premise
221	-	_	_	I-Premise
222	$	_	_	I-Premise
223	6	_	_	I-Premise
224	,	_	_	I-Premise
225	936	_	_	I-Premise
226	[	_	_	I-Premise
227	-	_	_	I-Premise
228	37	_	_	I-Premise
229	%	_	_	I-Premise
230	]	_	_	I-Premise
231	,	_	_	I-Premise
232	95	_	_	I-Premise
233	%	_	_	I-Premise
234	CI	_	_	I-Premise
235	:	_	_	I-Premise
236	-	_	_	I-Premise
237	$	_	_	I-Premise
238	9	_	_	I-Premise
239	,	_	_	I-Premise
240	548	_	_	I-Premise
241	,	_	_	I-Premise
242	$	_	_	I-Premise
243	4	_	_	I-Premise
244	,	_	_	I-Premise
245	281	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	The	_	_	B-Premise
249	direct	_	_	I-Premise
250	medical	_	_	I-Premise
251	in	_	_	I-Premise
252	-	_	_	I-Premise
253	hospital	_	_	I-Premise
254	costs	_	_	I-Premise
255	were	_	_	I-Premise
256	significantly	_	_	I-Premise
257	lower	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	UAE	_	_	I-Premise
261	group	_	_	I-Premise
262	:	_	_	I-Premise
263	$	_	_	I-Premise
264	6	_	_	I-Premise
265	,	_	_	I-Premise
266	688	_	_	I-Premise
267	vs	_	_	I-Premise
268	$	_	_	I-Premise
269	8	_	_	I-Premise
270	,	_	_	I-Premise
271	313	_	_	I-Premise
272	(	_	_	I-Premise
273	mean	_	_	I-Premise
274	difference	_	_	I-Premise
275	,	_	_	I-Premise
276	-	_	_	I-Premise
277	$	_	_	I-Premise
278	1	_	_	I-Premise
279	,	_	_	I-Premise
280	624	_	_	I-Premise
281	[	_	_	I-Premise
282	-	_	_	I-Premise
283	20	_	_	I-Premise
284	%	_	_	I-Premise
285	]	_	_	I-Premise
286	,	_	_	I-Premise
287	95	_	_	I-Premise
288	%	_	_	I-Premise
289	CI	_	_	I-Premise
290	:	_	_	I-Premise
291	-	_	_	I-Premise
292	$	_	_	I-Premise
293	2	_	_	I-Premise
294	,	_	_	I-Premise
295	605	_	_	I-Premise
296	,	_	_	I-Premise
297	-	_	_	I-Premise
298	$	_	_	I-Premise
299	586	_	_	I-Premise
300	)	_	_	I-Premise
301	.	_	_	I-Premise

302	Direct	_	_	B-Premise
303	medical	_	_	I-Premise
304	out	_	_	I-Premise
305	-	_	_	I-Premise
306	of	_	_	I-Premise
307	-	_	_	I-Premise
308	hospital	_	_	I-Premise
309	and	_	_	I-Premise
310	direct	_	_	I-Premise
311	nonmedical	_	_	I-Premise
312	costs	_	_	I-Premise
313	were	_	_	I-Premise
314	low	_	_	I-Premise
315	in	_	_	I-Premise
316	both	_	_	I-Premise
317	groups	_	_	I-Premise
318	(	_	_	I-Premise
319	mean	_	_	I-Premise
320	cost	_	_	I-Premise
321	difference	_	_	I-Premise
322	,	_	_	I-Premise
323	$	_	_	I-Premise
324	156	_	_	I-Premise
325	in	_	_	I-Premise
326	favor	_	_	I-Premise
327	of	_	_	I-Premise
328	hysterectomy	_	_	I-Premise
329	)	_	_	I-Premise
330	.	_	_	I-Premise

331	The	_	_	B-Premise
332	costs	_	_	I-Premise
333	related	_	_	I-Premise
334	to	_	_	I-Premise
335	absence	_	_	I-Premise
336	from	_	_	I-Premise
337	work	_	_	I-Premise
338	differed	_	_	I-Premise
339	significantly	_	_	I-Premise
340	between	_	_	I-Premise
341	the	_	_	I-Premise
342	treatment	_	_	I-Premise
343	strategies	_	_	I-Premise
344	in	_	_	I-Premise
345	favor	_	_	I-Premise
346	of	_	_	I-Premise
347	UAE	_	_	I-Premise
348	(	_	_	I-Premise
349	mean	_	_	I-Premise
350	difference	_	_	I-Premise
351	,	_	_	I-Premise
352	-	_	_	I-Premise
353	$	_	_	I-Premise
354	5	_	_	I-Premise
355	,	_	_	I-Premise
356	453	_	_	I-Premise
357	;	_	_	I-Premise
358	95	_	_	I-Premise
359	%	_	_	I-Premise
360	CI	_	_	I-Premise
361	:	_	_	I-Premise
362	-	_	_	I-Premise
363	$	_	_	I-Premise
364	7	_	_	I-Premise
365	,	_	_	I-Premise
366	718	_	_	I-Premise
367	,	_	_	I-Premise
368	-	_	_	I-Premise
369	$	_	_	I-Premise
370	3	_	_	I-Premise
371	,	_	_	I-Premise
372	107	_	_	I-Premise
373	)	_	_	I-Premise
374	.	_	_	I-Premise

375	The	_	_	O
376	costs	_	_	O
377	of	_	_	O
378	absence	_	_	O
379	from	_	_	O
380	work	_	_	O
381	accounted	_	_	O
382	for	_	_	O
383	79	_	_	O
384	%	_	_	O
385	of	_	_	O
386	the	_	_	O
387	difference	_	_	O
388	in	_	_	O
389	total	_	_	O
390	costs	_	_	O
391	.	_	_	O

392	The	_	_	B-Premise
393	24	_	_	I-Premise
394	-	_	_	I-Premise
395	month	_	_	I-Premise
396	cumulative	_	_	I-Premise
397	cost	_	_	I-Premise
398	of	_	_	I-Premise
399	UAE	_	_	I-Premise
400	is	_	_	I-Premise
401	lower	_	_	I-Premise
402	than	_	_	I-Premise
403	that	_	_	I-Premise
404	of	_	_	I-Premise
405	hysterectomy	_	_	I-Premise
406	.	_	_	I-Premise

407	From	_	_	B-Claim
408	a	_	_	I-Claim
409	societal	_	_	I-Claim
410	economic	_	_	I-Claim
411	perspective	_	_	I-Claim
412	,	_	_	I-Claim
413	UAE	_	_	I-Claim
414	is	_	_	I-Claim
415	the	_	_	I-Claim
416	superior	_	_	I-Claim
417	treatment	_	_	I-Claim
418	strategy	_	_	I-Claim
419	in	_	_	I-Claim
420	women	_	_	I-Claim
421	with	_	_	I-Claim
422	symptomatic	_	_	I-Claim
423	uterine	_	_	I-Claim
424	fibroids	_	_	I-Claim
425	.	_	_	I-Claim


0	Somatostatin	_	_	O
1	analogs	_	_	O
2	act	_	_	O
3	directly	_	_	O
4	on	_	_	O
5	breast	_	_	O
6	cancer	_	_	O
7	cells	_	_	O
8	and	_	_	O
9	indirectly	_	_	O
10	on	_	_	O
11	insulin	_	_	O
12	and	_	_	O
13	insulin	_	_	O
14	-	_	_	O
15	like	_	_	O
16	growth	_	_	O
17	factor	_	_	O
18	1	_	_	O
19	(	_	_	O
20	IGF	_	_	O
21	-	_	_	O
22	1	_	_	O
23	)	_	_	O
24	levels	_	_	O
25	.	_	_	O

26	This	_	_	O
27	trial	_	_	O
28	was	_	_	O
29	undertaken	_	_	O
30	to	_	_	O
31	assess	_	_	O
32	whether	_	_	O
33	octreotide	_	_	B-Claim
34	would	_	_	I-Claim
35	lower	_	_	I-Claim
36	insulin	_	_	I-Claim
37	and	_	_	I-Claim
38	IGF	_	_	I-Claim
39	-	_	_	I-Claim
40	1	_	_	I-Claim
41	levels	_	_	I-Claim
42	and	_	_	I-Claim
43	reduce	_	_	I-Claim
44	risk	_	_	I-Claim
45	of	_	_	I-Claim
46	breast	_	_	I-Claim
47	cancer	_	_	I-Claim
48	recurrence	_	_	I-Claim
49	.	_	_	I-Claim

50	The	_	_	O
51	NCIC	_	_	O
52	CTG	_	_	O
53	MA	_	_	O
54	.	_	_	O

55	14	_	_	O
56	(	_	_	O
57	NCIC	_	_	O
58	Clinical	_	_	O
59	Trials	_	_	O
60	Group	_	_	O
61	MA	_	_	O
62	.	_	_	O

63	14	_	_	O
64	)	_	_	O
65	trial	_	_	O
66	randomly	_	_	O
67	assigned	_	_	O
68	postmenopausal	_	_	O
69	women	_	_	O
70	to	_	_	O
71	5	_	_	O
72	years	_	_	O
73	of	_	_	O
74	tamoxifen	_	_	O
75	20	_	_	O
76	mg	_	_	O
77	daily	_	_	O
78	(	_	_	O
79	TAM	_	_	O
80	)	_	_	O
81	or	_	_	O
82	TAM	_	_	O
83	plus	_	_	O
84	2	_	_	O
85	years	_	_	O
86	of	_	_	O
87	octreotide	_	_	O
88	90	_	_	O
89	mg	_	_	O
90	depot	_	_	O
91	intramuscular	_	_	O
92	injections	_	_	O
93	monthly	_	_	O
94	(	_	_	O
95	TAM	_	_	O
96	-	_	_	O
97	OCT	_	_	O
98	)	_	_	O
99	as	_	_	O
100	adjuvant	_	_	O
101	therapy	_	_	O
102	.	_	_	O

103	The	_	_	O
104	primary	_	_	O
105	end	_	_	O
106	point	_	_	O
107	was	_	_	O
108	event	_	_	O
109	-	_	_	O
110	free	_	_	O
111	survival	_	_	O
112	(	_	_	O
113	EFS	_	_	O
114	)	_	_	O
115	.	_	_	O

116	Secondary	_	_	O
117	end	_	_	O
118	points	_	_	O
119	were	_	_	O
120	relapse	_	_	O
121	-	_	_	O
122	free	_	_	O
123	survival	_	_	O
124	(	_	_	O
125	RFS	_	_	O
126	)	_	_	O
127	,	_	_	O
128	overall	_	_	O
129	survival	_	_	O
130	(	_	_	O
131	OS	_	_	O
132	)	_	_	O
133	,	_	_	O
134	toxicity	_	_	O
135	,	_	_	O
136	and	_	_	O
137	effects	_	_	O
138	of	_	_	O
139	treatment	_	_	O
140	on	_	_	O
141	IGF	_	_	O
142	physiology	_	_	O
143	.	_	_	O

144	Among	_	_	O
145	667	_	_	O
146	women	_	_	O
147	with	_	_	O
148	a	_	_	O
149	median	_	_	O
150	follow	_	_	O
151	-	_	_	O
152	up	_	_	O
153	of	_	_	O
154	7	_	_	O
155	.	_	_	O

156	9	_	_	O
157	years	_	_	O
158	,	_	_	O
159	220	_	_	O
160	events	_	_	O
161	occurred	_	_	O
162	-	_	_	O
163	108	_	_	O
164	with	_	_	O
165	TAM	_	_	O
166	-	_	_	O
167	OCT	_	_	O
168	and	_	_	O
169	112	_	_	O
170	with	_	_	O
171	TAM	_	_	O
172	.	_	_	O

173	Adjusted	_	_	B-Premise
174	hazard	_	_	I-Premise
175	ratios	_	_	I-Premise
176	(	_	_	I-Premise
177	HRs	_	_	I-Premise
178	;	_	_	I-Premise
179	TAM	_	_	I-Premise
180	-	_	_	I-Premise
181	OCT	_	_	I-Premise
182	to	_	_	I-Premise
183	TAM	_	_	I-Premise
184	)	_	_	I-Premise
185	were	_	_	I-Premise
186	0	_	_	I-Premise
187	.	_	_	I-Premise

188	93	_	_	I-Premise
189	for	_	_	I-Premise
190	EFS	_	_	I-Premise
191	(	_	_	I-Premise
192	95	_	_	I-Premise
193	%	_	_	I-Premise
194	CI	_	_	I-Premise
195	,	_	_	I-Premise
196	0	_	_	I-Premise
197	.	_	_	I-Premise

198	71	_	_	I-Premise
199	to	_	_	I-Premise
200	1	_	_	I-Premise
201	.	_	_	I-Premise

202	22	_	_	I-Premise
203	;	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	.	_	_	I-Premise

207	62	_	_	I-Premise
208	)	_	_	I-Premise
209	,	_	_	I-Premise
210	0	_	_	I-Premise
211	.	_	_	I-Premise

212	84	_	_	I-Premise
213	for	_	_	I-Premise
214	RFS	_	_	I-Premise
215	(	_	_	I-Premise
216	95	_	_	I-Premise
217	%	_	_	I-Premise
218	CI	_	_	I-Premise
219	,	_	_	I-Premise
220	0	_	_	I-Premise
221	.	_	_	I-Premise

222	59	_	_	I-Premise
223	to	_	_	I-Premise
224	1	_	_	I-Premise
225	.	_	_	I-Premise

226	18	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	.	_	_	I-Premise

231	31	_	_	I-Premise
232	)	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	0	_	_	I-Premise
236	.	_	_	I-Premise

237	97	_	_	I-Premise
238	for	_	_	I-Premise
239	OS	_	_	I-Premise
240	(	_	_	I-Premise
241	95	_	_	I-Premise
242	%	_	_	I-Premise
243	CI	_	_	I-Premise
244	,	_	_	I-Premise
245	0	_	_	I-Premise
246	.	_	_	I-Premise

247	69	_	_	I-Premise
248	to	_	_	I-Premise
249	1	_	_	I-Premise
250	.	_	_	I-Premise

251	37	_	_	I-Premise
252	;	_	_	I-Premise
253	P	_	_	I-Premise
254	=	_	_	I-Premise
255	.	_	_	I-Premise

256	86	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	Among	_	_	B-Premise
260	patients	_	_	I-Premise
261	with	_	_	I-Premise
262	normal	_	_	I-Premise
263	baseline	_	_	I-Premise
264	gallbladder	_	_	I-Premise
265	imaging	_	_	I-Premise
266	,	_	_	I-Premise
267	cholecystectomy	_	_	I-Premise
268	was	_	_	I-Premise
269	required	_	_	I-Premise
270	in	_	_	I-Premise
271	23	_	_	I-Premise
272	.	_	_	I-Premise

273	0	_	_	I-Premise
274	%	_	_	I-Premise
275	of	_	_	I-Premise
276	those	_	_	I-Premise
277	receiving	_	_	I-Premise
278	TAM	_	_	I-Premise
279	-	_	_	I-Premise
280	OCT	_	_	I-Premise
281	but	_	_	I-Premise
282	in	_	_	I-Premise
283	only	_	_	I-Premise
284	1	_	_	I-Premise
285	.	_	_	I-Premise

286	4	_	_	I-Premise
287	%	_	_	I-Premise
288	of	_	_	I-Premise
289	those	_	_	I-Premise
290	receiving	_	_	I-Premise
291	TAM	_	_	I-Premise
292	(	_	_	I-Premise
293	P	_	_	I-Premise
294	<	_	_	I-Premise
295	.	_	_	I-Premise

296	001	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	At	_	_	B-Premise
300	4	_	_	I-Premise
301	months	_	_	I-Premise
302	,	_	_	I-Premise
303	TAM	_	_	I-Premise
304	-	_	_	I-Premise
305	OCT	_	_	I-Premise
306	had	_	_	I-Premise
307	significantly	_	_	I-Premise
308	(	_	_	I-Premise
309	P	_	_	I-Premise
310	<	_	_	I-Premise
311	.	_	_	I-Premise

312	001	_	_	I-Premise
313	)	_	_	I-Premise
314	lowered	_	_	I-Premise
315	IGF	_	_	I-Premise
316	-	_	_	I-Premise
317	1	_	_	I-Premise
318	,	_	_	I-Premise
319	IGF	_	_	I-Premise
320	binding	_	_	I-Premise
321	protein	_	_	I-Premise
322	3	_	_	I-Premise
323	,	_	_	I-Premise
324	and	_	_	I-Premise
325	C	_	_	I-Premise
326	-	_	_	I-Premise
327	peptide	_	_	I-Premise
328	levels	_	_	I-Premise
329	.	_	_	I-Premise

330	Older	_	_	B-Premise
331	age	_	_	I-Premise
332	(	_	_	I-Premise
333	P	_	_	I-Premise
334	=	_	_	I-Premise
335	.	_	_	I-Premise

336	02	_	_	I-Premise
337	)	_	_	I-Premise
338	,	_	_	I-Premise
339	tumor	_	_	I-Premise
340	size	_	_	I-Premise
341	(	_	_	I-Premise
342	P	_	_	I-Premise
343	=	_	_	I-Premise
344	.	_	_	I-Premise

345	001	_	_	I-Premise
346	)	_	_	I-Premise
347	,	_	_	I-Premise
348	nodal	_	_	I-Premise
349	status	_	_	I-Premise
350	(	_	_	I-Premise
351	P	_	_	I-Premise
352	=	_	_	I-Premise
353	.	_	_	I-Premise

354	01	_	_	I-Premise
355	)	_	_	I-Premise
356	,	_	_	I-Premise
357	high	_	_	I-Premise
358	C	_	_	I-Premise
359	-	_	_	I-Premise
360	peptide	_	_	I-Premise
361	levels	_	_	I-Premise
362	(	_	_	I-Premise
363	P	_	_	I-Premise
364	<	_	_	I-Premise
365	.	_	_	I-Premise

366	001	_	_	I-Premise
367	)	_	_	I-Premise
368	,	_	_	I-Premise
369	and	_	_	I-Premise
370	higher	_	_	I-Premise
371	body	_	_	I-Premise
372	mass	_	_	I-Premise
373	index	_	_	I-Premise
374	(	_	_	I-Premise
375	BMI	_	_	I-Premise
376	)	_	_	I-Premise
377	in	_	_	I-Premise
378	models	_	_	I-Premise
379	excluding	_	_	I-Premise
380	C	_	_	I-Premise
381	-	_	_	I-Premise
382	peptide	_	_	I-Premise
383	(	_	_	I-Premise
384	P	_	_	I-Premise
385	<	_	_	I-Premise
386	.	_	_	I-Premise

387	001	_	_	I-Premise
388	)	_	_	I-Premise
389	were	_	_	I-Premise
390	associated	_	_	I-Premise
391	with	_	_	I-Premise
392	poorer	_	_	I-Premise
393	EFS	_	_	I-Premise
394	in	_	_	I-Premise
395	multivariate	_	_	I-Premise
396	analysis	_	_	I-Premise
397	.	_	_	I-Premise

398	Octreotide	_	_	O
399	-	_	_	O
400	related	_	_	O
401	changes	_	_	O
402	in	_	_	O
403	circulating	_	_	O
404	IGF	_	_	O
405	-	_	_	O
406	1	_	_	O
407	and	_	_	O
408	C	_	_	O
409	-	_	_	O
410	peptide	_	_	O
411	levels	_	_	O
412	were	_	_	O
413	statistically	_	_	O
414	significant	_	_	O
415	.	_	_	O

416	Octreotide	_	_	B-Claim
417	did	_	_	I-Claim
418	not	_	_	I-Claim
419	add	_	_	I-Claim
420	significant	_	_	I-Claim
421	clinical	_	_	I-Claim
422	benefit	_	_	I-Claim
423	.	_	_	I-Claim

424	High	_	_	B-Claim
425	C	_	_	I-Claim
426	-	_	_	I-Claim
427	peptide	_	_	I-Claim
428	levels	_	_	I-Claim
429	(	_	_	I-Claim
430	surrogate	_	_	I-Claim
431	for	_	_	I-Claim
432	insulin	_	_	I-Claim
433	secretion	_	_	I-Claim
434	rate	_	_	I-Claim
435	)	_	_	I-Claim
436	and	_	_	I-Claim
437	high	_	_	I-Claim
438	BMI	_	_	I-Claim
439	were	_	_	I-Claim
440	associated	_	_	I-Claim
441	with	_	_	I-Claim
442	poor	_	_	I-Claim
443	outcome	_	_	I-Claim
444	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	health	_	_	O
3	-	_	_	O
4	related	_	_	O
5	quality	_	_	O
6	of	_	_	O
7	life	_	_	O
8	(	_	_	O
9	HRQOL	_	_	O
10	)	_	_	O
11	in	_	_	O
12	patients	_	_	O
13	with	_	_	O
14	metastatic	_	_	O
15	breast	_	_	O
16	cancer	_	_	O
17	receiving	_	_	O
18	the	_	_	O
19	combination	_	_	O
20	of	_	_	O
21	doxorubicin	_	_	O
22	and	_	_	O
23	paclitaxel	_	_	O
24	(	_	_	O
25	AT	_	_	O
26	)	_	_	O
27	or	_	_	O
28	doxorubicin	_	_	O
29	and	_	_	O
30	cyclophosphamide	_	_	O
31	(	_	_	O
32	AC	_	_	O
33	)	_	_	O
34	as	_	_	O
35	first	_	_	O
36	-	_	_	O
37	line	_	_	O
38	chemotherapy	_	_	O
39	treatment	_	_	O
40	.	_	_	O

41	Eligible	_	_	O
42	patients	_	_	O
43	(	_	_	O
44	n	_	_	O
45	=	_	_	O
46	275	_	_	O
47	)	_	_	O
48	with	_	_	O
49	anthracycline	_	_	O
50	-	_	_	O
51	naive	_	_	O
52	measurable	_	_	O
53	metastatic	_	_	O
54	breast	_	_	O
55	cancer	_	_	O
56	were	_	_	O
57	randomly	_	_	O
58	assigned	_	_	O
59	to	_	_	O
60	AT	_	_	O
61	(	_	_	O
62	doxorubicin	_	_	O
63	60	_	_	O
64	mg	_	_	O
65	/	_	_	O
66	m	_	_	O
67	(	_	_	O
68	2	_	_	O
69	)	_	_	O
70	as	_	_	O
71	an	_	_	O
72	intravenous	_	_	O
73	bolus	_	_	O
74	plus	_	_	O
75	paclitaxel	_	_	O
76	175	_	_	O
77	mg	_	_	O
78	/	_	_	O
79	m	_	_	O
80	(	_	_	O
81	2	_	_	O
82	)	_	_	O
83	as	_	_	O
84	a	_	_	O
85	3	_	_	O
86	-	_	_	O
87	hour	_	_	O
88	infusion	_	_	O
89	)	_	_	O
90	or	_	_	O
91	AC	_	_	O
92	(	_	_	O
93	doxorubicin	_	_	O
94	60	_	_	O
95	mg	_	_	O
96	/	_	_	O
97	m	_	_	O
98	(	_	_	O
99	2	_	_	O
100	)	_	_	O
101	plus	_	_	O
102	cyclophosphamide	_	_	O
103	600	_	_	O
104	mg	_	_	O
105	/	_	_	O
106	m	_	_	O
107	(	_	_	O
108	2	_	_	O
109	)	_	_	O
110	)	_	_	O
111	every	_	_	O
112	3	_	_	O
113	weeks	_	_	O
114	for	_	_	O
115	a	_	_	O
116	maximum	_	_	O
117	of	_	_	O
118	six	_	_	O
119	cycles	_	_	O
120	.	_	_	O

121	Dose	_	_	O
122	escalation	_	_	O
123	of	_	_	O
124	paclitaxel	_	_	O
125	(	_	_	O
126	200	_	_	O
127	mg	_	_	O
128	/	_	_	O
129	m	_	_	O
130	(	_	_	O
131	2	_	_	O
132	)	_	_	O
133	)	_	_	O
134	and	_	_	O
135	cyclophosphamide	_	_	O
136	(	_	_	O
137	750	_	_	O
138	mg	_	_	O
139	/	_	_	O
140	m	_	_	O
141	(	_	_	O
142	2	_	_	O
143	)	_	_	O
144	)	_	_	O
145	was	_	_	O
146	planned	_	_	O
147	at	_	_	O
148	cycle	_	_	O
149	2	_	_	O
150	to	_	_	O
151	reach	_	_	O
152	equivalent	_	_	O
153	myelosuppression	_	_	O
154	in	_	_	O
155	the	_	_	O
156	two	_	_	O
157	groups	_	_	O
158	.	_	_	O

159	HRQOL	_	_	O
160	was	_	_	O
161	assessed	_	_	O
162	with	_	_	O
163	the	_	_	O
164	European	_	_	O
165	Organization	_	_	O
166	for	_	_	O
167	Research	_	_	O
168	and	_	_	O
169	Treatment	_	_	O
170	of	_	_	O
171	Cancer	_	_	O
172	(	_	_	O
173	EORTC	_	_	O
174	)	_	_	O
175	Quality	_	_	O
176	of	_	_	O
177	Life	_	_	O
178	Questionnaire	_	_	O
179	C30	_	_	O
180	and	_	_	O
181	the	_	_	O
182	EORTC	_	_	O
183	Breast	_	_	O
184	Module	_	_	O
185	at	_	_	O
186	baseline	_	_	O
187	and	_	_	O
188	the	_	_	O
189	start	_	_	O
190	of	_	_	O
191	cycles	_	_	O
192	2	_	_	O
193	,	_	_	O
194	4	_	_	O
195	,	_	_	O
196	and	_	_	O
197	6	_	_	O
198	,	_	_	O
199	and	_	_	O
200	3	_	_	O
201	months	_	_	O
202	after	_	_	O
203	the	_	_	O
204	last	_	_	O
205	cycle	_	_	O
206	.	_	_	O

207	Seventy	_	_	O
208	-	_	_	O
209	nine	_	_	O
210	percent	_	_	O
211	of	_	_	O
212	the	_	_	O
213	patients	_	_	O
214	(	_	_	O
215	n	_	_	O
216	=	_	_	O
217	219	_	_	O
218	)	_	_	O
219	completed	_	_	O
220	a	_	_	O
221	baseline	_	_	O
222	measure	_	_	O
223	.	_	_	O

224	However	_	_	O
225	,	_	_	O
226	there	_	_	B-Premise
227	were	_	_	I-Premise
228	no	_	_	I-Premise
229	statistically	_	_	I-Premise
230	significant	_	_	I-Premise
231	differences	_	_	I-Premise
232	in	_	_	I-Premise
233	HRQOL	_	_	I-Premise
234	between	_	_	I-Premise
235	the	_	_	I-Premise
236	two	_	_	I-Premise
237	treatment	_	_	I-Premise
238	groups	_	_	I-Premise
239	.	_	_	I-Premise

240	In	_	_	B-Premise
241	both	_	_	I-Premise
242	groups	_	_	I-Premise
243	,	_	_	I-Premise
244	selected	_	_	I-Premise
245	aspects	_	_	I-Premise
246	of	_	_	I-Premise
247	HRQOL	_	_	I-Premise
248	were	_	_	I-Premise
249	impaired	_	_	I-Premise
250	over	_	_	I-Premise
251	time	_	_	I-Premise
252	,	_	_	I-Premise
253	with	_	_	I-Premise
254	increased	_	_	I-Premise
255	fatigue	_	_	I-Premise
256	,	_	_	I-Premise
257	although	_	_	B-Premise
258	some	_	_	I-Premise
259	clinically	_	_	I-Premise
260	significant	_	_	I-Premise
261	improvements	_	_	I-Premise
262	in	_	_	I-Premise
263	emotional	_	_	I-Premise
264	functioning	_	_	I-Premise
265	were	_	_	I-Premise
266	seen	_	_	I-Premise
267	,	_	_	I-Premise
268	as	_	_	I-Premise
269	well	_	_	I-Premise
270	as	_	_	I-Premise
271	a	_	_	I-Premise
272	reduction	_	_	I-Premise
273	in	_	_	I-Premise
274	pain	_	_	I-Premise
275	over	_	_	I-Premise
276	time	_	_	I-Premise
277	.	_	_	I-Premise

278	Overall	_	_	B-Claim
279	,	_	_	I-Claim
280	global	_	_	I-Claim
281	quality	_	_	I-Claim
282	of	_	_	I-Claim
283	life	_	_	I-Claim
284	was	_	_	I-Claim
285	maintained	_	_	I-Claim
286	in	_	_	I-Claim
287	both	_	_	I-Claim
288	treatment	_	_	I-Claim
289	groups	_	_	I-Claim
290	.	_	_	I-Claim

291	This	_	_	B-Claim
292	information	_	_	I-Claim
293	is	_	_	I-Claim
294	important	_	_	I-Claim
295	when	_	_	I-Claim
296	advising	_	_	I-Claim
297	women	_	_	I-Claim
298	patients	_	_	I-Claim
299	of	_	_	I-Claim
300	the	_	_	I-Claim
301	expected	_	_	I-Claim
302	HRQOL	_	_	I-Claim
303	consequences	_	_	I-Claim
304	of	_	_	I-Claim
305	treatment	_	_	I-Claim
306	regimens	_	_	I-Claim
307	and	_	_	I-Claim
308	should	_	_	I-Claim
309	help	_	_	I-Claim
310	clinicians	_	_	I-Claim
311	and	_	_	I-Claim
312	their	_	_	I-Claim
313	patients	_	_	I-Claim
314	make	_	_	I-Claim
315	informed	_	_	I-Claim
316	treatment	_	_	I-Claim
317	decisions	_	_	I-Claim
318	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	effects	_	_	O
10	on	_	_	O
11	health	_	_	O
12	-	_	_	O
13	related	_	_	O
14	quality	_	_	O
15	of	_	_	O
16	life	_	_	O
17	(	_	_	O
18	HRQOL	_	_	O
19	)	_	_	O
20	of	_	_	O
21	two	_	_	O
22	treatment	_	_	O
23	regimens	_	_	O
24	in	_	_	O
25	the	_	_	O
26	TEX	_	_	O
27	trial	_	_	O
28	during	_	_	O
29	9	_	_	O
30	month	_	_	O
31	from	_	_	O
32	random	_	_	O
33	assignment	_	_	O
34	,	_	_	O
35	with	_	_	O
36	emphasis	_	_	O
37	on	_	_	O
38	the	_	_	O
39	2	_	_	O
40	-	_	_	O
41	and	_	_	O
42	9	_	_	O
43	-	_	_	O
44	months	_	_	O
45	assessments	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	287	_	_	O
51	patients	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	treatment	_	_	O
56	in	_	_	O
57	3	_	_	O
58	-	_	_	O
59	week	_	_	O
60	cycles	_	_	O
61	with	_	_	O
62	either	_	_	O
63	epirubicin	_	_	O
64	plus	_	_	O
65	paclitaxel	_	_	O
66	(	_	_	O
67	ET	_	_	O
68	,	_	_	O
69	143	_	_	O
70	patients	_	_	O
71	)	_	_	O
72	,	_	_	O
73	or	_	_	O
74	epirubicin	_	_	O
75	,	_	_	O
76	paclitaxel	_	_	O
77	and	_	_	O
78	capecitabine	_	_	O
79	(	_	_	O
80	TEX	_	_	O
81	,	_	_	O
82	144	_	_	O
83	patients	_	_	O
84	)	_	_	O
85	.	_	_	O

86	HRQOL	_	_	O
87	was	_	_	O
88	assessed	_	_	O
89	by	_	_	O
90	the	_	_	O
91	EORTC	_	_	O
92	-	_	_	O
93	QLQ	_	_	O
94	C30	_	_	O
95	and	_	_	O
96	EORTC	_	_	O
97	QLQ	_	_	O
98	-	_	_	O
99	BR23	_	_	O
100	questionnaires	_	_	O
101	at	_	_	O
102	five	_	_	O
103	points	_	_	O
104	during	_	_	O
105	9	_	_	O
106	months	_	_	O
107	.	_	_	O

108	A	_	_	O
109	total	_	_	O
110	of	_	_	O
111	252	_	_	O
112	(	_	_	O
113	88	_	_	O
114	%	_	_	O
115	)	_	_	O
116	completed	_	_	O
117	questionnaires	_	_	O
118	before	_	_	O
119	randomization	_	_	O
120	.	_	_	O

121	Response	_	_	O
122	rate	_	_	O
123	for	_	_	O
124	the	_	_	O
125	following	_	_	O
126	assessments	_	_	O
127	was	_	_	O
128	>	_	_	O
129	75	_	_	O
130	%	_	_	O
131	.	_	_	O

132	There	_	_	B-Premise
133	were	_	_	I-Premise
134	no	_	_	I-Premise
135	statistically	_	_	I-Premise
136	significant	_	_	I-Premise
137	differences	_	_	I-Premise
138	between	_	_	I-Premise
139	the	_	_	I-Premise
140	TEX	_	_	I-Premise
141	group	_	_	I-Premise
142	and	_	_	I-Premise
143	the	_	_	I-Premise
144	ET	_	_	I-Premise
145	group	_	_	I-Premise
146	on	_	_	I-Premise
147	any	_	_	I-Premise
148	of	_	_	I-Premise
149	the	_	_	I-Premise
150	subscales	_	_	I-Premise
151	2	_	_	I-Premise
152	months	_	_	I-Premise
153	after	_	_	I-Premise
154	randomization	_	_	I-Premise
155	.	_	_	I-Premise

156	Small	_	_	B-Premise
157	clinical	_	_	I-Premise
158	differences	_	_	I-Premise
159	(	_	_	I-Premise
160	5	_	_	I-Premise
161	-	_	_	I-Premise
162	10	_	_	I-Premise
163	points	_	_	I-Premise
164	)	_	_	I-Premise
165	in	_	_	I-Premise
166	favor	_	_	I-Premise
167	of	_	_	I-Premise
168	the	_	_	I-Premise
169	ET	_	_	I-Premise
170	group	_	_	I-Premise
171	were	_	_	I-Premise
172	found	_	_	I-Premise
173	for	_	_	I-Premise
174	global	_	_	I-Premise
175	quality	_	_	I-Premise
176	of	_	_	I-Premise
177	life	_	_	I-Premise
178	,	_	_	I-Premise
179	role	_	_	I-Premise
180	functioning	_	_	I-Premise
181	,	_	_	I-Premise
182	social	_	_	I-Premise
183	functioning	_	_	I-Premise
184	,	_	_	I-Premise
185	and	_	_	I-Premise
186	insomnia	_	_	I-Premise
187	.	_	_	I-Premise

188	At	_	_	B-Premise
189	the	_	_	I-Premise
190	9	_	_	I-Premise
191	-	_	_	I-Premise
192	months	_	_	I-Premise
193	assessment	_	_	I-Premise
194	,	_	_	I-Premise
195	the	_	_	I-Premise
196	TEX	_	_	I-Premise
197	group	_	_	I-Premise
198	scored	_	_	I-Premise
199	statistically	_	_	I-Premise
200	significantly	_	_	I-Premise
201	higher	_	_	I-Premise
202	on	_	_	I-Premise
203	global	_	_	I-Premise
204	quality	_	_	I-Premise
205	of	_	_	I-Premise
206	life	_	_	I-Premise
207	and	_	_	I-Premise
208	physical	_	_	I-Premise
209	functioning	_	_	I-Premise
210	.	_	_	I-Premise

211	Small	_	_	B-Premise
212	clinically	_	_	I-Premise
213	significant	_	_	I-Premise
214	differences	_	_	I-Premise
215	were	_	_	I-Premise
216	found	_	_	I-Premise
217	for	_	_	I-Premise
218	global	_	_	I-Premise
219	quality	_	_	I-Premise
220	of	_	_	I-Premise
221	life	_	_	I-Premise
222	,	_	_	I-Premise
223	physical	_	_	I-Premise
224	functioning	_	_	I-Premise
225	,	_	_	I-Premise
226	role	_	_	I-Premise
227	functioning	_	_	I-Premise
228	,	_	_	I-Premise
229	emotional	_	_	I-Premise
230	functioning	_	_	I-Premise
231	,	_	_	I-Premise
232	dyspnoea	_	_	I-Premise
233	,	_	_	I-Premise
234	and	_	_	I-Premise
235	insomnia	_	_	I-Premise
236	,	_	_	I-Premise
237	all	_	_	I-Premise
238	in	_	_	I-Premise
239	favour	_	_	I-Premise
240	of	_	_	I-Premise
241	the	_	_	I-Premise
242	TEX	_	_	I-Premise
243	group	_	_	I-Premise
244	.	_	_	I-Premise

245	At	_	_	B-Claim
246	the	_	_	I-Claim
247	2	_	_	I-Claim
248	-	_	_	I-Claim
249	months	_	_	I-Claim
250	assessment	_	_	I-Claim
251	,	_	_	I-Claim
252	when	_	_	I-Claim
253	side	_	_	I-Claim
254	-	_	_	I-Claim
255	effects	_	_	I-Claim
256	of	_	_	I-Claim
257	chemotherapy	_	_	I-Claim
258	were	_	_	I-Claim
259	present	_	_	I-Claim
260	,	_	_	I-Claim
261	patients	_	_	I-Claim
262	in	_	_	I-Claim
263	the	_	_	I-Claim
264	TEX	_	_	I-Claim
265	group	_	_	I-Claim
266	appeared	_	_	I-Claim
267	to	_	_	I-Claim
268	fare	_	_	I-Claim
269	a	_	_	I-Claim
270	bit	_	_	I-Claim
271	worse	_	_	I-Claim
272	than	_	_	I-Claim
273	those	_	_	I-Claim
274	receiving	_	_	I-Claim
275	ET	_	_	I-Claim
276	.	_	_	I-Claim

277	However	_	_	O
278	,	_	_	O
279	after	_	_	B-Claim
280	9	_	_	I-Claim
281	months	_	_	I-Claim
282	,	_	_	I-Claim
283	when	_	_	I-Claim
284	the	_	_	I-Claim
285	patients	_	_	I-Claim
286	had	_	_	I-Claim
287	adapted	_	_	I-Claim
288	to	_	_	I-Claim
289	treatment	_	_	I-Claim
290	,	_	_	I-Claim
291	the	_	_	I-Claim
292	TEX	_	_	I-Claim
293	group	_	_	I-Claim
294	seemed	_	_	I-Claim
295	to	_	_	I-Claim
296	have	_	_	I-Claim
297	a	_	_	I-Claim
298	slightly	_	_	I-Claim
299	better	_	_	I-Claim
300	quality	_	_	I-Claim
301	of	_	_	I-Claim
302	life	_	_	I-Claim
303	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	whether	_	_	O
3	3	_	_	O
4	-	_	_	O
5	month	_	_	O
6	administration	_	_	O
7	of	_	_	O
8	CDB	_	_	O
9	-	_	_	O
10	2914	_	_	O
11	,	_	_	O
12	a	_	_	O
13	selective	_	_	O
14	progesterone	_	_	O
15	receptor	_	_	O
16	modulator	_	_	O
17	,	_	_	O
18	reduces	_	_	O
19	leiomyoma	_	_	O
20	size	_	_	O
21	and	_	_	O
22	symptoms	_	_	O
23	.	_	_	O

24	Premenopausal	_	_	O
25	women	_	_	O
26	with	_	_	O
27	symptomatic	_	_	O
28	uterine	_	_	O
29	leiomyomata	_	_	O
30	were	_	_	O
31	randomly	_	_	O
32	assigned	_	_	O
33	to	_	_	O
34	CDB	_	_	O
35	-	_	_	O
36	2914	_	_	O
37	at	_	_	O
38	10	_	_	O
39	mg	_	_	O
40	(	_	_	O
41	T1	_	_	O
42	)	_	_	O
43	or	_	_	O
44	20	_	_	O
45	mg	_	_	O
46	(	_	_	O
47	T2	_	_	O
48	)	_	_	O
49	daily	_	_	O
50	or	_	_	O
51	to	_	_	O
52	placebo	_	_	O
53	(	_	_	O
54	PLC	_	_	O
55	)	_	_	O
56	for	_	_	O
57	3	_	_	O
58	cycles	_	_	O
59	or	_	_	O
60	90	_	_	O
61	-	_	_	O
62	102	_	_	O
63	days	_	_	O
64	if	_	_	O
65	no	_	_	O
66	menses	_	_	O
67	occurred	_	_	O
68	.	_	_	O

69	The	_	_	O
70	primary	_	_	O
71	outcome	_	_	O
72	was	_	_	O
73	leiomyoma	_	_	O
74	volume	_	_	O
75	change	_	_	O
76	determined	_	_	O
77	by	_	_	O
78	magnetic	_	_	O
79	resonance	_	_	O
80	imaging	_	_	O
81	at	_	_	O
82	study	_	_	O
83	entry	_	_	O
84	and	_	_	O
85	within	_	_	O
86	2	_	_	O
87	weeks	_	_	O
88	of	_	_	O
89	hysterectomy	_	_	O
90	.	_	_	O

91	Secondary	_	_	O
92	outcomes	_	_	O
93	included	_	_	O
94	the	_	_	O
95	proportion	_	_	O
96	of	_	_	O
97	amenorrhea	_	_	O
98	,	_	_	O
99	change	_	_	O
100	in	_	_	O
101	hemoglobin	_	_	O
102	and	_	_	O
103	hematocrit	_	_	O
104	,	_	_	O
105	ovulation	_	_	O
106	inhibition	_	_	O
107	,	_	_	O
108	and	_	_	O
109	quality	_	_	O
110	-	_	_	O
111	of	_	_	O
112	-	_	_	O
113	life	_	_	O
114	assessment	_	_	O
115	.	_	_	O

116	Twenty	_	_	O
117	-	_	_	O
118	two	_	_	O
119	patients	_	_	O
120	were	_	_	O
121	allocated	_	_	O
122	,	_	_	O
123	and	_	_	O
124	18	_	_	O
125	completed	_	_	O
126	the	_	_	O
127	trial	_	_	O
128	.	_	_	O

129	Age	_	_	O
130	and	_	_	O
131	body	_	_	O
132	mass	_	_	O
133	index	_	_	O
134	were	_	_	O
135	similar	_	_	O
136	among	_	_	O
137	groups	_	_	O
138	.	_	_	O

139	Leiomyoma	_	_	O
140	volume	_	_	O
141	was	_	_	O
142	significantly	_	_	O
143	reduced	_	_	O
144	with	_	_	O
145	CDB	_	_	O
146	-	_	_	O
147	2914	_	_	O
148	administration	_	_	O
149	(	_	_	O
150	PLC	_	_	O
151	6	_	_	O
152	%	_	_	O
153	;	_	_	O
154	CDB	_	_	O
155	-	_	_	O
156	2914	_	_	O
157	-	_	_	O
158	29	_	_	O
159	%	_	_	O
160	;	_	_	O
161	P	_	_	O
162	=	_	_	O
163	.	_	_	O

164	01	_	_	O
165	)	_	_	O
166	,	_	_	O
167	decreasing	_	_	O
168	36	_	_	O
169	%	_	_	O
170	and	_	_	O
171	21	_	_	O
172	%	_	_	O
173	in	_	_	O
174	the	_	_	O
175	T1	_	_	O
176	and	_	_	O
177	T2	_	_	O
178	groups	_	_	O
179	,	_	_	O
180	respectively	_	_	O
181	.	_	_	O

182	During	_	_	O
183	treatment	_	_	O
184	,	_	_	O
185	hemoglobin	_	_	O
186	was	_	_	O
187	unchanged	_	_	O
188	,	_	_	O
189	and	_	_	O
190	the	_	_	O
191	median	_	_	O
192	estradiol	_	_	O
193	was	_	_	O
194	greater	_	_	O
195	than	_	_	O
196	50	_	_	O
197	pg	_	_	O
198	/	_	_	O
199	mL	_	_	O
200	in	_	_	O
201	all	_	_	O
202	groups	_	_	O
203	.	_	_	O

204	CDB	_	_	O
205	-	_	_	O
206	2914	_	_	O
207	eliminated	_	_	O
208	menstrual	_	_	O
209	bleeding	_	_	O
210	and	_	_	O
211	inhibited	_	_	O
212	ovulation	_	_	O
213	(	_	_	O
214	%	_	_	O
215	ovulatory	_	_	O
216	cycles	_	_	O
217	:	_	_	O
218	CDB	_	_	O
219	-	_	_	O
220	2914	_	_	O
221	,	_	_	O
222	20	_	_	O
223	%	_	_	O
224	;	_	_	O
225	PLC	_	_	O
226	,	_	_	O
227	83	_	_	O
228	%	_	_	O
229	;	_	_	O
230	P	_	_	O
231	=	_	_	O
232	.	_	_	O

233	001	_	_	O
234	)	_	_	O
235	.	_	_	O

236	CDB	_	_	O
237	-	_	_	O
238	2914	_	_	O
239	improved	_	_	O
240	the	_	_	O
241	concern	_	_	O
242	scores	_	_	O
243	of	_	_	O
244	the	_	_	O
245	uterine	_	_	O
246	leiomyoma	_	_	O
247	symptom	_	_	O
248	quality	_	_	O
249	-	_	_	O
250	of	_	_	O
251	-	_	_	O
252	life	_	_	O
253	subscale	_	_	O
254	(	_	_	O
255	P	_	_	O
256	=	_	_	O
257	.	_	_	O

258	04	_	_	O
259	)	_	_	O
260	.	_	_	O

261	One	_	_	O
262	CDB	_	_	O
263	-	_	_	O
264	2914	_	_	O
265	woman	_	_	O
266	developed	_	_	O
267	endometrial	_	_	O
268	cystic	_	_	O
269	hyperplasia	_	_	O
270	without	_	_	O
271	evidence	_	_	O
272	of	_	_	O
273	atypia	_	_	O
274	.	_	_	O

275	No	_	_	B-Premise
276	serious	_	_	I-Premise
277	adverse	_	_	I-Premise
278	events	_	_	I-Premise
279	were	_	_	I-Premise
280	reported	_	_	I-Premise
281	.	_	_	I-Premise

282	Compared	_	_	B-Premise
283	with	_	_	I-Premise
284	PLC	_	_	I-Premise
285	,	_	_	I-Premise
286	CDB	_	_	I-Premise
287	-	_	_	I-Premise
288	2914	_	_	I-Premise
289	significantly	_	_	I-Premise
290	reduced	_	_	I-Premise
291	leiomyoma	_	_	I-Premise
292	volume	_	_	I-Premise
293	after	_	_	I-Premise
294	three	_	_	I-Premise
295	cycles	_	_	I-Premise
296	,	_	_	I-Premise
297	or	_	_	I-Premise
298	90	_	_	I-Premise
299	-	_	_	I-Premise
300	102	_	_	I-Premise
301	days	_	_	I-Premise
302	.	_	_	I-Premise

303	CDB	_	_	B-Premise
304	-	_	_	I-Premise
305	2914	_	_	I-Premise
306	treatment	_	_	I-Premise
307	resulted	_	_	I-Premise
308	in	_	_	I-Premise
309	improvements	_	_	I-Premise
310	in	_	_	I-Premise
311	the	_	_	I-Premise
312	concern	_	_	I-Premise
313	subscale	_	_	I-Premise
314	of	_	_	I-Premise
315	the	_	_	I-Premise
316	Uterine	_	_	I-Premise
317	Fibroid	_	_	I-Premise
318	Symptom	_	_	I-Premise
319	Quality	_	_	I-Premise
320	of	_	_	I-Premise
321	Life	_	_	I-Premise
322	assessment	_	_	I-Premise
323	.	_	_	I-Premise

324	In	_	_	B-Claim
325	this	_	_	I-Claim
326	small	_	_	I-Claim
327	study	_	_	I-Claim
328	,	_	_	I-Claim
329	CDB	_	_	I-Claim
330	-	_	_	I-Claim
331	2914	_	_	I-Claim
332	was	_	_	I-Claim
333	well	_	_	I-Claim
334	-	_	_	I-Claim
335	tolerated	_	_	I-Claim
336	without	_	_	I-Claim
337	serious	_	_	I-Claim
338	adverse	_	_	I-Claim
339	events	_	_	I-Claim
340	.	_	_	I-Claim

341	Thus	_	_	B-Claim
342	,	_	_	I-Claim
343	there	_	_	I-Claim
344	may	_	_	I-Claim
345	be	_	_	I-Claim
346	a	_	_	I-Claim
347	role	_	_	I-Claim
348	for	_	_	I-Claim
349	CDB	_	_	I-Claim
350	-	_	_	I-Claim
351	2914	_	_	I-Claim
352	in	_	_	I-Claim
353	the	_	_	I-Claim
354	treatment	_	_	I-Claim
355	of	_	_	I-Claim
356	leiomyomata	_	_	I-Claim
357	.	_	_	I-Claim


0	The	_	_	O
1	AGO	_	_	O
2	-	_	_	O
3	ETC	_	_	O
4	trial	_	_	O
5	compared	_	_	O
6	5	_	_	O
7	-	_	_	O
8	year	_	_	O
9	relapse	_	_	O
10	-	_	_	O
11	free	_	_	O
12	survival	_	_	O
13	of	_	_	O
14	intense	_	_	O
15	dose	_	_	O
16	-	_	_	O
17	dense	_	_	O
18	(	_	_	O
19	IDD	_	_	O
20	)	_	_	O
21	sequential	_	_	O
22	chemotherapy	_	_	O
23	with	_	_	O
24	epirubicin	_	_	O
25	(	_	_	O
26	E	_	_	O
27	)	_	_	O
28	,	_	_	O
29	paclitaxel	_	_	O
30	(	_	_	O
31	T	_	_	O
32	)	_	_	O
33	,	_	_	O
34	and	_	_	O
35	cyclophosphamide	_	_	O
36	(	_	_	O
37	C	_	_	O
38	)	_	_	O
39	(	_	_	O
40	IDD	_	_	O
41	-	_	_	O
42	ETC	_	_	O
43	)	_	_	O
44	every	_	_	O
45	2	_	_	O
46	weeks	_	_	O
47	vs	_	_	O
48	conventional	_	_	O
49	scheduled	_	_	O
50	epirubicin	_	_	O
51	/	_	_	O
52	cyclophosphamide	_	_	O
53	followed	_	_	O
54	by	_	_	O
55	paclitaxel	_	_	O
56	(	_	_	O
57	EC	_	_	O
58	→	_	_	O
59	T	_	_	O
60	)	_	_	O
61	(	_	_	O
62	every	_	_	O
63	3	_	_	O
64	weeks	_	_	O
65	)	_	_	O
66	as	_	_	O
67	adjuvant	_	_	O
68	treatment	_	_	O
69	in	_	_	O
70	high	_	_	O
71	-	_	_	O
72	risk	_	_	O
73	breast	_	_	O
74	cancer	_	_	O
75	patients	_	_	O
76	.	_	_	O

77	The	_	_	O
78	objective	_	_	O
79	of	_	_	O
80	this	_	_	O
81	study	_	_	O
82	was	_	_	O
83	to	_	_	O
84	evaluate	_	_	O
85	the	_	_	O
86	safety	_	_	O
87	and	_	_	O
88	efficacy	_	_	O
89	of	_	_	O
90	epoetin	_	_	O
91	alfa	_	_	O
92	in	_	_	O
93	a	_	_	O
94	second	_	_	O
95	randomization	_	_	O
96	of	_	_	O
97	the	_	_	O
98	intense	_	_	O
99	dose	_	_	O
100	-	_	_	O
101	dense	_	_	O
102	arm	_	_	O
103	.	_	_	O

104	One	_	_	O
105	thousand	_	_	O
106	two	_	_	O
107	hundred	_	_	O
108	eighty	_	_	O
109	-	_	_	O
110	four	_	_	O
111	patients	_	_	O
112	were	_	_	O
113	enrolled	_	_	O
114	;	_	_	O
115	658	_	_	O
116	patients	_	_	O
117	were	_	_	O
118	randomly	_	_	O
119	assigned	_	_	O
120	to	_	_	O
121	the	_	_	O
122	IDD	_	_	O
123	-	_	_	O
124	ETC	_	_	O
125	treatment	_	_	O
126	group	_	_	O
127	.	_	_	O

128	Within	_	_	O
129	the	_	_	O
130	IDD	_	_	O
131	-	_	_	O
132	ETC	_	_	O
133	group	_	_	O
134	,	_	_	O
135	324	_	_	O
136	patients	_	_	O
137	were	_	_	O
138	further	_	_	O
139	randomly	_	_	O
140	assigned	_	_	O
141	to	_	_	O
142	the	_	_	O
143	epoetin	_	_	O
144	alfa	_	_	O
145	group	_	_	O
146	,	_	_	O
147	and	_	_	O
148	319	_	_	O
149	were	_	_	O
150	randomly	_	_	O
151	assigned	_	_	O
152	to	_	_	O
153	the	_	_	O
154	non	_	_	O
155	-	_	_	O
156	erythropoiesis	_	_	O
157	-	_	_	O
158	stimulating	_	_	O
159	agent	_	_	O
160	(	_	_	O
161	ESA	_	_	O
162	)	_	_	O
163	control	_	_	O
164	group	_	_	O
165	.	_	_	O

166	Primary	_	_	O
167	efficacy	_	_	O
168	endpoints	_	_	O
169	included	_	_	O
170	change	_	_	O
171	in	_	_	O
172	hemoglobin	_	_	O
173	level	_	_	O
174	from	_	_	O
175	baseline	_	_	O
176	to	_	_	O
177	Cycle	_	_	O
178	9	_	_	O
179	and	_	_	O
180	the	_	_	O
181	percentage	_	_	O
182	of	_	_	O
183	subjects	_	_	O
184	requiring	_	_	O
185	red	_	_	O
186	blood	_	_	O
187	cell	_	_	O
188	transfusion	_	_	O
189	.	_	_	O

190	Relapse	_	_	O
191	-	_	_	O
192	free	_	_	O
193	survival	_	_	O
194	,	_	_	O
195	overall	_	_	O
196	survival	_	_	O
197	,	_	_	O
198	and	_	_	O
199	intramammary	_	_	O
200	relapse	_	_	O
201	were	_	_	O
202	secondary	_	_	O
203	endpoints	_	_	O
204	estimated	_	_	O
205	with	_	_	O
206	Kaplan	_	_	O
207	-	_	_	O
208	Meier	_	_	O
209	and	_	_	O
210	Cox	_	_	O
211	regression	_	_	O
212	methods	_	_	O
213	.	_	_	O

214	Except	_	_	O
215	for	_	_	O
216	the	_	_	O
217	primary	_	_	O
218	hypothesis	_	_	O
219	,	_	_	O
220	all	_	_	O
221	statistical	_	_	O
222	tests	_	_	O
223	were	_	_	O
224	two	_	_	O
225	-	_	_	O
226	sided	_	_	O
227	.	_	_	O

228	Epoetin	_	_	B-Premise
229	alfa	_	_	I-Premise
230	avoided	_	_	I-Premise
231	the	_	_	I-Premise
232	decrease	_	_	I-Premise
233	in	_	_	I-Premise
234	hemoglobin	_	_	I-Premise
235	level	_	_	I-Premise
236	(	_	_	I-Premise
237	no	_	_	I-Premise
238	decrease	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	epoetin	_	_	I-Premise
242	alfa	_	_	I-Premise
243	group	_	_	I-Premise
244	vs	_	_	I-Premise
245	-	_	_	I-Premise
246	2	_	_	I-Premise
247	.	_	_	I-Premise

248	20g	_	_	I-Premise
249	/	_	_	I-Premise
250	dL	_	_	I-Premise
251	change	_	_	I-Premise
252	for	_	_	I-Premise
253	the	_	_	I-Premise
254	control	_	_	I-Premise
255	group	_	_	I-Premise
256	;	_	_	I-Premise
257	P	_	_	I-Premise
258	<	_	_	I-Premise
259	.	_	_	I-Premise

260	001	_	_	I-Premise
261	)	_	_	I-Premise
262	and	_	_	I-Premise
263	statistically	_	_	I-Premise
264	significantly	_	_	I-Premise
265	reduced	_	_	I-Premise
266	the	_	_	I-Premise
267	percentage	_	_	I-Premise
268	of	_	_	I-Premise
269	subjects	_	_	I-Premise
270	requiring	_	_	I-Premise
271	red	_	_	I-Premise
272	blood	_	_	I-Premise
273	cell	_	_	I-Premise
274	transfusion	_	_	I-Premise
275	(	_	_	I-Premise
276	12	_	_	I-Premise
277	.	_	_	I-Premise

278	8	_	_	I-Premise
279	%	_	_	I-Premise
280	vs	_	_	I-Premise
281	28	_	_	I-Premise
282	.	_	_	I-Premise

283	1	_	_	I-Premise
284	%	_	_	I-Premise
285	;	_	_	I-Premise
286	P	_	_	I-Premise
287	<	_	_	I-Premise
288	.	_	_	I-Premise

289	0001	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	The	_	_	B-Premise
293	incidence	_	_	I-Premise
294	of	_	_	I-Premise
295	thrombotic	_	_	I-Premise
296	events	_	_	I-Premise
297	was	_	_	I-Premise
298	7	_	_	I-Premise
299	%	_	_	I-Premise
300	in	_	_	I-Premise
301	the	_	_	I-Premise
302	epoetin	_	_	I-Premise
303	alfa	_	_	I-Premise
304	arm	_	_	I-Premise
305	vs	_	_	I-Premise
306	3	_	_	I-Premise
307	%	_	_	I-Premise
308	in	_	_	I-Premise
309	the	_	_	I-Premise
310	control	_	_	I-Premise
311	arm	_	_	I-Premise
312	.	_	_	I-Premise

313	After	_	_	B-Premise
314	a	_	_	I-Premise
315	median	_	_	I-Premise
316	follow	_	_	I-Premise
317	-	_	_	I-Premise
318	up	_	_	I-Premise
319	of	_	_	I-Premise
320	62	_	_	I-Premise
321	months	_	_	I-Premise
322	,	_	_	I-Premise
323	epoetin	_	_	I-Premise
324	alfa	_	_	I-Premise
325	treatment	_	_	I-Premise
326	did	_	_	I-Premise
327	not	_	_	I-Premise
328	affect	_	_	I-Premise
329	overall	_	_	I-Premise
330	survival	_	_	I-Premise
331	,	_	_	I-Premise
332	relapse	_	_	I-Premise
333	-	_	_	I-Premise
334	free	_	_	I-Premise
335	survival	_	_	I-Premise
336	,	_	_	I-Premise
337	or	_	_	I-Premise
338	intramammary	_	_	I-Premise
339	relapse	_	_	I-Premise
340	.	_	_	I-Premise

341	Epoetin	_	_	B-Claim
342	alfa	_	_	I-Claim
343	resulted	_	_	I-Claim
344	in	_	_	I-Claim
345	improved	_	_	I-Claim
346	hemoglobin	_	_	I-Claim
347	levels	_	_	I-Claim
348	and	_	_	I-Claim
349	decreased	_	_	I-Claim
350	transfusions	_	_	I-Claim
351	without	_	_	I-Claim
352	an	_	_	I-Claim
353	impact	_	_	I-Claim
354	on	_	_	I-Claim
355	relapse	_	_	I-Claim
356	-	_	_	I-Claim
357	free	_	_	I-Claim
358	or	_	_	I-Claim
359	overall	_	_	I-Claim
360	survival	_	_	I-Claim
361	.	_	_	I-Claim

362	However	_	_	B-Claim
363	,	_	_	I-Claim
364	epoetin	_	_	I-Claim
365	alfa	_	_	I-Claim
366	had	_	_	I-Claim
367	an	_	_	I-Claim
368	adverse	_	_	I-Claim
369	effect	_	_	I-Claim
370	,	_	_	I-Claim
371	resulting	_	_	I-Claim
372	in	_	_	I-Claim
373	increased	_	_	I-Claim
374	thrombosis	_	_	I-Claim
375	.	_	_	I-Claim


0	Combined	_	_	B-Claim
1	radiation	_	_	I-Claim
2	therapy	_	_	I-Claim
3	and	_	_	I-Claim
4	chemotherapy	_	_	I-Claim
5	after	_	_	I-Claim
6	surgery	_	_	I-Claim
7	,	_	_	I-Claim
8	compared	_	_	I-Claim
9	with	_	_	I-Claim
10	postsurgical	_	_	I-Claim
11	radiation	_	_	I-Claim
12	therapy	_	_	I-Claim
13	alone	_	_	I-Claim
14	,	_	_	I-Claim
15	has	_	_	I-Claim
16	been	_	_	I-Claim
17	shown	_	_	I-Claim
18	to	_	_	I-Claim
19	improve	_	_	I-Claim
20	disease	_	_	I-Claim
21	-	_	_	I-Claim
22	free	_	_	I-Claim
23	survival	_	_	I-Claim
24	and	_	_	I-Claim
25	overall	_	_	I-Claim
26	survival	_	_	I-Claim
27	significantly	_	_	I-Claim
28	among	_	_	I-Claim
29	patients	_	_	I-Claim
30	with	_	_	I-Claim
31	poor	_	_	I-Claim
32	-	_	_	I-Claim
33	prognosis	_	_	I-Claim
34	(	_	_	I-Claim
35	i	_	_	I-Claim
36	.	_	_	I-Claim

37	e	_	_	I-Claim
38	.	_	_	I-Claim

39	,	_	_	I-Claim
40	advanced	_	_	I-Claim
41	stage	_	_	I-Claim
42	disease	_	_	I-Claim
43	or	_	_	I-Claim
44	metastasis	_	_	I-Claim
45	to	_	_	I-Claim
46	regional	_	_	I-Claim
47	lymph	_	_	I-Claim
48	nodes	_	_	I-Claim
49	)	_	_	I-Claim
50	resectable	_	_	I-Claim
51	rectal	_	_	I-Claim
52	cancer	_	_	I-Claim
53	.	_	_	I-Claim

54	However	_	_	B-Claim
55	,	_	_	I-Claim
56	the	_	_	I-Claim
57	combined	_	_	I-Claim
58	therapy	_	_	I-Claim
59	is	_	_	I-Claim
60	associated	_	_	I-Claim
61	with	_	_	I-Claim
62	more	_	_	I-Claim
63	toxic	_	_	I-Claim
64	effects	_	_	I-Claim
65	,	_	_	I-Claim
66	raising	_	_	I-Claim
67	the	_	_	I-Claim
68	question	_	_	I-Claim
69	of	_	_	I-Claim
70	whether	_	_	I-Claim
71	the	_	_	I-Claim
72	benefits	_	_	I-Claim
73	of	_	_	I-Claim
74	the	_	_	I-Claim
75	treatment	_	_	I-Claim
76	justify	_	_	I-Claim
77	its	_	_	I-Claim
78	quality	_	_	I-Claim
79	-	_	_	I-Claim
80	of	_	_	I-Claim
81	-	_	_	I-Claim
82	life	_	_	I-Claim
83	costs	_	_	I-Claim
84	for	_	_	I-Claim
85	the	_	_	I-Claim
86	individual	_	_	I-Claim
87	patient	_	_	I-Claim
88	.	_	_	I-Claim

89	To	_	_	O
90	assess	_	_	O
91	the	_	_	O
92	trade	_	_	O
93	-	_	_	O
94	offs	_	_	O
95	between	_	_	O
96	improved	_	_	O
97	survival	_	_	O
98	and	_	_	O
99	increased	_	_	O
100	treatment	_	_	O
101	toxicity	_	_	O
102	,	_	_	O
103	we	_	_	O
104	reanalyzed	_	_	O
105	data	_	_	O
106	from	_	_	O
107	a	_	_	O
108	randomized	_	_	O
109	clinical	_	_	O
110	trial	_	_	O
111	that	_	_	O
112	compared	_	_	O
113	the	_	_	O
114	efficacy	_	_	O
115	of	_	_	O
116	combined	_	_	O
117	adjuvant	_	_	O
118	chemotherapy	_	_	O
119	and	_	_	O
120	radiation	_	_	O
121	therapy	_	_	O
122	with	_	_	O
123	adjuvant	_	_	O
124	radiation	_	_	O
125	therapy	_	_	O
126	alone	_	_	O
127	in	_	_	O
128	the	_	_	O
129	treatment	_	_	O
130	of	_	_	O
131	patients	_	_	O
132	with	_	_	O
133	poor	_	_	O
134	-	_	_	O
135	prognosis	_	_	O
136	resectable	_	_	O
137	rectal	_	_	O
138	cancer	_	_	O
139	.	_	_	O

140	The	_	_	O
141	data	_	_	O
142	were	_	_	O
143	from	_	_	O
144	a	_	_	O
145	North	_	_	O
146	Central	_	_	O
147	Cancer	_	_	O
148	Treatment	_	_	O
149	Group	_	_	O
150	trial	_	_	O
151	in	_	_	O
152	which	_	_	O
153	204	_	_	O
154	patients	_	_	O
155	with	_	_	O
156	poor	_	_	O
157	-	_	_	O
158	prognosis	_	_	O
159	rectal	_	_	O
160	cancer	_	_	O
161	were	_	_	O
162	randomly	_	_	O
163	assigned	_	_	O
164	to	_	_	O
165	receive	_	_	O
166	either	_	_	O
167	postoperative	_	_	O
168	radiation	_	_	O
169	therapy	_	_	O
170	alone	_	_	O
171	or	_	_	O
172	radiation	_	_	O
173	therapy	_	_	O
174	plus	_	_	O
175	fluorouracil	_	_	O
176	-	_	_	O
177	based	_	_	O
178	chemotherapy	_	_	O
179	.	_	_	O

180	A	_	_	O
181	quality	_	_	O
182	-	_	_	O
183	adjusted	_	_	O
184	time	_	_	O
185	without	_	_	O
186	symptoms	_	_	O
187	or	_	_	O
188	toxicity	_	_	O
189	(	_	_	O
190	Q	_	_	O
191	-	_	_	O
192	TWiST	_	_	O
193	)	_	_	O
194	analysis	_	_	O
195	was	_	_	O
196	used	_	_	O
197	to	_	_	O
198	account	_	_	O
199	for	_	_	O
200	freedom	_	_	O
201	from	_	_	O
202	symptomatic	_	_	O
203	disease	_	_	O
204	and	_	_	O
205	from	_	_	O
206	early	_	_	O
207	and	_	_	O
208	late	_	_	O
209	side	_	_	O
210	effects	_	_	O
211	of	_	_	O
212	treatment	_	_	O
213	.	_	_	O

214	All	_	_	O
215	reported	_	_	O
216	P	_	_	O
217	values	_	_	O
218	are	_	_	O
219	two	_	_	O
220	-	_	_	O
221	sided	_	_	O
222	.	_	_	O

223	As	_	_	B-Premise
224	reported	_	_	I-Premise
225	previously	_	_	I-Premise
226	,	_	_	I-Premise
227	the	_	_	I-Premise
228	combined	_	_	I-Premise
229	therapy	_	_	I-Premise
230	reduced	_	_	I-Premise
231	the	_	_	I-Premise
232	risk	_	_	I-Premise
233	of	_	_	I-Premise
234	relapse	_	_	I-Premise
235	by	_	_	I-Premise
236	34	_	_	I-Premise
237	%	_	_	I-Premise
238	(	_	_	I-Premise
239	95	_	_	I-Premise
240	%	_	_	I-Premise
241	confidence	_	_	I-Premise
242	interval	_	_	I-Premise
243	[	_	_	I-Premise
244	CI	_	_	I-Premise
245	]	_	_	I-Premise
246	=	_	_	I-Premise
247	12	_	_	I-Premise
248	%	_	_	I-Premise
249	-	_	_	I-Premise
250	50	_	_	I-Premise
251	%	_	_	I-Premise
252	;	_	_	I-Premise
253	P	_	_	I-Premise
254	=	_	_	I-Premise
255	.	_	_	I-Premise

256	0016	_	_	I-Premise
257	)	_	_	I-Premise
258	and	_	_	I-Premise
259	reduced	_	_	I-Premise
260	the	_	_	I-Premise
261	overall	_	_	I-Premise
262	death	_	_	I-Premise
263	rate	_	_	I-Premise
264	by	_	_	I-Premise
265	29	_	_	I-Premise
266	%	_	_	I-Premise
267	(	_	_	I-Premise
268	95	_	_	I-Premise
269	%	_	_	I-Premise
270	CI	_	_	I-Premise
271	=	_	_	I-Premise
272	7	_	_	I-Premise
273	%	_	_	I-Premise
274	-	_	_	I-Premise
275	45	_	_	I-Premise
276	%	_	_	I-Premise
277	;	_	_	I-Premise
278	P	_	_	I-Premise
279	=	_	_	I-Premise
280	.	_	_	I-Premise

281	025	_	_	I-Premise
282	)	_	_	I-Premise
283	in	_	_	I-Premise
284	comparison	_	_	I-Premise
285	with	_	_	I-Premise
286	adjuvant	_	_	I-Premise
287	radiation	_	_	I-Premise
288	therapy	_	_	I-Premise
289	alone	_	_	I-Premise
290	.	_	_	I-Premise

291	In	_	_	B-Premise
292	the	_	_	I-Premise
293	5	_	_	I-Premise
294	years	_	_	I-Premise
295	following	_	_	I-Premise
296	assignment	_	_	I-Premise
297	to	_	_	I-Premise
298	treatment	_	_	I-Premise
299	,	_	_	I-Premise
300	patients	_	_	I-Premise
301	who	_	_	I-Premise
302	received	_	_	I-Premise
303	the	_	_	I-Premise
304	combined	_	_	I-Premise
305	therapy	_	_	I-Premise
306	had	_	_	I-Premise
307	more	_	_	I-Premise
308	time	_	_	I-Premise
309	with	_	_	I-Premise
310	toxicity	_	_	I-Premise
311	(	_	_	I-Premise
312	3	_	_	I-Premise
313	.	_	_	I-Premise

314	1	_	_	I-Premise
315	months	_	_	I-Premise
316	;	_	_	I-Premise
317	95	_	_	I-Premise
318	%	_	_	I-Premise
319	CI	_	_	I-Premise
320	=	_	_	I-Premise
321	2	_	_	I-Premise
322	.	_	_	I-Premise

323	0	_	_	I-Premise
324	-	_	_	I-Premise
325	4	_	_	I-Premise
326	.	_	_	I-Premise

327	1	_	_	I-Premise
328	months	_	_	I-Premise
329	)	_	_	I-Premise
330	,	_	_	I-Premise
331	shorter	_	_	I-Premise
332	survival	_	_	I-Premise
333	after	_	_	I-Premise
334	relapse	_	_	I-Premise
335	(	_	_	I-Premise
336	3	_	_	I-Premise
337	.	_	_	I-Premise

338	6	_	_	I-Premise
339	months	_	_	I-Premise
340	less	_	_	I-Premise
341	;	_	_	I-Premise
342	95	_	_	I-Premise
343	%	_	_	I-Premise
344	CI	_	_	I-Premise
345	=	_	_	I-Premise
346	0	_	_	I-Premise
347	.	_	_	I-Premise

348	9	_	_	I-Premise
349	-	_	_	I-Premise
350	6	_	_	I-Premise
351	.	_	_	I-Premise

352	3	_	_	I-Premise
353	months	_	_	I-Premise
354	less	_	_	I-Premise
355	)	_	_	I-Premise
356	,	_	_	I-Premise
357	and	_	_	I-Premise
358	more	_	_	I-Premise
359	TWiST	_	_	I-Premise
360	(	_	_	I-Premise
361	6	_	_	I-Premise
362	.	_	_	I-Premise

363	1	_	_	I-Premise
364	months	_	_	I-Premise
365	;	_	_	I-Premise
366	95	_	_	I-Premise
367	%	_	_	I-Premise
368	CI	_	_	I-Premise
369	=	_	_	I-Premise
370	0	_	_	I-Premise
371	.	_	_	I-Premise

372	2	_	_	I-Premise
373	-	_	_	I-Premise
374	12	_	_	I-Premise
375	.	_	_	I-Premise

376	0	_	_	I-Premise
377	months	_	_	I-Premise
378	)	_	_	I-Premise
379	than	_	_	I-Premise
380	patients	_	_	I-Premise
381	who	_	_	I-Premise
382	received	_	_	I-Premise
383	adjuvant	_	_	I-Premise
384	radiation	_	_	I-Premise
385	therapy	_	_	I-Premise
386	alone	_	_	I-Premise
387	.	_	_	I-Premise

388	Despite	_	_	B-Claim
389	an	_	_	I-Claim
390	increase	_	_	I-Claim
391	in	_	_	I-Claim
392	the	_	_	I-Claim
393	amount	_	_	I-Claim
394	of	_	_	I-Claim
395	time	_	_	I-Claim
396	that	_	_	I-Claim
397	individuals	_	_	I-Claim
398	spent	_	_	I-Claim
399	with	_	_	I-Claim
400	early	_	_	I-Claim
401	and	_	_	I-Claim
402	late	_	_	I-Claim
403	toxic	_	_	I-Claim
404	effects	_	_	I-Claim
405	,	_	_	I-Claim
406	the	_	_	I-Claim
407	Q	_	_	I-Claim
408	-	_	_	I-Claim
409	TWiST	_	_	I-Claim
410	analysis	_	_	I-Claim
411	indicated	_	_	I-Claim
412	that	_	_	I-Claim
413	the	_	_	I-Claim
414	combined	_	_	I-Claim
415	therapy	_	_	I-Claim
416	conferred	_	_	I-Claim
417	significantly	_	_	I-Claim
418	greater	_	_	I-Claim
419	benefit	_	_	I-Claim
420	for	_	_	I-Claim
421	a	_	_	I-Claim
422	wide	_	_	I-Claim
423	range	_	_	I-Claim
424	of	_	_	I-Claim
425	patient	_	_	I-Claim
426	preferences	_	_	I-Claim
427	about	_	_	I-Claim
428	living	_	_	I-Claim
429	with	_	_	I-Claim
430	the	_	_	I-Claim
431	toxicity	_	_	I-Claim
432	of	_	_	I-Claim
433	treatment	_	_	I-Claim
434	or	_	_	I-Claim
435	the	_	_	I-Claim
436	symptoms	_	_	I-Claim
437	of	_	_	I-Claim
438	overt	_	_	I-Claim
439	disease	_	_	I-Claim
440	.	_	_	I-Claim

441	Use	_	_	B-Claim
442	of	_	_	I-Claim
443	combined	_	_	I-Claim
444	chemotherapy	_	_	I-Claim
445	and	_	_	I-Claim
446	radiation	_	_	I-Claim
447	therapy	_	_	I-Claim
448	as	_	_	I-Claim
449	an	_	_	I-Claim
450	adjuvant	_	_	I-Claim
451	to	_	_	I-Claim
452	surgery	_	_	I-Claim
453	for	_	_	I-Claim
454	patients	_	_	I-Claim
455	with	_	_	I-Claim
456	poor	_	_	I-Claim
457	-	_	_	I-Claim
458	prognosis	_	_	I-Claim
459	resectable	_	_	I-Claim
460	rectal	_	_	I-Claim
461	cancer	_	_	I-Claim
462	is	_	_	I-Claim
463	justified	_	_	I-Claim
464	,	_	_	I-Claim
465	since	_	_	B-Premise
466	the	_	_	I-Premise
467	improved	_	_	I-Premise
468	outcome	_	_	I-Premise
469	in	_	_	I-Premise
470	terms	_	_	I-Premise
471	of	_	_	I-Premise
472	delayed	_	_	I-Premise
473	recurrence	_	_	I-Premise
474	and	_	_	I-Premise
475	increased	_	_	I-Premise
476	survival	_	_	I-Premise
477	balances	_	_	I-Premise
478	the	_	_	I-Premise
479	time	_	_	I-Premise
480	spent	_	_	I-Premise
481	with	_	_	I-Premise
482	early	_	_	I-Premise
483	and	_	_	I-Premise
484	late	_	_	I-Premise
485	toxic	_	_	I-Premise
486	effects	_	_	I-Premise
487	.	_	_	I-Premise

488	The	_	_	B-Claim
489	Q	_	_	I-Claim
490	-	_	_	I-Claim
491	TWiST	_	_	I-Claim
492	method	_	_	I-Claim
493	is	_	_	I-Claim
494	an	_	_	I-Claim
495	excellent	_	_	I-Claim
496	way	_	_	I-Claim
497	to	_	_	I-Claim
498	compare	_	_	I-Claim
499	treatment	_	_	I-Claim
500	outcomes	_	_	I-Claim
501	that	_	_	I-Claim
502	include	_	_	I-Claim
503	quality	_	_	I-Claim
504	-	_	_	I-Claim
505	of	_	_	I-Claim
506	-	_	_	I-Claim
507	life	_	_	I-Claim
508	considerations	_	_	I-Claim
509	.	_	_	I-Claim


0	This	_	_	O
1	randomized	_	_	O
2	,	_	_	O
3	double	_	_	O
4	-	_	_	O
5	blind	_	_	O
6	,	_	_	O
7	placebo	_	_	O
8	-	_	_	O
9	controlled	_	_	O
10	clinical	_	_	O
11	trial	_	_	O
12	assessed	_	_	O
13	the	_	_	O
14	effects	_	_	O
15	of	_	_	O
16	epoetin	_	_	O
17	alfa	_	_	O
18	on	_	_	O
19	transfusion	_	_	O
20	requirements	_	_	O
21	,	_	_	O
22	hematopoietic	_	_	O
23	parameters	_	_	O
24	,	_	_	O
25	quality	_	_	O
26	of	_	_	O
27	life	_	_	O
28	(	_	_	O
29	QOL	_	_	O
30	)	_	_	O
31	,	_	_	O
32	and	_	_	O
33	safety	_	_	O
34	in	_	_	O
35	anemic	_	_	O
36	cancer	_	_	O
37	patients	_	_	O
38	receiving	_	_	O
39	nonplatinum	_	_	O
40	chemotherapy	_	_	O
41	.	_	_	O

42	The	_	_	O
43	study	_	_	O
44	also	_	_	O
45	explored	_	_	O
46	a	_	_	O
47	possible	_	_	O
48	relationship	_	_	O
49	between	_	_	O
50	increased	_	_	O
51	hemoglobin	_	_	O
52	and	_	_	O
53	survival	_	_	O
54	.	_	_	O

55	Three	_	_	O
56	hundred	_	_	O
57	seventy	_	_	O
58	-	_	_	O
59	five	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	solid	_	_	O
63	or	_	_	O
64	nonmyeloid	_	_	O
65	hematologic	_	_	O
66	malignancies	_	_	O
67	and	_	_	O
68	hemoglobin	_	_	O
69	levels	_	_	O
70	<	_	_	O
71	or	_	_	O
72	=	_	_	O
73	10	_	_	O
74	.	_	_	O

75	5	_	_	O
76	g	_	_	O
77	/	_	_	O
78	dL	_	_	O
79	,	_	_	O
80	or	_	_	O
81	greater	_	_	O
82	than	_	_	O
83	10	_	_	O
84	.	_	_	O

85	5	_	_	O
86	g	_	_	O
87	/	_	_	O
88	dL	_	_	O
89	but	_	_	O
90	<	_	_	O
91	or	_	_	O
92	=	_	_	O
93	12	_	_	O
94	.	_	_	O

95	0	_	_	O
96	g	_	_	O
97	/	_	_	O
98	dL	_	_	O
99	after	_	_	O
100	a	_	_	O
101	hemoglobin	_	_	O
102	decrease	_	_	O
103	of	_	_	O
104	>	_	_	O
105	or	_	_	O
106	=	_	_	O
107	1	_	_	O
108	.	_	_	O

109	5	_	_	O
110	g	_	_	O
111	/	_	_	O
112	dL	_	_	O
113	per	_	_	O
114	cycle	_	_	O
115	since	_	_	O
116	starting	_	_	O
117	chemotherapy	_	_	O
118	,	_	_	O
119	were	_	_	O
120	randomized	_	_	O
121	2	_	_	O
122	:	_	_	O
123	1	_	_	O
124	to	_	_	O
125	epoetin	_	_	O
126	alfa	_	_	O
127	150	_	_	O
128	to	_	_	O
129	300	_	_	O
130	IU	_	_	O
131	/	_	_	O
132	kg	_	_	O
133	(	_	_	O
134	n	_	_	O
135	=	_	_	O
136	251	_	_	O
137	)	_	_	O
138	or	_	_	O
139	placebo	_	_	O
140	(	_	_	O
141	n	_	_	O
142	=	_	_	O
143	124	_	_	O
144	)	_	_	O
145	three	_	_	O
146	times	_	_	O
147	per	_	_	O
148	week	_	_	O
149	subcutaneously	_	_	O
150	for	_	_	O
151	12	_	_	O
152	to	_	_	O
153	24	_	_	O
154	weeks	_	_	O
155	.	_	_	O

156	The	_	_	O
157	primary	_	_	O
158	end	_	_	O
159	point	_	_	O
160	was	_	_	O
161	proportion	_	_	O
162	of	_	_	O
163	patients	_	_	O
164	transfused	_	_	O
165	;	_	_	O
166	secondary	_	_	O
167	end	_	_	O
168	points	_	_	O
169	were	_	_	O
170	change	_	_	O
171	in	_	_	O
172	hemoglobin	_	_	O
173	and	_	_	O
174	QOL	_	_	O
175	.	_	_	O

176	The	_	_	O
177	protocol	_	_	O
178	was	_	_	O
179	amended	_	_	O
180	before	_	_	O
181	unblinding	_	_	O
182	to	_	_	O
183	prospectively	_	_	O
184	collect	_	_	O
185	and	_	_	O
186	assess	_	_	O
187	survival	_	_	O
188	data	_	_	O
189	12	_	_	O
190	months	_	_	O
191	after	_	_	O
192	the	_	_	O
193	last	_	_	O
194	patient	_	_	O
195	completed	_	_	O
196	the	_	_	O
197	study	_	_	O
198	.	_	_	O

199	Epoetin	_	_	B-Premise
200	alfa	_	_	I-Premise
201	,	_	_	I-Premise
202	compared	_	_	I-Premise
203	with	_	_	I-Premise
204	placebo	_	_	I-Premise
205	,	_	_	I-Premise
206	significantly	_	_	I-Premise
207	decreased	_	_	I-Premise
208	transfusion	_	_	I-Premise
209	requirements	_	_	I-Premise
210	(	_	_	I-Premise
211	P	_	_	I-Premise
212	=	_	_	I-Premise
213	.	_	_	I-Premise

214	0057	_	_	I-Premise
215	)	_	_	I-Premise
216	and	_	_	I-Premise
217	increased	_	_	I-Premise
218	hemoglobin	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	<	_	_	I-Premise
222	.	_	_	I-Premise

223	001	_	_	I-Premise
224	)	_	_	I-Premise
225	.	_	_	I-Premise

226	Improvement	_	_	B-Premise
227	of	_	_	I-Premise
228	all	_	_	I-Premise
229	primary	_	_	I-Premise
230	cancer	_	_	I-Premise
231	-	_	_	I-Premise
232	and	_	_	I-Premise
233	anemia	_	_	I-Premise
234	-	_	_	I-Premise
235	specific	_	_	I-Premise
236	QOL	_	_	I-Premise
237	domains	_	_	I-Premise
238	,	_	_	I-Premise
239	including	_	_	I-Premise
240	energy	_	_	I-Premise
241	level	_	_	I-Premise
242	,	_	_	I-Premise
243	ability	_	_	I-Premise
244	to	_	_	I-Premise
245	do	_	_	I-Premise
246	daily	_	_	I-Premise
247	activities	_	_	I-Premise
248	,	_	_	I-Premise
249	and	_	_	I-Premise
250	fatigue	_	_	I-Premise
251	,	_	_	I-Premise
252	was	_	_	I-Premise
253	significantly	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	<	_	_	I-Premise
257	.	_	_	I-Premise

258	01	_	_	I-Premise
259	)	_	_	I-Premise
260	greater	_	_	I-Premise
261	for	_	_	I-Premise
262	epoetin	_	_	I-Premise
263	alfa	_	_	I-Premise
264	versus	_	_	I-Premise
265	placebo	_	_	I-Premise
266	patients	_	_	I-Premise
267	.	_	_	I-Premise

268	Although	_	_	O
269	the	_	_	O
270	study	_	_	O
271	was	_	_	O
272	not	_	_	O
273	powered	_	_	O
274	for	_	_	O
275	survival	_	_	O
276	as	_	_	O
277	an	_	_	O
278	end	_	_	O
279	point	_	_	O
280	,	_	_	O
281	Kaplan	_	_	B-Premise
282	-	_	_	I-Premise
283	Meier	_	_	I-Premise
284	estimates	_	_	I-Premise
285	showed	_	_	I-Premise
286	a	_	_	I-Premise
287	trend	_	_	I-Premise
288	in	_	_	I-Premise
289	overall	_	_	I-Premise
290	survival	_	_	I-Premise
291	favoring	_	_	I-Premise
292	epoetin	_	_	I-Premise
293	alfa	_	_	I-Premise
294	(	_	_	I-Premise
295	P	_	_	I-Premise
296	=	_	_	I-Premise
297	.	_	_	I-Premise

298	13	_	_	I-Premise
299	,	_	_	I-Premise
300	log	_	_	I-Premise
301	-	_	_	I-Premise
302	rank	_	_	I-Premise
303	test	_	_	I-Premise
304	)	_	_	I-Premise
305	,	_	_	I-Premise
306	and	_	_	O
307	Cox	_	_	B-Premise
308	regression	_	_	I-Premise
309	analysis	_	_	I-Premise
310	showed	_	_	I-Premise
311	an	_	_	I-Premise
312	estimated	_	_	I-Premise
313	hazards	_	_	I-Premise
314	ratio	_	_	I-Premise
315	of	_	_	I-Premise
316	1	_	_	I-Premise
317	.	_	_	I-Premise

318	309	_	_	I-Premise
319	(	_	_	I-Premise
320	P	_	_	I-Premise
321	=	_	_	I-Premise
322	.	_	_	I-Premise

323	052	_	_	I-Premise
324	)	_	_	I-Premise
325	favoring	_	_	I-Premise
326	epoetin	_	_	I-Premise
327	alfa	_	_	I-Premise
328	.	_	_	I-Premise

329	Adverse	_	_	B-Premise
330	events	_	_	I-Premise
331	were	_	_	I-Premise
332	comparable	_	_	I-Premise
333	between	_	_	I-Premise
334	groups	_	_	I-Premise
335	.	_	_	I-Premise

336	Epoetin	_	_	B-Claim
337	alfa	_	_	I-Claim
338	safely	_	_	I-Claim
339	and	_	_	I-Claim
340	effectively	_	_	I-Claim
341	ameliorates	_	_	I-Claim
342	anemia	_	_	I-Claim
343	and	_	_	I-Claim
344	significantly	_	_	I-Claim
345	improves	_	_	I-Claim
346	QOL	_	_	I-Claim
347	in	_	_	I-Claim
348	cancer	_	_	I-Claim
349	patients	_	_	I-Claim
350	receiving	_	_	I-Claim
351	nonplatinum	_	_	I-Claim
352	chemotherapy	_	_	I-Claim
353	.	_	_	I-Claim

354	Encouraging	_	_	B-Claim
355	results	_	_	I-Claim
356	regarding	_	_	I-Claim
357	increased	_	_	I-Claim
358	survival	_	_	I-Claim
359	warrant	_	_	I-Claim
360	another	_	_	I-Claim
361	trial	_	_	I-Claim
362	designed	_	_	I-Claim
363	to	_	_	I-Claim
364	confirm	_	_	I-Claim
365	these	_	_	I-Claim
366	findings	_	_	I-Claim
367	.	_	_	I-Claim


0	The	_	_	O
1	management	_	_	O
2	of	_	_	O
3	recurrent	_	_	O
4	ovarian	_	_	O
5	cancer	_	_	O
6	remains	_	_	O
7	controversial	_	_	O
8	.	_	_	O

9	Single	_	_	O
10	-	_	_	O
11	agent	_	_	O
12	topotecan	_	_	O
13	is	_	_	O
14	an	_	_	O
15	established	_	_	O
16	treatment	_	_	O
17	option	_	_	O
18	,	_	_	O
19	and	_	_	O
20	preliminary	_	_	O
21	evidence	_	_	O
22	suggests	_	_	O
23	improved	_	_	O
24	tumor	_	_	O
25	control	_	_	O
26	by	_	_	O
27	combining	_	_	O
28	topotecan	_	_	O
29	with	_	_	O
30	etoposide	_	_	O
31	or	_	_	O
32	gemcitabine	_	_	O
33	.	_	_	O

34	Women	_	_	O
35	with	_	_	O
36	relapsed	_	_	O
37	ovarian	_	_	O
38	cancer	_	_	O
39	after	_	_	O
40	primary	_	_	O
41	surgery	_	_	O
42	and	_	_	O
43	platinum	_	_	O
44	-	_	_	O
45	based	_	_	O
46	chemotherapy	_	_	O
47	were	_	_	O
48	randomly	_	_	O
49	assigned	_	_	O
50	to	_	_	O
51	topotecan	_	_	O
52	monotherapy	_	_	O
53	1	_	_	O
54	.	_	_	O

55	25	_	_	O
56	mg	_	_	O
57	/	_	_	O
58	m	_	_	O
59	(	_	_	O
60	2	_	_	O
61	)	_	_	O
62	/	_	_	O
63	d	_	_	O
64	,	_	_	O
65	topotecan	_	_	O
66	1	_	_	O
67	.	_	_	O

68	0	_	_	O
69	mg	_	_	O
70	/	_	_	O
71	m	_	_	O
72	(	_	_	O
73	2	_	_	O
74	)	_	_	O
75	plus	_	_	O
76	oral	_	_	O
77	etoposide	_	_	O
78	50	_	_	O
79	mg	_	_	O
80	/	_	_	O
81	d	_	_	O
82	,	_	_	O
83	or	_	_	O
84	topotecan	_	_	O
85	0	_	_	O
86	.	_	_	O

87	5	_	_	O
88	mg	_	_	O
89	/	_	_	O
90	m	_	_	O
91	(	_	_	O
92	2	_	_	O
93	)	_	_	O
94	/	_	_	O
95	d	_	_	O
96	plus	_	_	O
97	gemcitabine	_	_	O
98	800	_	_	O
99	mg	_	_	O
100	/	_	_	O
101	m	_	_	O
102	(	_	_	O
103	2	_	_	O
104	)	_	_	O
105	on	_	_	O
106	day	_	_	O
107	1	_	_	O
108	and	_	_	O
109	600	_	_	O
110	mg	_	_	O
111	/	_	_	O
112	m	_	_	O
113	(	_	_	O
114	2	_	_	O
115	)	_	_	O
116	on	_	_	O
117	day	_	_	O
118	8	_	_	O
119	every	_	_	O
120	3	_	_	O
121	weeks	_	_	O
122	.	_	_	O

123	Patients	_	_	O
124	were	_	_	O
125	stratified	_	_	O
126	for	_	_	O
127	platinum	_	_	O
128	-	_	_	O
129	refractory	_	_	O
130	and	_	_	O
131	platinum	_	_	O
132	-	_	_	O
133	sensitive	_	_	O
134	disease	_	_	O
135	according	_	_	O
136	to	_	_	O
137	a	_	_	O
138	recurrence	_	_	O
139	-	_	_	O
140	free	_	_	O
141	interval	_	_	O
142	of	_	_	O
143	less	_	_	O
144	or	_	_	O
145	more	_	_	O
146	than	_	_	O
147	12	_	_	O
148	months	_	_	O
149	,	_	_	O
150	respectively	_	_	O
151	.	_	_	O

152	The	_	_	O
153	primary	_	_	O
154	end	_	_	O
155	point	_	_	O
156	was	_	_	O
157	overall	_	_	O
158	survival	_	_	O
159	.	_	_	O

160	Secondary	_	_	O
161	end	_	_	O
162	points	_	_	O
163	included	_	_	O
164	progression	_	_	O
165	-	_	_	O
166	free	_	_	O
167	survival	_	_	O
168	,	_	_	O
169	objective	_	_	O
170	response	_	_	O
171	rates	_	_	O
172	,	_	_	O
173	toxicity	_	_	O
174	,	_	_	O
175	and	_	_	O
176	quality	_	_	O
177	of	_	_	O
178	life	_	_	O
179	(	_	_	O
180	as	_	_	O
181	measured	_	_	O
182	by	_	_	O
183	the	_	_	O
184	European	_	_	O
185	Organisation	_	_	O
186	for	_	_	O
187	Research	_	_	O
188	and	_	_	O
189	Treatment	_	_	O
190	of	_	_	O
191	Cancer	_	_	O
192	[	_	_	O
193	EORTC	_	_	O
194	]	_	_	O
195	30	_	_	O
196	-	_	_	O
197	item	_	_	O
198	Quality	_	_	O
199	-	_	_	O
200	of	_	_	O
201	-	_	_	O
202	Life	_	_	O
203	Questionnaire	_	_	O
204	)	_	_	O
205	.	_	_	O

206	The	_	_	O
207	trial	_	_	O
208	enrolled	_	_	O
209	502	_	_	O
210	patients	_	_	O
211	with	_	_	O
212	a	_	_	O
213	mean	_	_	O
214	age	_	_	O
215	of	_	_	O
216	60	_	_	O
217	.	_	_	O

218	5	_	_	O
219	years	_	_	O
220	(	_	_	O
221	+	_	_	O
222	/	_	_	O
223	-	_	_	O
224	10	_	_	O
225	.	_	_	O

226	2	_	_	O
227	years	_	_	O
228	)	_	_	O
229	,	_	_	O
230	208	_	_	O
231	of	_	_	O
232	whom	_	_	O
233	were	_	_	O
234	platinum	_	_	O
235	resistant	_	_	O
236	.	_	_	O

237	Median	_	_	B-Premise
238	overall	_	_	I-Premise
239	survival	_	_	I-Premise
240	was	_	_	I-Premise
241	17	_	_	I-Premise
242	.	_	_	I-Premise

243	2	_	_	I-Premise
244	months	_	_	I-Premise
245	(	_	_	I-Premise
246	95	_	_	I-Premise
247	%	_	_	I-Premise
248	CI	_	_	I-Premise
249	,	_	_	I-Premise
250	13	_	_	I-Premise
251	.	_	_	I-Premise

252	5	_	_	I-Premise
253	to	_	_	I-Premise
254	21	_	_	I-Premise
255	.	_	_	I-Premise

256	9	_	_	I-Premise
257	months	_	_	I-Premise
258	)	_	_	I-Premise
259	with	_	_	I-Premise
260	topotecan	_	_	I-Premise
261	,	_	_	I-Premise
262	17	_	_	I-Premise
263	.	_	_	I-Premise

264	8	_	_	I-Premise
265	months	_	_	I-Premise
266	(	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	CI	_	_	I-Premise
270	,	_	_	I-Premise
271	13	_	_	I-Premise
272	.	_	_	I-Premise

273	7	_	_	I-Premise
274	to	_	_	I-Premise
275	20	_	_	I-Premise
276	.	_	_	I-Premise

277	0	_	_	I-Premise
278	months	_	_	I-Premise
279	)	_	_	I-Premise
280	with	_	_	I-Premise
281	topotecan	_	_	I-Premise
282	plus	_	_	I-Premise
283	etoposide	_	_	I-Premise
284	(	_	_	I-Premise
285	log	_	_	I-Premise
286	-	_	_	I-Premise
287	rank	_	_	I-Premise
288	P	_	_	I-Premise
289	=	_	_	I-Premise
290	.	_	_	I-Premise

291	7647	_	_	I-Premise
292	)	_	_	I-Premise
293	,	_	_	I-Premise
294	and	_	_	I-Premise
295	15	_	_	I-Premise
296	.	_	_	I-Premise

297	2	_	_	I-Premise
298	months	_	_	I-Premise
299	(	_	_	I-Premise
300	95	_	_	I-Premise
301	%	_	_	I-Premise
302	CI	_	_	I-Premise
303	,	_	_	I-Premise
304	11	_	_	I-Premise
305	.	_	_	I-Premise

306	3	_	_	I-Premise
307	to	_	_	I-Premise
308	20	_	_	I-Premise
309	.	_	_	I-Premise

310	9	_	_	I-Premise
311	months	_	_	I-Premise
312	)	_	_	I-Premise
313	with	_	_	I-Premise
314	topotecan	_	_	I-Premise
315	plus	_	_	I-Premise
316	gemcitabine	_	_	I-Premise
317	(	_	_	I-Premise
318	log	_	_	I-Premise
319	-	_	_	I-Premise
320	rank	_	_	I-Premise
321	P	_	_	I-Premise
322	=	_	_	I-Premise
323	.	_	_	I-Premise

324	2344	_	_	I-Premise
325	)	_	_	I-Premise
326	.	_	_	I-Premise

327	Platinum	_	_	B-Premise
328	-	_	_	I-Premise
329	sensitive	_	_	I-Premise
330	patients	_	_	I-Premise
331	lived	_	_	I-Premise
332	significantly	_	_	I-Premise
333	longer	_	_	I-Premise
334	than	_	_	I-Premise
335	platinum	_	_	I-Premise
336	-	_	_	I-Premise
337	refractory	_	_	I-Premise
338	patients	_	_	I-Premise
339	(	_	_	I-Premise
340	21	_	_	I-Premise
341	.	_	_	I-Premise

342	9	_	_	I-Premise
343	v	_	_	I-Premise
344	10	_	_	I-Premise
345	.	_	_	I-Premise

346	6	_	_	I-Premise
347	months	_	_	I-Premise
348	)	_	_	I-Premise
349	.	_	_	I-Premise

350	The	_	_	O
351	median	_	_	O
352	progression	_	_	O
353	-	_	_	O
354	free	_	_	O
355	survival	_	_	O
356	was	_	_	O
357	7	_	_	O
358	.	_	_	O

359	0	_	_	O
360	,	_	_	O
361	7	_	_	O
362	.	_	_	O

363	8	_	_	O
364	,	_	_	O
365	and	_	_	O
366	6	_	_	O
367	.	_	_	O

368	3	_	_	O
369	months	_	_	O
370	,	_	_	O
371	respectively	_	_	O
372	.	_	_	O

373	Objective	_	_	O
374	response	_	_	O
375	rates	_	_	O
376	were	_	_	O
377	27	_	_	O
378	.	_	_	O

379	8	_	_	O
380	%	_	_	O
381	,	_	_	O
382	36	_	_	O
383	.	_	_	O

384	1	_	_	O
385	%	_	_	O
386	,	_	_	O
387	and	_	_	O
388	31	_	_	O
389	.	_	_	O

390	6	_	_	O
391	%	_	_	O
392	,	_	_	O
393	respectively	_	_	O
394	.	_	_	O

395	Patients	_	_	B-Premise
396	under	_	_	I-Premise
397	combined	_	_	I-Premise
398	treatment	_	_	I-Premise
399	were	_	_	I-Premise
400	at	_	_	I-Premise
401	higher	_	_	I-Premise
402	risk	_	_	I-Premise
403	of	_	_	I-Premise
404	severe	_	_	I-Premise
405	thrombocytopenia	_	_	I-Premise
406	.	_	_	I-Premise

407	Nonplatinum	_	_	B-Claim
408	topotecan	_	_	I-Claim
409	combinations	_	_	I-Claim
410	do	_	_	I-Claim
411	not	_	_	I-Claim
412	provide	_	_	I-Claim
413	a	_	_	I-Claim
414	survival	_	_	I-Claim
415	advantage	_	_	I-Claim
416	over	_	_	I-Claim
417	topotecan	_	_	I-Claim
418	alone	_	_	I-Claim
419	in	_	_	I-Claim
420	women	_	_	I-Claim
421	with	_	_	I-Claim
422	relapsed	_	_	I-Claim
423	ovarian	_	_	I-Claim
424	cancer	_	_	I-Claim
425	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	protracted	_	_	O
3	venous	_	_	O
4	infusion	_	_	O
5	(	_	_	O
6	PVI	_	_	O
7	)	_	_	O
8	fluorouracil	_	_	O
9	(	_	_	O
10	5	_	_	O
11	-	_	_	O
12	FU	_	_	O
13	)	_	_	O
14	with	_	_	O
15	PVI	_	_	O
16	5	_	_	O
17	-	_	_	O
18	FU	_	_	O
19	plus	_	_	O
20	mitomycin	_	_	O
21	(	_	_	O
22	MMC	_	_	O
23	)	_	_	O
24	in	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	advanced	_	_	O
28	pancreatic	_	_	O
29	cancer	_	_	O
30	in	_	_	O
31	a	_	_	O
32	multicenter	_	_	O
33	,	_	_	O
34	prospectively	_	_	O
35	randomized	_	_	O
36	study	_	_	O
37	.	_	_	O

38	Two	_	_	O
39	hundred	_	_	O
40	eight	_	_	O
41	patients	_	_	O
42	were	_	_	O
43	randomized	_	_	O
44	to	_	_	O
45	PVI	_	_	O
46	5	_	_	O
47	-	_	_	O
48	FU	_	_	O
49	(	_	_	O
50	300	_	_	O
51	mg	_	_	O
52	/	_	_	O
53	m	_	_	O
54	(	_	_	O
55	2	_	_	O
56	)	_	_	O
57	/	_	_	O
58	d	_	_	O
59	for	_	_	O
60	a	_	_	O
61	maximum	_	_	O
62	of	_	_	O
63	24	_	_	O
64	weeks	_	_	O
65	)	_	_	O
66	or	_	_	O
67	PVI	_	_	O
68	5	_	_	O
69	-	_	_	O
70	FU	_	_	O
71	plus	_	_	O
72	MMC	_	_	O
73	(	_	_	O
74	7	_	_	O
75	mg	_	_	O
76	/	_	_	O
77	m	_	_	O
78	(	_	_	O
79	2	_	_	O
80	)	_	_	O
81	every	_	_	O
82	6	_	_	O
83	weeks	_	_	O
84	for	_	_	O
85	four	_	_	O
86	courses	_	_	O
87	)	_	_	O
88	.	_	_	O

89	The	_	_	O
90	major	_	_	O
91	end	_	_	O
92	points	_	_	O
93	were	_	_	O
94	tumor	_	_	O
95	response	_	_	O
96	,	_	_	O
97	survival	_	_	O
98	,	_	_	O
99	toxicity	_	_	O
100	,	_	_	O
101	and	_	_	O
102	quality	_	_	O
103	of	_	_	O
104	life	_	_	O
105	(	_	_	O
106	QOL	_	_	O
107	)	_	_	O
108	.	_	_	O

109	The	_	_	O
110	two	_	_	O
111	treatment	_	_	O
112	groups	_	_	O
113	were	_	_	O
114	balanced	_	_	O
115	for	_	_	O
116	baseline	_	_	O
117	demographic	_	_	O
118	factors	_	_	O
119	,	_	_	O
120	and	_	_	O
121	62	_	_	O
122	%	_	_	O
123	had	_	_	O
124	metastatic	_	_	O
125	disease	_	_	O
126	.	_	_	O

127	The	_	_	B-Premise
128	overall	_	_	I-Premise
129	response	_	_	I-Premise
130	rate	_	_	I-Premise
131	was	_	_	I-Premise
132	8	_	_	I-Premise
133	.	_	_	I-Premise

134	4	_	_	I-Premise
135	%	_	_	I-Premise
136	(	_	_	I-Premise
137	95	_	_	I-Premise
138	%	_	_	I-Premise
139	confidence	_	_	I-Premise
140	interval	_	_	I-Premise
141	[	_	_	I-Premise
142	CI	_	_	I-Premise
143	]	_	_	I-Premise
144	)	_	_	I-Premise
145	3	_	_	I-Premise
146	.	_	_	I-Premise

147	2	_	_	I-Premise
148	%	_	_	I-Premise
149	to	_	_	I-Premise
150	13	_	_	I-Premise
151	.	_	_	I-Premise

152	7	_	_	I-Premise
153	%	_	_	I-Premise
154	for	_	_	I-Premise
155	patients	_	_	I-Premise
156	treated	_	_	I-Premise
157	with	_	_	I-Premise
158	PVI	_	_	I-Premise
159	5	_	_	I-Premise
160	-	_	_	I-Premise
161	FU	_	_	I-Premise
162	alone	_	_	I-Premise
163	compared	_	_	I-Premise
164	with	_	_	I-Premise
165	17	_	_	I-Premise
166	.	_	_	I-Premise

167	6	_	_	I-Premise
168	%	_	_	I-Premise
169	;	_	_	I-Premise
170	95	_	_	I-Premise
171	%	_	_	I-Premise
172	CI	_	_	I-Premise
173	10	_	_	I-Premise
174	.	_	_	I-Premise

175	3	_	_	I-Premise
176	%	_	_	I-Premise
177	to	_	_	I-Premise
178	25	_	_	I-Premise
179	.	_	_	I-Premise

180	1	_	_	I-Premise
181	%	_	_	I-Premise
182	for	_	_	I-Premise
183	PVI	_	_	I-Premise
184	5	_	_	I-Premise
185	-	_	_	I-Premise
186	FU	_	_	I-Premise
187	plus	_	_	I-Premise
188	MMC	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	=	_	_	I-Premise
192	.	_	_	I-Premise

193	04	_	_	I-Premise
194	)	_	_	I-Premise
195	.	_	_	I-Premise

196	Median	_	_	B-Premise
197	failure	_	_	I-Premise
198	-	_	_	I-Premise
199	free	_	_	I-Premise
200	survival	_	_	I-Premise
201	was	_	_	I-Premise
202	2	_	_	I-Premise
203	.	_	_	I-Premise

204	8	_	_	I-Premise
205	months	_	_	I-Premise
206	for	_	_	I-Premise
207	PVI	_	_	I-Premise
208	5	_	_	I-Premise
209	-	_	_	I-Premise
210	FU	_	_	I-Premise
211	and	_	_	I-Premise
212	3	_	_	I-Premise
213	.	_	_	I-Premise

214	8	_	_	I-Premise
215	months	_	_	I-Premise
216	for	_	_	I-Premise
217	PVI	_	_	I-Premise
218	5	_	_	I-Premise
219	-	_	_	I-Premise
220	FU	_	_	I-Premise
221	plus	_	_	I-Premise
222	MMC	_	_	I-Premise
223	(	_	_	I-Premise
224	P	_	_	I-Premise
225	=	_	_	I-Premise
226	.	_	_	I-Premise

227	14	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	Median	_	_	B-Premise
231	survival	_	_	I-Premise
232	was	_	_	I-Premise
233	5	_	_	I-Premise
234	.	_	_	I-Premise

235	1	_	_	I-Premise
236	months	_	_	I-Premise
237	for	_	_	I-Premise
238	PVI	_	_	I-Premise
239	5	_	_	I-Premise
240	-	_	_	I-Premise
241	FU	_	_	I-Premise
242	and	_	_	I-Premise
243	6	_	_	I-Premise
244	.	_	_	I-Premise

245	5	_	_	I-Premise
246	months	_	_	I-Premise
247	for	_	_	I-Premise
248	PVI	_	_	I-Premise
249	5	_	_	I-Premise
250	-	_	_	I-Premise
251	FU	_	_	I-Premise
252	plus	_	_	I-Premise
253	MMC	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	.	_	_	I-Premise

258	34	_	_	I-Premise
259	)	_	_	I-Premise
260	.	_	_	I-Premise

261	Toxicities	_	_	B-Premise
262	in	_	_	I-Premise
263	both	_	_	I-Premise
264	arms	_	_	I-Premise
265	were	_	_	I-Premise
266	mild	_	_	I-Premise
267	.	_	_	I-Premise

268	There	_	_	B-Premise
269	was	_	_	I-Premise
270	an	_	_	I-Premise
271	increased	_	_	I-Premise
272	incidence	_	_	I-Premise
273	of	_	_	I-Premise
274	neutropenia	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	5	_	_	I-Premise
278	-	_	_	I-Premise
279	FU	_	_	I-Premise
280	plus	_	_	I-Premise
281	MMC	_	_	I-Premise
282	arm	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	<	_	_	I-Premise
286	.	_	_	I-Premise

287	01	_	_	I-Premise
288	)	_	_	I-Premise
289	,	_	_	I-Premise
290	although	_	_	I-Premise
291	no	_	_	I-Premise
292	differences	_	_	I-Premise
293	in	_	_	I-Premise
294	infection	_	_	I-Premise
295	were	_	_	I-Premise
296	seen	_	_	I-Premise
297	.	_	_	I-Premise

298	No	_	_	B-Premise
299	patients	_	_	I-Premise
300	developed	_	_	I-Premise
301	hemolytic	_	_	I-Premise
302	uremic	_	_	I-Premise
303	syndrome	_	_	I-Premise
304	.	_	_	I-Premise

305	Global	_	_	B-Claim
306	QOL	_	_	I-Claim
307	improved	_	_	I-Claim
308	significantly	_	_	I-Claim
309	after	_	_	I-Claim
310	24	_	_	I-Claim
311	weeks	_	_	I-Claim
312	of	_	_	I-Claim
313	treatment	_	_	I-Claim
314	compared	_	_	I-Claim
315	with	_	_	I-Claim
316	baseline	_	_	I-Claim
317	for	_	_	I-Claim
318	patients	_	_	I-Claim
319	receiving	_	_	I-Claim
320	5	_	_	I-Claim
321	-	_	_	I-Claim
322	FU	_	_	I-Claim
323	plus	_	_	I-Claim
324	MMC	_	_	I-Claim
325	,	_	_	I-Claim
326	although	_	_	B-Premise
327	there	_	_	I-Premise
328	was	_	_	I-Premise
329	no	_	_	I-Premise
330	statistically	_	_	I-Premise
331	significant	_	_	I-Premise
332	difference	_	_	I-Premise
333	in	_	_	I-Premise
334	QOL	_	_	I-Premise
335	between	_	_	I-Premise
336	arms	_	_	I-Premise
337	.	_	_	I-Premise

338	PVI	_	_	B-Claim
339	5	_	_	I-Claim
340	-	_	_	I-Claim
341	FU	_	_	I-Claim
342	plus	_	_	I-Claim
343	MMC	_	_	I-Claim
344	resulted	_	_	I-Claim
345	in	_	_	I-Claim
346	a	_	_	I-Claim
347	superior	_	_	I-Claim
348	response	_	_	I-Claim
349	rate	_	_	I-Claim
350	in	_	_	I-Claim
351	comparison	_	_	I-Claim
352	with	_	_	I-Claim
353	PVI	_	_	I-Claim
354	5	_	_	I-Claim
355	-	_	_	I-Claim
356	FU	_	_	I-Claim
357	alone	_	_	I-Claim
358	in	_	_	I-Claim
359	advanced	_	_	I-Claim
360	pancreatic	_	_	I-Claim
361	cancer	_	_	I-Claim
362	,	_	_	I-Claim
363	but	_	_	B-Claim
364	this	_	_	I-Claim
365	did	_	_	I-Claim
366	not	_	_	I-Claim
367	translate	_	_	I-Claim
368	into	_	_	I-Claim
369	a	_	_	I-Claim
370	survival	_	_	I-Claim
371	advantage	_	_	I-Claim
372	.	_	_	I-Claim

373	These	_	_	B-Claim
374	results	_	_	I-Claim
375	emphasize	_	_	I-Claim
376	the	_	_	I-Claim
377	importance	_	_	I-Claim
378	of	_	_	I-Claim
379	chemotherapy	_	_	I-Claim
380	in	_	_	I-Claim
381	this	_	_	I-Claim
382	setting	_	_	I-Claim
383	and	_	_	I-Claim
384	the	_	_	I-Claim
385	continuing	_	_	I-Claim
386	value	_	_	I-Claim
387	of	_	_	I-Claim
388	the	_	_	I-Claim
389	fluoropyrimidines	_	_	I-Claim
390	in	_	_	I-Claim
391	pancreatic	_	_	I-Claim
392	cancer	_	_	I-Claim
393	.	_	_	I-Claim


0	Analgesia	_	_	B-Claim
1	and	_	_	I-Claim
2	early	_	_	I-Claim
3	quality	_	_	I-Claim
4	of	_	_	I-Claim
5	recovery	_	_	I-Claim
6	may	_	_	I-Claim
7	be	_	_	I-Claim
8	improved	_	_	I-Claim
9	by	_	_	I-Claim
10	epidural	_	_	I-Claim
11	analgesia	_	_	I-Claim
12	.	_	_	I-Claim

13	We	_	_	O
14	aimed	_	_	O
15	to	_	_	O
16	assess	_	_	O
17	the	_	_	O
18	effect	_	_	O
19	of	_	_	O
20	receiving	_	_	O
21	epidural	_	_	O
22	analgesia	_	_	O
23	on	_	_	O
24	surgical	_	_	O
25	adverse	_	_	O
26	events	_	_	O
27	and	_	_	O
28	quality	_	_	O
29	of	_	_	O
30	life	_	_	O
31	after	_	_	O
32	laparotomy	_	_	O
33	for	_	_	O
34	endometrial	_	_	O
35	cancer	_	_	O
36	.	_	_	O

37	Patients	_	_	O
38	were	_	_	O
39	enrolled	_	_	O
40	in	_	_	O
41	an	_	_	O
42	international	_	_	O
43	,	_	_	O
44	multicentre	_	_	O
45	,	_	_	O
46	prospective	_	_	O
47	randomised	_	_	O
48	trial	_	_	O
49	of	_	_	O
50	outcomes	_	_	O
51	for	_	_	O
52	laparoscopic	_	_	O
53	versus	_	_	O
54	open	_	_	O
55	surgical	_	_	O
56	treatment	_	_	O
57	for	_	_	O
58	the	_	_	O
59	management	_	_	O
60	of	_	_	O
61	apparent	_	_	O
62	stage	_	_	O
63	I	_	_	O
64	endometrial	_	_	O
65	cancer	_	_	O
66	(	_	_	O
67	LACE	_	_	O
68	trial	_	_	O
69	)	_	_	O
70	.	_	_	O

71	The	_	_	O
72	current	_	_	O
73	analysis	_	_	O
74	focussed	_	_	O
75	on	_	_	O
76	patients	_	_	O
77	who	_	_	O
78	received	_	_	O
79	an	_	_	O
80	open	_	_	O
81	abdominal	_	_	O
82	hysterectomy	_	_	O
83	via	_	_	O
84	vertical	_	_	O
85	midline	_	_	O
86	incision	_	_	O
87	only	_	_	O
88	(	_	_	O
89	n	_	_	O
90	=	_	_	O
91	257	_	_	O
92	)	_	_	O
93	,	_	_	O
94	examining	_	_	O
95	outcomes	_	_	O
96	in	_	_	O
97	patients	_	_	O
98	who	_	_	O
99	did	_	_	O
100	(	_	_	O
101	n	_	_	O
102	=	_	_	O
103	108	_	_	O
104	)	_	_	O
105	and	_	_	O
106	did	_	_	O
107	not	_	_	O
108	(	_	_	O
109	n	_	_	O
110	=	_	_	O
111	149	_	_	O
112	)	_	_	O
113	receive	_	_	O
114	epidural	_	_	O
115	analgesia	_	_	O
116	.	_	_	O

117	Baseline	_	_	O
118	characteristics	_	_	O
119	were	_	_	O
120	comparable	_	_	O
121	between	_	_	O
122	patients	_	_	O
123	with	_	_	O
124	or	_	_	O
125	without	_	_	O
126	epidural	_	_	O
127	analgesia	_	_	O
128	.	_	_	O

129	More	_	_	B-Premise
130	patients	_	_	I-Premise
131	without	_	_	I-Premise
132	epidural	_	_	I-Premise
133	(	_	_	I-Premise
134	34	_	_	I-Premise
135	%	_	_	I-Premise
136	)	_	_	I-Premise
137	ceased	_	_	I-Premise
138	opioid	_	_	I-Premise
139	analgesia	_	_	I-Premise
140	3	_	_	I-Premise
141	-	_	_	I-Premise
142	5	_	_	I-Premise
143	days	_	_	I-Premise
144	after	_	_	I-Premise
145	surgery	_	_	I-Premise
146	compared	_	_	I-Premise
147	to	_	_	I-Premise
148	patients	_	_	I-Premise
149	who	_	_	I-Premise
150	had	_	_	I-Premise
151	an	_	_	I-Premise
152	epidural	_	_	I-Premise
153	(	_	_	I-Premise
154	7	_	_	I-Premise
155	%	_	_	I-Premise
156	;	_	_	I-Premise
157	p	_	_	I-Premise
158	<	_	_	I-Premise
159	0	_	_	I-Premise
160	.	_	_	I-Premise

161	01	_	_	I-Premise
162	)	_	_	I-Premise
163	.	_	_	I-Premise

164	Postoperative	_	_	B-Premise
165	complications	_	_	I-Premise
166	(	_	_	I-Premise
167	any	_	_	I-Premise
168	grade	_	_	I-Premise
169	)	_	_	I-Premise
170	occurred	_	_	I-Premise
171	in	_	_	I-Premise
172	86	_	_	I-Premise
173	%	_	_	I-Premise
174	of	_	_	I-Premise
175	patients	_	_	I-Premise
176	with	_	_	I-Premise
177	and	_	_	I-Premise
178	in	_	_	I-Premise
179	66	_	_	I-Premise
180	%	_	_	I-Premise
181	of	_	_	I-Premise
182	patients	_	_	I-Premise
183	without	_	_	I-Premise
184	an	_	_	I-Premise
185	epidural	_	_	I-Premise
186	(	_	_	I-Premise
187	p	_	_	I-Premise
188	<	_	_	I-Premise
189	0	_	_	I-Premise
190	.	_	_	I-Premise

191	01	_	_	I-Premise
192	)	_	_	I-Premise
193	but	_	_	O
194	there	_	_	B-Premise
195	was	_	_	I-Premise
196	no	_	_	I-Premise
197	difference	_	_	I-Premise
198	in	_	_	I-Premise
199	serious	_	_	I-Premise
200	adverse	_	_	I-Premise
201	events	_	_	I-Premise
202	(	_	_	I-Premise
203	p	_	_	I-Premise
204	=	_	_	I-Premise
205	0	_	_	I-Premise
206	.	_	_	I-Premise

207	19	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	Epidural	_	_	B-Premise
211	analgesia	_	_	I-Premise
212	was	_	_	I-Premise
213	associated	_	_	I-Premise
214	with	_	_	I-Premise
215	increased	_	_	I-Premise
216	length	_	_	I-Premise
217	of	_	_	I-Premise
218	stay	_	_	I-Premise
219	(	_	_	I-Premise
220	up	_	_	I-Premise
221	to	_	_	I-Premise
222	48	_	_	I-Premise
223	days	_	_	I-Premise
224	compared	_	_	I-Premise
225	to	_	_	I-Premise
226	up	_	_	I-Premise
227	to	_	_	I-Premise
228	34	_	_	I-Premise
229	days	_	_	I-Premise
230	in	_	_	I-Premise
231	the	_	_	I-Premise
232	non	_	_	I-Premise
233	-	_	_	I-Premise
234	epidural	_	_	I-Premise
235	group	_	_	I-Premise
236	)	_	_	I-Premise
237	.	_	_	I-Premise

238	There	_	_	B-Claim
239	was	_	_	I-Claim
240	no	_	_	I-Claim
241	difference	_	_	I-Claim
242	in	_	_	I-Claim
243	postoperative	_	_	I-Claim
244	quality	_	_	I-Claim
245	of	_	_	I-Claim
246	life	_	_	I-Claim
247	up	_	_	I-Claim
248	to	_	_	I-Claim
249	six	_	_	I-Claim
250	months	_	_	I-Claim
251	after	_	_	I-Claim
252	surgery	_	_	I-Claim
253	.	_	_	I-Claim

254	Epidural	_	_	B-Claim
255	analgesia	_	_	I-Claim
256	was	_	_	I-Claim
257	associated	_	_	I-Claim
258	with	_	_	I-Claim
259	an	_	_	I-Claim
260	increase	_	_	I-Claim
261	in	_	_	I-Claim
262	any	_	_	I-Claim
263	,	_	_	I-Claim
264	but	_	_	I-Claim
265	not	_	_	I-Claim
266	serious	_	_	I-Claim
267	,	_	_	I-Claim
268	postoperative	_	_	I-Claim
269	complications	_	_	I-Claim
270	and	_	_	I-Claim
271	length	_	_	I-Claim
272	of	_	_	I-Claim
273	stay	_	_	I-Claim
274	after	_	_	I-Claim
275	abdominal	_	_	I-Claim
276	hysterectomy	_	_	I-Claim
277	.	_	_	I-Claim

278	Randomised	_	_	B-Claim
279	controlled	_	_	I-Claim
280	trials	_	_	I-Claim
281	are	_	_	I-Claim
282	needed	_	_	I-Claim
283	to	_	_	I-Claim
284	examine	_	_	I-Claim
285	the	_	_	I-Claim
286	effect	_	_	I-Claim
287	of	_	_	I-Claim
288	epidural	_	_	I-Claim
289	analgesia	_	_	I-Claim
290	on	_	_	I-Claim
291	surgical	_	_	I-Claim
292	adverse	_	_	I-Claim
293	events	_	_	I-Claim
294	,	_	_	I-Claim
295	especially	_	_	O
296	as	_	_	O
297	the	_	_	B-Claim
298	present	_	_	I-Claim
299	data	_	_	I-Claim
300	do	_	_	I-Claim
301	not	_	_	I-Claim
302	support	_	_	I-Claim
303	a	_	_	I-Claim
304	quality	_	_	I-Claim
305	of	_	_	I-Claim
306	life	_	_	I-Claim
307	benefit	_	_	I-Claim
308	with	_	_	I-Claim
309	epidural	_	_	I-Claim
310	analgesia	_	_	I-Claim
311	.	_	_	I-Claim


0	Non	_	_	O
1	-	_	_	O
2	randomised	_	_	O
3	studies	_	_	O
4	have	_	_	O
5	suggested	_	_	O
6	that	_	_	O
7	the	_	_	B-Claim
8	postoperative	_	_	I-Claim
9	complications	_	_	I-Claim
10	of	_	_	I-Claim
11	(	_	_	I-Claim
12	Campos	_	_	I-Claim
13	LS	_	_	I-Claim
14	,	_	_	I-Claim
15	Limberger	_	_	I-Claim
16	LF	_	_	I-Claim
17	,	_	_	I-Claim
18	Stein	_	_	I-Claim
19	AT	_	_	I-Claim
20	,	_	_	I-Claim
21	Kalil	_	_	I-Claim
22	AN	_	_	I-Claim
23	)	_	_	I-Claim
24	laparoscopic	_	_	I-Claim
25	radical	_	_	I-Claim
26	hysterectomy	_	_	I-Claim
27	are	_	_	I-Claim
28	similar	_	_	I-Claim
29	to	_	_	I-Claim
30	those	_	_	I-Claim
31	in	_	_	I-Claim
32	abdominal	_	_	I-Claim
33	radical	_	_	I-Claim
34	hysterectomy	_	_	I-Claim
35	.	_	_	I-Claim

36	However	_	_	O
37	,	_	_	O
38	no	_	_	O
39	study	_	_	O
40	evaluating	_	_	O
41	postoperative	_	_	O
42	pain	_	_	O
43	comparing	_	_	O
44	both	_	_	O
45	techniques	_	_	O
46	has	_	_	O
47	been	_	_	O
48	published	_	_	O
49	thus	_	_	O
50	far	_	_	O
51	.	_	_	O

52	Our	_	_	O
53	objective	_	_	O
54	was	_	_	O
55	to	_	_	O
56	compare	_	_	O
57	pain	_	_	O
58	intensity	_	_	O
59	and	_	_	O
60	other	_	_	O
61	perioperative	_	_	O
62	outcomes	_	_	O
63	between	_	_	O
64	laparoscopic	_	_	O
65	radical	_	_	O
66	hysterectomy	_	_	O
67	(	_	_	O
68	LRH	_	_	O
69	)	_	_	O
70	and	_	_	O
71	abdominal	_	_	O
72	radical	_	_	O
73	hysterectomy	_	_	O
74	(	_	_	O
75	ARH	_	_	O
76	)	_	_	O
77	in	_	_	O
78	early	_	_	O
79	cervical	_	_	O
80	cancer	_	_	O
81	.	_	_	O

82	This	_	_	O
83	single	_	_	O
84	centre	_	_	O
85	,	_	_	O
86	randomised	_	_	O
87	,	_	_	O
88	controlled	_	_	O
89	trial	_	_	O
90	enrolled	_	_	O
91	30	_	_	O
92	cervical	_	_	O
93	cancer	_	_	O
94	patients	_	_	O
95	who	_	_	O
96	were	_	_	O
97	clinically	_	_	O
98	staged	_	_	O
99	IA2	_	_	O
100	with	_	_	O
101	lymph	_	_	O
102	vascular	_	_	O
103	invasion	_	_	O
104	and	_	_	O
105	IB	_	_	O
106	according	_	_	O
107	to	_	_	O
108	the	_	_	O
109	FIGO	_	_	O
110	(	_	_	O
111	International	_	_	O
112	Federation	_	_	O
113	of	_	_	O
114	Gynaecology	_	_	O
115	and	_	_	O
116	Obstetrics	_	_	O
117	)	_	_	O
118	classification	_	_	O
119	,	_	_	O
120	and	_	_	O
121	underwent	_	_	O
122	LRH	_	_	O
123	or	_	_	O
124	ARH	_	_	O
125	between	_	_	O
126	late	_	_	O
127	1999	_	_	O
128	and	_	_	O
129	early	_	_	O
130	2004	_	_	O
131	.	_	_	O

132	Postoperative	_	_	O
133	pain	_	_	O
134	,	_	_	O
135	as	_	_	O
136	measured	_	_	O
137	by	_	_	O
138	a	_	_	O
139	10	_	_	O
140	-	_	_	O
141	point	_	_	O
142	numerical	_	_	O
143	rate	_	_	O
144	scale	_	_	O
145	,	_	_	O
146	was	_	_	O
147	considered	_	_	O
148	the	_	_	O
149	primary	_	_	O
150	endpoint	_	_	O
151	.	_	_	O

152	Postoperative	_	_	O
153	pain	_	_	O
154	was	_	_	O
155	assessed	_	_	O
156	every	_	_	O
157	six	_	_	O
158	hours	_	_	O
159	during	_	_	O
160	a	_	_	O
161	patient	_	_	O
162	'	_	_	O
163	s	_	_	O
164	usual	_	_	O
165	postoperative	_	_	O
166	care	_	_	O
167	.	_	_	O

168	Perioperative	_	_	O
169	outcomes	_	_	O
170	were	_	_	O
171	also	_	_	O
172	registered	_	_	O
173	.	_	_	O

174	Both	_	_	O
175	surgical	_	_	O
176	techniques	_	_	O
177	were	_	_	O
178	executed	_	_	O
179	by	_	_	O
180	the	_	_	O
181	same	_	_	O
182	surgical	_	_	O
183	team	_	_	O
184	.	_	_	O

185	Secondary	_	_	O
186	outcomes	_	_	O
187	included	_	_	O
188	intraoperative	_	_	O
189	and	_	_	O
190	other	_	_	O
191	postoperative	_	_	O
192	surgicopathological	_	_	O
193	factors	_	_	O
194	and	_	_	O
195	5	_	_	O
196	-	_	_	O
197	year	_	_	O
198	survival	_	_	O
199	rates	_	_	O
200	.	_	_	O

201	IA2	_	_	O
202	patients	_	_	O
203	with	_	_	O
204	lymphatic	_	_	O
205	vascular	_	_	O
206	space	_	_	O
207	invasion	_	_	O
208	and	_	_	O
209	IB	_	_	O
210	cervical	_	_	O
211	cancer	_	_	O
212	patients	_	_	O
213	were	_	_	O
214	randomised	_	_	O
215	to	_	_	O
216	either	_	_	O
217	the	_	_	O
218	LRH	_	_	O
219	group	_	_	O
220	(	_	_	O
221	16	_	_	O
222	patients	_	_	O
223	)	_	_	O
224	or	_	_	O
225	the	_	_	O
226	ARH	_	_	O
227	group	_	_	O
228	(	_	_	O
229	14	_	_	O
230	patients	_	_	O
231	)	_	_	O
232	.	_	_	O

233	Four	_	_	B-Premise
234	patients	_	_	I-Premise
235	(	_	_	I-Premise
236	25	_	_	I-Premise
237	%	_	_	I-Premise
238	)	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	LRH	_	_	I-Premise
242	group	_	_	I-Premise
243	and	_	_	I-Premise
244	5	_	_	I-Premise
245	patients	_	_	I-Premise
246	(	_	_	I-Premise
247	36	_	_	I-Premise
248	%	_	_	I-Premise
249	)	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	ARH	_	_	I-Premise
253	group	_	_	I-Premise
254	presented	_	_	I-Premise
255	with	_	_	I-Premise
256	transoperative	_	_	I-Premise
257	or	_	_	I-Premise
258	serious	_	_	I-Premise
259	postoperative	_	_	I-Premise
260	complications	_	_	I-Premise
261	.	_	_	I-Premise

262	All	_	_	B-Premise
263	of	_	_	I-Premise
264	the	_	_	I-Premise
265	transoperative	_	_	I-Premise
266	complications	_	_	I-Premise
267	occurred	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	LRH	_	_	I-Premise
271	group	_	_	I-Premise
272	.	_	_	I-Premise

273	The	_	_	B-Premise
274	relative	_	_	I-Premise
275	risk	_	_	I-Premise
276	of	_	_	I-Premise
277	presenting	_	_	I-Premise
278	with	_	_	I-Premise
279	complications	_	_	I-Premise
280	was	_	_	I-Premise
281	0	_	_	I-Premise
282	.	_	_	I-Premise

283	70	_	_	I-Premise
284	;	_	_	I-Premise
285	CI	_	_	I-Premise
286	95	_	_	I-Premise
287	%	_	_	I-Premise
288	(	_	_	I-Premise
289	0	_	_	I-Premise
290	.	_	_	I-Premise

291	23	_	_	I-Premise
292	-	_	_	I-Premise
293	2	_	_	I-Premise
294	.	_	_	I-Premise

295	11	_	_	I-Premise
296	)	_	_	I-Premise
297	;	_	_	I-Premise
298	P	_	_	I-Premise
299	=	_	_	I-Premise
300	0	_	_	I-Premise
301	.	_	_	I-Premise

302	694	_	_	I-Premise
303	.	_	_	I-Premise

304	LRH	_	_	B-Premise
305	group	_	_	I-Premise
306	mean	_	_	I-Premise
307	pain	_	_	I-Premise
308	score	_	_	I-Premise
309	was	_	_	I-Premise
310	significantly	_	_	I-Premise
311	lower	_	_	I-Premise
312	than	_	_	I-Premise
313	ARH	_	_	I-Premise
314	after	_	_	I-Premise
315	36	_	_	I-Premise
316	h	_	_	I-Premise
317	of	_	_	I-Premise
318	observation	_	_	I-Premise
319	(	_	_	I-Premise
320	P	_	_	I-Premise
321	=	_	_	I-Premise
322	0	_	_	I-Premise
323	.	_	_	I-Premise

324	044	_	_	I-Premise
325	;	_	_	I-Premise
326	mean	_	_	I-Premise
327	difference	_	_	I-Premise
328	score	_	_	I-Premise
329	:	_	_	I-Premise
330	1	_	_	I-Premise
331	.	_	_	I-Premise

332	42	_	_	I-Premise
333	;	_	_	I-Premise
334	95	_	_	I-Premise
335	%	_	_	I-Premise
336	CI	_	_	I-Premise
337	:	_	_	I-Premise
338	0	_	_	I-Premise
339	.	_	_	I-Premise

340	04	_	_	I-Premise
341	-	_	_	I-Premise
342	2	_	_	I-Premise
343	.	_	_	I-Premise

344	80	_	_	I-Premise
345	)	_	_	I-Premise
346	.	_	_	I-Premise

347	The	_	_	O
348	survival	_	_	O
349	results	_	_	O
350	will	_	_	O
351	be	_	_	O
352	published	_	_	O
353	elsewhere	_	_	O
354	.	_	_	O

355	LRH	_	_	B-Claim
356	provided	_	_	I-Claim
357	lower	_	_	I-Claim
358	pain	_	_	I-Claim
359	scores	_	_	I-Claim
360	after	_	_	I-Claim
361	36	_	_	I-Claim
362	h	_	_	I-Claim
363	of	_	_	I-Claim
364	observation	_	_	I-Claim
365	in	_	_	I-Claim
366	this	_	_	I-Claim
367	series	_	_	I-Claim
368	.	_	_	I-Claim

369	The	_	_	B-Claim
370	perioperative	_	_	I-Claim
371	and	_	_	I-Claim
372	serious	_	_	I-Claim
373	postoperative	_	_	I-Claim
374	complications	_	_	I-Claim
375	ratios	_	_	I-Claim
376	were	_	_	I-Claim
377	comparable	_	_	I-Claim
378	between	_	_	I-Claim
379	the	_	_	I-Claim
380	groups	_	_	I-Claim
381	.	_	_	I-Claim


0	To	_	_	O
1	examine	_	_	O
2	the	_	_	O
3	impact	_	_	O
4	of	_	_	O
5	advanced	_	_	O
6	practice	_	_	O
7	nurse	_	_	O
8	(	_	_	O
9	APN	_	_	O
10	)	_	_	O
11	-	_	_	O
12	administered	_	_	O
13	low	_	_	O
14	-	_	_	O
15	level	_	_	O
16	laser	_	_	O
17	therapy	_	_	O
18	(	_	_	O
19	LLLT	_	_	O
20	)	_	_	O
21	as	_	_	O
22	both	_	_	O
23	a	_	_	O
24	stand	_	_	O
25	-	_	_	O
26	alone	_	_	O
27	and	_	_	O
28	complementary	_	_	O
29	treatment	_	_	O
30	for	_	_	O
31	arm	_	_	O
32	volume	_	_	O
33	,	_	_	O
34	symptoms	_	_	O
35	,	_	_	O
36	and	_	_	O
37	quality	_	_	O
38	of	_	_	O
39	life	_	_	O
40	(	_	_	O
41	QOL	_	_	O
42	)	_	_	O
43	in	_	_	O
44	women	_	_	O
45	with	_	_	O
46	breast	_	_	O
47	cancer	_	_	O
48	-	_	_	O
49	related	_	_	O
50	lymphedema	_	_	O
51	.	_	_	O

52	A	_	_	O
53	three	_	_	O
54	-	_	_	O
55	group	_	_	O
56	,	_	_	O
57	pilot	_	_	O
58	,	_	_	O
59	randomized	_	_	O
60	clinical	_	_	O
61	trial	_	_	O
62	.	_	_	O

63	A	_	_	O
64	private	_	_	O
65	rehabilitation	_	_	O
66	practice	_	_	O
67	in	_	_	O
68	the	_	_	O
69	southeastern	_	_	O
70	United	_	_	O
71	States	_	_	O
72	.	_	_	O

73	46	_	_	O
74	breast	_	_	O
75	cancer	_	_	O
76	survivors	_	_	O
77	with	_	_	O
78	treatment	_	_	O
79	-	_	_	O
80	related	_	_	O
81	lymphedema	_	_	O
82	.	_	_	O

83	Patients	_	_	O
84	were	_	_	O
85	screened	_	_	O
86	for	_	_	O
87	eligibility	_	_	O
88	and	_	_	O
89	then	_	_	O
90	randomized	_	_	O
91	to	_	_	O
92	either	_	_	O
93	manual	_	_	O
94	lymphatic	_	_	O
95	drainage	_	_	O
96	(	_	_	O
97	MLD	_	_	O
98	)	_	_	O
99	for	_	_	O
100	40	_	_	O
101	minutes	_	_	O
102	,	_	_	O
103	LLLT	_	_	O
104	for	_	_	O
105	20	_	_	O
106	minutes	_	_	O
107	,	_	_	O
108	or	_	_	O
109	20	_	_	O
110	minutes	_	_	O
111	of	_	_	O
112	MLD	_	_	O
113	followed	_	_	O
114	by	_	_	O
115	20	_	_	O
116	minutes	_	_	O
117	of	_	_	O
118	LLLT	_	_	O
119	.	_	_	O

120	Compression	_	_	O
121	bandaging	_	_	O
122	was	_	_	O
123	applied	_	_	O
124	after	_	_	O
125	each	_	_	O
126	treatment	_	_	O
127	.	_	_	O

128	Data	_	_	O
129	were	_	_	O
130	collected	_	_	O
131	pretreatment	_	_	O
132	,	_	_	O
133	daily	_	_	O
134	,	_	_	O
135	weekly	_	_	O
136	,	_	_	O
137	and	_	_	O
138	at	_	_	O
139	the	_	_	O
140	end	_	_	O
141	of	_	_	O
142	treatment	_	_	O
143	.	_	_	O

144	Independent	_	_	O
145	variables	_	_	O
146	consisted	_	_	O
147	of	_	_	O
148	three	_	_	O
149	types	_	_	O
150	of	_	_	O
151	APN	_	_	O
152	-	_	_	O
153	administered	_	_	O
154	lymphedema	_	_	O
155	treatment	_	_	O
156	.	_	_	O

157	Outcome	_	_	O
158	variables	_	_	O
159	included	_	_	O
160	limb	_	_	O
161	volume	_	_	O
162	,	_	_	O
163	extracellular	_	_	O
164	fluid	_	_	O
165	,	_	_	O
166	psychological	_	_	O
167	and	_	_	O
168	physical	_	_	O
169	symptoms	_	_	O
170	,	_	_	O
171	and	_	_	O
172	QOL	_	_	O
173	.	_	_	O

174	No	_	_	B-Premise
175	statistically	_	_	I-Premise
176	significant	_	_	I-Premise
177	between	_	_	I-Premise
178	-	_	_	I-Premise
179	group	_	_	I-Premise
180	differences	_	_	I-Premise
181	were	_	_	I-Premise
182	found	_	_	I-Premise
183	in	_	_	I-Premise
184	volume	_	_	I-Premise
185	reduction	_	_	I-Premise
186	;	_	_	I-Premise
187	however	_	_	B-Premise
188	,	_	_	I-Premise
189	all	_	_	I-Premise
190	groups	_	_	I-Premise
191	had	_	_	I-Premise
192	clinically	_	_	I-Premise
193	and	_	_	I-Premise
194	statistically	_	_	I-Premise
195	significant	_	_	I-Premise
196	reduction	_	_	I-Premise
197	in	_	_	I-Premise
198	volume	_	_	I-Premise
199	.	_	_	I-Premise

200	No	_	_	B-Premise
201	group	_	_	I-Premise
202	differences	_	_	I-Premise
203	were	_	_	I-Premise
204	noted	_	_	I-Premise
205	in	_	_	I-Premise
206	psychological	_	_	I-Premise
207	and	_	_	I-Premise
208	physical	_	_	I-Premise
209	symptoms	_	_	I-Premise
210	or	_	_	I-Premise
211	QOL	_	_	I-Premise
212	;	_	_	I-Premise
213	however	_	_	B-Premise
214	,	_	_	I-Premise
215	treatment	_	_	I-Premise
216	-	_	_	I-Premise
217	related	_	_	I-Premise
218	improvements	_	_	I-Premise
219	were	_	_	I-Premise
220	noted	_	_	I-Premise
221	in	_	_	I-Premise
222	symptom	_	_	I-Premise
223	burden	_	_	I-Premise
224	within	_	_	I-Premise
225	all	_	_	I-Premise
226	groups	_	_	I-Premise
227	.	_	_	I-Premise

228	Skin	_	_	B-Premise
229	improvement	_	_	I-Premise
230	was	_	_	I-Premise
231	noted	_	_	I-Premise
232	in	_	_	I-Premise
233	each	_	_	I-Premise
234	group	_	_	I-Premise
235	that	_	_	I-Premise
236	received	_	_	I-Premise
237	LLLT	_	_	I-Premise
238	.	_	_	I-Premise

239	LLLT	_	_	B-Claim
240	with	_	_	I-Claim
241	bandaging	_	_	I-Claim
242	may	_	_	I-Claim
243	offer	_	_	I-Claim
244	a	_	_	I-Claim
245	time	_	_	I-Claim
246	-	_	_	I-Claim
247	saving	_	_	I-Claim
248	therapeutic	_	_	I-Claim
249	option	_	_	I-Claim
250	to	_	_	I-Claim
251	conventional	_	_	I-Claim
252	MLD	_	_	I-Claim
253	.	_	_	I-Claim

254	Alternatively	_	_	O
255	,	_	_	O
256	compression	_	_	B-Claim
257	bandaging	_	_	I-Claim
258	alone	_	_	I-Claim
259	could	_	_	I-Claim
260	account	_	_	I-Claim
261	for	_	_	I-Claim
262	the	_	_	I-Claim
263	demonstrated	_	_	I-Claim
264	volume	_	_	I-Claim
265	reduction	_	_	I-Claim
266	.	_	_	I-Claim

267	APNs	_	_	B-Claim
268	can	_	_	I-Claim
269	effectively	_	_	I-Claim
270	treat	_	_	I-Claim
271	lymphedema	_	_	I-Claim
272	.	_	_	I-Claim

273	APNs	_	_	O
274	in	_	_	O
275	private	_	_	O
276	healthcare	_	_	O
277	practices	_	_	O
278	can	_	_	O
279	serve	_	_	O
280	as	_	_	O
281	valuable	_	_	O
282	research	_	_	O
283	collaborators	_	_	O
284	.	_	_	O

285	Lasers	_	_	B-Claim
286	may	_	_	I-Claim
287	provide	_	_	I-Claim
288	effective	_	_	I-Claim
289	,	_	_	I-Claim
290	less	_	_	I-Claim
291	burdensome	_	_	I-Claim
292	treatment	_	_	I-Claim
293	for	_	_	I-Claim
294	lymphedema	_	_	I-Claim
295	.	_	_	I-Claim

296	APNs	_	_	B-Claim
297	with	_	_	I-Claim
298	lymphedema	_	_	I-Claim
299	certification	_	_	I-Claim
300	can	_	_	I-Claim
301	effectively	_	_	I-Claim
302	treat	_	_	I-Claim
303	this	_	_	I-Claim
304	patient	_	_	I-Claim
305	population	_	_	I-Claim
306	with	_	_	I-Claim
307	the	_	_	I-Claim
308	use	_	_	I-Claim
309	of	_	_	I-Claim
310	LLLT	_	_	I-Claim
311	.	_	_	I-Claim

312	In	_	_	O
313	addition	_	_	O
314	,	_	_	O
315	bioelectrical	_	_	B-Claim
316	impedance	_	_	I-Claim
317	and	_	_	I-Claim
318	tape	_	_	I-Claim
319	measurements	_	_	I-Claim
320	can	_	_	I-Claim
321	be	_	_	I-Claim
322	used	_	_	I-Claim
323	to	_	_	I-Claim
324	assess	_	_	I-Claim
325	lymphedema	_	_	I-Claim
326	.	_	_	I-Claim


0	There	_	_	O
1	will	_	_	O
2	be	_	_	O
3	a	_	_	O
4	detectable	_	_	O
5	increase	_	_	O
6	in	_	_	O
7	overall	_	_	O
8	survival	_	_	O
9	(	_	_	O
10	OS	_	_	O
11	)	_	_	O
12	using	_	_	O
13	preoperative	_	_	O
14	(	_	_	O
15	PRE	_	_	O
16	)	_	_	O
17	as	_	_	O
18	opposed	_	_	O
19	to	_	_	O
20	perioperative	_	_	O
21	(	_	_	O
22	PERI	_	_	O
23	)	_	_	O
24	chemotherapy	_	_	O
25	in	_	_	O
26	resectable	_	_	O
27	StageI	_	_	O
28	-	_	_	O
29	II	_	_	O
30	non	_	_	O
31	-	_	_	O
32	small	_	_	O
33	-	_	_	O
34	cell	_	_	O
35	lung	_	_	O
36	cancer	_	_	O
37	(	_	_	O
38	NSCLC	_	_	O
39	)	_	_	O
40	.	_	_	O

41	This	_	_	O
42	multicenter	_	_	O
43	,	_	_	O
44	open	_	_	O
45	-	_	_	O
46	label	_	_	O
47	,	_	_	O
48	randomised	_	_	O
49	trial	_	_	O
50	with	_	_	O
51	a	_	_	O
52	2	_	_	O
53	×	_	_	O
54	2	_	_	O
55	factorial	_	_	O
56	design	_	_	O
57	first	_	_	O
58	compared	_	_	O
59	two	_	_	O
60	chemotherapy	_	_	O
61	strategies	_	_	O
62	(	_	_	O
63	PRE	_	_	O
64	versus	_	_	O
65	PERI	_	_	O
66	)	_	_	O
67	,	_	_	O
68	then	_	_	O
69	two	_	_	O
70	chemotherapy	_	_	O
71	regimens	_	_	O
72	(	_	_	O
73	gemcitabine	_	_	O
74	-	_	_	O
75	cisplatin	_	_	O
76	[	_	_	O
77	GP	_	_	O
78	]	_	_	O
79	versus	_	_	O
80	paclitaxel	_	_	O
81	-	_	_	O
82	carboplatin	_	_	O
83	[	_	_	O
84	TC	_	_	O
85	]	_	_	O
86	)	_	_	O
87	.	_	_	O

88	The	_	_	O
89	PRE	_	_	O
90	group	_	_	O
91	received	_	_	O
92	two	_	_	O
93	preoperative	_	_	O
94	cycles	_	_	O
95	followed	_	_	O
96	by	_	_	O
97	two	_	_	O
98	additional	_	_	O
99	preoperative	_	_	O
100	cycles	_	_	O
101	,	_	_	O
102	while	_	_	O
103	the	_	_	O
104	PERI	_	_	O
105	group	_	_	O
106	underwent	_	_	O
107	two	_	_	O
108	preoperative	_	_	O
109	cycles	_	_	O
110	followed	_	_	O
111	by	_	_	O
112	two	_	_	O
113	postoperative	_	_	O
114	cycles	_	_	O
115	,	_	_	O
116	the	_	_	O
117	3rd	_	_	O
118	and	_	_	O
119	4th	_	_	O
120	cycles	_	_	O
121	being	_	_	O
122	given	_	_	O
123	only	_	_	O
124	to	_	_	O
125	responders	_	_	O
126	in	_	_	O
127	both	_	_	O
128	cases	_	_	O
129	.	_	_	O

130	A	_	_	O
131	total	_	_	O
132	of	_	_	O
133	528	_	_	O
134	patients	_	_	O
135	were	_	_	O
136	randomised	_	_	O
137	,	_	_	O
138	267	_	_	O
139	of	_	_	O
140	which	_	_	O
141	were	_	_	O
142	assigned	_	_	O
143	to	_	_	O
144	the	_	_	O
145	PRE	_	_	O
146	group	_	_	O
147	and	_	_	O
148	261	_	_	O
149	to	_	_	O
150	the	_	_	O
151	PERI	_	_	O
152	group	_	_	O
153	.	_	_	O

154	Three	_	_	O
155	-	_	_	O
156	year	_	_	O
157	OS	_	_	O
158	did	_	_	O
159	not	_	_	O
160	differ	_	_	O
161	between	_	_	O
162	the	_	_	O
163	two	_	_	O
164	groups	_	_	O
165	(	_	_	O
166	67	_	_	O
167	.	_	_	O

168	4	_	_	O
169	%	_	_	O
170	and	_	_	O
171	67	_	_	O
172	.	_	_	O

173	7	_	_	O
174	%	_	_	O
175	,	_	_	O
176	respectively	_	_	O
177	;	_	_	O
178	hazard	_	_	O
179	ratio	_	_	O
180	(	_	_	O
181	HR	_	_	O
182	)	_	_	O
183	=	_	_	O
184	1	_	_	O
185	.	_	_	O

186	01	_	_	O
187	[	_	_	O
188	0	_	_	O
189	.	_	_	O

190	79	_	_	O
191	-	_	_	O
192	1	_	_	O
193	.	_	_	O

194	30	_	_	O
195	]	_	_	O
196	,	_	_	O
197	p	_	_	O
198	=	_	_	O
199	0	_	_	O
200	.	_	_	O

201	92	_	_	O
202	)	_	_	O
203	,	_	_	O
204	nor	_	_	O
205	did	_	_	O
206	3	_	_	O
207	-	_	_	O
208	year	_	_	O
209	disease	_	_	O
210	-	_	_	O
211	free	_	_	O
212	survival	_	_	O
213	,	_	_	O
214	response	_	_	O
215	rates	_	_	O
216	,	_	_	O
217	toxicity	_	_	O
218	,	_	_	O
219	or	_	_	O
220	postoperative	_	_	O
221	mortality	_	_	O
222	.	_	_	O

223	Pathological	_	_	B-Premise
224	complete	_	_	I-Premise
225	response	_	_	I-Premise
226	was	_	_	I-Premise
227	observed	_	_	I-Premise
228	in	_	_	I-Premise
229	22	_	_	I-Premise
230	(	_	_	I-Premise
231	8	_	_	I-Premise
232	.	_	_	I-Premise

233	2	_	_	I-Premise
234	%	_	_	I-Premise
235	)	_	_	I-Premise
236	and	_	_	I-Premise
237	16	_	_	I-Premise
238	patients	_	_	I-Premise
239	(	_	_	I-Premise
240	6	_	_	I-Premise
241	.	_	_	I-Premise

242	1	_	_	I-Premise
243	%	_	_	I-Premise
244	)	_	_	I-Premise
245	,	_	_	I-Premise
246	respectively	_	_	I-Premise
247	.	_	_	I-Premise

248	Although	_	_	B-Premise
249	quality	_	_	I-Premise
250	of	_	_	I-Premise
251	life	_	_	I-Premise
252	did	_	_	I-Premise
253	not	_	_	I-Premise
254	differ	_	_	I-Premise
255	significantly	_	_	I-Premise
256	,	_	_	I-Premise
257	chemotherapy	_	_	B-Premise
258	compliance	_	_	I-Premise
259	was	_	_	I-Premise
260	significantly	_	_	I-Premise
261	higher	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	PRE	_	_	I-Premise
265	group	_	_	I-Premise
266	.	_	_	I-Premise

267	The	_	_	B-Premise
268	proportion	_	_	I-Premise
269	of	_	_	I-Premise
270	responders	_	_	I-Premise
271	who	_	_	I-Premise
272	received	_	_	I-Premise
273	Cycles	_	_	I-Premise
274	3	_	_	I-Premise
275	and	_	_	I-Premise
276	4	_	_	I-Premise
277	was	_	_	I-Premise
278	significantly	_	_	I-Premise
279	higher	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	PRE	_	_	I-Premise
283	group	_	_	I-Premise
284	(	_	_	I-Premise
285	90	_	_	I-Premise
286	.	_	_	I-Premise

287	4	_	_	I-Premise
288	%	_	_	I-Premise
289	versus	_	_	I-Premise
290	75	_	_	I-Premise
291	.	_	_	I-Premise

292	2	_	_	I-Premise
293	%	_	_	I-Premise
294	,	_	_	I-Premise
295	p	_	_	I-Premise
296	=	_	_	I-Premise
297	0	_	_	I-Premise
298	.	_	_	I-Premise

299	001	_	_	I-Premise
300	)	_	_	I-Premise
301	.	_	_	I-Premise

302	In	_	_	B-Premise
303	responders	_	_	I-Premise
304	,	_	_	I-Premise
305	the	_	_	I-Premise
306	dose	_	_	I-Premise
307	intensity	_	_	I-Premise
308	of	_	_	I-Premise
309	Cycles	_	_	I-Premise
310	3	_	_	I-Premise
311	and	_	_	I-Premise
312	4	_	_	I-Premise
313	was	_	_	I-Premise
314	higher	_	_	I-Premise
315	in	_	_	I-Premise
316	the	_	_	I-Premise
317	PRE	_	_	I-Premise
318	group	_	_	I-Premise
319	than	_	_	I-Premise
320	in	_	_	I-Premise
321	the	_	_	I-Premise
322	PERI	_	_	I-Premise
323	group	_	_	I-Premise
324	(	_	_	I-Premise
325	mean	_	_	I-Premise
326	relative	_	_	I-Premise
327	dose	_	_	I-Premise
328	intensity	_	_	I-Premise
329	of	_	_	I-Premise
330	90	_	_	I-Premise
331	.	_	_	I-Premise

332	4	_	_	I-Premise
333	%	_	_	I-Premise
334	versus	_	_	I-Premise
335	82	_	_	I-Premise
336	.	_	_	I-Premise

337	6	_	_	I-Premise
338	%	_	_	I-Premise
339	,	_	_	I-Premise
340	respectively	_	_	I-Premise
341	;	_	_	I-Premise
342	p	_	_	I-Premise
343	=	_	_	I-Premise
344	0	_	_	I-Premise
345	.	_	_	I-Premise

346	0007	_	_	I-Premise
347	)	_	_	I-Premise
348	.	_	_	I-Premise

349	There	_	_	B-Premise
350	was	_	_	I-Premise
351	no	_	_	I-Premise
352	difference	_	_	I-Premise
353	between	_	_	I-Premise
354	GP	_	_	I-Premise
355	and	_	_	I-Premise
356	TC	_	_	I-Premise
357	in	_	_	I-Premise
358	3	_	_	I-Premise
359	-	_	_	I-Premise
360	year	_	_	I-Premise
361	OS	_	_	I-Premise
362	(	_	_	I-Premise
363	HR	_	_	I-Premise
364	=	_	_	I-Premise
365	0	_	_	I-Premise
366	.	_	_	I-Premise

367	97	_	_	I-Premise
368	[	_	_	I-Premise
369	95	_	_	I-Premise
370	%	_	_	I-Premise
371	confidence	_	_	I-Premise
372	interval	_	_	I-Premise
373	(	_	_	I-Premise
374	CI	_	_	I-Premise
375	)	_	_	I-Premise
376	:	_	_	I-Premise
377	0	_	_	I-Premise
378	.	_	_	I-Premise

379	76	_	_	I-Premise
380	-	_	_	I-Premise
381	1	_	_	I-Premise
382	.	_	_	I-Premise

383	25	_	_	I-Premise
384	]	_	_	I-Premise
385	,	_	_	I-Premise
386	p	_	_	I-Premise
387	=	_	_	I-Premise
388	0	_	_	I-Premise
389	.	_	_	I-Premise

390	80	_	_	I-Premise
391	)	_	_	I-Premise
392	or	_	_	I-Premise
393	response	_	_	I-Premise
394	rates	_	_	I-Premise
395	.	_	_	I-Premise

396	However	_	_	O
397	,	_	_	O
398	the	_	_	B-Premise
399	regimens	_	_	I-Premise
400	'	_	_	I-Premise
401	toxicity	_	_	I-Premise
402	profiles	_	_	I-Premise
403	differed	_	_	I-Premise
404	.	_	_	I-Premise

405	This	_	_	B-Claim
406	study	_	_	I-Claim
407	failed	_	_	I-Claim
408	to	_	_	I-Claim
409	demonstrate	_	_	I-Claim
410	any	_	_	I-Claim
411	difference	_	_	I-Claim
412	in	_	_	I-Claim
413	survival	_	_	I-Claim
414	between	_	_	I-Claim
415	patients	_	_	I-Claim
416	receiving	_	_	I-Claim
417	preoperative	_	_	I-Claim
418	and	_	_	I-Claim
419	perioperative	_	_	I-Claim
420	chemotherapy	_	_	I-Claim
421	in	_	_	I-Claim
422	early	_	_	I-Claim
423	-	_	_	I-Claim
424	stage	_	_	I-Claim
425	NSCLC	_	_	I-Claim
426	.	_	_	I-Claim

427	The	_	_	B-Claim
428	increase	_	_	I-Claim
429	from	_	_	I-Claim
430	two	_	_	I-Claim
431	to	_	_	I-Claim
432	four	_	_	I-Claim
433	preoperative	_	_	I-Claim
434	chemotherapy	_	_	I-Claim
435	cycles	_	_	I-Claim
436	did	_	_	I-Claim
437	not	_	_	I-Claim
438	increase	_	_	I-Claim
439	the	_	_	I-Claim
440	pathological	_	_	I-Claim
441	response	_	_	I-Claim
442	rate	_	_	I-Claim
443	.	_	_	I-Claim


0	Recombinant	_	_	B-Claim
1	human	_	_	I-Claim
2	erythropoietin	_	_	I-Claim
3	(	_	_	I-Claim
4	r	_	_	I-Claim
5	-	_	_	I-Claim
6	HuEPO	_	_	I-Claim
7	)	_	_	I-Claim
8	corrects	_	_	I-Claim
9	cancer	_	_	I-Claim
10	-	_	_	I-Claim
11	related	_	_	I-Claim
12	anemia	_	_	I-Claim
13	and	_	_	I-Claim
14	,	_	_	I-Claim
15	thereby	_	_	I-Claim
16	,	_	_	I-Claim
17	improves	_	_	I-Claim
18	quality	_	_	I-Claim
19	of	_	_	I-Claim
20	life	_	_	I-Claim
21	.	_	_	I-Claim

22	The	_	_	O
23	purpose	_	_	O
24	of	_	_	O
25	the	_	_	O
26	present	_	_	O
27	study	_	_	O
28	was	_	_	O
29	to	_	_	O
30	measure	_	_	O
31	the	_	_	O
32	impact	_	_	O
33	of	_	_	O
34	erythropoietin	_	_	O
35	on	_	_	O
36	hemoglobin	_	_	O
37	and	_	_	O
38	mood	_	_	O
39	state	_	_	O
40	in	_	_	O
41	patients	_	_	O
42	with	_	_	O
43	metastatic	_	_	O
44	breast	_	_	O
45	cancer	_	_	O
46	and	_	_	O
47	mild	_	_	O
48	anemia	_	_	O
49	(	_	_	O
50	Hgb	_	_	O
51	<	_	_	O
52	12	_	_	O
53	.	_	_	O

54	0	_	_	O
55	g	_	_	O
56	/	_	_	O
57	dL	_	_	O
58	)	_	_	O
59	.	_	_	O

60	Women	_	_	O
61	were	_	_	O
62	randomized	_	_	O
63	to	_	_	O
64	receive	_	_	O
65	usual	_	_	O
66	care	_	_	O
67	(	_	_	O
68	G1	_	_	O
69	)	_	_	O
70	or	_	_	O
71	usual	_	_	O
72	care	_	_	O
73	plus	_	_	O
74	r	_	_	O
75	-	_	_	O
76	HuEPO	_	_	O
77	(	_	_	O
78	G2	_	_	O
79	)	_	_	O
80	.	_	_	O

81	Usual	_	_	O
82	care	_	_	O
83	included	_	_	O
84	transfusions	_	_	O
85	as	_	_	O
86	necessary	_	_	O
87	and	_	_	O
88	fatigue	_	_	O
89	education	_	_	O
90	.	_	_	O

91	R	_	_	O
92	-	_	_	O
93	HuEPO	_	_	O
94	was	_	_	O
95	begun	_	_	O
96	at	_	_	O
97	40	_	_	O
98	,	_	_	O
99	000U	_	_	O
100	subcutaneously	_	_	O
101	per	_	_	O
102	week	_	_	O
103	.	_	_	O

104	At	_	_	O
105	4	_	_	O
106	weeks	_	_	O
107	,	_	_	O
108	the	_	_	O
109	dose	_	_	O
110	was	_	_	O
111	increased	_	_	O
112	to	_	_	O
113	60	_	_	O
114	,	_	_	O
115	000U	_	_	O
116	if	_	_	O
117	Hgb	_	_	O
118	had	_	_	O
119	not	_	_	O
120	increased	_	_	O
121	>	_	_	O
122	or	_	_	O
123	=	_	_	O
124	1	_	_	O
125	.	_	_	O

126	0	_	_	O
127	g	_	_	O
128	/	_	_	O
129	dL	_	_	O
130	.	_	_	O

131	The	_	_	O
132	drug	_	_	O
133	was	_	_	O
134	discontinued	_	_	O
135	at	_	_	O
136	8	_	_	O
137	weeks	_	_	O
138	if	_	_	O
139	hemoglobin	_	_	O
140	improvement	_	_	O
141	was	_	_	O
142	<	_	_	O
143	1	_	_	O
144	.	_	_	O

145	0	_	_	O
146	g	_	_	O
147	/	_	_	O
148	dL	_	_	O
149	.	_	_	O

150	The	_	_	O
151	study	_	_	O
152	was	_	_	O
153	terminated	_	_	O
154	early	_	_	O
155	(	_	_	O
156	n	_	_	O
157	=	_	_	O
158	27	_	_	O
159	,	_	_	O
160	G1	_	_	O
161	=	_	_	O
162	13	_	_	O
163	,	_	_	O
164	G2	_	_	O
165	=	_	_	O
166	14	_	_	O
167	)	_	_	O
168	when	_	_	O
169	4	_	_	O
170	/	_	_	O
171	14	_	_	O
172	(	_	_	O
173	28	_	_	O
174	.	_	_	O

175	5	_	_	O
176	%	_	_	O
177	)	_	_	O
178	subjects	_	_	O
179	in	_	_	O
180	G2	_	_	O
181	developed	_	_	O
182	thrombotic	_	_	O
183	events	_	_	O
184	(	_	_	O
185	deep	_	_	O
186	vein	_	_	O
187	thrombosis	_	_	O
188	[	_	_	O
189	DVT	_	_	O
190	]	_	_	O
191	in	_	_	O
192	1	_	_	O
193	;	_	_	O
194	DVT	_	_	O
195	plus	_	_	O
196	pulmonary	_	_	O
197	embolism	_	_	O
198	[	_	_	O
199	PE	_	_	O
200	]	_	_	O
201	in	_	_	O
202	1	_	_	O
203	;	_	_	O
204	DVT	_	_	O
205	plus	_	_	O
206	PE	_	_	O
207	1	_	_	O
208	month	_	_	O
209	after	_	_	O
210	drug	_	_	O
211	discontinuation	_	_	O
212	in	_	_	O
213	1	_	_	O
214	;	_	_	O
215	and	_	_	O
216	brachial	_	_	O
217	vein	_	_	O
218	thrombosis	_	_	O
219	with	_	_	O
220	infected	_	_	O
221	Mediport	_	_	O
222	in	_	_	O
223	1	_	_	O
224	)	_	_	O
225	.	_	_	O

226	In	_	_	B-Premise
227	all	_	_	I-Premise
228	four	_	_	I-Premise
229	patients	_	_	I-Premise
230	,	_	_	I-Premise
231	Hgb	_	_	I-Premise
232	levels	_	_	I-Premise
233	were	_	_	I-Premise
234	normal	_	_	I-Premise
235	at	_	_	I-Premise
236	the	_	_	I-Premise
237	time	_	_	I-Premise
238	of	_	_	I-Premise
239	the	_	_	I-Premise
240	event	_	_	I-Premise
241	.	_	_	I-Premise

242	No	_	_	B-Premise
243	patient	_	_	I-Premise
244	in	_	_	I-Premise
245	G1	_	_	I-Premise
246	developed	_	_	I-Premise
247	a	_	_	I-Premise
248	thrombotic	_	_	I-Premise
249	event	_	_	I-Premise
250	.	_	_	I-Premise

251	There	_	_	B-Premise
252	were	_	_	I-Premise
253	no	_	_	I-Premise
254	significant	_	_	I-Premise
255	differences	_	_	I-Premise
256	in	_	_	I-Premise
257	demographic	_	_	I-Premise
258	characteristics	_	_	I-Premise
259	or	_	_	I-Premise
260	current	_	_	I-Premise
261	chemotherapy	_	_	I-Premise
262	regimen	_	_	I-Premise
263	in	_	_	I-Premise
264	G1	_	_	I-Premise
265	vs	_	_	I-Premise
266	.	_	_	I-Premise

267	G2	_	_	I-Premise
268	.	_	_	I-Premise

269	The	_	_	O
270	decision	_	_	O
271	to	_	_	O
272	terminate	_	_	O
273	the	_	_	O
274	trial	_	_	O
275	was	_	_	O
276	made	_	_	O
277	after	_	_	O
278	considerable	_	_	O
279	deliberation	_	_	O
280	.	_	_	O

281	The	_	_	B-Premise
282	increased	_	_	I-Premise
283	incidence	_	_	I-Premise
284	of	_	_	I-Premise
285	thrombotic	_	_	I-Premise
286	events	_	_	I-Premise
287	in	_	_	I-Premise
288	the	_	_	I-Premise
289	r	_	_	I-Premise
290	-	_	_	I-Premise
291	HuEPO	_	_	I-Premise
292	(	_	_	I-Premise
293	G2	_	_	I-Premise
294	)	_	_	I-Premise
295	arm	_	_	I-Premise
296	of	_	_	I-Premise
297	this	_	_	I-Premise
298	study	_	_	I-Premise
299	exceeds	_	_	I-Premise
300	that	_	_	I-Premise
301	in	_	_	I-Premise
302	prior	_	_	I-Premise
303	studies	_	_	I-Premise
304	in	_	_	I-Premise
305	this	_	_	I-Premise
306	population	_	_	I-Premise
307	and	_	_	I-Premise
308	prior	_	_	I-Premise
309	r	_	_	I-Premise
310	-	_	_	I-Premise
311	HuEPO	_	_	I-Premise
312	trials	_	_	I-Premise
313	.	_	_	I-Premise

314	This	_	_	B-Claim
315	may	_	_	I-Claim
316	relate	_	_	I-Claim
317	to	_	_	I-Claim
318	the	_	_	I-Claim
319	administration	_	_	I-Claim
320	of	_	_	I-Claim
321	r	_	_	I-Claim
322	-	_	_	I-Claim
323	HuEPO	_	_	I-Claim
324	in	_	_	I-Claim
325	this	_	_	I-Claim
326	high	_	_	I-Claim
327	-	_	_	I-Claim
328	risk	_	_	I-Claim
329	population	_	_	I-Claim
330	,	_	_	I-Claim
331	but	_	_	B-Claim
332	the	_	_	I-Claim
333	small	_	_	I-Claim
334	sample	_	_	I-Claim
335	size	_	_	I-Claim
336	and	_	_	I-Claim
337	possible	_	_	I-Claim
338	predisposing	_	_	I-Claim
339	risk	_	_	I-Claim
340	factors	_	_	I-Claim
341	preclude	_	_	I-Claim
342	definitive	_	_	I-Claim
343	conclusions	_	_	I-Claim
344	.	_	_	I-Claim


0	Data	_	_	O
1	from	_	_	O
2	experimental	_	_	O
3	studies	_	_	O
4	suggest	_	_	O
5	that	_	_	O
6	octreotide	_	_	B-Claim
7	,	_	_	I-Claim
8	the	_	_	I-Claim
9	long	_	_	I-Claim
10	acting	_	_	I-Claim
11	somatostatin	_	_	I-Claim
12	analogue	_	_	I-Claim
13	,	_	_	I-Claim
14	improves	_	_	I-Claim
15	survival	_	_	I-Claim
16	of	_	_	I-Claim
17	animals	_	_	I-Claim
18	with	_	_	I-Claim
19	pancreatic	_	_	I-Claim
20	cancer	_	_	I-Claim
21	.	_	_	I-Claim

22	To	_	_	O
23	assess	_	_	O
24	the	_	_	O
25	antitumour	_	_	O
26	effect	_	_	O
27	of	_	_	O
28	octreotide	_	_	O
29	,	_	_	O
30	a	_	_	O
31	randomized	_	_	O
32	trial	_	_	O
33	was	_	_	O
34	performed	_	_	O
35	comparing	_	_	O
36	octreotide	_	_	O
37	with	_	_	O
38	supportive	_	_	O
39	care	_	_	O
40	in	_	_	O
41	advanced	_	_	O
42	pancreatic	_	_	O
43	cancer	_	_	O
44	patients	_	_	O
45	.	_	_	O

46	All	_	_	O
47	patients	_	_	O
48	,	_	_	O
49	aged	_	_	O
50	59	_	_	O
51	-	_	_	O
52	75	_	_	O
53	years	_	_	O
54	,	_	_	O
55	were	_	_	O
56	not	_	_	O
57	liable	_	_	O
58	to	_	_	O
59	radical	_	_	O
60	surgical	_	_	O
61	treatment	_	_	O
62	and	_	_	O
63	were	_	_	O
64	not	_	_	O
65	submitted	_	_	O
66	to	_	_	O
67	other	_	_	O
68	treatments	_	_	O
69	(	_	_	O
70	chemo	_	_	O
71	and	_	_	O
72	/	_	_	O
73	or	_	_	O
74	radiotherapy	_	_	O
75	)	_	_	O
76	.	_	_	O

77	Six	_	_	O
78	patients	_	_	O
79	were	_	_	O
80	enrolled	_	_	O
81	,	_	_	O
82	4	_	_	O
83	of	_	_	O
84	these	_	_	O
85	treated	_	_	O
86	with	_	_	O
87	octreotide	_	_	O
88	(	_	_	O
89	500	_	_	O
90	micrograms	_	_	O
91	two	_	_	O
92	times	_	_	O
93	a	_	_	O
94	day	_	_	O
95	subcutaneous	_	_	O
96	for	_	_	O
97	six	_	_	O
98	months	_	_	O
99	)	_	_	O
100	and	_	_	O
101	the	_	_	O
102	other	_	_	O
103	2	_	_	O
104	were	_	_	O
105	inserted	_	_	O
106	a	_	_	O
107	control	_	_	O
108	group	_	_	O
109	.	_	_	O

110	The	_	_	B-Premise
111	patients	_	_	I-Premise
112	treated	_	_	I-Premise
113	with	_	_	I-Premise
114	octreotide	_	_	I-Premise
115	showed	_	_	I-Premise
116	a	_	_	I-Premise
117	significant	_	_	I-Premise
118	advantage	_	_	I-Premise
119	in	_	_	I-Premise
120	quality	_	_	I-Premise
121	of	_	_	I-Premise
122	life	_	_	I-Premise
123	(	_	_	I-Premise
124	restored	_	_	I-Premise
125	appetite	_	_	I-Premise
126	,	_	_	I-Premise
127	improvement	_	_	I-Premise
128	of	_	_	I-Premise
129	digestion	_	_	I-Premise
130	and	_	_	I-Premise
131	intestine	_	_	I-Premise
132	function	_	_	I-Premise
133	,	_	_	I-Premise
134	remission	_	_	I-Premise
135	of	_	_	I-Premise
136	abdominal	_	_	I-Premise
137	pain	_	_	I-Premise
138	and	_	_	I-Premise
139	preservation	_	_	I-Premise
140	of	_	_	I-Premise
141	baseline	_	_	I-Premise
142	body	_	_	I-Premise
143	weight	_	_	I-Premise
144	)	_	_	I-Premise
145	with	_	_	I-Premise
146	a	_	_	I-Premise
147	mean	_	_	I-Premise
148	>	_	_	I-Premise
149	80	_	_	I-Premise
150	of	_	_	I-Premise
151	karnofsky	_	_	I-Premise
152	performance	_	_	I-Premise
153	score	_	_	I-Premise
154	.	_	_	I-Premise

155	Monitoring	_	_	B-Premise
156	of	_	_	I-Premise
157	tumour	_	_	I-Premise
158	size	_	_	I-Premise
159	changes	_	_	I-Premise
160	(	_	_	I-Premise
161	US	_	_	I-Premise
162	-	_	_	I-Premise
163	TC	_	_	I-Premise
164	)	_	_	I-Premise
165	over	_	_	I-Premise
166	the	_	_	I-Premise
167	6	_	_	I-Premise
168	months	_	_	I-Premise
169	study	_	_	I-Premise
170	period	_	_	I-Premise
171	,	_	_	I-Premise
172	showed	_	_	I-Premise
173	slackened	_	_	I-Premise
174	neoplastic	_	_	I-Premise
175	growth	_	_	I-Premise
176	in	_	_	I-Premise
177	all	_	_	I-Premise
178	treated	_	_	I-Premise
179	patients	_	_	I-Premise
180	,	_	_	I-Premise
181	whereas	_	_	B-Premise
182	neoplasm	_	_	I-Premise
183	grew	_	_	I-Premise
184	according	_	_	I-Premise
185	to	_	_	I-Premise
186	an	_	_	I-Premise
187	almost	_	_	I-Premise
188	exponential	_	_	I-Premise
189	trend	_	_	I-Premise
190	in	_	_	I-Premise
191	untreated	_	_	I-Premise
192	patients	_	_	I-Premise
193	.	_	_	O

194	Also	_	_	O
195	survival	_	_	B-Premise
196	was	_	_	I-Premise
197	better	_	_	I-Premise
198	in	_	_	I-Premise
199	treated	_	_	I-Premise
200	patients	_	_	I-Premise
201	:	_	_	O
202	in	_	_	O
203	particular	_	_	O
204	,	_	_	O
205	2	_	_	O
206	patients	_	_	O
207	out	_	_	O
208	of	_	_	O
209	4	_	_	O
210	who	_	_	O
211	completed	_	_	O
212	the	_	_	O
213	study	_	_	O
214	underwent	_	_	O
215	follow	_	_	O
216	-	_	_	O
217	up	_	_	O
218	until	_	_	O
219	they	_	_	O
220	died	_	_	O
221	12	_	_	O
222	and	_	_	O
223	16	_	_	O
224	months	_	_	O
225	after	_	_	O
226	beginning	_	_	O
227	of	_	_	O
228	treatment	_	_	O
229	,	_	_	O
230	respectively	_	_	O
231	.	_	_	O

232	Karnofsky	_	_	B-Premise
233	performance	_	_	I-Premise
234	score	_	_	I-Premise
235	was	_	_	I-Premise
236	particularly	_	_	I-Premise
237	high	_	_	I-Premise
238	in	_	_	I-Premise
239	both	_	_	I-Premise
240	patients	_	_	I-Premise
241	.	_	_	I-Premise

242	This	_	_	O
243	supports	_	_	O
244	the	_	_	O
245	view	_	_	O
246	that	_	_	O
247	octreotide	_	_	B-Claim
248	is	_	_	I-Claim
249	endowed	_	_	I-Claim
250	with	_	_	I-Claim
251	antiproliferative	_	_	I-Claim
252	activity	_	_	I-Claim
253	.	_	_	I-Claim

254	In	_	_	O
255	conclusion	_	_	O
256	octreotide	_	_	B-Claim
257	therapy	_	_	I-Claim
258	seems	_	_	I-Claim
259	to	_	_	I-Claim
260	confer	_	_	I-Claim
261	a	_	_	I-Claim
262	survival	_	_	I-Claim
263	benefit	_	_	I-Claim
264	and	_	_	I-Claim
265	a	_	_	I-Claim
266	better	_	_	I-Claim
267	quality	_	_	I-Claim
268	of	_	_	I-Claim
269	life	_	_	I-Claim
270	in	_	_	I-Claim
271	advanced	_	_	I-Claim
272	pancreatic	_	_	I-Claim
273	tumour	_	_	I-Claim
274	.	_	_	I-Claim

275	Additional	_	_	O
276	studies	_	_	O
277	are	_	_	O
278	needed	_	_	O
279	to	_	_	O
280	confirm	_	_	O
281	these	_	_	O
282	results	_	_	O
283	and	_	_	O
284	to	_	_	O
285	clarify	_	_	O
286	other	_	_	O
287	questions	_	_	O
288	about	_	_	O
289	dose	_	_	O
290	and	_	_	O
291	somatostatin	_	_	O
292	receptors	_	_	O
293	in	_	_	O
294	this	_	_	O
295	kind	_	_	O
296	of	_	_	O
297	tumour	_	_	O
298	.	_	_	O


0	Performance	_	_	O
1	status	_	_	O
2	(	_	_	O
3	PS	_	_	O
4	)	_	_	O
5	2	_	_	O
6	patients	_	_	O
7	with	_	_	O
8	non	_	_	O
9	-	_	_	O
10	small	_	_	O
11	cell	_	_	O
12	lung	_	_	O
13	cancer	_	_	O
14	(	_	_	O
15	NSCLC	_	_	O
16	)	_	_	O
17	experience	_	_	O
18	more	_	_	O
19	toxicity	_	_	O
20	,	_	_	O
21	lower	_	_	O
22	response	_	_	O
23	rates	_	_	O
24	,	_	_	O
25	and	_	_	O
26	shorter	_	_	O
27	survival	_	_	O
28	times	_	_	O
29	than	_	_	O
30	healthier	_	_	O
31	patients	_	_	O
32	treated	_	_	O
33	with	_	_	O
34	standard	_	_	O
35	chemotherapy	_	_	O
36	.	_	_	O

37	Paclitaxel	_	_	O
38	poliglumex	_	_	O
39	(	_	_	O
40	PPX	_	_	O
41	)	_	_	O
42	,	_	_	O
43	a	_	_	O
44	macromolecule	_	_	O
45	drug	_	_	O
46	conjugate	_	_	O
47	of	_	_	O
48	paclitaxel	_	_	O
49	and	_	_	O
50	polyglutamic	_	_	O
51	acid	_	_	O
52	,	_	_	O
53	reduces	_	_	O
54	systemic	_	_	O
55	exposure	_	_	O
56	to	_	_	O
57	peak	_	_	O
58	concentrations	_	_	O
59	of	_	_	O
60	free	_	_	O
61	paclitaxel	_	_	O
62	and	_	_	O
63	may	_	_	O
64	lead	_	_	O
65	to	_	_	O
66	increased	_	_	O
67	concentrations	_	_	O
68	in	_	_	O
69	tumors	_	_	O
70	due	_	_	O
71	to	_	_	O
72	enhanced	_	_	O
73	vascular	_	_	O
74	permeability	_	_	O
75	.	_	_	O

76	Chemotherapy	_	_	O
77	-	_	_	O
78	naive	_	_	O
79	PS	_	_	O
80	2	_	_	O
81	patients	_	_	O
82	with	_	_	O
83	advanced	_	_	O
84	NSCLC	_	_	O
85	were	_	_	O
86	randomized	_	_	O
87	to	_	_	O
88	receive	_	_	O
89	carboplatin	_	_	O
90	(	_	_	O
91	area	_	_	O
92	under	_	_	O
93	the	_	_	O
94	curve	_	_	O
95	=	_	_	O
96	6	_	_	O
97	)	_	_	O
98	and	_	_	O
99	either	_	_	O
100	PPX	_	_	O
101	(	_	_	O
102	210	_	_	O
103	mg	_	_	O
104	/	_	_	O
105	m	_	_	O
106	/	_	_	O
107	10	_	_	O
108	min	_	_	O
109	without	_	_	O
110	routine	_	_	O
111	steroid	_	_	O
112	premedication	_	_	O
113	)	_	_	O
114	or	_	_	O
115	paclitaxel	_	_	O
116	(	_	_	O
117	225	_	_	O
118	mg	_	_	O
119	/	_	_	O
120	m	_	_	O
121	/	_	_	O
122	3	_	_	O
123	h	_	_	O
124	with	_	_	O
125	standard	_	_	O
126	premedication	_	_	O
127	)	_	_	O
128	every	_	_	O
129	3	_	_	O
130	weeks	_	_	O
131	.	_	_	O

132	The	_	_	O
133	primary	_	_	O
134	end	_	_	O
135	point	_	_	O
136	was	_	_	O
137	overall	_	_	O
138	survival	_	_	O
139	.	_	_	O

140	A	_	_	O
141	total	_	_	O
142	of	_	_	O
143	400	_	_	O
144	patients	_	_	O
145	were	_	_	O
146	enrolled	_	_	O
147	.	_	_	O

148	Alopecia	_	_	B-Premise
149	,	_	_	I-Premise
150	arthralgias	_	_	I-Premise
151	/	_	_	I-Premise
152	myalgias	_	_	I-Premise
153	,	_	_	I-Premise
154	and	_	_	I-Premise
155	cardiac	_	_	I-Premise
156	events	_	_	I-Premise
157	were	_	_	I-Premise
158	significantly	_	_	I-Premise
159	less	_	_	I-Premise
160	frequent	_	_	I-Premise
161	with	_	_	I-Premise
162	PPX	_	_	I-Premise
163	/	_	_	I-Premise
164	carboplatin	_	_	I-Premise
165	,	_	_	I-Premise
166	whereas	_	_	I-Premise
167	grade	_	_	I-Premise
168	>	_	_	I-Premise
169	or	_	_	I-Premise
170	=	_	_	I-Premise
171	3	_	_	I-Premise
172	neutropenia	_	_	I-Premise
173	and	_	_	I-Premise
174	grade	_	_	I-Premise
175	3	_	_	I-Premise
176	neuropathy	_	_	I-Premise
177	showed	_	_	I-Premise
178	a	_	_	I-Premise
179	trend	_	_	I-Premise
180	of	_	_	I-Premise
181	worsening	_	_	I-Premise
182	.	_	_	I-Premise

183	There	_	_	B-Premise
184	was	_	_	I-Premise
185	no	_	_	I-Premise
186	significant	_	_	I-Premise
187	difference	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	incidence	_	_	I-Premise
191	of	_	_	I-Premise
192	hypersensitivity	_	_	I-Premise
193	reactions	_	_	I-Premise
194	despite	_	_	I-Premise
195	the	_	_	I-Premise
196	absence	_	_	I-Premise
197	of	_	_	I-Premise
198	routine	_	_	I-Premise
199	premedication	_	_	I-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	PPX	_	_	I-Premise
203	arm	_	_	I-Premise
204	.	_	_	I-Premise

205	Overall	_	_	B-Premise
206	survival	_	_	I-Premise
207	was	_	_	I-Premise
208	similar	_	_	I-Premise
209	between	_	_	I-Premise
210	treatment	_	_	I-Premise
211	arms	_	_	I-Premise
212	(	_	_	I-Premise
213	hazard	_	_	I-Premise
214	ratio	_	_	I-Premise
215	,	_	_	I-Premise
216	0	_	_	I-Premise
217	.	_	_	I-Premise

218	97	_	_	I-Premise
219	;	_	_	I-Premise
220	log	_	_	I-Premise
221	rank	_	_	I-Premise
222	p	_	_	I-Premise
223	=	_	_	I-Premise
224	0	_	_	I-Premise
225	.	_	_	I-Premise

226	769	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	Median	_	_	B-Premise
230	and	_	_	I-Premise
231	1	_	_	I-Premise
232	-	_	_	I-Premise
233	year	_	_	I-Premise
234	survival	_	_	I-Premise
235	rates	_	_	I-Premise
236	were	_	_	I-Premise
237	7	_	_	I-Premise
238	.	_	_	I-Premise

239	9	_	_	I-Premise
240	months	_	_	I-Premise
241	and	_	_	I-Premise
242	31	_	_	I-Premise
243	%	_	_	I-Premise
244	,	_	_	I-Premise
245	for	_	_	I-Premise
246	PPX	_	_	I-Premise
247	versus	_	_	I-Premise
248	8	_	_	I-Premise
249	months	_	_	I-Premise
250	and	_	_	I-Premise
251	31	_	_	I-Premise
252	%	_	_	I-Premise
253	for	_	_	I-Premise
254	paclitaxel	_	_	I-Premise
255	.	_	_	I-Premise

256	Disease	_	_	O
257	control	_	_	O
258	rates	_	_	O
259	were	_	_	O
260	64	_	_	O
261	%	_	_	O
262	and	_	_	O
263	69	_	_	O
264	%	_	_	O
265	for	_	_	O
266	PPX	_	_	O
267	and	_	_	O
268	paclitaxel	_	_	O
269	,	_	_	O
270	respectively	_	_	O
271	.	_	_	O

272	Time	_	_	O
273	to	_	_	O
274	progression	_	_	O
275	was	_	_	O
276	similar	_	_	O
277	:	_	_	O
278	3	_	_	O
279	.	_	_	O

280	9	_	_	O
281	months	_	_	O
282	for	_	_	O
283	PPX	_	_	O
284	/	_	_	O
285	carboplatin	_	_	O
286	versus	_	_	O
287	4	_	_	O
288	.	_	_	O

289	6	_	_	O
290	months	_	_	O
291	for	_	_	O
292	paclitaxel	_	_	O
293	/	_	_	O
294	carboplatin	_	_	O
295	(	_	_	O
296	p	_	_	O
297	=	_	_	O
298	0	_	_	O
299	.	_	_	O

300	210	_	_	O
301	)	_	_	O
302	.	_	_	O

303	PPX	_	_	B-Claim
304	/	_	_	I-Claim
305	carboplatin	_	_	I-Claim
306	failed	_	_	I-Claim
307	to	_	_	I-Claim
308	provide	_	_	I-Claim
309	superior	_	_	I-Claim
310	survival	_	_	I-Claim
311	compared	_	_	I-Claim
312	with	_	_	I-Claim
313	paclitaxel	_	_	I-Claim
314	/	_	_	I-Claim
315	carboplatin	_	_	I-Claim
316	in	_	_	I-Claim
317	the	_	_	I-Claim
318	first	_	_	I-Claim
319	-	_	_	I-Claim
320	line	_	_	I-Claim
321	treatment	_	_	I-Claim
322	of	_	_	I-Claim
323	PS	_	_	I-Claim
324	2	_	_	I-Claim
325	patients	_	_	I-Claim
326	with	_	_	I-Claim
327	NSCLC	_	_	I-Claim
328	,	_	_	I-Claim
329	but	_	_	B-Claim
330	the	_	_	I-Claim
331	results	_	_	I-Claim
332	with	_	_	I-Claim
333	respect	_	_	I-Claim
334	to	_	_	I-Claim
335	progression	_	_	I-Claim
336	-	_	_	I-Claim
337	free	_	_	I-Claim
338	survival	_	_	I-Claim
339	and	_	_	I-Claim
340	overall	_	_	I-Claim
341	survival	_	_	I-Claim
342	were	_	_	I-Claim
343	comparable	_	_	I-Claim
344	and	_	_	I-Claim
345	the	_	_	I-Claim
346	PPX	_	_	I-Claim
347	regimen	_	_	I-Claim
348	was	_	_	I-Claim
349	more	_	_	I-Claim
350	convenient	_	_	I-Claim
351	.	_	_	I-Claim


0	Surgical	_	_	O
1	resection	_	_	O
2	enhances	_	_	O
3	long	_	_	O
4	-	_	_	O
5	term	_	_	O
6	survival	_	_	O
7	after	_	_	O
8	lung	_	_	O
9	cancer	_	_	O
10	,	_	_	O
11	but	_	_	O
12	survivors	_	_	O
13	face	_	_	O
14	functional	_	_	O
15	deficits	_	_	O
16	and	_	_	O
17	report	_	_	O
18	on	_	_	O
19	poor	_	_	O
20	quality	_	_	O
21	of	_	_	O
22	life	_	_	O
23	long	_	_	O
24	time	_	_	O
25	after	_	_	O
26	surgery	_	_	O
27	.	_	_	O

28	This	_	_	O
29	study	_	_	O
30	evaluated	_	_	O
31	short	_	_	O
32	and	_	_	O
33	long	_	_	O
34	-	_	_	O
35	term	_	_	O
36	effects	_	_	O
37	of	_	_	O
38	supervised	_	_	O
39	group	_	_	O
40	exercise	_	_	O
41	training	_	_	O
42	on	_	_	O
43	health	_	_	O
44	-	_	_	O
45	related	_	_	O
46	quality	_	_	O
47	of	_	_	O
48	life	_	_	O
49	and	_	_	O
50	physical	_	_	O
51	performance	_	_	O
52	in	_	_	O
53	patients	_	_	O
54	,	_	_	O
55	who	_	_	O
56	were	_	_	O
57	radically	_	_	O
58	operated	_	_	O
59	for	_	_	O
60	lung	_	_	O
61	cancer	_	_	O
62	.	_	_	O

63	A	_	_	O
64	randomized	_	_	O
65	,	_	_	O
66	assessor	_	_	O
67	-	_	_	O
68	blinded	_	_	O
69	,	_	_	O
70	controlled	_	_	O
71	trial	_	_	O
72	was	_	_	O
73	performed	_	_	O
74	on	_	_	O
75	78	_	_	O
76	patients	_	_	O
77	undergoing	_	_	O
78	lung	_	_	O
79	cancer	_	_	O
80	surgery	_	_	O
81	.	_	_	O

82	The	_	_	O
83	intervention	_	_	O
84	group	_	_	O
85	(	_	_	O
86	IG	_	_	O
87	,	_	_	O
88	n	_	_	O
89	=	_	_	O
90	41	_	_	O
91	)	_	_	O
92	participated	_	_	O
93	in	_	_	O
94	supervised	_	_	O
95	out	_	_	O
96	-	_	_	O
97	patient	_	_	O
98	exercise	_	_	O
99	training	_	_	O
100	sessions	_	_	O
101	,	_	_	O
102	one	_	_	O
103	hour	_	_	O
104	once	_	_	O
105	a	_	_	O
106	week	_	_	O
107	for	_	_	O
108	ten	_	_	O
109	weeks	_	_	O
110	.	_	_	O

111	The	_	_	O
112	sessions	_	_	O
113	were	_	_	O
114	based	_	_	O
115	on	_	_	O
116	aerobic	_	_	O
117	exercises	_	_	O
118	with	_	_	O
119	target	_	_	O
120	intensity	_	_	O
121	of	_	_	O
122	60	_	_	O
123	-	_	_	O
124	80	_	_	O
125	%	_	_	O
126	of	_	_	O
127	work	_	_	O
128	capacity	_	_	O
129	,	_	_	O
130	resistance	_	_	O
131	training	_	_	O
132	and	_	_	O
133	dyspnoea	_	_	O
134	management	_	_	O
135	.	_	_	O

136	The	_	_	O
137	control	_	_	O
138	group	_	_	O
139	(	_	_	O
140	CG	_	_	O
141	,	_	_	O
142	n	_	_	O
143	=	_	_	O
144	37	_	_	O
145	)	_	_	O
146	received	_	_	O
147	one	_	_	O
148	individual	_	_	O
149	instruction	_	_	O
150	in	_	_	O
151	exercise	_	_	O
152	training	_	_	O
153	.	_	_	O

154	Measurements	_	_	O
155	consisted	_	_	O
156	of	_	_	O
157	:	_	_	O
158	health	_	_	O
159	-	_	_	O
160	related	_	_	O
161	quality	_	_	O
162	of	_	_	O
163	life	_	_	O
164	(	_	_	O
165	SF36	_	_	O
166	)	_	_	O
167	,	_	_	O
168	six	_	_	O
169	minute	_	_	O
170	walk	_	_	O
171	test	_	_	O
172	(	_	_	O
173	6MWT	_	_	O
174	)	_	_	O
175	and	_	_	O
176	lung	_	_	O
177	function	_	_	O
178	(	_	_	O
179	spirometry	_	_	O
180	)	_	_	O
181	,	_	_	O
182	assessed	_	_	O
183	three	_	_	O
184	weeks	_	_	O
185	after	_	_	O
186	surgery	_	_	O
187	and	_	_	O
188	after	_	_	O
189	four	_	_	O
190	and	_	_	O
191	twelve	_	_	O
192	months	_	_	O
193	.	_	_	O

194	Both	_	_	O
195	groups	_	_	O
196	were	_	_	O
197	comparable	_	_	O
198	at	_	_	O
199	baseline	_	_	O
200	on	_	_	O
201	demographic	_	_	O
202	characteristic	_	_	O
203	and	_	_	O
204	outcome	_	_	O
205	values	_	_	O
206	.	_	_	O

207	We	_	_	B-Premise
208	found	_	_	I-Premise
209	a	_	_	I-Premise
210	statistically	_	_	I-Premise
211	significant	_	_	I-Premise
212	effect	_	_	I-Premise
213	after	_	_	I-Premise
214	four	_	_	I-Premise
215	months	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	bodily	_	_	I-Premise
219	pain	_	_	I-Premise
220	domain	_	_	I-Premise
221	of	_	_	I-Premise
222	SF36	_	_	I-Premise
223	,	_	_	I-Premise
224	with	_	_	I-Premise
225	an	_	_	I-Premise
226	estimated	_	_	I-Premise
227	mean	_	_	I-Premise
228	difference	_	_	I-Premise
229	(	_	_	I-Premise
230	EMD	_	_	I-Premise
231	)	_	_	I-Premise
232	of	_	_	I-Premise
233	15	_	_	I-Premise
234	.	_	_	I-Premise

235	3	_	_	I-Premise
236	(	_	_	I-Premise
237	95	_	_	I-Premise
238	%	_	_	I-Premise
239	CI	_	_	I-Premise
240	:	_	_	I-Premise
241	4	_	_	I-Premise
242	to	_	_	I-Premise
243	26	_	_	I-Premise
244	.	_	_	I-Premise

245	6	_	_	I-Premise
246	,	_	_	I-Premise
247	p	_	_	I-Premise
248	=	_	_	I-Premise
249	0	_	_	I-Premise
250	.	_	_	I-Premise

251	01	_	_	I-Premise
252	)	_	_	I-Premise
253	and	_	_	I-Premise
254	a	_	_	I-Premise
255	trend	_	_	I-Premise
256	in	_	_	I-Premise
257	favour	_	_	I-Premise
258	of	_	_	I-Premise
259	the	_	_	I-Premise
260	intervention	_	_	I-Premise
261	for	_	_	I-Premise
262	role	_	_	I-Premise
263	physical	_	_	I-Premise
264	functioning	_	_	I-Premise
265	(	_	_	I-Premise
266	EMD	_	_	I-Premise
267	12	_	_	I-Premise
268	.	_	_	I-Premise

269	04	_	_	I-Premise
270	,	_	_	I-Premise
271	95	_	_	I-Premise
272	%	_	_	I-Premise
273	CI	_	_	I-Premise
274	:	_	_	I-Premise
275	-	_	_	I-Premise
276	1	_	_	I-Premise
277	to	_	_	I-Premise
278	25	_	_	I-Premise
279	.	_	_	I-Premise

280	1	_	_	I-Premise
281	,	_	_	I-Premise
282	p	_	_	I-Premise
283	=	_	_	I-Premise
284	0	_	_	I-Premise
285	.	_	_	I-Premise

286	07	_	_	I-Premise
287	)	_	_	I-Premise
288	and	_	_	I-Premise
289	physical	_	_	I-Premise
290	component	_	_	I-Premise
291	summary	_	_	I-Premise
292	(	_	_	I-Premise
293	EMD	_	_	I-Premise
294	3	_	_	I-Premise
295	.	_	_	I-Premise

296	76	_	_	I-Premise
297	,	_	_	I-Premise
298	95	_	_	I-Premise
299	%	_	_	I-Premise
300	CI	_	_	I-Premise
301	:	_	_	I-Premise
302	-	_	_	I-Premise
303	0	_	_	I-Premise
304	.	_	_	I-Premise

305	1	_	_	I-Premise
306	to	_	_	I-Premise
307	7	_	_	I-Premise
308	.	_	_	I-Premise

309	6	_	_	I-Premise
310	,	_	_	I-Premise
311	p	_	_	I-Premise
312	=	_	_	I-Premise
313	0	_	_	I-Premise
314	.	_	_	I-Premise

315	06	_	_	I-Premise
316	)	_	_	I-Premise
317	.	_	_	I-Premise

318	At	_	_	B-Premise
319	12	_	_	I-Premise
320	months	_	_	I-Premise
321	,	_	_	I-Premise
322	the	_	_	I-Premise
323	tendency	_	_	I-Premise
324	was	_	_	I-Premise
325	reversed	_	_	I-Premise
326	,	_	_	I-Premise
327	with	_	_	I-Premise
328	the	_	_	I-Premise
329	CG	_	_	I-Premise
330	presenting	_	_	I-Premise
331	overall	_	_	I-Premise
332	slightly	_	_	I-Premise
333	better	_	_	I-Premise
334	measures	_	_	I-Premise
335	.	_	_	I-Premise

336	We	_	_	B-Claim
337	found	_	_	I-Claim
338	no	_	_	I-Claim
339	effect	_	_	I-Claim
340	of	_	_	I-Claim
341	the	_	_	I-Claim
342	intervention	_	_	I-Claim
343	on	_	_	I-Claim
344	6MWT	_	_	I-Claim
345	or	_	_	I-Claim
346	lung	_	_	I-Claim
347	volumes	_	_	I-Claim
348	at	_	_	I-Claim
349	any	_	_	I-Claim
350	time	_	_	I-Claim
351	-	_	_	I-Claim
352	point	_	_	I-Claim
353	.	_	_	I-Claim

354	Supervised	_	_	B-Claim
355	compared	_	_	I-Claim
356	to	_	_	I-Claim
357	unsupervised	_	_	I-Claim
358	exercise	_	_	I-Claim
359	training	_	_	I-Claim
360	resulted	_	_	I-Claim
361	in	_	_	I-Claim
362	no	_	_	I-Claim
363	improvement	_	_	I-Claim
364	in	_	_	I-Claim
365	health	_	_	I-Claim
366	-	_	_	I-Claim
367	related	_	_	I-Claim
368	quality	_	_	I-Claim
369	of	_	_	I-Claim
370	life	_	_	I-Claim
371	,	_	_	I-Claim
372	except	_	_	B-Claim
373	for	_	_	I-Claim
374	the	_	_	I-Claim
375	bodily	_	_	I-Claim
376	pain	_	_	I-Claim
377	domain	_	_	I-Claim
378	,	_	_	I-Claim
379	four	_	_	I-Claim
380	months	_	_	I-Claim
381	after	_	_	I-Claim
382	lung	_	_	I-Claim
383	cancer	_	_	I-Claim
384	surgery	_	_	I-Claim
385	.	_	_	I-Claim

386	No	_	_	B-Claim
387	effects	_	_	I-Claim
388	of	_	_	I-Claim
389	the	_	_	I-Claim
390	intervention	_	_	I-Claim
391	were	_	_	I-Claim
392	found	_	_	I-Claim
393	for	_	_	I-Claim
394	any	_	_	I-Claim
395	outcome	_	_	I-Claim
396	after	_	_	I-Claim
397	one	_	_	I-Claim
398	year	_	_	I-Claim
399	.	_	_	I-Claim


0	Fatigue	_	_	O
1	is	_	_	O
2	one	_	_	O
3	of	_	_	O
4	the	_	_	O
5	most	_	_	O
6	common	_	_	O
7	symptoms	_	_	O
8	experienced	_	_	O
9	by	_	_	O
10	patients	_	_	O
11	with	_	_	O
12	cancer	_	_	O
13	.	_	_	O

14	This	_	_	O
15	trial	_	_	O
16	was	_	_	O
17	developed	_	_	O
18	to	_	_	O
19	evaluate	_	_	O
20	the	_	_	O
21	efficacy	_	_	O
22	of	_	_	O
23	long	_	_	O
24	-	_	_	O
25	acting	_	_	O
26	methylphenidate	_	_	O
27	for	_	_	O
28	improving	_	_	O
29	cancer	_	_	O
30	-	_	_	O
31	related	_	_	O
32	fatigue	_	_	O
33	and	_	_	O
34	to	_	_	O
35	assess	_	_	O
36	its	_	_	O
37	toxicities	_	_	O
38	.	_	_	O

39	Adults	_	_	O
40	with	_	_	O
41	cancer	_	_	O
42	were	_	_	O
43	randomly	_	_	O
44	assigned	_	_	O
45	in	_	_	O
46	a	_	_	O
47	double	_	_	O
48	-	_	_	O
49	blinded	_	_	O
50	manner	_	_	O
51	to	_	_	O
52	receive	_	_	O
53	methylphenidate	_	_	O
54	(	_	_	O
55	target	_	_	O
56	dose	_	_	O
57	,	_	_	O
58	54	_	_	O
59	mg	_	_	O
60	/	_	_	O
61	d	_	_	O
62	)	_	_	O
63	or	_	_	O
64	placebo	_	_	O
65	for	_	_	O
66	4	_	_	O
67	weeks	_	_	O
68	.	_	_	O

69	The	_	_	O
70	Brief	_	_	O
71	Fatigue	_	_	O
72	Inventory	_	_	O
73	was	_	_	O
74	the	_	_	O
75	primary	_	_	O
76	outcome	_	_	O
77	measure	_	_	O
78	,	_	_	O
79	while	_	_	O
80	secondary	_	_	O
81	outcome	_	_	O
82	measures	_	_	O
83	included	_	_	O
84	a	_	_	O
85	Symptom	_	_	O
86	Experience	_	_	O
87	Diary	_	_	O
88	(	_	_	O
89	SED	_	_	O
90	)	_	_	O
91	,	_	_	O
92	the	_	_	O
93	Short	_	_	O
94	Form	_	_	O
95	-	_	_	O
96	36	_	_	O
97	(	_	_	O
98	SF	_	_	O
99	-	_	_	O
100	36	_	_	O
101	)	_	_	O
102	Vitality	_	_	O
103	Subscale	_	_	O
104	,	_	_	O
105	a	_	_	O
106	linear	_	_	O
107	analog	_	_	O
108	self	_	_	O
109	-	_	_	O
110	assessment	_	_	O
111	,	_	_	O
112	the	_	_	O
113	Pittsburgh	_	_	O
114	Sleep	_	_	O
115	Quality	_	_	O
116	Index	_	_	O
117	,	_	_	O
118	and	_	_	O
119	the	_	_	O
120	Subject	_	_	O
121	Global	_	_	O
122	Impression	_	_	O
123	of	_	_	O
124	Change	_	_	O
125	.	_	_	O

126	In	_	_	O
127	total	_	_	O
128	,	_	_	O
129	148	_	_	O
130	patients	_	_	O
131	were	_	_	O
132	enrolled	_	_	O
133	.	_	_	O

134	Using	_	_	B-Premise
135	an	_	_	I-Premise
136	area	_	_	I-Premise
137	under	_	_	I-Premise
138	the	_	_	I-Premise
139	serum	_	_	I-Premise
140	concentration	_	_	I-Premise
141	-	_	_	I-Premise
142	time	_	_	I-Premise
143	curve	_	_	I-Premise
144	analysis	_	_	I-Premise
145	,	_	_	I-Premise
146	there	_	_	I-Premise
147	was	_	_	I-Premise
148	no	_	_	I-Premise
149	evidence	_	_	I-Premise
150	that	_	_	I-Premise
151	methylphenidate	_	_	I-Premise
152	,	_	_	I-Premise
153	as	_	_	I-Premise
154	compared	_	_	I-Premise
155	with	_	_	I-Premise
156	placebo	_	_	I-Premise
157	,	_	_	I-Premise
158	improved	_	_	I-Premise
159	the	_	_	I-Premise
160	primary	_	_	I-Premise
161	end	_	_	I-Premise
162	point	_	_	I-Premise
163	of	_	_	I-Premise
164	cancer	_	_	I-Premise
165	-	_	_	I-Premise
166	related	_	_	I-Premise
167	fatigue	_	_	I-Premise
168	in	_	_	I-Premise
169	this	_	_	I-Premise
170	patient	_	_	I-Premise
171	population	_	_	I-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	=	_	_	I-Premise
175	.	_	_	I-Premise

176	35	_	_	I-Premise
177	)	_	_	I-Premise
178	.	_	_	I-Premise

179	Comparisons	_	_	B-Premise
180	of	_	_	I-Premise
181	secondary	_	_	I-Premise
182	end	_	_	I-Premise
183	points	_	_	I-Premise
184	,	_	_	I-Premise
185	including	_	_	I-Premise
186	clinically	_	_	I-Premise
187	significant	_	_	I-Premise
188	changes	_	_	I-Premise
189	in	_	_	I-Premise
190	quality	_	_	I-Premise
191	-	_	_	I-Premise
192	of	_	_	I-Premise
193	-	_	_	I-Premise
194	life	_	_	I-Premise
195	variables	_	_	I-Premise
196	and	_	_	I-Premise
197	cancer	_	_	I-Premise
198	-	_	_	I-Premise
199	related	_	_	I-Premise
200	fatigue	_	_	I-Premise
201	change	_	_	I-Premise
202	from	_	_	I-Premise
203	baseline	_	_	I-Premise
204	,	_	_	I-Premise
205	were	_	_	I-Premise
206	similarly	_	_	I-Premise
207	negative	_	_	I-Premise
208	.	_	_	I-Premise

209	However	_	_	B-Premise
210	,	_	_	I-Premise
211	a	_	_	I-Premise
212	subset	_	_	I-Premise
213	analysis	_	_	I-Premise
214	suggested	_	_	I-Premise
215	that	_	_	I-Premise
216	patients	_	_	I-Premise
217	with	_	_	I-Premise
218	more	_	_	I-Premise
219	severe	_	_	I-Premise
220	fatigue	_	_	I-Premise
221	and	_	_	I-Premise
222	/	_	_	I-Premise
223	or	_	_	I-Premise
224	with	_	_	I-Premise
225	more	_	_	I-Premise
226	advanced	_	_	I-Premise
227	disease	_	_	I-Premise
228	did	_	_	I-Premise
229	have	_	_	I-Premise
230	some	_	_	I-Premise
231	fatigue	_	_	I-Premise
232	improvement	_	_	I-Premise
233	with	_	_	I-Premise
234	methylphenidate	_	_	I-Premise
235	(	_	_	I-Premise
236	eg	_	_	I-Premise
237	,	_	_	I-Premise
238	in	_	_	I-Premise
239	patients	_	_	I-Premise
240	with	_	_	I-Premise
241	stage	_	_	I-Premise
242	III	_	_	I-Premise
243	or	_	_	I-Premise
244	IV	_	_	I-Premise
245	disease	_	_	I-Premise
246	,	_	_	I-Premise
247	the	_	_	I-Premise
248	mean	_	_	I-Premise
249	improvement	_	_	I-Premise
250	in	_	_	I-Premise
251	usual	_	_	I-Premise
252	fatigue	_	_	I-Premise
253	was	_	_	I-Premise
254	19	_	_	I-Premise
255	.	_	_	I-Premise

256	7	_	_	I-Premise
257	with	_	_	I-Premise
258	methylphenidate	_	_	I-Premise
259	v	_	_	I-Premise
260	2	_	_	I-Premise
261	.	_	_	I-Premise

262	1	_	_	I-Premise
263	with	_	_	I-Premise
264	placebo	_	_	I-Premise
265	;	_	_	I-Premise
266	P	_	_	I-Premise
267	=	_	_	I-Premise
268	.	_	_	I-Premise

269	02	_	_	I-Premise
270	)	_	_	I-Premise
271	.	_	_	I-Premise

272	There	_	_	B-Premise
273	was	_	_	I-Premise
274	a	_	_	I-Premise
275	significant	_	_	I-Premise
276	difference	_	_	I-Premise
277	in	_	_	I-Premise
278	self	_	_	I-Premise
279	-	_	_	I-Premise
280	reported	_	_	I-Premise
281	toxicities	_	_	I-Premise
282	(	_	_	I-Premise
283	SED	_	_	I-Premise
284	)	_	_	I-Premise
285	,	_	_	I-Premise
286	with	_	_	I-Premise
287	increased	_	_	I-Premise
288	levels	_	_	I-Premise
289	of	_	_	I-Premise
290	nervousness	_	_	I-Premise
291	and	_	_	I-Premise
292	appetite	_	_	I-Premise
293	loss	_	_	I-Premise
294	in	_	_	I-Premise
295	the	_	_	I-Premise
296	methylphenidate	_	_	I-Premise
297	arm	_	_	I-Premise
298	.	_	_	I-Premise

299	This	_	_	B-Claim
300	clinical	_	_	I-Claim
301	trial	_	_	I-Claim
302	was	_	_	I-Claim
303	unable	_	_	I-Claim
304	to	_	_	I-Claim
305	support	_	_	I-Claim
306	the	_	_	I-Claim
307	primary	_	_	I-Claim
308	prestudy	_	_	I-Claim
309	hypothesis	_	_	I-Claim
310	that	_	_	I-Claim
311	the	_	_	I-Claim
312	chosen	_	_	I-Claim
313	long	_	_	I-Claim
314	-	_	_	I-Claim
315	acting	_	_	I-Claim
316	methylphenidate	_	_	I-Claim
317	product	_	_	I-Claim
318	would	_	_	I-Claim
319	decrease	_	_	I-Claim
320	cancer	_	_	I-Claim
321	-	_	_	I-Claim
322	related	_	_	I-Claim
323	fatigue	_	_	I-Claim
324	.	_	_	I-Claim


0	Patients	_	_	O
1	receiving	_	_	O
2	chemoradiation	_	_	O
3	for	_	_	O
4	cervical	_	_	O
5	cancer	_	_	O
6	are	_	_	O
7	at	_	_	O
8	risk	_	_	O
9	for	_	_	O
10	distress	_	_	O
11	,	_	_	O
12	chemoradiation	_	_	O
13	-	_	_	O
14	related	_	_	O
15	side	_	_	O
16	-	_	_	O
17	effects	_	_	O
18	,	_	_	O
19	and	_	_	O
20	immunosuppression	_	_	O
21	.	_	_	O

22	This	_	_	O
23	prospective	_	_	O
24	randomized	_	_	O
25	clinical	_	_	O
26	trial	_	_	O
27	examined	_	_	O
28	effects	_	_	O
29	of	_	_	O
30	a	_	_	O
31	complementary	_	_	O
32	therapy	_	_	O
33	,	_	_	O
34	Healing	_	_	O
35	Touch	_	_	O
36	(	_	_	O
37	HT	_	_	O
38	)	_	_	O
39	,	_	_	O
40	versus	_	_	O
41	relaxation	_	_	O
42	training	_	_	O
43	(	_	_	O
44	RT	_	_	O
45	)	_	_	O
46	and	_	_	O
47	usual	_	_	O
48	care	_	_	O
49	(	_	_	O
50	UC	_	_	O
51	)	_	_	O
52	for	_	_	O
53	(	_	_	O
54	1	_	_	O
55	)	_	_	O
56	supporting	_	_	O
57	cellular	_	_	O
58	immunity	_	_	O
59	,	_	_	O
60	(	_	_	O
61	2	_	_	O
62	)	_	_	O
63	improving	_	_	O
64	mood	_	_	O
65	and	_	_	O
66	quality	_	_	O
67	of	_	_	O
68	life	_	_	O
69	(	_	_	O
70	QOL	_	_	O
71	)	_	_	O
72	,	_	_	O
73	and	_	_	O
74	(	_	_	O
75	3	_	_	O
76	)	_	_	O
77	reducing	_	_	O
78	treatment	_	_	O
79	-	_	_	O
80	associated	_	_	O
81	toxicities	_	_	O
82	and	_	_	O
83	treatment	_	_	O
84	delay	_	_	O
85	in	_	_	O
86	cervical	_	_	O
87	cancer	_	_	O
88	patients	_	_	O
89	receiving	_	_	O
90	chemoradiation	_	_	O
91	.	_	_	O

92	Sixty	_	_	O
93	women	_	_	O
94	with	_	_	O
95	stages	_	_	O
96	IB1	_	_	O
97	to	_	_	O
98	IVA	_	_	O
99	cervical	_	_	O
100	cancer	_	_	O
101	were	_	_	O
102	randomly	_	_	O
103	assigned	_	_	O
104	to	_	_	O
105	receive	_	_	O
106	UC	_	_	O
107	or	_	_	O
108	4	_	_	O
109	×	_	_	O
110	/	_	_	O
111	weekly	_	_	O
112	individual	_	_	O
113	sessions	_	_	O
114	of	_	_	O
115	either	_	_	O
116	HT	_	_	O
117	or	_	_	O
118	RT	_	_	O
119	immediately	_	_	O
120	following	_	_	O
121	radiation	_	_	O
122	during	_	_	O
123	their	_	_	O
124	6	_	_	O
125	-	_	_	O
126	week	_	_	O
127	chemoradiation	_	_	O
128	treatment	_	_	O
129	.	_	_	O

130	Patients	_	_	O
131	completed	_	_	O
132	psychosocial	_	_	O
133	assessments	_	_	O
134	and	_	_	O
135	blood	_	_	O
136	sampling	_	_	O
137	before	_	_	O
138	chemoradiation	_	_	O
139	at	_	_	O
140	baseline	_	_	O
141	,	_	_	O
142	weeks	_	_	O
143	4	_	_	O
144	and	_	_	O
145	6	_	_	O
146	.	_	_	O

147	Multilevel	_	_	O
148	regression	_	_	O
149	analyses	_	_	O
150	using	_	_	O
151	orthogonal	_	_	O
152	contrasts	_	_	O
153	tested	_	_	O
154	for	_	_	O
155	differences	_	_	O
156	between	_	_	O
157	treatment	_	_	O
158	conditions	_	_	O
159	over	_	_	O
160	time	_	_	O
161	.	_	_	O

162	HT	_	_	B-Premise
163	patients	_	_	I-Premise
164	had	_	_	I-Premise
165	a	_	_	I-Premise
166	minimal	_	_	I-Premise
167	decrease	_	_	I-Premise
168	in	_	_	I-Premise
169	natural	_	_	I-Premise
170	killer	_	_	I-Premise
171	cell	_	_	I-Premise
172	cytotoxicity	_	_	I-Premise
173	(	_	_	I-Premise
174	NKCC	_	_	I-Premise
175	)	_	_	I-Premise
176	over	_	_	I-Premise
177	the	_	_	I-Premise
178	course	_	_	I-Premise
179	of	_	_	I-Premise
180	treatment	_	_	I-Premise
181	whereas	_	_	I-Premise
182	NKCC	_	_	I-Premise
183	of	_	_	I-Premise
184	RT	_	_	I-Premise
185	and	_	_	I-Premise
186	UC	_	_	I-Premise
187	patients	_	_	I-Premise
188	declined	_	_	I-Premise
189	sharply	_	_	I-Premise
190	during	_	_	I-Premise
191	chemoradiation	_	_	I-Premise
192	(	_	_	I-Premise
193	group	_	_	I-Premise
194	by	_	_	I-Premise
195	time	_	_	I-Premise
196	interaction	_	_	I-Premise
197	:	_	_	I-Premise
198	p	_	_	I-Premise
199	=	_	_	I-Premise
200	0	_	_	I-Premise
201	.	_	_	I-Premise

202	018	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	HT	_	_	B-Premise
206	patients	_	_	I-Premise
207	showed	_	_	I-Premise
208	greater	_	_	I-Premise
209	decreases	_	_	I-Premise
210	in	_	_	I-Premise
211	two	_	_	I-Premise
212	different	_	_	I-Premise
213	indicators	_	_	I-Premise
214	of	_	_	I-Premise
215	depressed	_	_	I-Premise
216	mood	_	_	I-Premise
217	(	_	_	I-Premise
218	CES	_	_	I-Premise
219	-	_	_	I-Premise
220	D	_	_	I-Premise
221	depressed	_	_	I-Premise
222	mood	_	_	I-Premise
223	subscale	_	_	I-Premise
224	and	_	_	I-Premise
225	POMS	_	_	I-Premise
226	depression	_	_	I-Premise
227	scale	_	_	I-Premise
228	)	_	_	I-Premise
229	compared	_	_	I-Premise
230	to	_	_	I-Premise
231	RT	_	_	I-Premise
232	and	_	_	I-Premise
233	UC	_	_	I-Premise
234	(	_	_	I-Premise
235	group	_	_	I-Premise
236	by	_	_	I-Premise
237	time	_	_	I-Premise
238	interactions	_	_	I-Premise
239	:	_	_	I-Premise
240	p	_	_	I-Premise
241	<	_	_	I-Premise
242	0	_	_	I-Premise
243	.	_	_	I-Premise

244	05	_	_	I-Premise
245	)	_	_	I-Premise
246	.	_	_	I-Premise

247	No	_	_	B-Premise
248	between	_	_	I-Premise
249	group	_	_	I-Premise
250	differences	_	_	I-Premise
251	were	_	_	I-Premise
252	observed	_	_	I-Premise
253	in	_	_	I-Premise
254	QOL	_	_	I-Premise
255	,	_	_	I-Premise
256	treatment	_	_	I-Premise
257	delay	_	_	I-Premise
258	,	_	_	I-Premise
259	or	_	_	I-Premise
260	clinically	_	_	I-Premise
261	-	_	_	I-Premise
262	rated	_	_	I-Premise
263	toxicities	_	_	I-Premise
264	.	_	_	I-Premise

265	HT	_	_	B-Claim
266	may	_	_	I-Claim
267	benefit	_	_	I-Claim
268	cervical	_	_	I-Claim
269	cancer	_	_	I-Claim
270	patients	_	_	I-Claim
271	by	_	_	I-Claim
272	moderating	_	_	I-Claim
273	effects	_	_	I-Claim
274	of	_	_	I-Claim
275	chemoradiation	_	_	I-Claim
276	on	_	_	I-Claim
277	depressed	_	_	I-Claim
278	mood	_	_	I-Claim
279	and	_	_	I-Claim
280	cellular	_	_	I-Claim
281	immunity	_	_	I-Claim
282	.	_	_	I-Claim

283	Effects	_	_	B-Claim
284	of	_	_	I-Claim
285	HT	_	_	I-Claim
286	on	_	_	I-Claim
287	toxicities	_	_	I-Claim
288	,	_	_	I-Claim
289	treatment	_	_	I-Claim
290	delay	_	_	I-Claim
291	,	_	_	I-Claim
292	QOL	_	_	I-Claim
293	,	_	_	I-Claim
294	and	_	_	I-Claim
295	fatigue	_	_	I-Claim
296	were	_	_	I-Claim
297	not	_	_	I-Claim
298	observed	_	_	I-Claim
299	.	_	_	I-Claim

300	Long	_	_	O
301	-	_	_	O
302	term	_	_	O
303	clinical	_	_	O
304	implications	_	_	O
305	of	_	_	O
306	findings	_	_	O
307	are	_	_	O
308	not	_	_	O
309	known	_	_	O
310	.	_	_	O


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	'	_	_	O
8	Casodex	_	_	O
9	'	_	_	O
10	monotherapy	_	_	O
11	(	_	_	O
12	150	_	_	O
13	mg	_	_	O
14	daily	_	_	O
15	)	_	_	O
16	for	_	_	O
17	metastatic	_	_	O
18	and	_	_	O
19	locally	_	_	O
20	advanced	_	_	O
21	prostate	_	_	O
22	cancer	_	_	O
23	.	_	_	O

24	A	_	_	O
25	total	_	_	O
26	of	_	_	O
27	1	_	_	O
28	,	_	_	O
29	453	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	either	_	_	O
33	confirmed	_	_	O
34	metastatic	_	_	O
35	disease	_	_	O
36	(	_	_	O
37	M1	_	_	O
38	)	_	_	O
39	,	_	_	O
40	or	_	_	O
41	T3	_	_	O
42	/	_	_	O
43	T4	_	_	O
44	non	_	_	O
45	-	_	_	O
46	metastatic	_	_	O
47	disease	_	_	O
48	with	_	_	O
49	elevated	_	_	O
50	prostate	_	_	O
51	-	_	_	O
52	specific	_	_	O
53	antigen	_	_	O
54	(	_	_	O
55	M0	_	_	O
56	)	_	_	O
57	were	_	_	O
58	recruited	_	_	O
59	into	_	_	O
60	one	_	_	O
61	of	_	_	O
62	two	_	_	O
63	identical	_	_	O
64	,	_	_	O
65	multicentre	_	_	O
66	,	_	_	O
67	randomised	_	_	O
68	studies	_	_	O
69	to	_	_	O
70	compare	_	_	O
71	'	_	_	O
72	Casodex	_	_	O
73	'	_	_	O
74	150	_	_	O
75	mg	_	_	O
76	/	_	_	O
77	day	_	_	O
78	with	_	_	O
79	castration	_	_	O
80	.	_	_	O

81	The	_	_	O
82	protocols	_	_	O
83	allowed	_	_	O
84	for	_	_	O
85	combined	_	_	O
86	analysis	_	_	O
87	.	_	_	O

88	At	_	_	B-Premise
89	a	_	_	I-Premise
90	median	_	_	I-Premise
91	follow	_	_	I-Premise
92	-	_	_	I-Premise
93	up	_	_	I-Premise
94	period	_	_	I-Premise
95	of	_	_	I-Premise
96	approximately	_	_	I-Premise
97	100	_	_	I-Premise
98	weeks	_	_	I-Premise
99	for	_	_	I-Premise
100	both	_	_	I-Premise
101	studies	_	_	I-Premise
102	,	_	_	I-Premise
103	'	_	_	I-Premise
104	Casodex	_	_	I-Premise
105	'	_	_	I-Premise
106	150	_	_	I-Premise
107	mg	_	_	I-Premise
108	was	_	_	I-Premise
109	found	_	_	I-Premise
110	to	_	_	I-Premise
111	be	_	_	I-Premise
112	less	_	_	I-Premise
113	effective	_	_	I-Premise
114	than	_	_	I-Premise
115	castration	_	_	I-Premise
116	in	_	_	I-Premise
117	patients	_	_	I-Premise
118	with	_	_	I-Premise
119	metastatic	_	_	I-Premise
120	disease	_	_	I-Premise
121	(	_	_	I-Premise
122	M1	_	_	I-Premise
123	)	_	_	I-Premise
124	at	_	_	I-Premise
125	entry	_	_	I-Premise
126	(	_	_	I-Premise
127	hazard	_	_	I-Premise
128	ratio	_	_	I-Premise
129	of	_	_	I-Premise
130	1	_	_	I-Premise
131	.	_	_	I-Premise

132	30	_	_	I-Premise
133	for	_	_	I-Premise
134	time	_	_	I-Premise
135	to	_	_	I-Premise
136	death	_	_	I-Premise
137	)	_	_	I-Premise
138	with	_	_	I-Premise
139	a	_	_	I-Premise
140	difference	_	_	I-Premise
141	in	_	_	I-Premise
142	median	_	_	I-Premise
143	survival	_	_	I-Premise
144	of	_	_	I-Premise
145	6	_	_	I-Premise
146	weeks	_	_	I-Premise
147	.	_	_	I-Premise

148	In	_	_	B-Premise
149	symptomatic	_	_	I-Premise
150	M1	_	_	I-Premise
151	patients	_	_	I-Premise
152	,	_	_	I-Premise
153	'	_	_	I-Premise
154	Casodex	_	_	I-Premise
155	'	_	_	I-Premise
156	was	_	_	I-Premise
157	associated	_	_	I-Premise
158	with	_	_	I-Premise
159	a	_	_	I-Premise
160	statistically	_	_	I-Premise
161	significant	_	_	I-Premise
162	improvement	_	_	I-Premise
163	in	_	_	I-Premise
164	subjective	_	_	I-Premise
165	response	_	_	I-Premise
166	(	_	_	I-Premise
167	70	_	_	I-Premise
168	%	_	_	I-Premise
169	)	_	_	I-Premise
170	compared	_	_	I-Premise
171	with	_	_	I-Premise
172	castration	_	_	I-Premise
173	(	_	_	I-Premise
174	58	_	_	I-Premise
175	%	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Analysis	_	_	B-Premise
179	of	_	_	I-Premise
180	a	_	_	I-Premise
181	validated	_	_	I-Premise
182	quality	_	_	I-Premise
183	-	_	_	I-Premise
184	of	_	_	I-Premise
185	-	_	_	I-Premise
186	life	_	_	I-Premise
187	questionnaire	_	_	I-Premise
188	proved	_	_	I-Premise
189	an	_	_	I-Premise
190	advantage	_	_	I-Premise
191	for	_	_	I-Premise
192	'	_	_	I-Premise
193	Casodex	_	_	I-Premise
194	'	_	_	I-Premise
195	in	_	_	I-Premise
196	sexual	_	_	I-Premise
197	interest	_	_	I-Premise
198	and	_	_	I-Premise
199	physical	_	_	I-Premise
200	capacity	_	_	I-Premise
201	.	_	_	I-Premise

202	'	_	_	B-Premise
203	Casodex	_	_	I-Premise
204	'	_	_	I-Premise
205	had	_	_	I-Premise
206	a	_	_	I-Premise
207	substantially	_	_	I-Premise
208	lower	_	_	I-Premise
209	incidence	_	_	I-Premise
210	of	_	_	I-Premise
211	hot	_	_	I-Premise
212	flushes	_	_	I-Premise
213	compared	_	_	I-Premise
214	to	_	_	I-Premise
215	castration	_	_	I-Premise
216	(	_	_	I-Premise
217	6	_	_	I-Premise
218	-	_	_	I-Premise
219	13	_	_	I-Premise
220	%	_	_	I-Premise
221	compared	_	_	I-Premise
222	with	_	_	I-Premise
223	39	_	_	I-Premise
224	-	_	_	I-Premise
225	44	_	_	I-Premise
226	%	_	_	I-Premise
227	)	_	_	I-Premise
228	and	_	_	I-Premise
229	the	_	_	I-Premise
230	most	_	_	I-Premise
231	commonly	_	_	I-Premise
232	reported	_	_	I-Premise
233	adverse	_	_	I-Premise
234	events	_	_	I-Premise
235	were	_	_	I-Premise
236	those	_	_	I-Premise
237	expected	_	_	I-Premise
238	for	_	_	I-Premise
239	a	_	_	I-Premise
240	potent	_	_	I-Premise
241	antiandrogen	_	_	I-Premise
242	.	_	_	I-Premise

243	However	_	_	O
244	,	_	_	O
245	in	_	_	B-Claim
246	patients	_	_	I-Claim
247	with	_	_	I-Claim
248	M0	_	_	I-Claim
249	disease	_	_	I-Claim
250	at	_	_	I-Claim
251	entry	_	_	I-Claim
252	,	_	_	I-Claim
253	the	_	_	I-Claim
254	data	_	_	I-Claim
255	are	_	_	I-Claim
256	still	_	_	I-Claim
257	immature	_	_	I-Claim
258	with	_	_	I-Claim
259	only	_	_	I-Claim
260	13	_	_	I-Claim
261	%	_	_	I-Claim
262	of	_	_	I-Claim
263	M0	_	_	I-Claim
264	patients	_	_	I-Claim
265	having	_	_	I-Claim
266	died	_	_	I-Claim
267	.	_	_	I-Claim

268	An	_	_	B-Claim
269	initial	_	_	I-Claim
270	analysis	_	_	I-Claim
271	of	_	_	I-Claim
272	this	_	_	I-Claim
273	immature	_	_	I-Claim
274	data	_	_	I-Claim
275	has	_	_	I-Claim
276	suggested	_	_	I-Claim
277	that	_	_	I-Claim
278	the	_	_	I-Claim
279	results	_	_	I-Claim
280	in	_	_	I-Claim
281	these	_	_	I-Claim
282	patients	_	_	I-Claim
283	may	_	_	I-Claim
284	be	_	_	I-Claim
285	different	_	_	I-Claim
286	to	_	_	I-Claim
287	those	_	_	I-Claim
288	obtained	_	_	I-Claim
289	in	_	_	I-Claim
290	patients	_	_	I-Claim
291	with	_	_	I-Claim
292	M1	_	_	I-Claim
293	disease	_	_	I-Claim
294	.	_	_	I-Claim

295	A	_	_	O
296	further	_	_	O
297	survival	_	_	O
298	analysis	_	_	O
299	in	_	_	O
300	patients	_	_	O
301	with	_	_	O
302	M0	_	_	O
303	disease	_	_	O
304	is	_	_	O
305	therefore	_	_	O
306	planned	_	_	O
307	when	_	_	O
308	the	_	_	O
309	data	_	_	O
310	are	_	_	O
311	more	_	_	O
312	mature	_	_	O
313	.	_	_	O

314	'	_	_	B-Claim
315	Casodex	_	_	I-Claim
316	'	_	_	I-Claim
317	150	_	_	I-Claim
318	mg	_	_	I-Claim
319	is	_	_	I-Claim
320	less	_	_	I-Claim
321	effective	_	_	I-Claim
322	than	_	_	I-Claim
323	castration	_	_	I-Claim
324	in	_	_	I-Claim
325	patients	_	_	I-Claim
326	with	_	_	I-Claim
327	M1	_	_	I-Claim
328	disease	_	_	I-Claim
329	.	_	_	I-Claim

330	However	_	_	O
331	,	_	_	O
332	'	_	_	B-Claim
333	Casodex	_	_	I-Claim
334	'	_	_	I-Claim
335	has	_	_	I-Claim
336	shown	_	_	I-Claim
337	a	_	_	I-Claim
338	benefit	_	_	I-Claim
339	in	_	_	I-Claim
340	terms	_	_	I-Claim
341	of	_	_	I-Claim
342	quality	_	_	I-Claim
343	of	_	_	I-Claim
344	life	_	_	I-Claim
345	and	_	_	I-Claim
346	subjective	_	_	I-Claim
347	response	_	_	I-Claim
348	when	_	_	I-Claim
349	compared	_	_	I-Claim
350	to	_	_	I-Claim
351	castration	_	_	I-Claim
352	and	_	_	I-Claim
353	has	_	_	I-Claim
354	an	_	_	I-Claim
355	acceptable	_	_	I-Claim
356	tolerability	_	_	I-Claim
357	profile	_	_	I-Claim
358	.	_	_	I-Claim

359	Thus	_	_	B-Claim
360	'	_	_	I-Claim
361	Casodex	_	_	I-Claim
362	'	_	_	I-Claim
363	150	_	_	I-Claim
364	mg	_	_	I-Claim
365	monotherapy	_	_	I-Claim
366	is	_	_	I-Claim
367	an	_	_	I-Claim
368	option	_	_	I-Claim
369	for	_	_	I-Claim
370	patients	_	_	I-Claim
371	with	_	_	I-Claim
372	M1	_	_	I-Claim
373	prostate	_	_	I-Claim
374	cancer	_	_	I-Claim
375	for	_	_	I-Claim
376	whom	_	_	I-Claim
377	surgical	_	_	I-Claim
378	or	_	_	I-Claim
379	medical	_	_	I-Claim
380	castration	_	_	I-Claim
381	is	_	_	I-Claim
382	not	_	_	I-Claim
383	indicated	_	_	I-Claim
384	or	_	_	I-Claim
385	is	_	_	I-Claim
386	not	_	_	I-Claim
387	acceptable	_	_	I-Claim
388	.	_	_	I-Claim


0	Low	_	_	B-Claim
1	anterior	_	_	I-Claim
2	resection	_	_	I-Claim
3	with	_	_	I-Claim
4	coloanal	_	_	I-Claim
5	anastomosis	_	_	I-Claim
6	prevents	_	_	I-Claim
7	a	_	_	I-Claim
8	definitive	_	_	I-Claim
9	stoma	_	_	I-Claim
10	in	_	_	I-Claim
11	patients	_	_	I-Claim
12	with	_	_	I-Claim
13	distal	_	_	I-Claim
14	rectal	_	_	I-Claim
15	cancer	_	_	I-Claim
16	.	_	_	I-Claim

17	However	_	_	B-Premise
18	,	_	_	I-Premise
19	imperative	_	_	I-Premise
20	stool	_	_	I-Premise
21	urge	_	_	I-Premise
22	,	_	_	I-Premise
23	stool	_	_	I-Premise
24	fragmentation	_	_	I-Premise
25	,	_	_	I-Premise
26	prolonged	_	_	I-Premise
27	stooling	_	_	I-Premise
28	sessions	_	_	I-Premise
29	,	_	_	I-Premise
30	and	_	_	I-Premise
31	minor	_	_	I-Premise
32	problems	_	_	I-Premise
33	of	_	_	I-Premise
34	incontinence	_	_	I-Premise
35	are	_	_	I-Premise
36	frequently	_	_	I-Premise
37	observed	_	_	I-Premise
38	in	_	_	I-Premise
39	the	_	_	I-Premise
40	postoperative	_	_	I-Premise
41	situation	_	_	I-Premise
42	and	_	_	I-Premise
43	negatively	_	_	I-Premise
44	affect	_	_	I-Premise
45	quality	_	_	I-Premise
46	of	_	_	I-Premise
47	life	_	_	I-Premise
48	.	_	_	I-Premise

49	Therefore	_	_	O
50	,	_	_	O
51	the	_	_	O
52	colonic	_	_	O
53	J	_	_	O
54	-	_	_	O
55	pouch	_	_	O
56	was	_	_	O
57	originally	_	_	O
58	constructed	_	_	O
59	to	_	_	O
60	create	_	_	O
61	a	_	_	O
62	stool	_	_	O
63	reservoir	_	_	O
64	.	_	_	O

65	In	_	_	O
66	a	_	_	O
67	randomized	_	_	O
68	,	_	_	O
69	prospective	_	_	O
70	study	_	_	O
71	,	_	_	O
72	the	_	_	O
73	short	_	_	O
74	(	_	_	O
75	5	_	_	O
76	cm	_	_	O
77	)	_	_	O
78	colonic	_	_	O
79	J	_	_	O
80	-	_	_	O
81	pouch	_	_	O
82	was	_	_	O
83	tested	_	_	O
84	for	_	_	O
85	function	_	_	O
86	and	_	_	O
87	continence	_	_	O
88	vs	_	_	O
89	.	_	_	O

90	straight	_	_	O
91	coloanal	_	_	O
92	anastomosis	_	_	O
93	.	_	_	O

94	Over	_	_	O
95	a	_	_	O
96	period	_	_	O
97	of	_	_	O
98	30	_	_	O
99	months	_	_	O
100	,	_	_	O
101	74	_	_	O
102	consecutive	_	_	O
103	patients	_	_	O
104	(	_	_	O
105	55	_	_	O
106	males	_	_	O
107	)	_	_	O
108	with	_	_	O
109	rectal	_	_	O
110	cancer	_	_	O
111	in	_	_	O
112	the	_	_	O
113	lower	_	_	O
114	and	_	_	O
115	middle	_	_	O
116	third	_	_	O
117	of	_	_	O
118	the	_	_	O
119	rectum	_	_	O
120	were	_	_	O
121	included	_	_	O
122	and	_	_	O
123	randomized	_	_	O
124	into	_	_	O
125	two	_	_	O
126	groups	_	_	O
127	.	_	_	O

128	Anastomosis	_	_	O
129	was	_	_	O
130	performed	_	_	O
131	either	_	_	O
132	as	_	_	O
133	a	_	_	O
134	coloanal	_	_	O
135	or	_	_	O
136	a	_	_	O
137	colon	_	_	O
138	-	_	_	O
139	pouch	_	_	O
140	-	_	_	O
141	anal	_	_	O
142	anastomosis	_	_	O
143	.	_	_	O

144	The	_	_	O
145	standardized	_	_	O
146	surgical	_	_	O
147	procedure	_	_	O
148	included	_	_	O
149	mobilization	_	_	O
150	of	_	_	O
151	the	_	_	O
152	left	_	_	O
153	hemicolon	_	_	O
154	,	_	_	O
155	central	_	_	O
156	ligation	_	_	O
157	of	_	_	O
158	the	_	_	O
159	inferior	_	_	O
160	mesenteric	_	_	O
161	artery	_	_	O
162	and	_	_	O
163	vein	_	_	O
164	,	_	_	O
165	preaortal	_	_	O
166	lymph	_	_	O
167	node	_	_	O
168	dissection	_	_	O
169	,	_	_	O
170	autonomic	_	_	O
171	nerve	_	_	O
172	preservation	_	_	O
173	,	_	_	O
174	and	_	_	O
175	total	_	_	O
176	mesorectal	_	_	O
177	excision	_	_	O
178	.	_	_	O

179	The	_	_	O
180	anastomosis	_	_	O
181	was	_	_	O
182	performed	_	_	O
183	at	_	_	O
184	the	_	_	O
185	upper	_	_	O
186	anal	_	_	O
187	canal	_	_	O
188	or	_	_	O
189	at	_	_	O
190	the	_	_	O
191	intersphincteric	_	_	O
192	level	_	_	O
193	.	_	_	O

194	All	_	_	O
195	patients	_	_	O
196	were	_	_	O
197	evaluated	_	_	O
198	preoperatively	_	_	O
199	and	_	_	O
200	six	_	_	O
201	months	_	_	O
202	postoperatively	_	_	O
203	for	_	_	O
204	fecal	_	_	O
205	continence	_	_	O
206	,	_	_	O
207	including	_	_	O
208	sphincter	_	_	O
209	manometry	_	_	O
210	and	_	_	O
211	defecation	_	_	O
212	habits	_	_	O
213	.	_	_	O

214	In	_	_	O
215	addition	_	_	O
216	,	_	_	O
217	quality	_	_	O
218	of	_	_	O
219	life	_	_	O
220	was	_	_	O
221	determined	_	_	O
222	by	_	_	O
223	use	_	_	O
224	of	_	_	O
225	a	_	_	O
226	standardized	_	_	O
227	questionnaire	_	_	O
228	(	_	_	O
229	European	_	_	O
230	Organization	_	_	O
231	for	_	_	O
232	Research	_	_	O
233	and	_	_	O
234	Treatment	_	_	O
235	of	_	_	O
236	Cancer	_	_	O
237	,	_	_	O
238	EORTC	_	_	O
239	-	_	_	O
240	QLQ	_	_	O
241	-	_	_	O
242	C30	_	_	O
243	)	_	_	O
244	.	_	_	O

245	Thirty	_	_	O
246	-	_	_	O
247	seven	_	_	O
248	patients	_	_	O
249	were	_	_	O
250	randomized	_	_	O
251	into	_	_	O
252	each	_	_	O
253	group	_	_	O
254	.	_	_	O

255	In	_	_	O
256	general	_	_	O
257	,	_	_	O
258	problems	_	_	B-Premise
259	with	_	_	I-Premise
260	continence	_	_	I-Premise
261	for	_	_	I-Premise
262	liquids	_	_	I-Premise
263	or	_	_	I-Premise
264	gas	_	_	I-Premise
265	occurred	_	_	I-Premise
266	less	_	_	I-Premise
267	frequently	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	colonic	_	_	I-Premise
271	J	_	_	I-Premise
272	-	_	_	I-Premise
273	pouch	_	_	I-Premise
274	group	_	_	I-Premise
275	6	_	_	I-Premise
276	months	_	_	I-Premise
277	after	_	_	I-Premise
278	surgery	_	_	I-Premise
279	.	_	_	I-Premise

280	The	_	_	B-Premise
281	frequency	_	_	I-Premise
282	of	_	_	I-Premise
283	bowel	_	_	I-Premise
284	movements	_	_	I-Premise
285	was	_	_	I-Premise
286	lower	_	_	I-Premise
287	in	_	_	I-Premise
288	the	_	_	I-Premise
289	J	_	_	I-Premise
290	-	_	_	I-Premise
291	pouch	_	_	I-Premise
292	group	_	_	I-Premise
293	(	_	_	I-Premise
294	2	_	_	I-Premise
295	.	_	_	I-Premise

296	5	_	_	I-Premise
297	per	_	_	I-Premise
298	day	_	_	I-Premise
299	)	_	_	I-Premise
300	than	_	_	I-Premise
301	in	_	_	I-Premise
302	the	_	_	I-Premise
303	coloanal	_	_	I-Premise
304	group	_	_	I-Premise
305	(	_	_	I-Premise
306	4	_	_	I-Premise
307	.	_	_	I-Premise

308	7	_	_	I-Premise
309	per	_	_	I-Premise
310	day	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Importantly	_	_	O
314	,	_	_	O
315	in	_	_	B-Premise
316	a	_	_	I-Premise
317	manometric	_	_	I-Premise
318	study	_	_	I-Premise
319	at	_	_	I-Premise
320	the	_	_	I-Premise
321	same	_	_	I-Premise
322	postoperative	_	_	I-Premise
323	point	_	_	I-Premise
324	,	_	_	I-Premise
325	neorectal	_	_	I-Premise
326	capacity	_	_	I-Premise
327	was	_	_	I-Premise
328	decreased	_	_	I-Premise
329	to	_	_	I-Premise
330	a	_	_	I-Premise
331	similar	_	_	I-Premise
332	degree	_	_	I-Premise
333	in	_	_	I-Premise
334	both	_	_	I-Premise
335	groups	_	_	I-Premise
336	compared	_	_	I-Premise
337	with	_	_	I-Premise
338	the	_	_	I-Premise
339	preoperative	_	_	I-Premise
340	rectal	_	_	I-Premise
341	volume	_	_	I-Premise
342	.	_	_	I-Premise

343	Thus	_	_	O
344	,	_	_	O
345	the	_	_	B-Premise
346	expected	_	_	I-Premise
347	and	_	_	I-Premise
348	postulated	_	_	I-Premise
349	reservoir	_	_	I-Premise
350	effect	_	_	I-Premise
351	could	_	_	I-Premise
352	not	_	_	I-Premise
353	be	_	_	I-Premise
354	achieved	_	_	I-Premise
355	by	_	_	I-Premise
356	forming	_	_	I-Premise
357	a	_	_	I-Premise
358	5	_	_	I-Premise
359	-	_	_	I-Premise
360	cm	_	_	I-Premise
361	colonic	_	_	I-Premise
362	J	_	_	I-Premise
363	-	_	_	I-Premise
364	pouch	_	_	I-Premise
365	.	_	_	I-Premise

366	The	_	_	B-Claim
367	colonic	_	_	I-Claim
368	J	_	_	I-Claim
369	-	_	_	I-Claim
370	pouch	_	_	I-Claim
371	was	_	_	I-Claim
372	superior	_	_	I-Claim
373	with	_	_	I-Claim
374	regard	_	_	I-Claim
375	to	_	_	I-Claim
376	continence	_	_	I-Claim
377	for	_	_	I-Claim
378	gas	_	_	I-Claim
379	and	_	_	I-Claim
380	liquids	_	_	I-Claim
381	compared	_	_	I-Claim
382	with	_	_	I-Claim
383	a	_	_	I-Claim
384	straight	_	_	I-Claim
385	coloanal	_	_	I-Claim
386	anastomosis	_	_	I-Claim
387	.	_	_	I-Claim

388	Furthermore	_	_	O
389	,	_	_	O
390	stool	_	_	B-Claim
391	frequency	_	_	I-Claim
392	was	_	_	I-Claim
393	significantly	_	_	I-Claim
394	lower	_	_	I-Claim
395	in	_	_	I-Claim
396	the	_	_	I-Claim
397	J	_	_	I-Claim
398	-	_	_	I-Claim
399	pouch	_	_	I-Claim
400	group	_	_	I-Claim
401	than	_	_	I-Claim
402	in	_	_	I-Claim
403	the	_	_	I-Claim
404	coloanal	_	_	I-Claim
405	reconstruction	_	_	I-Claim
406	group	_	_	I-Claim
407	.	_	_	I-Claim

408	However	_	_	O
409	,	_	_	O
410	because	_	_	B-Premise
411	neorectal	_	_	I-Premise
412	capacity	_	_	I-Premise
413	decreased	_	_	I-Premise
414	equally	_	_	I-Premise
415	in	_	_	I-Premise
416	both	_	_	I-Premise
417	groups	_	_	I-Premise
418	,	_	_	I-Premise
419	we	_	_	B-Claim
420	speculate	_	_	I-Claim
421	that	_	_	I-Claim
422	the	_	_	I-Claim
423	advantage	_	_	I-Claim
424	of	_	_	I-Claim
425	the	_	_	I-Claim
426	colonic	_	_	I-Claim
427	J	_	_	I-Claim
428	-	_	_	I-Claim
429	pouch	_	_	I-Claim
430	is	_	_	I-Claim
431	not	_	_	I-Claim
432	in	_	_	I-Claim
433	the	_	_	I-Claim
434	creation	_	_	I-Claim
435	of	_	_	I-Claim
436	a	_	_	I-Claim
437	larger	_	_	I-Claim
438	neorectal	_	_	I-Claim
439	reservoir	_	_	I-Claim
440	but	_	_	I-Claim
441	rather	_	_	I-Claim
442	may	_	_	I-Claim
443	be	_	_	I-Claim
444	related	_	_	I-Claim
445	to	_	_	I-Claim
446	decreased	_	_	I-Claim
447	motility	_	_	I-Claim
448	.	_	_	I-Claim


0	Patients	_	_	B-Claim
1	receiving	_	_	I-Claim
2	chemotherapy	_	_	I-Claim
3	for	_	_	I-Claim
4	cancer	_	_	I-Claim
5	often	_	_	I-Claim
6	develop	_	_	I-Claim
7	anemia	_	_	I-Claim
8	,	_	_	I-Claim
9	which	_	_	I-Claim
10	can	_	_	I-Claim
11	contribute	_	_	I-Claim
12	to	_	_	I-Claim
13	increased	_	_	I-Claim
14	morbidity	_	_	I-Claim
15	and	_	_	I-Claim
16	reduced	_	_	I-Claim
17	quality	_	_	I-Claim
18	of	_	_	I-Claim
19	life	_	_	I-Claim
20	(	_	_	I-Claim
21	QOL	_	_	I-Claim
22	)	_	_	I-Claim
23	.	_	_	I-Claim

24	Chemotherapy	_	_	B-Claim
25	-	_	_	I-Claim
26	induced	_	_	I-Claim
27	anemia	_	_	I-Claim
28	can	_	_	I-Claim
29	be	_	_	I-Claim
30	successfully	_	_	I-Claim
31	treated	_	_	I-Claim
32	using	_	_	I-Claim
33	recombinant	_	_	I-Claim
34	human	_	_	I-Claim
35	erythropoietin	_	_	I-Claim
36	(	_	_	I-Claim
37	rHuEPO	_	_	I-Claim
38	)	_	_	I-Claim
39	.	_	_	I-Claim

40	To	_	_	O
41	demonstrate	_	_	O
42	the	_	_	O
43	effectiveness	_	_	O
44	of	_	_	O
45	once	_	_	O
46	-	_	_	O
47	weekly	_	_	O
48	(	_	_	O
49	QW	_	_	O
50	)	_	_	O
51	rHuEPO	_	_	O
52	dosing	_	_	O
53	to	_	_	O
54	effect	_	_	O
55	improved	_	_	O
56	hemoglobin	_	_	O
57	levels	_	_	O
58	,	_	_	O
59	decreased	_	_	O
60	transfusion	_	_	O
61	use	_	_	O
62	,	_	_	O
63	and	_	_	O
64	improved	_	_	O
65	functional	_	_	O
66	outcomes	_	_	O
67	and	_	_	O
68	QOL	_	_	O
69	in	_	_	O
70	pediatric	_	_	O
71	leukemic	_	_	O
72	patients	_	_	O
73	(	_	_	O
74	ALL	_	_	O
75	)	_	_	O
76	receiving	_	_	O
77	maintenance	_	_	O
78	chemotherapy	_	_	O
79	.	_	_	O

80	This	_	_	O
81	was	_	_	O
82	a	_	_	O
83	prospective	_	_	O
84	randomized	_	_	O
85	,	_	_	O
86	single	_	_	O
87	-	_	_	O
88	center	_	_	O
89	,	_	_	O
90	open	_	_	O
91	-	_	_	O
92	label	_	_	O
93	,	_	_	O
94	12	_	_	O
95	-	_	_	O
96	week	_	_	O
97	case	_	_	O
98	-	_	_	O
99	control	_	_	O
100	study	_	_	O
101	of	_	_	O
102	epoetin	_	_	O
103	alfa	_	_	O
104	in	_	_	O
105	pediatric	_	_	O
106	patients	_	_	O
107	with	_	_	O
108	acute	_	_	O
109	lymphoblastic	_	_	O
110	leukemia	_	_	O
111	(	_	_	O
112	ALL	_	_	O
113	)	_	_	O
114	in	_	_	O
115	remission	_	_	O
116	receiving	_	_	O
117	maintenance	_	_	O
118	chemotherapy	_	_	O
119	.	_	_	O

120	Sixty	_	_	O
121	patients	_	_	O
122	were	_	_	O
123	randomly	_	_	O
124	assigned	_	_	O
125	to	_	_	O
126	receive	_	_	O
127	either	_	_	O
128	epoetin	_	_	O
129	alfa	_	_	O
130	(	_	_	O
131	rHuEPO	_	_	O
132	group	_	_	O
133	=	_	_	O
134	30	_	_	O
135	cases	_	_	O
136	,	_	_	O
137	17	_	_	O
138	males	_	_	O
139	and	_	_	O
140	13	_	_	O
141	females	_	_	O
142	,	_	_	O
143	age	_	_	O
144	;	_	_	O
145	6	_	_	O
146	.	_	_	O

147	8	_	_	O
148	+	_	_	O
149	/	_	_	O
150	-	_	_	O
151	2	_	_	O
152	.	_	_	O

153	33	_	_	O
154	years	_	_	O
155	)	_	_	O
156	,	_	_	O
157	or	_	_	O
158	no	_	_	O
159	epoetin	_	_	O
160	alfa	_	_	O
161	(	_	_	O
162	control	_	_	O
163	group	_	_	O
164	=	_	_	O
165	30	_	_	O
166	cases	_	_	O
167	,	_	_	O
168	16	_	_	O
169	males	_	_	O
170	and	_	_	O
171	14	_	_	O
172	females	_	_	O
173	,	_	_	O
174	age	_	_	O
175	;	_	_	O
176	6	_	_	O
177	.	_	_	O

178	76	_	_	O
179	+	_	_	O
180	/	_	_	O
181	-	_	_	O
182	2	_	_	O
183	.	_	_	O

184	28	_	_	O
185	years	_	_	O
186	)	_	_	O
187	.	_	_	O

188	Both	_	_	O
189	groups	_	_	O
190	were	_	_	O
191	matched	_	_	O
192	as	_	_	O
193	regard	_	_	O
194	age	_	_	O
195	,	_	_	O
196	sex	_	_	O
197	,	_	_	O
198	baseline	_	_	O
199	Hb	_	_	O
200	concentration	_	_	O
201	,	_	_	O
202	remission	_	_	O
203	state	_	_	O
204	,	_	_	O
205	chemotherapy	_	_	O
206	regimen	_	_	O
207	,	_	_	O
208	numbers	_	_	O
209	and	_	_	O
210	amount	_	_	O
211	of	_	_	O
212	blood	_	_	O
213	transfusion	_	_	O
214	,	_	_	O
215	and	_	_	O
216	leukemia	_	_	O
217	state	_	_	O
218	(	_	_	O
219	both	_	_	O
220	were	_	_	O
221	low	_	_	O
222	and	_	_	O
223	standard	_	_	O
224	risk	_	_	O
225	)	_	_	O
226	.	_	_	O

227	Epoetin	_	_	O
228	alfa	_	_	O
229	was	_	_	O
230	administered	_	_	O
231	at	_	_	O
232	a	_	_	O
233	dose	_	_	O
234	of	_	_	O
235	450	_	_	O
236	IU	_	_	O
237	/	_	_	O
238	kg	_	_	O
239	,	_	_	O
240	once	_	_	O
241	weekly	_	_	O
242	,	_	_	O
243	subcutaneously	_	_	O
244	(	_	_	O
245	s	_	_	O
246	.	_	_	O

247	c	_	_	O
248	.	_	_	O

249	)	_	_	O
250	for	_	_	O
251	12	_	_	O
252	consecutive	_	_	O
253	weeks	_	_	O
254	.	_	_	O

255	Endpoints	_	_	O
256	were	_	_	O
257	changes	_	_	O
258	in	_	_	O
259	hematologic	_	_	O
260	and	_	_	O
261	QOL	_	_	O
262	parameters	_	_	O
263	.	_	_	O

264	Among	_	_	B-Premise
265	the	_	_	I-Premise
266	30	_	_	I-Premise
267	patients	_	_	I-Premise
268	evaluable	_	_	I-Premise
269	for	_	_	I-Premise
270	hematologic	_	_	I-Premise
271	response	_	_	I-Premise
272	,	_	_	I-Premise
273	the	_	_	I-Premise
274	mean	_	_	I-Premise
275	increase	_	_	I-Premise
276	in	_	_	I-Premise
277	Hb	_	_	I-Premise
278	from	_	_	I-Premise
279	baseline	_	_	I-Premise
280	to	_	_	I-Premise
281	time	_	_	I-Premise
282	of	_	_	I-Premise
283	final	_	_	I-Premise
284	evaluation	_	_	I-Premise
285	was	_	_	I-Premise
286	3	_	_	I-Premise
287	.	_	_	I-Premise

288	08	_	_	I-Premise
289	+	_	_	I-Premise
290	/	_	_	I-Premise
291	-	_	_	I-Premise
292	1	_	_	I-Premise
293	.	_	_	I-Premise

294	48	_	_	I-Premise
295	g	_	_	I-Premise
296	/	_	_	I-Premise
297	dl	_	_	I-Premise
298	(	_	_	I-Premise
299	p	_	_	I-Premise
300	<	_	_	I-Premise
301	0	_	_	I-Premise
302	.	_	_	I-Premise

303	001	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	An	_	_	B-Premise
307	increase	_	_	I-Premise
308	in	_	_	I-Premise
309	Hb	_	_	I-Premise
310	of	_	_	I-Premise
311	>	_	_	I-Premise
312	or	_	_	I-Premise
313	=	_	_	I-Premise
314	2	_	_	I-Premise
315	g	_	_	I-Premise
316	/	_	_	I-Premise
317	dl	_	_	I-Premise
318	,	_	_	I-Premise
319	in	_	_	I-Premise
320	the	_	_	I-Premise
321	absence	_	_	I-Premise
322	of	_	_	I-Premise
323	blood	_	_	I-Premise
324	transfusion	_	_	I-Premise
325	,	_	_	I-Premise
326	occurred	_	_	I-Premise
327	in	_	_	I-Premise
328	70	_	_	I-Premise
329	%	_	_	I-Premise
330	of	_	_	I-Premise
331	patients	_	_	I-Premise
332	(	_	_	I-Premise
333	21	_	_	I-Premise
334	of	_	_	I-Premise
335	30	_	_	I-Premise
336	patients	_	_	I-Premise
337	)	_	_	I-Premise
338	who	_	_	I-Premise
339	were	_	_	I-Premise
340	on	_	_	I-Premise
341	the	_	_	I-Premise
342	study	_	_	I-Premise
343	for	_	_	I-Premise
344	>	_	_	I-Premise
345	or	_	_	I-Premise
346	=	_	_	I-Premise
347	30	_	_	I-Premise
348	days	_	_	I-Premise
349	.	_	_	I-Premise

350	The	_	_	B-Premise
351	overall	_	_	I-Premise
352	response	_	_	I-Premise
353	rate	_	_	I-Premise
354	(	_	_	I-Premise
355	Hb	_	_	I-Premise
356	increase	_	_	I-Premise
357	>	_	_	I-Premise
358	or	_	_	I-Premise
359	=	_	_	I-Premise
360	2	_	_	I-Premise
361	g	_	_	I-Premise
362	/	_	_	I-Premise
363	dl	_	_	I-Premise
364	or	_	_	I-Premise
365	Hb	_	_	I-Premise
366	>	_	_	I-Premise
367	or	_	_	I-Premise
368	=	_	_	I-Premise
369	12	_	_	I-Premise
370	g	_	_	I-Premise
371	/	_	_	I-Premise
372	dl	_	_	I-Premise
373	in	_	_	I-Premise
374	the	_	_	I-Premise
375	absence	_	_	I-Premise
376	of	_	_	I-Premise
377	blood	_	_	I-Premise
378	transfusion	_	_	I-Premise
379	)	_	_	I-Premise
380	was	_	_	I-Premise
381	90	_	_	I-Premise
382	%	_	_	I-Premise
383	(	_	_	I-Premise
384	27	_	_	I-Premise
385	of	_	_	I-Premise
386	30	_	_	I-Premise
387	patients	_	_	I-Premise
388	)	_	_	I-Premise
389	.	_	_	I-Premise

390	In	_	_	B-Premise
391	30	_	_	I-Premise
392	patients	_	_	I-Premise
393	who	_	_	I-Premise
394	were	_	_	I-Premise
395	evaluable	_	_	I-Premise
396	for	_	_	I-Premise
397	QOL	_	_	I-Premise
398	assessment	_	_	I-Premise
399	,	_	_	I-Premise
400	epoetin	_	_	I-Premise
401	-	_	_	I-Premise
402	alpha	_	_	I-Premise
403	therapy	_	_	I-Premise
404	was	_	_	I-Premise
405	found	_	_	I-Premise
406	to	_	_	I-Premise
407	significantly	_	_	I-Premise
408	(	_	_	I-Premise
409	p	_	_	I-Premise
410	<	_	_	I-Premise
411	0	_	_	I-Premise
412	.	_	_	I-Premise

413	001	_	_	I-Premise
414	)	_	_	I-Premise
415	improve	_	_	I-Premise
416	mean	_	_	I-Premise
417	cancer	_	_	I-Premise
418	linear	_	_	I-Premise
419	analog	_	_	I-Premise
420	scale	_	_	I-Premise
421	(	_	_	I-Premise
422	CLAS	_	_	I-Premise
423	)	_	_	I-Premise
424	scores	_	_	I-Premise
425	for	_	_	I-Premise
426	energy	_	_	I-Premise
427	level	_	_	I-Premise
428	,	_	_	I-Premise
429	ability	_	_	I-Premise
430	to	_	_	I-Premise
431	perform	_	_	I-Premise
432	daily	_	_	I-Premise
433	activity	_	_	I-Premise
434	,	_	_	I-Premise
435	and	_	_	I-Premise
436	overall	_	_	I-Premise
437	QOL	_	_	I-Premise
438	from	_	_	I-Premise
439	baseline	_	_	I-Premise
440	to	_	_	I-Premise
441	the	_	_	I-Premise
442	time	_	_	I-Premise
443	of	_	_	I-Premise
444	final	_	_	I-Premise
445	evaluation	_	_	I-Premise
446	.	_	_	I-Premise

447	QW	_	_	B-Premise
448	epoetin	_	_	I-Premise
449	-	_	_	I-Premise
450	alpha	_	_	I-Premise
451	was	_	_	I-Premise
452	found	_	_	I-Premise
453	to	_	_	I-Premise
454	be	_	_	I-Premise
455	well	_	_	I-Premise
456	tolerated	_	_	I-Premise
457	.	_	_	I-Premise

458	Treatment	_	_	B-Claim
459	with	_	_	I-Claim
460	QW	_	_	I-Claim
461	epoetin	_	_	I-Claim
462	-	_	_	I-Claim
463	alpha	_	_	I-Claim
464	was	_	_	I-Claim
465	found	_	_	I-Claim
466	to	_	_	I-Claim
467	increase	_	_	I-Claim
468	Hb	_	_	I-Claim
469	levels	_	_	I-Claim
470	,	_	_	I-Claim
471	decrease	_	_	I-Claim
472	transfusion	_	_	I-Claim
473	requirement	_	_	I-Claim
474	,	_	_	I-Claim
475	and	_	_	I-Claim
476	improve	_	_	I-Claim
477	functional	_	_	I-Claim
478	status	_	_	I-Claim
479	and	_	_	I-Claim
480	QOL	_	_	I-Claim
481	in	_	_	I-Claim
482	anemic	_	_	I-Claim
483	patients	_	_	I-Claim
484	with	_	_	I-Claim
485	ALL	_	_	I-Claim
486	in	_	_	I-Claim
487	maintenance	_	_	I-Claim
488	receiving	_	_	I-Claim
489	chemotherapy	_	_	I-Claim
490	.	_	_	I-Claim

491	The	_	_	B-Claim
492	once	_	_	I-Claim
493	-	_	_	I-Claim
494	weekly	_	_	I-Claim
495	schedule	_	_	I-Claim
496	is	_	_	I-Claim
497	convenient	_	_	I-Claim
498	,	_	_	I-Claim
499	safe	_	_	I-Claim
500	,	_	_	I-Claim
501	and	_	_	I-Claim
502	may	_	_	I-Claim
503	reduce	_	_	I-Claim
504	the	_	_	I-Claim
505	burden	_	_	I-Claim
506	on	_	_	I-Claim
507	patients	_	_	I-Claim
508	,	_	_	I-Claim
509	parents	_	_	I-Claim
510	,	_	_	I-Claim
511	and	_	_	I-Claim
512	their	_	_	I-Claim
513	caregivers	_	_	I-Claim
514	by	_	_	I-Claim
515	reducing	_	_	I-Claim
516	the	_	_	I-Claim
517	number	_	_	I-Claim
518	of	_	_	I-Claim
519	visits	_	_	I-Claim
520	to	_	_	I-Claim
521	the	_	_	I-Claim
522	clinic	_	_	I-Claim
523	.	_	_	I-Claim


0	Previous	_	_	O
1	studies	_	_	O
2	have	_	_	O
3	demonstrated	_	_	O
4	that	_	_	O
5	both	_	_	O
6	anastrozole	_	_	O
7	and	_	_	O
8	letrozole	_	_	O
9	are	_	_	O
10	well	_	_	O
11	tolerated	_	_	O
12	.	_	_	O

13	Letrozole	_	_	O
14	suppresses	_	_	O
15	estrogen	_	_	O
16	to	_	_	O
17	a	_	_	O
18	greater	_	_	O
19	degree	_	_	O
20	than	_	_	O
21	anastrozole	_	_	O
22	in	_	_	O
23	the	_	_	O
24	serum	_	_	O
25	and	_	_	O
26	breast	_	_	O
27	tumor	_	_	O
28	.	_	_	O

29	Concerns	_	_	O
30	have	_	_	O
31	been	_	_	O
32	raised	_	_	O
33	that	_	_	O
34	greater	_	_	O
35	potency	_	_	O
36	may	_	_	O
37	adversely	_	_	O
38	affect	_	_	O
39	patients	_	_	O
40	'	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	(	_	_	O
45	QOL	_	_	O
46	)	_	_	O
47	.	_	_	O

48	One	_	_	O
49	hundred	_	_	O
50	eighty	_	_	O
51	-	_	_	O
52	one	_	_	O
53	postmenopausal	_	_	O
54	women	_	_	O
55	with	_	_	O
56	invasive	_	_	O
57	estrogen	_	_	O
58	receptor	_	_	O
59	-	_	_	O
60	positive	_	_	O
61	breast	_	_	O
62	cancers	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	either	_	_	O
68	12	_	_	O
69	weeks	_	_	O
70	of	_	_	O
71	letrozole	_	_	O
72	followed	_	_	O
73	by	_	_	O
74	12	_	_	O
75	weeks	_	_	O
76	of	_	_	O
77	anastrozole	_	_	O
78	or	_	_	O
79	the	_	_	O
80	reverse	_	_	O
81	sequence	_	_	O
82	.	_	_	O

83	One	_	_	O
84	hundred	_	_	O
85	and	_	_	O
86	six	_	_	O
87	received	_	_	O
88	immediate	_	_	O
89	adjuvant	_	_	O
90	aromatase	_	_	O
91	inhibitors	_	_	O
92	(	_	_	O
93	AIs	_	_	O
94	)	_	_	O
95	following	_	_	O
96	surgery	_	_	O
97	,	_	_	O
98	and	_	_	O
99	75	_	_	O
100	received	_	_	O
101	extended	_	_	O
102	adjuvant	_	_	O
103	therapy	_	_	O
104	.	_	_	O

105	The	_	_	O
106	Functional	_	_	O
107	Assessment	_	_	O
108	of	_	_	O
109	Cancer	_	_	O
110	Therapy	_	_	O
111	Endocrine	_	_	O
112	Subscale	_	_	O
113	(	_	_	O
114	FACT	_	_	O
115	-	_	_	O
116	B	_	_	O
117	-	_	_	O
118	ES	_	_	O
119	)	_	_	O
120	QOL	_	_	O
121	questionnaires	_	_	O
122	were	_	_	O
123	completed	_	_	O
124	to	_	_	O
125	assess	_	_	O
126	QOL	_	_	O
127	on	_	_	O
128	each	_	_	O
129	drug	_	_	O
130	.	_	_	O

131	Additional	_	_	O
132	side	_	_	O
133	-	_	_	O
134	effect	_	_	O
135	profiles	_	_	O
136	were	_	_	O
137	collected	_	_	O
138	.	_	_	O

139	Each	_	_	O
140	patient	_	_	O
141	completed	_	_	O
142	a	_	_	O
143	patient	_	_	O
144	preference	_	_	O
145	form	_	_	O
146	.	_	_	O

147	Twenty	_	_	O
148	-	_	_	O
149	one	_	_	O
150	patients	_	_	O
151	withdrew	_	_	O
152	before	_	_	O
153	study	_	_	O
154	end	_	_	O
155	,	_	_	O
156	10	_	_	O
157	/	_	_	O
158	179	_	_	O
159	(	_	_	O
160	5	_	_	O
161	.	_	_	O

162	6	_	_	O
163	%	_	_	O
164	)	_	_	O
165	while	_	_	O
166	taking	_	_	O
167	letrozole	_	_	O
168	and	_	_	O
169	4	_	_	O
170	/	_	_	O
171	173	_	_	O
172	(	_	_	O
173	2	_	_	O
174	.	_	_	O

175	3	_	_	O
176	%	_	_	O
177	)	_	_	O
178	while	_	_	O
179	taking	_	_	O
180	anastrozole	_	_	O
181	(	_	_	O
182	P	_	_	O
183	=	_	_	O
184	0	_	_	O
185	.	_	_	O

186	12	_	_	O
187	)	_	_	O
188	.	_	_	O

189	Tamoxifen	_	_	B-Premise
190	-	_	_	I-Premise
191	naïve	_	_	I-Premise
192	patients	_	_	I-Premise
193	had	_	_	I-Premise
194	a	_	_	I-Premise
195	higher	_	_	I-Premise
196	mean	_	_	I-Premise
197	ES	_	_	I-Premise
198	(	_	_	I-Premise
199	endocrine	_	_	I-Premise
200	symptoms	_	_	I-Premise
201	subscale	_	_	I-Premise
202	)	_	_	I-Premise
203	score	_	_	I-Premise
204	at	_	_	I-Premise
205	entry	_	_	I-Premise
206	versus	_	_	I-Premise
207	those	_	_	I-Premise
208	having	_	_	I-Premise
209	extended	_	_	I-Premise
210	therapy	_	_	I-Premise
211	(	_	_	I-Premise
212	66	_	_	I-Premise
213	.	_	_	I-Premise

214	0	_	_	I-Premise
215	vs	_	_	I-Premise
216	.	_	_	I-Premise

217	61	_	_	I-Premise
218	.	_	_	I-Premise

219	9	_	_	I-Premise
220	;	_	_	I-Premise
221	P	_	_	I-Premise
222	=	_	_	I-Premise
223	0	_	_	I-Premise
224	.	_	_	I-Premise

225	001	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	There	_	_	B-Premise
229	was	_	_	I-Premise
230	no	_	_	I-Premise
231	significant	_	_	I-Premise
232	change	_	_	I-Premise
233	in	_	_	I-Premise
234	FACT	_	_	I-Premise
235	-	_	_	I-Premise
236	B	_	_	I-Premise
237	-	_	_	I-Premise
238	ES	_	_	I-Premise
239	(	_	_	I-Premise
240	overall	_	_	I-Premise
241	)	_	_	I-Premise
242	scores	_	_	I-Premise
243	or	_	_	I-Premise
244	ES	_	_	I-Premise
245	scores	_	_	I-Premise
246	while	_	_	I-Premise
247	patients	_	_	I-Premise
248	were	_	_	I-Premise
249	taking	_	_	I-Premise
250	anastrozole	_	_	I-Premise
251	or	_	_	I-Premise
252	letrozole	_	_	I-Premise
253	and	_	_	I-Premise
254	no	_	_	I-Premise
255	significant	_	_	I-Premise
256	differences	_	_	I-Premise
257	between	_	_	I-Premise
258	drugs	_	_	I-Premise
259	.	_	_	I-Premise

260	Nearly	_	_	B-Premise
261	80	_	_	I-Premise
262	%	_	_	I-Premise
263	of	_	_	I-Premise
264	patients	_	_	I-Premise
265	reported	_	_	I-Premise
266	one	_	_	I-Premise
267	or	_	_	I-Premise
268	more	_	_	I-Premise
269	side	_	_	I-Premise
270	effects	_	_	I-Premise
271	with	_	_	I-Premise
272	either	_	_	I-Premise
273	agent	_	_	I-Premise
274	.	_	_	I-Premise

275	No	_	_	B-Premise
276	differences	_	_	I-Premise
277	in	_	_	I-Premise
278	frequency	_	_	I-Premise
279	,	_	_	I-Premise
280	grade	_	_	I-Premise
281	,	_	_	I-Premise
282	or	_	_	I-Premise
283	range	_	_	I-Premise
284	of	_	_	I-Premise
285	side	_	_	I-Premise
286	effects	_	_	I-Premise
287	were	_	_	I-Premise
288	seen	_	_	I-Premise
289	between	_	_	I-Premise
290	drugs	_	_	I-Premise
291	.	_	_	I-Premise

292	Of	_	_	O
293	160	_	_	O
294	patients	_	_	O
295	,	_	_	O
296	49	_	_	O
297	(	_	_	O
298	30	_	_	O
299	.	_	_	O

300	6	_	_	O
301	%	_	_	O
302	)	_	_	O
303	preferred	_	_	O
304	letrozole	_	_	O
305	,	_	_	O
306	57	_	_	O
307	(	_	_	O
308	35	_	_	O
309	.	_	_	O

310	6	_	_	O
311	%	_	_	O
312	)	_	_	O
313	preferred	_	_	O
314	anastrozole	_	_	O
315	,	_	_	O
316	and	_	_	O
317	54	_	_	O
318	(	_	_	O
319	33	_	_	O
320	.	_	_	O

321	8	_	_	O
322	%	_	_	O
323	)	_	_	O
324	had	_	_	O
325	no	_	_	O
326	preference	_	_	O
327	(	_	_	O
328	P	_	_	O
329	=	_	_	O
330	0	_	_	O
331	.	_	_	O

332	26	_	_	O
333	,	_	_	O
334	Pearson	_	_	O
335	'	_	_	O
336	s	_	_	O
337	Chi	_	_	O
338	-	_	_	O
339	squared	_	_	O
340	test	_	_	O
341	)	_	_	O
342	.	_	_	O

343	In	_	_	O
344	conclusion	_	_	O
345	,	_	_	O
346	both	_	_	B-Claim
347	AIs	_	_	I-Claim
348	are	_	_	I-Claim
349	equally	_	_	I-Claim
350	well	_	_	I-Claim
351	tolerated	_	_	I-Claim
352	.	_	_	I-Claim

353	There	_	_	B-Claim
354	were	_	_	I-Claim
355	no	_	_	I-Claim
356	significant	_	_	I-Claim
357	differences	_	_	I-Claim
358	in	_	_	I-Claim
359	QOL	_	_	I-Claim
360	scores	_	_	I-Claim
361	between	_	_	I-Claim
362	the	_	_	I-Claim
363	two	_	_	I-Claim
364	drugs	_	_	I-Claim
365	.	_	_	I-Claim


0	One	_	_	O
1	attempt	_	_	O
2	to	_	_	O
3	improve	_	_	O
4	long	_	_	O
5	-	_	_	O
6	term	_	_	O
7	survival	_	_	O
8	in	_	_	O
9	patients	_	_	O
10	with	_	_	O
11	advanced	_	_	O
12	ovarian	_	_	O
13	cancer	_	_	O
14	was	_	_	O
15	thought	_	_	O
16	to	_	_	O
17	be	_	_	O
18	the	_	_	O
19	addition	_	_	O
20	of	_	_	O
21	more	_	_	O
22	non	_	_	O
23	-	_	_	O
24	cross	_	_	O
25	-	_	_	O
26	resistant	_	_	O
27	drugs	_	_	O
28	to	_	_	O
29	platinum	_	_	O
30	-	_	_	O
31	paclitaxel	_	_	O
32	combination	_	_	O
33	regimens	_	_	O
34	.	_	_	O

35	Gemcitabine	_	_	O
36	was	_	_	O
37	among	_	_	O
38	the	_	_	O
39	candidates	_	_	O
40	for	_	_	O
41	a	_	_	O
42	third	_	_	O
43	drug	_	_	O
44	.	_	_	O

45	We	_	_	O
46	performed	_	_	O
47	a	_	_	O
48	prospective	_	_	O
49	,	_	_	O
50	randomized	_	_	O
51	,	_	_	O
52	phase	_	_	O
53	III	_	_	O
54	,	_	_	O
55	intergroup	_	_	O
56	trial	_	_	O
57	to	_	_	O
58	compare	_	_	O
59	carboplatin	_	_	O
60	plus	_	_	O
61	paclitaxel	_	_	O
62	(	_	_	O
63	TC	_	_	O
64	;	_	_	O
65	area	_	_	O
66	under	_	_	O
67	the	_	_	O
68	curve	_	_	O
69	[	_	_	O
70	AUC	_	_	O
71	]	_	_	O
72	5	_	_	O
73	and	_	_	O
74	175	_	_	O
75	mg	_	_	O
76	/	_	_	O
77	m	_	_	O
78	(	_	_	O
79	2	_	_	O
80	)	_	_	O
81	,	_	_	O
82	respectively	_	_	O
83	)	_	_	O
84	with	_	_	O
85	the	_	_	O
86	same	_	_	O
87	combination	_	_	O
88	and	_	_	O
89	additional	_	_	O
90	gemcitabine	_	_	O
91	800	_	_	O
92	mg	_	_	O
93	/	_	_	O
94	m	_	_	O
95	(	_	_	O
96	2	_	_	O
97	)	_	_	O
98	on	_	_	O
99	days	_	_	O
100	1	_	_	O
101	and	_	_	O
102	8	_	_	O
103	(	_	_	O
104	TCG	_	_	O
105	)	_	_	O
106	in	_	_	O
107	previously	_	_	O
108	untreated	_	_	O
109	patients	_	_	O
110	with	_	_	O
111	advanced	_	_	O
112	epithelial	_	_	O
113	ovarian	_	_	O
114	cancer	_	_	O
115	.	_	_	O

116	TC	_	_	O
117	was	_	_	O
118	administered	_	_	O
119	intravenously	_	_	O
120	(	_	_	O
121	IV	_	_	O
122	)	_	_	O
123	on	_	_	O
124	day	_	_	O
125	1	_	_	O
126	every	_	_	O
127	21	_	_	O
128	days	_	_	O
129	for	_	_	O
130	a	_	_	O
131	planned	_	_	O
132	minimum	_	_	O
133	of	_	_	O
134	six	_	_	O
135	courses	_	_	O
136	.	_	_	O

137	Gemcitabine	_	_	O
138	was	_	_	O
139	administered	_	_	O
140	by	_	_	O
141	IV	_	_	O
142	on	_	_	O
143	days	_	_	O
144	1	_	_	O
145	and	_	_	O
146	8	_	_	O
147	of	_	_	O
148	each	_	_	O
149	cycle	_	_	O
150	in	_	_	O
151	the	_	_	O
152	TCG	_	_	O
153	arm	_	_	O
154	.	_	_	O

155	Between	_	_	O
156	2002	_	_	O
157	and	_	_	O
158	2004	_	_	O
159	,	_	_	O
160	1	_	_	O
161	,	_	_	O
162	742	_	_	O
163	patients	_	_	O
164	were	_	_	O
165	randomly	_	_	O
166	assigned	_	_	O
167	;	_	_	O
168	882	_	_	O
169	and	_	_	O
170	860	_	_	O
171	patients	_	_	O
172	received	_	_	O
173	TC	_	_	O
174	and	_	_	O
175	TCG	_	_	O
176	,	_	_	O
177	respectively	_	_	O
178	.	_	_	O

179	Grades	_	_	B-Premise
180	3	_	_	I-Premise
181	to	_	_	I-Premise
182	4	_	_	I-Premise
183	hematologic	_	_	I-Premise
184	toxicity	_	_	I-Premise
185	and	_	_	I-Premise
186	fatigue	_	_	I-Premise
187	occurred	_	_	I-Premise
188	more	_	_	I-Premise
189	frequently	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	TCG	_	_	I-Premise
193	arm	_	_	I-Premise
194	.	_	_	I-Premise

195	Accordingly	_	_	O
196	,	_	_	O
197	quality	_	_	B-Claim
198	-	_	_	I-Claim
199	of	_	_	I-Claim
200	-	_	_	I-Claim
201	life	_	_	I-Claim
202	analysis	_	_	I-Claim
203	during	_	_	I-Claim
204	chemotherapy	_	_	I-Claim
205	showed	_	_	I-Claim
206	a	_	_	I-Claim
207	disadvantage	_	_	I-Claim
208	in	_	_	I-Claim
209	the	_	_	I-Claim
210	TCG	_	_	I-Claim
211	arm	_	_	I-Claim
212	.	_	_	I-Claim

213	Although	_	_	B-Premise
214	objective	_	_	I-Premise
215	response	_	_	I-Premise
216	was	_	_	I-Premise
217	slightly	_	_	I-Premise
218	higher	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	TCG	_	_	I-Premise
222	arm	_	_	I-Premise
223	,	_	_	I-Premise
224	this	_	_	B-Premise
225	did	_	_	I-Premise
226	not	_	_	I-Premise
227	translate	_	_	I-Premise
228	into	_	_	I-Premise
229	improved	_	_	I-Premise
230	progression	_	_	I-Premise
231	-	_	_	I-Premise
232	free	_	_	I-Premise
233	survival	_	_	I-Premise
234	(	_	_	I-Premise
235	PFS	_	_	I-Premise
236	)	_	_	I-Premise
237	or	_	_	I-Premise
238	overall	_	_	I-Premise
239	survival	_	_	I-Premise
240	(	_	_	I-Premise
241	OS	_	_	I-Premise
242	)	_	_	I-Premise
243	.	_	_	I-Premise

244	Median	_	_	B-Premise
245	PFS	_	_	I-Premise
246	was	_	_	I-Premise
247	17	_	_	I-Premise
248	.	_	_	I-Premise

249	8	_	_	I-Premise
250	months	_	_	I-Premise
251	for	_	_	I-Premise
252	the	_	_	I-Premise
253	TCG	_	_	I-Premise
254	arm	_	_	I-Premise
255	and	_	_	I-Premise
256	19	_	_	I-Premise
257	.	_	_	I-Premise

258	3	_	_	I-Premise
259	months	_	_	I-Premise
260	for	_	_	I-Premise
261	the	_	_	I-Premise
262	TC	_	_	I-Premise
263	arm	_	_	I-Premise
264	(	_	_	I-Premise
265	hazard	_	_	I-Premise
266	ratio	_	_	I-Premise
267	[	_	_	I-Premise
268	HR	_	_	I-Premise
269	]	_	_	I-Premise
270	,	_	_	I-Premise
271	1	_	_	I-Premise
272	.	_	_	I-Premise

273	18	_	_	I-Premise
274	;	_	_	I-Premise
275	95	_	_	I-Premise
276	%	_	_	I-Premise
277	CI	_	_	I-Premise
278	,	_	_	I-Premise
279	1	_	_	I-Premise
280	.	_	_	I-Premise

281	06	_	_	I-Premise
282	to	_	_	I-Premise
283	1	_	_	I-Premise
284	.	_	_	I-Premise

285	32	_	_	I-Premise
286	;	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	.	_	_	I-Premise

290	0044	_	_	I-Premise
291	)	_	_	I-Premise
292	.	_	_	I-Premise

293	Median	_	_	B-Premise
294	OS	_	_	I-Premise
295	was	_	_	I-Premise
296	49	_	_	I-Premise
297	.	_	_	I-Premise

298	5	_	_	I-Premise
299	for	_	_	I-Premise
300	the	_	_	I-Premise
301	TCG	_	_	I-Premise
302	arm	_	_	I-Premise
303	and	_	_	I-Premise
304	51	_	_	I-Premise
305	.	_	_	I-Premise

306	5	_	_	I-Premise
307	months	_	_	I-Premise
308	for	_	_	I-Premise
309	the	_	_	I-Premise
310	TC	_	_	I-Premise
311	arm	_	_	I-Premise
312	(	_	_	I-Premise
313	HR	_	_	I-Premise
314	,	_	_	I-Premise
315	1	_	_	I-Premise
316	.	_	_	I-Premise

317	05	_	_	I-Premise
318	;	_	_	I-Premise
319	95	_	_	I-Premise
320	%	_	_	I-Premise
321	CI	_	_	I-Premise
322	,	_	_	I-Premise
323	0	_	_	I-Premise
324	.	_	_	I-Premise

325	91	_	_	I-Premise
326	to	_	_	I-Premise
327	1	_	_	I-Premise
328	.	_	_	I-Premise

329	20	_	_	I-Premise
330	;	_	_	I-Premise
331	P	_	_	I-Premise
332	=	_	_	I-Premise
333	.	_	_	I-Premise

334	5106	_	_	I-Premise
335	)	_	_	I-Premise
336	.	_	_	I-Premise

337	The	_	_	B-Claim
338	addition	_	_	I-Claim
339	of	_	_	I-Claim
340	gemcitabine	_	_	I-Claim
341	to	_	_	I-Claim
342	carboplatin	_	_	I-Claim
343	plus	_	_	I-Claim
344	paclitaxel	_	_	I-Claim
345	increased	_	_	I-Claim
346	treatment	_	_	I-Claim
347	burden	_	_	I-Claim
348	,	_	_	I-Claim
349	reduced	_	_	I-Claim
350	PFS	_	_	I-Claim
351	time	_	_	I-Claim
352	,	_	_	I-Claim
353	and	_	_	I-Claim
354	did	_	_	I-Claim
355	not	_	_	I-Claim
356	improve	_	_	I-Claim
357	OS	_	_	I-Claim
358	in	_	_	I-Claim
359	patients	_	_	I-Claim
360	with	_	_	I-Claim
361	advanced	_	_	I-Claim
362	epithelial	_	_	I-Claim
363	ovarian	_	_	I-Claim
364	cancer	_	_	I-Claim
365	.	_	_	I-Claim

366	Therefore	_	_	B-Claim
367	,	_	_	I-Claim
368	we	_	_	I-Claim
369	recommend	_	_	I-Claim
370	no	_	_	I-Claim
371	additional	_	_	I-Claim
372	clinical	_	_	I-Claim
373	use	_	_	I-Claim
374	of	_	_	I-Claim
375	TCG	_	_	I-Claim
376	in	_	_	I-Claim
377	this	_	_	I-Claim
378	population	_	_	I-Claim
379	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aims	_	_	O
3	to	_	_	O
4	evaluate	_	_	O
5	the	_	_	O
6	feasibility	_	_	O
7	and	_	_	O
8	efficacy	_	_	O
9	of	_	_	O
10	an	_	_	O
11	8	_	_	O
12	-	_	_	O
13	week	_	_	O
14	supervised	_	_	O
15	exercise	_	_	O
16	program	_	_	O
17	in	_	_	O
18	de	_	_	O
19	-	_	_	O
20	conditioned	_	_	O
21	cancer	_	_	O
22	survivors	_	_	O
23	within	_	_	O
24	2	_	_	O
25	-	_	_	O
26	6	_	_	O
27	months	_	_	O
28	of	_	_	O
29	chemotherapy	_	_	O
30	completion	_	_	O
31	.	_	_	O

32	Participants	_	_	O
33	were	_	_	O
34	randomly	_	_	O
35	assigned	_	_	O
36	to	_	_	O
37	an	_	_	O
38	8	_	_	O
39	-	_	_	O
40	week	_	_	O
41	,	_	_	O
42	twice	_	_	O
43	-	_	_	O
44	weekly	_	_	O
45	,	_	_	O
46	supervised	_	_	O
47	aerobic	_	_	O
48	exercise	_	_	O
49	training	_	_	O
50	regime	_	_	O
51	(	_	_	O
52	n	_	_	O
53	=	_	_	O
54	23	_	_	O
55	)	_	_	O
56	or	_	_	O
57	a	_	_	O
58	usual	_	_	O
59	care	_	_	O
60	group	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	20	_	_	O
65	)	_	_	O
66	.	_	_	O

67	Feasibility	_	_	O
68	was	_	_	O
69	assessed	_	_	O
70	by	_	_	O
71	recruitment	_	_	O
72	rate	_	_	O
73	,	_	_	O
74	program	_	_	O
75	adherence	_	_	O
76	and	_	_	O
77	participant	_	_	O
78	feedback	_	_	O
79	.	_	_	O

80	The	_	_	O
81	primary	_	_	O
82	outcome	_	_	O
83	was	_	_	O
84	aerobic	_	_	O
85	fitness	_	_	O
86	assessed	_	_	O
87	by	_	_	O
88	the	_	_	O
89	Modified	_	_	O
90	Bruce	_	_	O
91	fitness	_	_	O
92	test	_	_	O
93	at	_	_	O
94	baseline	_	_	O
95	(	_	_	O
96	0	_	_	O
97	weeks	_	_	O
98	)	_	_	O
99	,	_	_	O
100	post	_	_	O
101	-	_	_	O
102	intervention	_	_	O
103	(	_	_	O
104	8	_	_	O
105	weeks	_	_	O
106	)	_	_	O
107	and	_	_	O
108	at	_	_	O
109	3	_	_	O
110	-	_	_	O
111	month	_	_	O
112	follow	_	_	O
113	-	_	_	O
114	up	_	_	O
115	.	_	_	O

116	Secondary	_	_	O
117	outcomes	_	_	O
118	included	_	_	O
119	physical	_	_	O
120	activity	_	_	O
121	,	_	_	O
122	waist	_	_	O
123	circumference	_	_	O
124	,	_	_	O
125	fatigue	_	_	O
126	and	_	_	O
127	quality	_	_	O
128	of	_	_	O
129	life	_	_	O
130	.	_	_	O

131	The	_	_	O
132	recruitment	_	_	O
133	rate	_	_	O
134	was	_	_	O
135	81	_	_	O
136	%	_	_	O
137	and	_	_	O
138	adherence	_	_	O
139	to	_	_	O
140	the	_	_	O
141	supervised	_	_	O
142	exercise	_	_	O
143	was	_	_	O
144	78	_	_	O
145	.	_	_	O

146	3	_	_	O
147	%	_	_	O
148	.	_	_	O

149	Meaningful	_	_	B-Premise
150	differences	_	_	I-Premise
151	in	_	_	I-Premise
152	aerobic	_	_	I-Premise
153	fitness	_	_	I-Premise
154	between	_	_	I-Premise
155	the	_	_	I-Premise
156	exercise	_	_	I-Premise
157	and	_	_	I-Premise
158	usual	_	_	I-Premise
159	care	_	_	I-Premise
160	groups	_	_	I-Premise
161	at	_	_	I-Premise
162	both	_	_	I-Premise
163	the	_	_	I-Premise
164	8	_	_	I-Premise
165	-	_	_	I-Premise
166	week	_	_	I-Premise
167	[	_	_	I-Premise
168	mean	_	_	I-Premise
169	3	_	_	I-Premise
170	.	_	_	I-Premise

171	0	_	_	I-Premise
172	mL	_	_	I-Premise
173	kg	_	_	I-Premise
174	(	_	_	I-Premise
175	-	_	_	I-Premise
176	1	_	_	I-Premise
177	)	_	_	I-Premise
178	min	_	_	I-Premise
179	(	_	_	I-Premise
180	-	_	_	I-Premise
181	1	_	_	I-Premise
182	)	_	_	I-Premise
183	(	_	_	I-Premise
184	95	_	_	I-Premise
185	%	_	_	I-Premise
186	CI	_	_	I-Premise
187	-	_	_	I-Premise
188	1	_	_	I-Premise
189	.	_	_	I-Premise

190	1	_	_	I-Premise
191	-	_	_	I-Premise
192	7	_	_	I-Premise
193	.	_	_	I-Premise

194	0	_	_	I-Premise
195	)	_	_	I-Premise
196	]	_	_	I-Premise
197	and	_	_	I-Premise
198	3	_	_	I-Premise
199	-	_	_	I-Premise
200	month	_	_	I-Premise
201	follow	_	_	I-Premise
202	-	_	_	I-Premise
203	up	_	_	I-Premise
204	[	_	_	I-Premise
205	2	_	_	I-Premise
206	.	_	_	I-Premise

207	1	_	_	I-Premise
208	mL	_	_	I-Premise
209	kg	_	_	I-Premise
210	(	_	_	I-Premise
211	-	_	_	I-Premise
212	1	_	_	I-Premise
213	)	_	_	I-Premise
214	min	_	_	I-Premise
215	(	_	_	I-Premise
216	-	_	_	I-Premise
217	1	_	_	I-Premise
218	)	_	_	I-Premise
219	(	_	_	I-Premise
220	-	_	_	I-Premise
221	2	_	_	I-Premise
222	.	_	_	I-Premise

223	3	_	_	I-Premise
224	-	_	_	I-Premise
225	6	_	_	I-Premise
226	.	_	_	I-Premise

227	6	_	_	I-Premise
228	)	_	_	I-Premise
229	]	_	_	I-Premise
230	were	_	_	I-Premise
231	found	_	_	I-Premise
232	,	_	_	I-Premise
233	although	_	_	B-Premise
234	these	_	_	I-Premise
235	differences	_	_	I-Premise
236	did	_	_	I-Premise
237	not	_	_	I-Premise
238	achieve	_	_	I-Premise
239	statistical	_	_	I-Premise
240	significance	_	_	I-Premise
241	(	_	_	I-Premise
242	p	_	_	I-Premise
243	values	_	_	I-Premise
244	>	_	_	I-Premise
245	0	_	_	I-Premise
246	.	_	_	I-Premise

247	14	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	Self	_	_	B-Premise
251	-	_	_	I-Premise
252	reported	_	_	I-Premise
253	physical	_	_	I-Premise
254	activity	_	_	I-Premise
255	increased	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	exercise	_	_	I-Premise
259	group	_	_	I-Premise
260	(	_	_	I-Premise
261	EG	_	_	I-Premise
262	)	_	_	I-Premise
263	compared	_	_	I-Premise
264	to	_	_	I-Premise
265	the	_	_	I-Premise
266	usual	_	_	I-Premise
267	care	_	_	I-Premise
268	group	_	_	I-Premise
269	at	_	_	I-Premise
270	both	_	_	I-Premise
271	8	_	_	I-Premise
272	-	_	_	I-Premise
273	week	_	_	I-Premise
274	(	_	_	I-Premise
275	p	_	_	I-Premise
276	=	_	_	I-Premise
277	0	_	_	I-Premise
278	.	_	_	I-Premise

279	01	_	_	I-Premise
280	)	_	_	I-Premise
281	and	_	_	I-Premise
282	3	_	_	I-Premise
283	-	_	_	I-Premise
284	month	_	_	I-Premise
285	follow	_	_	I-Premise
286	-	_	_	I-Premise
287	up	_	_	I-Premise
288	(	_	_	I-Premise
289	p	_	_	I-Premise
290	=	_	_	I-Premise
291	0	_	_	I-Premise
292	.	_	_	I-Premise

293	03	_	_	I-Premise
294	)	_	_	I-Premise
295	and	_	_	I-Premise
296	significant	_	_	I-Premise
297	differences	_	_	I-Premise
298	in	_	_	I-Premise
299	favour	_	_	I-Premise
300	of	_	_	I-Premise
301	the	_	_	I-Premise
302	EG	_	_	I-Premise
303	were	_	_	I-Premise
304	found	_	_	I-Premise
305	for	_	_	I-Premise
306	physical	_	_	I-Premise
307	well	_	_	I-Premise
308	-	_	_	I-Premise
309	being	_	_	I-Premise
310	at	_	_	I-Premise
311	both	_	_	I-Premise
312	the	_	_	I-Premise
313	8	_	_	I-Premise
314	-	_	_	I-Premise
315	week	_	_	I-Premise
316	(	_	_	I-Premise
317	p	_	_	I-Premise
318	=	_	_	I-Premise
319	0	_	_	I-Premise
320	.	_	_	I-Premise

321	03	_	_	I-Premise
322	)	_	_	I-Premise
323	and	_	_	I-Premise
324	3	_	_	I-Premise
325	-	_	_	I-Premise
326	month	_	_	I-Premise
327	follow	_	_	I-Premise
328	-	_	_	I-Premise
329	up	_	_	I-Premise
330	(	_	_	I-Premise
331	p	_	_	I-Premise
332	=	_	_	I-Premise
333	0	_	_	I-Premise
334	.	_	_	I-Premise

335	04	_	_	I-Premise
336	)	_	_	I-Premise
337	.	_	_	I-Premise

338	Improvements	_	_	B-Premise
339	in	_	_	I-Premise
340	fatigue	_	_	I-Premise
341	(	_	_	I-Premise
342	p	_	_	I-Premise
343	=	_	_	I-Premise
344	0	_	_	I-Premise
345	.	_	_	I-Premise

346	01	_	_	I-Premise
347	)	_	_	I-Premise
348	,	_	_	I-Premise
349	total	_	_	I-Premise
350	quality	_	_	I-Premise
351	of	_	_	I-Premise
352	life	_	_	I-Premise
353	plus	_	_	I-Premise
354	fatigue	_	_	I-Premise
355	(	_	_	I-Premise
356	p	_	_	I-Premise
357	=	_	_	I-Premise
358	0	_	_	I-Premise
359	.	_	_	I-Premise

360	04	_	_	I-Premise
361	)	_	_	I-Premise
362	,	_	_	I-Premise
363	and	_	_	I-Premise
364	a	_	_	I-Premise
365	composite	_	_	I-Premise
366	physical	_	_	I-Premise
367	functioning	_	_	I-Premise
368	score	_	_	I-Premise
369	(	_	_	I-Premise
370	p	_	_	I-Premise
371	=	_	_	I-Premise
372	0	_	_	I-Premise
373	.	_	_	I-Premise

374	01	_	_	I-Premise
375	)	_	_	I-Premise
376	at	_	_	I-Premise
377	the	_	_	I-Premise
378	3	_	_	I-Premise
379	-	_	_	I-Premise
380	month	_	_	I-Premise
381	follow	_	_	I-Premise
382	-	_	_	I-Premise
383	up	_	_	I-Premise
384	were	_	_	I-Premise
385	also	_	_	I-Premise
386	found	_	_	I-Premise
387	.	_	_	I-Premise

388	The	_	_	B-Claim
389	PEACH	_	_	I-Claim
390	trial	_	_	I-Claim
391	suggests	_	_	I-Claim
392	that	_	_	I-Claim
393	8	_	_	I-Claim
394	weeks	_	_	I-Claim
395	of	_	_	I-Claim
396	supervised	_	_	I-Claim
397	aerobic	_	_	I-Claim
398	exercise	_	_	I-Claim
399	training	_	_	I-Claim
400	was	_	_	I-Claim
401	feasible	_	_	I-Claim
402	and	_	_	I-Claim
403	may	_	_	I-Claim
404	improve	_	_	I-Claim
405	aerobic	_	_	I-Claim
406	fitness	_	_	I-Claim
407	,	_	_	I-Claim
408	fatigue	_	_	I-Claim
409	and	_	_	I-Claim
410	quality	_	_	I-Claim
411	of	_	_	I-Claim
412	life	_	_	I-Claim
413	in	_	_	I-Claim
414	de	_	_	I-Claim
415	-	_	_	I-Claim
416	conditioned	_	_	I-Claim
417	cancer	_	_	I-Claim
418	survivors	_	_	I-Claim
419	during	_	_	I-Claim
420	the	_	_	I-Claim
421	early	_	_	I-Claim
422	survivorship	_	_	I-Claim
423	phase	_	_	I-Claim
424	.	_	_	I-Claim

425	Exercise	_	_	B-Claim
426	interventions	_	_	I-Claim
427	commenced	_	_	I-Claim
428	in	_	_	I-Claim
429	the	_	_	I-Claim
430	early	_	_	I-Claim
431	survivorship	_	_	I-Claim
432	phase	_	_	I-Claim
433	appear	_	_	I-Claim
434	safe	_	_	I-Claim
435	,	_	_	I-Claim
436	feasible	_	_	I-Claim
437	and	_	_	I-Claim
438	may	_	_	I-Claim
439	lead	_	_	I-Claim
440	to	_	_	I-Claim
441	improvements	_	_	I-Claim
442	in	_	_	I-Claim
443	QOL	_	_	I-Claim
444	and	_	_	I-Claim
445	fatigue	_	_	I-Claim
446	.	_	_	I-Claim


0	We	_	_	O
1	previously	_	_	O
2	reported	_	_	O
3	that	_	_	O
4	treatment	_	_	O
5	of	_	_	O
6	patients	_	_	O
7	with	_	_	O
8	symptomatic	_	_	O
9	advanced	_	_	O
10	non	_	_	O
11	-	_	_	O
12	small	_	_	O
13	cell	_	_	O
14	lung	_	_	O
15	cancer	_	_	O
16	with	_	_	O
17	single	_	_	O
18	agent	_	_	O
19	Gemcitabine	_	_	O
20	(	_	_	O
21	GEM	_	_	O
22	)	_	_	O
23	resulted	_	_	O
24	in	_	_	O
25	a	_	_	O
26	superior	_	_	O
27	clinical	_	_	O
28	-	_	_	O
29	benefit	_	_	O
30	response	_	_	O
31	rate	_	_	O
32	(	_	_	O
33	RR	_	_	O
34	)	_	_	O
35	compared	_	_	O
36	to	_	_	O
37	cisplatin	_	_	O
38	-	_	_	O
39	based	_	_	O
40	combination	_	_	O
41	chemotherapy	_	_	O
42	.	_	_	O

43	We	_	_	O
44	now	_	_	O
45	report	_	_	O
46	the	_	_	O
47	detailed	_	_	O
48	individual	_	_	O
49	symptom	_	_	O
50	control	_	_	O
51	analysis	_	_	O
52	,	_	_	O
53	and	_	_	O
54	the	_	_	O
55	influence	_	_	O
56	of	_	_	O
57	cisplatin	_	_	O
58	-	_	_	O
59	use	_	_	O
60	,	_	_	O
61	age	_	_	O
62	,	_	_	O
63	performance	_	_	O
64	status	_	_	O
65	(	_	_	O
66	PS	_	_	O
67	)	_	_	O
68	and	_	_	O
69	duration	_	_	O
70	of	_	_	O
71	treatment	_	_	O
72	.	_	_	O

73	Patients	_	_	O
74	received	_	_	O
75	either	_	_	O
76	GEM	_	_	O
77	(	_	_	O
78	1000	_	_	O
79	mg	_	_	O
80	/	_	_	O
81	m	_	_	O
82	(	_	_	O
83	2	_	_	O
84	)	_	_	O
85	,	_	_	O
86	days	_	_	O
87	1	_	_	O
88	,	_	_	O
89	8	_	_	O
90	and	_	_	O
91	15	_	_	O
92	)	_	_	O
93	or	_	_	O
94	cisplatin	_	_	O
95	(	_	_	O
96	100	_	_	O
97	mg	_	_	O
98	/	_	_	O
99	m	_	_	O
100	(	_	_	O
101	2	_	_	O
102	)	_	_	O
103	,	_	_	O
104	day	_	_	O
105	1	_	_	O
106	)	_	_	O
107	plus	_	_	O
108	Vindesine	_	_	O
109	(	_	_	O
110	3	_	_	O
111	mg	_	_	O
112	/	_	_	O
113	m	_	_	O
114	(	_	_	O
115	2	_	_	O
116	)	_	_	O
117	,	_	_	O
118	days	_	_	O
119	1	_	_	O
120	and	_	_	O
121	15	_	_	O
122	)	_	_	O
123	(	_	_	O
124	PV	_	_	O
125	)	_	_	O
126	,	_	_	O
127	both	_	_	O
128	every	_	_	O
129	4	_	_	O
130	weeks	_	_	O
131	.	_	_	O

132	Scores	_	_	O
133	of	_	_	O
134	9	_	_	O
135	symptoms	_	_	O
136	were	_	_	O
137	listed	_	_	O
138	weekly	_	_	O
139	by	_	_	O
140	the	_	_	O
141	patient	_	_	O
142	on	_	_	O
143	visual	_	_	O
144	analogue	_	_	O
145	scales	_	_	O
146	.	_	_	O

147	Improvement	_	_	O
148	of	_	_	O
149	a	_	_	O
150	symptom	_	_	O
151	was	_	_	O
152	defined	_	_	O
153	as	_	_	O
154	2	_	_	O
155	consecutive	_	_	O
156	cycles	_	_	O
157	of	_	_	O
158	improvement	_	_	O
159	over	_	_	O
160	baseline	_	_	O
161	.	_	_	O

162	Baseline	_	_	O
163	symptoms	_	_	O
164	in	_	_	O
165	the	_	_	O
166	169	_	_	O
167	patients	_	_	O
168	were	_	_	O
169	well	_	_	O
170	balanced	_	_	O
171	between	_	_	O
172	the	_	_	O
173	2	_	_	O
174	arms	_	_	O
175	(	_	_	O
176	84	_	_	O
177	GEM	_	_	O
178	,	_	_	O
179	85	_	_	O
180	PV	_	_	O
181	)	_	_	O
182	.	_	_	O

183	Both	_	_	B-Premise
184	patients	_	_	I-Premise
185	with	_	_	I-Premise
186	objective	_	_	I-Premise
187	response	_	_	I-Premise
188	and	_	_	I-Premise
189	disease	_	_	I-Premise
190	stabilisation	_	_	I-Premise
191	had	_	_	I-Premise
192	clearly	_	_	I-Premise
193	better	_	_	I-Premise
194	symptom	_	_	I-Premise
195	control	_	_	I-Premise
196	than	_	_	I-Premise
197	those	_	_	I-Premise
198	with	_	_	I-Premise
199	disease	_	_	I-Premise
200	progression	_	_	I-Premise
201	.	_	_	I-Premise

202	Symptom	_	_	B-Premise
203	control	_	_	I-Premise
204	in	_	_	I-Premise
205	both	_	_	I-Premise
206	arms	_	_	I-Premise
207	was	_	_	I-Premise
208	similar	_	_	I-Premise
209	for	_	_	I-Premise
210	'	_	_	I-Premise
211	disease	_	_	I-Premise
212	-	_	_	I-Premise
213	specific	_	_	I-Premise
214	'	_	_	I-Premise
215	symptoms	_	_	I-Premise
216	such	_	_	I-Premise
217	as	_	_	I-Premise
218	cough	_	_	I-Premise
219	,	_	_	I-Premise
220	dyspnea	_	_	I-Premise
221	,	_	_	I-Premise
222	pain	_	_	I-Premise
223	or	_	_	I-Premise
224	haemoptysis	_	_	I-Premise
225	.	_	_	I-Premise

226	Compared	_	_	B-Premise
227	to	_	_	I-Premise
228	PV	_	_	I-Premise
229	,	_	_	I-Premise
230	a	_	_	I-Premise
231	significantly	_	_	I-Premise
232	larger	_	_	I-Premise
233	number	_	_	I-Premise
234	of	_	_	I-Premise
235	GEM	_	_	I-Premise
236	-	_	_	I-Premise
237	patients	_	_	I-Premise
238	had	_	_	I-Premise
239	better	_	_	I-Premise
240	scores	_	_	I-Premise
241	for	_	_	I-Premise
242	'	_	_	I-Premise
243	constitutional	_	_	I-Premise
244	'	_	_	I-Premise
245	items	_	_	I-Premise
246	such	_	_	I-Premise
247	as	_	_	I-Premise
248	anorexia	_	_	I-Premise
249	(	_	_	I-Premise
250	P	_	_	I-Premise
251	=	_	_	I-Premise
252	0	_	_	I-Premise
253	.	_	_	I-Premise

254	007	_	_	I-Premise
255	)	_	_	I-Premise
256	,	_	_	I-Premise
257	ability	_	_	I-Premise
258	to	_	_	I-Premise
259	carry	_	_	I-Premise
260	on	_	_	I-Premise
261	with	_	_	I-Premise
262	daily	_	_	I-Premise
263	activities	_	_	I-Premise
264	(	_	_	I-Premise
265	P	_	_	I-Premise
266	=	_	_	I-Premise
267	0	_	_	I-Premise
268	.	_	_	I-Premise

269	04	_	_	I-Premise
270	)	_	_	I-Premise
271	and	_	_	I-Premise
272	overall	_	_	I-Premise
273	impression	_	_	I-Premise
274	of	_	_	I-Premise
275	quality	_	_	I-Premise
276	-	_	_	I-Premise
277	of	_	_	I-Premise
278	-	_	_	I-Premise
279	life	_	_	I-Premise
280	(	_	_	I-Premise
281	P	_	_	I-Premise
282	=	_	_	I-Premise
283	0	_	_	I-Premise
284	.	_	_	I-Premise

285	008	_	_	I-Premise
286	)	_	_	I-Premise
287	.	_	_	I-Premise

288	Symptom	_	_	B-Premise
289	control	_	_	I-Premise
290	was	_	_	I-Premise
291	very	_	_	I-Premise
292	similar	_	_	I-Premise
293	in	_	_	I-Premise
294	younger	_	_	I-Premise
295	(	_	_	I-Premise
296	<	_	_	I-Premise
297	65	_	_	I-Premise
298	years	_	_	I-Premise
299	)	_	_	I-Premise
300	versus	_	_	I-Premise
301	older	_	_	I-Premise
302	(	_	_	I-Premise
303	>	_	_	I-Premise
304	/	_	_	I-Premise
305	=	_	_	I-Premise
306	65	_	_	I-Premise
307	years	_	_	I-Premise
308	)	_	_	I-Premise
309	patients	_	_	I-Premise
310	,	_	_	I-Premise
311	and	_	_	I-Premise
312	only	_	_	I-Premise
313	slightly	_	_	I-Premise
314	better	_	_	I-Premise
315	in	_	_	I-Premise
316	those	_	_	I-Premise
317	with	_	_	I-Premise
318	a	_	_	I-Premise
319	Karnofsky	_	_	I-Premise
320	PS	_	_	I-Premise
321	>	_	_	I-Premise
322	/	_	_	I-Premise
323	=	_	_	I-Premise
324	80	_	_	I-Premise
325	%	_	_	I-Premise
326	compared	_	_	I-Premise
327	to	_	_	I-Premise
328	those	_	_	I-Premise
329	<	_	_	I-Premise
330	80	_	_	I-Premise
331	%	_	_	I-Premise
332	.	_	_	I-Premise

333	Most	_	_	B-Premise
334	of	_	_	I-Premise
335	the	_	_	I-Premise
336	symptom	_	_	I-Premise
337	improvement	_	_	I-Premise
338	occurred	_	_	I-Premise
339	in	_	_	I-Premise
340	the	_	_	I-Premise
341	first	_	_	I-Premise
342	3	_	_	I-Premise
343	cycles	_	_	I-Premise
344	,	_	_	I-Premise
345	with	_	_	I-Premise
346	some	_	_	I-Premise
347	further	_	_	I-Premise
348	symptom	_	_	I-Premise
349	improvement	_	_	I-Premise
350	in	_	_	I-Premise
351	the	_	_	I-Premise
352	following	_	_	I-Premise
353	cycles	_	_	I-Premise
354	in	_	_	I-Premise
355	the	_	_	I-Premise
356	GEM	_	_	I-Premise
357	-	_	_	I-Premise
358	arm	_	_	I-Premise
359	only	_	_	I-Premise
360	.	_	_	I-Premise

361	Both	_	_	B-Claim
362	GEM	_	_	I-Claim
363	and	_	_	I-Claim
364	PV	_	_	I-Claim
365	yield	_	_	I-Claim
366	a	_	_	I-Claim
367	symptom	_	_	I-Claim
368	control	_	_	I-Claim
369	rate	_	_	I-Claim
370	much	_	_	I-Claim
371	higher	_	_	I-Claim
372	than	_	_	I-Claim
373	expected	_	_	I-Claim
374	by	_	_	I-Claim
375	the	_	_	I-Claim
376	objective	_	_	I-Claim
377	tumour	_	_	I-Claim
378	RR	_	_	I-Claim
379	.	_	_	I-Claim

380	GEM	_	_	B-Claim
381	is	_	_	I-Claim
382	equally	_	_	I-Claim
383	effective	_	_	I-Claim
384	in	_	_	I-Claim
385	controlling	_	_	I-Claim
386	'	_	_	I-Claim
387	disease	_	_	I-Claim
388	-	_	_	I-Claim
389	specific	_	_	I-Claim
390	'	_	_	I-Claim
391	symptoms	_	_	I-Claim
392	,	_	_	I-Claim
393	but	_	_	I-Claim
394	superior	_	_	I-Claim
395	in	_	_	I-Claim
396	controlling	_	_	I-Claim
397	'	_	_	I-Claim
398	constitutional	_	_	I-Claim
399	'	_	_	I-Claim
400	symptoms	_	_	I-Claim
401	.	_	_	I-Claim

402	Most	_	_	B-Premise
403	of	_	_	I-Premise
404	the	_	_	I-Premise
405	symptom	_	_	I-Premise
406	control	_	_	I-Premise
407	was	_	_	I-Premise
408	achieved	_	_	I-Premise
409	during	_	_	I-Premise
410	the	_	_	I-Premise
411	first	_	_	I-Premise
412	3	_	_	I-Premise
413	cycles	_	_	I-Premise
414	of	_	_	I-Premise
415	treatment	_	_	I-Premise
416	,	_	_	I-Premise
417	with	_	_	I-Premise
418	some	_	_	I-Premise
419	further	_	_	I-Premise
420	improvement	_	_	I-Premise
421	thereafter	_	_	I-Premise
422	in	_	_	I-Premise
423	the	_	_	I-Premise
424	GEM	_	_	I-Premise
425	-	_	_	I-Premise
426	arm	_	_	I-Premise
427	only	_	_	I-Premise
428	.	_	_	I-Premise


0	Patient	_	_	O
1	-	_	_	O
2	reported	_	_	O
3	symptoms	_	_	O
4	and	_	_	O
5	health	_	_	O
6	-	_	_	O
7	related	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QoL	_	_	O
13	)	_	_	O
14	benefits	_	_	O
15	were	_	_	O
16	investigated	_	_	O
17	in	_	_	O
18	a	_	_	O
19	randomized	_	_	O
20	,	_	_	O
21	phase	_	_	O
22	III	_	_	O
23	trial	_	_	O
24	of	_	_	O
25	afatinib	_	_	O
26	or	_	_	O
27	cisplatin	_	_	O
28	/	_	_	O
29	pemetrexed	_	_	O
30	.	_	_	O

31	Three	_	_	O
32	hundred	_	_	O
33	forty	_	_	O
34	-	_	_	O
35	five	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	advanced	_	_	O
39	epidermal	_	_	O
40	growth	_	_	O
41	factor	_	_	O
42	receptor	_	_	O
43	(	_	_	O
44	EGFR	_	_	O
45	)	_	_	O
46	mutation	_	_	O
47	-	_	_	O
48	positive	_	_	O
49	lung	_	_	O
50	adenocarcinoma	_	_	O
51	were	_	_	O
52	randomly	_	_	O
53	assigned	_	_	O
54	2	_	_	O
55	:	_	_	O
56	1	_	_	O
57	to	_	_	O
58	afatinib	_	_	O
59	40	_	_	O
60	mg	_	_	O
61	per	_	_	O
62	day	_	_	O
63	or	_	_	O
64	up	_	_	O
65	to	_	_	O
66	six	_	_	O
67	cycles	_	_	O
68	of	_	_	O
69	cisplatin	_	_	O
70	/	_	_	O
71	pemetrexed	_	_	O
72	.	_	_	O

73	Lung	_	_	O
74	cancer	_	_	O
75	symptoms	_	_	O
76	and	_	_	O
77	health	_	_	O
78	-	_	_	O
79	related	_	_	O
80	QoL	_	_	O
81	were	_	_	O
82	assessed	_	_	O
83	every	_	_	O
84	21	_	_	O
85	days	_	_	O
86	until	_	_	O
87	progression	_	_	O
88	using	_	_	O
89	the	_	_	O
90	European	_	_	O
91	Organisation	_	_	O
92	for	_	_	O
93	Research	_	_	O
94	and	_	_	O
95	Treatment	_	_	O
96	of	_	_	O
97	Cancer	_	_	O
98	Quality	_	_	O
99	of	_	_	O
100	Life	_	_	O
101	Questionnaire	_	_	O
102	C30	_	_	O
103	and	_	_	O
104	Lung	_	_	O
105	Cancer	_	_	O
106	-	_	_	O
107	13	_	_	O
108	questionnaires	_	_	O
109	.	_	_	O

110	Analyses	_	_	O
111	of	_	_	O
112	cough	_	_	O
113	,	_	_	O
114	dyspnea	_	_	O
115	,	_	_	O
116	and	_	_	O
117	pain	_	_	O
118	were	_	_	O
119	preplanned	_	_	O
120	,	_	_	O
121	including	_	_	O
122	percentage	_	_	O
123	of	_	_	O
124	patients	_	_	O
125	who	_	_	O
126	improved	_	_	O
127	on	_	_	O
128	therapy	_	_	O
129	,	_	_	O
130	time	_	_	O
131	to	_	_	O
132	deterioration	_	_	O
133	of	_	_	O
134	symptoms	_	_	O
135	,	_	_	O
136	and	_	_	O
137	change	_	_	O
138	in	_	_	O
139	symptoms	_	_	O
140	over	_	_	O
141	time	_	_	O
142	.	_	_	O

143	Questionnaire	_	_	O
144	compliance	_	_	O
145	was	_	_	O
146	high	_	_	O
147	.	_	_	O

148	Compared	_	_	B-Premise
149	with	_	_	I-Premise
150	chemotherapy	_	_	I-Premise
151	,	_	_	I-Premise
152	afatinib	_	_	I-Premise
153	significantly	_	_	I-Premise
154	delayed	_	_	I-Premise
155	the	_	_	I-Premise
156	time	_	_	I-Premise
157	to	_	_	I-Premise
158	deterioration	_	_	I-Premise
159	for	_	_	I-Premise
160	cough	_	_	I-Premise
161	(	_	_	I-Premise
162	hazard	_	_	I-Premise
163	ratio	_	_	I-Premise
164	[	_	_	I-Premise
165	HR	_	_	I-Premise
166	]	_	_	I-Premise
167	,	_	_	I-Premise
168	0	_	_	I-Premise
169	.	_	_	I-Premise

170	60	_	_	I-Premise
171	;	_	_	I-Premise
172	95	_	_	I-Premise
173	%	_	_	I-Premise
174	CI	_	_	I-Premise
175	,	_	_	I-Premise
176	0	_	_	I-Premise
177	.	_	_	I-Premise

178	41	_	_	I-Premise
179	to	_	_	I-Premise
180	0	_	_	I-Premise
181	.	_	_	I-Premise

182	87	_	_	I-Premise
183	;	_	_	I-Premise
184	P	_	_	I-Premise
185	=	_	_	I-Premise
186	.	_	_	I-Premise

187	007	_	_	I-Premise
188	)	_	_	I-Premise
189	and	_	_	I-Premise
190	dyspnea	_	_	I-Premise
191	(	_	_	I-Premise
192	HR	_	_	I-Premise
193	,	_	_	I-Premise
194	0	_	_	I-Premise
195	.	_	_	I-Premise

196	68	_	_	I-Premise
197	;	_	_	I-Premise
198	95	_	_	I-Premise
199	%	_	_	I-Premise
200	CI	_	_	I-Premise
201	,	_	_	I-Premise
202	0	_	_	I-Premise
203	.	_	_	I-Premise

204	50	_	_	I-Premise
205	to	_	_	I-Premise
206	0	_	_	I-Premise
207	.	_	_	I-Premise

208	93	_	_	I-Premise
209	;	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	.	_	_	I-Premise

213	015	_	_	I-Premise
214	)	_	_	I-Premise
215	,	_	_	I-Premise
216	but	_	_	I-Premise
217	not	_	_	I-Premise
218	pain	_	_	I-Premise
219	(	_	_	I-Premise
220	HR	_	_	I-Premise
221	,	_	_	I-Premise
222	0	_	_	I-Premise
223	.	_	_	I-Premise

224	83	_	_	I-Premise
225	;	_	_	I-Premise
226	95	_	_	I-Premise
227	%	_	_	I-Premise
228	CI	_	_	I-Premise
229	,	_	_	I-Premise
230	0	_	_	I-Premise
231	.	_	_	I-Premise

232	62	_	_	I-Premise
233	to	_	_	I-Premise
234	1	_	_	I-Premise
235	.	_	_	I-Premise

236	10	_	_	I-Premise
237	;	_	_	I-Premise
238	P	_	_	I-Premise
239	=	_	_	I-Premise
240	.	_	_	I-Premise

241	19	_	_	I-Premise
242	)	_	_	I-Premise
243	.	_	_	I-Premise

244	More	_	_	B-Premise
245	patients	_	_	I-Premise
246	on	_	_	I-Premise
247	afatinib	_	_	I-Premise
248	(	_	_	I-Premise
249	64	_	_	I-Premise
250	%	_	_	I-Premise
251	)	_	_	I-Premise
252	versus	_	_	I-Premise
253	chemotherapy	_	_	I-Premise
254	(	_	_	I-Premise
255	50	_	_	I-Premise
256	%	_	_	I-Premise
257	)	_	_	I-Premise
258	experienced	_	_	I-Premise
259	improvements	_	_	I-Premise
260	in	_	_	I-Premise
261	dyspnea	_	_	I-Premise
262	scores	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.	_	_	I-Premise

267	010	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	Differences	_	_	B-Premise
271	in	_	_	I-Premise
272	mean	_	_	I-Premise
273	scores	_	_	I-Premise
274	over	_	_	I-Premise
275	time	_	_	I-Premise
276	significantly	_	_	I-Premise
277	favored	_	_	I-Premise
278	afatinib	_	_	I-Premise
279	over	_	_	I-Premise
280	chemotherapy	_	_	I-Premise
281	for	_	_	I-Premise
282	cough	_	_	I-Premise
283	(	_	_	I-Premise
284	P	_	_	I-Premise
285	<	_	_	I-Premise
286	.	_	_	I-Premise

287	001	_	_	I-Premise
288	)	_	_	I-Premise
289	and	_	_	I-Premise
290	dyspnea	_	_	I-Premise
291	(	_	_	I-Premise
292	P	_	_	I-Premise
293	<	_	_	I-Premise
294	.	_	_	I-Premise

295	001	_	_	I-Premise
296	)	_	_	I-Premise
297	.	_	_	I-Premise

298	Afatinib	_	_	B-Premise
299	showed	_	_	I-Premise
300	significantly	_	_	I-Premise
301	better	_	_	I-Premise
302	mean	_	_	I-Premise
303	scores	_	_	I-Premise
304	over	_	_	I-Premise
305	time	_	_	I-Premise
306	in	_	_	I-Premise
307	global	_	_	I-Premise
308	health	_	_	I-Premise
309	status	_	_	I-Premise
310	/	_	_	I-Premise
311	QoL	_	_	I-Premise
312	(	_	_	I-Premise
313	P	_	_	I-Premise
314	=	_	_	I-Premise
315	.	_	_	I-Premise

316	015	_	_	I-Premise
317	)	_	_	I-Premise
318	and	_	_	I-Premise
319	physical	_	_	I-Premise
320	(	_	_	I-Premise
321	P	_	_	I-Premise
322	<	_	_	I-Premise
323	.	_	_	I-Premise

324	001	_	_	I-Premise
325	)	_	_	I-Premise
326	,	_	_	I-Premise
327	role	_	_	I-Premise
328	(	_	_	I-Premise
329	P	_	_	I-Premise
330	=	_	_	I-Premise
331	.	_	_	I-Premise

332	004	_	_	I-Premise
333	)	_	_	I-Premise
334	,	_	_	I-Premise
335	and	_	_	I-Premise
336	cognitive	_	_	I-Premise
337	(	_	_	I-Premise
338	P	_	_	I-Premise
339	=	_	_	I-Premise
340	.	_	_	I-Premise

341	007	_	_	I-Premise
342	)	_	_	I-Premise
343	functioning	_	_	I-Premise
344	compared	_	_	I-Premise
345	with	_	_	I-Premise
346	chemotherapy	_	_	I-Premise
347	.	_	_	I-Premise

348	Fatigue	_	_	B-Premise
349	and	_	_	I-Premise
350	nausea	_	_	I-Premise
351	were	_	_	I-Premise
352	worse	_	_	I-Premise
353	with	_	_	I-Premise
354	chemotherapy	_	_	I-Premise
355	,	_	_	I-Premise
356	whereas	_	_	I-Premise
357	diarrhea	_	_	I-Premise
358	,	_	_	I-Premise
359	dysphagia	_	_	I-Premise
360	,	_	_	I-Premise
361	and	_	_	I-Premise
362	sore	_	_	I-Premise
363	mouth	_	_	I-Premise
364	were	_	_	I-Premise
365	worse	_	_	I-Premise
366	with	_	_	I-Premise
367	afatinib	_	_	I-Premise
368	(	_	_	I-Premise
369	all	_	_	I-Premise
370	P	_	_	I-Premise
371	<	_	_	I-Premise
372	.	_	_	I-Premise

373	01	_	_	I-Premise
374	)	_	_	I-Premise
375	.	_	_	I-Premise

376	In	_	_	B-Claim
377	patients	_	_	I-Claim
378	with	_	_	I-Claim
379	lung	_	_	I-Claim
380	adenocarcinoma	_	_	I-Claim
381	with	_	_	I-Claim
382	EGFR	_	_	I-Claim
383	mutations	_	_	I-Claim
384	,	_	_	I-Claim
385	first	_	_	I-Claim
386	-	_	_	I-Claim
387	line	_	_	I-Claim
388	afatinib	_	_	I-Claim
389	was	_	_	I-Claim
390	associated	_	_	I-Claim
391	with	_	_	I-Claim
392	better	_	_	I-Claim
393	control	_	_	I-Claim
394	of	_	_	I-Claim
395	cough	_	_	I-Claim
396	and	_	_	I-Claim
397	dyspnea	_	_	I-Claim
398	compared	_	_	I-Claim
399	with	_	_	I-Claim
400	chemotherapy	_	_	I-Claim
401	,	_	_	I-Claim
402	although	_	_	I-Claim
403	diarrhea	_	_	I-Claim
404	,	_	_	I-Claim
405	dysphagia	_	_	I-Claim
406	,	_	_	I-Claim
407	and	_	_	I-Claim
408	sore	_	_	I-Claim
409	mouth	_	_	I-Claim
410	were	_	_	I-Claim
411	worse	_	_	I-Claim
412	.	_	_	I-Claim

413	Global	_	_	B-Claim
414	health	_	_	I-Claim
415	status	_	_	I-Claim
416	/	_	_	I-Claim
417	QoL	_	_	I-Claim
418	was	_	_	I-Claim
419	also	_	_	I-Claim
420	improved	_	_	I-Claim
421	over	_	_	I-Claim
422	time	_	_	I-Claim
423	with	_	_	I-Claim
424	afatinib	_	_	I-Claim
425	compared	_	_	I-Claim
426	with	_	_	I-Claim
427	chemotherapy	_	_	I-Claim
428	.	_	_	I-Claim


0	The	_	_	O
1	primary	_	_	O
2	goal	_	_	O
3	of	_	_	O
4	this	_	_	O
5	study	_	_	O
6	was	_	_	O
7	to	_	_	O
8	evaluate	_	_	O
9	the	_	_	O
10	feasibility	_	_	O
11	and	_	_	O
12	effectiveness	_	_	O
13	of	_	_	O
14	a	_	_	O
15	structured	_	_	O
16	,	_	_	O
17	multidisciplinary	_	_	O
18	intervention	_	_	O
19	targeted	_	_	O
20	to	_	_	O
21	maintain	_	_	O
22	the	_	_	O
23	overall	_	_	O
24	quality	_	_	O
25	of	_	_	O
26	life	_	_	O
27	(	_	_	O
28	QOL	_	_	O
29	)	_	_	O
30	,	_	_	O
31	which	_	_	O
32	is	_	_	O
33	more	_	_	O
34	comprehensive	_	_	O
35	than	_	_	O
36	psychosocial	_	_	O
37	distress	_	_	O
38	,	_	_	O
39	of	_	_	O
40	patients	_	_	O
41	undergoing	_	_	O
42	radiation	_	_	O
43	therapy	_	_	O
44	for	_	_	O
45	advanced	_	_	O
46	-	_	_	O
47	stage	_	_	O
48	cancer	_	_	O
49	.	_	_	O

50	Radiation	_	_	O
51	therapy	_	_	O
52	patients	_	_	O
53	with	_	_	O
54	advanced	_	_	O
55	cancer	_	_	O
56	and	_	_	O
57	an	_	_	O
58	estimated	_	_	O
59	5	_	_	O
60	-	_	_	O
61	year	_	_	O
62	survival	_	_	O
63	rate	_	_	O
64	of	_	_	O
65	0	_	_	O
66	%	_	_	O
67	to	_	_	O
68	50	_	_	O
69	%	_	_	O
70	were	_	_	O
71	randomly	_	_	O
72	assigned	_	_	O
73	to	_	_	O
74	either	_	_	O
75	an	_	_	O
76	eight	_	_	O
77	-	_	_	O
78	session	_	_	O
79	structured	_	_	O
80	multidisciplinary	_	_	O
81	intervention	_	_	O
82	arm	_	_	O
83	or	_	_	O
84	a	_	_	O
85	standard	_	_	O
86	care	_	_	O
87	arm	_	_	O
88	.	_	_	O

89	The	_	_	O
90	eight	_	_	O
91	90	_	_	O
92	-	_	_	O
93	minute	_	_	O
94	sessions	_	_	O
95	addressed	_	_	O
96	the	_	_	O
97	five	_	_	O
98	domains	_	_	O
99	of	_	_	O
100	QOL	_	_	O
101	including	_	_	O
102	cognitive	_	_	O
103	,	_	_	O
104	physical	_	_	O
105	,	_	_	O
106	emotional	_	_	O
107	,	_	_	O
108	spiritual	_	_	O
109	,	_	_	O
110	and	_	_	O
111	social	_	_	O
112	functioning	_	_	O
113	.	_	_	O

114	The	_	_	O
115	primary	_	_	O
116	end	_	_	O
117	point	_	_	O
118	of	_	_	O
119	maintaining	_	_	O
120	overall	_	_	O
121	QOL	_	_	O
122	was	_	_	O
123	assessed	_	_	O
124	by	_	_	O
125	a	_	_	O
126	single	_	_	O
127	-	_	_	O
128	item	_	_	O
129	linear	_	_	O
130	analog	_	_	O
131	scale	_	_	O
132	(	_	_	O
133	Linear	_	_	O
134	Analog	_	_	O
135	Scale	_	_	O
136	of	_	_	O
137	Assessment	_	_	O
138	or	_	_	O
139	modified	_	_	O
140	Spitzer	_	_	O
141	Uniscale	_	_	O
142	)	_	_	O
143	.	_	_	O

144	QOL	_	_	O
145	was	_	_	O
146	assessed	_	_	O
147	at	_	_	O
148	baseline	_	_	O
149	,	_	_	O
150	week	_	_	O
151	4	_	_	O
152	(	_	_	O
153	end	_	_	O
154	of	_	_	O
155	multidisciplinary	_	_	O
156	intervention	_	_	O
157	)	_	_	O
158	,	_	_	O
159	week	_	_	O
160	8	_	_	O
161	,	_	_	O
162	and	_	_	O
163	week	_	_	O
164	27	_	_	O
165	.	_	_	O

166	Of	_	_	B-Premise
167	the	_	_	I-Premise
168	103	_	_	I-Premise
169	participants	_	_	I-Premise
170	,	_	_	I-Premise
171	overall	_	_	I-Premise
172	QOL	_	_	I-Premise
173	at	_	_	I-Premise
174	week	_	_	I-Premise
175	4	_	_	I-Premise
176	was	_	_	I-Premise
177	maintained	_	_	I-Premise
178	by	_	_	I-Premise
179	the	_	_	I-Premise
180	patients	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	intervention	_	_	I-Premise
184	(	_	_	I-Premise
185	n	_	_	I-Premise
186	=	_	_	I-Premise
187	49	_	_	I-Premise
188	)	_	_	I-Premise
189	,	_	_	I-Premise
190	whereas	_	_	I-Premise
191	QOL	_	_	I-Premise
192	at	_	_	I-Premise
193	week	_	_	I-Premise
194	4	_	_	I-Premise
195	significantly	_	_	I-Premise
196	decreased	_	_	I-Premise
197	for	_	_	I-Premise
198	patients	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	control	_	_	I-Premise
202	group	_	_	I-Premise
203	(	_	_	I-Premise
204	n	_	_	I-Premise
205	=	_	_	I-Premise
206	54	_	_	I-Premise
207	)	_	_	I-Premise
208	.	_	_	I-Premise

209	This	_	_	B-Premise
210	change	_	_	I-Premise
211	reflected	_	_	I-Premise
212	a	_	_	I-Premise
213	3	_	_	I-Premise
214	-	_	_	I-Premise
215	point	_	_	I-Premise
216	increase	_	_	I-Premise
217	from	_	_	I-Premise
218	baseline	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	intervention	_	_	I-Premise
222	group	_	_	I-Premise
223	and	_	_	I-Premise
224	a	_	_	I-Premise
225	9	_	_	I-Premise
226	-	_	_	I-Premise
227	point	_	_	I-Premise
228	decrease	_	_	I-Premise
229	from	_	_	I-Premise
230	baseline	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	control	_	_	I-Premise
234	group	_	_	I-Premise
235	(	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	.	_	_	I-Premise

239	009	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	Intervention	_	_	B-Premise
243	participants	_	_	I-Premise
244	maintained	_	_	I-Premise
245	their	_	_	I-Premise
246	QOL	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	controls	_	_	I-Premise
250	gradually	_	_	I-Premise
251	returned	_	_	I-Premise
252	to	_	_	I-Premise
253	baseline	_	_	I-Premise
254	by	_	_	I-Premise
255	the	_	_	I-Premise
256	end	_	_	I-Premise
257	of	_	_	I-Premise
258	the	_	_	I-Premise
259	6	_	_	I-Premise
260	-	_	_	I-Premise
261	month	_	_	I-Premise
262	follow	_	_	I-Premise
263	-	_	_	I-Premise
264	up	_	_	I-Premise
265	period	_	_	I-Premise
266	.	_	_	I-Premise

267	Although	_	_	B-Claim
268	intervention	_	_	I-Claim
269	participants	_	_	I-Claim
270	maintained	_	_	I-Claim
271	and	_	_	I-Claim
272	actually	_	_	I-Claim
273	improved	_	_	I-Claim
274	their	_	_	I-Claim
275	QOL	_	_	I-Claim
276	during	_	_	I-Claim
277	radiation	_	_	I-Claim
278	therapy	_	_	I-Claim
279	,	_	_	I-Claim
280	control	_	_	I-Claim
281	participants	_	_	I-Claim
282	experienced	_	_	I-Claim
283	a	_	_	I-Claim
284	significant	_	_	I-Claim
285	decrease	_	_	I-Claim
286	in	_	_	I-Claim
287	their	_	_	I-Claim
288	QOL	_	_	I-Claim
289	.	_	_	O

290	Thus	_	_	B-Claim
291	,	_	_	I-Claim
292	a	_	_	I-Claim
293	structured	_	_	I-Claim
294	multidisciplinary	_	_	I-Claim
295	intervention	_	_	I-Claim
296	can	_	_	I-Claim
297	help	_	_	I-Claim
298	maintain	_	_	I-Claim
299	or	_	_	I-Claim
300	even	_	_	I-Claim
301	improve	_	_	I-Claim
302	QOL	_	_	I-Claim
303	in	_	_	I-Claim
304	patients	_	_	I-Claim
305	with	_	_	I-Claim
306	advanced	_	_	I-Claim
307	cancer	_	_	I-Claim
308	who	_	_	I-Claim
309	are	_	_	I-Claim
310	undergoing	_	_	I-Claim
311	cancer	_	_	I-Claim
312	treatment	_	_	I-Claim
313	.	_	_	I-Claim


0	This	_	_	O
1	randomised	_	_	O
2	trial	_	_	O
3	compared	_	_	O
4	three	_	_	O
5	chemotherapy	_	_	O
6	regimens	_	_	O
7	in	_	_	O
8	the	_	_	O
9	first	_	_	O
10	-	_	_	O
11	line	_	_	O
12	treatment	_	_	O
13	of	_	_	O
14	advanced	_	_	O
15	colorectal	_	_	O
16	cancer	_	_	O
17	,	_	_	O
18	in	_	_	O
19	terms	_	_	O
20	of	_	_	O
21	their	_	_	O
22	effect	_	_	O
23	on	_	_	O
24	overall	_	_	O
25	and	_	_	O
26	progression	_	_	O
27	-	_	_	O
28	free	_	_	O
29	survival	_	_	O
30	;	_	_	O
31	other	_	_	O
32	endpoints	_	_	O
33	included	_	_	O
34	toxicity	_	_	O
35	,	_	_	O
36	symptom	_	_	O
37	palliation	_	_	O
38	,	_	_	O
39	and	_	_	O
40	quality	_	_	O
41	of	_	_	O
42	life	_	_	O
43	.	_	_	O

44	905	_	_	O
45	patients	_	_	O
46	were	_	_	O
47	randomly	_	_	O
48	assigned	_	_	O
49	the	_	_	O
50	de	_	_	O
51	Gramont	_	_	O
52	regimen	_	_	O
53	(	_	_	O
54	n	_	_	O
55	=	_	_	O
56	303	_	_	O
57	;	_	_	O
58	folinic	_	_	O
59	acid	_	_	O
60	200	_	_	O
61	mg	_	_	O
62	/	_	_	O
63	m	_	_	O
64	(	_	_	O
65	2	_	_	O
66	)	_	_	O
67	,	_	_	O
68	fluorouracil	_	_	O
69	bolus	_	_	O
70	400	_	_	O
71	mg	_	_	O
72	/	_	_	O
73	m	_	_	O
74	(	_	_	O
75	2	_	_	O
76	)	_	_	O
77	,	_	_	O
78	and	_	_	O
79	infusion	_	_	O
80	600	_	_	O
81	mg	_	_	O
82	/	_	_	O
83	m	_	_	O
84	(	_	_	O
85	2	_	_	O
86	)	_	_	O
87	on	_	_	O
88	days	_	_	O
89	1	_	_	O
90	and	_	_	O
91	2	_	_	O
92	,	_	_	O
93	repeated	_	_	O
94	every	_	_	O
95	14	_	_	O
96	days	_	_	O
97	)	_	_	O
98	,	_	_	O
99	the	_	_	O
100	Lokich	_	_	O
101	regimen	_	_	O
102	(	_	_	O
103	n	_	_	O
104	=	_	_	O
105	301	_	_	O
106	;	_	_	O
107	protracted	_	_	O
108	venous	_	_	O
109	infusion	_	_	O
110	of	_	_	O
111	fluorouracil	_	_	O
112	300	_	_	O
113	mg	_	_	O
114	/	_	_	O
115	m	_	_	O
116	(	_	_	O
117	2	_	_	O
118	)	_	_	O
119	daily	_	_	O
120	)	_	_	O
121	,	_	_	O
122	or	_	_	O
123	raltitrexed	_	_	O
124	(	_	_	O
125	n	_	_	O
126	=	_	_	O
127	301	_	_	O
128	;	_	_	O
129	3	_	_	O
130	mg	_	_	O
131	/	_	_	O
132	m	_	_	O
133	(	_	_	O
134	2	_	_	O
135	)	_	_	O
136	intravenously	_	_	O
137	every	_	_	O
138	21	_	_	O
139	days	_	_	O
140	)	_	_	O
141	.	_	_	O

142	Analyses	_	_	O
143	were	_	_	O
144	by	_	_	O
145	intention	_	_	O
146	to	_	_	O
147	treat	_	_	O
148	.	_	_	O

149	Median	_	_	O
150	follow	_	_	O
151	-	_	_	O
152	up	_	_	O
153	of	_	_	O
154	survivors	_	_	O
155	was	_	_	O
156	67	_	_	O
157	weeks	_	_	O
158	.	_	_	O

159	For	_	_	B-Premise
160	the	_	_	I-Premise
161	de	_	_	I-Premise
162	Gramont	_	_	I-Premise
163	,	_	_	I-Premise
164	Lokich	_	_	I-Premise
165	,	_	_	I-Premise
166	and	_	_	I-Premise
167	raltitrexed	_	_	I-Premise
168	groups	_	_	I-Premise
169	,	_	_	I-Premise
170	respectively	_	_	I-Premise
171	,	_	_	I-Premise
172	median	_	_	I-Premise
173	survival	_	_	I-Premise
174	was	_	_	I-Premise
175	294	_	_	I-Premise
176	,	_	_	I-Premise
177	302	_	_	I-Premise
178	,	_	_	I-Premise
179	and	_	_	I-Premise
180	266	_	_	I-Premise
181	days	_	_	I-Premise
182	.	_	_	I-Premise

183	The	_	_	B-Premise
184	hazard	_	_	I-Premise
185	ratios	_	_	I-Premise
186	for	_	_	I-Premise
187	overall	_	_	I-Premise
188	survival	_	_	I-Premise
189	were	_	_	I-Premise
190	0	_	_	I-Premise
191	.	_	_	I-Premise

192	88	_	_	I-Premise
193	(	_	_	I-Premise
194	95	_	_	I-Premise
195	%	_	_	I-Premise
196	CI	_	_	I-Premise
197	0	_	_	I-Premise
198	.	_	_	I-Premise

199	70	_	_	I-Premise
200	-	_	_	I-Premise
201	1	_	_	I-Premise
202	.	_	_	I-Premise

203	12	_	_	I-Premise
204	,	_	_	I-Premise
205	p	_	_	I-Premise
206	=	_	_	I-Premise
207	0	_	_	I-Premise
208	.	_	_	I-Premise

209	17	_	_	I-Premise
210	)	_	_	I-Premise
211	for	_	_	I-Premise
212	de	_	_	I-Premise
213	Gramont	_	_	I-Premise
214	versus	_	_	I-Premise
215	Lokich	_	_	I-Premise
216	,	_	_	I-Premise
217	and	_	_	I-Premise
218	0	_	_	I-Premise
219	.	_	_	I-Premise

220	99	_	_	I-Premise
221	(	_	_	I-Premise
222	0	_	_	I-Premise
223	.	_	_	I-Premise

224	79	_	_	I-Premise
225	-	_	_	I-Premise
226	1	_	_	I-Premise
227	.	_	_	I-Premise

228	25	_	_	I-Premise
229	,	_	_	I-Premise
230	p	_	_	I-Premise
231	=	_	_	I-Premise
232	0	_	_	I-Premise
233	.	_	_	I-Premise

234	94	_	_	I-Premise
235	)	_	_	I-Premise
236	for	_	_	I-Premise
237	de	_	_	I-Premise
238	Gramont	_	_	I-Premise
239	versus	_	_	I-Premise
240	raltitrexed	_	_	I-Premise
241	.	_	_	I-Premise

242	An	_	_	B-Premise
243	increase	_	_	I-Premise
244	in	_	_	I-Premise
245	treatment	_	_	I-Premise
246	-	_	_	I-Premise
247	related	_	_	I-Premise
248	deaths	_	_	I-Premise
249	was	_	_	I-Premise
250	seen	_	_	I-Premise
251	on	_	_	I-Premise
252	raltitrexed	_	_	I-Premise
253	(	_	_	I-Premise
254	de	_	_	I-Premise
255	Gramont	_	_	I-Premise
256	one	_	_	I-Premise
257	,	_	_	I-Premise
258	Lokich	_	_	I-Premise
259	two	_	_	I-Premise
260	,	_	_	I-Premise
261	raltitrexed	_	_	I-Premise
262	18	_	_	I-Premise
263	)	_	_	I-Premise
264	due	_	_	I-Premise
265	to	_	_	I-Premise
266	combined	_	_	I-Premise
267	gastrointestinal	_	_	I-Premise
268	and	_	_	I-Premise
269	haematological	_	_	I-Premise
270	toxicity	_	_	I-Premise
271	.	_	_	I-Premise

272	Patients	_	_	B-Premise
273	'	_	_	I-Premise
274	assessment	_	_	I-Premise
275	of	_	_	I-Premise
276	quality	_	_	I-Premise
277	of	_	_	I-Premise
278	life	_	_	I-Premise
279	showed	_	_	I-Premise
280	that	_	_	I-Premise
281	raltitrexed	_	_	I-Premise
282	was	_	_	I-Premise
283	inferior	_	_	I-Premise
284	to	_	_	I-Premise
285	the	_	_	I-Premise
286	fluorouracil	_	_	I-Premise
287	-	_	_	I-Premise
288	based	_	_	I-Premise
289	regimens	_	_	I-Premise
290	,	_	_	I-Premise
291	especially	_	_	I-Premise
292	in	_	_	I-Premise
293	terms	_	_	I-Premise
294	of	_	_	I-Premise
295	palliation	_	_	I-Premise
296	and	_	_	I-Premise
297	functioning	_	_	I-Premise
298	.	_	_	I-Premise

299	The	_	_	B-Claim
300	deGramont	_	_	I-Claim
301	and	_	_	I-Claim
302	Lokich	_	_	I-Claim
303	regimens	_	_	I-Claim
304	were	_	_	I-Claim
305	similar	_	_	I-Claim
306	in	_	_	I-Claim
307	terms	_	_	I-Claim
308	of	_	_	I-Claim
309	survival	_	_	I-Claim
310	,	_	_	I-Claim
311	quality	_	_	I-Claim
312	of	_	_	I-Claim
313	life	_	_	I-Claim
314	,	_	_	I-Claim
315	and	_	_	I-Claim
316	response	_	_	I-Claim
317	rates	_	_	I-Claim
318	.	_	_	I-Claim

319	The	_	_	B-Claim
320	Lokich	_	_	I-Claim
321	regimen	_	_	I-Claim
322	was	_	_	I-Claim
323	associated	_	_	I-Claim
324	with	_	_	I-Claim
325	more	_	_	I-Claim
326	central	_	_	I-Claim
327	line	_	_	I-Claim
328	complications	_	_	I-Claim
329	and	_	_	I-Claim
330	hand	_	_	I-Claim
331	-	_	_	I-Claim
332	foot	_	_	I-Claim
333	syndrome	_	_	I-Claim
334	.	_	_	I-Claim

335	Raltitrexed	_	_	B-Claim
336	showed	_	_	I-Claim
337	similar	_	_	I-Claim
338	response	_	_	I-Claim
339	rates	_	_	I-Claim
340	and	_	_	I-Claim
341	overall	_	_	I-Claim
342	survival	_	_	I-Claim
343	to	_	_	I-Claim
344	the	_	_	I-Claim
345	de	_	_	I-Claim
346	Gramont	_	_	I-Claim
347	regimen	_	_	I-Claim
348	and	_	_	I-Claim
349	was	_	_	I-Claim
350	easier	_	_	I-Claim
351	to	_	_	I-Claim
352	administer	_	_	I-Claim
353	,	_	_	I-Claim
354	but	_	_	B-Claim
355	resulted	_	_	I-Claim
356	in	_	_	I-Claim
357	greater	_	_	I-Claim
358	toxicity	_	_	I-Claim
359	and	_	_	I-Claim
360	inferior	_	_	I-Claim
361	quality	_	_	I-Claim
362	of	_	_	I-Claim
363	life	_	_	I-Claim
364	.	_	_	I-Claim


0	Morbidity	_	_	B-Claim
1	is	_	_	I-Claim
2	an	_	_	I-Claim
3	important	_	_	I-Claim
4	issue	_	_	I-Claim
5	in	_	_	I-Claim
6	cancer	_	_	I-Claim
7	research	_	_	I-Claim
8	.	_	_	I-Claim

9	The	_	_	B-Claim
10	observer	_	_	I-Claim
11	-	_	_	I-Claim
12	based	_	_	I-Claim
13	toxicity	_	_	I-Claim
14	scoring	_	_	I-Claim
15	system	_	_	I-Claim
16	used	_	_	I-Claim
17	by	_	_	I-Claim
18	DAHANCA	_	_	I-Claim
19	(	_	_	I-Claim
20	the	_	_	I-Claim
21	Danish	_	_	I-Claim
22	head	_	_	I-Claim
23	and	_	_	I-Claim
24	neck	_	_	I-Claim
25	cancer	_	_	I-Claim
26	study	_	_	I-Claim
27	group	_	_	I-Claim
28	)	_	_	I-Claim
29	has	_	_	I-Claim
30	proved	_	_	I-Claim
31	itself	_	_	I-Claim
32	sensitive	_	_	I-Claim
33	to	_	_	I-Claim
34	differences	_	_	I-Claim
35	in	_	_	I-Claim
36	toxicity	_	_	I-Claim
37	in	_	_	I-Claim
38	a	_	_	I-Claim
39	large	_	_	I-Claim
40	randomised	_	_	I-Claim
41	study	_	_	I-Claim
42	,	_	_	I-Claim
43	but	_	_	B-Claim
44	like	_	_	I-Claim
45	other	_	_	I-Claim
46	toxicity	_	_	I-Claim
47	scoring	_	_	I-Claim
48	systems	_	_	I-Claim
49	it	_	_	I-Claim
50	has	_	_	I-Claim
51	not	_	_	I-Claim
52	been	_	_	I-Claim
53	formally	_	_	I-Claim
54	validated	_	_	I-Claim
55	.	_	_	I-Claim

56	Conversely	_	_	O
57	,	_	_	O
58	the	_	_	O
59	EORTC	_	_	O
60	quality	_	_	O
61	of	_	_	O
62	life	_	_	O
63	questionnaire	_	_	O
64	(	_	_	O
65	QLQ	_	_	O
66	)	_	_	O
67	has	_	_	O
68	been	_	_	O
69	validated	_	_	O
70	as	_	_	O
71	a	_	_	O
72	tool	_	_	O
73	for	_	_	O
74	collecting	_	_	O
75	information	_	_	O
76	about	_	_	O
77	the	_	_	O
78	consequences	_	_	O
79	of	_	_	O
80	disease	_	_	O
81	and	_	_	O
82	treatment	_	_	O
83	on	_	_	O
84	the	_	_	O
85	well	_	_	O
86	being	_	_	O
87	of	_	_	O
88	cancer	_	_	O
89	patients	_	_	O
90	.	_	_	O

91	The	_	_	O
92	purpose	_	_	O
93	of	_	_	O
94	this	_	_	O
95	study	_	_	O
96	was	_	_	O
97	to	_	_	O
98	examine	_	_	O
99	the	_	_	O
100	relationship	_	_	O
101	between	_	_	O
102	the	_	_	O
103	two	_	_	O
104	methods	_	_	O
105	of	_	_	O
106	side	_	_	O
107	effect	_	_	O
108	recording	_	_	O
109	.	_	_	O

110	One	_	_	O
111	hundred	_	_	O
112	and	_	_	O
113	sixteen	_	_	O
114	recurrence	_	_	O
115	free	_	_	O
116	patients	_	_	O
117	with	_	_	O
118	laryngeal	_	_	O
119	(	_	_	O
120	n	_	_	O
121	=	_	_	O
122	44	_	_	O
123	)	_	_	O
124	,	_	_	O
125	pharyngeal	_	_	O
126	(	_	_	O
127	n	_	_	O
128	=	_	_	O
129	34	_	_	O
130	)	_	_	O
131	and	_	_	O
132	oral	_	_	O
133	cavity	_	_	O
134	(	_	_	O
135	n	_	_	O
136	=	_	_	O
137	38	_	_	O
138	)	_	_	O
139	cancer	_	_	O
140	attending	_	_	O
141	follow	_	_	O
142	-	_	_	O
143	up	_	_	O
144	after	_	_	O
145	radiotherapy	_	_	O
146	(	_	_	O
147	n	_	_	O
148	=	_	_	O
149	83	_	_	O
150	)	_	_	O
151	or	_	_	O
152	surgery	_	_	O
153	(	_	_	O
154	n	_	_	O
155	=	_	_	O
156	33	_	_	O
157	)	_	_	O
158	completed	_	_	O
159	EORTC	_	_	O
160	C30	_	_	O
161	,	_	_	O
162	the	_	_	O
163	core	_	_	O
164	questionnaire	_	_	O
165	concerning	_	_	O
166	general	_	_	O
167	symptoms	_	_	O
168	and	_	_	O
169	function	_	_	O
170	and	_	_	O
171	EORTC	_	_	O
172	H	_	_	O
173	&	_	_	O
174	amp	_	_	O
175	;	_	_	O
176	N35	_	_	O
177	the	_	_	O
178	head	_	_	O
179	and	_	_	O
180	neck	_	_	O
181	specific	_	_	O
182	questionnaire	_	_	O
183	.	_	_	O

184	The	_	_	O
185	attending	_	_	O
186	physicians	_	_	O
187	in	_	_	O
188	the	_	_	O
189	follow	_	_	O
190	-	_	_	O
191	up	_	_	O
192	clinic	_	_	O
193	evaluated	_	_	O
194	and	_	_	O
195	recorded	_	_	O
196	DAHANCA	_	_	O
197	toxicity	_	_	O
198	scores	_	_	O
199	on	_	_	O
200	the	_	_	O
201	same	_	_	O
202	patients	_	_	O
203	.	_	_	O

204	The	_	_	B-Premise
205	DAHANCA	_	_	I-Premise
206	toxicity	_	_	I-Premise
207	scoring	_	_	I-Premise
208	system	_	_	I-Premise
209	and	_	_	I-Premise
210	the	_	_	I-Premise
211	EORTC	_	_	I-Premise
212	QLQ	_	_	I-Premise
213	correlated	_	_	I-Premise
214	with	_	_	I-Premise
215	several	_	_	I-Premise
216	clinical	_	_	I-Premise
217	endpoints	_	_	I-Premise
218	.	_	_	I-Premise

219	The	_	_	B-Premise
220	conceptually	_	_	I-Premise
221	similar	_	_	I-Premise
222	endpoints	_	_	I-Premise
223	of	_	_	I-Premise
224	the	_	_	I-Premise
225	two	_	_	I-Premise
226	methods	_	_	I-Premise
227	correlated	_	_	I-Premise
228	significantly	_	_	I-Premise
229	.	_	_	I-Premise

230	The	_	_	B-Premise
231	objective	_	_	I-Premise
232	endpoints	_	_	I-Premise
233	of	_	_	I-Premise
234	the	_	_	I-Premise
235	DAHANCA	_	_	I-Premise
236	scoring	_	_	I-Premise
237	system	_	_	I-Premise
238	were	_	_	I-Premise
239	only	_	_	I-Premise
240	correlated	_	_	I-Premise
241	with	_	_	I-Premise
242	quality	_	_	I-Premise
243	of	_	_	I-Premise
244	life	_	_	I-Premise
245	endpoints	_	_	I-Premise
246	to	_	_	I-Premise
247	a	_	_	I-Premise
248	very	_	_	I-Premise
249	low	_	_	I-Premise
250	degree	_	_	I-Premise
251	.	_	_	I-Premise

252	The	_	_	B-Premise
253	DAHANCA	_	_	I-Premise
254	toxicity	_	_	I-Premise
255	scores	_	_	I-Premise
256	had	_	_	I-Premise
257	a	_	_	I-Premise
258	low	_	_	I-Premise
259	sensitivity	_	_	I-Premise
260	(	_	_	I-Premise
261	0	_	_	I-Premise
262	.	_	_	I-Premise

263	48	_	_	I-Premise
264	-	_	_	I-Premise
265	0	_	_	I-Premise
266	.	_	_	I-Premise

267	74	_	_	I-Premise
268	)	_	_	I-Premise
269	in	_	_	I-Premise
270	detecting	_	_	I-Premise
271	equivalent	_	_	I-Premise
272	subjective	_	_	I-Premise
273	complaints	_	_	I-Premise
274	from	_	_	I-Premise
275	the	_	_	I-Premise
276	questionnaires	_	_	I-Premise
277	and	_	_	I-Premise
278	the	_	_	I-Premise
279	observer	_	_	I-Premise
280	-	_	_	I-Premise
281	based	_	_	I-Premise
282	scoring	_	_	I-Premise
283	system	_	_	I-Premise
284	severely	_	_	I-Premise
285	underestimated	_	_	I-Premise
286	patient	_	_	I-Premise
287	complaints	_	_	I-Premise
288	.	_	_	I-Premise

289	A	_	_	B-Premise
290	specific	_	_	I-Premise
291	patient	_	_	I-Premise
292	group	_	_	I-Premise
293	where	_	_	I-Premise
294	the	_	_	I-Premise
295	DAHANCA	_	_	I-Premise
296	score	_	_	I-Premise
297	had	_	_	I-Premise
298	a	_	_	I-Premise
299	higher	_	_	I-Premise
300	tendency	_	_	I-Premise
301	to	_	_	I-Premise
302	fail	_	_	I-Premise
303	could	_	_	I-Premise
304	not	_	_	I-Premise
305	be	_	_	I-Premise
306	detected	_	_	I-Premise
307	.	_	_	I-Premise

308	The	_	_	B-Claim
309	DAHANCA	_	_	I-Claim
310	toxicity	_	_	I-Claim
311	score	_	_	I-Claim
312	is	_	_	I-Claim
313	an	_	_	I-Claim
314	effective	_	_	I-Claim
315	instrument	_	_	I-Claim
316	in	_	_	I-Claim
317	assessing	_	_	I-Claim
318	objective	_	_	I-Claim
319	treatment	_	_	I-Claim
320	induced	_	_	I-Claim
321	toxicity	_	_	I-Claim
322	in	_	_	I-Claim
323	head	_	_	I-Claim
324	and	_	_	I-Claim
325	neck	_	_	I-Claim
326	cancer	_	_	I-Claim
327	patients	_	_	I-Claim
328	but	_	_	I-Claim
329	insensitive	_	_	I-Claim
330	and	_	_	I-Claim
331	non	_	_	I-Claim
332	-	_	_	I-Claim
333	specific	_	_	I-Claim
334	with	_	_	I-Claim
335	regard	_	_	I-Claim
336	to	_	_	I-Claim
337	patient	_	_	I-Claim
338	assessed	_	_	I-Claim
339	subjective	_	_	I-Claim
340	endpoints	_	_	I-Claim
341	.	_	_	I-Claim

342	This	_	_	B-Claim
343	weakness	_	_	I-Claim
344	seems	_	_	I-Claim
345	inherent	_	_	I-Claim
346	in	_	_	I-Claim
347	an	_	_	I-Claim
348	observer	_	_	I-Claim
349	-	_	_	I-Claim
350	based	_	_	I-Claim
351	scoring	_	_	I-Claim
352	system	_	_	I-Claim
353	,	_	_	I-Claim
354	and	_	_	I-Claim
355	will	_	_	I-Claim
356	probably	_	_	I-Claim
357	also	_	_	I-Claim
358	apply	_	_	I-Claim
359	to	_	_	I-Claim
360	newer	_	_	I-Claim
361	ones	_	_	I-Claim
362	like	_	_	I-Claim
363	CTCAE	_	_	I-Claim
364	3	_	_	I-Claim
365	.	_	_	I-Claim

366	0	_	_	I-Claim
367	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	economic	_	_	O
6	efficiency	_	_	O
7	of	_	_	O
8	a	_	_	O
9	multimedia	_	_	O
10	,	_	_	O
11	multimodal	_	_	O
12	physical	_	_	O
13	activity	_	_	O
14	program	_	_	O
15	for	_	_	O
16	women	_	_	O
17	undergoing	_	_	O
18	adjuvant	_	_	O
19	therapy	_	_	O
20	following	_	_	O
21	surgery	_	_	O
22	for	_	_	O
23	breast	_	_	O
24	cancer	_	_	O
25	.	_	_	O

26	We	_	_	O
27	conducted	_	_	O
28	a	_	_	O
29	randomized	_	_	O
30	trial	_	_	O
31	with	_	_	O
32	concurrent	_	_	O
33	incremental	_	_	O
34	cost	_	_	O
35	-	_	_	O
36	effectiveness	_	_	O
37	analysis	_	_	O
38	and	_	_	O
39	blinded	_	_	O
40	baseline	_	_	O
41	,	_	_	O
42	3	_	_	O
43	,	_	_	O
44	6	_	_	O
45	and	_	_	O
46	12	_	_	O
47	-	_	_	O
48	month	_	_	O
49	follow	_	_	O
50	-	_	_	O
51	up	_	_	O
52	assessments	_	_	O
53	amongst	_	_	O
54	women	_	_	O
55	undergoing	_	_	O
56	adjuvant	_	_	O
57	therapy	_	_	O
58	following	_	_	O
59	surgery	_	_	O
60	for	_	_	O
61	breast	_	_	O
62	cancer	_	_	O
63	(	_	_	O
64	n	_	_	O
65	=	_	_	O
66	89	_	_	O
67	)	_	_	O
68	.	_	_	O

69	The	_	_	O
70	intervention	_	_	O
71	was	_	_	O
72	a	_	_	O
73	multimedia	_	_	O
74	,	_	_	O
75	multimodal	_	_	O
76	exercise	_	_	O
77	program	_	_	O
78	comprising	_	_	O
79	strength	_	_	O
80	,	_	_	O
81	balance	_	_	O
82	and	_	_	O
83	endurance	_	_	O
84	training	_	_	O
85	elements	_	_	O
86	.	_	_	O

87	The	_	_	O
88	control	_	_	O
89	was	_	_	O
90	sham	_	_	O
91	flexibility	_	_	O
92	and	_	_	O
93	relaxation	_	_	O
94	program	_	_	O
95	delivered	_	_	O
96	using	_	_	O
97	similar	_	_	O
98	materials	_	_	O
99	.	_	_	O

100	The	_	_	O
101	primary	_	_	O
102	outcome	_	_	O
103	was	_	_	O
104	health	_	_	O
105	-	_	_	O
106	related	_	_	O
107	quality	_	_	O
108	of	_	_	O
109	life	_	_	O
110	(	_	_	O
111	EQ	_	_	O
112	-	_	_	O
113	5D	_	_	O
114	&	_	_	O
115	amp	_	_	O
116	;	_	_	O
117	VAS	_	_	O
118	,	_	_	O
119	EORTC	_	_	O
120	C30	_	_	O
121	,	_	_	O
122	BR23	_	_	O
123	)	_	_	O
124	.	_	_	O

125	Economic	_	_	O
126	outcomes	_	_	O
127	included	_	_	O
128	direct	_	_	O
129	health	_	_	O
130	care	_	_	O
131	costs	_	_	O
132	and	_	_	O
133	productivity	_	_	O
134	gains	_	_	O
135	and	_	_	O
136	losses	_	_	O
137	.	_	_	O

138	Participants	_	_	B-Premise
139	in	_	_	I-Premise
140	the	_	_	I-Premise
141	intervention	_	_	I-Premise
142	group	_	_	I-Premise
143	demonstrated	_	_	I-Premise
144	greater	_	_	I-Premise
145	improvement	_	_	I-Premise
146	in	_	_	I-Premise
147	health	_	_	I-Premise
148	-	_	_	I-Premise
149	related	_	_	I-Premise
150	quality	_	_	I-Premise
151	of	_	_	I-Premise
152	life	_	_	I-Premise
153	between	_	_	I-Premise
154	baseline	_	_	I-Premise
155	and	_	_	I-Premise
156	the	_	_	I-Premise
157	3	_	_	I-Premise
158	-	_	_	I-Premise
159	month	_	_	I-Premise
160	assessment	_	_	I-Premise
161	[	_	_	I-Premise
162	mean	_	_	I-Premise
163	(	_	_	I-Premise
164	sd	_	_	I-Premise
165	)	_	_	I-Premise
166	EQ	_	_	I-Premise
167	-	_	_	I-Premise
168	5D	_	_	I-Premise
169	VAS	_	_	I-Premise
170	(	_	_	I-Premise
171	0	_	_	I-Premise
172	-	_	_	I-Premise
173	100	_	_	I-Premise
174	)	_	_	I-Premise
175	baseline	_	_	I-Premise
176	:	_	_	I-Premise
177	72	_	_	I-Premise
178	.	_	_	I-Premise

179	6	_	_	I-Premise
180	(	_	_	I-Premise
181	15	_	_	I-Premise
182	.	_	_	I-Premise

183	6	_	_	I-Premise
184	)	_	_	I-Premise
185	,	_	_	I-Premise
186	3	_	_	I-Premise
187	month	_	_	I-Premise
188	:	_	_	I-Premise
189	80	_	_	I-Premise
190	.	_	_	I-Premise

191	6	_	_	I-Premise
192	(	_	_	I-Premise
193	11	_	_	I-Premise
194	.	_	_	I-Premise

195	6	_	_	I-Premise
196	)	_	_	I-Premise
197	]	_	_	I-Premise
198	when	_	_	I-Premise
199	compared	_	_	I-Premise
200	to	_	_	I-Premise
201	control	_	_	I-Premise
202	group	_	_	I-Premise
203	participants	_	_	I-Premise
204	[	_	_	I-Premise
205	baseline	_	_	I-Premise
206	:	_	_	I-Premise
207	77	_	_	I-Premise
208	.	_	_	I-Premise

209	5	_	_	I-Premise
210	(	_	_	I-Premise
211	13	_	_	I-Premise
212	.	_	_	I-Premise

213	5	_	_	I-Premise
214	)	_	_	I-Premise
215	,	_	_	I-Premise
216	3	_	_	I-Premise
217	month	_	_	I-Premise
218	:	_	_	I-Premise
219	74	_	_	I-Premise
220	.	_	_	I-Premise

221	1	_	_	I-Premise
222	(	_	_	I-Premise
223	20	_	_	I-Premise
224	.	_	_	I-Premise

225	6	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	P	_	_	I-Premise
229	=	_	_	I-Premise
230	0	_	_	I-Premise
231	.	_	_	I-Premise

232	006	_	_	I-Premise
233	]	_	_	I-Premise
234	and	_	_	I-Premise
235	also	_	_	I-Premise
236	improved	_	_	I-Premise
237	more	_	_	I-Premise
238	in	_	_	I-Premise
239	terms	_	_	I-Premise
240	of	_	_	I-Premise
241	physical	_	_	I-Premise
242	function	_	_	I-Premise
243	[	_	_	I-Premise
244	mean	_	_	I-Premise
245	(	_	_	I-Premise
246	sd	_	_	I-Premise
247	)	_	_	I-Premise
248	EORTC	_	_	I-Premise
249	C30	_	_	I-Premise
250	physical	_	_	I-Premise
251	function	_	_	I-Premise
252	scale	_	_	I-Premise
253	intervention	_	_	I-Premise
254	(	_	_	I-Premise
255	0	_	_	I-Premise
256	-	_	_	I-Premise
257	100	_	_	I-Premise
258	)	_	_	I-Premise
259	baseline	_	_	I-Premise
260	:	_	_	I-Premise
261	84	_	_	I-Premise
262	.	_	_	I-Premise

263	9	_	_	I-Premise
264	(	_	_	I-Premise
265	14	_	_	I-Premise
266	.	_	_	I-Premise

267	8	_	_	I-Premise
268	)	_	_	I-Premise
269	,	_	_	I-Premise
270	3	_	_	I-Premise
271	month	_	_	I-Premise
272	:	_	_	I-Premise
273	86	_	_	I-Premise
274	.	_	_	I-Premise

275	9	_	_	I-Premise
276	(	_	_	I-Premise
277	10	_	_	I-Premise
278	.	_	_	I-Premise

279	7	_	_	I-Premise
280	)	_	_	I-Premise
281	,	_	_	I-Premise
282	control	_	_	I-Premise
283	baseline	_	_	I-Premise
284	:	_	_	I-Premise
285	91	_	_	I-Premise
286	.	_	_	I-Premise

287	3	_	_	I-Premise
288	(	_	_	I-Premise
289	9	_	_	I-Premise
290	.	_	_	I-Premise

291	6	_	_	I-Premise
292	)	_	_	I-Premise
293	,	_	_	I-Premise
294	3	_	_	I-Premise
295	month	_	_	I-Premise
296	:	_	_	I-Premise
297	86	_	_	I-Premise
298	.	_	_	I-Premise

299	7	_	_	I-Premise
300	(	_	_	I-Premise
301	14	_	_	I-Premise
302	.	_	_	I-Premise

303	9	_	_	I-Premise
304	)	_	_	I-Premise
305	,	_	_	I-Premise
306	P	_	_	I-Premise
307	=	_	_	I-Premise
308	0	_	_	I-Premise
309	.	_	_	I-Premise

310	02	_	_	I-Premise
311	]	_	_	I-Premise
312	.	_	_	I-Premise

313	These	_	_	O
314	improvements	_	_	O
315	were	_	_	O
316	not	_	_	O
317	sustained	_	_	O
318	beyond	_	_	O
319	this	_	_	O
320	point	_	_	O
321	.	_	_	O

322	Upper	_	_	B-Premise
323	limb	_	_	I-Premise
324	volumes	_	_	I-Premise
325	were	_	_	I-Premise
326	also	_	_	I-Premise
327	lower	_	_	I-Premise
328	amongst	_	_	I-Premise
329	intervention	_	_	I-Premise
330	group	_	_	I-Premise
331	participants	_	_	I-Premise
332	.	_	_	I-Premise

333	However	_	_	O
334	,	_	_	O
335	there	_	_	B-Premise
336	was	_	_	I-Premise
337	low	_	_	I-Premise
338	probability	_	_	I-Premise
339	that	_	_	I-Premise
340	the	_	_	I-Premise
341	intervention	_	_	I-Premise
342	would	_	_	I-Premise
343	be	_	_	I-Premise
344	both	_	_	I-Premise
345	less	_	_	I-Premise
346	costly	_	_	I-Premise
347	and	_	_	I-Premise
348	more	_	_	I-Premise
349	effective	_	_	I-Premise
350	than	_	_	I-Premise
351	the	_	_	I-Premise
352	control	_	_	I-Premise
353	condition	_	_	I-Premise
354	(	_	_	I-Premise
355	range	_	_	I-Premise
356	probability	_	_	I-Premise
357	=	_	_	I-Premise
358	0	_	_	I-Premise
359	.	_	_	I-Premise

360	05	_	_	I-Premise
361	-	_	_	I-Premise
362	50	_	_	I-Premise
363	.	_	_	I-Premise

364	02	_	_	I-Premise
365	%	_	_	I-Premise
366	depending	_	_	I-Premise
367	on	_	_	I-Premise
368	approach	_	_	I-Premise
369	)	_	_	I-Premise
370	.	_	_	I-Premise

371	Provision	_	_	B-Claim
372	of	_	_	I-Claim
373	multimodal	_	_	I-Claim
374	exercise	_	_	I-Claim
375	programs	_	_	I-Claim
376	will	_	_	I-Claim
377	improve	_	_	I-Claim
378	the	_	_	I-Claim
379	short	_	_	I-Claim
380	-	_	_	I-Claim
381	term	_	_	I-Claim
382	health	_	_	I-Claim
383	of	_	_	I-Claim
384	women	_	_	I-Claim
385	undergoing	_	_	I-Claim
386	adjuvant	_	_	I-Claim
387	therapy	_	_	I-Claim
388	for	_	_	I-Claim
389	breast	_	_	I-Claim
390	cancer	_	_	I-Claim
391	but	_	_	I-Claim
392	are	_	_	I-Claim
393	of	_	_	I-Claim
394	questionable	_	_	I-Claim
395	economic	_	_	I-Claim
396	efficiency	_	_	I-Claim
397	.	_	_	I-Claim


0	This	_	_	O
1	study	_	_	O
2	aims	_	_	O
3	to	_	_	O
4	describe	_	_	O
5	and	_	_	O
6	compare	_	_	O
7	health	_	_	O
8	-	_	_	O
9	related	_	_	O
10	quality	_	_	O
11	of	_	_	O
12	life	_	_	O
13	(	_	_	O
14	HRQL	_	_	O
15	)	_	_	O
16	in	_	_	O
17	patients	_	_	O
18	with	_	_	O
19	node	_	_	O
20	-	_	_	O
21	positive	_	_	O
22	and	_	_	O
23	high	_	_	O
24	-	_	_	O
25	risk	_	_	O
26	node	_	_	O
27	-	_	_	O
28	negative	_	_	O
29	HER2	_	_	O
30	-	_	_	O
31	positive	_	_	O
32	early	_	_	O
33	breast	_	_	O
34	cancer	_	_	O
35	receiving	_	_	O
36	adjuvant	_	_	O
37	docetaxel	_	_	O
38	and	_	_	O
39	trastuzumab	_	_	O
40	-	_	_	O
41	based	_	_	O
42	or	_	_	O
43	docetaxel	_	_	O
44	-	_	_	O
45	based	_	_	O
46	regimens	_	_	O
47	alone	_	_	O
48	.	_	_	O

49	Eligible	_	_	O
50	patients	_	_	O
51	(	_	_	O
52	n	_	_	O
53	=	_	_	O
54	3	_	_	O
55	,	_	_	O
56	222	_	_	O
57	)	_	_	O
58	were	_	_	O
59	randomly	_	_	O
60	assigned	_	_	O
61	to	_	_	O
62	either	_	_	O
63	four	_	_	O
64	cycles	_	_	O
65	of	_	_	O
66	adjuvant	_	_	O
67	doxorubicin	_	_	O
68	and	_	_	O
69	cyclophosphamide	_	_	O
70	followed	_	_	O
71	by	_	_	O
72	four	_	_	O
73	cycles	_	_	O
74	of	_	_	O
75	docetaxel	_	_	O
76	(	_	_	O
77	AC	_	_	O
78	→	_	_	O
79	T	_	_	O
80	)	_	_	O
81	or	_	_	O
82	one	_	_	O
83	of	_	_	O
84	two	_	_	O
85	trastuzumab	_	_	O
86	-	_	_	O
87	containing	_	_	O
88	regimens	_	_	O
89	:	_	_	O
90	adjuvant	_	_	O
91	doxorubicin	_	_	O
92	and	_	_	O
93	cyclophosphamide	_	_	O
94	followed	_	_	O
95	by	_	_	O
96	docetaxel	_	_	O
97	plus	_	_	O
98	trastuzumab	_	_	O
99	administered	_	_	O
100	for	_	_	O
101	1	_	_	O
102	year	_	_	O
103	(	_	_	O
104	AC	_	_	O
105	→	_	_	O
106	TH	_	_	O
107	)	_	_	O
108	or	_	_	O
109	six	_	_	O
110	cycles	_	_	O
111	of	_	_	O
112	docetaxel	_	_	O
113	plus	_	_	O
114	carboplatin	_	_	O
115	combined	_	_	O
116	with	_	_	O
117	trastuzumab	_	_	O
118	administered	_	_	O
119	for	_	_	O
120	1	_	_	O
121	year	_	_	O
122	(	_	_	O
123	TCH	_	_	O
124	)	_	_	O
125	.	_	_	O

126	The	_	_	O
127	European	_	_	O
128	Organization	_	_	O
129	for	_	_	O
130	Research	_	_	O
131	and	_	_	O
132	Treatment	_	_	O
133	of	_	_	O
134	Cancer	_	_	O
135	(	_	_	O
136	EORTC	_	_	O
137	)	_	_	O
138	Quality	_	_	O
139	of	_	_	O
140	Life	_	_	O
141	Questionnaire	_	_	O
142	C30	_	_	O
143	and	_	_	O
144	BR	_	_	O
145	-	_	_	O
146	23	_	_	O
147	were	_	_	O
148	administered	_	_	O
149	at	_	_	O
150	baseline	_	_	O
151	,	_	_	O
152	the	_	_	O
153	start	_	_	O
154	of	_	_	O
155	cycle	_	_	O
156	4	_	_	O
157	(	_	_	O
158	mid	_	_	O
159	)	_	_	O
160	,	_	_	O
161	and	_	_	O
162	the	_	_	O
163	end	_	_	O
164	of	_	_	O
165	chemotherapy	_	_	O
166	(	_	_	O
167	EOC	_	_	O
168	)	_	_	O
169	,	_	_	O
170	as	_	_	O
171	well	_	_	O
172	as	_	_	O
173	at	_	_	O
174	6	_	_	O
175	,	_	_	O
176	12	_	_	O
177	,	_	_	O
178	and	_	_	O
179	24	_	_	O
180	months	_	_	O
181	after	_	_	O
182	chemotherapy	_	_	O
183	.	_	_	O

184	Compliance	_	_	B-Premise
185	rates	_	_	I-Premise
186	for	_	_	I-Premise
187	the	_	_	I-Premise
188	EORTC	_	_	I-Premise
189	questionnaires	_	_	I-Premise
190	were	_	_	I-Premise
191	acceptable	_	_	I-Premise
192	at	_	_	I-Premise
193	72	_	_	I-Premise
194	%	_	_	I-Premise
195	-	_	_	I-Premise
196	93	_	_	I-Premise
197	%	_	_	I-Premise
198	of	_	_	I-Premise
199	eligible	_	_	I-Premise
200	patients	_	_	I-Premise
201	out	_	_	I-Premise
202	to	_	_	I-Premise
203	the	_	_	I-Premise
204	12	_	_	I-Premise
205	-	_	_	I-Premise
206	month	_	_	I-Premise
207	assessment	_	_	I-Premise
208	.	_	_	I-Premise

209	Systemic	_	_	B-Premise
210	side	_	_	I-Premise
211	effect	_	_	I-Premise
212	(	_	_	I-Premise
213	SE	_	_	I-Premise
214	)	_	_	I-Premise
215	change	_	_	I-Premise
216	scores	_	_	I-Premise
217	were	_	_	I-Premise
218	significantly	_	_	I-Premise
219	improved	_	_	I-Premise
220	for	_	_	I-Premise
221	TCH	_	_	I-Premise
222	-	_	_	I-Premise
223	treated	_	_	I-Premise
224	patients	_	_	I-Premise
225	compared	_	_	I-Premise
226	with	_	_	I-Premise
227	AC	_	_	I-Premise
228	→	_	_	I-Premise
229	TH	_	_	I-Premise
230	and	_	_	I-Premise
231	AC	_	_	I-Premise
232	→	_	_	I-Premise
233	T	_	_	I-Premise
234	at	_	_	I-Premise
235	EOC	_	_	I-Premise
236	,	_	_	I-Premise
237	suggesting	_	_	I-Premise
238	improved	_	_	I-Premise
239	tolerability	_	_	I-Premise
240	.	_	_	I-Premise

241	Physical	_	_	B-Premise
242	functioning	_	_	I-Premise
243	(	_	_	I-Premise
244	PF	_	_	I-Premise
245	)	_	_	I-Premise
246	was	_	_	I-Premise
247	only	_	_	I-Premise
248	slightly	_	_	I-Premise
249	worse	_	_	I-Premise
250	at	_	_	I-Premise
251	midpoint	_	_	I-Premise
252	for	_	_	I-Premise
253	those	_	_	I-Premise
254	receiving	_	_	I-Premise
255	TCH	_	_	I-Premise
256	,	_	_	I-Premise
257	compared	_	_	I-Premise
258	with	_	_	I-Premise
259	patients	_	_	I-Premise
260	who	_	_	I-Premise
261	were	_	_	I-Premise
262	just	_	_	I-Premise
263	starting	_	_	I-Premise
264	on	_	_	I-Premise
265	taxane	_	_	I-Premise
266	in	_	_	I-Premise
267	an	_	_	I-Premise
268	AC	_	_	I-Premise
269	→	_	_	I-Premise
270	TH	_	_	I-Premise
271	regimen	_	_	I-Premise
272	,	_	_	I-Premise
273	but	_	_	I-Premise
274	was	_	_	I-Premise
275	otherwise	_	_	I-Premise
276	similar	_	_	I-Premise
277	between	_	_	I-Premise
278	arms	_	_	I-Premise
279	.	_	_	I-Premise

280	All	_	_	B-Claim
281	treatment	_	_	I-Claim
282	arms	_	_	I-Claim
283	recovered	_	_	I-Claim
284	from	_	_	I-Claim
285	the	_	_	I-Claim
286	deterioration	_	_	I-Claim
287	in	_	_	I-Claim
288	SE	_	_	I-Claim
289	,	_	_	I-Claim
290	PF	_	_	I-Claim
291	,	_	_	I-Claim
292	and	_	_	I-Claim
293	Global	_	_	I-Claim
294	Health	_	_	I-Claim
295	Scale	_	_	I-Claim
296	scores	_	_	I-Claim
297	by	_	_	I-Claim
298	1	_	_	I-Claim
299	year	_	_	I-Claim
300	and	_	_	I-Claim
301	median	_	_	I-Claim
302	future	_	_	I-Claim
303	perspective	_	_	I-Claim
304	change	_	_	I-Claim
305	scores	_	_	I-Claim
306	continued	_	_	I-Claim
307	to	_	_	I-Claim
308	improve	_	_	I-Claim
309	throughout	_	_	I-Claim
310	treatment	_	_	I-Claim
311	and	_	_	I-Claim
312	follow	_	_	I-Claim
313	-	_	_	I-Claim
314	up	_	_	I-Claim
315	.	_	_	I-Claim

316	HRQL	_	_	B-Claim
317	outcomes	_	_	I-Claim
318	for	_	_	I-Claim
319	adjuvant	_	_	I-Claim
320	docetaxel	_	_	I-Claim
321	and	_	_	I-Claim
322	trastuzumab	_	_	I-Claim
323	-	_	_	I-Claim
324	based	_	_	I-Claim
325	regimens	_	_	I-Claim
326	are	_	_	I-Claim
327	favorable	_	_	I-Claim
328	and	_	_	I-Claim
329	support	_	_	I-Claim
330	TCH	_	_	I-Claim
331	as	_	_	I-Claim
332	a	_	_	I-Claim
333	more	_	_	I-Claim
334	tolerable	_	_	I-Claim
335	treatment	_	_	I-Claim
336	option	_	_	I-Claim
337	.	_	_	I-Claim


0	Metal	_	_	O
1	stent	_	_	O
2	placement	_	_	O
3	and	_	_	O
4	single	_	_	O
5	dose	_	_	O
6	brachytherapy	_	_	O
7	are	_	_	O
8	commonly	_	_	O
9	used	_	_	O
10	treatment	_	_	O
11	modalities	_	_	O
12	for	_	_	O
13	the	_	_	O
14	palliation	_	_	O
15	of	_	_	O
16	inoperable	_	_	O
17	oesophageal	_	_	O
18	carcinoma	_	_	O
19	.	_	_	O

20	We	_	_	O
21	investigated	_	_	O
22	generic	_	_	O
23	and	_	_	O
24	disease	_	_	O
25	-	_	_	O
26	specific	_	_	O
27	health	_	_	O
28	-	_	_	O
29	related	_	_	O
30	quality	_	_	O
31	of	_	_	O
32	life	_	_	O
33	(	_	_	O
34	HRQoL	_	_	O
35	)	_	_	O
36	after	_	_	O
37	these	_	_	O
38	palliative	_	_	O
39	treatments	_	_	O
40	.	_	_	O

41	Patients	_	_	O
42	with	_	_	O
43	dysphagia	_	_	O
44	from	_	_	O
45	inoperable	_	_	O
46	oesophageal	_	_	O
47	carcinoma	_	_	O
48	were	_	_	O
49	randomised	_	_	O
50	to	_	_	O
51	placement	_	_	O
52	of	_	_	O
53	a	_	_	O
54	covered	_	_	O
55	Ultraflex	_	_	O
56	stent	_	_	O
57	(	_	_	O
58	n	_	_	O
59	=	_	_	O
60	108	_	_	O
61	)	_	_	O
62	or	_	_	O
63	single	_	_	O
64	dose	_	_	O
65	(	_	_	O
66	12	_	_	O
67	Gy	_	_	O
68	)	_	_	O
69	brachytherapy	_	_	O
70	(	_	_	O
71	n	_	_	O
72	=	_	_	O
73	101	_	_	O
74	)	_	_	O
75	.	_	_	O

76	We	_	_	O
77	obtained	_	_	O
78	longitudinal	_	_	O
79	data	_	_	O
80	on	_	_	O
81	disease	_	_	O
82	-	_	_	O
83	specific	_	_	O
84	(	_	_	O
85	dysphagia	_	_	O
86	score	_	_	O
87	,	_	_	O
88	European	_	_	O
89	Organisation	_	_	O
90	for	_	_	O
91	Research	_	_	O
92	and	_	_	O
93	Treatment	_	_	O
94	of	_	_	O
95	Cancer	_	_	O
96	(	_	_	O
97	EORTC	_	_	O
98	)	_	_	O
99	OES	_	_	O
100	-	_	_	O
101	23	_	_	O
102	,	_	_	O
103	visual	_	_	O
104	analogue	_	_	O
105	pain	_	_	O
106	scale	_	_	O
107	)	_	_	O
108	and	_	_	O
109	generic	_	_	O
110	(	_	_	O
111	EORTC	_	_	O
112	Quality	_	_	O
113	of	_	_	O
114	Life	_	_	O
115	-	_	_	O
116	Core	_	_	O
117	30	_	_	O
118	Questionnaire	_	_	O
119	(	_	_	O
120	QLQ	_	_	O
121	-	_	_	O
122	C30	_	_	O
123	)	_	_	O
124	,	_	_	O
125	Euroqol	_	_	O
126	(	_	_	O
127	EQ	_	_	O
128	)	_	_	O
129	-	_	_	O
130	5D	_	_	O
131	)	_	_	O
132	HRQoL	_	_	O
133	at	_	_	O
134	monthly	_	_	O
135	home	_	_	O
136	visits	_	_	O
137	by	_	_	O
138	a	_	_	O
139	specially	_	_	O
140	-	_	_	O
141	trained	_	_	O
142	research	_	_	O
143	nurse	_	_	O
144	.	_	_	O

145	We	_	_	O
146	compared	_	_	O
147	HRQoL	_	_	O
148	between	_	_	O
149	the	_	_	O
150	two	_	_	O
151	treatments	_	_	O
152	and	_	_	O
153	analysed	_	_	O
154	changes	_	_	O
155	in	_	_	O
156	HRQoL	_	_	O
157	during	_	_	O
158	follow	_	_	O
159	-	_	_	O
160	up	_	_	O
161	.	_	_	O

162	Dysphagia	_	_	B-Premise
163	improved	_	_	I-Premise
164	more	_	_	I-Premise
165	rapidly	_	_	I-Premise
166	after	_	_	I-Premise
167	stent	_	_	I-Premise
168	placement	_	_	I-Premise
169	than	_	_	I-Premise
170	after	_	_	I-Premise
171	brachytherapy	_	_	I-Premise
172	,	_	_	I-Premise
173	but	_	_	B-Premise
174	long	_	_	I-Premise
175	-	_	_	I-Premise
176	term	_	_	I-Premise
177	relief	_	_	I-Premise
178	of	_	_	I-Premise
179	dysphagia	_	_	I-Premise
180	was	_	_	I-Premise
181	better	_	_	I-Premise
182	after	_	_	I-Premise
183	brachytherapy	_	_	I-Premise
184	.	_	_	I-Premise

185	For	_	_	B-Premise
186	generic	_	_	I-Premise
187	HRQoL	_	_	I-Premise
188	,	_	_	I-Premise
189	there	_	_	I-Premise
190	was	_	_	I-Premise
191	an	_	_	I-Premise
192	overall	_	_	I-Premise
193	significant	_	_	I-Premise
194	difference	_	_	I-Premise
195	in	_	_	I-Premise
196	favour	_	_	I-Premise
197	of	_	_	I-Premise
198	brachytherapy	_	_	I-Premise
199	on	_	_	I-Premise
200	four	_	_	I-Premise
201	out	_	_	I-Premise
202	of	_	_	I-Premise
203	five	_	_	I-Premise
204	functional	_	_	I-Premise
205	scales	_	_	I-Premise
206	of	_	_	I-Premise
207	the	_	_	I-Premise
208	EORTC	_	_	I-Premise
209	QLQ	_	_	I-Premise
210	-	_	_	I-Premise
211	C30	_	_	I-Premise
212	(	_	_	I-Premise
213	role	_	_	I-Premise
214	,	_	_	I-Premise
215	emotional	_	_	I-Premise
216	,	_	_	I-Premise
217	cognitive	_	_	I-Premise
218	and	_	_	I-Premise
219	social	_	_	I-Premise
220	)	_	_	I-Premise
221	(	_	_	I-Premise
222	P	_	_	I-Premise
223	<	_	_	I-Premise
224	0	_	_	I-Premise
225	.	_	_	I-Premise

226	05	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	Generic	_	_	B-Premise
230	HRQoL	_	_	I-Premise
231	deteriorated	_	_	I-Premise
232	over	_	_	I-Premise
233	time	_	_	I-Premise
234	on	_	_	I-Premise
235	all	_	_	I-Premise
236	functional	_	_	I-Premise
237	scales	_	_	I-Premise
238	of	_	_	I-Premise
239	the	_	_	I-Premise
240	EORTC	_	_	I-Premise
241	QLQ	_	_	I-Premise
242	C	_	_	I-Premise
243	-	_	_	I-Premise
244	30	_	_	I-Premise
245	and	_	_	I-Premise
246	EQ	_	_	I-Premise
247	-	_	_	I-Premise
248	5D	_	_	I-Premise
249	,	_	_	I-Premise
250	in	_	_	I-Premise
251	particular	_	_	I-Premise
252	physical	_	_	I-Premise
253	and	_	_	I-Premise
254	role	_	_	I-Premise
255	functioning	_	_	I-Premise
256	(	_	_	I-Premise
257	on	_	_	I-Premise
258	average	_	_	I-Premise
259	-	_	_	I-Premise
260	23	_	_	I-Premise
261	and	_	_	I-Premise
262	-	_	_	I-Premise
263	24	_	_	I-Premise
264	on	_	_	I-Premise
265	a	_	_	I-Premise
266	100	_	_	I-Premise
267	points	_	_	I-Premise
268	scale	_	_	I-Premise
269	during	_	_	I-Premise
270	0	_	_	I-Premise
271	.	_	_	I-Premise

272	5	_	_	I-Premise
273	years	_	_	I-Premise
274	of	_	_	I-Premise
275	follow	_	_	I-Premise
276	-	_	_	I-Premise
277	up	_	_	I-Premise
278	)	_	_	I-Premise
279	.	_	_	I-Premise

280	This	_	_	B-Premise
281	decline	_	_	I-Premise
282	was	_	_	I-Premise
283	more	_	_	I-Premise
284	pronounced	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	stent	_	_	I-Premise
288	group	_	_	I-Premise
289	.	_	_	I-Premise

290	Major	_	_	B-Premise
291	improvements	_	_	I-Premise
292	were	_	_	I-Premise
293	seen	_	_	I-Premise
294	on	_	_	I-Premise
295	the	_	_	I-Premise
296	dysphagia	_	_	I-Premise
297	and	_	_	I-Premise
298	eating	_	_	I-Premise
299	scales	_	_	I-Premise
300	of	_	_	I-Premise
301	the	_	_	I-Premise
302	EORTC	_	_	I-Premise
303	OES	_	_	I-Premise
304	-	_	_	I-Premise
305	23	_	_	I-Premise
306	,	_	_	I-Premise
307	in	_	_	I-Premise
308	contrast	_	_	I-Premise
309	to	_	_	I-Premise
310	other	_	_	I-Premise
311	scales	_	_	I-Premise
312	of	_	_	I-Premise
313	this	_	_	I-Premise
314	disease	_	_	I-Premise
315	-	_	_	I-Premise
316	specific	_	_	I-Premise
317	measure	_	_	I-Premise
318	,	_	_	I-Premise
319	which	_	_	I-Premise
320	remained	_	_	I-Premise
321	almost	_	_	I-Premise
322	stable	_	_	I-Premise
323	during	_	_	I-Premise
324	follow	_	_	I-Premise
325	-	_	_	I-Premise
326	up	_	_	I-Premise
327	.	_	_	I-Premise

328	Reported	_	_	B-Premise
329	levels	_	_	I-Premise
330	of	_	_	I-Premise
331	chest	_	_	I-Premise
332	or	_	_	I-Premise
333	abdominal	_	_	I-Premise
334	pain	_	_	I-Premise
335	remained	_	_	I-Premise
336	stable	_	_	I-Premise
337	during	_	_	I-Premise
338	follow	_	_	I-Premise
339	-	_	_	I-Premise
340	up	_	_	I-Premise
341	in	_	_	I-Premise
342	both	_	_	I-Premise
343	treatment	_	_	I-Premise
344	groups	_	_	I-Premise
345	,	_	_	I-Premise
346	general	_	_	B-Premise
347	pain	_	_	I-Premise
348	levels	_	_	I-Premise
349	increased	_	_	I-Premise
350	to	_	_	I-Premise
351	a	_	_	I-Premise
352	minor	_	_	I-Premise
353	extent	_	_	I-Premise
354	.	_	_	I-Premise

355	The	_	_	B-Claim
356	effects	_	_	I-Claim
357	of	_	_	I-Claim
358	single	_	_	I-Claim
359	dose	_	_	I-Claim
360	brachytherapy	_	_	I-Claim
361	on	_	_	I-Claim
362	HRQoL	_	_	I-Claim
363	compared	_	_	I-Claim
364	favourably	_	_	I-Claim
365	to	_	_	I-Claim
366	those	_	_	I-Claim
367	of	_	_	I-Claim
368	stent	_	_	I-Claim
369	placement	_	_	I-Claim
370	for	_	_	I-Claim
371	the	_	_	I-Claim
372	palliation	_	_	I-Claim
373	of	_	_	I-Claim
374	oesophageal	_	_	I-Claim
375	cancer	_	_	I-Claim
376	.	_	_	I-Claim

377	Future	_	_	B-Claim
378	studies	_	_	I-Claim
379	on	_	_	I-Claim
380	palliative	_	_	I-Claim
381	care	_	_	I-Claim
382	for	_	_	I-Claim
383	oesophageal	_	_	I-Claim
384	cancer	_	_	I-Claim
385	should	_	_	I-Claim
386	at	_	_	I-Claim
387	least	_	_	I-Claim
388	include	_	_	I-Claim
389	generic	_	_	I-Claim
390	HRQoL	_	_	I-Claim
391	scales	_	_	I-Claim
392	,	_	_	I-Claim
393	since	_	_	B-Premise
394	these	_	_	I-Premise
395	were	_	_	I-Premise
396	more	_	_	I-Premise
397	responsive	_	_	I-Premise
398	in	_	_	I-Premise
399	measuring	_	_	I-Premise
400	patients	_	_	I-Premise
401	'	_	_	I-Premise
402	functioning	_	_	I-Premise
403	and	_	_	I-Premise
404	well	_	_	I-Premise
405	-	_	_	I-Premise
406	being	_	_	I-Premise
407	during	_	_	I-Premise
408	follow	_	_	I-Premise
409	-	_	_	I-Premise
410	up	_	_	I-Premise
411	than	_	_	I-Premise
412	disease	_	_	I-Premise
413	-	_	_	I-Premise
414	specific	_	_	I-Premise
415	HRQoL	_	_	I-Premise
416	scales	_	_	I-Premise
417	.	_	_	I-Premise


0	We	_	_	O
1	compared	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	effects	_	_	O
5	and	_	_	O
6	impact	_	_	O
7	on	_	_	O
8	quality	_	_	O
9	of	_	_	O
10	life	_	_	O
11	(	_	_	O
12	QOL	_	_	O
13	)	_	_	O
14	of	_	_	O
15	patients	_	_	O
16	who	_	_	O
17	received	_	_	O
18	a	_	_	O
19	3	_	_	O
20	-	_	_	O
21	month	_	_	O
22	course	_	_	O
23	of	_	_	O
24	flutamide	_	_	O
25	monotherapy	_	_	O
26	before	_	_	O
27	radical	_	_	O
28	prostatectomy	_	_	O
29	with	_	_	O
30	those	_	_	O
31	who	_	_	O
32	received	_	_	O
33	a	_	_	O
34	3	_	_	O
35	-	_	_	O
36	month	_	_	O
37	course	_	_	O
38	of	_	_	O
39	luteinizing	_	_	O
40	hormone	_	_	O
41	-	_	_	O
42	releasing	_	_	O
43	hormone	_	_	O
44	(	_	_	O
45	LHRH	_	_	O
46	)	_	_	O
47	agonist	_	_	O
48	monotherapy	_	_	O
49	.	_	_	O

50	Thirty	_	_	O
51	-	_	_	O
52	seven	_	_	O
53	patients	_	_	O
54	with	_	_	O
55	non	_	_	O
56	-	_	_	O
57	metastatic	_	_	O
58	prostate	_	_	O
59	cancer	_	_	O
60	were	_	_	O
61	enrolled	_	_	O
62	in	_	_	O
63	this	_	_	O
64	study	_	_	O
65	(	_	_	O
66	19	_	_	O
67	,	_	_	O
68	flutamide	_	_	O
69	;	_	_	O
70	18	_	_	O
71	,	_	_	O
72	LHRH	_	_	O
73	agonist	_	_	O
74	)	_	_	O
75	.	_	_	O

76	The	_	_	O
77	rates	_	_	O
78	of	_	_	O
79	change	_	_	O
80	of	_	_	O
81	serum	_	_	O
82	prostate	_	_	O
83	-	_	_	O
84	specific	_	_	O
85	antigen	_	_	O
86	(	_	_	O
87	PSA	_	_	O
88	)	_	_	O
89	and	_	_	O
90	testosterone	_	_	O
91	levels	_	_	O
92	,	_	_	O
93	downsizing	_	_	O
94	of	_	_	O
95	prostate	_	_	O
96	volume	_	_	O
97	,	_	_	O
98	the	_	_	O
99	rate	_	_	O
100	of	_	_	O
101	organ	_	_	O
102	confined	_	_	O
103	disease	_	_	O
104	,	_	_	O
105	adverse	_	_	O
106	effects	_	_	O
107	and	_	_	O
108	perioperative	_	_	O
109	scores	_	_	O
110	measured	_	_	O
111	using	_	_	O
112	the	_	_	O
113	European	_	_	O
114	Organization	_	_	O
115	for	_	_	O
116	Research	_	_	O
117	and	_	_	O
118	Treatment	_	_	O
119	of	_	_	O
120	Cancer	_	_	O
121	Prostate	_	_	O
122	Cancer	_	_	O
123	Quality	_	_	O
124	of	_	_	O
125	Life	_	_	O
126	Questionnaire	_	_	O
127	(	_	_	O
128	EORTC	_	_	O
129	-	_	_	O
130	P	_	_	O
131	)	_	_	O
132	and	_	_	O
133	the	_	_	O
134	Sapporo	_	_	O
135	Medical	_	_	O
136	University	_	_	O
137	Sexual	_	_	O
138	Function	_	_	O
139	Questionnaire	_	_	O
140	(	_	_	O
141	SMUF	_	_	O
142	)	_	_	O
143	were	_	_	O
144	analyzed	_	_	O
145	.	_	_	O

146	At	_	_	B-Premise
147	radical	_	_	I-Premise
148	prostatectomy	_	_	I-Premise
149	,	_	_	I-Premise
150	pathological	_	_	I-Premise
151	variables	_	_	I-Premise
152	were	_	_	I-Premise
153	not	_	_	I-Premise
154	significantly	_	_	I-Premise
155	different	_	_	I-Premise
156	in	_	_	I-Premise
157	the	_	_	I-Premise
158	two	_	_	I-Premise
159	groups	_	_	I-Premise
160	.	_	_	I-Premise

161	Serum	_	_	B-Premise
162	testosterone	_	_	I-Premise
163	level	_	_	I-Premise
164	was	_	_	I-Premise
165	significantly	_	_	I-Premise
166	higher	_	_	I-Premise
167	(	_	_	I-Premise
168	mean	_	_	I-Premise
169	359	_	_	I-Premise
170	.	_	_	I-Premise

171	2	_	_	I-Premise
172	compared	_	_	I-Premise
173	to	_	_	I-Premise
174	10	_	_	I-Premise
175	.	_	_	I-Premise

176	5	_	_	I-Premise
177	,	_	_	I-Premise
178	P	_	_	I-Premise
179	<	_	_	I-Premise
180	0	_	_	I-Premise
181	.	_	_	I-Premise

182	001	_	_	I-Premise
183	)	_	_	I-Premise
184	,	_	_	I-Premise
185	complete	_	_	B-Premise
186	response	_	_	I-Premise
187	rate	_	_	I-Premise
188	of	_	_	I-Premise
189	PSA	_	_	I-Premise
190	(	_	_	I-Premise
191	13	_	_	I-Premise
192	%	_	_	I-Premise
193	compared	_	_	I-Premise
194	to	_	_	I-Premise
195	57	_	_	I-Premise
196	%	_	_	I-Premise
197	,	_	_	I-Premise
198	P	_	_	I-Premise
199	=	_	_	I-Premise
200	0	_	_	I-Premise
201	.	_	_	I-Premise

202	028	_	_	I-Premise
203	)	_	_	I-Premise
204	and	_	_	I-Premise
205	rate	_	_	I-Premise
206	of	_	_	I-Premise
207	downsizing	_	_	I-Premise
208	of	_	_	I-Premise
209	prostate	_	_	I-Premise
210	volume	_	_	I-Premise
211	(	_	_	I-Premise
212	mean	_	_	I-Premise
213	,	_	_	I-Premise
214	-	_	_	I-Premise
215	17	_	_	I-Premise
216	.	_	_	I-Premise

217	7	_	_	I-Premise
218	%	_	_	I-Premise
219	compared	_	_	I-Premise
220	to	_	_	I-Premise
221	-	_	_	I-Premise
222	35	_	_	I-Premise
223	.	_	_	I-Premise

224	4	_	_	I-Premise
225	%	_	_	I-Premise
226	,	_	_	I-Premise
227	P	_	_	I-Premise
228	=	_	_	I-Premise
229	0	_	_	I-Premise
230	.	_	_	I-Premise

231	038	_	_	I-Premise
232	)	_	_	I-Premise
233	were	_	_	I-Premise
234	significantly	_	_	I-Premise
235	lower	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	flutamide	_	_	I-Premise
239	group	_	_	I-Premise
240	than	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	LHRH	_	_	I-Premise
244	group	_	_	I-Premise
245	.	_	_	I-Premise

246	After	_	_	B-Premise
247	neoadjuvant	_	_	I-Premise
248	hormone	_	_	I-Premise
249	therapy	_	_	I-Premise
250	,	_	_	I-Premise
251	the	_	_	I-Premise
252	scores	_	_	I-Premise
253	on	_	_	I-Premise
254	the	_	_	I-Premise
255	sexual	_	_	I-Premise
256	problem	_	_	I-Premise
257	domain	_	_	I-Premise
258	of	_	_	I-Premise
259	EORTC	_	_	I-Premise
260	-	_	_	I-Premise
261	P	_	_	I-Premise
262	(	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	0	_	_	I-Premise
266	.	_	_	I-Premise

267	033	_	_	I-Premise
268	)	_	_	I-Premise
269	and	_	_	I-Premise
270	sexual	_	_	I-Premise
271	desire	_	_	I-Premise
272	score	_	_	I-Premise
273	of	_	_	I-Premise
274	SMUF	_	_	I-Premise
275	(	_	_	I-Premise
276	P	_	_	I-Premise
277	=	_	_	I-Premise
278	0	_	_	I-Premise
279	.	_	_	I-Premise

280	021	_	_	I-Premise
281	)	_	_	I-Premise
282	were	_	_	I-Premise
283	significantly	_	_	I-Premise
284	higher	_	_	I-Premise
285	in	_	_	I-Premise
286	the	_	_	I-Premise
287	flutamide	_	_	I-Premise
288	group	_	_	I-Premise
289	than	_	_	I-Premise
290	in	_	_	I-Premise
291	the	_	_	I-Premise
292	LHRH	_	_	I-Premise
293	group	_	_	I-Premise
294	.	_	_	I-Premise

295	At	_	_	B-Premise
296	a	_	_	I-Premise
297	median	_	_	I-Premise
298	follow	_	_	I-Premise
299	-	_	_	I-Premise
300	up	_	_	I-Premise
301	of	_	_	I-Premise
302	34	_	_	I-Premise
303	months	_	_	I-Premise
304	after	_	_	I-Premise
305	prostatectomy	_	_	I-Premise
306	,	_	_	I-Premise
307	biochemical	_	_	I-Premise
308	failure	_	_	I-Premise
309	-	_	_	I-Premise
310	free	_	_	I-Premise
311	survival	_	_	I-Premise
312	rate	_	_	I-Premise
313	in	_	_	I-Premise
314	the	_	_	I-Premise
315	flutamide	_	_	I-Premise
316	group	_	_	I-Premise
317	did	_	_	I-Premise
318	not	_	_	I-Premise
319	differ	_	_	I-Premise
320	from	_	_	I-Premise
321	that	_	_	I-Premise
322	in	_	_	I-Premise
323	the	_	_	I-Premise
324	LHRH	_	_	I-Premise
325	group	_	_	I-Premise
326	.	_	_	I-Premise

327	This	_	_	B-Claim
328	study	_	_	I-Claim
329	suggests	_	_	I-Claim
330	that	_	_	I-Claim
331	flutamide	_	_	I-Claim
332	monotherapy	_	_	I-Claim
333	can	_	_	I-Claim
334	be	_	_	I-Claim
335	an	_	_	I-Claim
336	acceptable	_	_	I-Claim
337	modality	_	_	I-Claim
338	as	_	_	I-Claim
339	an	_	_	I-Claim
340	option	_	_	I-Claim
341	for	_	_	I-Claim
342	neoadjuvant	_	_	I-Claim
343	hormone	_	_	I-Claim
344	therapy	_	_	I-Claim
345	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	cost	_	_	O
4	-	_	_	O
5	effectiveness	_	_	O
6	of	_	_	O
7	Mohs	_	_	O
8	micrographic	_	_	O
9	surgery	_	_	O
10	(	_	_	O
11	MMS	_	_	O
12	)	_	_	O
13	compared	_	_	O
14	with	_	_	O
15	the	_	_	O
16	surgical	_	_	O
17	excision	_	_	O
18	for	_	_	O
19	both	_	_	O
20	primary	_	_	O
21	and	_	_	O
22	recurrent	_	_	O
23	basal	_	_	O
24	cell	_	_	O
25	carcinoma	_	_	O
26	(	_	_	O
27	BCC	_	_	O
28	)	_	_	O
29	.	_	_	O

30	A	_	_	O
31	cost	_	_	O
32	-	_	_	O
33	effectiveness	_	_	O
34	study	_	_	O
35	performed	_	_	O
36	alongside	_	_	O
37	a	_	_	O
38	prospective	_	_	O
39	randomized	_	_	O
40	clinical	_	_	O
41	trial	_	_	O
42	in	_	_	O
43	which	_	_	O
44	MMS	_	_	O
45	was	_	_	O
46	compared	_	_	O
47	with	_	_	O
48	surgical	_	_	O
49	excision	_	_	O
50	.	_	_	O

51	The	_	_	O
52	study	_	_	O
53	was	_	_	O
54	carried	_	_	O
55	out	_	_	O
56	from	_	_	O
57	1999	_	_	O
58	to	_	_	O
59	2002	_	_	O
60	at	_	_	O
61	the	_	_	O
62	dermatology	_	_	O
63	outpatient	_	_	O
64	clinic	_	_	O
65	of	_	_	O
66	the	_	_	O
67	University	_	_	O
68	Hospital	_	_	O
69	Maastricht	_	_	O
70	,	_	_	O
71	Maastricht	_	_	O
72	,	_	_	O
73	The	_	_	O
74	Netherlands	_	_	O
75	.	_	_	O

76	A	_	_	O
77	total	_	_	O
78	of	_	_	O
79	408	_	_	O
80	primary	_	_	O
81	(	_	_	O
82	374	_	_	O
83	patients	_	_	O
84	)	_	_	O
85	and	_	_	O
86	204	_	_	O
87	recurrent	_	_	O
88	(	_	_	O
89	191	_	_	O
90	patients	_	_	O
91	)	_	_	O
92	cases	_	_	O
93	of	_	_	O
94	facial	_	_	O
95	BCC	_	_	O
96	were	_	_	O
97	included	_	_	O
98	.	_	_	O

99	The	_	_	O
100	mean	_	_	O
101	total	_	_	O
102	treatment	_	_	O
103	costs	_	_	O
104	of	_	_	O
105	MMS	_	_	O
106	and	_	_	O
107	surgical	_	_	O
108	excision	_	_	O
109	for	_	_	O
110	both	_	_	O
111	primary	_	_	O
112	and	_	_	O
113	recurrent	_	_	O
114	BCC	_	_	O
115	and	_	_	O
116	the	_	_	O
117	incremental	_	_	O
118	cost	_	_	O
119	-	_	_	O
120	effectiveness	_	_	O
121	ratio	_	_	O
122	,	_	_	O
123	calculated	_	_	O
124	as	_	_	O
125	the	_	_	O
126	difference	_	_	O
127	in	_	_	O
128	costs	_	_	O
129	between	_	_	O
130	MMS	_	_	O
131	and	_	_	O
132	surgical	_	_	O
133	excision	_	_	O
134	divided	_	_	O
135	by	_	_	O
136	their	_	_	O
137	difference	_	_	O
138	in	_	_	O
139	effectiveness	_	_	O
140	.	_	_	O

141	The	_	_	O
142	resulting	_	_	O
143	ratio	_	_	O
144	is	_	_	O
145	defined	_	_	O
146	as	_	_	O
147	the	_	_	O
148	incremental	_	_	O
149	costs	_	_	O
150	of	_	_	O
151	MMS	_	_	O
152	compared	_	_	O
153	with	_	_	O
154	surgical	_	_	O
155	excision	_	_	O
156	to	_	_	O
157	prevent	_	_	O
158	1	_	_	O
159	additional	_	_	O
160	recurrence	_	_	O
161	.	_	_	O

162	Compared	_	_	B-Premise
163	with	_	_	I-Premise
164	surgical	_	_	I-Premise
165	excision	_	_	I-Premise
166	,	_	_	I-Premise
167	the	_	_	I-Premise
168	total	_	_	I-Premise
169	treatment	_	_	I-Premise
170	costs	_	_	I-Premise
171	of	_	_	I-Premise
172	MMS	_	_	I-Premise
173	are	_	_	I-Premise
174	significantly	_	_	I-Premise
175	higher	_	_	I-Premise
176	(	_	_	I-Premise
177	cost	_	_	I-Premise
178	difference	_	_	I-Premise
179	:	_	_	I-Premise
180	primary	_	_	I-Premise
181	BCC	_	_	I-Premise
182	,	_	_	I-Premise
183	254	_	_	I-Premise
184	euros	_	_	I-Premise
185	;	_	_	I-Premise
186	95	_	_	I-Premise
187	%	_	_	I-Premise
188	confidence	_	_	I-Premise
189	interval	_	_	I-Premise
190	,	_	_	I-Premise
191	181	_	_	I-Premise
192	-	_	_	I-Premise
193	324	_	_	I-Premise
194	euros	_	_	I-Premise
195	;	_	_	I-Premise
196	recurrent	_	_	I-Premise
197	BCC	_	_	I-Premise
198	,	_	_	I-Premise
199	249	_	_	I-Premise
200	euros	_	_	I-Premise
201	;	_	_	I-Premise
202	95	_	_	I-Premise
203	%	_	_	I-Premise
204	confidence	_	_	I-Premise
205	interval	_	_	I-Premise
206	,	_	_	I-Premise
207	175	_	_	I-Premise
208	-	_	_	I-Premise
209	323	_	_	I-Premise
210	euros	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	For	_	_	B-Premise
214	primary	_	_	I-Premise
215	BCC	_	_	I-Premise
216	,	_	_	I-Premise
217	the	_	_	I-Premise
218	incremental	_	_	I-Premise
219	cost	_	_	I-Premise
220	-	_	_	I-Premise
221	effectiveness	_	_	I-Premise
222	ratio	_	_	I-Premise
223	was	_	_	I-Premise
224	29	_	_	I-Premise
225	,	_	_	I-Premise
226	231	_	_	I-Premise
227	euros	_	_	I-Premise
228	,	_	_	I-Premise
229	while	_	_	I-Premise
230	the	_	_	I-Premise
231	ratio	_	_	I-Premise
232	for	_	_	I-Premise
233	recurrent	_	_	I-Premise
234	BCC	_	_	I-Premise
235	amounted	_	_	I-Premise
236	to	_	_	I-Premise
237	8094	_	_	I-Premise
238	euros	_	_	I-Premise
239	.	_	_	I-Premise

240	The	_	_	B-Premise
241	acceptability	_	_	I-Premise
242	curves	_	_	I-Premise
243	showed	_	_	I-Premise
244	that	_	_	I-Premise
245	for	_	_	I-Premise
246	these	_	_	I-Premise
247	ratios	_	_	I-Premise
248	,	_	_	I-Premise
249	the	_	_	I-Premise
250	probability	_	_	I-Premise
251	of	_	_	I-Premise
252	MMS	_	_	I-Premise
253	being	_	_	I-Premise
254	more	_	_	I-Premise
255	cost	_	_	I-Premise
256	-	_	_	I-Premise
257	effective	_	_	I-Premise
258	than	_	_	I-Premise
259	surgical	_	_	I-Premise
260	excision	_	_	I-Premise
261	never	_	_	I-Premise
262	reached	_	_	I-Premise
263	50	_	_	I-Premise
264	%	_	_	I-Premise
265	.	_	_	I-Premise

266	At	_	_	B-Claim
267	present	_	_	I-Claim
268	,	_	_	I-Claim
269	it	_	_	I-Claim
270	does	_	_	I-Claim
271	not	_	_	I-Claim
272	seem	_	_	I-Claim
273	cost	_	_	I-Claim
274	-	_	_	I-Claim
275	effective	_	_	I-Claim
276	to	_	_	I-Claim
277	introduce	_	_	I-Claim
278	MMS	_	_	I-Claim
279	on	_	_	I-Claim
280	a	_	_	I-Claim
281	large	_	_	I-Claim
282	scale	_	_	I-Claim
283	for	_	_	I-Claim
284	both	_	_	I-Claim
285	primary	_	_	I-Claim
286	and	_	_	I-Claim
287	recurrent	_	_	I-Claim
288	BCC	_	_	I-Claim
289	.	_	_	I-Claim

290	However	_	_	O
291	,	_	_	O
292	because	_	_	B-Premise
293	a	_	_	I-Premise
294	5	_	_	I-Premise
295	-	_	_	I-Premise
296	year	_	_	I-Premise
297	period	_	_	I-Premise
298	is	_	_	I-Premise
299	normally	_	_	I-Premise
300	required	_	_	I-Premise
301	to	_	_	I-Premise
302	determine	_	_	I-Premise
303	definite	_	_	I-Premise
304	recurrence	_	_	I-Premise
305	rates	_	_	I-Premise
306	,	_	_	O
307	it	_	_	B-Claim
308	is	_	_	I-Claim
309	possible	_	_	I-Claim
310	that	_	_	I-Claim
311	MMS	_	_	I-Claim
312	may	_	_	I-Claim
313	become	_	_	I-Claim
314	a	_	_	I-Claim
315	cost	_	_	I-Claim
316	-	_	_	I-Claim
317	effective	_	_	I-Claim
318	treatment	_	_	I-Claim
319	for	_	_	I-Claim
320	recurrent	_	_	I-Claim
321	BCC	_	_	I-Claim
322	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	comparatively	_	_	O
3	,	_	_	O
4	in	_	_	O
5	terms	_	_	O
6	of	_	_	O
7	quality	_	_	O
8	-	_	_	O
9	adjusted	_	_	O
10	survival	_	_	O
11	,	_	_	O
12	three	_	_	O
13	front	_	_	O
14	-	_	_	O
15	line	_	_	O
16	treatments	_	_	O
17	in	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	stage	_	_	O
21	B	_	_	O
22	-	_	_	O
23	or	_	_	O
24	C	_	_	O
25	-	_	_	O
26	chronic	_	_	O
27	lymphocytic	_	_	O
28	leukemia	_	_	O
29	(	_	_	O
30	CLL	_	_	O
31	)	_	_	O
32	.	_	_	O

33	To	_	_	O
34	describe	_	_	O
35	better	_	_	O
36	and	_	_	O
37	compare	_	_	O
38	the	_	_	O
39	survival	_	_	O
40	after	_	_	O
41	randomization	_	_	O
42	of	_	_	O
43	patients	_	_	O
44	from	_	_	O
45	the	_	_	O
46	CLL90	_	_	O
47	trial	_	_	O
48	that	_	_	O
49	randomly	_	_	O
50	compared	_	_	O
51	ChOP	_	_	O
52	(	_	_	O
53	cyclophosphamide	_	_	O
54	,	_	_	O
55	doxorubicin	_	_	O
56	,	_	_	O
57	oncovin	_	_	O
58	,	_	_	O
59	prednisone	_	_	O
60	)	_	_	O
61	,	_	_	O
62	CAP	_	_	O
63	(	_	_	O
64	cyclophosphamide	_	_	O
65	,	_	_	O
66	doxorubicin	_	_	O
67	,	_	_	O
68	prednisone	_	_	O
69	)	_	_	O
70	and	_	_	O
71	fludarabine	_	_	O
72	in	_	_	O
73	advanced	_	_	O
74	CLL	_	_	O
75	,	_	_	O
76	we	_	_	O
77	performed	_	_	O
78	a	_	_	O
79	quality	_	_	O
80	-	_	_	O
81	adjusted	_	_	O
82	survival	_	_	O
83	analysis	_	_	O
84	.	_	_	O

85	This	_	_	O
86	consisted	_	_	O
87	of	_	_	O
88	defining	_	_	O
89	four	_	_	O
90	clinical	_	_	O
91	states	_	_	O
92	(	_	_	O
93	toxicity	_	_	O
94	,	_	_	O
95	treatment	_	_	O
96	free	_	_	O
97	of	_	_	O
98	toxicity	_	_	O
99	,	_	_	O
100	no	_	_	O
101	treatment	_	_	O
102	nor	_	_	O
103	symptoms	_	_	O
104	,	_	_	O
105	relapse	_	_	O
106	)	_	_	O
107	,	_	_	O
108	then	_	_	O
109	summing	_	_	O
110	up	_	_	O
111	the	_	_	O
112	average	_	_	O
113	times	_	_	O
114	spent	_	_	O
115	in	_	_	O
116	each	_	_	O
117	state	_	_	O
118	weighted	_	_	O
119	by	_	_	O
120	utility	_	_	O
121	coefficients	_	_	O
122	that	_	_	O
123	reflect	_	_	O
124	relative	_	_	O
125	value	_	_	O
126	according	_	_	O
127	to	_	_	O
128	quality	_	_	O
129	of	_	_	O
130	life	_	_	O
131	.	_	_	O

132	The	_	_	O
133	resulting	_	_	O
134	quality	_	_	O
135	-	_	_	O
136	adjusted	_	_	O
137	time	_	_	O
138	without	_	_	O
139	symptoms	_	_	O
140	or	_	_	O
141	toxicity	_	_	O
142	(	_	_	O
143	Q	_	_	O
144	-	_	_	O
145	TWIST	_	_	O
146	)	_	_	O
147	was	_	_	O
148	compared	_	_	O
149	between	_	_	O
150	randomized	_	_	O
151	groups	_	_	O
152	,	_	_	O
153	and	_	_	O
154	sensitivity	_	_	O
155	(	_	_	O
156	threshold	_	_	O
157	)	_	_	O
158	analyses	_	_	O
159	to	_	_	O
160	the	_	_	O
161	choice	_	_	O
162	of	_	_	O
163	utility	_	_	O
164	coefficients	_	_	O
165	was	_	_	O
166	performed	_	_	O
167	.	_	_	O

168	Over	_	_	B-Premise
169	73	_	_	I-Premise
170	months	_	_	I-Premise
171	after	_	_	I-Premise
172	randomization	_	_	I-Premise
173	,	_	_	I-Premise
174	the	_	_	I-Premise
175	fludarabine	_	_	I-Premise
176	group	_	_	I-Premise
177	gained	_	_	I-Premise
178	a	_	_	I-Premise
179	mean	_	_	I-Premise
180	of	_	_	I-Premise
181	45	_	_	I-Premise
182	days	_	_	I-Premise
183	of	_	_	I-Premise
184	toxicity	_	_	I-Premise
185	-	_	_	I-Premise
186	free	_	_	I-Premise
187	survival	_	_	I-Premise
188	at	_	_	I-Premise
189	CAP	_	_	I-Premise
190	,	_	_	I-Premise
191	and	_	_	I-Premise
192	61	_	_	I-Premise
193	days	_	_	I-Premise
194	over	_	_	I-Premise
195	ChOP	_	_	I-Premise
196	.	_	_	I-Premise

197	The	_	_	B-Premise
198	mean	_	_	I-Premise
199	TWIST	_	_	I-Premise
200	was	_	_	I-Premise
201	27	_	_	I-Premise
202	.	_	_	I-Premise

203	05	_	_	I-Premise
204	months	_	_	I-Premise
205	with	_	_	I-Premise
206	CAP	_	_	I-Premise
207	,	_	_	I-Premise
208	31	_	_	I-Premise
209	.	_	_	I-Premise

210	5	_	_	I-Premise
211	months	_	_	I-Premise
212	with	_	_	I-Premise
213	ChOP	_	_	I-Premise
214	and	_	_	I-Premise
215	32	_	_	I-Premise
216	.	_	_	I-Premise

217	95	_	_	I-Premise
218	months	_	_	I-Premise
219	with	_	_	I-Premise
220	fludarabine	_	_	I-Premise
221	.	_	_	I-Premise

222	The	_	_	B-Premise
223	threshold	_	_	I-Premise
224	analyses	_	_	I-Premise
225	showed	_	_	I-Premise
226	that	_	_	I-Premise
227	,	_	_	I-Premise
228	whatever	_	_	I-Premise
229	the	_	_	I-Premise
230	utility	_	_	I-Premise
231	weights	_	_	I-Premise
232	,	_	_	I-Premise
233	the	_	_	I-Premise
234	mean	_	_	I-Premise
235	Q	_	_	I-Premise
236	-	_	_	I-Premise
237	TWIST	_	_	I-Premise
238	was	_	_	I-Premise
239	always	_	_	I-Premise
240	greater	_	_	I-Premise
241	with	_	_	I-Premise
242	ChOP	_	_	I-Premise
243	or	_	_	I-Premise
244	fludarabine	_	_	I-Premise
245	as	_	_	I-Premise
246	compared	_	_	I-Premise
247	to	_	_	I-Premise
248	CAP	_	_	I-Premise
249	.	_	_	I-Premise

250	Fludarabine	_	_	B-Claim
251	was	_	_	I-Claim
252	consistently	_	_	I-Claim
253	a	_	_	I-Claim
254	better	_	_	I-Claim
255	treatment	_	_	I-Claim
256	than	_	_	I-Claim
257	ChOP	_	_	I-Claim
258	,	_	_	I-Claim
259	except	_	_	B-Premise
260	in	_	_	I-Premise
261	the	_	_	I-Premise
262	unlikely	_	_	I-Premise
263	case	_	_	I-Premise
264	of	_	_	I-Premise
265	high	_	_	I-Premise
266	utility	_	_	I-Premise
267	weights	_	_	I-Premise
268	attributed	_	_	I-Premise
269	to	_	_	I-Premise
270	toxicity	_	_	I-Premise
271	and	_	_	I-Premise
272	low	_	_	I-Premise
273	utility	_	_	I-Premise
274	weights	_	_	I-Premise
275	attributed	_	_	I-Premise
276	to	_	_	I-Premise
277	treatment	_	_	I-Premise
278	.	_	_	I-Premise

279	Nevertheless	_	_	O
280	,	_	_	O
281	from	_	_	B-Premise
282	a	_	_	I-Premise
283	clinical	_	_	I-Premise
284	point	_	_	I-Premise
285	of	_	_	I-Premise
286	view	_	_	I-Premise
287	,	_	_	I-Premise
288	differences	_	_	I-Premise
289	between	_	_	I-Premise
290	ChOP	_	_	I-Premise
291	and	_	_	I-Premise
292	fludarabine	_	_	I-Premise
293	were	_	_	I-Premise
294	moderate	_	_	I-Premise
295	or	_	_	I-Premise
296	event	_	_	I-Premise
297	slight	_	_	I-Premise
298	(	_	_	I-Premise
299	mean	_	_	I-Premise
300	difference	_	_	I-Premise
301	in	_	_	I-Premise
302	TWIST	_	_	I-Premise
303	of	_	_	I-Premise
304	1	_	_	I-Premise
305	.	_	_	I-Premise

306	45	_	_	I-Premise
307	months	_	_	I-Premise
308	)	_	_	I-Premise
309	.	_	_	I-Premise

310	We	_	_	O
311	conclude	_	_	O
312	that	_	_	O
313	patients	_	_	B-Claim
314	with	_	_	I-Claim
315	advanced	_	_	I-Claim
316	CLL	_	_	I-Claim
317	have	_	_	I-Claim
318	a	_	_	I-Claim
319	moderate	_	_	I-Claim
320	benefit	_	_	I-Claim
321	in	_	_	I-Claim
322	terms	_	_	I-Claim
323	of	_	_	I-Claim
324	Q	_	_	I-Claim
325	-	_	_	I-Claim
326	TWIST	_	_	I-Claim
327	when	_	_	I-Claim
328	treated	_	_	I-Claim
329	with	_	_	I-Claim
330	fludarabine	_	_	I-Claim
331	over	_	_	I-Claim
332	ChOP	_	_	I-Claim
333	.	_	_	I-Claim

334	These	_	_	B-Claim
335	two	_	_	I-Claim
336	treatments	_	_	I-Claim
337	are	_	_	I-Claim
338	always	_	_	I-Claim
339	superior	_	_	I-Claim
340	to	_	_	I-Claim
341	CAP	_	_	I-Claim
342	.	_	_	I-Claim


0	Cancer	_	_	B-Claim
1	-	_	_	I-Claim
2	related	_	_	I-Claim
3	fatigue	_	_	I-Claim
4	is	_	_	I-Claim
5	the	_	_	I-Claim
6	most	_	_	I-Claim
7	disabling	_	_	I-Claim
8	symptom	_	_	I-Claim
9	experienced	_	_	I-Claim
10	by	_	_	I-Claim
11	breast	_	_	I-Claim
12	cancer	_	_	I-Claim
13	patients	_	_	I-Claim
14	following	_	_	I-Claim
15	the	_	_	I-Claim
16	cancer	_	_	I-Claim
17	treatment	_	_	I-Claim
18	.	_	_	I-Claim

19	The	_	_	B-Premise
20	positive	_	_	I-Premise
21	effects	_	_	I-Premise
22	of	_	_	I-Premise
23	physical	_	_	I-Premise
24	activity	_	_	I-Premise
25	in	_	_	I-Premise
26	the	_	_	I-Premise
27	rehabilitation	_	_	I-Premise
28	of	_	_	I-Premise
29	breast	_	_	I-Premise
30	cancer	_	_	I-Premise
31	patients	_	_	I-Premise
32	are	_	_	I-Premise
33	documented	_	_	I-Premise
34	in	_	_	I-Premise
35	several	_	_	I-Premise
36	studies	_	_	I-Premise
37	.	_	_	I-Premise

38	In	_	_	O
39	a	_	_	O
40	randomized	_	_	O
41	controlled	_	_	O
42	study	_	_	O
43	the	_	_	O
44	effects	_	_	O
45	of	_	_	O
46	a	_	_	O
47	structured	_	_	O
48	physical	_	_	O
49	training	_	_	O
50	program	_	_	O
51	on	_	_	O
52	fatigue	_	_	O
53	and	_	_	O
54	health	_	_	O
55	-	_	_	O
56	related	_	_	O
57	quality	_	_	O
58	of	_	_	O
59	life	_	_	O
60	were	_	_	O
61	evaluated	_	_	O
62	.	_	_	O

63	63	_	_	O
64	breast	_	_	O
65	cancer	_	_	O
66	patients	_	_	O
67	with	_	_	O
68	cancer	_	_	O
69	-	_	_	O
70	related	_	_	O
71	chronic	_	_	O
72	fatigue	_	_	O
73	were	_	_	O
74	randomized	_	_	O
75	at	_	_	O
76	the	_	_	O
77	beginning	_	_	O
78	of	_	_	O
79	the	_	_	O
80	inpatient	_	_	O
81	rehabilitation	_	_	O
82	.	_	_	O

83	The	_	_	O
84	control	_	_	O
85	group	_	_	O
86	received	_	_	O
87	the	_	_	O
88	standard	_	_	O
89	complex	_	_	O
90	rehabilitation	_	_	O
91	program	_	_	O
92	,	_	_	O
93	the	_	_	O
94	intervention	_	_	O
95	group	_	_	O
96	a	_	_	O
97	structured	_	_	O
98	physical	_	_	O
99	training	_	_	O
100	program	_	_	O
101	and	_	_	O
102	additional	_	_	O
103	muscle	_	_	O
104	strength	_	_	O
105	and	_	_	O
106	aerobic	_	_	O
107	exercises	_	_	O
108	.	_	_	O

109	The	_	_	O
110	effects	_	_	O
111	of	_	_	O
112	the	_	_	O
113	treatment	_	_	O
114	were	_	_	O
115	evaluated	_	_	O
116	by	_	_	O
117	questionnaires	_	_	O
118	at	_	_	O
119	the	_	_	O
120	start	_	_	O
121	of	_	_	O
122	rehabilitation	_	_	O
123	(	_	_	O
124	t1	_	_	O
125	)	_	_	O
126	,	_	_	O
127	end	_	_	O
128	of	_	_	O
129	rehabilitation	_	_	O
130	(	_	_	O
131	t2	_	_	O
132	)	_	_	O
133	,	_	_	O
134	and	_	_	O
135	3	_	_	O
136	months	_	_	O
137	after	_	_	O
138	t2	_	_	O
139	(	_	_	O
140	t3	_	_	O
141	)	_	_	O
142	.	_	_	O

143	Isometric	_	_	O
144	muscle	_	_	O
145	strength	_	_	O
146	and	_	_	O
147	aerobic	_	_	O
148	capacity	_	_	O
149	were	_	_	O
150	evaluated	_	_	O
151	at	_	_	O
152	t1	_	_	O
153	and	_	_	O
154	t2	_	_	O
155	.	_	_	O

156	There	_	_	B-Premise
157	was	_	_	I-Premise
158	an	_	_	I-Premise
159	improvement	_	_	I-Premise
160	of	_	_	I-Premise
161	muscle	_	_	I-Premise
162	strength	_	_	I-Premise
163	at	_	_	I-Premise
164	the	_	_	I-Premise
165	end	_	_	I-Premise
166	of	_	_	I-Premise
167	rehabilitation	_	_	I-Premise
168	for	_	_	I-Premise
169	both	_	_	I-Premise
170	groups	_	_	I-Premise
171	.	_	_	I-Premise

172	The	_	_	B-Premise
173	increase	_	_	I-Premise
174	from	_	_	I-Premise
175	t1	_	_	I-Premise
176	to	_	_	I-Premise
177	t2	_	_	I-Premise
178	was	_	_	I-Premise
179	significantly	_	_	I-Premise
180	higher	_	_	I-Premise
181	for	_	_	I-Premise
182	the	_	_	I-Premise
183	training	_	_	I-Premise
184	group	_	_	I-Premise
185	.	_	_	I-Premise

186	The	_	_	B-Premise
187	scores	_	_	I-Premise
188	for	_	_	I-Premise
189	global	_	_	I-Premise
190	quality	_	_	I-Premise
191	of	_	_	I-Premise
192	life	_	_	I-Premise
193	,	_	_	I-Premise
194	physical	_	_	I-Premise
195	well	_	_	I-Premise
196	-	_	_	I-Premise
197	being	_	_	I-Premise
198	,	_	_	I-Premise
199	and	_	_	I-Premise
200	functionality	_	_	I-Premise
201	increased	_	_	I-Premise
202	from	_	_	I-Premise
203	t1	_	_	I-Premise
204	to	_	_	I-Premise
205	t2	_	_	I-Premise
206	,	_	_	I-Premise
207	but	_	_	B-Premise
208	further	_	_	I-Premise
209	improvement	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	follow	_	_	I-Premise
213	-	_	_	I-Premise
214	up	_	_	I-Premise
215	(	_	_	I-Premise
216	t3	_	_	I-Premise
217	)	_	_	I-Premise
218	was	_	_	I-Premise
219	only	_	_	I-Premise
220	observed	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	training	_	_	I-Premise
224	group	_	_	I-Premise
225	.	_	_	I-Premise

226	The	_	_	B-Premise
227	cancer	_	_	I-Premise
228	-	_	_	I-Premise
229	related	_	_	I-Premise
230	fatigue	_	_	I-Premise
231	was	_	_	I-Premise
232	significantly	_	_	I-Premise
233	reduced	_	_	I-Premise
234	in	_	_	I-Premise
235	the	_	_	I-Premise
236	training	_	_	I-Premise
237	group	_	_	I-Premise
238	from	_	_	I-Premise
239	t1	_	_	I-Premise
240	to	_	_	I-Premise
241	t3	_	_	I-Premise
242	,	_	_	I-Premise
243	however	_	_	I-Premise
244	,	_	_	I-Premise
245	not	_	_	I-Premise
246	in	_	_	I-Premise
247	the	_	_	I-Premise
248	control	_	_	I-Premise
249	group	_	_	I-Premise
250	.	_	_	I-Premise

251	Structured	_	_	B-Claim
252	physical	_	_	I-Claim
253	training	_	_	I-Claim
254	programs	_	_	I-Claim
255	initiated	_	_	I-Claim
256	during	_	_	I-Claim
257	inpatient	_	_	I-Claim
258	rehabilitation	_	_	I-Claim
259	and	_	_	I-Claim
260	continuously	_	_	I-Claim
261	practiced	_	_	I-Claim
262	in	_	_	I-Claim
263	the	_	_	I-Claim
264	time	_	_	I-Claim
265	thereafter	_	_	I-Claim
266	can	_	_	I-Claim
267	improve	_	_	I-Claim
268	symptoms	_	_	I-Claim
269	of	_	_	I-Claim
270	chronic	_	_	I-Claim
271	fatigue	_	_	I-Claim
272	and	_	_	I-Claim
273	quality	_	_	I-Claim
274	of	_	_	I-Claim
275	life	_	_	I-Claim
276	in	_	_	I-Claim
277	breast	_	_	I-Claim
278	cancer	_	_	I-Claim
279	patients	_	_	I-Claim
280	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	two	_	_	O
8	doses	_	_	O
9	of	_	_	O
10	gefitinib	_	_	O
11	(	_	_	O
12	Iressa	_	_	O
13	[	_	_	O
14	ZD1839	_	_	O
15	]	_	_	O
16	;	_	_	O
17	AstraZeneca	_	_	O
18	,	_	_	O
19	Wilmington	_	_	O
20	,	_	_	O
21	DE	_	_	O
22	)	_	_	O
23	,	_	_	O
24	a	_	_	O
25	novel	_	_	O
26	epidermal	_	_	O
27	growth	_	_	O
28	factor	_	_	O
29	receptor	_	_	O
30	tyrosine	_	_	O
31	kinase	_	_	O
32	inhibitor	_	_	O
33	,	_	_	O
34	in	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	pretreated	_	_	O
38	advanced	_	_	O
39	non	_	_	O
40	-	_	_	O
41	small	_	_	O
42	-	_	_	O
43	cell	_	_	O
44	lung	_	_	O
45	cancer	_	_	O
46	(	_	_	O
47	NSCLC	_	_	O
48	)	_	_	O
49	.	_	_	O

50	This	_	_	O
51	was	_	_	O
52	a	_	_	O
53	randomized	_	_	O
54	,	_	_	O
55	double	_	_	O
56	-	_	_	O
57	blind	_	_	O
58	,	_	_	O
59	parallel	_	_	O
60	-	_	_	O
61	group	_	_	O
62	,	_	_	O
63	multicenter	_	_	O
64	phase	_	_	O
65	II	_	_	O
66	trial	_	_	O
67	.	_	_	O

68	Two	_	_	O
69	hundred	_	_	O
70	ten	_	_	O
71	patients	_	_	O
72	with	_	_	O
73	advanced	_	_	O
74	NSCLC	_	_	O
75	who	_	_	O
76	were	_	_	O
77	previously	_	_	O
78	treated	_	_	O
79	with	_	_	O
80	one	_	_	O
81	or	_	_	O
82	two	_	_	O
83	chemotherapy	_	_	O
84	regimens	_	_	O
85	(	_	_	O
86	at	_	_	O
87	least	_	_	O
88	one	_	_	O
89	containing	_	_	O
90	platinum	_	_	O
91	)	_	_	O
92	were	_	_	O
93	randomly	_	_	O
94	assigned	_	_	O
95	to	_	_	O
96	receive	_	_	O
97	either	_	_	O
98	250	_	_	O
99	-	_	_	O
100	mg	_	_	O
101	or	_	_	O
102	500	_	_	O
103	-	_	_	O
104	mg	_	_	O
105	oral	_	_	O
106	doses	_	_	O
107	of	_	_	O
108	gefitinib	_	_	O
109	once	_	_	O
110	daily	_	_	O
111	.	_	_	O

112	Efficacy	_	_	B-Premise
113	was	_	_	I-Premise
114	similar	_	_	I-Premise
115	for	_	_	I-Premise
116	the	_	_	I-Premise
117	250	_	_	I-Premise
118	-	_	_	I-Premise
119	and	_	_	I-Premise
120	500	_	_	I-Premise
121	-	_	_	I-Premise
122	mg	_	_	I-Premise
123	/	_	_	I-Premise
124	d	_	_	I-Premise
125	groups	_	_	I-Premise
126	.	_	_	I-Premise

127	Objective	_	_	B-Premise
128	tumor	_	_	I-Premise
129	response	_	_	I-Premise
130	rates	_	_	I-Premise
131	were	_	_	I-Premise
132	18	_	_	I-Premise
133	.	_	_	I-Premise

134	4	_	_	I-Premise
135	%	_	_	I-Premise
136	(	_	_	I-Premise
137	95	_	_	I-Premise
138	%	_	_	I-Premise
139	confidence	_	_	I-Premise
140	interval	_	_	I-Premise
141	[	_	_	I-Premise
142	CI	_	_	I-Premise
143	]	_	_	I-Premise
144	,	_	_	I-Premise
145	11	_	_	I-Premise
146	.	_	_	I-Premise

147	5	_	_	I-Premise
148	to	_	_	I-Premise
149	27	_	_	I-Premise
150	.	_	_	I-Premise

151	3	_	_	I-Premise
152	)	_	_	I-Premise
153	and	_	_	I-Premise
154	19	_	_	I-Premise
155	.	_	_	I-Premise

156	0	_	_	I-Premise
157	%	_	_	I-Premise
158	(	_	_	I-Premise
159	95	_	_	I-Premise
160	%	_	_	I-Premise
161	CI	_	_	I-Premise
162	,	_	_	I-Premise
163	12	_	_	I-Premise
164	.	_	_	I-Premise

165	1	_	_	I-Premise
166	to	_	_	I-Premise
167	27	_	_	I-Premise
168	.	_	_	I-Premise

169	9	_	_	I-Premise
170	)	_	_	I-Premise
171	;	_	_	I-Premise
172	among	_	_	I-Premise
173	evaluable	_	_	I-Premise
174	patients	_	_	I-Premise
175	,	_	_	I-Premise
176	symptom	_	_	I-Premise
177	improvement	_	_	I-Premise
178	rates	_	_	I-Premise
179	were	_	_	I-Premise
180	40	_	_	I-Premise
181	.	_	_	I-Premise

182	3	_	_	I-Premise
183	%	_	_	I-Premise
184	(	_	_	I-Premise
185	95	_	_	I-Premise
186	%	_	_	I-Premise
187	CI	_	_	I-Premise
188	,	_	_	I-Premise
189	28	_	_	I-Premise
190	.	_	_	I-Premise

191	5	_	_	I-Premise
192	to	_	_	I-Premise
193	53	_	_	I-Premise
194	.	_	_	I-Premise

195	0	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	37	_	_	I-Premise
199	.	_	_	I-Premise

200	0	_	_	I-Premise
201	%	_	_	I-Premise
202	(	_	_	I-Premise
203	95	_	_	I-Premise
204	%	_	_	I-Premise
205	CI	_	_	I-Premise
206	,	_	_	I-Premise
207	26	_	_	I-Premise
208	.	_	_	I-Premise

209	0	_	_	I-Premise
210	to	_	_	I-Premise
211	49	_	_	I-Premise
212	.	_	_	I-Premise

213	1	_	_	I-Premise
214	)	_	_	I-Premise
215	;	_	_	I-Premise
216	median	_	_	I-Premise
217	progression	_	_	I-Premise
218	-	_	_	I-Premise
219	free	_	_	I-Premise
220	survival	_	_	I-Premise
221	times	_	_	I-Premise
222	were	_	_	I-Premise
223	2	_	_	I-Premise
224	.	_	_	I-Premise

225	7	_	_	I-Premise
226	and	_	_	I-Premise
227	2	_	_	I-Premise
228	.	_	_	I-Premise

229	8	_	_	I-Premise
230	months	_	_	I-Premise
231	;	_	_	I-Premise
232	and	_	_	I-Premise
233	median	_	_	I-Premise
234	overall	_	_	I-Premise
235	survival	_	_	I-Premise
236	times	_	_	I-Premise
237	were	_	_	I-Premise
238	7	_	_	I-Premise
239	.	_	_	I-Premise

240	6	_	_	I-Premise
241	and	_	_	I-Premise
242	8	_	_	I-Premise
243	.	_	_	I-Premise

244	0	_	_	I-Premise
245	months	_	_	I-Premise
246	,	_	_	I-Premise
247	respectively	_	_	I-Premise
248	.	_	_	I-Premise

249	Symptom	_	_	B-Premise
250	improvements	_	_	I-Premise
251	were	_	_	I-Premise
252	recorded	_	_	I-Premise
253	for	_	_	I-Premise
254	69	_	_	I-Premise
255	.	_	_	I-Premise

256	2	_	_	I-Premise
257	%	_	_	I-Premise
258	(	_	_	I-Premise
259	250	_	_	I-Premise
260	mg	_	_	I-Premise
261	/	_	_	I-Premise
262	d	_	_	I-Premise
263	)	_	_	I-Premise
264	and	_	_	I-Premise
265	85	_	_	I-Premise
266	.	_	_	I-Premise

267	7	_	_	I-Premise
268	%	_	_	I-Premise
269	(	_	_	I-Premise
270	500	_	_	I-Premise
271	mg	_	_	I-Premise
272	/	_	_	I-Premise
273	d	_	_	I-Premise
274	)	_	_	I-Premise
275	of	_	_	I-Premise
276	patients	_	_	I-Premise
277	with	_	_	I-Premise
278	a	_	_	I-Premise
279	tumor	_	_	I-Premise
280	response	_	_	I-Premise
281	.	_	_	I-Premise

282	Adverse	_	_	B-Premise
283	events	_	_	I-Premise
284	(	_	_	I-Premise
285	AEs	_	_	I-Premise
286	)	_	_	I-Premise
287	at	_	_	I-Premise
288	both	_	_	I-Premise
289	dose	_	_	I-Premise
290	levels	_	_	I-Premise
291	were	_	_	I-Premise
292	generally	_	_	I-Premise
293	mild	_	_	I-Premise
294	(	_	_	I-Premise
295	grade	_	_	I-Premise
296	1	_	_	I-Premise
297	or	_	_	I-Premise
298	2	_	_	I-Premise
299	)	_	_	I-Premise
300	and	_	_	I-Premise
301	consisted	_	_	I-Premise
302	mainly	_	_	I-Premise
303	of	_	_	I-Premise
304	skin	_	_	I-Premise
305	reactions	_	_	I-Premise
306	and	_	_	I-Premise
307	diarrhea	_	_	I-Premise
308	.	_	_	I-Premise

309	Drug	_	_	B-Premise
310	-	_	_	I-Premise
311	related	_	_	I-Premise
312	toxicities	_	_	I-Premise
313	were	_	_	I-Premise
314	more	_	_	I-Premise
315	frequent	_	_	I-Premise
316	in	_	_	I-Premise
317	the	_	_	I-Premise
318	higher	_	_	I-Premise
319	-	_	_	I-Premise
320	dose	_	_	I-Premise
321	group	_	_	I-Premise
322	.	_	_	I-Premise

323	Withdrawal	_	_	B-Premise
324	due	_	_	I-Premise
325	to	_	_	I-Premise
326	drug	_	_	I-Premise
327	-	_	_	I-Premise
328	related	_	_	I-Premise
329	AEs	_	_	I-Premise
330	was	_	_	I-Premise
331	1	_	_	I-Premise
332	.	_	_	I-Premise

333	9	_	_	I-Premise
334	%	_	_	I-Premise
335	and	_	_	I-Premise
336	9	_	_	I-Premise
337	.	_	_	I-Premise

338	4	_	_	I-Premise
339	%	_	_	I-Premise
340	for	_	_	I-Premise
341	patients	_	_	I-Premise
342	receiving	_	_	I-Premise
343	gefitinib	_	_	I-Premise
344	250	_	_	I-Premise
345	and	_	_	I-Premise
346	500	_	_	I-Premise
347	mg	_	_	I-Premise
348	/	_	_	I-Premise
349	d	_	_	I-Premise
350	,	_	_	I-Premise
351	respectively	_	_	I-Premise
352	.	_	_	I-Premise

353	Gefitinib	_	_	B-Claim
354	showed	_	_	I-Claim
355	clinically	_	_	I-Claim
356	meaningful	_	_	I-Claim
357	antitumor	_	_	I-Claim
358	activity	_	_	I-Claim
359	and	_	_	I-Claim
360	provided	_	_	I-Claim
361	symptom	_	_	I-Claim
362	relief	_	_	I-Claim
363	as	_	_	I-Claim
364	second	_	_	I-Claim
365	-	_	_	I-Claim
366	and	_	_	I-Claim
367	third	_	_	I-Claim
368	-	_	_	I-Claim
369	line	_	_	I-Claim
370	treatment	_	_	I-Claim
371	in	_	_	I-Claim
372	these	_	_	I-Claim
373	patients	_	_	I-Claim
374	.	_	_	I-Claim

375	At	_	_	B-Claim
376	250	_	_	I-Claim
377	mg	_	_	I-Claim
378	/	_	_	I-Claim
379	d	_	_	I-Claim
380	,	_	_	I-Claim
381	gefitinib	_	_	I-Claim
382	had	_	_	I-Claim
383	a	_	_	I-Claim
384	favorable	_	_	I-Claim
385	AE	_	_	I-Claim
386	profile	_	_	I-Claim
387	.	_	_	I-Claim

388	Gefitinib	_	_	B-Claim
389	250	_	_	I-Claim
390	mg	_	_	I-Claim
391	/	_	_	I-Claim
392	d	_	_	I-Claim
393	is	_	_	I-Claim
394	an	_	_	I-Claim
395	important	_	_	I-Claim
396	,	_	_	I-Claim
397	novel	_	_	I-Claim
398	treatment	_	_	I-Claim
399	option	_	_	I-Claim
400	for	_	_	I-Claim
401	patients	_	_	I-Claim
402	with	_	_	I-Claim
403	pretreated	_	_	I-Claim
404	advanced	_	_	I-Claim
405	NSCLC	_	_	I-Claim
406	.	_	_	I-Claim


0	There	_	_	O
1	are	_	_	O
2	patients	_	_	O
3	with	_	_	O
4	stage	_	_	O
5	I	_	_	O
6	-	_	_	O
7	III	_	_	O
8	non	_	_	O
9	-	_	_	O
10	small	_	_	O
11	cell	_	_	O
12	lung	_	_	O
13	cancer	_	_	O
14	(	_	_	O
15	NSCLC	_	_	O
16	)	_	_	O
17	who	_	_	O
18	are	_	_	O
19	not	_	_	O
20	suitable	_	_	O
21	for	_	_	O
22	curative	_	_	O
23	radical	_	_	O
24	chemoradiation	_	_	O
25	therapy	_	_	O
26	.	_	_	O

27	There	_	_	O
28	are	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	an	_	_	O
32	isolated	_	_	O
33	solitary	_	_	O
34	extracranial	_	_	O
35	metastasis	_	_	O
36	who	_	_	O
37	have	_	_	O
38	improved	_	_	O
39	outcomes	_	_	O
40	compared	_	_	O
41	with	_	_	O
42	those	_	_	O
43	with	_	_	O
44	cranial	_	_	O
45	or	_	_	O
46	multiple	_	_	O
47	metastases	_	_	O
48	.	_	_	O

49	Patients	_	_	O
50	of	_	_	O
51	good	_	_	O
52	performance	_	_	O
53	status	_	_	O
54	receiving	_	_	O
55	moderate	_	_	O
56	dose	_	_	O
57	radiation	_	_	O
58	therapy	_	_	O
59	have	_	_	O
60	improved	_	_	O
61	survival	_	_	O
62	.	_	_	O

63	Two	_	_	O
64	regimens	_	_	O
65	of	_	_	O
66	moderate	_	_	O
67	dose	_	_	O
68	chemoradiation	_	_	O
69	therapy	_	_	O
70	for	_	_	O
71	such	_	_	O
72	patients	_	_	O
73	were	_	_	O
74	compared	_	_	O
75	in	_	_	O
76	a	_	_	O
77	randomized	_	_	O
78	phase	_	_	O
79	II	_	_	O
80	trial	_	_	O
81	.	_	_	O

82	Patients	_	_	O
83	were	_	_	O
84	eligible	_	_	O
85	if	_	_	O
86	they	_	_	O
87	had	_	_	O
88	stage	_	_	O
89	I	_	_	O
90	-	_	_	O
91	IIIB	_	_	O
92	NSCLC	_	_	O
93	,	_	_	O
94	unsuitable	_	_	O
95	for	_	_	O
96	curative	_	_	O
97	therapy	_	_	O
98	,	_	_	O
99	or	_	_	O
100	stage	_	_	O
101	IV	_	_	O
102	with	_	_	O
103	a	_	_	O
104	PET	_	_	O
105	-	_	_	O
106	detected	_	_	O
107	extracranial	_	_	O
108	solitary	_	_	O
109	metastasis	_	_	O
110	.	_	_	O

111	Patients	_	_	O
112	were	_	_	O
113	randomized	_	_	O
114	to	_	_	O
115	the	_	_	O
116	following	_	_	O
117	groups	_	_	O
118	-	_	_	O
119	arm	_	_	O
120	A	_	_	O
121	:	_	_	O
122	40	_	_	O
123	Gy	_	_	O
124	/	_	_	O
125	20	_	_	O
126	fractions	_	_	O
127	/	_	_	O
128	4	_	_	O
129	weeks	_	_	O
130	with	_	_	O
131	concurrent	_	_	O
132	weekly	_	_	O
133	vinorelbine	_	_	O
134	25	_	_	O
135	mg	_	_	O
136	/	_	_	O
137	m	_	_	O
138	+	_	_	O
139	cisplatin	_	_	O
140	20	_	_	O
141	mg	_	_	O
142	/	_	_	O
143	m	_	_	O
144	or	_	_	O
145	arm	_	_	O
146	B	_	_	O
147	:	_	_	O
148	30	_	_	O
149	Gy	_	_	O
150	/	_	_	O
151	15	_	_	O
152	fractions	_	_	O
153	/	_	_	O
154	3	_	_	O
155	weeks	_	_	O
156	with	_	_	O
157	concurrent	_	_	O
158	weekly	_	_	O
159	gemcitabine	_	_	O
160	200	_	_	O
161	mg	_	_	O
162	.	_	_	O

163	Primary	_	_	O
164	end	_	_	O
165	points	_	_	O
166	were	_	_	O
167	feasibility	_	_	O
168	,	_	_	O
169	response	_	_	O
170	rates	_	_	O
171	,	_	_	O
172	and	_	_	O
173	toxicity	_	_	O
174	.	_	_	O

175	Secondary	_	_	O
176	end	_	_	O
177	points	_	_	O
178	were	_	_	O
179	progression	_	_	O
180	-	_	_	O
181	free	_	_	O
182	survival	_	_	O
183	,	_	_	O
184	overall	_	_	O
185	survival	_	_	O
186	,	_	_	O
187	and	_	_	O
188	quality	_	_	O
189	of	_	_	O
190	life	_	_	O
191	.	_	_	O

192	Eighty	_	_	O
193	-	_	_	O
194	four	_	_	O
195	patients	_	_	O
196	were	_	_	O
197	randomized	_	_	O
198	.	_	_	O

199	Compliance	_	_	O
200	was	_	_	O
201	above	_	_	O
202	90	_	_	O
203	%	_	_	O
204	for	_	_	O
205	both	_	_	O
206	arms	_	_	O
207	.	_	_	O

208	The	_	_	B-Premise
209	overall	_	_	I-Premise
210	response	_	_	I-Premise
211	rate	_	_	I-Premise
212	was	_	_	I-Premise
213	51	_	_	I-Premise
214	%	_	_	I-Premise
215	in	_	_	I-Premise
216	arm	_	_	I-Premise
217	A	_	_	I-Premise
218	and	_	_	I-Premise
219	38	_	_	I-Premise
220	%	_	_	I-Premise
221	in	_	_	I-Premise
222	arm	_	_	I-Premise
223	B	_	_	I-Premise
224	(	_	_	I-Premise
225	p	_	_	I-Premise
226	=	_	_	I-Premise
227	0	_	_	I-Premise
228	.	_	_	I-Premise

229	147	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Grade	_	_	B-Premise
233	3	_	_	I-Premise
234	/	_	_	I-Premise
235	4	_	_	I-Premise
236	toxicity	_	_	I-Premise
237	in	_	_	I-Premise
238	both	_	_	I-Premise
239	arms	_	_	I-Premise
240	was	_	_	I-Premise
241	acceptable	_	_	I-Premise
242	.	_	_	I-Premise

243	There	_	_	B-Premise
244	was	_	_	I-Premise
245	no	_	_	I-Premise
246	difference	_	_	I-Premise
247	in	_	_	I-Premise
248	median	_	_	I-Premise
249	progression	_	_	I-Premise
250	-	_	_	I-Premise
251	free	_	_	I-Premise
252	survival	_	_	I-Premise
253	between	_	_	I-Premise
254	the	_	_	I-Premise
255	two	_	_	I-Premise
256	arms	_	_	I-Premise
257	(	_	_	I-Premise
258	5	_	_	I-Premise
259	.	_	_	I-Premise

260	5	_	_	I-Premise
261	versus	_	_	I-Premise
262	5	_	_	I-Premise
263	.	_	_	I-Premise

264	0	_	_	I-Premise
265	months	_	_	I-Premise
266	,	_	_	I-Premise
267	p	_	_	I-Premise
268	=	_	_	I-Premise
269	0	_	_	I-Premise
270	.	_	_	I-Premise

271	19	_	_	I-Premise
272	)	_	_	I-Premise
273	.	_	_	I-Premise

274	Patients	_	_	B-Premise
275	in	_	_	I-Premise
276	arm	_	_	I-Premise
277	A	_	_	I-Premise
278	had	_	_	I-Premise
279	longer	_	_	I-Premise
280	median	_	_	I-Premise
281	survival	_	_	I-Premise
282	but	_	_	B-Premise
283	this	_	_	I-Premise
284	did	_	_	I-Premise
285	not	_	_	I-Premise
286	reach	_	_	I-Premise
287	statistical	_	_	I-Premise
288	significance	_	_	I-Premise
289	(	_	_	I-Premise
290	13	_	_	I-Premise
291	.	_	_	I-Premise

292	1	_	_	I-Premise
293	versus	_	_	I-Premise
294	8	_	_	I-Premise
295	.	_	_	I-Premise

296	3	_	_	I-Premise
297	months	_	_	I-Premise
298	,	_	_	I-Premise
299	p	_	_	I-Premise
300	=	_	_	I-Premise
301	0	_	_	I-Premise
302	.	_	_	I-Premise

303	25	_	_	I-Premise
304	)	_	_	I-Premise
305	.	_	_	I-Premise

306	No	_	_	B-Claim
307	difference	_	_	I-Claim
308	in	_	_	I-Claim
309	quality	_	_	I-Claim
310	of	_	_	I-Claim
311	life	_	_	I-Claim
312	was	_	_	I-Claim
313	observed	_	_	I-Claim
314	.	_	_	I-Claim

315	Arm	_	_	O
316	A	_	_	O
317	was	_	_	O
318	chosen	_	_	O
319	for	_	_	O
320	a	_	_	O
321	future	_	_	O
322	phase	_	_	O
323	II	_	_	O
324	comparison	_	_	O
325	with	_	_	O
326	radiation	_	_	B-Claim
327	therapy	_	_	I-Claim
328	alone	_	_	I-Claim
329	as	_	_	I-Claim
330	it	_	_	I-Claim
331	demonstrated	_	_	I-Claim
332	a	_	_	I-Claim
333	response	_	_	I-Claim
334	rate	_	_	I-Claim
335	greater	_	_	I-Claim
336	than	_	_	I-Claim
337	50	_	_	I-Claim
338	%	_	_	I-Claim
339	,	_	_	I-Claim
340	and	_	_	I-Claim
341	data	_	_	I-Claim
342	suggested	_	_	I-Claim
343	that	_	_	I-Claim
344	arm	_	_	I-Claim
345	A	_	_	I-Claim
346	had	_	_	I-Claim
347	superior	_	_	I-Claim
348	survival	_	_	I-Claim
349	to	_	_	I-Claim
350	arm	_	_	I-Claim
351	B	_	_	I-Claim
352	.	_	_	I-Claim


0	Capecitabine	_	_	O
1	/	_	_	O
2	taxane	_	_	O
3	combinations	_	_	O
4	are	_	_	O
5	highly	_	_	O
6	active	_	_	O
7	in	_	_	O
8	metastatic	_	_	O
9	breast	_	_	O
10	cancer	_	_	O
11	(	_	_	O
12	MBC	_	_	O
13	)	_	_	O
14	.	_	_	O

15	We	_	_	O
16	conducted	_	_	O
17	a	_	_	O
18	randomized	_	_	O
19	,	_	_	O
20	phase	_	_	O
21	III	_	_	O
22	,	_	_	O
23	noninferiority	_	_	O
24	trial	_	_	O
25	comparing	_	_	O
26	capecitabine	_	_	O
27	plus	_	_	O
28	paclitaxel	_	_	O
29	(	_	_	O
30	XP	_	_	O
31	)	_	_	O
32	with	_	_	O
33	epirubicin	_	_	O
34	plus	_	_	O
35	paclitaxel	_	_	O
36	(	_	_	O
37	EP	_	_	O
38	)	_	_	O
39	as	_	_	O
40	first	_	_	O
41	-	_	_	O
42	line	_	_	O
43	therapy	_	_	O
44	for	_	_	O
45	MBC	_	_	O
46	,	_	_	O
47	regarding	_	_	O
48	progression	_	_	O
49	-	_	_	O
50	free	_	_	O
51	survival	_	_	O
52	(	_	_	O
53	PFS	_	_	O
54	)	_	_	O
55	as	_	_	O
56	primary	_	_	O
57	efficacy	_	_	O
58	endpoint	_	_	O
59	.	_	_	O

60	Females	_	_	O
61	who	_	_	O
62	had	_	_	O
63	received	_	_	O
64	no	_	_	O
65	prior	_	_	O
66	chemotherapy	_	_	O
67	for	_	_	O
68	MBC	_	_	O
69	were	_	_	O
70	randomized	_	_	O
71	to	_	_	O
72	six	_	_	O
73	3	_	_	O
74	-	_	_	O
75	weekly	_	_	O
76	cycles	_	_	O
77	of	_	_	O
78	XP	_	_	O
79	(	_	_	O
80	capecitabine	_	_	O
81	1000	_	_	O
82	mg	_	_	O
83	/	_	_	O
84	m	_	_	O
85	(	_	_	O
86	2	_	_	O
87	)	_	_	O
88	b	_	_	O
89	.	_	_	O

90	i	_	_	O
91	.	_	_	O

92	d	_	_	O
93	.	_	_	O

94	,	_	_	O
95	days	_	_	O
96	1	_	_	O
97	-	_	_	O
98	14	_	_	O
99	;	_	_	O
100	paclitaxel	_	_	O
101	175	_	_	O
102	mg	_	_	O
103	/	_	_	O
104	m	_	_	O
105	(	_	_	O
106	2	_	_	O
107	)	_	_	O
108	3	_	_	O
109	-	_	_	O
110	h	_	_	O
111	infusion	_	_	O
112	,	_	_	O
113	day	_	_	O
114	1	_	_	O
115	)	_	_	O
116	or	_	_	O
117	EP	_	_	O
118	(	_	_	O
119	epirubicin	_	_	O
120	60	_	_	O
121	mg	_	_	O
122	/	_	_	O
123	m	_	_	O
124	(	_	_	O
125	2	_	_	O
126	)	_	_	O
127	1	_	_	O
128	-	_	_	O
129	h	_	_	O
130	infusion	_	_	O
131	,	_	_	O
132	day	_	_	O
133	1	_	_	O
134	;	_	_	O
135	paclitaxel	_	_	O
136	as	_	_	O
137	above	_	_	O
138	)	_	_	O
139	.	_	_	O

140	Secondary	_	_	O
141	endpoints	_	_	O
142	included	_	_	O
143	response	_	_	O
144	rate	_	_	O
145	,	_	_	O
146	overall	_	_	O
147	survival	_	_	O
148	,	_	_	O
149	tolerability	_	_	O
150	,	_	_	O
151	and	_	_	O
152	quality	_	_	O
153	of	_	_	O
154	life	_	_	O
155	(	_	_	O
156	QoL	_	_	O
157	)	_	_	O
158	.	_	_	O

159	Each	_	_	O
160	arm	_	_	O
161	included	_	_	O
162	170	_	_	O
163	patients	_	_	O
164	,	_	_	O
165	most	_	_	O
166	of	_	_	O
167	whom	_	_	O
168	received	_	_	O
169	all	_	_	O
170	six	_	_	O
171	cycles	_	_	O
172	as	_	_	O
173	planned	_	_	O
174	.	_	_	O

175	The	_	_	O
176	difference	_	_	O
177	in	_	_	O
178	means	_	_	O
179	of	_	_	O
180	(	_	_	O
181	logarithmic	_	_	O
182	)	_	_	O
183	PFS	_	_	O
184	times	_	_	O
185	(	_	_	O
186	-	_	_	O
187	0	_	_	O
188	.	_	_	O

189	205	_	_	O
190	)	_	_	O
191	did	_	_	O
192	not	_	_	O
193	meet	_	_	O
194	the	_	_	O
195	pre	_	_	O
196	-	_	_	O
197	defined	_	_	O
198	level	_	_	O
199	for	_	_	O
200	noninferiority	_	_	O
201	(	_	_	O
202	-	_	_	O
203	0	_	_	O
204	.	_	_	O

205	186	_	_	O
206	)	_	_	O
207	.	_	_	O

208	However	_	_	O
209	,	_	_	O
210	PFS	_	_	B-Premise
211	was	_	_	I-Premise
212	similar	_	_	I-Premise
213	in	_	_	I-Premise
214	the	_	_	I-Premise
215	two	_	_	I-Premise
216	arms	_	_	I-Premise
217	[	_	_	I-Premise
218	HR	_	_	I-Premise
219	:	_	_	I-Premise
220	XP	_	_	I-Premise
221	vs	_	_	I-Premise
222	.	_	_	I-Premise

223	EP	_	_	I-Premise
224	:	_	_	I-Premise
225	1	_	_	I-Premise
226	.	_	_	I-Premise

227	012	_	_	I-Premise
228	(	_	_	I-Premise
229	95	_	_	I-Premise
230	%	_	_	I-Premise
231	CI	_	_	I-Premise
232	0	_	_	I-Premise
233	.	_	_	I-Premise

234	785	_	_	I-Premise
235	-	_	_	I-Premise
236	1	_	_	I-Premise
237	.	_	_	I-Premise

238	304	_	_	I-Premise
239	)	_	_	I-Premise
240	;	_	_	I-Premise
241	median	_	_	I-Premise
242	10	_	_	I-Premise
243	.	_	_	I-Premise

244	4	_	_	I-Premise
245	months	_	_	I-Premise
246	XP	_	_	I-Premise
247	vs	_	_	I-Premise
248	.	_	_	I-Premise

249	9	_	_	I-Premise
250	.	_	_	I-Premise

251	2	_	_	I-Premise
252	months	_	_	I-Premise
253	EP	_	_	I-Premise
254	]	_	_	I-Premise
255	.	_	_	I-Premise

256	Overall	_	_	B-Premise
257	survival	_	_	I-Premise
258	was	_	_	I-Premise
259	also	_	_	I-Premise
260	similar	_	_	I-Premise
261	[	_	_	I-Premise
262	HR	_	_	I-Premise
263	1	_	_	I-Premise
264	.	_	_	I-Premise

265	027	_	_	I-Premise
266	(	_	_	I-Premise
267	95	_	_	I-Premise
268	%	_	_	I-Premise
269	CI	_	_	I-Premise
270	0	_	_	I-Premise
271	.	_	_	I-Premise

272	740	_	_	I-Premise
273	-	_	_	I-Premise
274	1	_	_	I-Premise
275	.	_	_	I-Premise

276	424	_	_	I-Premise
277	)	_	_	I-Premise
278	;	_	_	I-Premise
279	median	_	_	I-Premise
280	22	_	_	I-Premise
281	.	_	_	I-Premise

282	0	_	_	I-Premise
283	vs	_	_	I-Premise
284	.	_	_	I-Premise

285	26	_	_	I-Premise
286	.	_	_	I-Premise

287	1	_	_	I-Premise
288	months	_	_	I-Premise
289	]	_	_	I-Premise
290	,	_	_	I-Premise
291	and	_	_	I-Premise
292	response	_	_	I-Premise
293	rate	_	_	I-Premise
294	was	_	_	I-Premise
295	47	_	_	I-Premise
296	%	_	_	I-Premise
297	versus	_	_	I-Premise
298	42	_	_	I-Premise
299	%	_	_	I-Premise
300	.	_	_	I-Premise

301	Both	_	_	B-Premise
302	regimens	_	_	I-Premise
303	were	_	_	I-Premise
304	tolerable	_	_	I-Premise
305	:	_	_	I-Premise
306	there	_	_	I-Premise
307	were	_	_	I-Premise
308	more	_	_	I-Premise
309	grade	_	_	I-Premise
310	3	_	_	I-Premise
311	/	_	_	I-Premise
312	4	_	_	I-Premise
313	diarrhea	_	_	I-Premise
314	and	_	_	I-Premise
315	grade	_	_	I-Premise
316	3	_	_	I-Premise
317	hand	_	_	I-Premise
318	-	_	_	I-Premise
319	foot	_	_	I-Premise
320	syndromes	_	_	I-Premise
321	with	_	_	I-Premise
322	XP	_	_	I-Premise
323	and	_	_	I-Premise
324	more	_	_	I-Premise
325	grade	_	_	I-Premise
326	3	_	_	I-Premise
327	/	_	_	I-Premise
328	4	_	_	I-Premise
329	hematologic	_	_	I-Premise
330	toxicities	_	_	I-Premise
331	with	_	_	I-Premise
332	EP	_	_	I-Premise
333	.	_	_	I-Premise

334	There	_	_	B-Premise
335	were	_	_	I-Premise
336	no	_	_	I-Premise
337	major	_	_	I-Premise
338	differences	_	_	I-Premise
339	in	_	_	I-Premise
340	QoL	_	_	I-Premise
341	.	_	_	I-Premise

342	Although	_	_	B-Claim
343	,	_	_	I-Claim
344	noninferiority	_	_	I-Claim
345	of	_	_	I-Claim
346	XP	_	_	I-Claim
347	to	_	_	I-Claim
348	EP	_	_	I-Claim
349	was	_	_	I-Claim
350	formally	_	_	I-Claim
351	not	_	_	I-Claim
352	proven	_	_	I-Claim
353	,	_	_	I-Claim
354	first	_	_	B-Claim
355	-	_	_	I-Claim
356	line	_	_	I-Claim
357	XP	_	_	I-Claim
358	was	_	_	I-Claim
359	active	_	_	I-Claim
360	and	_	_	I-Claim
361	feasible	_	_	I-Claim
362	.	_	_	I-Claim

363	XP	_	_	B-Claim
364	is	_	_	I-Claim
365	a	_	_	I-Claim
366	valid	_	_	I-Claim
367	first	_	_	I-Claim
368	-	_	_	I-Claim
369	line	_	_	I-Claim
370	alternative	_	_	I-Claim
371	to	_	_	I-Claim
372	anthracycline	_	_	I-Claim
373	/	_	_	I-Claim
374	taxane	_	_	I-Claim
375	regimens	_	_	I-Claim
376	,	_	_	I-Claim
377	especially	_	_	I-Claim
378	in	_	_	I-Claim
379	patients	_	_	I-Claim
380	previously	_	_	I-Claim
381	treated	_	_	I-Claim
382	with	_	_	I-Claim
383	adjuvant	_	_	I-Claim
384	anthracyclines	_	_	I-Claim
385	.	_	_	I-Claim


0	Prospective	_	_	B-Claim
1	investigations	_	_	I-Claim
2	of	_	_	I-Claim
3	complete	_	_	I-Claim
4	decongestive	_	_	I-Claim
5	lymphatic	_	_	I-Claim
6	physiotherapy	_	_	I-Claim
7	(	_	_	I-Claim
8	CDPT	_	_	I-Claim
9	)	_	_	I-Claim
10	,	_	_	I-Claim
11	including	_	_	I-Claim
12	manual	_	_	I-Claim
13	lymphatic	_	_	I-Claim
14	drainage	_	_	I-Claim
15	(	_	_	I-Claim
16	MLD	_	_	I-Claim
17	)	_	_	I-Claim
18	,	_	_	I-Claim
19	have	_	_	I-Claim
20	validated	_	_	I-Claim
21	the	_	_	I-Claim
22	efficacy	_	_	I-Claim
23	of	_	_	I-Claim
24	these	_	_	I-Claim
25	interventions	_	_	I-Claim
26	for	_	_	I-Claim
27	the	_	_	I-Claim
28	initial	_	_	I-Claim
29	reduction	_	_	I-Claim
30	of	_	_	I-Claim
31	edema	_	_	I-Claim
32	and	_	_	I-Claim
33	long	_	_	I-Claim
34	-	_	_	I-Claim
35	term	_	_	I-Claim
36	maintenance	_	_	I-Claim
37	of	_	_	I-Claim
38	limb	_	_	I-Claim
39	volume	_	_	I-Claim
40	in	_	_	I-Claim
41	lymphedema	_	_	I-Claim
42	.	_	_	I-Claim

43	However	_	_	O
44	,	_	_	O
45	CDPT	_	_	O
46	demands	_	_	O
47	substantial	_	_	O
48	time	_	_	O
49	and	_	_	O
50	effort	_	_	O
51	from	_	_	O
52	patients	_	_	O
53	to	_	_	O
54	maintain	_	_	O
55	these	_	_	O
56	benefits	_	_	O
57	;	_	_	O
58	the	_	_	B-Claim
59	treatments	_	_	I-Claim
60	are	_	_	I-Claim
61	not	_	_	I-Claim
62	always	_	_	I-Claim
63	well	_	_	I-Claim
64	-	_	_	I-Claim
65	accepted	_	_	I-Claim
66	,	_	_	I-Claim
67	and	_	_	O
68	patients	_	_	B-Claim
69	may	_	_	I-Claim
70	suffer	_	_	I-Claim
71	from	_	_	I-Claim
72	a	_	_	I-Claim
73	deterioration	_	_	I-Claim
74	in	_	_	I-Claim
75	quality	_	_	I-Claim
76	-	_	_	I-Claim
77	of	_	_	I-Claim
78	-	_	_	I-Claim
79	life	_	_	I-Claim
80	or	_	_	I-Claim
81	a	_	_	I-Claim
82	time	_	_	I-Claim
83	-	_	_	I-Claim
84	dependent	_	_	I-Claim
85	loss	_	_	I-Claim
86	of	_	_	I-Claim
87	initial	_	_	I-Claim
88	treatment	_	_	I-Claim
89	benefits	_	_	I-Claim
90	.	_	_	I-Claim

91	A	_	_	O
92	new	_	_	O
93	device	_	_	O
94	designed	_	_	O
95	for	_	_	O
96	home	_	_	O
97	use	_	_	O
98	by	_	_	O
99	the	_	_	O
100	patient	_	_	O
101	,	_	_	O
102	the	_	_	O
103	Flexitouch	_	_	O
104	,	_	_	O
105	has	_	_	O
106	been	_	_	O
107	developed	_	_	O
108	to	_	_	O
109	mechanically	_	_	O
110	simulate	_	_	O
111	MLD	_	_	O
112	.	_	_	O

113	We	_	_	O
114	have	_	_	O
115	undertaken	_	_	O
116	a	_	_	O
117	prospective	_	_	O
118	,	_	_	O
119	randomized	_	_	O
120	,	_	_	O
121	crossover	_	_	O
122	study	_	_	O
123	of	_	_	O
124	the	_	_	O
125	efficacy	_	_	O
126	of	_	_	O
127	the	_	_	O
128	Flexitouch	_	_	O
129	,	_	_	O
130	when	_	_	O
131	compared	_	_	O
132	to	_	_	O
133	massage	_	_	O
134	,	_	_	O
135	in	_	_	O
136	the	_	_	O
137	self	_	_	O
138	-	_	_	O
139	administered	_	_	O
140	maintenance	_	_	O
141	therapy	_	_	O
142	of	_	_	O
143	lymphedema	_	_	O
144	.	_	_	O

145	A	_	_	O
146	prospective	_	_	O
147	,	_	_	O
148	randomized	_	_	O
149	,	_	_	O
150	crossover	_	_	O
151	study	_	_	O
152	of	_	_	O
153	maintenance	_	_	O
154	therapy	_	_	O
155	was	_	_	O
156	performed	_	_	O
157	in	_	_	O
158	10	_	_	O
159	patients	_	_	O
160	with	_	_	O
161	unilateral	_	_	O
162	breast	_	_	O
163	cancer	_	_	O
164	-	_	_	O
165	associated	_	_	O
166	lymphedema	_	_	O
167	of	_	_	O
168	the	_	_	O
169	arm	_	_	O
170	.	_	_	O

171	Each	_	_	O
172	observation	_	_	O
173	phase	_	_	O
174	included	_	_	O
175	self	_	_	O
176	-	_	_	O
177	administered	_	_	O
178	treatment	_	_	O
179	with	_	_	O
180	the	_	_	O
181	Flexitouch	_	_	O
182	or	_	_	O
183	massage	_	_	O
184	,	_	_	O
185	1	_	_	O
186	hour	_	_	O
187	daily	_	_	O
188	for	_	_	O
189	14	_	_	O
190	days	_	_	O
191	,	_	_	O
192	respectively	_	_	O
193	,	_	_	O
194	followed	_	_	O
195	by	_	_	O
196	crossover	_	_	O
197	to	_	_	O
198	the	_	_	O
199	alternate	_	_	O
200	treatment	_	_	O
201	phase	_	_	O
202	.	_	_	O

203	Each	_	_	O
204	treatment	_	_	O
205	phase	_	_	O
206	was	_	_	O
207	preceded	_	_	O
208	by	_	_	O
209	a	_	_	O
210	1	_	_	O
211	week	_	_	O
212	treatment	_	_	O
213	washout	_	_	O
214	,	_	_	O
215	with	_	_	O
216	use	_	_	O
217	of	_	_	O
218	garment	_	_	O
219	only	_	_	O
220	.	_	_	O

221	The	_	_	O
222	sequence	_	_	O
223	of	_	_	O
224	treatment	_	_	O
225	was	_	_	O
226	randomly	_	_	O
227	assigned	_	_	O
228	.	_	_	O

229	The	_	_	O
230	potential	_	_	O
231	impact	_	_	O
232	of	_	_	O
233	treatment	_	_	O
234	modality	_	_	O
235	on	_	_	O
236	quality	_	_	O
237	of	_	_	O
238	life	_	_	O
239	was	_	_	O
240	assessed	_	_	O
241	with	_	_	O
242	serial	_	_	O
243	administration	_	_	O
244	of	_	_	O
245	the	_	_	O
246	SF	_	_	O
247	-	_	_	O
248	36	_	_	O
249	.	_	_	O

250	Statistical	_	_	O
251	analysis	_	_	O
252	disclosed	_	_	O
253	that	_	_	O
254	the	_	_	O
255	order	_	_	O
256	of	_	_	O
257	treatment	_	_	O
258	had	_	_	O
259	no	_	_	O
260	outcome	_	_	O
261	influence	_	_	O
262	,	_	_	O
263	permitting	_	_	O
264	10	_	_	O
265	comparisons	_	_	O
266	within	_	_	O
267	each	_	_	O
268	treatment	_	_	O
269	group	_	_	O
270	.	_	_	O

271	Post	_	_	B-Premise
272	-	_	_	I-Premise
273	treatment	_	_	I-Premise
274	arm	_	_	I-Premise
275	volume	_	_	I-Premise
276	reduced	_	_	I-Premise
277	significantly	_	_	I-Premise
278	after	_	_	I-Premise
279	the	_	_	I-Premise
280	Flexitouch	_	_	I-Premise
281	,	_	_	I-Premise
282	but	_	_	I-Premise
283	not	_	_	I-Premise
284	after	_	_	I-Premise
285	self	_	_	I-Premise
286	-	_	_	I-Premise
287	administered	_	_	I-Premise
288	massage	_	_	I-Premise
289	.	_	_	I-Premise

290	The	_	_	B-Premise
291	patients	_	_	I-Premise
292	'	_	_	I-Premise
293	mean	_	_	I-Premise
294	weight	_	_	I-Premise
295	decreased	_	_	I-Premise
296	significantly	_	_	I-Premise
297	with	_	_	I-Premise
298	Flexitouch	_	_	I-Premise
299	use	_	_	I-Premise
300	,	_	_	I-Premise
301	but	_	_	I-Premise
302	not	_	_	I-Premise
303	with	_	_	I-Premise
304	massage	_	_	I-Premise
305	.	_	_	I-Premise

306	The	_	_	B-Premise
307	Flexitouch	_	_	I-Premise
308	device	_	_	I-Premise
309	was	_	_	I-Premise
310	apparently	_	_	I-Premise
311	well	_	_	I-Premise
312	-	_	_	I-Premise
313	tolerated	_	_	I-Premise
314	and	_	_	I-Premise
315	accepted	_	_	I-Premise
316	by	_	_	I-Premise
317	patients	_	_	I-Premise
318	.	_	_	I-Premise

319	Serial	_	_	B-Premise
320	SF	_	_	I-Premise
321	-	_	_	I-Premise
322	36	_	_	I-Premise
323	administration	_	_	I-Premise
324	showed	_	_	I-Premise
325	no	_	_	I-Premise
326	deterioration	_	_	I-Premise
327	in	_	_	I-Premise
328	physical	_	_	I-Premise
329	or	_	_	I-Premise
330	psychosocial	_	_	I-Premise
331	scores	_	_	I-Premise
332	compared	_	_	I-Premise
333	to	_	_	I-Premise
334	baseline	_	_	I-Premise
335	measurements	_	_	I-Premise
336	;	_	_	I-Premise
337	there	_	_	B-Premise
338	were	_	_	I-Premise
339	no	_	_	I-Premise
340	statistical	_	_	I-Premise
341	differences	_	_	I-Premise
342	in	_	_	I-Premise
343	scores	_	_	I-Premise
344	when	_	_	I-Premise
345	the	_	_	I-Premise
346	two	_	_	I-Premise
347	treatment	_	_	I-Premise
348	modalities	_	_	I-Premise
349	were	_	_	I-Premise
350	compared	_	_	I-Premise
351	.	_	_	I-Premise

352	This	_	_	B-Claim
353	short	_	_	I-Claim
354	-	_	_	I-Claim
355	term	_	_	I-Claim
356	prospective	_	_	I-Claim
357	evaluation	_	_	I-Claim
358	of	_	_	I-Claim
359	the	_	_	I-Claim
360	Flexitouch	_	_	I-Claim
361	suggests	_	_	I-Claim
362	that	_	_	I-Claim
363	the	_	_	I-Claim
364	device	_	_	I-Claim
365	may	_	_	I-Claim
366	provide	_	_	I-Claim
367	better	_	_	I-Claim
368	maintenance	_	_	I-Claim
369	edema	_	_	I-Claim
370	control	_	_	I-Claim
371	than	_	_	I-Claim
372	self	_	_	I-Claim
373	-	_	_	I-Claim
374	adiminstered	_	_	I-Claim
375	massage	_	_	I-Claim
376	in	_	_	I-Claim
377	breast	_	_	I-Claim
378	cancer	_	_	I-Claim
379	-	_	_	I-Claim
380	associated	_	_	I-Claim
381	lymphedema	_	_	I-Claim
382	.	_	_	I-Claim

383	The	_	_	B-Claim
384	apparent	_	_	I-Claim
385	ease	_	_	I-Claim
386	of	_	_	I-Claim
387	use	_	_	I-Claim
388	and	_	_	I-Claim
389	reliability	_	_	I-Claim
390	of	_	_	I-Claim
391	response	_	_	I-Claim
392	to	_	_	I-Claim
393	the	_	_	I-Claim
394	device	_	_	I-Claim
395	suggest	_	_	I-Claim
396	that	_	_	I-Claim
397	further	_	_	I-Claim
398	broad	_	_	I-Claim
399	-	_	_	I-Claim
400	scale	_	_	I-Claim
401	testing	_	_	I-Claim
402	is	_	_	I-Claim
403	warranted	_	_	I-Claim
404	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	evaluate	_	_	O
8	laparoscopy	_	_	O
9	-	_	_	O
10	assisted	_	_	O
11	distal	_	_	O
12	gastrectomy	_	_	O
13	(	_	_	O
14	LADG	_	_	O
15	)	_	_	O
16	compared	_	_	O
17	to	_	_	O
18	open	_	_	O
19	distal	_	_	O
20	gastrectomy	_	_	O
21	(	_	_	O
22	ODG	_	_	O
23	)	_	_	O
24	in	_	_	O
25	the	_	_	O
26	treatment	_	_	O
27	of	_	_	O
28	early	_	_	O
29	gastric	_	_	O
30	cancer	_	_	O
31	with	_	_	O
32	respect	_	_	O
33	to	_	_	O
34	survival	_	_	O
35	,	_	_	O
36	surgical	_	_	O
37	outcomes	_	_	O
38	,	_	_	O
39	complications	_	_	O
40	,	_	_	O
41	and	_	_	O
42	quality	_	_	O
43	of	_	_	O
44	life	_	_	O
45	(	_	_	O
46	QOL	_	_	O
47	)	_	_	O
48	.	_	_	O

49	One	_	_	O
50	hundred	_	_	O
51	sixty	_	_	O
52	-	_	_	O
53	four	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	cT1N0M0	_	_	O
57	and	_	_	O
58	cT1N1M0	_	_	O
59	distal	_	_	O
60	gastric	_	_	O
61	cancer	_	_	O
62	were	_	_	O
63	randomly	_	_	O
64	assigned	_	_	O
65	to	_	_	O
66	either	_	_	O
67	the	_	_	O
68	LADG	_	_	O
69	group	_	_	O
70	or	_	_	O
71	the	_	_	O
72	ODG	_	_	O
73	group	_	_	O
74	.	_	_	O

75	The	_	_	O
76	primary	_	_	O
77	end	_	_	O
78	point	_	_	O
79	was	_	_	O
80	the	_	_	O
81	5	_	_	O
82	-	_	_	O
83	year	_	_	O
84	disease	_	_	O
85	-	_	_	O
86	free	_	_	O
87	survival	_	_	O
88	(	_	_	O
89	DFS	_	_	O
90	)	_	_	O
91	rate	_	_	O
92	.	_	_	O

93	Complications	_	_	O
94	were	_	_	O
95	classified	_	_	O
96	using	_	_	O
97	the	_	_	O
98	accordion	_	_	O
99	severity	_	_	O
100	classification	_	_	O
101	of	_	_	O
102	postoperative	_	_	O
103	complications	_	_	O
104	scheme	_	_	O
105	.	_	_	O

106	QOL	_	_	O
107	was	_	_	O
108	measured	_	_	O
109	using	_	_	O
110	the	_	_	O
111	European	_	_	O
112	Organization	_	_	O
113	for	_	_	O
114	Research	_	_	O
115	and	_	_	O
116	Treatment	_	_	O
117	of	_	_	O
118	Cancer	_	_	O
119	QLQ	_	_	O
120	-	_	_	O
121	C30	_	_	O
122	and	_	_	O
123	QLQ	_	_	O
124	-	_	_	O
125	STO22	_	_	O
126	preoperatively	_	_	O
127	and	_	_	O
128	postoperatively	_	_	O
129	during	_	_	O
130	regular	_	_	O
131	follow	_	_	O
132	-	_	_	O
133	up	_	_	O
134	visits	_	_	O
135	.	_	_	O

136	This	_	_	O
137	trial	_	_	O
138	is	_	_	O
139	registered	_	_	O
140	at	_	_	O
141	ClinicalTrials	_	_	O
142	.	_	_	O

143	gov	_	_	O
144	.	_	_	O

145	The	_	_	O
146	median	_	_	O
147	(	_	_	O
148	range	_	_	O
149	)	_	_	O
150	follow	_	_	O
151	-	_	_	O
152	up	_	_	O
153	period	_	_	O
154	was	_	_	O
155	74	_	_	O
156	.	_	_	O

157	3	_	_	O
158	(	_	_	O
159	24	_	_	O
160	.	_	_	O

161	8	_	_	O
162	-	_	_	O
163	90	_	_	O
164	.	_	_	O

165	8	_	_	O
166	)	_	_	O
167	months	_	_	O
168	.	_	_	O

169	The	_	_	B-Premise
170	LADG	_	_	I-Premise
171	and	_	_	I-Premise
172	ODG	_	_	I-Premise
173	groups	_	_	I-Premise
174	showed	_	_	I-Premise
175	similar	_	_	I-Premise
176	survival	_	_	I-Premise
177	[	_	_	I-Premise
178	5	_	_	I-Premise
179	-	_	_	I-Premise
180	year	_	_	I-Premise
181	DFS	_	_	I-Premise
182	rate	_	_	I-Premise
183	:	_	_	I-Premise
184	98	_	_	I-Premise
185	.	_	_	I-Premise

186	8	_	_	I-Premise
187	%	_	_	I-Premise
188	vs	_	_	I-Premise
189	.	_	_	I-Premise

190	97	_	_	I-Premise
191	.	_	_	I-Premise

192	6	_	_	I-Premise
193	%	_	_	I-Premise
194	,	_	_	I-Premise
195	respectively	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	=	_	_	I-Premise
199	0	_	_	I-Premise
200	.	_	_	I-Premise

201	514	_	_	I-Premise
202	)	_	_	I-Premise
203	,	_	_	I-Premise
204	5	_	_	I-Premise
205	-	_	_	I-Premise
206	year	_	_	I-Premise
207	overall	_	_	I-Premise
208	survival	_	_	I-Premise
209	(	_	_	I-Premise
210	OS	_	_	I-Premise
211	)	_	_	I-Premise
212	rate	_	_	I-Premise
213	:	_	_	I-Premise
214	97	_	_	I-Premise
215	.	_	_	I-Premise

216	6	_	_	I-Premise
217	vs	_	_	I-Premise
218	.	_	_	I-Premise

219	96	_	_	I-Premise
220	.	_	_	I-Premise

221	3	_	_	I-Premise
222	%	_	_	I-Premise
223	,	_	_	I-Premise
224	respectively	_	_	I-Premise
225	(	_	_	I-Premise
226	P	_	_	I-Premise
227	=	_	_	I-Premise
228	0	_	_	I-Premise
229	.	_	_	I-Premise

230	721	_	_	I-Premise
231	)	_	_	I-Premise
232	]	_	_	I-Premise
233	or	_	_	I-Premise
234	overall	_	_	I-Premise
235	complication	_	_	I-Premise
236	rate	_	_	I-Premise
237	(	_	_	I-Premise
238	29	_	_	I-Premise
239	.	_	_	I-Premise

240	3	_	_	I-Premise
241	vs	_	_	I-Premise
242	.	_	_	I-Premise

243	42	_	_	I-Premise
244	.	_	_	I-Premise

245	7	_	_	I-Premise
246	%	_	_	I-Premise
247	,	_	_	I-Premise
248	respectively	_	_	I-Premise
249	;	_	_	I-Premise
250	P	_	_	I-Premise
251	=	_	_	I-Premise
252	0	_	_	I-Premise
253	.	_	_	I-Premise

254	073	_	_	I-Premise
255	)	_	_	I-Premise
256	.	_	_	I-Premise

257	Mild	_	_	B-Premise
258	complications	_	_	I-Premise
259	were	_	_	I-Premise
260	significantly	_	_	I-Premise
261	less	_	_	I-Premise
262	frequent	_	_	I-Premise
263	in	_	_	I-Premise
264	the	_	_	I-Premise
265	LADG	_	_	I-Premise
266	group	_	_	I-Premise
267	than	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	ODG	_	_	I-Premise
271	group	_	_	I-Premise
272	(	_	_	I-Premise
273	23	_	_	I-Premise
274	.	_	_	I-Premise

275	2	_	_	I-Premise
276	vs	_	_	I-Premise
277	.	_	_	I-Premise

278	41	_	_	I-Premise
279	.	_	_	I-Premise

280	5	_	_	I-Premise
281	%	_	_	I-Premise
282	;	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	0	_	_	I-Premise
286	.	_	_	I-Premise

287	012	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	The	_	_	B-Premise
291	rates	_	_	I-Premise
292	of	_	_	I-Premise
293	moderate	_	_	I-Premise
294	,	_	_	I-Premise
295	severe	_	_	I-Premise
296	,	_	_	I-Premise
297	and	_	_	I-Premise
298	long	_	_	I-Premise
299	-	_	_	I-Premise
300	term	_	_	I-Premise
301	complications	_	_	I-Premise
302	(	_	_	I-Premise
303	i	_	_	I-Premise
304	.	_	_	I-Premise

305	e	_	_	I-Premise
306	.	_	_	I-Premise

307	,	_	_	I-Premise
308	31	_	_	I-Premise
309	days	_	_	I-Premise
310	to	_	_	I-Premise
311	5	_	_	I-Premise
312	years	_	_	I-Premise
313	after	_	_	I-Premise
314	surgery	_	_	I-Premise
315	)	_	_	I-Premise
316	did	_	_	I-Premise
317	not	_	_	I-Premise
318	differ	_	_	I-Premise
319	significantly	_	_	I-Premise
320	between	_	_	I-Premise
321	groups	_	_	I-Premise
322	.	_	_	I-Premise

323	No	_	_	B-Premise
324	clinically	_	_	I-Premise
325	meaningful	_	_	I-Premise
326	differences	_	_	I-Premise
327	were	_	_	I-Premise
328	detected	_	_	I-Premise
329	between	_	_	I-Premise
330	the	_	_	I-Premise
331	two	_	_	I-Premise
332	groups	_	_	I-Premise
333	in	_	_	I-Premise
334	long	_	_	I-Premise
335	-	_	_	I-Premise
336	term	_	_	I-Premise
337	QOL	_	_	I-Premise
338	.	_	_	I-Premise

339	LADG	_	_	B-Claim
340	showed	_	_	I-Claim
341	similar	_	_	I-Claim
342	DFS	_	_	I-Claim
343	and	_	_	I-Claim
344	OS	_	_	I-Claim
345	compared	_	_	I-Claim
346	to	_	_	I-Claim
347	ODG	_	_	I-Claim
348	in	_	_	I-Claim
349	treating	_	_	I-Claim
350	early	_	_	I-Claim
351	gastric	_	_	I-Claim
352	cancer	_	_	I-Claim
353	.	_	_	I-Claim

354	Marginal	_	_	B-Claim
355	benefits	_	_	I-Claim
356	in	_	_	I-Claim
357	mild	_	_	I-Claim
358	complications	_	_	I-Claim
359	were	_	_	I-Claim
360	observed	_	_	I-Claim
361	with	_	_	I-Claim
362	LADG	_	_	I-Claim
363	.	_	_	I-Claim

364	LADG	_	_	B-Claim
365	did	_	_	I-Claim
366	not	_	_	I-Claim
367	show	_	_	I-Claim
368	advantages	_	_	I-Claim
369	over	_	_	I-Claim
370	ODG	_	_	I-Claim
371	regarding	_	_	I-Claim
372	other	_	_	I-Claim
373	complications	_	_	I-Claim
374	and	_	_	I-Claim
375	long	_	_	I-Claim
376	-	_	_	I-Claim
377	term	_	_	I-Claim
378	QOL	_	_	I-Claim
379	.	_	_	I-Claim


0	Major	_	_	O
1	depressive	_	_	O
2	disorder	_	_	O
3	develops	_	_	O
4	in	_	_	O
5	up	_	_	O
6	to	_	_	O
7	half	_	_	O
8	the	_	_	O
9	patients	_	_	O
10	undergoing	_	_	O
11	treatment	_	_	O
12	for	_	_	O
13	head	_	_	O
14	and	_	_	O
15	neck	_	_	O
16	cancer	_	_	O
17	,	_	_	O
18	resulting	_	_	O
19	in	_	_	O
20	significant	_	_	O
21	morbidity	_	_	O
22	;	_	_	O
23	therefore	_	_	O
24	,	_	_	O
25	preventing	_	_	O
26	depression	_	_	O
27	during	_	_	O
28	cancer	_	_	O
29	treatment	_	_	O
30	may	_	_	O
31	be	_	_	O
32	of	_	_	O
33	great	_	_	O
34	benefit	_	_	O
35	.	_	_	O

36	To	_	_	O
37	determine	_	_	O
38	whether	_	_	O
39	prophylactic	_	_	O
40	use	_	_	O
41	of	_	_	O
42	the	_	_	O
43	antidepressant	_	_	O
44	escitalopram	_	_	O
45	oxalate	_	_	O
46	would	_	_	O
47	decrease	_	_	O
48	the	_	_	O
49	incidence	_	_	O
50	of	_	_	O
51	depression	_	_	O
52	in	_	_	O
53	patients	_	_	O
54	receiving	_	_	O
55	primary	_	_	O
56	therapy	_	_	O
57	for	_	_	O
58	head	_	_	O
59	and	_	_	O
60	neck	_	_	O
61	cancer	_	_	O
62	.	_	_	O

63	A	_	_	O
64	randomized	_	_	O
65	,	_	_	O
66	double	_	_	O
67	-	_	_	O
68	blind	_	_	O
69	,	_	_	O
70	placebo	_	_	O
71	-	_	_	O
72	controlled	_	_	O
73	trial	_	_	O
74	of	_	_	O
75	escitalopram	_	_	O
76	vs	_	_	O
77	placebo	_	_	O
78	was	_	_	O
79	conducted	_	_	O
80	in	_	_	O
81	a	_	_	O
82	group	_	_	O
83	of	_	_	O
84	nondepressed	_	_	O
85	patients	_	_	O
86	diagnosed	_	_	O
87	as	_	_	O
88	having	_	_	O
89	head	_	_	O
90	and	_	_	O
91	neck	_	_	O
92	cancer	_	_	O
93	who	_	_	O
94	were	_	_	O
95	about	_	_	O
96	to	_	_	O
97	enter	_	_	O
98	cancer	_	_	O
99	treatment	_	_	O
100	.	_	_	O

101	Patients	_	_	O
102	were	_	_	O
103	stratified	_	_	O
104	by	_	_	O
105	sex	_	_	O
106	,	_	_	O
107	site	_	_	O
108	,	_	_	O
109	stage	_	_	O
110	(	_	_	O
111	early	_	_	O
112	vs	_	_	O
113	advanced	_	_	O
114	)	_	_	O
115	,	_	_	O
116	and	_	_	O
117	primary	_	_	O
118	modality	_	_	O
119	of	_	_	O
120	treatment	_	_	O
121	(	_	_	O
122	radiation	_	_	O
123	vs	_	_	O
124	surgery	_	_	O
125	)	_	_	O
126	.	_	_	O

127	The	_	_	O
128	primary	_	_	O
129	outcome	_	_	O
130	measure	_	_	O
131	was	_	_	O
132	the	_	_	O
133	number	_	_	O
134	of	_	_	O
135	participants	_	_	O
136	who	_	_	O
137	developed	_	_	O
138	moderate	_	_	O
139	or	_	_	O
140	greater	_	_	O
141	depression	_	_	O
142	(	_	_	O
143	scores	_	_	O
144	on	_	_	O
145	the	_	_	O
146	Quick	_	_	O
147	Inventory	_	_	O
148	of	_	_	O
149	Depressive	_	_	O
150	Symptomology	_	_	O
151	-	_	_	O
152	Self	_	_	O
153	Rated	_	_	O
154	of	_	_	O
155	≥	_	_	O
156	11	_	_	O
157	)	_	_	O
158	.	_	_	O

159	From	_	_	O
160	January	_	_	O
161	6	_	_	O
162	,	_	_	O
163	2008	_	_	O
164	,	_	_	O
165	to	_	_	O
166	December	_	_	O
167	28	_	_	O
168	,	_	_	O
169	2011	_	_	O
170	,	_	_	O
171	148	_	_	O
172	patients	_	_	O
173	were	_	_	O
174	randomized	_	_	O
175	.	_	_	O

176	Significantly	_	_	B-Premise
177	fewer	_	_	I-Premise
178	patients	_	_	I-Premise
179	receiving	_	_	I-Premise
180	escitalopram	_	_	I-Premise
181	developed	_	_	I-Premise
182	depression	_	_	I-Premise
183	(	_	_	I-Premise
184	24	_	_	I-Premise
185	.	_	_	I-Premise

186	6	_	_	I-Premise
187	%	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	placebo	_	_	I-Premise
191	group	_	_	I-Premise
192	vs	_	_	I-Premise
193	10	_	_	I-Premise
194	.	_	_	I-Premise

195	0	_	_	I-Premise
196	%	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	escitalopram	_	_	I-Premise
200	group	_	_	I-Premise
201	;	_	_	I-Premise
202	stratified	_	_	I-Premise
203	log	_	_	I-Premise
204	-	_	_	I-Premise
205	rank	_	_	I-Premise
206	test	_	_	I-Premise
207	,	_	_	I-Premise
208	P	_	_	I-Premise
209	=	_	_	I-Premise
210	.	_	_	I-Premise

211	04	_	_	I-Premise
212	)	_	_	I-Premise
213	.	_	_	I-Premise

214	A	_	_	O
215	Cox	_	_	O
216	proportional	_	_	O
217	hazards	_	_	O
218	regression	_	_	O
219	model	_	_	O
220	compared	_	_	O
221	the	_	_	O
222	2	_	_	O
223	treatment	_	_	O
224	groups	_	_	O
225	after	_	_	O
226	controlling	_	_	O
227	for	_	_	O
228	age	_	_	O
229	,	_	_	O
230	baseline	_	_	O
231	smoking	_	_	O
232	status	_	_	O
233	,	_	_	O
234	and	_	_	O
235	stratification	_	_	O
236	variables	_	_	O
237	.	_	_	O

238	The	_	_	B-Premise
239	hazard	_	_	I-Premise
240	ratio	_	_	I-Premise
241	of	_	_	I-Premise
242	0	_	_	I-Premise
243	.	_	_	I-Premise

244	37	_	_	I-Premise
245	(	_	_	I-Premise
246	95	_	_	I-Premise
247	%	_	_	I-Premise
248	CI	_	_	I-Premise
249	,	_	_	I-Premise
250	0	_	_	I-Premise
251	.	_	_	I-Premise

252	14	_	_	I-Premise
253	-	_	_	I-Premise
254	0	_	_	I-Premise
255	.	_	_	I-Premise

256	96	_	_	I-Premise
257	)	_	_	I-Premise
258	demonstrated	_	_	I-Premise
259	an	_	_	I-Premise
260	advantage	_	_	I-Premise
261	of	_	_	I-Premise
262	escitalopram	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	.	_	_	I-Premise

267	04	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	Patients	_	_	B-Premise
271	undergoing	_	_	I-Premise
272	radiotherapy	_	_	I-Premise
273	as	_	_	I-Premise
274	the	_	_	I-Premise
275	initial	_	_	I-Premise
276	modality	_	_	I-Premise
277	were	_	_	I-Premise
278	significantly	_	_	I-Premise
279	more	_	_	I-Premise
280	likely	_	_	I-Premise
281	to	_	_	I-Premise
282	develop	_	_	I-Premise
283	depression	_	_	I-Premise
284	than	_	_	I-Premise
285	those	_	_	I-Premise
286	undergoing	_	_	I-Premise
287	surgery	_	_	I-Premise
288	(	_	_	I-Premise
289	radiotherapy	_	_	I-Premise
290	compared	_	_	I-Premise
291	with	_	_	I-Premise
292	surgery	_	_	I-Premise
293	group	_	_	I-Premise
294	;	_	_	I-Premise
295	hazard	_	_	I-Premise
296	ratio	_	_	I-Premise
297	,	_	_	I-Premise
298	3	_	_	I-Premise
299	.	_	_	I-Premise

300	6	_	_	I-Premise
301	;	_	_	I-Premise
302	95	_	_	I-Premise
303	%	_	_	I-Premise
304	CI	_	_	I-Premise
305	,	_	_	I-Premise
306	1	_	_	I-Premise
307	.	_	_	I-Premise

308	38	_	_	I-Premise
309	-	_	_	I-Premise
310	9	_	_	I-Premise
311	.	_	_	I-Premise

312	40	_	_	I-Premise
313	;	_	_	I-Premise
314	P	_	_	I-Premise
315	=	_	_	I-Premise
316	.	_	_	I-Premise

317	009	_	_	I-Premise
318	)	_	_	I-Premise
319	.	_	_	I-Premise

320	Patients	_	_	B-Premise
321	in	_	_	I-Premise
322	the	_	_	I-Premise
323	escitalopram	_	_	I-Premise
324	group	_	_	I-Premise
325	who	_	_	I-Premise
326	completed	_	_	I-Premise
327	the	_	_	I-Premise
328	study	_	_	I-Premise
329	and	_	_	I-Premise
330	were	_	_	I-Premise
331	not	_	_	I-Premise
332	depressed	_	_	I-Premise
333	rated	_	_	I-Premise
334	their	_	_	I-Premise
335	overall	_	_	I-Premise
336	quality	_	_	I-Premise
337	of	_	_	I-Premise
338	life	_	_	I-Premise
339	as	_	_	I-Premise
340	significantly	_	_	I-Premise
341	better	_	_	I-Premise
342	for	_	_	I-Premise
343	3	_	_	I-Premise
344	consecutive	_	_	I-Premise
345	months	_	_	I-Premise
346	after	_	_	I-Premise
347	cessation	_	_	I-Premise
348	of	_	_	I-Premise
349	drug	_	_	I-Premise
350	use	_	_	I-Premise
351	.	_	_	I-Premise

352	In	_	_	B-Claim
353	nondepressed	_	_	I-Claim
354	patients	_	_	I-Claim
355	undergoing	_	_	I-Claim
356	treatment	_	_	I-Claim
357	for	_	_	I-Claim
358	head	_	_	I-Claim
359	and	_	_	I-Claim
360	neck	_	_	I-Claim
361	cancer	_	_	I-Claim
362	,	_	_	I-Claim
363	prophylactic	_	_	I-Claim
364	escitalopram	_	_	I-Claim
365	reduced	_	_	I-Claim
366	the	_	_	I-Claim
367	risk	_	_	I-Claim
368	of	_	_	I-Claim
369	developing	_	_	I-Claim
370	depression	_	_	I-Claim
371	by	_	_	I-Claim
372	more	_	_	I-Claim
373	than	_	_	I-Claim
374	50	_	_	I-Claim
375	%	_	_	I-Claim
376	.	_	_	I-Claim

377	In	_	_	B-Claim
378	nondepressed	_	_	I-Claim
379	patients	_	_	I-Claim
380	who	_	_	I-Claim
381	completed	_	_	I-Claim
382	the	_	_	I-Claim
383	trial	_	_	I-Claim
384	,	_	_	I-Claim
385	quality	_	_	I-Claim
386	of	_	_	I-Claim
387	life	_	_	I-Claim
388	was	_	_	I-Claim
389	also	_	_	I-Claim
390	significantly	_	_	I-Claim
391	better	_	_	I-Claim
392	for	_	_	I-Claim
393	3	_	_	I-Claim
394	consecutive	_	_	I-Claim
395	months	_	_	I-Claim
396	after	_	_	I-Claim
397	cessation	_	_	I-Claim
398	of	_	_	I-Claim
399	drug	_	_	I-Claim
400	use	_	_	I-Claim
401	in	_	_	I-Claim
402	the	_	_	I-Claim
403	escitalopram	_	_	I-Claim
404	group	_	_	I-Claim
405	.	_	_	I-Claim

406	These	_	_	B-Claim
407	findings	_	_	I-Claim
408	have	_	_	I-Claim
409	important	_	_	I-Claim
410	implications	_	_	I-Claim
411	for	_	_	I-Claim
412	the	_	_	I-Claim
413	treatment	_	_	I-Claim
414	of	_	_	I-Claim
415	patients	_	_	I-Claim
416	with	_	_	I-Claim
417	head	_	_	I-Claim
418	and	_	_	I-Claim
419	neck	_	_	I-Claim
420	cancer	_	_	I-Claim
421	.	_	_	I-Claim


0	Cancer	_	_	O
1	treatment	_	_	O
2	can	_	_	O
3	profoundly	_	_	O
4	impact	_	_	O
5	the	_	_	O
6	patient	_	_	O
7	'	_	_	O
8	s	_	_	O
9	quality	_	_	O
10	of	_	_	O
11	life	_	_	O
12	(	_	_	O
13	QOL	_	_	O
14	)	_	_	O
15	.	_	_	O

16	It	_	_	O
17	has	_	_	O
18	been	_	_	O
19	well	_	_	O
20	documented	_	_	O
21	that	_	_	O
22	there	_	_	O
23	are	_	_	O
24	gender	_	_	O
25	differences	_	_	O
26	in	_	_	O
27	the	_	_	O
28	symptoms	_	_	O
29	associated	_	_	O
30	with	_	_	O
31	cancer	_	_	O
32	treatment	_	_	O
33	.	_	_	O

34	This	_	_	O
35	study	_	_	O
36	explores	_	_	O
37	the	_	_	O
38	impact	_	_	O
39	of	_	_	O
40	gender	_	_	O
41	on	_	_	O
42	QOL	_	_	O
43	for	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	newly	_	_	O
47	diagnosed	_	_	O
48	advanced	_	_	O
49	cancer	_	_	O
50	.	_	_	O

51	A	_	_	O
52	randomized	_	_	O
53	,	_	_	O
54	controlled	_	_	O
55	clinical	_	_	O
56	trial	_	_	O
57	in	_	_	O
58	patients	_	_	O
59	receiving	_	_	O
60	radiotherapy	_	_	O
61	for	_	_	O
62	advanced	_	_	O
63	cancer	_	_	O
64	demonstrated	_	_	O
65	maintenance	_	_	O
66	of	_	_	O
67	QOL	_	_	O
68	with	_	_	O
69	a	_	_	O
70	six	_	_	O
71	session	_	_	O
72	multidisciplinary	_	_	O
73	structured	_	_	O
74	intervention	_	_	O
75	compared	_	_	O
76	to	_	_	O
77	controls	_	_	O
78	.	_	_	O

79	This	_	_	O
80	current	_	_	O
81	study	_	_	O
82	reports	_	_	O
83	the	_	_	O
84	gender	_	_	O
85	differences	_	_	O
86	in	_	_	O
87	that	_	_	O
88	trial	_	_	O
89	.	_	_	O

90	Outcome	_	_	O
91	measures	_	_	O
92	included	_	_	O
93	the	_	_	O
94	functional	_	_	O
95	assessment	_	_	O
96	of	_	_	O
97	cancer	_	_	O
98	therapy	_	_	O
99	-	_	_	O
100	general	_	_	O
101	(	_	_	O
102	FACT	_	_	O
103	-	_	_	O
104	G	_	_	O
105	)	_	_	O
106	,	_	_	O
107	linear	_	_	O
108	analog	_	_	O
109	self	_	_	O
110	-	_	_	O
111	assessment	_	_	O
112	(	_	_	O
113	LASA	_	_	O
114	)	_	_	O
115	,	_	_	O
116	and	_	_	O
117	profile	_	_	O
118	of	_	_	O
119	mood	_	_	O
120	states	_	_	O
121	(	_	_	O
122	POMS	_	_	O
123	)	_	_	O
124	at	_	_	O
125	baseline	_	_	O
126	and	_	_	O
127	weeks	_	_	O
128	4	_	_	O
129	,	_	_	O
130	27	_	_	O
131	,	_	_	O
132	and	_	_	O
133	52	_	_	O
134	.	_	_	O

135	Kruskal	_	_	O
136	-	_	_	O
137	Wallis	_	_	O
138	was	_	_	O
139	used	_	_	O
140	to	_	_	O
141	compare	_	_	O
142	QOL	_	_	O
143	scores	_	_	O
144	.	_	_	O

145	One	_	_	O
146	hundred	_	_	O
147	thirty	_	_	O
148	-	_	_	O
149	one	_	_	O
150	patients	_	_	O
151	(	_	_	O
152	45	_	_	O
153	women	_	_	O
154	and	_	_	O
155	86	_	_	O
156	men	_	_	O
157	,	_	_	O
158	mean	_	_	O
159	age	_	_	O
160	58	_	_	O
161	.	_	_	O

162	7	_	_	O
163	)	_	_	O
164	participated	_	_	O
165	in	_	_	O
166	the	_	_	O
167	clinical	_	_	O
168	trial	_	_	O
169	.	_	_	O

170	At	_	_	B-Premise
171	week	_	_	I-Premise
172	4	_	_	I-Premise
173	postintervention	_	_	I-Premise
174	,	_	_	I-Premise
175	women	_	_	I-Premise
176	in	_	_	I-Premise
177	the	_	_	I-Premise
178	intervention	_	_	I-Premise
179	group	_	_	I-Premise
180	had	_	_	I-Premise
181	statistically	_	_	I-Premise
182	significant	_	_	I-Premise
183	improvement	_	_	I-Premise
184	in	_	_	I-Premise
185	their	_	_	I-Premise
186	FACT	_	_	I-Premise
187	-	_	_	I-Premise
188	G	_	_	I-Premise
189	score	_	_	I-Premise
190	,	_	_	I-Premise
191	FACT	_	_	I-Premise
192	-	_	_	I-Premise
193	G	_	_	I-Premise
194	physical	_	_	I-Premise
195	well	_	_	I-Premise
196	-	_	_	I-Premise
197	being	_	_	I-Premise
198	subscale	_	_	I-Premise
199	,	_	_	I-Premise
200	LASA	_	_	I-Premise
201	fatigue	_	_	I-Premise
202	,	_	_	I-Premise
203	POMS	_	_	I-Premise
204	total	_	_	I-Premise
205	score	_	_	I-Premise
206	,	_	_	I-Premise
207	POMS	_	_	I-Premise
208	fatigue	_	_	I-Premise
209	-	_	_	I-Premise
210	inertia	_	_	I-Premise
211	subscale	_	_	I-Premise
212	,	_	_	I-Premise
213	and	_	_	I-Premise
214	POMS	_	_	I-Premise
215	confusion	_	_	I-Premise
216	-	_	_	I-Premise
217	bewilderment	_	_	I-Premise
218	subscale	_	_	I-Premise
219	(	_	_	I-Premise
220	p	_	_	I-Premise
221	<	_	_	I-Premise
222	0	_	_	I-Premise
223	.	_	_	I-Premise

224	05	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	Men	_	_	B-Premise
228	receiving	_	_	I-Premise
229	the	_	_	I-Premise
230	intervention	_	_	I-Premise
231	had	_	_	I-Premise
232	a	_	_	I-Premise
233	smaller	_	_	I-Premise
234	decrease	_	_	I-Premise
235	in	_	_	I-Premise
236	FACT	_	_	I-Premise
237	-	_	_	I-Premise
238	G	_	_	I-Premise
239	score	_	_	I-Premise
240	compared	_	_	I-Premise
241	to	_	_	I-Premise
242	controls	_	_	I-Premise
243	(	_	_	I-Premise
244	p	_	_	I-Premise
245	=	_	_	I-Premise
246	0	_	_	I-Premise
247	.	_	_	I-Premise

248	048	_	_	I-Premise
249	)	_	_	I-Premise
250	and	_	_	I-Premise
251	also	_	_	I-Premise
252	worsened	_	_	I-Premise
253	on	_	_	I-Premise
254	the	_	_	I-Premise
255	LASA	_	_	I-Premise
256	financial	_	_	I-Premise
257	(	_	_	I-Premise
258	p	_	_	I-Premise
259	=	_	_	I-Premise
260	0	_	_	I-Premise
261	.	_	_	I-Premise

262	02	_	_	I-Premise
263	)	_	_	I-Premise
264	.	_	_	I-Premise

265	At	_	_	B-Premise
266	week	_	_	I-Premise
267	27	_	_	I-Premise
268	,	_	_	I-Premise
269	the	_	_	I-Premise
270	only	_	_	I-Premise
271	gender	_	_	I-Premise
272	difference	_	_	I-Premise
273	was	_	_	I-Premise
274	that	_	_	I-Premise
275	intervention	_	_	I-Premise
276	group	_	_	I-Premise
277	men	_	_	I-Premise
278	had	_	_	I-Premise
279	more	_	_	I-Premise
280	POMS	_	_	I-Premise
281	anger	_	_	I-Premise
282	-	_	_	I-Premise
283	hostility	_	_	I-Premise
284	(	_	_	I-Premise
285	p	_	_	I-Premise
286	=	_	_	I-Premise
287	0	_	_	I-Premise
288	.	_	_	I-Premise

289	009	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	By	_	_	B-Premise
293	week	_	_	I-Premise
294	52	_	_	I-Premise
295	,	_	_	I-Premise
296	there	_	_	I-Premise
297	were	_	_	I-Premise
298	no	_	_	I-Premise
299	statistically	_	_	I-Premise
300	significant	_	_	I-Premise
301	gender	_	_	I-Premise
302	differences	_	_	I-Premise
303	in	_	_	I-Premise
304	any	_	_	I-Premise
305	of	_	_	I-Premise
306	the	_	_	I-Premise
307	QOL	_	_	I-Premise
308	measures	_	_	I-Premise
309	.	_	_	I-Premise

310	Gender	_	_	B-Claim
311	-	_	_	I-Claim
312	based	_	_	I-Claim
313	differences	_	_	I-Claim
314	appear	_	_	I-Claim
315	to	_	_	I-Claim
316	play	_	_	I-Claim
317	a	_	_	I-Claim
318	role	_	_	I-Claim
319	in	_	_	I-Claim
320	the	_	_	I-Claim
321	early	_	_	I-Claim
322	,	_	_	I-Claim
323	but	_	_	I-Claim
324	not	_	_	I-Claim
325	late	_	_	I-Claim
326	,	_	_	I-Claim
327	response	_	_	I-Claim
328	to	_	_	I-Claim
329	a	_	_	I-Claim
330	multidisciplinary	_	_	I-Claim
331	intervention	_	_	I-Claim
332	to	_	_	I-Claim
333	improve	_	_	I-Claim
334	QOL	_	_	I-Claim
335	for	_	_	I-Claim
336	patients	_	_	I-Claim
337	with	_	_	I-Claim
338	advanced	_	_	I-Claim
339	cancer	_	_	I-Claim
340	,	_	_	I-Claim
341	suggesting	_	_	O
342	that	_	_	O
343	early	_	_	B-Claim
344	interventions	_	_	I-Claim
345	can	_	_	I-Claim
346	be	_	_	I-Claim
347	tailored	_	_	I-Claim
348	for	_	_	I-Claim
349	each	_	_	I-Claim
350	gender	_	_	I-Claim
351	.	_	_	I-Claim


0	Intravenous	_	_	O
1	(	_	_	O
2	IV	_	_	O
3	)	_	_	O
4	granulocyte	_	_	O
5	colony	_	_	O
6	stimulating	_	_	O
7	factor	_	_	O
8	(	_	_	O
9	G	_	_	O
10	-	_	_	O
11	CSF	_	_	O
12	)	_	_	O
13	might	_	_	O
14	be	_	_	O
15	safer	_	_	O
16	and	_	_	O
17	more	_	_	O
18	convenient	_	_	O
19	than	_	_	O
20	subcutaneous	_	_	O
21	(	_	_	O
22	SC	_	_	O
23	)	_	_	O
24	administration	_	_	O
25	to	_	_	O
26	hospitalized	_	_	O
27	hemato	_	_	O
28	-	_	_	O
29	oncological	_	_	O
30	patients	_	_	O
31	receiving	_	_	O
32	chemotherapy	_	_	O
33	.	_	_	O

34	To	_	_	O
35	compare	_	_	O
36	IV	_	_	O
37	vs	_	_	O
38	.	_	_	O

39	SC	_	_	O
40	G	_	_	O
41	-	_	_	O
42	CSF	_	_	O
43	administration	_	_	O
44	,	_	_	O
45	we	_	_	O
46	conducted	_	_	O
47	a	_	_	O
48	randomized	_	_	O
49	,	_	_	O
50	open	_	_	O
51	-	_	_	O
52	label	_	_	O
53	trial	_	_	O
54	.	_	_	O

55	We	_	_	O
56	included	_	_	O
57	inpatients	_	_	O
58	receiving	_	_	O
59	chemotherapy	_	_	O
60	for	_	_	O
61	acute	_	_	O
62	myeloid	_	_	O
63	leukemia	_	_	O
64	,	_	_	O
65	acute	_	_	O
66	lymphoblastic	_	_	O
67	leukemia	_	_	O
68	,	_	_	O
69	lymphoma	_	_	O
70	or	_	_	O
71	multiple	_	_	O
72	myeloma	_	_	O
73	,	_	_	O
74	and	_	_	O
75	allogeneic	_	_	O
76	or	_	_	O
77	autologous	_	_	O
78	hematopoietic	_	_	O
79	cell	_	_	O
80	transplantation	_	_	O
81	(	_	_	O
82	HCT	_	_	O
83	)	_	_	O
84	.	_	_	O

85	Patients	_	_	O
86	were	_	_	O
87	randomized	_	_	O
88	to	_	_	O
89	5	_	_	O
90	mcg	_	_	O
91	/	_	_	O
92	kg	_	_	O
93	single	_	_	O
94	daily	_	_	O
95	dose	_	_	O
96	of	_	_	O
97	IV	_	_	O
98	bolus	_	_	O
99	versus	_	_	O
100	SC	_	_	O
101	filgrastim	_	_	O
102	given	_	_	O
103	for	_	_	O
104	its	_	_	O
105	clinical	_	_	O
106	indications	_	_	O
107	.	_	_	O

108	Patients	_	_	O
109	were	_	_	O
110	crossed	_	_	O
111	-	_	_	O
112	over	_	_	O
113	to	_	_	O
114	the	_	_	O
115	alternate	_	_	O
116	study	_	_	O
117	arm	_	_	O
118	on	_	_	O
119	the	_	_	O
120	subsequent	_	_	O
121	chemotherapy	_	_	O
122	course	_	_	O
123	.	_	_	O

124	The	_	_	O
125	primary	_	_	O
126	outcomes	_	_	O
127	were	_	_	O
128	time	_	_	O
129	from	_	_	O
130	initiation	_	_	O
131	of	_	_	O
132	filgrastim	_	_	O
133	to	_	_	O
134	recovery	_	_	O
135	of	_	_	O
136	stable	_	_	O
137	neutrophil	_	_	O
138	count	_	_	O
139	of	_	_	O
140	>	_	_	O
141	500	_	_	O
142	cells	_	_	O
143	/	_	_	O
144	µL	_	_	O
145	and	_	_	O
146	a	_	_	O
147	composite	_	_	O
148	clinical	_	_	O
149	outcome	_	_	O
150	of	_	_	O
151	infection	_	_	O
152	or	_	_	O
153	death	_	_	O
154	assessed	_	_	O
155	for	_	_	O
156	the	_	_	O
157	first	_	_	O
158	course	_	_	O
159	post	_	_	O
160	-	_	_	O
161	randomization	_	_	O
162	.	_	_	O

163	The	_	_	O
164	study	_	_	O
165	was	_	_	O
166	stopped	_	_	O
167	on	_	_	O
168	the	_	_	O
169	second	_	_	O
170	interim	_	_	O
171	analysis	_	_	O
172	.	_	_	O

173	Of	_	_	O
174	120	_	_	O
175	patients	_	_	O
176	randomized	_	_	O
177	,	_	_	O
178	118	_	_	O
179	were	_	_	O
180	evaluated	_	_	O
181	in	_	_	O
182	the	_	_	O
183	first	_	_	O
184	treatment	_	_	O
185	course	_	_	O
186	.	_	_	O

187	The	_	_	B-Premise
188	mean	_	_	I-Premise
189	time	_	_	I-Premise
190	to	_	_	I-Premise
191	neutropenia	_	_	I-Premise
192	resolution	_	_	I-Premise
193	was	_	_	I-Premise
194	longer	_	_	I-Premise
195	with	_	_	I-Premise
196	IV	_	_	I-Premise
197	G	_	_	I-Premise
198	-	_	_	I-Premise
199	CSF	_	_	I-Premise
200	[	_	_	I-Premise
201	7	_	_	I-Premise
202	.	_	_	I-Premise

203	9	_	_	I-Premise
204	days	_	_	I-Premise
205	,	_	_	I-Premise
206	95	_	_	I-Premise
207	%	_	_	I-Premise
208	confidence	_	_	I-Premise
209	interval	_	_	I-Premise
210	(	_	_	I-Premise
211	CI	_	_	I-Premise
212	)	_	_	I-Premise
213	6	_	_	I-Premise
214	.	_	_	I-Premise

215	6	_	_	I-Premise
216	-	_	_	I-Premise
217	9	_	_	I-Premise
218	.	_	_	I-Premise

219	1	_	_	I-Premise
220	]	_	_	I-Premise
221	compared	_	_	I-Premise
222	with	_	_	I-Premise
223	SC	_	_	I-Premise
224	G	_	_	I-Premise
225	-	_	_	I-Premise
226	CSF	_	_	I-Premise
227	(	_	_	I-Premise
228	5	_	_	I-Premise
229	.	_	_	I-Premise

230	4	_	_	I-Premise
231	days	_	_	I-Premise
232	,	_	_	I-Premise
233	95	_	_	I-Premise
234	%	_	_	I-Premise
235	CI	_	_	I-Premise
236	4	_	_	I-Premise
237	.	_	_	I-Premise

238	6	_	_	I-Premise
239	-	_	_	I-Premise
240	6	_	_	I-Premise
241	.	_	_	I-Premise

242	2	_	_	I-Premise
243	)	_	_	I-Premise
244	,	_	_	I-Premise
245	log	_	_	I-Premise
246	-	_	_	I-Premise
247	rank	_	_	I-Premise
248	P	_	_	I-Premise
249	=	_	_	I-Premise
250	0	_	_	I-Premise
251	.	_	_	I-Premise

252	001	_	_	I-Premise
253	.	_	_	I-Premise

254	Longer	_	_	B-Premise
255	neutropenia	_	_	I-Premise
256	duration	_	_	I-Premise
257	was	_	_	I-Premise
258	observed	_	_	I-Premise
259	in	_	_	I-Premise
260	all	_	_	I-Premise
261	patient	_	_	I-Premise
262	subgroups	_	_	I-Premise
263	,	_	_	I-Premise
264	except	_	_	B-Premise
265	for	_	_	I-Premise
266	patients	_	_	I-Premise
267	undergoing	_	_	I-Premise
268	autologous	_	_	I-Premise
269	HCT	_	_	I-Premise
270	.	_	_	I-Premise

271	There	_	_	B-Premise
272	was	_	_	I-Premise
273	no	_	_	I-Premise
274	significant	_	_	I-Premise
275	difference	_	_	I-Premise
276	between	_	_	I-Premise
277	groups	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	occurrence	_	_	I-Premise
281	of	_	_	I-Premise
282	infection	_	_	I-Premise
283	or	_	_	I-Premise
284	death	_	_	I-Premise
285	,	_	_	I-Premise
286	but	_	_	B-Premise
287	more	_	_	I-Premise
288	deaths	_	_	I-Premise
289	were	_	_	I-Premise
290	observed	_	_	I-Premise
291	with	_	_	I-Premise
292	IV	_	_	I-Premise
293	(	_	_	I-Premise
294	4	_	_	I-Premise
295	/	_	_	I-Premise
296	57	_	_	I-Premise
297	,	_	_	I-Premise
298	7	_	_	I-Premise
299	%	_	_	I-Premise
300	)	_	_	I-Premise
301	versus	_	_	I-Premise
302	SC	_	_	I-Premise
303	(	_	_	I-Premise
304	1	_	_	I-Premise
305	/	_	_	I-Premise
306	61	_	_	I-Premise
307	,	_	_	I-Premise
308	1	_	_	I-Premise
309	.	_	_	I-Premise

310	6	_	_	I-Premise
311	%	_	_	I-Premise
312	)	_	_	I-Premise
313	G	_	_	I-Premise
314	-	_	_	I-Premise
315	CSF	_	_	I-Premise
316	administration	_	_	I-Premise
317	,	_	_	I-Premise
318	P	_	_	I-Premise
319	=	_	_	I-Premise
320	0	_	_	I-Premise
321	.	_	_	I-Premise

322	196	_	_	I-Premise
323	.	_	_	I-Premise

324	Similar	_	_	O
325	results	_	_	O
326	were	_	_	O
327	observed	_	_	O
328	when	_	_	O
329	all	_	_	O
330	158	_	_	O
331	courses	_	_	O
332	following	_	_	O
333	cross	_	_	O
334	-	_	_	O
335	over	_	_	O
336	were	_	_	O
337	analyzed	_	_	O
338	.	_	_	O

339	Patients	_	_	B-Claim
340	reported	_	_	I-Claim
341	similar	_	_	I-Claim
342	pain	_	_	I-Claim
343	and	_	_	I-Claim
344	satisfaction	_	_	I-Claim
345	scores	_	_	I-Claim
346	in	_	_	I-Claim
347	both	_	_	I-Claim
348	groups	_	_	I-Claim
349	.	_	_	I-Claim

350	Bolus	_	_	B-Claim
351	IV	_	_	I-Claim
352	administration	_	_	I-Claim
353	of	_	_	I-Claim
354	G	_	_	I-Claim
355	-	_	_	I-Claim
356	CSF	_	_	I-Claim
357	results	_	_	I-Claim
358	in	_	_	I-Claim
359	longer	_	_	I-Claim
360	neutropenia	_	_	I-Claim
361	duration	_	_	I-Claim
362	than	_	_	I-Claim
363	SC	_	_	I-Claim
364	administration	_	_	I-Claim
365	,	_	_	I-Claim
366	with	_	_	I-Claim
367	no	_	_	I-Claim
368	difference	_	_	I-Claim
369	in	_	_	I-Claim
370	clinical	_	_	I-Claim
371	or	_	_	I-Claim
372	quality	_	_	I-Claim
373	-	_	_	I-Claim
374	of	_	_	I-Claim
375	-	_	_	I-Claim
376	life	_	_	I-Claim
377	measures	_	_	I-Claim
378	.	_	_	I-Claim


0	The	_	_	O
1	standard	_	_	O
2	treatment	_	_	O
3	for	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	clinically	_	_	O
7	resectable	_	_	O
8	rectal	_	_	O
9	cancer	_	_	O
10	is	_	_	O
11	surgery	_	_	O
12	.	_	_	O

13	Postoperative	_	_	B-Claim
14	radiochemotherapy	_	_	I-Claim
15	is	_	_	I-Claim
16	recommended	_	_	I-Claim
17	for	_	_	I-Claim
18	patients	_	_	I-Claim
19	with	_	_	I-Claim
20	advanced	_	_	I-Claim
21	disease	_	_	I-Claim
22	(	_	_	I-Claim
23	pT3	_	_	I-Claim
24	/	_	_	I-Claim
25	4	_	_	I-Claim
26	or	_	_	I-Claim
27	pN	_	_	I-Claim
28	+	_	_	I-Claim
29	)	_	_	I-Claim
30	.	_	_	I-Claim

31	In	_	_	B-Claim
32	recent	_	_	I-Claim
33	years	_	_	I-Claim
34	,	_	_	I-Claim
35	encouraging	_	_	I-Claim
36	results	_	_	I-Claim
37	of	_	_	I-Claim
38	preoperative	_	_	I-Claim
39	radiotherapy	_	_	I-Claim
40	have	_	_	I-Claim
41	been	_	_	I-Claim
42	reported	_	_	I-Claim
43	.	_	_	I-Claim

44	This	_	_	O
45	prospective	_	_	O
46	randomized	_	_	O
47	phase	_	_	O
48	-	_	_	O
49	III	_	_	O
50	trial	_	_	O
51	(	_	_	O
52	CAO	_	_	O
53	/	_	_	O
54	ARO	_	_	O
55	/	_	_	O
56	AIO	_	_	O
57	-	_	_	O
58	94	_	_	O
59	)	_	_	O
60	compares	_	_	O
61	the	_	_	O
62	efficacy	_	_	O
63	of	_	_	O
64	neoadjuvant	_	_	O
65	radiochemotherapy	_	_	O
66	to	_	_	O
67	standard	_	_	O
68	postoperative	_	_	O
69	radiochemotherapy	_	_	O
70	.	_	_	O

71	We	_	_	O
72	report	_	_	O
73	on	_	_	O
74	the	_	_	O
75	design	_	_	O
76	of	_	_	O
77	the	_	_	O
78	study	_	_	O
79	and	_	_	O
80	first	_	_	O
81	results	_	_	O
82	with	_	_	O
83	regard	_	_	O
84	to	_	_	O
85	toxicity	_	_	O
86	of	_	_	O
87	radiochemotherapy	_	_	O
88	and	_	_	O
89	postoperative	_	_	O
90	morbidity	_	_	O
91	.	_	_	O

92	Patients	_	_	O
93	with	_	_	O
94	locally	_	_	O
95	advanced	_	_	O
96	operable	_	_	O
97	rectal	_	_	O
98	cancer	_	_	O
99	(	_	_	O
100	uT3	_	_	O
101	/	_	_	O
102	4	_	_	O
103	or	_	_	O
104	uN	_	_	O
105	+	_	_	O
106	,	_	_	O
107	Mason	_	_	O
108	CS	_	_	O
109	III	_	_	O
110	/	_	_	O
111	IV	_	_	O
112	)	_	_	O
113	were	_	_	O
114	randomly	_	_	O
115	assigned	_	_	O
116	to	_	_	O
117	pre	_	_	O
118	-	_	_	O
119	or	_	_	O
120	postoperative	_	_	O
121	radiochemotherapy	_	_	O
122	:	_	_	O
123	A	_	_	O
124	total	_	_	O
125	dose	_	_	O
126	of	_	_	O
127	50	_	_	O
128	.	_	_	O

129	4	_	_	O
130	Gy	_	_	O
131	(	_	_	O
132	single	_	_	O
133	dose	_	_	O
134	1	_	_	O
135	.	_	_	O

136	8	_	_	O
137	Gy	_	_	O
138	)	_	_	O
139	was	_	_	O
140	applied	_	_	O
141	to	_	_	O
142	the	_	_	O
143	tumor	_	_	O
144	and	_	_	O
145	the	_	_	O
146	pelvic	_	_	O
147	lymph	_	_	O
148	nodes	_	_	O
149	.	_	_	O

150	5	_	_	O
151	-	_	_	O
152	FU	_	_	O
153	(	_	_	O
154	1	_	_	O
155	,	_	_	O
156	000	_	_	O
157	mg	_	_	O
158	/	_	_	O
159	m2	_	_	O
160	/	_	_	O
161	d	_	_	O
162	)	_	_	O
163	was	_	_	O
164	administered	_	_	O
165	concomitantly	_	_	O
166	in	_	_	O
167	the	_	_	O
168	first	_	_	O
169	and	_	_	O
170	fifth	_	_	O
171	week	_	_	O
172	of	_	_	O
173	radiation	_	_	O
174	as	_	_	O
175	120	_	_	O
176	-	_	_	O
177	h	_	_	O
178	continuous	_	_	O
179	infusion	_	_	O
180	.	_	_	O

181	Four	_	_	O
182	additional	_	_	O
183	cycles	_	_	O
184	of	_	_	O
185	5	_	_	O
186	-	_	_	O
187	FU	_	_	O
188	chemotherapy	_	_	O
189	(	_	_	O
190	500	_	_	O
191	mg	_	_	O
192	/	_	_	O
193	m2	_	_	O
194	/	_	_	O
195	d	_	_	O
196	,	_	_	O
197	i	_	_	O
198	.	_	_	O

199	v	_	_	O
200	.	_	_	O

201	bolus	_	_	O
202	)	_	_	O
203	were	_	_	O
204	applied	_	_	O
205	.	_	_	O

206	Radiochemotherapy	_	_	O
207	was	_	_	O
208	identical	_	_	O
209	in	_	_	O
210	both	_	_	O
211	arms	_	_	O
212	except	_	_	O
213	for	_	_	O
214	a	_	_	O
215	small	_	_	O
216	-	_	_	O
217	volume	_	_	O
218	boost	_	_	O
219	of	_	_	O
220	5	_	_	O
221	.	_	_	O

222	4	_	_	O
223	Gy	_	_	O
224	in	_	_	O
225	the	_	_	O
226	postoperative	_	_	O
227	setting	_	_	O
228	.	_	_	O

229	Time	_	_	O
230	interval	_	_	O
231	between	_	_	O
232	radiochemotherapy	_	_	O
233	and	_	_	O
234	surgery	_	_	O
235	was	_	_	O
236	4	_	_	O
237	-	_	_	O
238	6	_	_	O
239	weeks	_	_	O
240	in	_	_	O
241	both	_	_	O
242	arms	_	_	O
243	.	_	_	O

244	Techniques	_	_	O
245	of	_	_	O
246	surgery	_	_	O
247	were	_	_	O
248	standardized	_	_	O
249	and	_	_	O
250	included	_	_	O
251	total	_	_	O
252	mesorectal	_	_	O
253	excision	_	_	O
254	.	_	_	O

255	In	_	_	O
256	addition	_	_	O
257	,	_	_	O
258	stratification	_	_	O
259	according	_	_	O
260	to	_	_	O
261	surgeons	_	_	O
262	involved	_	_	O
263	has	_	_	O
264	been	_	_	O
265	provided	_	_	O
266	for	_	_	O
267	.	_	_	O

268	Primary	_	_	O
269	endpoints	_	_	O
270	of	_	_	O
271	the	_	_	O
272	study	_	_	O
273	are	_	_	O
274	5	_	_	O
275	-	_	_	O
276	year	_	_	O
277	overall	_	_	O
278	-	_	_	O
279	survival	_	_	O
280	,	_	_	O
281	local	_	_	O
282	and	_	_	O
283	distant	_	_	O
284	control	_	_	O
285	,	_	_	O
286	secondary	_	_	O
287	endpoints	_	_	O
288	include	_	_	O
289	rate	_	_	O
290	of	_	_	O
291	curative	_	_	O
292	(	_	_	O
293	R0	_	_	O
294	)	_	_	O
295	resections	_	_	O
296	and	_	_	O
297	sphincter	_	_	O
298	saving	_	_	O
299	procedures	_	_	O
300	,	_	_	O
301	toxicity	_	_	O
302	of	_	_	O
303	radiochemotherapy	_	_	O
304	,	_	_	O
305	surgical	_	_	O
306	complications	_	_	O
307	and	_	_	O
308	quality	_	_	O
309	of	_	_	O
310	life	_	_	O
311	.	_	_	O

312	As	_	_	O
313	of	_	_	O
314	15th	_	_	O
315	November	_	_	O
316	2000	_	_	O
317	,	_	_	O
318	628	_	_	O
319	patients	_	_	O
320	were	_	_	O
321	randomized	_	_	O
322	from	_	_	O
323	26	_	_	O
324	participating	_	_	O
325	institutions	_	_	O
326	:	_	_	O
327	310	_	_	O
328	patients	_	_	O
329	were	_	_	O
330	randomized	_	_	O
331	to	_	_	O
332	postoperative	_	_	O
333	radiochemotherapy	_	_	O
334	,	_	_	O
335	318	_	_	O
336	patients	_	_	O
337	to	_	_	O
338	preoperative	_	_	O
339	radiochemotherapy	_	_	O
340	.	_	_	O

341	Acute	_	_	B-Premise
342	toxicity	_	_	I-Premise
343	(	_	_	I-Premise
344	WHO	_	_	I-Premise
345	)	_	_	I-Premise
346	of	_	_	I-Premise
347	radiochemotherapy	_	_	I-Premise
348	was	_	_	I-Premise
349	low	_	_	I-Premise
350	,	_	_	I-Premise
351	with	_	_	I-Premise
352	less	_	_	I-Premise
353	than	_	_	I-Premise
354	15	_	_	I-Premise
355	%	_	_	I-Premise
356	of	_	_	I-Premise
357	patients	_	_	I-Premise
358	experiencing	_	_	I-Premise
359	Grade	_	_	I-Premise
360	3	_	_	I-Premise
361	or	_	_	I-Premise
362	higher	_	_	I-Premise
363	toxicity	_	_	I-Premise
364	:	_	_	O
365	The	_	_	B-Premise
366	principal	_	_	I-Premise
367	toxicity	_	_	I-Premise
368	was	_	_	I-Premise
369	diarrhea	_	_	I-Premise
370	,	_	_	I-Premise
371	with	_	_	I-Premise
372	12	_	_	I-Premise
373	%	_	_	I-Premise
374	in	_	_	I-Premise
375	the	_	_	I-Premise
376	postoperative	_	_	I-Premise
377	radiochemotherapy	_	_	I-Premise
378	arm	_	_	I-Premise
379	and	_	_	I-Premise
380	10	_	_	I-Premise
381	%	_	_	I-Premise
382	in	_	_	I-Premise
383	the	_	_	I-Premise
384	preoperative	_	_	I-Premise
385	radiochemotherapy	_	_	I-Premise
386	arm	_	_	I-Premise
387	having	_	_	I-Premise
388	Grade	_	_	I-Premise
389	-	_	_	I-Premise
390	3	_	_	I-Premise
391	,	_	_	I-Premise
392	and	_	_	I-Premise
393	1	_	_	I-Premise
394	%	_	_	I-Premise
395	in	_	_	I-Premise
396	either	_	_	I-Premise
397	arm	_	_	I-Premise
398	having	_	_	I-Premise
399	Grade	_	_	I-Premise
400	-	_	_	I-Premise
401	4	_	_	I-Premise
402	diarrhea	_	_	I-Premise
403	.	_	_	I-Premise

404	Erythema	_	_	B-Premise
405	,	_	_	I-Premise
406	nausea	_	_	I-Premise
407	and	_	_	I-Premise
408	leukopenia	_	_	I-Premise
409	were	_	_	I-Premise
410	the	_	_	I-Premise
411	next	_	_	I-Premise
412	common	_	_	I-Premise
413	toxicities	_	_	I-Premise
414	,	_	_	I-Premise
415	with	_	_	I-Premise
416	less	_	_	I-Premise
417	than	_	_	I-Premise
418	3	_	_	I-Premise
419	%	_	_	I-Premise
420	of	_	_	I-Premise
421	patients	_	_	I-Premise
422	in	_	_	I-Premise
423	either	_	_	I-Premise
424	arm	_	_	I-Premise
425	suffering	_	_	I-Premise
426	Grade	_	_	I-Premise
427	3	_	_	I-Premise
428	or	_	_	I-Premise
429	greater	_	_	I-Premise
430	leukopenia	_	_	I-Premise
431	or	_	_	I-Premise
432	nausea	_	_	I-Premise
433	.	_	_	I-Premise

434	Postoperative	_	_	B-Premise
435	complication	_	_	I-Premise
436	rates	_	_	I-Premise
437	were	_	_	I-Premise
438	similar	_	_	I-Premise
439	in	_	_	I-Premise
440	both	_	_	I-Premise
441	arms	_	_	I-Premise
442	,	_	_	I-Premise
443	with	_	_	I-Premise
444	12	_	_	I-Premise
445	%	_	_	I-Premise
446	(	_	_	I-Premise
447	postoperative	_	_	I-Premise
448	radiochemotherapy	_	_	I-Premise
449	)	_	_	I-Premise
450	and	_	_	I-Premise
451	13	_	_	I-Premise
452	%	_	_	I-Premise
453	(	_	_	I-Premise
454	preoperative	_	_	I-Premise
455	radiochemotherapy	_	_	I-Premise
456	)	_	_	I-Premise
457	of	_	_	I-Premise
458	patients	_	_	I-Premise
459	,	_	_	I-Premise
460	respectively	_	_	I-Premise
461	,	_	_	I-Premise
462	suffering	_	_	I-Premise
463	from	_	_	I-Premise
464	anastomotic	_	_	I-Premise
465	leakage	_	_	I-Premise
466	,	_	_	I-Premise
467	4	_	_	I-Premise
468	%	_	_	I-Premise
469	(	_	_	I-Premise
470	postoperative	_	_	I-Premise
471	radiochemotherapy	_	_	I-Premise
472	)	_	_	I-Premise
473	and	_	_	I-Premise
474	3	_	_	I-Premise
475	%	_	_	I-Premise
476	(	_	_	I-Premise
477	preoperative	_	_	I-Premise
478	radiochemotherapy	_	_	I-Premise
479	)	_	_	I-Premise
480	from	_	_	I-Premise
481	postoperative	_	_	I-Premise
482	bleeding	_	_	I-Premise
483	,	_	_	I-Premise
484	and	_	_	I-Premise
485	6	_	_	I-Premise
486	%	_	_	I-Premise
487	(	_	_	I-Premise
488	postoperative	_	_	I-Premise
489	radiochemotherapy	_	_	I-Premise
490	)	_	_	I-Premise
491	and	_	_	I-Premise
492	5	_	_	I-Premise
493	%	_	_	I-Premise
494	(	_	_	I-Premise
495	preoperative	_	_	I-Premise
496	radiochemotherapy	_	_	I-Premise
497	)	_	_	I-Premise
498	from	_	_	I-Premise
499	delayed	_	_	I-Premise
500	wound	_	_	I-Premise
501	healing	_	_	I-Premise
502	.	_	_	I-Premise

503	The	_	_	B-Claim
504	patient	_	_	I-Claim
505	accrual	_	_	I-Claim
506	of	_	_	I-Claim
507	our	_	_	I-Claim
508	trial	_	_	I-Claim
509	is	_	_	I-Claim
510	satisfactory	_	_	I-Claim
511	,	_	_	I-Claim
512	neoadjuvant	_	_	B-Claim
513	radiochemotherapy	_	_	I-Claim
514	is	_	_	I-Claim
515	well	_	_	I-Claim
516	tolerated	_	_	I-Claim
517	and	_	_	I-Claim
518	bears	_	_	I-Claim
519	no	_	_	I-Claim
520	higher	_	_	I-Claim
521	risk	_	_	I-Claim
522	for	_	_	I-Claim
523	postoperative	_	_	I-Claim
524	morbidity	_	_	I-Claim
525	.	_	_	I-Claim


0	Hepatic	_	_	O
1	metastases	_	_	O
2	derive	_	_	O
3	most	_	_	O
4	of	_	_	O
5	their	_	_	O
6	blood	_	_	O
7	supply	_	_	O
8	from	_	_	O
9	the	_	_	O
10	hepatic	_	_	O
11	artery	_	_	O
12	;	_	_	O
13	therefore	_	_	O
14	,	_	_	O
15	for	_	_	B-Claim
16	patients	_	_	I-Claim
17	with	_	_	I-Claim
18	hepatic	_	_	I-Claim
19	metastases	_	_	I-Claim
20	from	_	_	I-Claim
21	colorectal	_	_	I-Claim
22	cancer	_	_	I-Claim
23	,	_	_	I-Claim
24	hepatic	_	_	I-Claim
25	arterial	_	_	I-Claim
26	infusion	_	_	I-Claim
27	(	_	_	I-Claim
28	HAI	_	_	I-Claim
29	)	_	_	I-Claim
30	of	_	_	I-Claim
31	chemotherapy	_	_	I-Claim
32	may	_	_	I-Claim
33	improve	_	_	I-Claim
34	outcome	_	_	I-Claim
35	.	_	_	I-Claim

36	In	_	_	O
37	a	_	_	O
38	multi	_	_	O
39	-	_	_	O
40	institutional	_	_	O
41	trial	_	_	O
42	,	_	_	O
43	135	_	_	O
44	patients	_	_	O
45	were	_	_	O
46	randomly	_	_	O
47	assigned	_	_	O
48	to	_	_	O
49	receive	_	_	O
50	HAI	_	_	O
51	versus	_	_	O
52	systemic	_	_	O
53	bolus	_	_	O
54	fluorouracil	_	_	O
55	and	_	_	O
56	leucovorin	_	_	O
57	.	_	_	O

58	The	_	_	O
59	primary	_	_	O
60	end	_	_	O
61	point	_	_	O
62	was	_	_	O
63	survival	_	_	O
64	;	_	_	O
65	secondary	_	_	O
66	end	_	_	O
67	points	_	_	O
68	were	_	_	O
69	response	_	_	O
70	,	_	_	O
71	recurrence	_	_	O
72	,	_	_	O
73	toxicity	_	_	O
74	,	_	_	O
75	quality	_	_	O
76	of	_	_	O
77	life	_	_	O
78	,	_	_	O
79	cost	_	_	O
80	,	_	_	O
81	and	_	_	O
82	the	_	_	O
83	influence	_	_	O
84	of	_	_	O
85	molecular	_	_	O
86	markers	_	_	O
87	.	_	_	O

88	Overall	_	_	B-Premise
89	survival	_	_	I-Premise
90	was	_	_	I-Premise
91	significantly	_	_	I-Premise
92	longer	_	_	I-Premise
93	for	_	_	I-Premise
94	HAI	_	_	I-Premise
95	versus	_	_	I-Premise
96	systemic	_	_	I-Premise
97	treatment	_	_	I-Premise
98	(	_	_	I-Premise
99	median	_	_	I-Premise
100	,	_	_	I-Premise
101	24	_	_	I-Premise
102	.	_	_	I-Premise

103	4	_	_	I-Premise
104	v	_	_	I-Premise
105	20	_	_	I-Premise
106	months	_	_	I-Premise
107	;	_	_	I-Premise
108	P	_	_	I-Premise
109	=	_	_	I-Premise
110	.	_	_	I-Premise

111	0034	_	_	I-Premise
112	)	_	_	I-Premise
113	,	_	_	I-Premise
114	as	_	_	I-Premise
115	were	_	_	I-Premise
116	response	_	_	I-Premise
117	rates	_	_	I-Premise
118	(	_	_	I-Premise
119	47	_	_	I-Premise
120	%	_	_	I-Premise
121	and	_	_	I-Premise
122	24	_	_	I-Premise
123	%	_	_	I-Premise
124	;	_	_	I-Premise
125	P	_	_	I-Premise
126	=	_	_	I-Premise
127	.	_	_	I-Premise

128	012	_	_	I-Premise
129	)	_	_	I-Premise
130	and	_	_	I-Premise
131	time	_	_	I-Premise
132	to	_	_	I-Premise
133	hepatic	_	_	I-Premise
134	progression	_	_	I-Premise
135	(	_	_	I-Premise
136	THP	_	_	I-Premise
137	;	_	_	I-Premise
138	9	_	_	I-Premise
139	.	_	_	I-Premise

140	8	_	_	I-Premise
141	v	_	_	I-Premise
142	7	_	_	I-Premise
143	.	_	_	I-Premise

144	3	_	_	I-Premise
145	months	_	_	I-Premise
146	;	_	_	I-Premise
147	P	_	_	I-Premise
148	=	_	_	I-Premise
149	.	_	_	I-Premise

150	034	_	_	I-Premise
151	)	_	_	I-Premise
152	.	_	_	I-Premise

153	Time	_	_	B-Premise
154	to	_	_	I-Premise
155	extrahepatic	_	_	I-Premise
156	progression	_	_	I-Premise
157	(	_	_	I-Premise
158	7	_	_	I-Premise
159	.	_	_	I-Premise

160	7	_	_	I-Premise
161	v	_	_	I-Premise
162	14	_	_	I-Premise
163	.	_	_	I-Premise

164	8	_	_	I-Premise
165	months	_	_	I-Premise
166	;	_	_	I-Premise
167	P	_	_	I-Premise
168	=	_	_	I-Premise
169	.	_	_	I-Premise

170	029	_	_	I-Premise
171	)	_	_	I-Premise
172	was	_	_	I-Premise
173	significantly	_	_	I-Premise
174	shorter	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	HAI	_	_	I-Premise
178	group	_	_	I-Premise
179	.	_	_	I-Premise

180	Quality	_	_	B-Premise
181	-	_	_	I-Premise
182	of	_	_	I-Premise
183	-	_	_	I-Premise
184	life	_	_	I-Premise
185	measurements	_	_	I-Premise
186	showed	_	_	I-Premise
187	improved	_	_	I-Premise
188	physical	_	_	I-Premise
189	functioning	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	HAI	_	_	I-Premise
193	group	_	_	I-Premise
194	at	_	_	I-Premise
195	the	_	_	I-Premise
196	3	_	_	I-Premise
197	-	_	_	I-Premise
198	and	_	_	I-Premise
199	6	_	_	I-Premise
200	-	_	_	I-Premise
201	month	_	_	I-Premise
202	follow	_	_	I-Premise
203	-	_	_	I-Premise
204	up	_	_	I-Premise
205	assessments	_	_	I-Premise
206	.	_	_	I-Premise

207	Toxicity	_	_	B-Premise
208	included	_	_	I-Premise
209	grade	_	_	I-Premise
210	>	_	_	I-Premise
211	or	_	_	I-Premise
212	=	_	_	I-Premise
213	3	_	_	I-Premise
214	neutropenia	_	_	I-Premise
215	(	_	_	I-Premise
216	2	_	_	I-Premise
217	%	_	_	I-Premise
218	and	_	_	I-Premise
219	45	_	_	I-Premise
220	%	_	_	I-Premise
221	;	_	_	I-Premise
222	P	_	_	I-Premise
223	<	_	_	I-Premise
224	.	_	_	I-Premise

225	01	_	_	I-Premise
226	)	_	_	I-Premise
227	,	_	_	I-Premise
228	stomatitis	_	_	I-Premise
229	(	_	_	I-Premise
230	0	_	_	I-Premise
231	%	_	_	I-Premise
232	and	_	_	I-Premise
233	24	_	_	I-Premise
234	%	_	_	I-Premise
235	;	_	_	I-Premise
236	P	_	_	I-Premise
237	<	_	_	I-Premise
238	.	_	_	I-Premise

239	01	_	_	I-Premise
240	)	_	_	I-Premise
241	,	_	_	I-Premise
242	and	_	_	I-Premise
243	bilirubin	_	_	I-Premise
244	elevation	_	_	I-Premise
245	(	_	_	I-Premise
246	18	_	_	I-Premise
247	.	_	_	I-Premise

248	6	_	_	I-Premise
249	%	_	_	I-Premise
250	and	_	_	I-Premise
251	0	_	_	I-Premise
252	;	_	_	I-Premise
253	P	_	_	I-Premise
254	<	_	_	I-Premise
255	.	_	_	I-Premise

256	01	_	_	I-Premise
257	)	_	_	I-Premise
258	in	_	_	I-Premise
259	the	_	_	I-Premise
260	HAI	_	_	I-Premise
261	and	_	_	I-Premise
262	systemic	_	_	I-Premise
263	treatment	_	_	I-Premise
264	groups	_	_	I-Premise
265	,	_	_	I-Premise
266	respectively	_	_	I-Premise
267	.	_	_	I-Premise

268	A	_	_	B-Premise
269	greater	_	_	I-Premise
270	proportion	_	_	I-Premise
271	of	_	_	I-Premise
272	men	_	_	I-Premise
273	versus	_	_	I-Premise
274	women	_	_	I-Premise
275	receiving	_	_	I-Premise
276	HAI	_	_	I-Premise
277	experienced	_	_	I-Premise
278	biliary	_	_	I-Premise
279	toxicity	_	_	I-Premise
280	(	_	_	I-Premise
281	37	_	_	I-Premise
282	%	_	_	I-Premise
283	and	_	_	I-Premise
284	15	_	_	I-Premise
285	%	_	_	I-Premise
286	,	_	_	I-Premise
287	respectively	_	_	I-Premise
288	;	_	_	I-Premise
289	P	_	_	I-Premise
290	=	_	_	I-Premise
291	.	_	_	I-Premise

292	05	_	_	I-Premise
293	)	_	_	I-Premise
294	.	_	_	I-Premise

295	For	_	_	B-Premise
296	HAI	_	_	I-Premise
297	patients	_	_	I-Premise
298	with	_	_	I-Premise
299	thymidylate	_	_	I-Premise
300	synthase	_	_	I-Premise
301	levels	_	_	I-Premise
302	in	_	_	I-Premise
303	tumor	_	_	I-Premise
304	less	_	_	I-Premise
305	than	_	_	I-Premise
306	or	_	_	I-Premise
307	>	_	_	I-Premise
308	or	_	_	I-Premise
309	=	_	_	I-Premise
310	4	_	_	I-Premise
311	,	_	_	I-Premise
312	the	_	_	I-Premise
313	median	_	_	I-Premise
314	survival	_	_	I-Premise
315	was	_	_	I-Premise
316	24	_	_	I-Premise
317	and	_	_	I-Premise
318	14	_	_	I-Premise
319	months	_	_	I-Premise
320	,	_	_	I-Premise
321	respectively	_	_	I-Premise
322	(	_	_	I-Premise
323	P	_	_	I-Premise
324	=	_	_	I-Premise
325	.	_	_	I-Premise

326	17	_	_	I-Premise
327	)	_	_	I-Premise
328	.	_	_	I-Premise

329	HAI	_	_	B-Claim
330	therapy	_	_	I-Claim
331	increased	_	_	I-Claim
332	overall	_	_	I-Claim
333	survival	_	_	I-Claim
334	,	_	_	I-Claim
335	response	_	_	I-Claim
336	rate	_	_	I-Claim
337	,	_	_	I-Claim
338	THP	_	_	I-Claim
339	,	_	_	I-Claim
340	and	_	_	I-Claim
341	was	_	_	I-Claim
342	associated	_	_	I-Claim
343	with	_	_	I-Claim
344	better	_	_	I-Claim
345	physical	_	_	I-Claim
346	functioning	_	_	I-Claim
347	compared	_	_	I-Claim
348	with	_	_	I-Claim
349	systemic	_	_	I-Claim
350	therapy	_	_	I-Claim
351	.	_	_	I-Claim

352	Additional	_	_	B-Claim
353	studies	_	_	I-Claim
354	need	_	_	I-Claim
355	to	_	_	I-Claim
356	address	_	_	I-Claim
357	the	_	_	I-Claim
358	overall	_	_	I-Claim
359	benefit	_	_	I-Claim
360	and	_	_	I-Claim
361	cost	_	_	I-Claim
362	of	_	_	I-Claim
363	new	_	_	I-Claim
364	chemotherapy	_	_	I-Claim
365	agents	_	_	I-Claim
366	versus	_	_	I-Claim
367	HAI	_	_	I-Claim
368	alone	_	_	I-Claim
369	or	_	_	I-Claim
370	the	_	_	I-Claim
371	combination	_	_	I-Claim
372	of	_	_	I-Claim
373	HAI	_	_	I-Claim
374	with	_	_	I-Claim
375	new	_	_	I-Claim
376	agents	_	_	I-Claim
377	.	_	_	I-Claim


0	Tumor	_	_	B-Claim
1	necrosis	_	_	I-Claim
2	factor	_	_	I-Claim
3	-	_	_	I-Claim
4	alpha	_	_	I-Claim
5	(	_	_	I-Claim
6	TNF	_	_	I-Claim
7	-	_	_	I-Claim
8	alpha	_	_	I-Claim
9	)	_	_	I-Claim
10	is	_	_	I-Claim
11	a	_	_	I-Claim
12	putative	_	_	I-Claim
13	mediator	_	_	I-Claim
14	of	_	_	I-Claim
15	the	_	_	I-Claim
16	cancer	_	_	I-Claim
17	anorexia	_	_	I-Claim
18	/	_	_	I-Claim
19	weight	_	_	I-Claim
20	loss	_	_	I-Claim
21	syndrome	_	_	I-Claim
22	.	_	_	I-Claim

23	The	_	_	O
24	current	_	_	O
25	study	_	_	O
26	was	_	_	O
27	designed	_	_	O
28	to	_	_	O
29	determine	_	_	O
30	whether	_	_	O
31	etanercept	_	_	O
32	(	_	_	O
33	a	_	_	O
34	dimeric	_	_	O
35	fusion	_	_	O
36	protein	_	_	O
37	consisting	_	_	O
38	of	_	_	O
39	the	_	_	O
40	extracellular	_	_	O
41	ligand	_	_	O
42	-	_	_	O
43	binding	_	_	O
44	portion	_	_	O
45	of	_	_	O
46	the	_	_	O
47	human	_	_	O
48	75	_	_	O
49	-	_	_	O
50	kilodalton	_	_	O
51	TNF	_	_	O
52	receptor	_	_	O
53	linked	_	_	O
54	to	_	_	O
55	the	_	_	O
56	Fc	_	_	O
57	portion	_	_	O
58	of	_	_	O
59	human	_	_	O
60	immunoglobulin	_	_	O
61	[	_	_	O
62	Ig	_	_	O
63	]	_	_	O
64	G1	_	_	O
65	)	_	_	O
66	could	_	_	O
67	palliate	_	_	O
68	this	_	_	O
69	syndrome	_	_	O
70	.	_	_	O

71	A	_	_	O
72	total	_	_	O
73	of	_	_	O
74	63	_	_	O
75	evaluable	_	_	O
76	patients	_	_	O
77	were	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	receive	_	_	O
82	either	_	_	O
83	etanercept	_	_	O
84	at	_	_	O
85	a	_	_	O
86	dose	_	_	O
87	of	_	_	O
88	25	_	_	O
89	mg	_	_	O
90	subcutaneously	_	_	O
91	twice	_	_	O
92	weekly	_	_	O
93	versus	_	_	O
94	a	_	_	O
95	comparably	_	_	O
96	administered	_	_	O
97	placebo	_	_	O
98	.	_	_	O

99	All	_	_	O
100	patients	_	_	O
101	had	_	_	O
102	an	_	_	O
103	incurable	_	_	O
104	malignancy	_	_	O
105	,	_	_	O
106	acknowledged	_	_	O
107	loss	_	_	O
108	of	_	_	O
109	weight	_	_	O
110	and	_	_	O
111	/	_	_	O
112	or	_	_	O
113	appetite	_	_	O
114	as	_	_	O
115	a	_	_	O
116	concern	_	_	O
117	,	_	_	O
118	and	_	_	O
119	reported	_	_	O
120	a	_	_	O
121	weight	_	_	O
122	loss	_	_	O
123	of	_	_	O
124	>	_	_	O
125	2	_	_	O
126	.	_	_	O

127	27	_	_	O
128	kg	_	_	O
129	over	_	_	O
130	2	_	_	O
131	months	_	_	O
132	and	_	_	O
133	/	_	_	O
134	or	_	_	O
135	a	_	_	O
136	daily	_	_	O
137	intake	_	_	O
138	of	_	_	O
139	<	_	_	O
140	20	_	_	O
141	calories	_	_	O
142	/	_	_	O
143	kg	_	_	O
144	body	_	_	O
145	weight	_	_	O
146	.	_	_	O

147	Over	_	_	B-Premise
148	time	_	_	I-Premise
149	,	_	_	I-Premise
150	weight	_	_	I-Premise
151	gain	_	_	I-Premise
152	was	_	_	I-Premise
153	found	_	_	I-Premise
154	to	_	_	I-Premise
155	be	_	_	I-Premise
156	minimal	_	_	I-Premise
157	in	_	_	I-Premise
158	both	_	_	I-Premise
159	treatment	_	_	I-Premise
160	arms	_	_	I-Premise
161	;	_	_	I-Premise
162	no	_	_	I-Premise
163	patient	_	_	I-Premise
164	gained	_	_	I-Premise
165	>	_	_	I-Premise
166	or	_	_	I-Premise
167	=	_	_	I-Premise
168	10	_	_	I-Premise
169	%	_	_	I-Premise
170	of	_	_	I-Premise
171	their	_	_	I-Premise
172	baseline	_	_	I-Premise
173	weight	_	_	I-Premise
174	.	_	_	I-Premise

175	Previously	_	_	B-Premise
176	validated	_	_	I-Premise
177	appetite	_	_	I-Premise
178	questionnaires	_	_	I-Premise
179	revealed	_	_	I-Premise
180	negligible	_	_	I-Premise
181	improvements	_	_	I-Premise
182	in	_	_	I-Premise
183	both	_	_	I-Premise
184	treatment	_	_	I-Premise
185	arms	_	_	I-Premise
186	.	_	_	I-Premise

187	The	_	_	B-Premise
188	median	_	_	I-Premise
189	survival	_	_	I-Premise
190	was	_	_	I-Premise
191	also	_	_	I-Premise
192	comparable	_	_	I-Premise
193	(	_	_	I-Premise
194	175	_	_	I-Premise
195	days	_	_	I-Premise
196	vs	_	_	I-Premise
197	148	_	_	I-Premise
198	days	_	_	I-Premise
199	in	_	_	I-Premise
200	etanercept	_	_	I-Premise
201	-	_	_	I-Premise
202	treated	_	_	I-Premise
203	and	_	_	I-Premise
204	placebo	_	_	I-Premise
205	-	_	_	I-Premise
206	exposed	_	_	I-Premise
207	patients	_	_	I-Premise
208	,	_	_	I-Premise
209	respectively	_	_	I-Premise
210	;	_	_	I-Premise
211	P	_	_	I-Premise
212	=	_	_	I-Premise
213	.	_	_	I-Premise

214	82	_	_	I-Premise
215	)	_	_	I-Premise
216	.	_	_	I-Premise

217	Finally	_	_	O
218	,	_	_	O
219	preliminary	_	_	B-Premise
220	data	_	_	I-Premise
221	regarding	_	_	I-Premise
222	adverse	_	_	I-Premise
223	events	_	_	I-Premise
224	demonstrated	_	_	I-Premise
225	that	_	_	I-Premise
226	patients	_	_	I-Premise
227	treated	_	_	I-Premise
228	with	_	_	I-Premise
229	etanercept	_	_	I-Premise
230	had	_	_	I-Premise
231	higher	_	_	I-Premise
232	rates	_	_	I-Premise
233	of	_	_	I-Premise
234	neurotoxicity	_	_	I-Premise
235	(	_	_	I-Premise
236	29	_	_	I-Premise
237	%	_	_	I-Premise
238	vs	_	_	I-Premise
239	0	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	but	_	_	I-Premise
243	lower	_	_	I-Premise
244	rates	_	_	I-Premise
245	of	_	_	I-Premise
246	anemia	_	_	I-Premise
247	(	_	_	I-Premise
248	0	_	_	I-Premise
249	%	_	_	I-Premise
250	vs	_	_	I-Premise
251	19	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	and	_	_	I-Premise
255	thrombocytopenia	_	_	I-Premise
256	(	_	_	I-Premise
257	0	_	_	I-Premise
258	%	_	_	I-Premise
259	vs	_	_	I-Premise
260	14	_	_	I-Premise
261	%	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Infection	_	_	B-Premise
265	rates	_	_	I-Premise
266	were	_	_	I-Premise
267	negligible	_	_	I-Premise
268	in	_	_	I-Premise
269	both	_	_	I-Premise
270	groups	_	_	I-Premise
271	.	_	_	I-Premise

272	Genotyping	_	_	B-Premise
273	for	_	_	I-Premise
274	TNF	_	_	I-Premise
275	-	_	_	I-Premise
276	alpha	_	_	I-Premise
277	-	_	_	I-Premise
278	238	_	_	I-Premise
279	and	_	_	I-Premise
280	TNF	_	_	I-Premise
281	-	_	_	I-Premise
282	alpha	_	_	I-Premise
283	-	_	_	I-Premise
284	308	_	_	I-Premise
285	polymorphisms	_	_	I-Premise
286	revealed	_	_	I-Premise
287	no	_	_	I-Premise
288	clinical	_	_	I-Premise
289	significance	_	_	I-Premise
290	for	_	_	I-Premise
291	these	_	_	I-Premise
292	genotypes	_	_	I-Premise
293	,	_	_	I-Premise
294	except	_	_	I-Premise
295	for	_	_	I-Premise
296	a	_	_	I-Premise
297	preliminary	_	_	I-Premise
298	association	_	_	I-Premise
299	between	_	_	I-Premise
300	presence	_	_	I-Premise
301	of	_	_	I-Premise
302	the	_	_	I-Premise
303	-	_	_	I-Premise
304	238	_	_	I-Premise
305	G	_	_	I-Premise
306	/	_	_	I-Premise
307	A	_	_	I-Premise
308	genotype	_	_	I-Premise
309	and	_	_	I-Premise
310	relatively	_	_	I-Premise
311	less	_	_	I-Premise
312	favorable	_	_	I-Premise
313	survival	_	_	I-Premise
314	.	_	_	I-Premise

315	Etanercept	_	_	B-Claim
316	,	_	_	I-Claim
317	as	_	_	I-Claim
318	prescribed	_	_	I-Claim
319	in	_	_	I-Claim
320	the	_	_	I-Claim
321	current	_	_	I-Claim
322	trial	_	_	I-Claim
323	,	_	_	I-Claim
324	does	_	_	I-Claim
325	not	_	_	I-Claim
326	appear	_	_	I-Claim
327	to	_	_	I-Claim
328	palliate	_	_	I-Claim
329	the	_	_	I-Claim
330	cancer	_	_	I-Claim
331	anorexia	_	_	I-Claim
332	/	_	_	I-Claim
333	weight	_	_	I-Claim
334	loss	_	_	I-Claim
335	syndrome	_	_	I-Claim
336	in	_	_	I-Claim
337	patients	_	_	I-Claim
338	with	_	_	I-Claim
339	advanced	_	_	I-Claim
340	disease	_	_	I-Claim
341	.	_	_	I-Claim


0	Malnutrition	_	_	B-Claim
1	occurs	_	_	I-Claim
2	frequently	_	_	I-Claim
3	in	_	_	I-Claim
4	patients	_	_	I-Claim
5	with	_	_	I-Claim
6	cancer	_	_	I-Claim
7	of	_	_	I-Claim
8	the	_	_	I-Claim
9	gastrointestinal	_	_	I-Claim
10	(	_	_	I-Claim
11	GI	_	_	I-Claim
12	)	_	_	I-Claim
13	or	_	_	I-Claim
14	head	_	_	I-Claim
15	and	_	_	I-Claim
16	neck	_	_	I-Claim
17	area	_	_	I-Claim
18	and	_	_	I-Claim
19	can	_	_	I-Claim
20	lead	_	_	I-Claim
21	to	_	_	I-Claim
22	negative	_	_	I-Claim
23	outcomes	_	_	I-Claim
24	.	_	_	I-Claim

25	The	_	_	O
26	aim	_	_	O
27	of	_	_	O
28	this	_	_	O
29	study	_	_	O
30	is	_	_	O
31	to	_	_	O
32	determine	_	_	O
33	the	_	_	O
34	impact	_	_	O
35	of	_	_	O
36	early	_	_	O
37	and	_	_	O
38	intensive	_	_	O
39	nutrition	_	_	O
40	intervention	_	_	O
41	(	_	_	O
42	NI	_	_	O
43	)	_	_	O
44	on	_	_	O
45	body	_	_	O
46	weight	_	_	O
47	,	_	_	O
48	body	_	_	O
49	composition	_	_	O
50	,	_	_	O
51	nutritional	_	_	O
52	status	_	_	O
53	,	_	_	O
54	global	_	_	O
55	quality	_	_	O
56	of	_	_	O
57	life	_	_	O
58	(	_	_	O
59	QoL	_	_	O
60	)	_	_	O
61	and	_	_	O
62	physical	_	_	O
63	function	_	_	O
64	compared	_	_	O
65	to	_	_	O
66	usual	_	_	O
67	practice	_	_	O
68	in	_	_	O
69	oncology	_	_	O
70	outpatients	_	_	O
71	receiving	_	_	O
72	radiotherapy	_	_	O
73	to	_	_	O
74	the	_	_	O
75	GI	_	_	O
76	or	_	_	O
77	head	_	_	O
78	and	_	_	O
79	neck	_	_	O
80	area	_	_	O
81	.	_	_	O

82	Outpatients	_	_	O
83	commencing	_	_	O
84	at	_	_	O
85	least	_	_	O
86	20	_	_	O
87	fractions	_	_	O
88	of	_	_	O
89	radiotherapy	_	_	O
90	to	_	_	O
91	the	_	_	O
92	GI	_	_	O
93	or	_	_	O
94	head	_	_	O
95	and	_	_	O
96	neck	_	_	O
97	area	_	_	O
98	were	_	_	O
99	randomised	_	_	O
100	to	_	_	O
101	receive	_	_	O
102	intensive	_	_	O
103	,	_	_	O
104	individualised	_	_	O
105	nutrition	_	_	O
106	counselling	_	_	O
107	by	_	_	O
108	a	_	_	O
109	dietitian	_	_	O
110	using	_	_	O
111	a	_	_	O
112	standard	_	_	O
113	protocol	_	_	O
114	and	_	_	O
115	oral	_	_	O
116	supplements	_	_	O
117	if	_	_	O
118	required	_	_	O
119	,	_	_	O
120	or	_	_	O
121	the	_	_	O
122	usual	_	_	O
123	practice	_	_	O
124	of	_	_	O
125	the	_	_	O
126	centre	_	_	O
127	(	_	_	O
128	general	_	_	O
129	advice	_	_	O
130	and	_	_	O
131	nutrition	_	_	O
132	booklet	_	_	O
133	)	_	_	O
134	.	_	_	O

135	Outcome	_	_	O
136	parameters	_	_	O
137	were	_	_	O
138	measured	_	_	O
139	at	_	_	O
140	baseline	_	_	O
141	and	_	_	O
142	4	_	_	O
143	,	_	_	O
144	8	_	_	O
145	and	_	_	O
146	12	_	_	O
147	weeks	_	_	O
148	after	_	_	O
149	commencing	_	_	O
150	radiotherapy	_	_	O
151	using	_	_	O
152	valid	_	_	O
153	and	_	_	O
154	reliable	_	_	O
155	tools	_	_	O
156	.	_	_	O

157	A	_	_	O
158	total	_	_	O
159	of	_	_	O
160	60	_	_	O
161	patients	_	_	O
162	(	_	_	O
163	51	_	_	O
164	M	_	_	O
165	:	_	_	O
166	9	_	_	O
167	F	_	_	O
168	;	_	_	O
169	mean	_	_	O
170	age	_	_	O
171	61	_	_	O
172	.	_	_	O

173	9	_	_	O
174	+	_	_	O
175	/	_	_	O
176	-	_	_	O
177	14	_	_	O
178	.	_	_	O

179	0	_	_	O
180	years	_	_	O
181	)	_	_	O
182	were	_	_	O
183	randomised	_	_	O
184	to	_	_	O
185	receive	_	_	O
186	either	_	_	O
187	NI	_	_	O
188	(	_	_	O
189	n	_	_	O
190	=	_	_	O
191	29	_	_	O
192	)	_	_	O
193	or	_	_	O
194	usual	_	_	O
195	care	_	_	O
196	(	_	_	O
197	UC	_	_	O
198	)	_	_	O
199	(	_	_	O
200	n	_	_	O
201	=	_	_	O
202	31	_	_	O
203	)	_	_	O
204	.	_	_	O

205	The	_	_	B-Premise
206	NI	_	_	I-Premise
207	group	_	_	I-Premise
208	had	_	_	I-Premise
209	statistically	_	_	I-Premise
210	smaller	_	_	I-Premise
211	deteriorations	_	_	I-Premise
212	in	_	_	I-Premise
213	weight	_	_	I-Premise
214	(	_	_	I-Premise
215	P	_	_	I-Premise
216	<	_	_	I-Premise
217	0	_	_	I-Premise
218	.	_	_	I-Premise

219	001	_	_	I-Premise
220	)	_	_	I-Premise
221	,	_	_	I-Premise
222	nutritional	_	_	I-Premise
223	status	_	_	I-Premise
224	(	_	_	I-Premise
225	P	_	_	I-Premise
226	=	_	_	I-Premise
227	0	_	_	I-Premise
228	.	_	_	I-Premise

229	020	_	_	I-Premise
230	)	_	_	I-Premise
231	and	_	_	I-Premise
232	global	_	_	I-Premise
233	QoL	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	0	_	_	I-Premise
238	.	_	_	I-Premise

239	009	_	_	I-Premise
240	)	_	_	I-Premise
241	compared	_	_	I-Premise
242	with	_	_	I-Premise
243	those	_	_	I-Premise
244	receiving	_	_	I-Premise
245	UC	_	_	I-Premise
246	.	_	_	I-Premise

247	Clinically	_	_	B-Premise
248	,	_	_	I-Premise
249	but	_	_	I-Premise
250	not	_	_	I-Premise
251	statistically	_	_	I-Premise
252	significant	_	_	I-Premise
253	differences	_	_	I-Premise
254	in	_	_	I-Premise
255	fat	_	_	I-Premise
256	-	_	_	I-Premise
257	free	_	_	I-Premise
258	mass	_	_	I-Premise
259	were	_	_	I-Premise
260	observed	_	_	I-Premise
261	between	_	_	I-Premise
262	the	_	_	I-Premise
263	groups	_	_	I-Premise
264	(	_	_	I-Premise
265	P	_	_	I-Premise
266	=	_	_	I-Premise
267	0	_	_	I-Premise
268	.	_	_	I-Premise

269	195	_	_	I-Premise
270	)	_	_	I-Premise
271	.	_	_	I-Premise

272	Early	_	_	B-Claim
273	and	_	_	I-Claim
274	intensive	_	_	I-Claim
275	NI	_	_	I-Claim
276	appears	_	_	I-Claim
277	beneficial	_	_	I-Claim
278	in	_	_	I-Claim
279	terms	_	_	I-Claim
280	of	_	_	I-Claim
281	minimising	_	_	I-Claim
282	weight	_	_	I-Claim
283	loss	_	_	I-Claim
284	,	_	_	I-Claim
285	deterioration	_	_	I-Claim
286	in	_	_	I-Claim
287	nutritional	_	_	I-Claim
288	status	_	_	I-Claim
289	,	_	_	I-Claim
290	global	_	_	I-Claim
291	QoL	_	_	I-Claim
292	and	_	_	I-Claim
293	physical	_	_	I-Claim
294	function	_	_	I-Claim
295	in	_	_	I-Claim
296	oncology	_	_	I-Claim
297	outpatients	_	_	I-Claim
298	receiving	_	_	I-Claim
299	radiotherapy	_	_	I-Claim
300	to	_	_	I-Claim
301	the	_	_	I-Claim
302	GI	_	_	I-Claim
303	or	_	_	I-Claim
304	head	_	_	I-Claim
305	and	_	_	I-Claim
306	neck	_	_	I-Claim
307	area	_	_	I-Claim
308	.	_	_	I-Claim

309	Weight	_	_	B-Claim
310	maintenance	_	_	I-Claim
311	in	_	_	I-Claim
312	this	_	_	I-Claim
313	population	_	_	I-Claim
314	leads	_	_	I-Claim
315	to	_	_	I-Claim
316	beneficial	_	_	I-Claim
317	outcomes	_	_	I-Claim
318	and	_	_	I-Claim
319	suggests	_	_	I-Claim
320	that	_	_	I-Claim
321	this	_	_	I-Claim
322	,	_	_	I-Claim
323	rather	_	_	I-Claim
324	than	_	_	I-Claim
325	weight	_	_	I-Claim
326	gain	_	_	I-Claim
327	,	_	_	I-Claim
328	may	_	_	I-Claim
329	be	_	_	I-Claim
330	a	_	_	I-Claim
331	more	_	_	I-Claim
332	appropriate	_	_	I-Claim
333	aim	_	_	I-Claim
334	of	_	_	I-Claim
335	NI	_	_	I-Claim
336	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	of	_	_	O
5	exercise	_	_	O
6	training	_	_	O
7	on	_	_	O
8	cardiopulmonary	_	_	O
9	function	_	_	O
10	and	_	_	O
11	quality	_	_	O
12	of	_	_	O
13	life	_	_	O
14	(	_	_	O
15	QOL	_	_	O
16	)	_	_	O
17	in	_	_	O
18	postmenopausal	_	_	O
19	breast	_	_	O
20	cancer	_	_	O
21	survivors	_	_	O
22	who	_	_	O
23	had	_	_	O
24	completed	_	_	O
25	surgery	_	_	O
26	,	_	_	O
27	radiotherapy	_	_	O
28	,	_	_	O
29	and	_	_	O
30	/	_	_	O
31	or	_	_	O
32	chemotherapy	_	_	O
33	with	_	_	O
34	or	_	_	O
35	without	_	_	O
36	current	_	_	O
37	hormone	_	_	O
38	therapy	_	_	O
39	use	_	_	O
40	.	_	_	O

41	Fifty	_	_	O
42	-	_	_	O
43	three	_	_	O
44	postmenopausal	_	_	O
45	breast	_	_	O
46	cancer	_	_	O
47	survivors	_	_	O
48	were	_	_	O
49	randomly	_	_	O
50	assigned	_	_	O
51	to	_	_	O
52	an	_	_	O
53	exercise	_	_	O
54	(	_	_	O
55	n	_	_	O
56	=	_	_	O
57	25	_	_	O
58	)	_	_	O
59	or	_	_	O
60	control	_	_	O
61	(	_	_	O
62	n	_	_	O
63	=	_	_	O
64	28	_	_	O
65	)	_	_	O
66	group	_	_	O
67	.	_	_	O

68	The	_	_	O
69	exercise	_	_	O
70	group	_	_	O
71	trained	_	_	O
72	on	_	_	O
73	cycle	_	_	O
74	ergometers	_	_	O
75	three	_	_	O
76	times	_	_	O
77	per	_	_	O
78	week	_	_	O
79	for	_	_	O
80	15	_	_	O
81	weeks	_	_	O
82	at	_	_	O
83	a	_	_	O
84	power	_	_	O
85	output	_	_	O
86	that	_	_	O
87	elicited	_	_	O
88	the	_	_	O
89	ventilatory	_	_	O
90	equivalent	_	_	O
91	for	_	_	O
92	carbon	_	_	O
93	dioxide	_	_	O
94	.	_	_	O

95	The	_	_	O
96	control	_	_	O
97	group	_	_	O
98	did	_	_	O
99	not	_	_	O
100	train	_	_	O
101	.	_	_	O

102	The	_	_	O
103	primary	_	_	O
104	outcomes	_	_	O
105	were	_	_	O
106	changes	_	_	O
107	in	_	_	O
108	peak	_	_	O
109	oxygen	_	_	O
110	consumption	_	_	O
111	and	_	_	O
112	overall	_	_	O
113	QOL	_	_	O
114	from	_	_	O
115	baseline	_	_	O
116	to	_	_	O
117	postintervention	_	_	O
118	.	_	_	O

119	Peak	_	_	O
120	oxygen	_	_	O
121	consumption	_	_	O
122	was	_	_	O
123	assessed	_	_	O
124	by	_	_	O
125	a	_	_	O
126	graded	_	_	O
127	exercise	_	_	O
128	test	_	_	O
129	using	_	_	O
130	gas	_	_	O
131	exchange	_	_	O
132	analysis	_	_	O
133	.	_	_	O

134	Overall	_	_	O
135	QOL	_	_	O
136	was	_	_	O
137	assessed	_	_	O
138	by	_	_	O
139	the	_	_	O
140	Functional	_	_	O
141	Assessment	_	_	O
142	of	_	_	O
143	Cancer	_	_	O
144	Therapy	_	_	O
145	-	_	_	O
146	Breast	_	_	O
147	scale	_	_	O
148	.	_	_	O

149	Fifty	_	_	O
150	-	_	_	O
151	two	_	_	O
152	participants	_	_	O
153	completed	_	_	O
154	the	_	_	O
155	trial	_	_	O
156	.	_	_	O

157	The	_	_	O
158	exercise	_	_	O
159	group	_	_	O
160	completed	_	_	O
161	98	_	_	O
162	.	_	_	O

163	4	_	_	O
164	%	_	_	O
165	of	_	_	O
166	the	_	_	O
167	exercise	_	_	O
168	sessions	_	_	O
169	.	_	_	O

170	Baseline	_	_	O
171	values	_	_	O
172	for	_	_	O
173	peak	_	_	O
174	oxygen	_	_	O
175	consumption	_	_	O
176	(	_	_	O
177	P	_	_	O
178	=	_	_	O
179	.	_	_	O

180	254	_	_	O
181	)	_	_	O
182	and	_	_	O
183	overall	_	_	O
184	QOL	_	_	O
185	(	_	_	O
186	P	_	_	O
187	=	_	_	O
188	.	_	_	O

189	286	_	_	O
190	)	_	_	O
191	did	_	_	O
192	not	_	_	O
193	differ	_	_	O
194	between	_	_	O
195	groups	_	_	O
196	.	_	_	O

197	Peak	_	_	B-Premise
198	oxygen	_	_	I-Premise
199	consumption	_	_	I-Premise
200	increased	_	_	I-Premise
201	by	_	_	I-Premise
202	0	_	_	I-Premise
203	.	_	_	I-Premise

204	24	_	_	I-Premise
205	L	_	_	I-Premise
206	/	_	_	I-Premise
207	min	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	exercise	_	_	I-Premise
211	group	_	_	I-Premise
212	,	_	_	I-Premise
213	whereas	_	_	B-Premise
214	it	_	_	I-Premise
215	decreased	_	_	I-Premise
216	by	_	_	I-Premise
217	0	_	_	I-Premise
218	.	_	_	I-Premise

219	05	_	_	I-Premise
220	L	_	_	I-Premise
221	/	_	_	I-Premise
222	min	_	_	I-Premise
223	in	_	_	I-Premise
224	the	_	_	I-Premise
225	control	_	_	I-Premise
226	group	_	_	I-Premise
227	(	_	_	I-Premise
228	mean	_	_	I-Premise
229	difference	_	_	I-Premise
230	,	_	_	I-Premise
231	0	_	_	I-Premise
232	.	_	_	I-Premise

233	29	_	_	I-Premise
234	L	_	_	I-Premise
235	/	_	_	I-Premise
236	min	_	_	I-Premise
237	;	_	_	I-Premise
238	95	_	_	I-Premise
239	%	_	_	I-Premise
240	confidence	_	_	I-Premise
241	interval	_	_	I-Premise
242	[	_	_	I-Premise
243	CI	_	_	I-Premise
244	]	_	_	I-Premise
245	,	_	_	I-Premise
246	0	_	_	I-Premise
247	.	_	_	I-Premise

248	18	_	_	I-Premise
249	to	_	_	I-Premise
250	0	_	_	I-Premise
251	.	_	_	I-Premise

252	40	_	_	I-Premise
253	;	_	_	I-Premise
254	P	_	_	I-Premise
255	<	_	_	I-Premise
256	.	_	_	I-Premise

257	001	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	Overall	_	_	B-Premise
261	QOL	_	_	I-Premise
262	increased	_	_	I-Premise
263	by	_	_	I-Premise
264	9	_	_	I-Premise
265	.	_	_	I-Premise

266	1	_	_	I-Premise
267	points	_	_	I-Premise
268	in	_	_	I-Premise
269	the	_	_	I-Premise
270	exercise	_	_	I-Premise
271	group	_	_	I-Premise
272	compared	_	_	I-Premise
273	with	_	_	I-Premise
274	0	_	_	I-Premise
275	.	_	_	I-Premise

276	3	_	_	I-Premise
277	points	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	control	_	_	I-Premise
281	group	_	_	I-Premise
282	(	_	_	I-Premise
283	mean	_	_	I-Premise
284	difference	_	_	I-Premise
285	,	_	_	I-Premise
286	8	_	_	I-Premise
287	.	_	_	I-Premise

288	8	_	_	I-Premise
289	points	_	_	I-Premise
290	;	_	_	I-Premise
291	95	_	_	I-Premise
292	%	_	_	I-Premise
293	CI	_	_	I-Premise
294	,	_	_	I-Premise
295	3	_	_	I-Premise
296	.	_	_	I-Premise

297	6	_	_	I-Premise
298	to	_	_	I-Premise
299	14	_	_	I-Premise
300	.	_	_	I-Premise

301	0	_	_	I-Premise
302	;	_	_	I-Premise
303	P	_	_	I-Premise
304	=	_	_	I-Premise
305	.	_	_	I-Premise

306	001	_	_	I-Premise
307	)	_	_	I-Premise
308	.	_	_	I-Premise

309	Pearson	_	_	B-Premise
310	correlations	_	_	I-Premise
311	indicated	_	_	I-Premise
312	that	_	_	I-Premise
313	change	_	_	I-Premise
314	in	_	_	I-Premise
315	peak	_	_	I-Premise
316	oxygen	_	_	I-Premise
317	consumption	_	_	I-Premise
318	correlated	_	_	I-Premise
319	with	_	_	I-Premise
320	change	_	_	I-Premise
321	in	_	_	I-Premise
322	overall	_	_	I-Premise
323	QOL	_	_	I-Premise
324	(	_	_	I-Premise
325	r	_	_	I-Premise
326	=	_	_	I-Premise
327	0	_	_	I-Premise
328	.	_	_	I-Premise

329	45	_	_	I-Premise
330	;	_	_	I-Premise
331	P	_	_	I-Premise
332	<	_	_	I-Premise
333	.	_	_	I-Premise

334	01	_	_	I-Premise
335	)	_	_	I-Premise
336	.	_	_	I-Premise

337	Exercise	_	_	B-Claim
338	training	_	_	I-Claim
339	had	_	_	I-Claim
340	beneficial	_	_	I-Claim
341	effects	_	_	I-Claim
342	on	_	_	I-Claim
343	cardiopulmonary	_	_	I-Claim
344	function	_	_	I-Claim
345	and	_	_	I-Claim
346	QOL	_	_	I-Claim
347	in	_	_	I-Claim
348	postmenopausal	_	_	I-Claim
349	breast	_	_	I-Claim
350	cancer	_	_	I-Claim
351	survivors	_	_	I-Claim
352	.	_	_	I-Claim


0	Cerebral	_	_	B-Claim
1	metastasis	_	_	I-Claim
2	is	_	_	I-Claim
3	a	_	_	I-Claim
4	common	_	_	I-Claim
5	oncologic	_	_	I-Claim
6	problem	_	_	I-Claim
7	that	_	_	I-Claim
8	occurs	_	_	I-Claim
9	in	_	_	I-Claim
10	15	_	_	I-Claim
11	-	_	_	I-Claim
12	30	_	_	I-Claim
13	%	_	_	I-Claim
14	of	_	_	I-Claim
15	cancer	_	_	I-Claim
16	patients	_	_	I-Claim
17	;	_	_	I-Claim
18	approximately	_	_	O
19	half	_	_	O
20	such	_	_	O
21	metastases	_	_	O
22	are	_	_	O
23	single	_	_	O
24	.	_	_	O

25	Previous	_	_	O
26	retrospective	_	_	O
27	studies	_	_	O
28	and	_	_	O
29	two	_	_	O
30	randomized	_	_	O
31	trials	_	_	O
32	reported	_	_	O
33	that	_	_	O
34	the	_	_	O
35	addition	_	_	O
36	of	_	_	O
37	surgical	_	_	O
38	extirpation	_	_	O
39	prior	_	_	O
40	to	_	_	O
41	radiation	_	_	O
42	therapy	_	_	O
43	increased	_	_	O
44	survival	_	_	O
45	,	_	_	O
46	neurologic	_	_	O
47	function	_	_	O
48	,	_	_	O
49	and	_	_	O
50	quality	_	_	O
51	of	_	_	O
52	life	_	_	O
53	compared	_	_	O
54	with	_	_	O
55	radiation	_	_	O
56	alone	_	_	O
57	in	_	_	O
58	patients	_	_	O
59	with	_	_	O
60	a	_	_	O
61	single	_	_	O
62	brain	_	_	O
63	metastasis	_	_	O
64	.	_	_	O

65	A	_	_	O
66	randomized	_	_	O
67	controlled	_	_	O
68	trial	_	_	O
69	was	_	_	O
70	conducted	_	_	O
71	in	_	_	O
72	which	_	_	O
73	patients	_	_	O
74	with	_	_	O
75	a	_	_	O
76	single	_	_	O
77	brain	_	_	O
78	metastasis	_	_	O
79	were	_	_	O
80	allocated	_	_	O
81	to	_	_	O
82	undergo	_	_	O
83	radiation	_	_	O
84	alone	_	_	O
85	or	_	_	O
86	surgery	_	_	O
87	plus	_	_	O
88	radiation	_	_	O
89	.	_	_	O

90	Radiation	_	_	O
91	consisted	_	_	O
92	of	_	_	O
93	3000	_	_	O
94	centigray	_	_	O
95	to	_	_	O
96	the	_	_	O
97	whole	_	_	O
98	brain	_	_	O
99	in	_	_	O
100	10	_	_	O
101	fractions	_	_	O
102	.	_	_	O

103	Forty	_	_	O
104	-	_	_	O
105	three	_	_	O
106	patients	_	_	O
107	received	_	_	O
108	radiation	_	_	O
109	alone	_	_	O
110	and	_	_	O
111	41	_	_	O
112	patients	_	_	O
113	surgery	_	_	O
114	plus	_	_	O
115	radiation	_	_	O
116	.	_	_	O

117	All	_	_	O
118	but	_	_	O
119	two	_	_	O
120	of	_	_	O
121	the	_	_	O
122	study	_	_	O
123	patients	_	_	O
124	died	_	_	O
125	.	_	_	O

126	No	_	_	B-Premise
127	difference	_	_	I-Premise
128	in	_	_	I-Premise
129	survival	_	_	I-Premise
130	was	_	_	I-Premise
131	detected	_	_	I-Premise
132	between	_	_	I-Premise
133	the	_	_	I-Premise
134	groups	_	_	I-Premise
135	;	_	_	I-Premise
136	the	_	_	B-Premise
137	median	_	_	I-Premise
138	survival	_	_	I-Premise
139	for	_	_	I-Premise
140	the	_	_	I-Premise
141	radiation	_	_	I-Premise
142	group	_	_	I-Premise
143	was	_	_	I-Premise
144	6	_	_	I-Premise
145	.	_	_	I-Premise

146	3	_	_	I-Premise
147	months	_	_	I-Premise
148	(	_	_	I-Premise
149	95	_	_	I-Premise
150	%	_	_	I-Premise
151	confidence	_	_	I-Premise
152	interval	_	_	I-Premise
153	,	_	_	I-Premise
154	3	_	_	I-Premise
155	-	_	_	I-Premise
156	11	_	_	I-Premise
157	.	_	_	I-Premise

158	4	_	_	I-Premise
159	)	_	_	I-Premise
160	compared	_	_	I-Premise
161	with	_	_	I-Premise
162	5	_	_	I-Premise
163	.	_	_	I-Premise

164	6	_	_	I-Premise
165	months	_	_	I-Premise
166	for	_	_	I-Premise
167	the	_	_	I-Premise
168	surgery	_	_	I-Premise
169	plus	_	_	I-Premise
170	radiation	_	_	I-Premise
171	group	_	_	I-Premise
172	(	_	_	I-Premise
173	95	_	_	I-Premise
174	%	_	_	I-Premise
175	confidence	_	_	I-Premise
176	interval	_	_	I-Premise
177	,	_	_	I-Premise
178	3	_	_	I-Premise
179	.	_	_	I-Premise

180	9	_	_	I-Premise
181	-	_	_	I-Premise
182	7	_	_	I-Premise
183	.	_	_	I-Premise

184	2	_	_	I-Premise
185	)	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	0	_	_	I-Premise
190	.	_	_	I-Premise

191	24	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	Most	_	_	B-Premise
195	patients	_	_	I-Premise
196	died	_	_	I-Premise
197	within	_	_	I-Premise
198	the	_	_	I-Premise
199	first	_	_	I-Premise
200	year	_	_	I-Premise
201	(	_	_	I-Premise
202	69	_	_	I-Premise
203	.	_	_	I-Premise

204	8	_	_	I-Premise
205	%	_	_	I-Premise
206	in	_	_	I-Premise
207	the	_	_	I-Premise
208	radiation	_	_	I-Premise
209	arm	_	_	I-Premise
210	vs	_	_	I-Premise
211	.	_	_	I-Premise

212	87	_	_	I-Premise
213	.	_	_	I-Premise

214	8	_	_	I-Premise
215	%	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	surgery	_	_	I-Premise
219	plus	_	_	I-Premise
220	radiation	_	_	I-Premise
221	arm	_	_	I-Premise
222	)	_	_	I-Premise
223	.	_	_	I-Premise

224	There	_	_	B-Premise
225	were	_	_	I-Premise
226	no	_	_	I-Premise
227	significant	_	_	I-Premise
228	differences	_	_	I-Premise
229	in	_	_	I-Premise
230	the	_	_	I-Premise
231	30	_	_	I-Premise
232	-	_	_	I-Premise
233	day	_	_	I-Premise
234	mortality	_	_	I-Premise
235	,	_	_	I-Premise
236	morbidity	_	_	I-Premise
237	,	_	_	I-Premise
238	or	_	_	I-Premise
239	causes	_	_	I-Premise
240	of	_	_	I-Premise
241	death	_	_	I-Premise
242	.	_	_	I-Premise

243	Extracranial	_	_	B-Premise
244	metastases	_	_	I-Premise
245	was	_	_	I-Premise
246	an	_	_	I-Premise
247	important	_	_	I-Premise
248	predictor	_	_	I-Premise
249	of	_	_	I-Premise
250	mortality	_	_	I-Premise
251	(	_	_	I-Premise
252	relative	_	_	I-Premise
253	risk	_	_	I-Premise
254	,	_	_	I-Premise
255	2	_	_	I-Premise
256	.	_	_	I-Premise

257	3	_	_	I-Premise
258	)	_	_	I-Premise
259	.	_	_	I-Premise

260	The	_	_	B-Premise
261	mean	_	_	I-Premise
262	proportion	_	_	I-Premise
263	of	_	_	I-Premise
264	days	_	_	I-Premise
265	that	_	_	I-Premise
266	the	_	_	I-Premise
267	Karnofsky	_	_	I-Premise
268	performance	_	_	I-Premise
269	status	_	_	I-Premise
270	was	_	_	I-Premise
271	>	_	_	I-Premise
272	or	_	_	I-Premise
273	=	_	_	I-Premise
274	70	_	_	I-Premise
275	%	_	_	I-Premise
276	did	_	_	I-Premise
277	not	_	_	I-Premise
278	differ	_	_	I-Premise
279	between	_	_	I-Premise
280	the	_	_	I-Premise
281	2	_	_	I-Premise
282	groups	_	_	I-Premise
283	.	_	_	I-Premise

284	This	_	_	B-Claim
285	trial	_	_	I-Claim
286	failed	_	_	I-Claim
287	to	_	_	I-Claim
288	demonstrate	_	_	I-Claim
289	that	_	_	I-Claim
290	the	_	_	I-Claim
291	addition	_	_	I-Claim
292	of	_	_	I-Claim
293	surgery	_	_	I-Claim
294	to	_	_	I-Claim
295	radiation	_	_	I-Claim
296	therapy	_	_	I-Claim
297	improved	_	_	I-Claim
298	outcome	_	_	I-Claim
299	of	_	_	I-Claim
300	patients	_	_	I-Claim
301	with	_	_	I-Claim
302	a	_	_	I-Claim
303	single	_	_	I-Claim
304	brain	_	_	I-Claim
305	metastasis	_	_	I-Claim
306	.	_	_	I-Claim

307	Thus	_	_	B-Claim
308	,	_	_	I-Claim
309	the	_	_	I-Claim
310	efficacy	_	_	I-Claim
311	of	_	_	I-Claim
312	surgery	_	_	I-Claim
313	plus	_	_	I-Claim
314	radiation	_	_	I-Claim
315	compared	_	_	I-Claim
316	with	_	_	I-Claim
317	radiation	_	_	I-Claim
318	alone	_	_	I-Claim
319	needs	_	_	I-Claim
320	to	_	_	I-Claim
321	be	_	_	I-Claim
322	addressed	_	_	I-Claim
323	by	_	_	I-Claim
324	further	_	_	I-Claim
325	clinical	_	_	I-Claim
326	trials	_	_	I-Claim
327	and	_	_	I-Claim
328	/	_	_	I-Claim
329	or	_	_	I-Claim
330	a	_	_	I-Claim
331	meta	_	_	I-Claim
332	-	_	_	I-Claim
333	analysis	_	_	I-Claim
334	.	_	_	I-Claim


0	Debilitating	_	_	B-Claim
1	hot	_	_	I-Claim
2	flushes	_	_	I-Claim
3	and	_	_	I-Claim
4	sleep	_	_	I-Claim
5	dysfunction	_	_	I-Claim
6	often	_	_	I-Claim
7	affect	_	_	I-Claim
8	survivors	_	_	I-Claim
9	of	_	_	I-Claim
10	breast	_	_	I-Claim
11	cancer	_	_	I-Claim
12	,	_	_	I-Claim
13	most	_	_	I-Claim
14	notably	_	_	I-Claim
15	in	_	_	I-Claim
16	those	_	_	I-Claim
17	taking	_	_	I-Claim
18	anti	_	_	I-Claim
19	-	_	_	I-Claim
20	oestrogen	_	_	I-Claim
21	medications	_	_	I-Claim
22	.	_	_	I-Claim

23	Conventional	_	_	B-Claim
24	treatments	_	_	I-Claim
25	have	_	_	I-Claim
26	been	_	_	I-Claim
27	only	_	_	I-Claim
28	partially	_	_	I-Claim
29	effective	_	_	I-Claim
30	in	_	_	I-Claim
31	diminishing	_	_	I-Claim
32	these	_	_	I-Claim
33	issues	_	_	I-Claim
34	,	_	_	I-Claim
35	and	_	_	I-Claim
36	some	_	_	I-Claim
37	have	_	_	I-Claim
38	serious	_	_	I-Claim
39	risks	_	_	I-Claim
40	.	_	_	I-Claim

41	We	_	_	O
42	did	_	_	O
43	a	_	_	O
44	pilot	_	_	O
45	study	_	_	O
46	to	_	_	O
47	investigate	_	_	O
48	our	_	_	O
49	hypothesis	_	_	O
50	that	_	_	O
51	stellate	_	_	O
52	-	_	_	O
53	ganglion	_	_	O
54	block	_	_	O
55	can	_	_	O
56	be	_	_	O
57	a	_	_	O
58	safe	_	_	O
59	and	_	_	O
60	effective	_	_	O
61	treatment	_	_	O
62	for	_	_	O
63	hot	_	_	O
64	flushes	_	_	O
65	and	_	_	O
66	sleep	_	_	O
67	dysfunction	_	_	O
68	in	_	_	O
69	this	_	_	O
70	patient	_	_	O
71	population	_	_	O
72	.	_	_	O

73	13	_	_	O
74	survivors	_	_	O
75	of	_	_	O
76	breast	_	_	O
77	cancer	_	_	O
78	(	_	_	O
79	in	_	_	O
80	remission	_	_	O
81	)	_	_	O
82	with	_	_	O
83	severe	_	_	O
84	hot	_	_	O
85	flushes	_	_	O
86	and	_	_	O
87	night	_	_	O
88	awakenings	_	_	O
89	were	_	_	O
90	treated	_	_	O
91	with	_	_	O
92	stellate	_	_	O
93	-	_	_	O
94	ganglion	_	_	O
95	block	_	_	O
96	at	_	_	O
97	the	_	_	O
98	anterolateral	_	_	O
99	aspect	_	_	O
100	of	_	_	O
101	the	_	_	O
102	C6	_	_	O
103	vertebra	_	_	O
104	on	_	_	O
105	the	_	_	O
106	right	_	_	O
107	side	_	_	O
108	under	_	_	O
109	fluoroscopy	_	_	O
110	.	_	_	O

111	Patients	_	_	O
112	recorded	_	_	O
113	hot	_	_	O
114	flushes	_	_	O
115	in	_	_	O
116	a	_	_	O
117	daily	_	_	O
118	diary	_	_	O
119	by	_	_	O
120	use	_	_	O
121	of	_	_	O
122	the	_	_	O
123	Hot	_	_	O
124	-	_	_	O
125	Flash	_	_	O
126	Score	_	_	O
127	,	_	_	O
128	devised	_	_	O
129	by	_	_	O
130	Sloan	_	_	O
131	and	_	_	O
132	colleagues	_	_	O
133	,	_	_	O
134	and	_	_	O
135	night	_	_	O
136	awakenings	_	_	O
137	by	_	_	O
138	use	_	_	O
139	of	_	_	O
140	the	_	_	O
141	Pittsburgh	_	_	O
142	Sleep	_	_	O
143	Quality	_	_	O
144	Index	_	_	O
145	.	_	_	O

146	Both	_	_	O
147	instruments	_	_	O
148	were	_	_	O
149	used	_	_	O
150	1	_	_	O
151	week	_	_	O
152	before	_	_	O
153	the	_	_	O
154	procedure	_	_	O
155	[	_	_	O
156	A40	_	_	O
157	]	_	_	O
158	and	_	_	O
159	then	_	_	O
160	weekly	_	_	O
161	after	_	_	O
162	the	_	_	O
163	procedure	_	_	O
164	for	_	_	O
165	12	_	_	O
166	weeks	_	_	O
167	.	_	_	O

168	We	_	_	O
169	used	_	_	O
170	the	_	_	O
171	generalised	_	_	O
172	-	_	_	O
173	estimating	_	_	O
174	-	_	_	O
175	equations	_	_	O
176	method	_	_	O
177	to	_	_	O
178	analyse	_	_	O
179	the	_	_	O
180	longitudinal	_	_	O
181	measurements	_	_	O
182	of	_	_	O
183	the	_	_	O
184	number	_	_	O
185	of	_	_	O
186	hot	_	_	O
187	flushes	_	_	O
188	and	_	_	O
189	night	_	_	O
190	awakenings	_	_	O
191	over	_	_	O
192	time	_	_	O
193	.	_	_	O

194	This	_	_	O
195	method	_	_	O
196	is	_	_	O
197	a	_	_	O
198	popular	_	_	O
199	approach	_	_	O
200	to	_	_	O
201	analysing	_	_	O
202	datasets	_	_	O
203	that	_	_	O
204	have	_	_	O
205	repeated	_	_	O
206	measures	_	_	O
207	from	_	_	O
208	the	_	_	O
209	same	_	_	O
210	person	_	_	O
211	,	_	_	O
212	and	_	_	O
213	is	_	_	O
214	robust	_	_	O
215	because	_	_	O
216	it	_	_	O
217	does	_	_	O
218	not	_	_	O
219	need	_	_	O
220	the	_	_	O
221	complete	_	_	O
222	distribution	_	_	O
223	of	_	_	O
224	the	_	_	O
225	outcomes	_	_	O
226	to	_	_	O
227	be	_	_	O
228	specified	_	_	O
229	.	_	_	O

230	This	_	_	O
231	trial	_	_	O
232	is	_	_	O
233	registered	_	_	O
234	on	_	_	O
235	the	_	_	O
236	International	_	_	O
237	Standard	_	_	O
238	Randomised	_	_	O
239	Controlled	_	_	O
240	Trial	_	_	O
241	Number	_	_	O
242	register	_	_	O
243	(	_	_	O
244	ISRCTN14318565	_	_	O
245	)	_	_	O
246	.	_	_	O

247	There	_	_	O
248	were	_	_	O
249	no	_	_	O
250	adverse	_	_	O
251	events	_	_	O
252	resulting	_	_	O
253	from	_	_	O
254	the	_	_	O
255	stellate	_	_	O
256	-	_	_	O
257	ganglion	_	_	O
258	block	_	_	O
259	,	_	_	O
260	although	_	_	O
261	patients	_	_	O
262	had	_	_	O
263	temporary	_	_	O
264	Horner	_	_	O
265	'	_	_	O
266	s	_	_	O
267	syndrome	_	_	O
268	indicating	_	_	O
269	the	_	_	O
270	effectiveness	_	_	O
271	of	_	_	O
272	the	_	_	O
273	block	_	_	O
274	.	_	_	O

275	Five	_	_	O
276	patients	_	_	O
277	had	_	_	O
278	only	_	_	O
279	one	_	_	O
280	stellate	_	_	O
281	-	_	_	O
282	ganglion	_	_	O
283	block	_	_	O
284	and	_	_	O
285	eight	_	_	O
286	had	_	_	O
287	two	_	_	O
288	stellate	_	_	O
289	-	_	_	O
290	ganglion	_	_	O
291	blocks	_	_	O
292	.	_	_	O

293	The	_	_	B-Premise
294	total	_	_	I-Premise
295	number	_	_	I-Premise
296	of	_	_	I-Premise
297	hot	_	_	I-Premise
298	flushes	_	_	I-Premise
299	decreased	_	_	I-Premise
300	from	_	_	I-Premise
301	a	_	_	I-Premise
302	mean	_	_	I-Premise
303	of	_	_	I-Premise
304	79	_	_	I-Premise
305	.	_	_	I-Premise

306	4	_	_	I-Premise
307	(	_	_	I-Premise
308	SD	_	_	I-Premise
309	37	_	_	I-Premise
310	.	_	_	I-Premise

311	4	_	_	I-Premise
312	)	_	_	I-Premise
313	per	_	_	I-Premise
314	week	_	_	I-Premise
315	before	_	_	I-Premise
316	the	_	_	I-Premise
317	procedure	_	_	I-Premise
318	to	_	_	I-Premise
319	a	_	_	I-Premise
320	mean	_	_	I-Premise
321	of	_	_	I-Premise
322	49	_	_	I-Premise
323	.	_	_	I-Premise

324	9	_	_	I-Premise
325	(	_	_	I-Premise
326	SD	_	_	I-Premise
327	39	_	_	I-Premise
328	.	_	_	I-Premise

329	9	_	_	I-Premise
330	)	_	_	I-Premise
331	per	_	_	I-Premise
332	week	_	_	I-Premise
333	during	_	_	I-Premise
334	the	_	_	I-Premise
335	first	_	_	I-Premise
336	2	_	_	I-Premise
337	weeks	_	_	I-Premise
338	after	_	_	I-Premise
339	the	_	_	I-Premise
340	procedure	_	_	I-Premise
341	(	_	_	I-Premise
342	p	_	_	I-Premise
343	=	_	_	I-Premise
344	0	_	_	I-Premise
345	.	_	_	I-Premise

346	0002	_	_	I-Premise
347	)	_	_	I-Premise
348	.	_	_	I-Premise

349	The	_	_	B-Premise
350	total	_	_	I-Premise
351	number	_	_	I-Premise
352	of	_	_	I-Premise
353	hot	_	_	I-Premise
354	flushes	_	_	I-Premise
355	continued	_	_	I-Premise
356	to	_	_	I-Premise
357	decrease	_	_	I-Premise
358	over	_	_	I-Premise
359	the	_	_	I-Premise
360	remaining	_	_	I-Premise
361	follow	_	_	I-Premise
362	-	_	_	I-Premise
363	up	_	_	I-Premise
364	period	_	_	I-Premise
365	(	_	_	I-Premise
366	weeks	_	_	I-Premise
367	3	_	_	I-Premise
368	-	_	_	I-Premise
369	12	_	_	I-Premise
370	)	_	_	I-Premise
371	,	_	_	I-Premise
372	and	_	_	I-Premise
373	stabilised	_	_	I-Premise
374	at	_	_	I-Premise
375	a	_	_	I-Premise
376	mean	_	_	I-Premise
377	of	_	_	I-Premise
378	8	_	_	I-Premise
379	.	_	_	I-Premise

380	1	_	_	I-Premise
381	(	_	_	I-Premise
382	SD	_	_	I-Premise
383	5	_	_	I-Premise
384	.	_	_	I-Premise

385	6	_	_	I-Premise
386	)	_	_	I-Premise
387	per	_	_	I-Premise
388	week	_	_	I-Premise
389	(	_	_	I-Premise
390	p	_	_	I-Premise
391	<	_	_	I-Premise
392	0	_	_	I-Premise
393	.	_	_	I-Premise

394	0001	_	_	I-Premise
395	)	_	_	I-Premise
396	.	_	_	I-Premise

397	The	_	_	B-Premise
398	number	_	_	I-Premise
399	of	_	_	I-Premise
400	very	_	_	I-Premise
401	severe	_	_	I-Premise
402	hot	_	_	I-Premise
403	flushes	_	_	I-Premise
404	was	_	_	I-Premise
405	decreased	_	_	I-Premise
406	to	_	_	I-Premise
407	near	_	_	I-Premise
408	zero	_	_	I-Premise
409	by	_	_	I-Premise
410	the	_	_	I-Premise
411	end	_	_	I-Premise
412	of	_	_	I-Premise
413	the	_	_	I-Premise
414	follow	_	_	I-Premise
415	-	_	_	I-Premise
416	up	_	_	I-Premise
417	period	_	_	I-Premise
418	(	_	_	I-Premise
419	week	_	_	I-Premise
420	12	_	_	I-Premise
421	;	_	_	I-Premise
422	p	_	_	I-Premise
423	<	_	_	I-Premise
424	0	_	_	I-Premise
425	.	_	_	I-Premise

426	0001	_	_	I-Premise
427	)	_	_	I-Premise
428	.	_	_	I-Premise

429	Night	_	_	B-Premise
430	awakenings	_	_	I-Premise
431	decreased	_	_	I-Premise
432	from	_	_	I-Premise
433	a	_	_	I-Premise
434	mean	_	_	I-Premise
435	of	_	_	I-Premise
436	19	_	_	I-Premise
437	.	_	_	I-Premise

438	5	_	_	I-Premise
439	(	_	_	I-Premise
440	SD	_	_	I-Premise
441	14	_	_	I-Premise
442	.	_	_	I-Premise

443	8	_	_	I-Premise
444	)	_	_	I-Premise
445	per	_	_	I-Premise
446	week	_	_	I-Premise
447	before	_	_	I-Premise
448	the	_	_	I-Premise
449	procedure	_	_	I-Premise
450	to	_	_	I-Premise
451	a	_	_	I-Premise
452	mean	_	_	I-Premise
453	of	_	_	I-Premise
454	7	_	_	I-Premise
455	.	_	_	I-Premise

456	3	_	_	I-Premise
457	(	_	_	I-Premise
458	SD	_	_	I-Premise
459	7	_	_	I-Premise
460	.	_	_	I-Premise

461	1	_	_	I-Premise
462	)	_	_	I-Premise
463	per	_	_	I-Premise
464	week	_	_	I-Premise
465	during	_	_	I-Premise
466	the	_	_	I-Premise
467	first	_	_	I-Premise
468	2	_	_	I-Premise
469	weeks	_	_	I-Premise
470	after	_	_	I-Premise
471	the	_	_	I-Premise
472	procedure	_	_	I-Premise
473	(	_	_	I-Premise
474	p	_	_	I-Premise
475	<	_	_	I-Premise
476	0	_	_	I-Premise
477	.	_	_	I-Premise

478	0001	_	_	I-Premise
479	)	_	_	I-Premise
480	.	_	_	I-Premise

481	The	_	_	B-Premise
482	total	_	_	I-Premise
483	number	_	_	I-Premise
484	of	_	_	I-Premise
485	night	_	_	I-Premise
486	awakenings	_	_	I-Premise
487	continued	_	_	I-Premise
488	to	_	_	I-Premise
489	decrease	_	_	I-Premise
490	over	_	_	I-Premise
491	the	_	_	I-Premise
492	remaining	_	_	I-Premise
493	follow	_	_	I-Premise
494	-	_	_	I-Premise
495	up	_	_	I-Premise
496	period	_	_	I-Premise
497	(	_	_	I-Premise
498	weeks	_	_	I-Premise
499	3	_	_	I-Premise
500	-	_	_	I-Premise
501	12	_	_	I-Premise
502	)	_	_	I-Premise
503	and	_	_	I-Premise
504	stabilised	_	_	I-Premise
505	at	_	_	I-Premise
506	a	_	_	I-Premise
507	mean	_	_	I-Premise
508	of	_	_	I-Premise
509	1	_	_	I-Premise
510	.	_	_	I-Premise

511	4	_	_	I-Premise
512	(	_	_	I-Premise
513	SD	_	_	I-Premise
514	1	_	_	I-Premise
515	.	_	_	I-Premise

516	2	_	_	I-Premise
517	)	_	_	I-Premise
518	per	_	_	I-Premise
519	week	_	_	I-Premise
520	(	_	_	I-Premise
521	p	_	_	I-Premise
522	<	_	_	I-Premise
523	0	_	_	I-Premise
524	.	_	_	I-Premise

525	0001	_	_	I-Premise
526	)	_	_	I-Premise
527	.	_	_	I-Premise

528	The	_	_	B-Claim
529	findings	_	_	I-Claim
530	of	_	_	I-Claim
531	this	_	_	I-Claim
532	study	_	_	I-Claim
533	suggest	_	_	I-Claim
534	that	_	_	I-Claim
535	stellate	_	_	I-Claim
536	-	_	_	I-Claim
537	ganglion	_	_	I-Claim
538	block	_	_	I-Claim
539	can	_	_	I-Claim
540	provide	_	_	I-Claim
541	survivors	_	_	I-Claim
542	of	_	_	I-Claim
543	breast	_	_	I-Claim
544	cancer	_	_	I-Claim
545	with	_	_	I-Claim
546	relief	_	_	I-Claim
547	from	_	_	I-Claim
548	hot	_	_	I-Claim
549	flushes	_	_	I-Claim
550	and	_	_	I-Claim
551	sleep	_	_	I-Claim
552	dysfunction	_	_	I-Claim
553	with	_	_	I-Claim
554	few	_	_	I-Claim
555	or	_	_	I-Claim
556	no	_	_	I-Claim
557	side	_	_	I-Claim
558	-	_	_	I-Claim
559	effects	_	_	I-Claim
560	.	_	_	I-Claim

561	Long	_	_	B-Claim
562	-	_	_	I-Claim
563	term	_	_	I-Claim
564	relief	_	_	I-Claim
565	of	_	_	I-Claim
566	symptoms	_	_	I-Claim
567	has	_	_	I-Claim
568	the	_	_	I-Claim
569	potential	_	_	I-Claim
570	to	_	_	I-Claim
571	improve	_	_	I-Claim
572	overall	_	_	I-Claim
573	quality	_	_	I-Claim
574	of	_	_	I-Claim
575	life	_	_	I-Claim
576	and	_	_	I-Claim
577	increase	_	_	I-Claim
578	compliance	_	_	I-Claim
579	with	_	_	I-Claim
580	anti	_	_	I-Claim
581	-	_	_	I-Claim
582	oestrogen	_	_	I-Claim
583	medications	_	_	I-Claim
584	for	_	_	I-Claim
585	breast	_	_	I-Claim
586	cancer	_	_	I-Claim
587	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	whether	_	_	O
3	the	_	_	O
4	relative	_	_	O
5	dose	_	_	O
6	-	_	_	O
7	intensity	_	_	O
8	of	_	_	O
9	cyclophosphamide	_	_	O
10	,	_	_	O
11	doxorubicin	_	_	O
12	,	_	_	O
13	vincristine	_	_	O
14	,	_	_	O
15	and	_	_	O
16	prednisone	_	_	O
17	(	_	_	O
18	CHOP	_	_	O
19	)	_	_	O
20	chemotherapy	_	_	O
21	could	_	_	O
22	be	_	_	O
23	improved	_	_	O
24	by	_	_	O
25	prophylactic	_	_	O
26	administration	_	_	O
27	of	_	_	O
28	granulocyte	_	_	O
29	colony	_	_	O
30	-	_	_	O
31	stimulating	_	_	O
32	factor	_	_	O
33	(	_	_	O
34	G	_	_	O
35	-	_	_	O
36	CSF	_	_	O
37	)	_	_	O
38	in	_	_	O
39	elderly	_	_	O
40	patients	_	_	O
41	with	_	_	O
42	aggressive	_	_	O
43	non	_	_	O
44	-	_	_	O
45	Hodgkin	_	_	O
46	'	_	_	O
47	s	_	_	O
48	lymphoma	_	_	O
49	(	_	_	O
50	NHL	_	_	O
51	)	_	_	O
52	.	_	_	O

53	Patients	_	_	O
54	aged	_	_	O
55	65	_	_	O
56	to	_	_	O
57	90	_	_	O
58	years	_	_	O
59	(	_	_	O
60	median	_	_	O
61	,	_	_	O
62	72	_	_	O
63	years	_	_	O
64	)	_	_	O
65	with	_	_	O
66	stage	_	_	O
67	II	_	_	O
68	to	_	_	O
69	IV	_	_	O
70	aggressive	_	_	O
71	NHL	_	_	O
72	were	_	_	O
73	randomly	_	_	O
74	assigned	_	_	O
75	to	_	_	O
76	receive	_	_	O
77	standard	_	_	O
78	CHOP	_	_	O
79	every	_	_	O
80	3	_	_	O
81	weeks	_	_	O
82	or	_	_	O
83	CHOP	_	_	O
84	plus	_	_	O
85	G	_	_	O
86	-	_	_	O
87	CSF	_	_	O
88	every	_	_	O
89	3	_	_	O
90	weeks	_	_	O
91	on	_	_	O
92	days	_	_	O
93	2	_	_	O
94	to	_	_	O
95	11	_	_	O
96	of	_	_	O
97	each	_	_	O
98	cycle	_	_	O
99	.	_	_	O

100	In	_	_	B-Premise
101	389	_	_	I-Premise
102	eligible	_	_	I-Premise
103	patients	_	_	I-Premise
104	,	_	_	I-Premise
105	the	_	_	I-Premise
106	relative	_	_	I-Premise
107	dose	_	_	I-Premise
108	intensities	_	_	I-Premise
109	(	_	_	I-Premise
110	RDIs	_	_	I-Premise
111	)	_	_	I-Premise
112	of	_	_	I-Premise
113	cyclophosphamide	_	_	I-Premise
114	(	_	_	I-Premise
115	median	_	_	I-Premise
116	,	_	_	I-Premise
117	96	_	_	I-Premise
118	.	_	_	I-Premise

119	3	_	_	I-Premise
120	%	_	_	I-Premise
121	v	_	_	I-Premise
122	93	_	_	I-Premise
123	.	_	_	I-Premise

124	9	_	_	I-Premise
125	%	_	_	I-Premise
126	;	_	_	I-Premise
127	P	_	_	I-Premise
128	=	_	_	I-Premise
129	.	_	_	I-Premise

130	01	_	_	I-Premise
131	)	_	_	I-Premise
132	and	_	_	I-Premise
133	doxorubicin	_	_	I-Premise
134	(	_	_	I-Premise
135	median	_	_	I-Premise
136	,	_	_	I-Premise
137	95	_	_	I-Premise
138	.	_	_	I-Premise

139	4	_	_	I-Premise
140	%	_	_	I-Premise
141	v	_	_	I-Premise
142	93	_	_	I-Premise
143	.	_	_	I-Premise

144	3	_	_	I-Premise
145	%	_	_	I-Premise
146	;	_	_	I-Premise
147	P	_	_	I-Premise
148	=	_	_	I-Premise
149	.	_	_	I-Premise

150	04	_	_	I-Premise
151	)	_	_	I-Premise
152	were	_	_	I-Premise
153	higher	_	_	I-Premise
154	in	_	_	I-Premise
155	patients	_	_	I-Premise
156	treated	_	_	I-Premise
157	with	_	_	I-Premise
158	CHOP	_	_	I-Premise
159	plus	_	_	I-Premise
160	G	_	_	I-Premise
161	-	_	_	I-Premise
162	CSF	_	_	I-Premise
163	.	_	_	I-Premise

164	The	_	_	B-Premise
165	complete	_	_	I-Premise
166	response	_	_	I-Premise
167	rates	_	_	I-Premise
168	were	_	_	I-Premise
169	55	_	_	I-Premise
170	%	_	_	I-Premise
171	and	_	_	I-Premise
172	52	_	_	I-Premise
173	%	_	_	I-Premise
174	for	_	_	I-Premise
175	CHOP	_	_	I-Premise
176	and	_	_	I-Premise
177	CHOP	_	_	I-Premise
178	plus	_	_	I-Premise
179	G	_	_	I-Premise
180	-	_	_	I-Premise
181	CSF	_	_	I-Premise
182	,	_	_	I-Premise
183	respectively	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=	_	_	I-Premise
187	.	_	_	I-Premise

188	63	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	The	_	_	B-Premise
192	actuarial	_	_	I-Premise
193	overall	_	_	I-Premise
194	survival	_	_	I-Premise
195	at	_	_	I-Premise
196	5	_	_	I-Premise
197	years	_	_	I-Premise
198	was	_	_	I-Premise
199	22	_	_	I-Premise
200	%	_	_	I-Premise
201	with	_	_	I-Premise
202	CHOP	_	_	I-Premise
203	alone	_	_	I-Premise
204	,	_	_	I-Premise
205	compared	_	_	I-Premise
206	with	_	_	I-Premise
207	24	_	_	I-Premise
208	%	_	_	I-Premise
209	with	_	_	I-Premise
210	CHOP	_	_	I-Premise
211	plus	_	_	I-Premise
212	G	_	_	I-Premise
213	-	_	_	I-Premise
214	CSF	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.	_	_	I-Premise

219	76	_	_	I-Premise
220	)	_	_	I-Premise
221	,	_	_	I-Premise
222	with	_	_	I-Premise
223	a	_	_	I-Premise
224	median	_	_	I-Premise
225	follow	_	_	I-Premise
226	-	_	_	I-Premise
227	up	_	_	I-Premise
228	of	_	_	I-Premise
229	33	_	_	I-Premise
230	months	_	_	I-Premise
231	.	_	_	I-Premise

232	Patients	_	_	B-Premise
233	treated	_	_	I-Premise
234	with	_	_	I-Premise
235	CHOP	_	_	I-Premise
236	plus	_	_	I-Premise
237	G	_	_	I-Premise
238	-	_	_	I-Premise
239	CSF	_	_	I-Premise
240	had	_	_	I-Premise
241	an	_	_	I-Premise
242	identical	_	_	I-Premise
243	incidence	_	_	I-Premise
244	of	_	_	I-Premise
245	infections	_	_	I-Premise
246	,	_	_	I-Premise
247	with	_	_	I-Premise
248	World	_	_	I-Premise
249	Health	_	_	I-Premise
250	Organization	_	_	I-Premise
251	grade	_	_	I-Premise
252	3	_	_	I-Premise
253	to	_	_	I-Premise
254	4	_	_	I-Premise
255	(	_	_	I-Premise
256	34	_	_	I-Premise
257	of	_	_	I-Premise
258	1	_	_	I-Premise
259	,	_	_	I-Premise
260	191	_	_	I-Premise
261	cycles	_	_	I-Premise
262	v	_	_	I-Premise
263	36	_	_	I-Premise
264	of	_	_	I-Premise
265	1	_	_	I-Premise
266	,	_	_	I-Premise
267	195	_	_	I-Premise
268	cycles	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	Only	_	_	B-Premise
272	the	_	_	I-Premise
273	cumulative	_	_	I-Premise
274	days	_	_	I-Premise
275	with	_	_	I-Premise
276	antibiotics	_	_	I-Premise
277	were	_	_	I-Premise
278	fewer	_	_	I-Premise
279	with	_	_	I-Premise
280	CHOP	_	_	I-Premise
281	plus	_	_	I-Premise
282	G	_	_	I-Premise
283	-	_	_	I-Premise
284	CSF	_	_	I-Premise
285	(	_	_	I-Premise
286	median	_	_	I-Premise
287	,	_	_	I-Premise
288	0	_	_	I-Premise
289	v	_	_	I-Premise
290	6	_	_	I-Premise
291	days	_	_	I-Premise
292	;	_	_	I-Premise
293	P	_	_	I-Premise
294	=	_	_	I-Premise
295	.	_	_	I-Premise

296	006	_	_	I-Premise
297	)	_	_	I-Premise
298	than	_	_	I-Premise
299	with	_	_	I-Premise
300	CHOP	_	_	I-Premise
301	alone	_	_	I-Premise
302	.	_	_	I-Premise

303	The	_	_	B-Premise
304	number	_	_	I-Premise
305	of	_	_	I-Premise
306	hospital	_	_	I-Premise
307	admissions	_	_	I-Premise
308	and	_	_	I-Premise
309	the	_	_	I-Premise
310	number	_	_	I-Premise
311	of	_	_	I-Premise
312	days	_	_	I-Premise
313	in	_	_	I-Premise
314	hospital	_	_	I-Premise
315	were	_	_	I-Premise
316	not	_	_	I-Premise
317	different	_	_	I-Premise
318	.	_	_	I-Premise

319	In	_	_	B-Claim
320	elderly	_	_	I-Claim
321	patients	_	_	I-Claim
322	,	_	_	I-Claim
323	G	_	_	I-Claim
324	-	_	_	I-Claim
325	CSF	_	_	I-Claim
326	improved	_	_	I-Claim
327	the	_	_	I-Claim
328	RDI	_	_	I-Claim
329	of	_	_	I-Claim
330	CHOP	_	_	I-Claim
331	,	_	_	I-Claim
332	but	_	_	B-Premise
333	this	_	_	I-Premise
334	did	_	_	I-Premise
335	not	_	_	I-Premise
336	lead	_	_	I-Premise
337	to	_	_	I-Premise
338	a	_	_	I-Premise
339	higher	_	_	I-Premise
340	complete	_	_	I-Premise
341	response	_	_	I-Premise
342	rate	_	_	I-Premise
343	or	_	_	I-Premise
344	better	_	_	I-Premise
345	overall	_	_	I-Premise
346	survival	_	_	I-Premise
347	.	_	_	I-Premise

348	G	_	_	B-Claim
349	-	_	_	I-Claim
350	CSF	_	_	I-Claim
351	did	_	_	I-Claim
352	not	_	_	I-Claim
353	prevent	_	_	I-Claim
354	serious	_	_	I-Claim
355	infections	_	_	I-Claim
356	.	_	_	I-Claim


0	Androgen	_	_	B-Claim
1	deprivation	_	_	I-Claim
2	therapy	_	_	I-Claim
3	is	_	_	I-Claim
4	a	_	_	I-Claim
5	common	_	_	I-Claim
6	treatment	_	_	I-Claim
7	in	_	_	I-Claim
8	men	_	_	I-Claim
9	with	_	_	I-Claim
10	prostate	_	_	I-Claim
11	cancer	_	_	I-Claim
12	that	_	_	I-Claim
13	may	_	_	I-Claim
14	cause	_	_	I-Claim
15	fatigue	_	_	I-Claim
16	,	_	_	I-Claim
17	functional	_	_	I-Claim
18	decline	_	_	I-Claim
19	,	_	_	I-Claim
20	increased	_	_	I-Claim
21	body	_	_	I-Claim
22	fatness	_	_	I-Claim
23	,	_	_	I-Claim
24	and	_	_	I-Claim
25	loss	_	_	I-Claim
26	of	_	_	I-Claim
27	lean	_	_	I-Claim
28	body	_	_	I-Claim
29	tissue	_	_	I-Claim
30	.	_	_	I-Claim

31	These	_	_	B-Claim
32	physical	_	_	I-Claim
33	changes	_	_	I-Claim
34	can	_	_	I-Claim
35	negatively	_	_	I-Claim
36	affect	_	_	I-Claim
37	health	_	_	I-Claim
38	-	_	_	I-Claim
39	related	_	_	I-Claim
40	quality	_	_	I-Claim
41	of	_	_	I-Claim
42	life	_	_	I-Claim
43	.	_	_	I-Claim

44	Resistance	_	_	B-Claim
45	exercise	_	_	I-Claim
46	may	_	_	I-Claim
47	help	_	_	I-Claim
48	to	_	_	I-Claim
49	counter	_	_	I-Claim
50	some	_	_	I-Claim
51	of	_	_	I-Claim
52	these	_	_	I-Claim
53	side	_	_	I-Claim
54	effects	_	_	I-Claim
55	by	_	_	I-Claim
56	reducing	_	_	I-Claim
57	fatigue	_	_	I-Claim
58	,	_	_	I-Claim
59	elevating	_	_	I-Claim
60	mood	_	_	I-Claim
61	,	_	_	I-Claim
62	building	_	_	I-Claim
63	muscle	_	_	I-Claim
64	mass	_	_	I-Claim
65	,	_	_	I-Claim
66	and	_	_	I-Claim
67	reducing	_	_	I-Claim
68	body	_	_	I-Claim
69	fat	_	_	I-Claim
70	.	_	_	I-Claim

71	In	_	_	O
72	a	_	_	O
73	two	_	_	O
74	-	_	_	O
75	site	_	_	O
76	study	_	_	O
77	,	_	_	O
78	155	_	_	O
79	men	_	_	O
80	with	_	_	O
81	prostate	_	_	O
82	cancer	_	_	O
83	who	_	_	O
84	were	_	_	O
85	scheduled	_	_	O
86	to	_	_	O
87	receive	_	_	O
88	androgen	_	_	O
89	deprivation	_	_	O
90	therapy	_	_	O
91	for	_	_	O
92	at	_	_	O
93	least	_	_	O
94	3	_	_	O
95	months	_	_	O
96	after	_	_	O
97	recruitment	_	_	O
98	were	_	_	O
99	randomly	_	_	O
100	assigned	_	_	O
101	to	_	_	O
102	an	_	_	O
103	intervention	_	_	O
104	group	_	_	O
105	that	_	_	O
106	participated	_	_	O
107	in	_	_	O
108	a	_	_	O
109	resistance	_	_	O
110	exercise	_	_	O
111	program	_	_	O
112	three	_	_	O
113	times	_	_	O
114	per	_	_	O
115	week	_	_	O
116	for	_	_	O
117	12	_	_	O
118	weeks	_	_	O
119	(	_	_	O
120	82	_	_	O
121	men	_	_	O
122	)	_	_	O
123	or	_	_	O
124	to	_	_	O
125	a	_	_	O
126	waiting	_	_	O
127	list	_	_	O
128	control	_	_	O
129	group	_	_	O
130	(	_	_	O
131	73	_	_	O
132	men	_	_	O
133	)	_	_	O
134	.	_	_	O

135	The	_	_	O
136	primary	_	_	O
137	outcomes	_	_	O
138	were	_	_	O
139	fatigue	_	_	O
140	and	_	_	O
141	disease	_	_	O
142	-	_	_	O
143	specific	_	_	O
144	quality	_	_	O
145	of	_	_	O
146	life	_	_	O
147	as	_	_	O
148	assessed	_	_	O
149	by	_	_	O
150	self	_	_	O
151	-	_	_	O
152	reported	_	_	O
153	questionnaires	_	_	O
154	after	_	_	O
155	12	_	_	O
156	weeks	_	_	O
157	.	_	_	O

158	Secondary	_	_	O
159	outcomes	_	_	O
160	were	_	_	O
161	muscular	_	_	O
162	fitness	_	_	O
163	and	_	_	O
164	body	_	_	O
165	composition	_	_	O
166	.	_	_	O

167	Men	_	_	B-Premise
168	assigned	_	_	I-Premise
169	to	_	_	I-Premise
170	resistance	_	_	I-Premise
171	exercise	_	_	I-Premise
172	had	_	_	I-Premise
173	less	_	_	I-Premise
174	interference	_	_	I-Premise
175	from	_	_	I-Premise
176	fatigue	_	_	I-Premise
177	on	_	_	I-Premise
178	activities	_	_	I-Premise
179	of	_	_	I-Premise
180	daily	_	_	I-Premise
181	living	_	_	I-Premise
182	(	_	_	I-Premise
183	P	_	_	I-Premise
184	=	_	_	I-Premise
185	.	_	_	I-Premise

186	002	_	_	I-Premise
187	)	_	_	I-Premise
188	and	_	_	I-Premise
189	higher	_	_	I-Premise
190	quality	_	_	I-Premise
191	of	_	_	I-Premise
192	life	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	=	_	_	I-Premise
196	.	_	_	I-Premise

197	001	_	_	I-Premise
198	)	_	_	I-Premise
199	than	_	_	I-Premise
200	men	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	control	_	_	I-Premise
204	group	_	_	I-Premise
205	.	_	_	I-Premise

206	Men	_	_	B-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	intervention	_	_	I-Premise
210	group	_	_	I-Premise
211	demonstrated	_	_	I-Premise
212	higher	_	_	I-Premise
213	levels	_	_	I-Premise
214	of	_	_	I-Premise
215	upper	_	_	I-Premise
216	body	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	.	_	_	I-Premise

221	009	_	_	I-Premise
222	)	_	_	I-Premise
223	and	_	_	I-Premise
224	lower	_	_	I-Premise
225	body	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	.	_	_	I-Premise

230	001	_	_	I-Premise
231	)	_	_	I-Premise
232	muscular	_	_	I-Premise
233	fitness	_	_	I-Premise
234	than	_	_	I-Premise
235	men	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	control	_	_	I-Premise
239	group	_	_	I-Premise
240	.	_	_	I-Premise

241	The	_	_	B-Premise
242	12	_	_	I-Premise
243	-	_	_	I-Premise
244	week	_	_	I-Premise
245	resistance	_	_	I-Premise
246	exercise	_	_	I-Premise
247	intervention	_	_	I-Premise
248	did	_	_	I-Premise
249	not	_	_	I-Premise
250	improve	_	_	I-Premise
251	body	_	_	I-Premise
252	composition	_	_	I-Premise
253	as	_	_	I-Premise
254	measured	_	_	I-Premise
255	by	_	_	I-Premise
256	changes	_	_	I-Premise
257	in	_	_	I-Premise
258	body	_	_	I-Premise
259	weight	_	_	I-Premise
260	,	_	_	I-Premise
261	body	_	_	I-Premise
262	mass	_	_	I-Premise
263	index	_	_	I-Premise
264	,	_	_	I-Premise
265	waist	_	_	I-Premise
266	circumference	_	_	I-Premise
267	,	_	_	I-Premise
268	or	_	_	I-Premise
269	subcutaneous	_	_	I-Premise
270	skinfolds	_	_	I-Premise
271	.	_	_	I-Premise

272	Resistance	_	_	B-Claim
273	exercise	_	_	I-Claim
274	reduces	_	_	I-Claim
275	fatigue	_	_	I-Claim
276	and	_	_	I-Claim
277	improves	_	_	I-Claim
278	quality	_	_	I-Claim
279	of	_	_	I-Claim
280	life	_	_	I-Claim
281	and	_	_	I-Claim
282	muscular	_	_	I-Claim
283	fitness	_	_	I-Claim
284	in	_	_	I-Claim
285	men	_	_	I-Claim
286	with	_	_	I-Claim
287	prostate	_	_	I-Claim
288	cancer	_	_	I-Claim
289	receiving	_	_	I-Claim
290	androgen	_	_	I-Claim
291	deprivation	_	_	I-Claim
292	therapy	_	_	I-Claim
293	.	_	_	I-Claim

294	This	_	_	B-Claim
295	form	_	_	I-Claim
296	of	_	_	I-Claim
297	exercise	_	_	I-Claim
298	can	_	_	I-Claim
299	be	_	_	I-Claim
300	an	_	_	I-Claim
301	important	_	_	I-Claim
302	component	_	_	I-Claim
303	of	_	_	I-Claim
304	supportive	_	_	I-Claim
305	care	_	_	I-Claim
306	for	_	_	I-Claim
307	these	_	_	I-Claim
308	patients	_	_	I-Claim
309	.	_	_	I-Claim


0	The	_	_	O
1	study	_	_	O
2	was	_	_	O
3	designed	_	_	O
4	to	_	_	O
5	compare	_	_	O
6	the	_	_	O
7	effects	_	_	O
8	of	_	_	O
9	treatment	_	_	O
10	with	_	_	O
11	a	_	_	O
12	combination	_	_	O
13	of	_	_	O
14	trastuzumab	_	_	O
15	(	_	_	O
16	Herceptin	_	_	O
17	;	_	_	O
18	Genentech	_	_	O
19	,	_	_	O
20	Inc	_	_	O
21	,	_	_	O
22	South	_	_	O
23	San	_	_	O
24	Francisco	_	_	O
25	,	_	_	O
26	CA	_	_	O
27	)	_	_	O
28	and	_	_	O
29	chemotherapy	_	_	O
30	versus	_	_	O
31	chemotherapy	_	_	O
32	alone	_	_	O
33	on	_	_	O
34	health	_	_	O
35	-	_	_	O
36	related	_	_	O
37	quality	_	_	O
38	of	_	_	O
39	life	_	_	O
40	(	_	_	O
41	HRQL	_	_	O
42	)	_	_	O
43	in	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	HER	_	_	O
47	-	_	_	O
48	2	_	_	O
49	/	_	_	O
50	neu	_	_	O
51	overexpressing	_	_	O
52	,	_	_	O
53	metastatic	_	_	O
54	breast	_	_	O
55	cancer	_	_	O
56	.	_	_	O

57	A	_	_	O
58	sample	_	_	O
59	of	_	_	O
60	400	_	_	O
61	patients	_	_	O
62	,	_	_	O
63	not	_	_	O
64	previously	_	_	O
65	treated	_	_	O
66	for	_	_	O
67	metastatic	_	_	O
68	disease	_	_	O
69	and	_	_	O
70	randomized	_	_	O
71	to	_	_	O
72	receive	_	_	O
73	either	_	_	O
74	trastuzumab	_	_	O
75	plus	_	_	O
76	chemotherapy	_	_	O
77	(	_	_	O
78	208	_	_	O
79	patients	_	_	O
80	)	_	_	O
81	or	_	_	O
82	chemotherapy	_	_	O
83	alone	_	_	O
84	(	_	_	O
85	192	_	_	O
86	patients	_	_	O
87	)	_	_	O
88	,	_	_	O
89	completed	_	_	O
90	the	_	_	O
91	European	_	_	O
92	Organization	_	_	O
93	for	_	_	O
94	Research	_	_	O
95	and	_	_	O
96	Treatment	_	_	O
97	Care	_	_	O
98	Quality	_	_	O
99	of	_	_	O
100	Life	_	_	O
101	Questionnaire	_	_	O
102	at	_	_	O
103	baseline	_	_	O
104	and	_	_	O
105	on	_	_	O
106	at	_	_	O
107	least	_	_	O
108	one	_	_	O
109	subsequent	_	_	O
110	occasion	_	_	O
111	at	_	_	O
112	8	_	_	O
113	,	_	_	O
114	20	_	_	O
115	,	_	_	O
116	32	_	_	O
117	,	_	_	O
118	44	_	_	O
119	,	_	_	O
120	and	_	_	O
121	56	_	_	O
122	weeks	_	_	O
123	.	_	_	O

124	HRQL	_	_	O
125	improvement	_	_	O
126	or	_	_	O
127	worsening	_	_	O
128	was	_	_	O
129	defined	_	_	O
130	as	_	_	O
131	a	_	_	O
132	>	_	_	O
133	or	_	_	O
134	=	_	_	O
135	10	_	_	O
136	-	_	_	O
137	point	_	_	O
138	change	_	_	O
139	(	_	_	O
140	range	_	_	O
141	,	_	_	O
142	0	_	_	O
143	to	_	_	O
144	100	_	_	O
145	points	_	_	O
146	)	_	_	O
147	in	_	_	O
148	the	_	_	O
149	scores	_	_	O
150	of	_	_	O
151	six	_	_	O
152	preselected	_	_	O
153	domains	_	_	O
154	(	_	_	O
155	global	_	_	O
156	quality	_	_	O
157	of	_	_	O
158	life	_	_	O
159	[	_	_	O
160	QOL	_	_	O
161	]	_	_	O
162	,	_	_	O
163	physical	_	_	O
164	,	_	_	O
165	role	_	_	O
166	,	_	_	O
167	social	_	_	O
168	,	_	_	O
169	and	_	_	O
170	emotional	_	_	O
171	functioning	_	_	O
172	,	_	_	O
173	and	_	_	O
174	fatigue	_	_	O
175	)	_	_	O
176	.	_	_	O

177	Stable	_	_	O
178	HRQL	_	_	O
179	was	_	_	O
180	defined	_	_	O
181	as	_	_	O
182	a	_	_	O
183	change	_	_	O
184	of	_	_	O
185	less	_	_	O
186	than	_	_	O
187	10	_	_	O
188	.	_	_	O

189	A	_	_	O
190	Bonferroni	_	_	O
191	correction	_	_	O
192	was	_	_	O
193	applied	_	_	O
194	for	_	_	O
195	multiple	_	_	O
196	testing	_	_	O
197	.	_	_	O

198	After	_	_	B-Premise
199	completion	_	_	I-Premise
200	of	_	_	I-Premise
201	chemotherapy	_	_	I-Premise
202	,	_	_	I-Premise
203	patients	_	_	I-Premise
204	treated	_	_	I-Premise
205	with	_	_	I-Premise
206	trastuzumab	_	_	I-Premise
207	and	_	_	I-Premise
208	chemotherapy	_	_	I-Premise
209	reported	_	_	I-Premise
210	significant	_	_	I-Premise
211	improvement	_	_	I-Premise
212	in	_	_	I-Premise
213	fatigue	_	_	I-Premise
214	(	_	_	I-Premise
215	P	_	_	I-Premise
216	<	_	_	I-Premise
217	.	_	_	I-Premise

218	05	_	_	I-Premise
219	)	_	_	I-Premise
220	as	_	_	I-Premise
221	compared	_	_	I-Premise
222	with	_	_	I-Premise
223	their	_	_	I-Premise
224	baseline	_	_	I-Premise
225	scores	_	_	I-Premise
226	.	_	_	I-Premise

227	Higher	_	_	B-Premise
228	proportions	_	_	I-Premise
229	of	_	_	I-Premise
230	patients	_	_	I-Premise
231	receiving	_	_	I-Premise
232	the	_	_	I-Premise
233	combined	_	_	I-Premise
234	therapy	_	_	I-Premise
235	achieved	_	_	I-Premise
236	improvement	_	_	I-Premise
237	in	_	_	I-Premise
238	global	_	_	I-Premise
239	QOL	_	_	I-Premise
240	(	_	_	I-Premise
241	P	_	_	I-Premise
242	<	_	_	I-Premise
243	.	_	_	I-Premise

244	05	_	_	I-Premise
245	)	_	_	I-Premise
246	than	_	_	I-Premise
247	did	_	_	I-Premise
248	patients	_	_	I-Premise
249	treated	_	_	I-Premise
250	with	_	_	I-Premise
251	chemotherapy	_	_	I-Premise
252	alone	_	_	I-Premise
253	.	_	_	I-Premise

254	Higher	_	_	B-Premise
255	proportions	_	_	I-Premise
256	of	_	_	I-Premise
257	the	_	_	I-Premise
258	combined	_	_	I-Premise
259	therapy	_	_	I-Premise
260	group	_	_	I-Premise
261	also	_	_	I-Premise
262	achieved	_	_	I-Premise
263	improvement	_	_	I-Premise
264	in	_	_	I-Premise
265	physical	_	_	I-Premise
266	and	_	_	I-Premise
267	role	_	_	I-Premise
268	functioning	_	_	I-Premise
269	and	_	_	I-Premise
270	in	_	_	I-Premise
271	fatigue	_	_	I-Premise
272	as	_	_	I-Premise
273	compared	_	_	I-Premise
274	with	_	_	I-Premise
275	the	_	_	I-Premise
276	chemotherapy	_	_	I-Premise
277	group	_	_	I-Premise
278	,	_	_	I-Premise
279	but	_	_	B-Premise
280	the	_	_	I-Premise
281	differences	_	_	I-Premise
282	were	_	_	I-Premise
283	not	_	_	I-Premise
284	statistically	_	_	I-Premise
285	significant	_	_	I-Premise
286	.	_	_	I-Premise

287	There	_	_	B-Premise
288	were	_	_	I-Premise
289	no	_	_	I-Premise
290	differences	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	proportions	_	_	I-Premise
294	of	_	_	I-Premise
295	patients	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	two	_	_	I-Premise
299	groups	_	_	I-Premise
300	that	_	_	I-Premise
301	reported	_	_	I-Premise
302	worsening	_	_	I-Premise
303	.	_	_	I-Premise

304	Statistically	_	_	B-Claim
305	significantly	_	_	I-Claim
306	higher	_	_	I-Claim
307	proportions	_	_	I-Claim
308	of	_	_	I-Claim
309	patients	_	_	I-Claim
310	treated	_	_	I-Claim
311	with	_	_	I-Claim
312	a	_	_	I-Claim
313	combination	_	_	I-Claim
314	of	_	_	I-Claim
315	trastuzumab	_	_	I-Claim
316	and	_	_	I-Claim
317	chemotherapy	_	_	I-Claim
318	reported	_	_	I-Claim
319	improved	_	_	I-Claim
320	global	_	_	I-Claim
321	QOL	_	_	I-Claim
322	than	_	_	I-Claim
323	did	_	_	I-Claim
324	patients	_	_	I-Claim
325	treated	_	_	I-Claim
326	by	_	_	I-Claim
327	chemotherapy	_	_	I-Claim
328	alone	_	_	I-Claim
329	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	determine	_	_	O
7	the	_	_	O
8	effectiveness	_	_	O
9	of	_	_	O
10	a	_	_	O
11	mindfulness	_	_	O
12	-	_	_	O
13	based	_	_	O
14	stress	_	_	O
15	-	_	_	O
16	reduction	_	_	O
17	(	_	_	O
18	MBSR	_	_	O
19	)	_	_	O
20	program	_	_	O
21	on	_	_	O
22	quality	_	_	O
23	of	_	_	O
24	life	_	_	O
25	(	_	_	O
26	QOL	_	_	O
27	)	_	_	O
28	and	_	_	O
29	psychosocial	_	_	O
30	outcomes	_	_	O
31	in	_	_	O
32	women	_	_	O
33	with	_	_	O
34	early	_	_	O
35	-	_	_	O
36	stage	_	_	O
37	breast	_	_	O
38	cancer	_	_	O
39	,	_	_	O
40	using	_	_	O
41	a	_	_	O
42	three	_	_	O
43	-	_	_	O
44	arm	_	_	O
45	randomized	_	_	O
46	controlled	_	_	O
47	clinical	_	_	O
48	trial	_	_	O
49	(	_	_	O
50	RCT	_	_	O
51	)	_	_	O
52	.	_	_	O

53	This	_	_	O
54	RCT	_	_	O
55	consisting	_	_	O
56	of	_	_	O
57	172	_	_	O
58	women	_	_	O
59	,	_	_	O
60	aged	_	_	O
61	20	_	_	O
62	-	_	_	O
63	65	_	_	O
64	with	_	_	O
65	stage	_	_	O
66	I	_	_	O
67	or	_	_	O
68	II	_	_	O
69	breast	_	_	O
70	cancer	_	_	O
71	consisted	_	_	O
72	of	_	_	O
73	the	_	_	O
74	8	_	_	O
75	-	_	_	O
76	week	_	_	O
77	MBSR	_	_	O
78	,	_	_	O
79	which	_	_	O
80	was	_	_	O
81	compared	_	_	O
82	to	_	_	O
83	a	_	_	O
84	nutrition	_	_	O
85	education	_	_	O
86	program	_	_	O
87	(	_	_	O
88	NEP	_	_	O
89	)	_	_	O
90	and	_	_	O
91	usual	_	_	O
92	supportive	_	_	O
93	care	_	_	O
94	(	_	_	O
95	UC	_	_	O
96	)	_	_	O
97	.	_	_	O

98	Follow	_	_	O
99	-	_	_	O
100	up	_	_	O
101	was	_	_	O
102	performed	_	_	O
103	at	_	_	O
104	three	_	_	O
105	post	_	_	O
106	-	_	_	O
107	intervention	_	_	O
108	points	_	_	O
109	:	_	_	O
110	4	_	_	O
111	months	_	_	O
112	,	_	_	O
113	1	_	_	O
114	,	_	_	O
115	and	_	_	O
116	2	_	_	O
117	years	_	_	O
118	.	_	_	O

119	Standardized	_	_	O
120	,	_	_	O
121	validated	_	_	O
122	self	_	_	O
123	-	_	_	O
124	administered	_	_	O
125	questionnaires	_	_	O
126	were	_	_	O
127	adopted	_	_	O
128	to	_	_	O
129	assess	_	_	O
130	psychosocial	_	_	O
131	variables	_	_	O
132	.	_	_	O

133	Statistical	_	_	O
134	analysis	_	_	O
135	included	_	_	O
136	descriptive	_	_	O
137	and	_	_	O
138	regression	_	_	O
139	analyses	_	_	O
140	incorporating	_	_	O
141	both	_	_	O
142	intention	_	_	O
143	-	_	_	O
144	to	_	_	O
145	-	_	_	O
146	treat	_	_	O
147	and	_	_	O
148	post	_	_	O
149	hoc	_	_	O
150	multivariable	_	_	O
151	approaches	_	_	O
152	of	_	_	O
153	the	_	_	O
154	163	_	_	O
155	women	_	_	O
156	with	_	_	O
157	complete	_	_	O
158	data	_	_	O
159	at	_	_	O
160	baseline	_	_	O
161	,	_	_	O
162	those	_	_	O
163	who	_	_	O
164	were	_	_	O
165	randomized	_	_	O
166	to	_	_	O
167	MBSR	_	_	O
168	experienced	_	_	O
169	a	_	_	O
170	significant	_	_	O
171	improvement	_	_	O
172	in	_	_	O
173	the	_	_	O
174	primary	_	_	O
175	measures	_	_	O
176	of	_	_	O
177	QOL	_	_	O
178	and	_	_	O
179	coping	_	_	O
180	outcomes	_	_	O
181	compared	_	_	O
182	to	_	_	O
183	the	_	_	O
184	NEP	_	_	O
185	,	_	_	O
186	UC	_	_	O
187	,	_	_	O
188	or	_	_	O
189	both	_	_	O
190	,	_	_	O
191	including	_	_	O
192	the	_	_	O
193	spirituality	_	_	O
194	subscale	_	_	O
195	of	_	_	O
196	the	_	_	O
197	FACT	_	_	O
198	-	_	_	O
199	B	_	_	O
200	as	_	_	O
201	well	_	_	O
202	as	_	_	O
203	dealing	_	_	O
204	with	_	_	O
205	illness	_	_	O
206	scale	_	_	O
207	increases	_	_	O
208	in	_	_	O
209	active	_	_	O
210	behavioral	_	_	O
211	coping	_	_	O
212	and	_	_	O
213	active	_	_	O
214	cognitive	_	_	O
215	coping	_	_	O
216	.	_	_	O

217	Secondary	_	_	B-Premise
218	outcome	_	_	I-Premise
219	improvements	_	_	I-Premise
220	resulting	_	_	I-Premise
221	in	_	_	I-Premise
222	significant	_	_	I-Premise
223	between	_	_	I-Premise
224	-	_	_	I-Premise
225	group	_	_	I-Premise
226	contrasts	_	_	I-Premise
227	favoring	_	_	I-Premise
228	the	_	_	I-Premise
229	MBSR	_	_	I-Premise
230	group	_	_	I-Premise
231	at	_	_	I-Premise
232	4	_	_	I-Premise
233	months	_	_	I-Premise
234	included	_	_	I-Premise
235	meaningfulness	_	_	I-Premise
236	,	_	_	I-Premise
237	depression	_	_	I-Premise
238	,	_	_	I-Premise
239	paranoid	_	_	I-Premise
240	ideation	_	_	I-Premise
241	,	_	_	I-Premise
242	hostility	_	_	I-Premise
243	,	_	_	I-Premise
244	anxiety	_	_	I-Premise
245	,	_	_	I-Premise
246	unhappiness	_	_	I-Premise
247	,	_	_	I-Premise
248	and	_	_	I-Premise
249	emotional	_	_	I-Premise
250	control	_	_	I-Premise
251	.	_	_	I-Premise

252	Results	_	_	B-Premise
253	tended	_	_	I-Premise
254	to	_	_	I-Premise
255	decline	_	_	I-Premise
256	at	_	_	I-Premise
257	12	_	_	I-Premise
258	months	_	_	I-Premise
259	and	_	_	I-Premise
260	even	_	_	I-Premise
261	more	_	_	I-Premise
262	at	_	_	I-Premise
263	24	_	_	I-Premise
264	months	_	_	I-Premise
265	,	_	_	I-Premise
266	though	_	_	I-Premise
267	at	_	_	I-Premise
268	all	_	_	I-Premise
269	times	_	_	I-Premise
270	,	_	_	I-Premise
271	they	_	_	I-Premise
272	were	_	_	I-Premise
273	as	_	_	I-Premise
274	robust	_	_	I-Premise
275	in	_	_	I-Premise
276	women	_	_	I-Premise
277	with	_	_	I-Premise
278	lower	_	_	I-Premise
279	expectation	_	_	I-Premise
280	of	_	_	I-Premise
281	effect	_	_	I-Premise
282	as	_	_	I-Premise
283	in	_	_	I-Premise
284	those	_	_	I-Premise
285	with	_	_	I-Premise
286	higher	_	_	I-Premise
287	expectation	_	_	I-Premise
288	.	_	_	I-Premise

289	The	_	_	B-Claim
290	MBSR	_	_	I-Claim
291	intervention	_	_	I-Claim
292	appears	_	_	I-Claim
293	to	_	_	I-Claim
294	benefit	_	_	I-Claim
295	psychosocial	_	_	I-Claim
296	adjustment	_	_	I-Claim
297	in	_	_	I-Claim
298	cancer	_	_	I-Claim
299	patients	_	_	I-Claim
300	,	_	_	I-Claim
301	over	_	_	I-Claim
302	and	_	_	I-Claim
303	above	_	_	I-Claim
304	the	_	_	I-Claim
305	effects	_	_	I-Claim
306	of	_	_	I-Claim
307	usual	_	_	I-Claim
308	care	_	_	I-Claim
309	or	_	_	I-Claim
310	a	_	_	I-Claim
311	credible	_	_	I-Claim
312	control	_	_	I-Claim
313	condition	_	_	I-Claim
314	.	_	_	I-Claim

315	The	_	_	B-Claim
316	universality	_	_	I-Claim
317	of	_	_	I-Claim
318	effects	_	_	I-Claim
319	across	_	_	I-Claim
320	levels	_	_	I-Claim
321	of	_	_	I-Claim
322	expectation	_	_	I-Claim
323	indicates	_	_	I-Claim
324	a	_	_	I-Claim
325	potential	_	_	I-Claim
326	to	_	_	I-Claim
327	utilize	_	_	I-Claim
328	this	_	_	I-Claim
329	stress	_	_	I-Claim
330	reduction	_	_	I-Claim
331	approach	_	_	I-Claim
332	as	_	_	I-Claim
333	complementary	_	_	I-Claim
334	therapy	_	_	I-Claim
335	in	_	_	I-Claim
336	oncologic	_	_	I-Claim
337	practice	_	_	I-Claim
338	.	_	_	I-Claim


0	The	_	_	O
1	standard	_	_	O
2	treatment	_	_	O
3	for	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	clinically	_	_	O
7	resectable	_	_	O
8	rectal	_	_	O
9	cancer	_	_	O
10	is	_	_	O
11	surgery	_	_	O
12	.	_	_	O

13	Postoperative	_	_	B-Claim
14	radiochemotherapy	_	_	I-Claim
15	(	_	_	I-Claim
16	RCT	_	_	I-Claim
17	)	_	_	I-Claim
18	is	_	_	I-Claim
19	recommended	_	_	I-Claim
20	for	_	_	I-Claim
21	advanced	_	_	I-Claim
22	disease	_	_	I-Claim
23	(	_	_	I-Claim
24	pT3	_	_	I-Claim
25	/	_	_	I-Claim
26	4	_	_	I-Claim
27	or	_	_	I-Claim
28	pN	_	_	I-Claim
29	+	_	_	I-Claim
30	)	_	_	I-Claim
31	.	_	_	I-Claim

32	In	_	_	O
33	recent	_	_	O
34	years	_	_	O
35	,	_	_	O
36	encouraging	_	_	O
37	results	_	_	O
38	of	_	_	O
39	pre	_	_	O
40	-	_	_	O
41	operative	_	_	O
42	radiotherapy	_	_	O
43	have	_	_	O
44	been	_	_	O
45	reported	_	_	O
46	.	_	_	O

47	This	_	_	O
48	prospective	_	_	O
49	randomized	_	_	O
50	phase	_	_	O
51	-	_	_	O
52	III	_	_	O
53	-	_	_	O
54	trial	_	_	O
55	(	_	_	O
56	CAO	_	_	O
57	/	_	_	O
58	ARO	_	_	O
59	/	_	_	O
60	AIO	_	_	O
61	-	_	_	O
62	94	_	_	O
63	)	_	_	O
64	compares	_	_	O
65	the	_	_	O
66	efficacy	_	_	O
67	of	_	_	O
68	neoadjuvant	_	_	O
69	RCT	_	_	O
70	to	_	_	O
71	standard	_	_	O
72	postoperative	_	_	O
73	RCT	_	_	O
74	.	_	_	O

75	We	_	_	O
76	report	_	_	O
77	on	_	_	O
78	the	_	_	O
79	design	_	_	O
80	of	_	_	O
81	the	_	_	O
82	study	_	_	O
83	and	_	_	O
84	first	_	_	O
85	results	_	_	O
86	with	_	_	O
87	regard	_	_	O
88	to	_	_	O
89	toxicity	_	_	O
90	of	_	_	O
91	RCT	_	_	O
92	and	_	_	O
93	postoperative	_	_	O
94	morbidity	_	_	O
95	.	_	_	O

96	Patients	_	_	O
97	with	_	_	O
98	locally	_	_	O
99	advanced	_	_	O
100	operable	_	_	O
101	rectal	_	_	O
102	cancer	_	_	O
103	(	_	_	O
104	uT3	_	_	O
105	/	_	_	O
106	4	_	_	O
107	or	_	_	O
108	uN	_	_	O
109	+	_	_	O
110	,	_	_	O
111	Mason	_	_	O
112	CS	_	_	O
113	III	_	_	O
114	/	_	_	O
115	IV	_	_	O
116	)	_	_	O
117	were	_	_	O
118	randomly	_	_	O
119	assigned	_	_	O
120	to	_	_	O
121	pre	_	_	O
122	or	_	_	O
123	postoperative	_	_	O
124	RCT	_	_	O
125	:	_	_	O
126	A	_	_	O
127	total	_	_	O
128	dose	_	_	O
129	of	_	_	O
130	50	_	_	O
131	.	_	_	O

132	4	_	_	O
133	Gy	_	_	O
134	(	_	_	O
135	single	_	_	O
136	dose	_	_	O
137	1	_	_	O
138	.	_	_	O

139	8	_	_	O
140	Gy	_	_	O
141	)	_	_	O
142	was	_	_	O
143	applied	_	_	O
144	to	_	_	O
145	the	_	_	O
146	tumour	_	_	O
147	and	_	_	O
148	the	_	_	O
149	pelvic	_	_	O
150	lymph	_	_	O
151	nodes	_	_	O
152	.	_	_	O

153	5	_	_	O
154	-	_	_	O
155	FU	_	_	O
156	(	_	_	O
157	1000	_	_	O
158	mg	_	_	O
159	/	_	_	O
160	m2	_	_	O
161	/	_	_	O
162	d	_	_	O
163	)	_	_	O
164	was	_	_	O
165	administered	_	_	O
166	concomitantly	_	_	O
167	in	_	_	O
168	the	_	_	O
169	1th	_	_	O
170	and	_	_	O
171	5th	_	_	O
172	week	_	_	O
173	of	_	_	O
174	radiation	_	_	O
175	as	_	_	O
176	120	_	_	O
177	h	_	_	O
178	-	_	_	O
179	continuous	_	_	O
180	infusion	_	_	O
181	.	_	_	O

182	Four	_	_	O
183	additional	_	_	O
184	cycles	_	_	O
185	of	_	_	O
186	5	_	_	O
187	-	_	_	O
188	FU	_	_	O
189	-	_	_	O
190	chemotherapy	_	_	O
191	(	_	_	O
192	500	_	_	O
193	mg	_	_	O
194	/	_	_	O
195	m2	_	_	O
196	/	_	_	O
197	d	_	_	O
198	,	_	_	O
199	i	_	_	O
200	.	_	_	O

201	v	_	_	O
202	.	_	_	O

203	-	_	_	O
204	bolus	_	_	O
205	)	_	_	O
206	were	_	_	O
207	applied	_	_	O
208	.	_	_	O

209	RCT	_	_	O
210	was	_	_	O
211	identical	_	_	O
212	in	_	_	O
213	both	_	_	O
214	arms	_	_	O
215	except	_	_	O
216	for	_	_	O
217	a	_	_	O
218	small	_	_	O
219	-	_	_	O
220	volume	_	_	O
221	boost	_	_	O
222	of	_	_	O
223	5	_	_	O
224	.	_	_	O

225	4	_	_	O
226	Gy	_	_	O
227	postoperatively	_	_	O
228	.	_	_	O

229	The	_	_	O
230	time	_	_	O
231	interval	_	_	O
232	between	_	_	O
233	RCT	_	_	O
234	and	_	_	O
235	surgery	_	_	O
236	was	_	_	O
237	4	_	_	O
238	-	_	_	O
239	6	_	_	O
240	weeks	_	_	O
241	in	_	_	O
242	both	_	_	O
243	arms	_	_	O
244	.	_	_	O

245	Techniques	_	_	O
246	of	_	_	O
247	surgery	_	_	O
248	were	_	_	O
249	standardized	_	_	O
250	and	_	_	O
251	included	_	_	O
252	total	_	_	O
253	mesorectal	_	_	O
254	excision	_	_	O
255	.	_	_	O

256	Primary	_	_	O
257	endpoints	_	_	O
258	of	_	_	O
259	the	_	_	O
260	study	_	_	O
261	are	_	_	O
262	5	_	_	O
263	-	_	_	O
264	year	_	_	O
265	survival	_	_	O
266	and	_	_	O
267	local	_	_	O
268	and	_	_	O
269	distant	_	_	O
270	control	_	_	O
271	.	_	_	O

272	Secondary	_	_	O
273	endpoints	_	_	O
274	include	_	_	O
275	the	_	_	O
276	rate	_	_	O
277	of	_	_	O
278	curative	_	_	O
279	(	_	_	O
280	R0	_	_	O
281	)	_	_	O
282	resection	_	_	O
283	and	_	_	O
284	sphincter	_	_	O
285	saving	_	_	O
286	procedures	_	_	O
287	,	_	_	O
288	toxicity	_	_	O
289	of	_	_	O
290	RCT	_	_	O
291	,	_	_	O
292	surgical	_	_	O
293	complications	_	_	O
294	and	_	_	O
295	quality	_	_	O
296	of	_	_	O
297	life	_	_	O
298	.	_	_	O

299	As	_	_	O
300	of	_	_	O
301	July	_	_	O
302	2002	_	_	O
303	,	_	_	O
304	805	_	_	O
305	patients	_	_	O
306	were	_	_	O
307	randomized	_	_	O
308	from	_	_	O
309	26	_	_	O
310	participating	_	_	O
311	institutions	_	_	O
312	.	_	_	O

313	Acute	_	_	B-Premise
314	toxicity	_	_	I-Premise
315	(	_	_	I-Premise
316	WHO	_	_	I-Premise
317	)	_	_	I-Premise
318	of	_	_	I-Premise
319	RCT	_	_	I-Premise
320	was	_	_	I-Premise
321	low	_	_	I-Premise
322	,	_	_	I-Premise
323	with	_	_	I-Premise
324	less	_	_	I-Premise
325	than	_	_	I-Premise
326	15	_	_	I-Premise
327	%	_	_	I-Premise
328	of	_	_	I-Premise
329	patients	_	_	I-Premise
330	experiencing	_	_	I-Premise
331	grade	_	_	I-Premise
332	3	_	_	I-Premise
333	or	_	_	I-Premise
334	higher	_	_	I-Premise
335	toxicity	_	_	I-Premise
336	:	_	_	O
337	The	_	_	B-Premise
338	principal	_	_	I-Premise
339	toxicity	_	_	I-Premise
340	was	_	_	I-Premise
341	diarrhea	_	_	I-Premise
342	,	_	_	I-Premise
343	with	_	_	I-Premise
344	12	_	_	I-Premise
345	%	_	_	I-Premise
346	in	_	_	I-Premise
347	the	_	_	I-Premise
348	postoperative	_	_	I-Premise
349	RCT	_	_	I-Premise
350	-	_	_	I-Premise
351	arm	_	_	I-Premise
352	and	_	_	I-Premise
353	11	_	_	I-Premise
354	%	_	_	I-Premise
355	in	_	_	I-Premise
356	the	_	_	I-Premise
357	pre	_	_	I-Premise
358	-	_	_	I-Premise
359	operative	_	_	I-Premise
360	RCT	_	_	I-Premise
361	-	_	_	I-Premise
362	arm	_	_	I-Premise
363	having	_	_	I-Premise
364	grade	_	_	I-Premise
365	3	_	_	I-Premise
366	-	_	_	I-Premise
367	,	_	_	I-Premise
368	and	_	_	I-Premise
369	1	_	_	I-Premise
370	%	_	_	I-Premise
371	in	_	_	I-Premise
372	either	_	_	I-Premise
373	arm	_	_	I-Premise
374	having	_	_	I-Premise
375	grade	_	_	I-Premise
376	4	_	_	I-Premise
377	-	_	_	I-Premise
378	diarrhea	_	_	I-Premise
379	.	_	_	I-Premise

380	Erythema	_	_	B-Premise
381	,	_	_	I-Premise
382	nausea	_	_	I-Premise
383	and	_	_	I-Premise
384	leukopenia	_	_	I-Premise
385	were	_	_	I-Premise
386	the	_	_	I-Premise
387	next	_	_	I-Premise
388	common	_	_	I-Premise
389	toxicities	_	_	I-Premise
390	,	_	_	I-Premise
391	with	_	_	I-Premise
392	less	_	_	I-Premise
393	than	_	_	I-Premise
394	3	_	_	I-Premise
395	%	_	_	I-Premise
396	of	_	_	I-Premise
397	patients	_	_	I-Premise
398	in	_	_	I-Premise
399	either	_	_	I-Premise
400	arm	_	_	I-Premise
401	suffering	_	_	I-Premise
402	grade	_	_	I-Premise
403	3	_	_	I-Premise
404	or	_	_	I-Premise
405	greater	_	_	I-Premise
406	leukopenia	_	_	I-Premise
407	or	_	_	I-Premise
408	nausea	_	_	I-Premise
409	.	_	_	I-Premise

410	Postoperative	_	_	B-Premise
411	complication	_	_	I-Premise
412	rates	_	_	I-Premise
413	were	_	_	I-Premise
414	similar	_	_	I-Premise
415	in	_	_	I-Premise
416	both	_	_	I-Premise
417	arms	_	_	I-Premise
418	,	_	_	I-Premise
419	with	_	_	I-Premise
420	12	_	_	I-Premise
421	%	_	_	I-Premise
422	(	_	_	I-Premise
423	postop	_	_	I-Premise
424	.	_	_	I-Premise

425	RCT	_	_	I-Premise
426	)	_	_	I-Premise
427	and	_	_	I-Premise
428	12	_	_	I-Premise
429	%	_	_	I-Premise
430	(	_	_	I-Premise
431	pre	_	_	I-Premise
432	-	_	_	I-Premise
433	op	_	_	I-Premise
434	.	_	_	I-Premise

435	RCT	_	_	I-Premise
436	)	_	_	I-Premise
437	of	_	_	I-Premise
438	patients	_	_	I-Premise
439	,	_	_	I-Premise
440	respectively	_	_	I-Premise
441	,	_	_	I-Premise
442	suffering	_	_	I-Premise
443	from	_	_	I-Premise
444	anastomotic	_	_	I-Premise
445	leakage	_	_	I-Premise
446	,	_	_	I-Premise
447	3	_	_	I-Premise
448	%	_	_	I-Premise
449	(	_	_	I-Premise
450	postop	_	_	I-Premise
451	.	_	_	I-Premise

452	RCT	_	_	I-Premise
453	)	_	_	I-Premise
454	and	_	_	I-Premise
455	3	_	_	I-Premise
456	%	_	_	I-Premise
457	(	_	_	I-Premise
458	pre	_	_	I-Premise
459	-	_	_	I-Premise
460	op	_	_	I-Premise
461	.	_	_	I-Premise

462	RCT	_	_	I-Premise
463	)	_	_	I-Premise
464	from	_	_	I-Premise
465	postoperative	_	_	I-Premise
466	bleeding	_	_	I-Premise
467	,	_	_	I-Premise
468	and	_	_	I-Premise
469	6	_	_	I-Premise
470	%	_	_	I-Premise
471	(	_	_	I-Premise
472	postop	_	_	I-Premise
473	.	_	_	I-Premise

474	RCT	_	_	I-Premise
475	)	_	_	I-Premise
476	and	_	_	I-Premise
477	4	_	_	I-Premise
478	%	_	_	I-Premise
479	(	_	_	I-Premise
480	pre	_	_	I-Premise
481	-	_	_	I-Premise
482	op	_	_	I-Premise
483	.	_	_	I-Premise

484	RCT	_	_	I-Premise
485	)	_	_	I-Premise
486	from	_	_	I-Premise
487	delayed	_	_	I-Premise
488	wound	_	_	I-Premise
489	healing	_	_	I-Premise
490	.	_	_	I-Premise

491	The	_	_	B-Claim
492	patient	_	_	I-Claim
493	accrual	_	_	I-Claim
494	to	_	_	I-Claim
495	the	_	_	I-Claim
496	trial	_	_	I-Claim
497	is	_	_	I-Claim
498	satisfactory	_	_	I-Claim
499	.	_	_	O

500	Neoadjuvant	_	_	B-Claim
501	RCT	_	_	I-Claim
502	is	_	_	I-Claim
503	well	_	_	I-Claim
504	tolerated	_	_	I-Claim
505	and	_	_	I-Claim
506	bears	_	_	I-Claim
507	no	_	_	I-Claim
508	higher	_	_	I-Claim
509	risk	_	_	I-Claim
510	for	_	_	I-Claim
511	postoperative	_	_	I-Claim
512	morbidity	_	_	I-Claim
513	.	_	_	I-Claim


0	To	_	_	O
1	observe	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	effectiveness	_	_	O
5	of	_	_	O
6	a	_	_	O
7	topical	_	_	O
8	application	_	_	O
9	of	_	_	O
10	Xiaozheng	_	_	O
11	Zhitong	_	_	O
12	:	_	_	O
13	Paste	_	_	O
14	(	_	_	O
15	,	_	_	O
16	XZP	_	_	O
17	)	_	_	O
18	in	_	_	O
19	alleviating	_	_	O
20	the	_	_	O
21	cancerous	_	_	O
22	pain	_	_	O
23	of	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	middle	_	_	O
27	/	_	_	O
28	late	_	_	O
29	stage	_	_	O
30	cancer	_	_	O
31	By	_	_	O
32	:	_	_	O
33	adopting	_	_	O
34	a	_	_	O
35	random	_	_	O
36	number	_	_	O
37	table	_	_	O
38	,	_	_	O
39	124	_	_	O
40	patients	_	_	O
41	enrolled	_	_	O
42	were	_	_	O
43	randomized	_	_	O
44	into	_	_	O
45	the	_	_	O
46	treatment	_	_	O
47	group	_	_	O
48	(	_	_	O
49	64	_	_	O
50	patients	_	_	O
51	)	_	_	O
52	and	_	_	O
53	the	_	_	O
54	control	_	_	O
55	group	_	_	O
56	(	_	_	O
57	60	_	_	O
58	patients	_	_	O
59	)	_	_	O
60	.	_	_	O

61	In	_	_	O
62	addition	_	_	O
63	to	_	_	O
64	the	_	_	O
65	basic	_	_	O
66	therapy	_	_	O
67	[	_	_	O
68	including	_	_	O
69	the	_	_	O
70	three	_	_	O
71	-	_	_	O
72	ladder	_	_	O
73	(	_	_	O
74	3L	_	_	O
75	)	_	_	O
76	analgesia	_	_	O
77	]	_	_	O
78	used	_	_	O
79	in	_	_	O
80	both	_	_	O
81	groups	_	_	O
82	,	_	_	O
83	topical	_	_	O
84	application	_	_	O
85	of	_	_	O
86	XZP	_	_	O
87	was	_	_	O
88	given	_	_	O
89	to	_	_	O
90	patients	_	_	O
91	in	_	_	O
92	the	_	_	O
93	treatment	_	_	O
94	group	_	_	O
95	for	_	_	O
96	pain	_	_	O
97	alleviation	_	_	O
98	.	_	_	O

99	The	_	_	O
100	analgesic	_	_	O
101	efficacy	_	_	O
102	was	_	_	O
103	recorded	_	_	O
104	in	_	_	O
105	terms	_	_	O
106	of	_	_	O
107	pain	_	_	O
108	intensity	_	_	O
109	,	_	_	O
110	analgesia	_	_	O
111	initiating	_	_	O
112	time	_	_	O
113	and	_	_	O
114	sustaining	_	_	O
115	time	_	_	O
116	,	_	_	O
117	and	_	_	O
118	the	_	_	O
119	optimal	_	_	O
120	analgesic	_	_	O
121	effect	_	_	O
122	revealing	_	_	O
123	time	_	_	O
124	.	_	_	O

125	Meanwhile	_	_	O
126	,	_	_	O
127	the	_	_	O
128	quality	_	_	O
129	of	_	_	O
130	life	_	_	O
131	(	_	_	O
132	QOL	_	_	O
133	)	_	_	O
134	and	_	_	O
135	adverse	_	_	O
136	reactions	_	_	O
137	that	_	_	O
138	occurred	_	_	O
139	in	_	_	O
140	patients	_	_	O
141	were	_	_	O
142	recorded	_	_	O
143	as	_	_	O
144	well	_	_	O
145	.	_	_	O

146	The	_	_	B-Premise
147	total	_	_	I-Premise
148	effective	_	_	I-Premise
149	rate	_	_	I-Premise
150	in	_	_	I-Premise
151	the	_	_	I-Premise
152	treatment	_	_	I-Premise
153	group	_	_	I-Premise
154	was	_	_	I-Premise
155	:	_	_	I-Premise
156	84	_	_	I-Premise
157	.	_	_	I-Premise

158	38	_	_	I-Premise
159	%	_	_	I-Premise
160	(	_	_	I-Premise
161	54	_	_	I-Premise
162	/	_	_	I-Premise
163	64	_	_	I-Premise
164	)	_	_	I-Premise
165	,	_	_	I-Premise
166	and	_	_	I-Premise
167	in	_	_	I-Premise
168	the	_	_	I-Premise
169	control	_	_	I-Premise
170	group	_	_	I-Premise
171	it	_	_	I-Premise
172	was	_	_	I-Premise
173	88	_	_	I-Premise
174	.	_	_	I-Premise

175	33	_	_	I-Premise
176	%	_	_	I-Premise
177	(	_	_	I-Premise
178	53	_	_	I-Premise
179	/	_	_	I-Premise
180	60	_	_	I-Premise
181	)	_	_	I-Premise
182	,	_	_	I-Premise
183	showing	_	_	I-Premise
184	no	_	_	I-Premise
185	significant	_	_	I-Premise
186	difference	_	_	I-Premise
187	between	_	_	I-Premise
188	them	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	>	_	_	I-Premise
192	0	_	_	I-Premise
193	.	_	_	I-Premise

194	05	_	_	I-Premise
195	)	_	_	I-Premise
196	,	_	_	I-Premise
197	but	_	_	B-Premise
198	the	_	_	I-Premise
199	analgesia	_	_	I-Premise
200	initiating	_	_	I-Premise
201	time	_	_	I-Premise
202	and	_	_	I-Premise
203	the	_	_	I-Premise
204	optimal	_	_	I-Premise
205	analgesia	_	_	I-Premise
206	effect	_	_	I-Premise
207	revealing	_	_	I-Premise
208	time	_	_	I-Premise
209	in	_	_	I-Premise
210	the	_	_	I-Premise
211	treatment	_	_	I-Premise
212	group	_	_	I-Premise
213	were	_	_	I-Premise
214	significantly	_	_	I-Premise
215	shorter	_	_	I-Premise
216	(	_	_	I-Premise
217	both	_	_	I-Premise
218	P	_	_	I-Premise
219	<	_	_	I-Premise
220	0	_	_	I-Premise
221	.	_	_	I-Premise

222	01	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	Moreover	_	_	O
226	,	_	_	O
227	XZP	_	_	B-Premise
228	was	_	_	I-Premise
229	better	_	_	I-Premise
230	in	_	_	I-Premise
231	improving	_	_	I-Premise
232	patients	_	_	I-Premise
233	'	_	_	I-Premise
234	QOL	_	_	I-Premise
235	,	_	_	I-Premise
236	showing	_	_	I-Premise
237	more	_	_	I-Premise
238	significant	_	_	I-Premise
239	improvements	_	_	I-Premise
240	in	_	_	I-Premise
241	the	_	_	I-Premise
242	treatment	_	_	I-Premise
243	group	_	_	I-Premise
244	than	_	_	I-Premise
245	those	_	_	I-Premise
246	in	_	_	I-Premise
247	the	_	_	I-Premise
248	control	_	_	I-Premise
249	group	_	_	I-Premise
250	in	_	_	I-Premise
251	aspects	_	_	I-Premise
252	of	_	_	I-Premise
253	mental	_	_	I-Premise
254	condition	_	_	I-Premise
255	,	_	_	I-Premise
256	walking	_	_	I-Premise
257	capacity	_	_	I-Premise
258	,	_	_	I-Premise
259	working	_	_	I-Premise
260	capacity	_	_	I-Premise
261	,	_	_	I-Premise
262	social	_	_	I-Premise
263	acceptability	_	_	I-Premise
264	,	_	_	I-Premise
265	sleep	_	_	I-Premise
266	and	_	_	I-Premise
267	joy	_	_	I-Premise
268	of	_	_	I-Premise
269	living	_	_	I-Premise
270	(	_	_	I-Premise
271	P	_	_	I-Premise
272	<	_	_	I-Premise
273	0	_	_	I-Premise
274	.	_	_	I-Premise

275	05	_	_	I-Premise
276	or	_	_	I-Premise
277	P	_	_	I-Premise
278	<	_	_	I-Premise
279	0	_	_	I-Premise
280	.	_	_	I-Premise

281	01	_	_	I-Premise
282	)	_	_	I-Premise
283	.	_	_	I-Premise

284	Lower	_	_	B-Premise
285	incidence	_	_	I-Premise
286	of	_	_	I-Premise
287	adverse	_	_	I-Premise
288	reactions	_	_	I-Premise
289	,	_	_	I-Premise
290	such	_	_	I-Premise
291	as	_	_	I-Premise
292	nausea	_	_	I-Premise
293	,	_	_	I-Premise
294	vomiting	_	_	I-Premise
295	,	_	_	I-Premise
296	mouth	_	_	I-Premise
297	dryness	_	_	I-Premise
298	,	_	_	I-Premise
299	dizziness	_	_	I-Premise
300	,	_	_	I-Premise
301	etc	_	_	I-Premise
302	.	_	_	I-Premise

303	,	_	_	I-Premise
304	especially	_	_	I-Premise
305	constipation	_	_	I-Premise
306	,	_	_	I-Premise
307	was	_	_	I-Premise
308	noted	_	_	I-Premise
309	in	_	_	I-Premise
310	the	_	_	I-Premise
311	treatment	_	_	I-Premise
312	group	_	_	I-Premise
313	(	_	_	I-Premise
314	P	_	_	I-Premise
315	<	_	_	I-Premise
316	0	_	_	I-Premise
317	.	_	_	I-Premise

318	05	_	_	I-Premise
319	or	_	_	I-Premise
320	P	_	_	I-Premise
321	<	_	_	I-Premise
322	0	_	_	I-Premise
323	.	_	_	I-Premise

324	01	_	_	I-Premise
325	)	_	_	I-Premise
326	.	_	_	I-Premise

327	Applying	_	_	B-Claim
328	an	_	_	I-Claim
329	external	_	_	I-Claim
330	compress	_	_	I-Claim
331	:	_	_	I-Claim
332	of	_	_	I-Claim
333	XZP	_	_	I-Claim
334	showed	_	_	I-Claim
335	a	_	_	I-Claim
336	synergistic	_	_	I-Claim
337	action	_	_	I-Claim
338	with	_	_	I-Claim
339	3L	_	_	I-Claim
340	analgesia	_	_	I-Claim
341	for	_	_	I-Claim
342	shortening	_	_	I-Claim
343	the	_	_	I-Claim
344	initiating	_	_	I-Claim
345	time	_	_	I-Claim
346	and	_	_	I-Claim
347	the	_	_	I-Claim
348	optimal	_	_	I-Claim
349	effect	_	_	I-Claim
350	revealing	_	_	I-Claim
351	time	_	_	I-Claim
352	,	_	_	I-Claim
353	and	_	_	I-Claim
354	could	_	_	I-Claim
355	evidently	_	_	I-Claim
356	enhance	_	_	I-Claim
357	patients	_	_	I-Claim
358	'	_	_	I-Claim
359	QOL	_	_	I-Claim
360	with	_	_	I-Claim
361	fewer	_	_	I-Claim
362	adverse	_	_	I-Claim
363	reactions	_	_	I-Claim
364	.	_	_	I-Claim


0	Sentinel	_	_	O
1	lymph	_	_	O
2	node	_	_	O
3	resection	_	_	O
4	(	_	_	O
5	SNR	_	_	O
6	)	_	_	O
7	may	_	_	O
8	reduce	_	_	O
9	morbidity	_	_	O
10	while	_	_	O
11	providing	_	_	O
12	the	_	_	O
13	same	_	_	O
14	clinical	_	_	O
15	utility	_	_	O
16	as	_	_	O
17	conventional	_	_	O
18	axillary	_	_	O
19	dissection	_	_	O
20	(	_	_	O
21	AD	_	_	O
22	)	_	_	O
23	.	_	_	O

24	National	_	_	O
25	Surgical	_	_	O
26	Adjuvant	_	_	O
27	Breast	_	_	O
28	and	_	_	O
29	Bowel	_	_	O
30	Project	_	_	O
31	(	_	_	O
32	NSABP	_	_	O
33	)	_	_	O
34	B	_	_	O
35	-	_	_	O
36	32	_	_	O
37	is	_	_	O
38	a	_	_	O
39	randomized	_	_	O
40	phase	_	_	O
41	III	_	_	O
42	trial	_	_	O
43	comparing	_	_	O
44	SNR	_	_	O
45	immediately	_	_	O
46	followed	_	_	O
47	by	_	_	O
48	AD	_	_	O
49	(	_	_	O
50	SNAD	_	_	O
51	)	_	_	O
52	to	_	_	O
53	SNR	_	_	O
54	and	_	_	O
55	subsequent	_	_	O
56	AD	_	_	O
57	if	_	_	O
58	SN	_	_	O
59	is	_	_	O
60	positive	_	_	O
61	.	_	_	O

62	We	_	_	O
63	report	_	_	O
64	the	_	_	O
65	definitive	_	_	O
66	patient	_	_	O
67	-	_	_	O
68	reported	_	_	O
69	outcomes	_	_	O
70	(	_	_	O
71	PRO	_	_	O
72	)	_	_	O
73	comparisons	_	_	O
74	.	_	_	O

75	Eligible	_	_	O
76	patients	_	_	O
77	had	_	_	O
78	clinically	_	_	O
79	node	_	_	O
80	-	_	_	O
81	negative	_	_	O
82	,	_	_	O
83	operable	_	_	O
84	invasive	_	_	O
85	breast	_	_	O
86	cancer	_	_	O
87	.	_	_	O

88	The	_	_	O
89	PRO	_	_	O
90	substudy	_	_	O
91	included	_	_	O
92	all	_	_	O
93	SN	_	_	O
94	-	_	_	O
95	negative	_	_	O
96	participants	_	_	O
97	enrolled	_	_	O
98	May	_	_	O
99	2001	_	_	O
100	to	_	_	O
101	February	_	_	O
102	2004	_	_	O
103	at	_	_	O
104	community	_	_	O
105	institutions	_	_	O
106	in	_	_	O
107	the	_	_	O
108	United	_	_	O
109	States	_	_	O
110	(	_	_	O
111	n	_	_	O
112	=	_	_	O
113	749	_	_	O
114	;	_	_	O
115	78	_	_	O
116	%	_	_	O
117	age	_	_	O
118	>	_	_	O
119	or	_	_	O
120	=	_	_	O
121	50	_	_	O
122	;	_	_	O
123	87	_	_	O
124	%	_	_	O
125	clinical	_	_	O
126	tumor	_	_	O
127	size	_	_	O
128	<	_	_	O
129	or	_	_	O
130	=	_	_	O
131	2	_	_	O
132	.	_	_	O

133	0	_	_	O
134	cm	_	_	O
135	;	_	_	O
136	84	_	_	O
137	%	_	_	O
138	lumpectomy	_	_	O
139	;	_	_	O
140	87	_	_	O
141	%	_	_	O
142	white	_	_	O
143	)	_	_	O
144	.	_	_	O

145	They	_	_	O
146	completed	_	_	O
147	questionnaires	_	_	O
148	presurgery	_	_	O
149	,	_	_	O
150	1	_	_	O
151	and	_	_	O
152	2	_	_	O
153	to	_	_	O
154	3	_	_	O
155	weeks	_	_	O
156	postoperatively	_	_	O
157	,	_	_	O
158	and	_	_	O
159	every	_	_	O
160	6	_	_	O
161	months	_	_	O
162	through	_	_	O
163	year	_	_	O
164	3	_	_	O
165	.	_	_	O

166	Arm	_	_	O
167	symptoms	_	_	O
168	,	_	_	O
169	arm	_	_	O
170	use	_	_	O
171	avoidance	_	_	O
172	,	_	_	O
173	activity	_	_	O
174	limitations	_	_	O
175	,	_	_	O
176	and	_	_	O
177	quality	_	_	O
178	of	_	_	O
179	life	_	_	O
180	(	_	_	O
181	QOL	_	_	O
182	)	_	_	O
183	were	_	_	O
184	compared	_	_	O
185	with	_	_	O
186	intent	_	_	O
187	-	_	_	O
188	to	_	_	O
189	-	_	_	O
190	treat	_	_	O
191	two	_	_	O
192	-	_	_	O
193	sample	_	_	O
194	t	_	_	O
195	-	_	_	O
196	tests	_	_	O
197	and	_	_	O
198	repeated	_	_	O
199	measures	_	_	O
200	analyses	_	_	O
201	.	_	_	O

202	Arm	_	_	B-Premise
203	symptoms	_	_	I-Premise
204	were	_	_	I-Premise
205	significantly	_	_	I-Premise
206	more	_	_	I-Premise
207	bothersome	_	_	I-Premise
208	for	_	_	I-Premise
209	SNAD	_	_	I-Premise
210	compared	_	_	I-Premise
211	with	_	_	I-Premise
212	SNR	_	_	I-Premise
213	patients	_	_	I-Premise
214	at	_	_	I-Premise
215	6	_	_	I-Premise
216	months	_	_	I-Premise
217	(	_	_	I-Premise
218	mean	_	_	I-Premise
219	,	_	_	I-Premise
220	4	_	_	I-Premise
221	.	_	_	I-Premise

222	8	_	_	I-Premise
223	v	_	_	I-Premise
224	3	_	_	I-Premise
225	.	_	_	I-Premise

226	0	_	_	I-Premise
227	;	_	_	I-Premise
228	P	_	_	I-Premise
229	<	_	_	I-Premise
230	.	_	_	I-Premise

231	001	_	_	I-Premise
232	)	_	_	I-Premise
233	and	_	_	I-Premise
234	at	_	_	I-Premise
235	12	_	_	I-Premise
236	months	_	_	I-Premise
237	(	_	_	I-Premise
238	3	_	_	I-Premise
239	.	_	_	I-Premise

240	6	_	_	I-Premise
241	v	_	_	I-Premise
242	2	_	_	I-Premise
243	.	_	_	I-Premise

244	5	_	_	I-Premise
245	;	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.	_	_	I-Premise

249	006	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Longitudinally	_	_	B-Premise
253	,	_	_	I-Premise
254	SNAD	_	_	I-Premise
255	patients	_	_	I-Premise
256	were	_	_	I-Premise
257	more	_	_	I-Premise
258	likely	_	_	I-Premise
259	to	_	_	I-Premise
260	experience	_	_	I-Premise
261	ipsilateral	_	_	I-Premise
262	arm	_	_	I-Premise
263	and	_	_	I-Premise
264	breast	_	_	I-Premise
265	symptoms	_	_	I-Premise
266	,	_	_	I-Premise
267	restricted	_	_	I-Premise
268	work	_	_	I-Premise
269	and	_	_	I-Premise
270	social	_	_	I-Premise
271	activity	_	_	I-Premise
272	,	_	_	I-Premise
273	and	_	_	I-Premise
274	impaired	_	_	I-Premise
275	QOL	_	_	I-Premise
276	(	_	_	I-Premise
277	P	_	_	I-Premise
278	<	_	_	I-Premise
279	or	_	_	I-Premise
280	=	_	_	I-Premise
281	.	_	_	I-Premise

282	002	_	_	I-Premise
283	all	_	_	I-Premise
284	items	_	_	I-Premise
285	)	_	_	I-Premise
286	.	_	_	I-Premise

287	From	_	_	B-Premise
288	12	_	_	I-Premise
289	to	_	_	I-Premise
290	36	_	_	I-Premise
291	months	_	_	I-Premise
292	,	_	_	I-Premise
293	fewer	_	_	I-Premise
294	than	_	_	I-Premise
295	15	_	_	I-Premise
296	%	_	_	I-Premise
297	of	_	_	I-Premise
298	either	_	_	I-Premise
299	SNAD	_	_	I-Premise
300	or	_	_	I-Premise
301	SNR	_	_	I-Premise
302	patients	_	_	I-Premise
303	reported	_	_	I-Premise
304	moderate	_	_	I-Premise
305	or	_	_	I-Premise
306	greater	_	_	I-Premise
307	severity	_	_	I-Premise
308	of	_	_	I-Premise
309	any	_	_	I-Premise
310	given	_	_	I-Premise
311	symptom	_	_	I-Premise
312	or	_	_	I-Premise
313	activity	_	_	I-Premise
314	limitation	_	_	I-Premise
315	.	_	_	I-Premise

316	Arm	_	_	B-Claim
317	morbidity	_	_	I-Claim
318	was	_	_	I-Claim
319	greater	_	_	I-Claim
320	with	_	_	I-Claim
321	SNAD	_	_	I-Claim
322	than	_	_	I-Claim
323	with	_	_	I-Claim
324	SNR	_	_	I-Claim
325	.	_	_	I-Claim

326	Despite	_	_	O
327	considerable	_	_	O
328	fears	_	_	O
329	about	_	_	O
330	complications	_	_	O
331	from	_	_	O
332	AD	_	_	O
333	for	_	_	O
334	breast	_	_	O
335	cancer	_	_	O
336	,	_	_	O
337	this	_	_	B-Claim
338	study	_	_	I-Claim
339	demonstrates	_	_	I-Claim
340	that	_	_	I-Claim
341	initial	_	_	I-Claim
342	problems	_	_	I-Claim
343	with	_	_	I-Claim
344	either	_	_	I-Claim
345	surgery	_	_	I-Claim
346	resolve	_	_	I-Claim
347	over	_	_	I-Claim
348	time	_	_	I-Claim
349	.	_	_	I-Claim


0	Colonic	_	_	O
1	pouches	_	_	O
2	have	_	_	O
3	been	_	_	O
4	used	_	_	O
5	for	_	_	O
6	20	_	_	O
7	years	_	_	O
8	to	_	_	O
9	provide	_	_	O
10	reservoir	_	_	O
11	function	_	_	O
12	after	_	_	O
13	reconstructive	_	_	O
14	proctectomy	_	_	O
15	for	_	_	O
16	rectal	_	_	O
17	cancer	_	_	O
18	.	_	_	O

19	More	_	_	B-Claim
20	recently	_	_	I-Claim
21	coloplasty	_	_	I-Claim
22	has	_	_	I-Claim
23	been	_	_	I-Claim
24	advocated	_	_	I-Claim
25	as	_	_	I-Claim
26	an	_	_	I-Claim
27	alternative	_	_	I-Claim
28	to	_	_	I-Claim
29	a	_	_	I-Claim
30	colonic	_	_	I-Claim
31	pouch	_	_	I-Claim
32	.	_	_	I-Claim

33	However	_	_	O
34	there	_	_	O
35	have	_	_	O
36	been	_	_	O
37	no	_	_	O
38	long	_	_	O
39	-	_	_	O
40	term	_	_	O
41	randomized	_	_	O
42	,	_	_	O
43	controlled	_	_	O
44	trials	_	_	O
45	to	_	_	O
46	compare	_	_	O
47	functional	_	_	O
48	outcomes	_	_	O
49	of	_	_	O
50	coloplasty	_	_	O
51	,	_	_	O
52	colonic	_	_	O
53	J	_	_	O
54	-	_	_	O
55	Pouch	_	_	O
56	(	_	_	O
57	JP	_	_	O
58	)	_	_	O
59	,	_	_	O
60	or	_	_	O
61	a	_	_	O
62	straight	_	_	O
63	anastomosis	_	_	O
64	(	_	_	O
65	SA	_	_	O
66	)	_	_	O
67	after	_	_	O
68	the	_	_	O
69	treatment	_	_	O
70	of	_	_	O
71	low	_	_	O
72	rectal	_	_	O
73	cancer	_	_	O
74	.	_	_	O

75	:	_	_	O
76	To	_	_	O
77	compare	_	_	O
78	the	_	_	O
79	complications	_	_	O
80	,	_	_	O
81	long	_	_	O
82	-	_	_	O
83	term	_	_	O
84	functional	_	_	O
85	outcome	_	_	O
86	,	_	_	O
87	and	_	_	O
88	quality	_	_	O
89	of	_	_	O
90	life	_	_	O
91	(	_	_	O
92	QOL	_	_	O
93	)	_	_	O
94	of	_	_	O
95	patients	_	_	O
96	undergoing	_	_	O
97	a	_	_	O
98	coloplasty	_	_	O
99	,	_	_	O
100	JP	_	_	O
101	,	_	_	O
102	or	_	_	O
103	an	_	_	O
104	SA	_	_	O
105	in	_	_	O
106	reconstruction	_	_	O
107	of	_	_	O
108	the	_	_	O
109	lower	_	_	O
110	gastrointestinal	_	_	O
111	tract	_	_	O
112	after	_	_	O
113	proctectomy	_	_	O
114	for	_	_	O
115	low	_	_	O
116	rectal	_	_	O
117	cancer	_	_	O
118	.	_	_	O

119	A	_	_	O
120	multicenter	_	_	O
121	study	_	_	O
122	enrolled	_	_	O
123	patients	_	_	O
124	with	_	_	O
125	low	_	_	O
126	rectal	_	_	O
127	cancer	_	_	O
128	,	_	_	O
129	who	_	_	O
130	were	_	_	O
131	randomized	_	_	O
132	intraoperatively	_	_	O
133	to	_	_	O
134	coloplasty	_	_	O
135	(	_	_	O
136	CP	_	_	O
137	-	_	_	O
138	1	_	_	O
139	)	_	_	O
140	or	_	_	O
141	SA	_	_	O
142	if	_	_	O
143	JP	_	_	O
144	was	_	_	O
145	not	_	_	O
146	feasible	_	_	O
147	,	_	_	O
148	or	_	_	O
149	JP	_	_	O
150	or	_	_	O
151	coloplasty	_	_	O
152	(	_	_	O
153	CP	_	_	O
154	-	_	_	O
155	2	_	_	O
156	)	_	_	O
157	if	_	_	O
158	a	_	_	O
159	JP	_	_	O
160	was	_	_	O
161	feasible	_	_	O
162	.	_	_	O

163	Patients	_	_	O
164	were	_	_	O
165	followed	_	_	O
166	for	_	_	O
167	24	_	_	O
168	months	_	_	O
169	with	_	_	O
170	SF	_	_	O
171	-	_	_	O
172	36	_	_	O
173	surveys	_	_	O
174	to	_	_	O
175	evaluate	_	_	O
176	the	_	_	O
177	QOL	_	_	O
178	.	_	_	O

179	Bowel	_	_	O
180	function	_	_	O
181	was	_	_	O
182	measured	_	_	O
183	quantitatively	_	_	O
184	and	_	_	O
185	using	_	_	O
186	Fecal	_	_	O
187	Incontinence	_	_	O
188	Severity	_	_	O
189	Index	_	_	O
190	(	_	_	O
191	FISI	_	_	O
192	)	_	_	O
193	.	_	_	O

194	Urinary	_	_	O
195	function	_	_	O
196	and	_	_	O
197	sexual	_	_	O
198	function	_	_	O
199	were	_	_	O
200	also	_	_	O
201	assessed	_	_	O
202	.	_	_	O

203	Three	_	_	O
204	hundred	_	_	O
205	sixty	_	_	O
206	-	_	_	O
207	four	_	_	O
208	patients	_	_	O
209	were	_	_	O
210	randomized	_	_	O
211	.	_	_	O

212	All	_	_	O
213	patients	_	_	O
214	were	_	_	O
215	evaluated	_	_	O
216	for	_	_	O
217	complications	_	_	O
218	and	_	_	O
219	recurrence	_	_	O
220	.	_	_	O

221	Mean	_	_	O
222	age	_	_	O
223	was	_	_	O
224	60	_	_	O
225	+	_	_	O
226	/	_	_	O
227	-	_	_	O
228	12	_	_	O
229	years	_	_	O
230	,	_	_	O
231	71	_	_	O
232	%	_	_	O
233	were	_	_	O
234	male	_	_	O
235	.	_	_	O

236	Twenty	_	_	B-Premise
237	-	_	_	I-Premise
238	three	_	_	I-Premise
239	(	_	_	I-Premise
240	7	_	_	I-Premise
241	.	_	_	I-Premise

242	4	_	_	I-Premise
243	%	_	_	I-Premise
244	)	_	_	I-Premise
245	died	_	_	I-Premise
246	within	_	_	I-Premise
247	24	_	_	I-Premise
248	months	_	_	I-Premise
249	of	_	_	I-Premise
250	surgery	_	_	I-Premise
251	.	_	_	I-Premise

252	No	_	_	B-Premise
253	significant	_	_	I-Premise
254	difference	_	_	I-Premise
255	was	_	_	I-Premise
256	observed	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	complications	_	_	I-Premise
260	among	_	_	I-Premise
261	the	_	_	I-Premise
262	4	_	_	I-Premise
263	groups	_	_	I-Premise
264	.	_	_	I-Premise

265	Two	_	_	O
266	hundred	_	_	O
267	ninety	_	_	O
268	-	_	_	O
269	seven	_	_	O
270	of	_	_	O
271	364	_	_	O
272	were	_	_	O
273	evaluated	_	_	O
274	for	_	_	O
275	functional	_	_	O
276	outcome	_	_	O
277	at	_	_	O
278	24	_	_	O
279	months	_	_	O
280	.	_	_	O

281	There	_	_	B-Premise
282	was	_	_	I-Premise
283	no	_	_	I-Premise
284	difference	_	_	I-Premise
285	in	_	_	I-Premise
286	bowel	_	_	I-Premise
287	function	_	_	I-Premise
288	between	_	_	I-Premise
289	the	_	_	I-Premise
290	CP	_	_	I-Premise
291	-	_	_	I-Premise
292	1	_	_	I-Premise
293	and	_	_	I-Premise
294	SA	_	_	I-Premise
295	groups	_	_	I-Premise
296	.	_	_	I-Premise

297	JP	_	_	B-Premise
298	patients	_	_	I-Premise
299	had	_	_	I-Premise
300	fewer	_	_	I-Premise
301	bowel	_	_	I-Premise
302	movements	_	_	I-Premise
303	,	_	_	I-Premise
304	less	_	_	I-Premise
305	clustering	_	_	I-Premise
306	,	_	_	I-Premise
307	used	_	_	I-Premise
308	fewer	_	_	I-Premise
309	pads	_	_	I-Premise
310	and	_	_	I-Premise
311	had	_	_	I-Premise
312	a	_	_	I-Premise
313	lower	_	_	I-Premise
314	FISI	_	_	I-Premise
315	than	_	_	I-Premise
316	the	_	_	I-Premise
317	CP	_	_	I-Premise
318	-	_	_	I-Premise
319	2	_	_	I-Premise
320	group	_	_	I-Premise
321	.	_	_	I-Premise

322	Other	_	_	B-Premise
323	parameters	_	_	I-Premise
324	were	_	_	I-Premise
325	not	_	_	I-Premise
326	statistically	_	_	I-Premise
327	different	_	_	I-Premise
328	.	_	_	I-Premise

329	QOL	_	_	B-Premise
330	scores	_	_	I-Premise
331	at	_	_	I-Premise
332	24	_	_	I-Premise
333	months	_	_	I-Premise
334	were	_	_	I-Premise
335	similar	_	_	I-Premise
336	for	_	_	I-Premise
337	each	_	_	I-Premise
338	of	_	_	I-Premise
339	the	_	_	I-Premise
340	4	_	_	I-Premise
341	groups	_	_	I-Premise
342	.	_	_	I-Premise

343	In	_	_	B-Claim
344	patients	_	_	I-Claim
345	undergoing	_	_	I-Claim
346	a	_	_	I-Claim
347	restorative	_	_	I-Claim
348	resection	_	_	I-Claim
349	for	_	_	I-Claim
350	low	_	_	I-Claim
351	rectal	_	_	I-Claim
352	cancer	_	_	I-Claim
353	,	_	_	I-Claim
354	a	_	_	I-Claim
355	colonic	_	_	I-Claim
356	JP	_	_	I-Claim
357	offers	_	_	I-Claim
358	significant	_	_	I-Claim
359	advantages	_	_	I-Claim
360	in	_	_	I-Claim
361	function	_	_	I-Claim
362	over	_	_	I-Claim
363	an	_	_	I-Claim
364	SA	_	_	I-Claim
365	or	_	_	I-Claim
366	a	_	_	I-Claim
367	coloplasty	_	_	I-Claim
368	.	_	_	I-Claim

369	In	_	_	B-Claim
370	patients	_	_	I-Claim
371	who	_	_	I-Claim
372	cannot	_	_	I-Claim
373	have	_	_	I-Claim
374	a	_	_	I-Claim
375	pouch	_	_	I-Claim
376	,	_	_	I-Claim
377	coloplasty	_	_	I-Claim
378	seems	_	_	I-Claim
379	not	_	_	I-Claim
380	to	_	_	I-Claim
381	improve	_	_	I-Claim
382	the	_	_	I-Claim
383	bowel	_	_	I-Claim
384	function	_	_	I-Claim
385	of	_	_	I-Claim
386	patients	_	_	I-Claim
387	over	_	_	I-Claim
388	that	_	_	I-Claim
389	with	_	_	I-Claim
390	an	_	_	I-Claim
391	SA	_	_	I-Claim
392	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	a	_	_	O
8	slow	_	_	O
9	-	_	_	O
10	release	_	_	O
11	formulation	_	_	O
12	of	_	_	O
13	cytarabine	_	_	O
14	(	_	_	O
15	DepoCyt	_	_	O
16	;	_	_	O
17	Chiron	_	_	O
18	Corp	_	_	O
19	,	_	_	O
20	Emeryville	_	_	O
21	,	_	_	O
22	CA	_	_	O
23	,	_	_	O
24	and	_	_	O
25	Skye	_	_	O
26	Pharma	_	_	O
27	,	_	_	O
28	Inc	_	_	O
29	,	_	_	O
30	San	_	_	O
31	Diego	_	_	O
32	,	_	_	O
33	CA	_	_	O
34	)	_	_	O
35	that	_	_	O
36	maintains	_	_	O
37	cytotoxic	_	_	O
38	concentrations	_	_	O
39	of	_	_	O
40	cytarabine	_	_	O
41	(	_	_	O
42	ara	_	_	O
43	-	_	_	O
44	C	_	_	O
45	)	_	_	O
46	in	_	_	O
47	the	_	_	O
48	CSF	_	_	O
49	of	_	_	O
50	most	_	_	O
51	patients	_	_	O
52	for	_	_	O
53	more	_	_	O
54	than	_	_	O
55	14	_	_	O
56	days	_	_	O
57	.	_	_	O

58	Twenty	_	_	O
59	-	_	_	O
60	eight	_	_	O
61	patients	_	_	O
62	with	_	_	O
63	lymphoma	_	_	O
64	and	_	_	O
65	a	_	_	O
66	positive	_	_	O
67	CSF	_	_	O
68	cytology	_	_	O
69	were	_	_	O
70	randomized	_	_	O
71	to	_	_	O
72	receive	_	_	O
73	DepoCyt	_	_	O
74	50	_	_	O
75	mg	_	_	O
76	once	_	_	O
77	every	_	_	O
78	2	_	_	O
79	weeks	_	_	O
80	or	_	_	O
81	free	_	_	O
82	ara	_	_	O
83	-	_	_	O
84	C	_	_	O
85	50	_	_	O
86	mg	_	_	O
87	twice	_	_	O
88	a	_	_	O
89	week	_	_	O
90	for	_	_	O
91	1	_	_	O
92	month	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	whose	_	_	O
96	CSF	_	_	O
97	cytology	_	_	O
98	converted	_	_	O
99	to	_	_	O
100	negative	_	_	O
101	and	_	_	O
102	who	_	_	O
103	did	_	_	O
104	not	_	_	O
105	have	_	_	O
106	neurologic	_	_	O
107	progression	_	_	O
108	received	_	_	O
109	an	_	_	O
110	additional	_	_	O
111	3	_	_	O
112	months	_	_	O
113	of	_	_	O
114	consolidation	_	_	O
115	therapy	_	_	O
116	and	_	_	O
117	then	_	_	O
118	4	_	_	O
119	months	_	_	O
120	of	_	_	O
121	maintenance	_	_	O
122	therapy	_	_	O
123	.	_	_	O

124	All	_	_	O
125	patients	_	_	O
126	received	_	_	O
127	dexamethasone	_	_	O
128	4	_	_	O
129	mg	_	_	O
130	orally	_	_	O
131	bid	_	_	O
132	on	_	_	O
133	days	_	_	O
134	1	_	_	O
135	through	_	_	O
136	5	_	_	O
137	of	_	_	O
138	each	_	_	O
139	2	_	_	O
140	-	_	_	O
141	week	_	_	O
142	cycle	_	_	O
143	.	_	_	O

144	The	_	_	B-Premise
145	response	_	_	I-Premise
146	rate	_	_	I-Premise
147	was	_	_	I-Premise
148	71	_	_	I-Premise
149	%	_	_	I-Premise
150	for	_	_	I-Premise
151	DepoCyt	_	_	I-Premise
152	and	_	_	I-Premise
153	15	_	_	I-Premise
154	%	_	_	I-Premise
155	for	_	_	I-Premise
156	ara	_	_	I-Premise
157	-	_	_	I-Premise
158	C	_	_	I-Premise
159	on	_	_	I-Premise
160	an	_	_	I-Premise
161	intent	_	_	I-Premise
162	-	_	_	I-Premise
163	to	_	_	I-Premise
164	-	_	_	I-Premise
165	treat	_	_	I-Premise
166	basis	_	_	I-Premise
167	(	_	_	I-Premise
168	P	_	_	I-Premise
169	=	_	_	I-Premise
170	.	_	_	I-Premise

171	006	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	All	_	_	B-Premise
175	of	_	_	I-Premise
176	the	_	_	I-Premise
177	patients	_	_	I-Premise
178	on	_	_	I-Premise
179	the	_	_	I-Premise
180	DepoCyt	_	_	I-Premise
181	arm	_	_	I-Premise
182	but	_	_	I-Premise
183	only	_	_	I-Premise
184	53	_	_	I-Premise
185	%	_	_	I-Premise
186	of	_	_	I-Premise
187	those	_	_	I-Premise
188	on	_	_	I-Premise
189	the	_	_	I-Premise
190	ara	_	_	I-Premise
191	-	_	_	I-Premise
192	C	_	_	I-Premise
193	arm	_	_	I-Premise
194	were	_	_	I-Premise
195	able	_	_	I-Premise
196	to	_	_	I-Premise
197	complete	_	_	I-Premise
198	the	_	_	I-Premise
199	planned	_	_	I-Premise
200	1	_	_	I-Premise
201	-	_	_	I-Premise
202	month	_	_	I-Premise
203	induction	_	_	I-Premise
204	therapy	_	_	I-Premise
205	regimen	_	_	I-Premise
206	.	_	_	I-Premise

207	Time	_	_	B-Premise
208	to	_	_	I-Premise
209	neurologic	_	_	I-Premise
210	progression	_	_	I-Premise
211	and	_	_	I-Premise
212	survival	_	_	I-Premise
213	trend	_	_	I-Premise
214	in	_	_	I-Premise
215	favor	_	_	I-Premise
216	of	_	_	I-Premise
217	DepoCyt	_	_	I-Premise
218	(	_	_	I-Premise
219	median	_	_	I-Premise
220	,	_	_	I-Premise
221	78	_	_	I-Premise
222	.	_	_	I-Premise

223	5	_	_	I-Premise
224	v	_	_	I-Premise
225	42	_	_	I-Premise
226	days	_	_	I-Premise
227	and	_	_	I-Premise
228	99	_	_	I-Premise
229	.	_	_	I-Premise

230	5	_	_	I-Premise
231	v	_	_	I-Premise
232	63	_	_	I-Premise
233	days	_	_	I-Premise
234	,	_	_	I-Premise
235	respectively	_	_	I-Premise
236	;	_	_	I-Premise
237	P	_	_	I-Premise
238	>	_	_	I-Premise
239	.	_	_	I-Premise

240	05	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	DepoCyt	_	_	B-Premise
244	treatment	_	_	I-Premise
245	was	_	_	I-Premise
246	associated	_	_	I-Premise
247	with	_	_	I-Premise
248	an	_	_	I-Premise
249	improved	_	_	I-Premise
250	mean	_	_	I-Premise
251	change	_	_	I-Premise
252	in	_	_	I-Premise
253	Karnofsky	_	_	I-Premise
254	performance	_	_	I-Premise
255	score	_	_	I-Premise
256	at	_	_	I-Premise
257	the	_	_	I-Premise
258	end	_	_	I-Premise
259	of	_	_	I-Premise
260	induction	_	_	I-Premise
261	(	_	_	I-Premise
262	P	_	_	I-Premise
263	=	_	_	I-Premise
264	.	_	_	I-Premise

265	041	_	_	I-Premise
266	)	_	_	I-Premise
267	.	_	_	I-Premise

268	The	_	_	B-Premise
269	major	_	_	I-Premise
270	adverse	_	_	I-Premise
271	events	_	_	I-Premise
272	on	_	_	I-Premise
273	both	_	_	I-Premise
274	arms	_	_	I-Premise
275	were	_	_	I-Premise
276	headache	_	_	I-Premise
277	and	_	_	I-Premise
278	arachnoiditis	_	_	I-Premise
279	,	_	_	I-Premise
280	which	_	_	I-Premise
281	were	_	_	I-Premise
282	often	_	_	I-Premise
283	caused	_	_	I-Premise
284	by	_	_	I-Premise
285	the	_	_	I-Premise
286	underlying	_	_	I-Premise
287	disease	_	_	I-Premise
288	.	_	_	I-Premise

289	DepoCyt	_	_	B-Claim
290	injected	_	_	I-Claim
291	once	_	_	I-Claim
292	every	_	_	I-Claim
293	2	_	_	I-Claim
294	weeks	_	_	I-Claim
295	produced	_	_	I-Claim
296	a	_	_	I-Claim
297	high	_	_	I-Claim
298	response	_	_	I-Claim
299	rate	_	_	I-Claim
300	and	_	_	I-Claim
301	a	_	_	I-Claim
302	better	_	_	I-Claim
303	quality	_	_	I-Claim
304	of	_	_	I-Claim
305	life	_	_	I-Claim
306	as	_	_	I-Claim
307	measured	_	_	I-Claim
308	by	_	_	I-Claim
309	Karnofsky	_	_	I-Claim
310	score	_	_	I-Claim
311	relative	_	_	I-Claim
312	to	_	_	I-Claim
313	that	_	_	I-Claim
314	produced	_	_	I-Claim
315	by	_	_	I-Claim
316	free	_	_	I-Claim
317	ara	_	_	I-Claim
318	-	_	_	I-Claim
319	C	_	_	I-Claim
320	injected	_	_	I-Claim
321	twice	_	_	I-Claim
322	a	_	_	I-Claim
323	week	_	_	I-Claim
324	.	_	_	I-Claim


0	In	_	_	O
1	1980	_	_	O
2	the	_	_	O
3	EORTC	_	_	O
4	-	_	_	O
5	BCCG	_	_	O
6	initiated	_	_	O
7	a	_	_	O
8	multicentre	_	_	O
9	randomised	_	_	O
10	clinical	_	_	O
11	trial	_	_	O
12	comparing	_	_	O
13	modified	_	_	O
14	radical	_	_	O
15	mastectomy	_	_	O
16	(	_	_	O
17	MRM	_	_	O
18	)	_	_	O
19	with	_	_	O
20	breast	_	_	O
21	-	_	_	O
22	conserving	_	_	O
23	therapy	_	_	O
24	(	_	_	O
25	BCT	_	_	O
26	)	_	_	O
27	in	_	_	O
28	stage	_	_	O
29	I	_	_	O
30	and	_	_	O
31	II	_	_	O
32	breast	_	_	O
33	cancer	_	_	O
34	.	_	_	O

35	The	_	_	O
36	main	_	_	O
37	endpoint	_	_	O
38	of	_	_	O
39	the	_	_	O
40	trial	_	_	O
41	was	_	_	O
42	survival	_	_	O
43	.	_	_	O

44	A	_	_	O
45	brief	_	_	O
46	quality	_	_	O
47	of	_	_	O
48	life	_	_	O
49	(	_	_	O
50	QoL	_	_	O
51	)	_	_	O
52	questionnaire	_	_	O
53	consisting	_	_	O
54	of	_	_	O
55	two	_	_	O
56	multi	_	_	O
57	-	_	_	O
58	item	_	_	O
59	scales	_	_	O
60	(	_	_	O
61	body	_	_	O
62	image	_	_	O
63	and	_	_	O
64	fear	_	_	O
65	of	_	_	O
66	recurrence	_	_	O
67	)	_	_	O
68	and	_	_	O
69	two	_	_	O
70	single	_	_	O
71	items	_	_	O
72	(	_	_	O
73	satisfaction	_	_	O
74	with	_	_	O
75	treatment	_	_	O
76	and	_	_	O
77	cosmetic	_	_	O
78	result	_	_	O
79	)	_	_	O
80	was	_	_	O
81	included	_	_	O
82	in	_	_	O
83	the	_	_	O
84	trial	_	_	O
85	.	_	_	O

86	A	_	_	O
87	cosmetic	_	_	O
88	evaluation	_	_	O
89	of	_	_	O
90	the	_	_	O
91	breast	_	_	O
92	after	_	_	O
93	conservative	_	_	O
94	surgery	_	_	O
95	was	_	_	O
96	also	_	_	O
97	performed	_	_	O
98	.	_	_	O

99	This	_	_	O
100	report	_	_	O
101	concentrates	_	_	O
102	on	_	_	O
103	the	_	_	O
104	results	_	_	O
105	of	_	_	O
106	the	_	_	O
107	QoL	_	_	O
108	study	_	_	O
109	and	_	_	O
110	the	_	_	O
111	cosmetic	_	_	O
112	evaluation	_	_	O
113	.	_	_	O

114	Multitrait	_	_	O
115	scaling	_	_	O
116	analysis	_	_	O
117	was	_	_	O
118	employed	_	_	O
119	to	_	_	O
120	verify	_	_	O
121	the	_	_	O
122	hypothesised	_	_	O
123	scale	_	_	O
124	structure	_	_	O
125	of	_	_	O
126	the	_	_	O
127	questionnaire	_	_	O
128	.	_	_	O

129	Treatment	_	_	O
130	comparison	_	_	O
131	of	_	_	O
132	the	_	_	O
133	QoL	_	_	O
134	scores	_	_	O
135	at	_	_	O
136	2	_	_	O
137	years	_	_	O
138	post	_	_	O
139	-	_	_	O
140	treatment	_	_	O
141	was	_	_	O
142	performed	_	_	O
143	using	_	_	O
144	a	_	_	O
145	stratified	_	_	O
146	Wilcoxon	_	_	O
147	rank	_	_	O
148	sum	_	_	O
149	test	_	_	O
150	.	_	_	O

151	Both	_	_	O
152	patients	_	_	O
153	'	_	_	O
154	and	_	_	O
155	doctors	_	_	O
156	'	_	_	O
157	ratings	_	_	O
158	of	_	_	O
159	the	_	_	O
160	cosmetic	_	_	O
161	result	_	_	O
162	were	_	_	O
163	documented	_	_	O
164	on	_	_	O
165	the	_	_	O
166	clinical	_	_	O
167	follow	_	_	O
168	-	_	_	O
169	up	_	_	O
170	form	_	_	O
171	.	_	_	O

172	A	_	_	O
173	multivariate	_	_	O
174	analysis	_	_	O
175	was	_	_	O
176	performed	_	_	O
177	to	_	_	O
178	identify	_	_	O
179	which	_	_	O
180	factors	_	_	O
181	influenced	_	_	O
182	the	_	_	O
183	cosmetic	_	_	O
184	outcome	_	_	O
185	.	_	_	O

186	In	_	_	O
187	total	_	_	O
188	,	_	_	O
189	127	_	_	O
190	patients	_	_	O
191	in	_	_	O
192	the	_	_	O
193	MRM	_	_	O
194	arm	_	_	O
195	and	_	_	O
196	151	_	_	O
197	in	_	_	O
198	the	_	_	O
199	BCT	_	_	O
200	arm	_	_	O
201	completed	_	_	O
202	a	_	_	O
203	QoL	_	_	O
204	questionnaire	_	_	O
205	at	_	_	O
206	approximately	_	_	O
207	2	_	_	O
208	years	_	_	O
209	after	_	_	O
210	randomisation	_	_	O
211	(	_	_	O
212	months	_	_	O
213	25	_	_	O
214	-	_	_	O
215	36	_	_	O
216	)	_	_	O
217	.	_	_	O

218	The	_	_	B-Premise
219	Cronbach	_	_	I-Premise
220	'	_	_	I-Premise
221	s	_	_	I-Premise
222	alpha	_	_	I-Premise
223	coefficients	_	_	I-Premise
224	were	_	_	I-Premise
225	0	_	_	I-Premise
226	.	_	_	I-Premise

227	79	_	_	I-Premise
228	and	_	_	I-Premise
229	0	_	_	I-Premise
230	.	_	_	I-Premise

231	73	_	_	I-Premise
232	for	_	_	I-Premise
233	the	_	_	I-Premise
234	body	_	_	I-Premise
235	image	_	_	I-Premise
236	and	_	_	I-Premise
237	fear	_	_	I-Premise
238	of	_	_	I-Premise
239	recurrence	_	_	I-Premise
240	scales	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	.	_	_	I-Premise

244	Significant	_	_	B-Premise
245	benefit	_	_	I-Premise
246	in	_	_	I-Premise
247	body	_	_	I-Premise
248	image	_	_	I-Premise
249	and	_	_	I-Premise
250	satisfaction	_	_	I-Premise
251	with	_	_	I-Premise
252	treatment	_	_	I-Premise
253	was	_	_	I-Premise
254	observed	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	BCT	_	_	I-Premise
258	patients	_	_	I-Premise
259	.	_	_	I-Premise

260	No	_	_	B-Premise
261	significant	_	_	I-Premise
262	difference	_	_	I-Premise
263	was	_	_	I-Premise
264	observed	_	_	I-Premise
265	in	_	_	I-Premise
266	fear	_	_	I-Premise
267	of	_	_	I-Premise
268	recurrence	_	_	I-Premise
269	between	_	_	I-Premise
270	the	_	_	I-Premise
271	two	_	_	I-Premise
272	groups	_	_	I-Premise
273	.	_	_	I-Premise

274	Ratings	_	_	B-Premise
275	of	_	_	I-Premise
276	cosmetic	_	_	I-Premise
277	results	_	_	I-Premise
278	decreased	_	_	I-Premise
279	with	_	_	I-Premise
280	time	_	_	I-Premise
281	,	_	_	I-Premise
282	in	_	_	I-Premise
283	line	_	_	I-Premise
284	with	_	_	I-Premise
285	clinical	_	_	I-Premise
286	observations	_	_	I-Premise
287	of	_	_	I-Premise
288	long	_	_	I-Premise
289	-	_	_	I-Premise
290	term	_	_	I-Premise
291	side	_	_	I-Premise
292	-	_	_	I-Premise
293	effects	_	_	I-Premise
294	of	_	_	I-Premise
295	radiotherapy	_	_	I-Premise
296	.	_	_	I-Premise

297	Wide	_	_	B-Claim
298	excision	_	_	I-Claim
299	appeared	_	_	I-Claim
300	to	_	_	I-Claim
301	be	_	_	I-Claim
302	the	_	_	I-Claim
303	most	_	_	I-Claim
304	important	_	_	I-Claim
305	predictive	_	_	I-Claim
306	factor	_	_	I-Claim
307	for	_	_	I-Claim
308	poor	_	_	I-Claim
309	cosmetic	_	_	I-Claim
310	result	_	_	I-Claim
311	.	_	_	I-Claim

312	In	_	_	B-Claim
313	this	_	_	I-Claim
314	multicentre	_	_	I-Claim
315	randomised	_	_	I-Claim
316	study	_	_	I-Claim
317	,	_	_	I-Claim
318	BCT	_	_	I-Claim
319	helped	_	_	I-Claim
320	to	_	_	I-Claim
321	maintain	_	_	I-Claim
322	the	_	_	I-Claim
323	patients	_	_	I-Claim
324	'	_	_	I-Claim
325	body	_	_	I-Claim
326	image	_	_	I-Claim
327	,	_	_	I-Claim
328	resulted	_	_	I-Claim
329	in	_	_	I-Claim
330	higher	_	_	I-Claim
331	satisfaction	_	_	I-Claim
332	with	_	_	I-Claim
333	treatment	_	_	I-Claim
334	and	_	_	I-Claim
335	yielded	_	_	I-Claim
336	no	_	_	I-Claim
337	significant	_	_	I-Claim
338	difference	_	_	I-Claim
339	from	_	_	I-Claim
340	MRM	_	_	I-Claim
341	with	_	_	I-Claim
342	respect	_	_	I-Claim
343	to	_	_	I-Claim
344	fear	_	_	I-Claim
345	of	_	_	I-Claim
346	recurrence	_	_	I-Claim
347	.	_	_	I-Claim


0	For	_	_	B-Claim
1	several	_	_	I-Claim
2	decades	_	_	I-Claim
3	,	_	_	I-Claim
4	both	_	_	I-Claim
5	preoperative	_	_	I-Claim
6	intra	_	_	I-Claim
7	-	_	_	I-Claim
8	arterial	_	_	I-Claim
9	chemotherapy	_	_	I-Claim
10	and	_	_	I-Claim
11	preoperative	_	_	I-Claim
12	irradiation	_	_	I-Claim
13	have	_	_	I-Claim
14	been	_	_	I-Claim
15	accepted	_	_	I-Claim
16	treatments	_	_	I-Claim
17	for	_	_	I-Claim
18	patients	_	_	I-Claim
19	with	_	_	I-Claim
20	tumors	_	_	I-Claim
21	of	_	_	I-Claim
22	the	_	_	I-Claim
23	head	_	_	I-Claim
24	and	_	_	I-Claim
25	neck	_	_	I-Claim
26	.	_	_	I-Claim

27	Unfortunately	_	_	O
28	,	_	_	O
29	arguments	_	_	O
30	have	_	_	O
31	often	_	_	O
32	been	_	_	O
33	put	_	_	O
34	forward	_	_	O
35	in	_	_	O
36	favor	_	_	O
37	of	_	_	O
38	one	_	_	O
39	or	_	_	O
40	other	_	_	O
41	of	_	_	O
42	the	_	_	O
43	two	_	_	O
44	methods	_	_	O
45	,	_	_	O
46	but	_	_	O
47	without	_	_	O
48	the	_	_	O
49	performance	_	_	O
50	of	_	_	O
51	an	_	_	O
52	objective	_	_	O
53	,	_	_	O
54	randomized	_	_	O
55	investigation	_	_	O
56	.	_	_	O

57	To	_	_	O
58	resolve	_	_	O
59	this	_	_	O
60	situation	_	_	O
61	,	_	_	O
62	the	_	_	O
63	authors	_	_	O
64	have	_	_	O
65	carried	_	_	O
66	out	_	_	O
67	a	_	_	O
68	multicenter	_	_	O
69	,	_	_	O
70	randomized	_	_	O
71	prospective	_	_	O
72	study	_	_	O
73	of	_	_	O
74	selected	_	_	O
75	patients	_	_	O
76	with	_	_	O
77	a	_	_	O
78	view	_	_	O
79	to	_	_	O
80	deciding	_	_	O
81	which	_	_	O
82	method	_	_	O
83	affords	_	_	O
84	better	_	_	O
85	results	_	_	O
86	in	_	_	O
87	complex	_	_	O
88	tumor	_	_	O
89	therapy	_	_	O
90	from	_	_	O
91	the	_	_	O
92	aspects	_	_	O
93	of	_	_	O
94	survival	_	_	O
95	and	_	_	O
96	postoperative	_	_	O
97	quality	_	_	O
98	of	_	_	O
99	life	_	_	O
100	.	_	_	O

101	One	_	_	O
102	hundred	_	_	O
103	thirty	_	_	O
104	-	_	_	O
105	one	_	_	O
106	patients	_	_	O
107	with	_	_	O
108	operable	_	_	O
109	sublingual	_	_	O
110	or	_	_	O
111	lingual	_	_	O
112	squamous	_	_	O
113	cell	_	_	O
114	carcinoma	_	_	O
115	in	_	_	O
116	stages	_	_	O
117	T2NXM0	_	_	O
118	to	_	_	O
119	T4MXM0	_	_	O
120	were	_	_	O
121	randomized	_	_	O
122	into	_	_	O
123	2	_	_	O
124	groups	_	_	O
125	:	_	_	O
126	1	_	_	O
127	group	_	_	O
128	participated	_	_	O
129	in	_	_	O
130	preoperative	_	_	O
131	chemotherapy	_	_	O
132	with	_	_	O
133	cisplatin	_	_	O
134	and	_	_	O
135	epirubicin	_	_	O
136	(	_	_	O
137	total	_	_	O
138	doses	_	_	O
139	:	_	_	O
140	200	_	_	O
141	mg	_	_	O
142	cisplatin	_	_	O
143	,	_	_	O
144	120	_	_	O
145	mg	_	_	O
146	epirubicin	_	_	O
147	)	_	_	O
148	via	_	_	O
149	the	_	_	O
150	external	_	_	O
151	carotid	_	_	O
152	artery	_	_	O
153	,	_	_	O
154	whereas	_	_	O
155	the	_	_	O
156	other	_	_	O
157	group	_	_	O
158	received	_	_	O
159	preoperative	_	_	O
160	radiation	_	_	O
161	therapy	_	_	O
162	(	_	_	O
163	46	_	_	O
164	grays	_	_	O
165	)	_	_	O
166	.	_	_	O

167	Following	_	_	O
168	subsequent	_	_	O
169	radical	_	_	O
170	surgery	_	_	O
171	,	_	_	O
172	the	_	_	O
173	patients	_	_	O
174	received	_	_	O
175	regular	_	_	O
176	follow	_	_	O
177	-	_	_	O
178	up	_	_	O
179	for	_	_	O
180	5	_	_	O
181	years	_	_	O
182	.	_	_	O

183	By	_	_	O
184	the	_	_	O
185	end	_	_	O
186	of	_	_	O
187	the	_	_	O
188	5	_	_	O
189	years	_	_	O
190	,	_	_	O
191	95	_	_	O
192	of	_	_	O
193	the	_	_	O
194	131	_	_	O
195	patients	_	_	O
196	had	_	_	O
197	conformed	_	_	O
198	to	_	_	O
199	the	_	_	O
200	protocol	_	_	O
201	.	_	_	O

202	Of	_	_	O
203	those	_	_	O
204	95	_	_	O
205	,	_	_	O
206	47	_	_	O
207	had	_	_	O
208	received	_	_	O
209	preoperative	_	_	O
210	chemotherapy	_	_	O
211	and	_	_	O
212	48	_	_	O
213	preoperative	_	_	O
214	irradiation	_	_	O
215	.	_	_	O

216	After	_	_	B-Premise
217	5	_	_	I-Premise
218	years	_	_	I-Premise
219	,	_	_	I-Premise
220	18	_	_	I-Premise
221	of	_	_	I-Premise
222	the	_	_	I-Premise
223	47	_	_	I-Premise
224	patients	_	_	I-Premise
225	who	_	_	I-Premise
226	received	_	_	I-Premise
227	chemotherapy	_	_	I-Premise
228	and	_	_	I-Premise
229	15	_	_	I-Premise
230	of	_	_	I-Premise
231	the	_	_	I-Premise
232	48	_	_	I-Premise
233	patients	_	_	I-Premise
234	who	_	_	I-Premise
235	received	_	_	I-Premise
236	irradiation	_	_	I-Premise
237	were	_	_	I-Premise
238	still	_	_	I-Premise
239	alive	_	_	I-Premise
240	and	_	_	I-Premise
241	tumor	_	_	I-Premise
242	free	_	_	I-Premise
243	.	_	_	I-Premise

244	A	_	_	B-Premise
245	few	_	_	I-Premise
246	more	_	_	I-Premise
247	patients	_	_	I-Premise
248	had	_	_	I-Premise
249	died	_	_	I-Premise
250	of	_	_	I-Premise
251	recurrence	_	_	I-Premise
252	or	_	_	I-Premise
253	regional	_	_	I-Premise
254	metastasis	_	_	I-Premise
255	in	_	_	I-Premise
256	the	_	_	I-Premise
257	chemotherapy	_	_	I-Premise
258	group	_	_	I-Premise
259	(	_	_	I-Premise
260	23	_	_	I-Premise
261	patients	_	_	I-Premise
262	)	_	_	I-Premise
263	than	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	irradiation	_	_	I-Premise
267	group	_	_	I-Premise
268	(	_	_	I-Premise
269	20	_	_	I-Premise
270	patients	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	Occurrence	_	_	B-Premise
274	of	_	_	I-Premise
275	a	_	_	I-Premise
276	second	_	_	I-Premise
277	carcinoma	_	_	I-Premise
278	was	_	_	I-Premise
279	3	_	_	I-Premise
280	times	_	_	I-Premise
281	as	_	_	I-Premise
282	frequent	_	_	I-Premise
283	in	_	_	I-Premise
284	the	_	_	I-Premise
285	irradiation	_	_	I-Premise
286	group	_	_	I-Premise
287	(	_	_	I-Premise
288	9	_	_	I-Premise
289	patients	_	_	I-Premise
290	)	_	_	I-Premise
291	as	_	_	I-Premise
292	in	_	_	I-Premise
293	the	_	_	I-Premise
294	chemotherapy	_	_	I-Premise
295	group	_	_	I-Premise
296	(	_	_	I-Premise
297	3	_	_	I-Premise
298	patients	_	_	I-Premise
299	)	_	_	I-Premise
300	.	_	_	I-Premise

301	Overall	_	_	O
302	,	_	_	O
303	the	_	_	B-Claim
304	survival	_	_	I-Claim
305	rates	_	_	I-Claim
306	were	_	_	I-Claim
307	by	_	_	I-Claim
308	-	_	_	I-Claim
309	and	_	_	I-Claim
310	-	_	_	I-Claim
311	large	_	_	I-Claim
312	the	_	_	I-Claim
313	same	_	_	I-Claim
314	for	_	_	I-Claim
315	the	_	_	I-Claim
316	two	_	_	I-Claim
317	groups	_	_	I-Claim
318	.	_	_	I-Claim

319	Regarding	_	_	B-Claim
320	postoperative	_	_	I-Claim
321	quality	_	_	I-Claim
322	of	_	_	I-Claim
323	life	_	_	I-Claim
324	,	_	_	I-Claim
325	the	_	_	I-Claim
326	chemotherapy	_	_	I-Claim
327	group	_	_	I-Claim
328	presented	_	_	I-Claim
329	a	_	_	I-Claim
330	more	_	_	I-Claim
331	favorable	_	_	I-Claim
332	picture	_	_	I-Claim
333	.	_	_	I-Claim

334	The	_	_	B-Claim
335	long	_	_	I-Claim
336	term	_	_	I-Claim
337	survival	_	_	I-Claim
338	results	_	_	I-Claim
339	subsequent	_	_	I-Claim
340	to	_	_	I-Claim
341	preoperative	_	_	I-Claim
342	intra	_	_	I-Claim
343	-	_	_	I-Claim
344	arterial	_	_	I-Claim
345	chemotherapy	_	_	I-Claim
346	or	_	_	I-Claim
347	preoperative	_	_	I-Claim
348	radiotherapy	_	_	I-Claim
349	were	_	_	I-Claim
350	practically	_	_	I-Claim
351	the	_	_	I-Claim
352	same	_	_	I-Claim
353	.	_	_	I-Claim

354	Regarding	_	_	B-Claim
355	postoperative	_	_	I-Claim
356	quality	_	_	I-Claim
357	of	_	_	I-Claim
358	life	_	_	I-Claim
359	,	_	_	I-Claim
360	patients	_	_	I-Claim
361	who	_	_	I-Claim
362	underwent	_	_	I-Claim
363	intra	_	_	I-Claim
364	-	_	_	I-Claim
365	arterial	_	_	I-Claim
366	chemotherapy	_	_	I-Claim
367	appeared	_	_	I-Claim
368	to	_	_	I-Claim
369	be	_	_	I-Claim
370	in	_	_	I-Claim
371	a	_	_	I-Claim
372	slightly	_	_	I-Claim
373	more	_	_	I-Claim
374	favorable	_	_	I-Claim
375	situation	_	_	I-Claim
376	.	_	_	I-Claim

377	The	_	_	O
378	authors	_	_	O
379	consider	_	_	O
380	it	_	_	O
381	important	_	_	O
382	to	_	_	O
383	stress	_	_	O
384	these	_	_	O
385	findings	_	_	O
386	,	_	_	O
387	as	_	_	O
388	they	_	_	O
389	are	_	_	O
390	not	_	_	O
391	aware	_	_	O
392	of	_	_	O
393	a	_	_	O
394	similar	_	_	O
395	randomized	_	_	O
396	study	_	_	O
397	of	_	_	O
398	patients	_	_	O
399	with	_	_	O
400	tumors	_	_	O
401	of	_	_	O
402	the	_	_	O
403	oral	_	_	O
404	cavity	_	_	O
405	.	_	_	O


0	Bone	_	_	B-Claim
1	metastases	_	_	I-Claim
2	occur	_	_	I-Claim
3	in	_	_	I-Claim
4	most	_	_	I-Claim
5	women	_	_	I-Claim
6	with	_	_	I-Claim
7	advanced	_	_	I-Claim
8	breast	_	_	I-Claim
9	cancer	_	_	I-Claim
10	and	_	_	I-Claim
11	can	_	_	I-Claim
12	lead	_	_	I-Claim
13	to	_	_	I-Claim
14	considerable	_	_	I-Claim
15	morbidity	_	_	I-Claim
16	and	_	_	I-Claim
17	a	_	_	I-Claim
18	rapid	_	_	I-Claim
19	deterioration	_	_	I-Claim
20	in	_	_	I-Claim
21	the	_	_	I-Claim
22	patient	_	_	I-Claim
23	'	_	_	I-Claim
24	s	_	_	I-Claim
25	quality	_	_	I-Claim
26	of	_	_	I-Claim
27	life	_	_	I-Claim
28	.	_	_	I-Claim

29	It	_	_	O
30	was	_	_	O
31	the	_	_	O
32	aim	_	_	O
33	of	_	_	O
34	the	_	_	O
35	present	_	_	O
36	study	_	_	O
37	to	_	_	O
38	assess	_	_	O
39	changes	_	_	O
40	in	_	_	O
41	quality	_	_	O
42	of	_	_	O
43	life	_	_	O
44	and	_	_	O
45	bone	_	_	O
46	pain	_	_	O
47	due	_	_	O
48	to	_	_	O
49	intravenous	_	_	O
50	(	_	_	O
51	i	_	_	O
52	.	_	_	O

53	v	_	_	O
54	.	_	_	O

55	)	_	_	O
56	ibandronate	_	_	O
57	,	_	_	O
58	a	_	_	O
59	potent	_	_	O
60	third	_	_	O
61	-	_	_	O
62	generation	_	_	O
63	bisphosphonate	_	_	O
64	.	_	_	O

65	In	_	_	O
66	a	_	_	O
67	phase	_	_	O
68	III	_	_	O
69	randomised	_	_	O
70	,	_	_	O
71	double	_	_	O
72	-	_	_	O
73	blind	_	_	O
74	,	_	_	O
75	placebo	_	_	O
76	-	_	_	O
77	controlled	_	_	O
78	trial	_	_	O
79	in	_	_	O
80	patients	_	_	O
81	with	_	_	O
82	bone	_	_	O
83	metastases	_	_	O
84	due	_	_	O
85	to	_	_	O
86	breast	_	_	O
87	cancer	_	_	O
88	,	_	_	O
89	466	_	_	O
90	women	_	_	O
91	were	_	_	O
92	randomised	_	_	O
93	to	_	_	O
94	receive	_	_	O
95	placebo	_	_	O
96	,	_	_	O
97	2	_	_	O
98	mg	_	_	O
99	ibandronate	_	_	O
100	or	_	_	O
101	6	_	_	O
102	mg	_	_	O
103	ibandronate	_	_	O
104	for	_	_	O
105	up	_	_	O
106	to	_	_	O
107	96	_	_	O
108	weeks	_	_	O
109	.	_	_	O

110	Treatment	_	_	O
111	was	_	_	O
112	administered	_	_	O
113	i	_	_	O
114	.	_	_	O

115	v	_	_	O
116	.	_	_	O

117	at	_	_	O
118	3	_	_	O
119	-	_	_	O
120	or	_	_	O
121	4	_	_	O
122	-	_	_	O
123	weekly	_	_	O
124	intervals	_	_	O
125	.	_	_	O

126	Clinical	_	_	O
127	endpoints	_	_	O
128	included	_	_	O
129	the	_	_	O
130	incidence	_	_	O
131	of	_	_	O
132	adverse	_	_	O
133	events	_	_	O
134	,	_	_	O
135	quality	_	_	O
136	of	_	_	O
137	life	_	_	O
138	(	_	_	O
139	assessed	_	_	O
140	using	_	_	O
141	the	_	_	O
142	European	_	_	O
143	Organisation	_	_	O
144	for	_	_	O
145	the	_	_	O
146	Research	_	_	O
147	and	_	_	O
148	Treatment	_	_	O
149	of	_	_	O
150	Cancer	_	_	O
151	(	_	_	O
152	EORTC	_	_	O
153	)	_	_	O
154	Quality	_	_	O
155	of	_	_	O
156	Life	_	_	O
157	Scale	_	_	O
158	-	_	_	O
159	Core	_	_	O
160	30	_	_	O
161	questionnaire	_	_	O
162	(	_	_	O
163	QLQ	_	_	O
164	-	_	_	O
165	C30	_	_	O
166	)	_	_	O
167	)	_	_	O
168	,	_	_	O
169	and	_	_	O
170	bone	_	_	O
171	pain	_	_	O
172	(	_	_	O
173	assessed	_	_	O
174	on	_	_	O
175	a	_	_	O
176	5	_	_	O
177	-	_	_	O
178	point	_	_	O
179	scale	_	_	O
180	from	_	_	O
181	0	_	_	O
182	=	_	_	O
183	none	_	_	O
184	to	_	_	O
185	4	_	_	O
186	=	_	_	O
187	intolerable	_	_	O
188	)	_	_	O
189	.	_	_	O

190	Ibandronate	_	_	B-Premise
191	was	_	_	I-Premise
192	generally	_	_	I-Premise
193	well	_	_	I-Premise
194	tolerated	_	_	I-Premise
195	.	_	_	I-Premise

196	Compared	_	_	B-Premise
197	with	_	_	I-Premise
198	baseline	_	_	I-Premise
199	measurements	_	_	I-Premise
200	,	_	_	I-Premise
201	the	_	_	I-Premise
202	bone	_	_	I-Premise
203	pain	_	_	I-Premise
204	score	_	_	I-Premise
205	was	_	_	I-Premise
206	increased	_	_	I-Premise
207	at	_	_	I-Premise
208	the	_	_	I-Premise
209	last	_	_	I-Premise
210	assessment	_	_	I-Premise
211	in	_	_	I-Premise
212	both	_	_	I-Premise
213	the	_	_	I-Premise
214	placebo	_	_	I-Premise
215	and	_	_	I-Premise
216	2	_	_	I-Premise
217	mg	_	_	I-Premise
218	ibandronate	_	_	I-Premise
219	groups	_	_	I-Premise
220	,	_	_	I-Premise
221	but	_	_	B-Premise
222	was	_	_	I-Premise
223	significantly	_	_	I-Premise
224	reduced	_	_	I-Premise
225	in	_	_	I-Premise
226	the	_	_	I-Premise
227	patients	_	_	I-Premise
228	receiving	_	_	I-Premise
229	6	_	_	I-Premise
230	mg	_	_	I-Premise
231	ibandronate	_	_	I-Premise
232	(	_	_	I-Premise
233	-	_	_	I-Premise
234	0	_	_	I-Premise
235	.	_	_	I-Premise

236	28	_	_	I-Premise
237	+	_	_	I-Premise
238	/	_	_	I-Premise
239	-	_	_	I-Premise
240	1	_	_	I-Premise
241	.	_	_	I-Premise

242	11	_	_	I-Premise
243	,	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	0	_	_	I-Premise
247	.	_	_	I-Premise

248	001	_	_	I-Premise
249	)	_	_	I-Premise
250	.	_	_	I-Premise

251	A	_	_	B-Premise
252	significant	_	_	I-Premise
253	improvement	_	_	I-Premise
254	in	_	_	I-Premise
255	quality	_	_	I-Premise
256	of	_	_	I-Premise
257	life	_	_	I-Premise
258	was	_	_	I-Premise
259	demonstrated	_	_	I-Premise
260	for	_	_	I-Premise
261	patients	_	_	I-Premise
262	treated	_	_	I-Premise
263	with	_	_	I-Premise
264	ibandronate	_	_	I-Premise
265	(	_	_	I-Premise
266	P	_	_	I-Premise
267	<	_	_	I-Premise
268	0	_	_	I-Premise
269	.	_	_	I-Premise

270	05	_	_	I-Premise
271	)	_	_	I-Premise
272	for	_	_	I-Premise
273	all	_	_	I-Premise
274	global	_	_	I-Premise
275	health	_	_	I-Premise
276	status	_	_	I-Premise
277	.	_	_	I-Premise

278	Overall	_	_	B-Premise
279	,	_	_	I-Premise
280	at	_	_	I-Premise
281	the	_	_	I-Premise
282	last	_	_	I-Premise
283	assessment	_	_	I-Premise
284	,	_	_	I-Premise
285	the	_	_	I-Premise
286	6	_	_	I-Premise
287	mg	_	_	I-Premise
288	ibandronate	_	_	I-Premise
289	group	_	_	I-Premise
290	showed	_	_	I-Premise
291	significantly	_	_	I-Premise
292	better	_	_	I-Premise
293	functioning	_	_	I-Premise
294	compared	_	_	I-Premise
295	with	_	_	I-Premise
296	placebo	_	_	I-Premise
297	(	_	_	I-Premise
298	P	_	_	I-Premise
299	=	_	_	I-Premise
300	0	_	_	I-Premise
301	.	_	_	I-Premise

302	004	_	_	I-Premise
303	)	_	_	I-Premise
304	,	_	_	I-Premise
305	and	_	_	I-Premise
306	had	_	_	I-Premise
307	significantly	_	_	I-Premise
308	better	_	_	I-Premise
309	scores	_	_	I-Premise
310	on	_	_	I-Premise
311	the	_	_	I-Premise
312	domains	_	_	I-Premise
313	of	_	_	I-Premise
314	physical	_	_	I-Premise
315	,	_	_	I-Premise
316	emotional	_	_	I-Premise
317	,	_	_	I-Premise
318	and	_	_	I-Premise
319	social	_	_	I-Premise
320	functioning	_	_	I-Premise
321	,	_	_	I-Premise
322	and	_	_	I-Premise
323	in	_	_	I-Premise
324	global	_	_	I-Premise
325	health	_	_	I-Premise
326	status	_	_	I-Premise
327	(	_	_	I-Premise
328	P	_	_	I-Premise
329	<	_	_	I-Premise
330	0	_	_	I-Premise
331	.	_	_	I-Premise

332	05	_	_	I-Premise
333	)	_	_	I-Premise
334	.	_	_	I-Premise

335	Significant	_	_	B-Premise
336	improvements	_	_	I-Premise
337	in	_	_	I-Premise
338	the	_	_	I-Premise
339	symptoms	_	_	I-Premise
340	of	_	_	I-Premise
341	fatigue	_	_	I-Premise
342	and	_	_	I-Premise
343	pain	_	_	I-Premise
344	were	_	_	I-Premise
345	also	_	_	I-Premise
346	observed	_	_	I-Premise
347	in	_	_	I-Premise
348	the	_	_	I-Premise
349	6	_	_	I-Premise
350	mg	_	_	I-Premise
351	ibandronate	_	_	I-Premise
352	group	_	_	I-Premise
353	.	_	_	I-Premise

354	I	_	_	B-Claim
355	.	_	_	I-Claim

356	v	_	_	I-Claim
357	.	_	_	I-Claim

358	ibandronate	_	_	I-Claim
359	treatment	_	_	I-Claim
360	leads	_	_	I-Claim
361	to	_	_	I-Claim
362	significant	_	_	I-Claim
363	improvements	_	_	I-Claim
364	in	_	_	I-Claim
365	quality	_	_	I-Claim
366	of	_	_	I-Claim
367	life	_	_	I-Claim
368	,	_	_	I-Claim
369	and	_	_	I-Claim
370	is	_	_	I-Claim
371	an	_	_	I-Claim
372	effective	_	_	I-Claim
373	and	_	_	I-Claim
374	well	_	_	I-Claim
375	-	_	_	I-Claim
376	tolerated	_	_	I-Claim
377	palliative	_	_	I-Claim
378	treatment	_	_	I-Claim
379	in	_	_	I-Claim
380	patients	_	_	I-Claim
381	with	_	_	I-Claim
382	bone	_	_	I-Claim
383	metastases	_	_	I-Claim
384	due	_	_	I-Claim
385	to	_	_	I-Claim
386	breast	_	_	I-Claim
387	cancer	_	_	I-Claim
388	.	_	_	I-Claim


0	In	_	_	O
1	a	_	_	O
2	prospective	_	_	O
3	randomized	_	_	O
4	study	_	_	O
5	,	_	_	O
6	287	_	_	O
7	patients	_	_	O
8	with	_	_	O
9	advanced	_	_	O
10	non	_	_	O
11	-	_	_	O
12	small	_	_	O
13	cell	_	_	O
14	lung	_	_	O
15	cancer	_	_	O
16	(	_	_	O
17	NSCLC	_	_	O
18	)	_	_	O
19	stage	_	_	O
20	IIIb	_	_	O
21	or	_	_	O
22	IV	_	_	O
23	with	_	_	O
24	ECOG	_	_	O
25	performance	_	_	O
26	status	_	_	O
27	(	_	_	O
28	PS	_	_	O
29	)	_	_	O
30	0	_	_	O
31	-	_	_	O
32	1	_	_	O
33	or	_	_	O
34	2	_	_	O
35	were	_	_	O
36	randomly	_	_	O
37	assigned	_	_	O
38	to	_	_	O
39	receive	_	_	O
40	either	_	_	O
41	best	_	_	O
42	supportive	_	_	O
43	care	_	_	O
44	(	_	_	O
45	BSC	_	_	O
46	)	_	_	O
47	or	_	_	O
48	supportive	_	_	O
49	care	_	_	O
50	plus	_	_	O
51	combination	_	_	O
52	chemotherapy	_	_	O
53	(	_	_	O
54	IEP	_	_	O
55	regimen	_	_	O
56	:	_	_	O
57	ifosfamide	_	_	O
58	3	_	_	O
59	gm	_	_	O
60	/	_	_	O
61	m2	_	_	O
62	IV	_	_	O
63	with	_	_	O
64	mesna	_	_	O
65	uroprotection	_	_	O
66	,	_	_	O
67	epirubicin	_	_	O
68	60	_	_	O
69	mg	_	_	O
70	/	_	_	O
71	m2	_	_	O
72	IV	_	_	O
73	on	_	_	O
74	day	_	_	O
75	1	_	_	O
76	and	_	_	O
77	cisplatin	_	_	O
78	60	_	_	O
79	mg	_	_	O
80	/	_	_	O
81	m2	_	_	O
82	IV	_	_	O
83	on	_	_	O
84	day	_	_	O
85	2	_	_	O
86	;	_	_	O
87	or	_	_	O
88	MVP	_	_	O
89	regimen	_	_	O
90	:	_	_	O
91	mitomycin	_	_	O
92	-	_	_	O
93	C	_	_	O
94	8	_	_	O
95	mg	_	_	O
96	/	_	_	O
97	m2	_	_	O
98	,	_	_	O
99	cisplatin	_	_	O
100	100	_	_	O
101	mg	_	_	O
102	/	_	_	O
103	m2	_	_	O
104	IV	_	_	O
105	on	_	_	O
106	day	_	_	O
107	1	_	_	O
108	,	_	_	O
109	vinblastine	_	_	O
110	4	_	_	O
111	mg	_	_	O
112	/	_	_	O
113	m2	_	_	O
114	IV	_	_	O
115	on	_	_	O
116	days	_	_	O
117	1	_	_	O
118	and	_	_	O
119	15	_	_	O
120	)	_	_	O
121	.	_	_	O

122	Serial	_	_	O
123	assessment	_	_	O
124	of	_	_	O
125	Karnofsky	_	_	O
126	performance	_	_	O
127	status	_	_	O
128	(	_	_	O
129	KPS	_	_	O
130	)	_	_	O
131	,	_	_	O
132	modified	_	_	O
133	Functional	_	_	O
134	Living	_	_	O
135	Index	_	_	O
136	-	_	_	O
137	Cancer	_	_	O
138	(	_	_	O
139	T	_	_	O
140	-	_	_	O
141	FLIC	_	_	O
142	)	_	_	O
143	and	_	_	O
144	modified	_	_	O
145	Quality	_	_	O
146	of	_	_	O
147	Life	_	_	O
148	-	_	_	O
149	Index	_	_	O
150	(	_	_	O
151	T	_	_	O
152	-	_	_	O
153	QLI	_	_	O
154	)	_	_	O
155	were	_	_	O
156	used	_	_	O
157	to	_	_	O
158	estimate	_	_	O
159	the	_	_	O
160	quality	_	_	O
161	of	_	_	O
162	life	_	_	O
163	.	_	_	O

164	Interviews	_	_	O
165	were	_	_	O
166	done	_	_	O
167	at	_	_	O
168	entry	_	_	O
169	,	_	_	O
170	at	_	_	O
171	the	_	_	O
172	third	_	_	O
173	month	_	_	O
174	and	_	_	O
175	at	_	_	O
176	2	_	_	O
177	months	_	_	O
178	post	_	_	O
179	complete	_	_	O
180	treatment	_	_	O
181	.	_	_	O

182	At	_	_	O
183	least	_	_	O
184	two	_	_	O
185	courses	_	_	O
186	of	_	_	O
187	chemotherapy	_	_	O
188	were	_	_	O
189	considered	_	_	O
190	to	_	_	O
191	be	_	_	O
192	adequate	_	_	O
193	for	_	_	O
194	response	_	_	O
195	evaluation	_	_	O
196	.	_	_	O

197	Patients	_	_	O
198	were	_	_	O
199	treated	_	_	O
200	for	_	_	O
201	a	_	_	O
202	total	_	_	O
203	of	_	_	O
204	four	_	_	O
205	to	_	_	O
206	six	_	_	O
207	courses	_	_	O
208	or	_	_	O
209	until	_	_	O
210	progression	_	_	O
211	of	_	_	O
212	disease	_	_	O
213	.	_	_	O

214	Partial	_	_	B-Premise
215	response	_	_	I-Premise
216	rates	_	_	I-Premise
217	were	_	_	I-Premise
218	40	_	_	I-Premise
219	and	_	_	I-Premise
220	41	_	_	I-Premise
221	.	_	_	I-Premise

222	7	_	_	I-Premise
223	%	_	_	I-Premise
224	in	_	_	I-Premise
225	IEP	_	_	I-Premise
226	and	_	_	I-Premise
227	MVP	_	_	I-Premise
228	arms	_	_	I-Premise
229	.	_	_	I-Premise

230	Median	_	_	B-Premise
231	survival	_	_	I-Premise
232	durations	_	_	I-Premise
233	were	_	_	I-Premise
234	5	_	_	I-Premise
235	.	_	_	I-Premise

236	9	_	_	I-Premise
237	and	_	_	I-Premise
238	8	_	_	I-Premise
239	.	_	_	I-Premise

240	1	_	_	I-Premise
241	months	_	_	I-Premise
242	for	_	_	I-Premise
243	the	_	_	I-Premise
244	IEP	_	_	I-Premise
245	and	_	_	I-Premise
246	MVP	_	_	I-Premise
247	chemotherapy	_	_	I-Premise
248	arms	_	_	I-Premise
249	,	_	_	I-Premise
250	and	_	_	I-Premise
251	4	_	_	I-Premise
252	.	_	_	I-Premise

253	1	_	_	I-Premise
254	months	_	_	I-Premise
255	for	_	_	I-Premise
256	BSC	_	_	I-Premise
257	(	_	_	I-Premise
258	log	_	_	I-Premise
259	-	_	_	I-Premise
260	rank	_	_	I-Premise
261	test	_	_	I-Premise
262	:	_	_	I-Premise
263	P	_	_	I-Premise
264	=	_	_	I-Premise
265	0	_	_	I-Premise
266	.	_	_	I-Premise

267	0003	_	_	I-Premise
268	)	_	_	I-Premise
269	.	_	_	I-Premise

270	One	_	_	B-Premise
271	year	_	_	I-Premise
272	survival	_	_	I-Premise
273	was	_	_	I-Premise
274	13	_	_	I-Premise
275	,	_	_	I-Premise
276	29	_	_	I-Premise
277	.	_	_	I-Premise

278	8	_	_	I-Premise
279	and	_	_	I-Premise
280	39	_	_	I-Premise
281	.	_	_	I-Premise

282	3	_	_	I-Premise
283	%	_	_	I-Premise
284	for	_	_	I-Premise
285	the	_	_	I-Premise
286	BSC	_	_	I-Premise
287	,	_	_	I-Premise
288	IEP	_	_	I-Premise
289	and	_	_	I-Premise
290	MVP	_	_	I-Premise
291	regimens	_	_	I-Premise
292	,	_	_	I-Premise
293	respectively	_	_	I-Premise
294	.	_	_	I-Premise

295	Two	_	_	B-Premise
296	years	_	_	I-Premise
297	survival	_	_	I-Premise
298	was	_	_	I-Premise
299	7	_	_	I-Premise
300	.	_	_	I-Premise

301	8	_	_	I-Premise
302	,	_	_	I-Premise
303	6	_	_	I-Premise
304	.	_	_	I-Premise

305	4	_	_	I-Premise
306	and	_	_	I-Premise
307	13	_	_	I-Premise
308	.	_	_	I-Premise

309	1	_	_	I-Premise
310	%	_	_	I-Premise
311	for	_	_	I-Premise
312	the	_	_	I-Premise
313	BSC	_	_	I-Premise
314	,	_	_	I-Premise
315	IEP	_	_	I-Premise
316	and	_	_	I-Premise
317	MVP	_	_	I-Premise
318	regimens	_	_	I-Premise
319	,	_	_	I-Premise
320	respectively	_	_	I-Premise
321	.	_	_	I-Premise

322	Improvement	_	_	B-Premise
323	in	_	_	I-Premise
324	quality	_	_	I-Premise
325	of	_	_	I-Premise
326	life	_	_	I-Premise
327	(	_	_	I-Premise
328	QOL	_	_	I-Premise
329	)	_	_	I-Premise
330	scores	_	_	I-Premise
331	at	_	_	I-Premise
332	the	_	_	I-Premise
333	first	_	_	I-Premise
334	,	_	_	I-Premise
335	second	_	_	I-Premise
336	and	_	_	I-Premise
337	third	_	_	I-Premise
338	interview	_	_	I-Premise
339	were	_	_	I-Premise
340	seen	_	_	I-Premise
341	in	_	_	I-Premise
342	chemotherapy	_	_	I-Premise
343	arms	_	_	I-Premise
344	only	_	_	I-Premise
345	,	_	_	I-Premise
346	not	_	_	I-Premise
347	in	_	_	I-Premise
348	the	_	_	I-Premise
349	BSC	_	_	I-Premise
350	arm	_	_	I-Premise
351	.	_	_	I-Premise

352	We	_	_	O
353	conclude	_	_	O
354	that	_	_	O
355	combination	_	_	B-Claim
356	chemotherapy	_	_	I-Claim
357	improves	_	_	I-Claim
358	the	_	_	I-Claim
359	quality	_	_	I-Claim
360	of	_	_	I-Claim
361	life	_	_	I-Claim
362	as	_	_	I-Claim
363	well	_	_	I-Claim
364	as	_	_	I-Claim
365	prolonging	_	_	I-Claim
366	the	_	_	I-Claim
367	survival	_	_	I-Claim
368	of	_	_	I-Claim
369	patients	_	_	I-Claim
370	with	_	_	I-Claim
371	advanced	_	_	I-Claim
372	NSCLC	_	_	I-Claim
373	.	_	_	I-Claim


0	The	_	_	O
1	Australian	_	_	O
2	and	_	_	O
3	New	_	_	O
4	Zealand	_	_	O
5	Germ	_	_	O
6	Cell	_	_	O
7	Trials	_	_	O
8	Group	_	_	O
9	conducted	_	_	O
10	a	_	_	O
11	multicenter	_	_	O
12	randomized	_	_	O
13	phase	_	_	O
14	III	_	_	O
15	trial	_	_	O
16	in	_	_	O
17	men	_	_	O
18	with	_	_	O
19	good	_	_	O
20	-	_	_	O
21	prognosis	_	_	O
22	germ	_	_	O
23	cell	_	_	O
24	tumors	_	_	O
25	of	_	_	O
26	two	_	_	O
27	standard	_	_	O
28	chemotherapy	_	_	O
29	regimens	_	_	O
30	that	_	_	O
31	contained	_	_	O
32	bleomycin	_	_	O
33	,	_	_	O
34	etoposide	_	_	O
35	,	_	_	O
36	and	_	_	O
37	cisplatin	_	_	O
38	but	_	_	O
39	differed	_	_	O
40	in	_	_	O
41	the	_	_	O
42	scheduling	_	_	O
43	and	_	_	O
44	total	_	_	O
45	dose	_	_	O
46	of	_	_	O
47	cisplatin	_	_	O
48	,	_	_	O
49	the	_	_	O
50	total	_	_	O
51	dose	_	_	O
52	of	_	_	O
53	bleomycin	_	_	O
54	,	_	_	O
55	and	_	_	O
56	the	_	_	O
57	scheduling	_	_	O
58	and	_	_	O
59	dose	_	_	O
60	intensity	_	_	O
61	of	_	_	O
62	etoposide	_	_	O
63	.	_	_	O

64	The	_	_	O
65	trial	_	_	O
66	was	_	_	O
67	stopped	_	_	O
68	early	_	_	O
69	at	_	_	O
70	a	_	_	O
71	median	_	_	O
72	follow	_	_	O
73	-	_	_	O
74	up	_	_	O
75	of	_	_	O
76	33	_	_	O
77	months	_	_	O
78	after	_	_	O
79	a	_	_	O
80	planned	_	_	O
81	interim	_	_	O
82	analysis	_	_	O
83	found	_	_	O
84	a	_	_	O
85	survival	_	_	O
86	benefit	_	_	O
87	for	_	_	O
88	the	_	_	O
89	more	_	_	O
90	dose	_	_	O
91	-	_	_	O
92	intense	_	_	O
93	regimen	_	_	O
94	.	_	_	O

95	The	_	_	O
96	aim	_	_	O
97	of	_	_	O
98	this	_	_	O
99	analysis	_	_	O
100	was	_	_	O
101	to	_	_	O
102	determine	_	_	O
103	if	_	_	O
104	this	_	_	O
105	survival	_	_	O
106	benefit	_	_	O
107	was	_	_	O
108	maintained	_	_	O
109	with	_	_	O
110	long	_	_	O
111	-	_	_	O
112	term	_	_	O
113	follow	_	_	O
114	-	_	_	O
115	up	_	_	O
116	.	_	_	O

117	Between	_	_	O
118	February	_	_	O
119	1994	_	_	O
120	and	_	_	O
121	April	_	_	O
122	2000	_	_	O
123	,	_	_	O
124	166	_	_	O
125	men	_	_	O
126	with	_	_	O
127	good	_	_	O
128	-	_	_	O
129	prognosis	_	_	O
130	metastatic	_	_	O
131	germ	_	_	O
132	cell	_	_	O
133	tumors	_	_	O
134	defined	_	_	O
135	by	_	_	O
136	modified	_	_	O
137	Memorial	_	_	O
138	Sloan	_	_	O
139	-	_	_	O
140	Kettering	_	_	O
141	criteria	_	_	O
142	were	_	_	O
143	randomly	_	_	O
144	assigned	_	_	O
145	to	_	_	O
146	receive	_	_	O
147	3B	_	_	O
148	(	_	_	O
149	90	_	_	O
150	)	_	_	O
151	E	_	_	O
152	(	_	_	O
153	500	_	_	O
154	)	_	_	O
155	P	_	_	O
156	(	_	_	O
157	three	_	_	O
158	cycles	_	_	O
159	,	_	_	O
160	repeated	_	_	O
161	every	_	_	O
162	21	_	_	O
163	days	_	_	O
164	,	_	_	O
165	of	_	_	O
166	30	_	_	O
167	kU	_	_	O
168	bleomycin	_	_	O
169	on	_	_	O
170	days	_	_	O
171	1	_	_	O
172	,	_	_	O
173	8	_	_	O
174	,	_	_	O
175	and	_	_	O
176	15	_	_	O
177	;	_	_	O
178	100	_	_	O
179	mg	_	_	O
180	/	_	_	O
181	m	_	_	O
182	(	_	_	O
183	2	_	_	O
184	)	_	_	O
185	etoposide	_	_	O
186	on	_	_	O
187	days	_	_	O
188	1	_	_	O
189	-	_	_	O
190	5	_	_	O
191	;	_	_	O
192	and	_	_	O
193	20	_	_	O
194	mg	_	_	O
195	/	_	_	O
196	m	_	_	O
197	(	_	_	O
198	2	_	_	O
199	)	_	_	O
200	cisplatin	_	_	O
201	on	_	_	O
202	days	_	_	O
203	1	_	_	O
204	-	_	_	O
205	5	_	_	O
206	;	_	_	O
207	n	_	_	O
208	=	_	_	O
209	83	_	_	O
210	)	_	_	O
211	or	_	_	O
212	4B	_	_	O
213	(	_	_	O
214	30	_	_	O
215	)	_	_	O
216	E	_	_	O
217	(	_	_	O
218	360	_	_	O
219	)	_	_	O
220	P	_	_	O
221	(	_	_	O
222	four	_	_	O
223	cycles	_	_	O
224	,	_	_	O
225	repeated	_	_	O
226	every	_	_	O
227	21	_	_	O
228	days	_	_	O
229	,	_	_	O
230	of	_	_	O
231	30	_	_	O
232	kU	_	_	O
233	bleomycin	_	_	O
234	on	_	_	O
235	day	_	_	O
236	1	_	_	O
237	,	_	_	O
238	120	_	_	O
239	mg	_	_	O
240	/	_	_	O
241	m	_	_	O
242	(	_	_	O
243	2	_	_	O
244	)	_	_	O
245	etoposide	_	_	O
246	on	_	_	O
247	days	_	_	O
248	1	_	_	O
249	-	_	_	O
250	3	_	_	O
251	,	_	_	O
252	and	_	_	O
253	100	_	_	O
254	mg	_	_	O
255	/	_	_	O
256	m	_	_	O
257	(	_	_	O
258	2	_	_	O
259	)	_	_	O
260	cisplatin	_	_	O
261	on	_	_	O
262	day	_	_	O
263	1	_	_	O
264	;	_	_	O
265	n	_	_	O
266	=	_	_	O
267	83	_	_	O
268	)	_	_	O
269	.	_	_	O

270	Endpoints	_	_	O
271	included	_	_	O
272	overall	_	_	O
273	survival	_	_	O
274	,	_	_	O
275	progression	_	_	O
276	-	_	_	O
277	free	_	_	O
278	survival	_	_	O
279	,	_	_	O
280	and	_	_	O
281	quality	_	_	O
282	of	_	_	O
283	life	_	_	O
284	and	_	_	O
285	side	_	_	O
286	effects	_	_	O
287	,	_	_	O
288	which	_	_	O
289	were	_	_	O
290	assessed	_	_	O
291	using	_	_	O
292	the	_	_	O
293	Spitzer	_	_	O
294	Quality	_	_	O
295	of	_	_	O
296	Life	_	_	O
297	Index	_	_	O
298	and	_	_	O
299	the	_	_	O
300	GLQ	_	_	O
301	-	_	_	O
302	8	_	_	O
303	,	_	_	O
304	respectively	_	_	O
305	,	_	_	O
306	before	_	_	O
307	random	_	_	O
308	assignment	_	_	O
309	and	_	_	O
310	during	_	_	O
311	and	_	_	O
312	after	_	_	O
313	treatment	_	_	O
314	.	_	_	O

315	All	_	_	O
316	analyses	_	_	O
317	were	_	_	O
318	by	_	_	O
319	intention	_	_	O
320	to	_	_	O
321	treat	_	_	O
322	.	_	_	O

323	All	_	_	O
324	P	_	_	O
325	values	_	_	O
326	are	_	_	O
327	two	_	_	O
328	-	_	_	O
329	sided	_	_	O
330	.	_	_	O

331	The	_	_	O
332	median	_	_	O
333	follow	_	_	O
334	-	_	_	O
335	up	_	_	O
336	was	_	_	O
337	8	_	_	O
338	.	_	_	O

339	5	_	_	O
340	years	_	_	O
341	.	_	_	O

342	All	_	_	O
343	but	_	_	O
344	five	_	_	O
345	survivors	_	_	O
346	(	_	_	O
347	3	_	_	O
348	%	_	_	O
349	)	_	_	O
350	were	_	_	O
351	followed	_	_	O
352	up	_	_	O
353	for	_	_	O
354	at	_	_	O
355	least	_	_	O
356	5	_	_	O
357	years	_	_	O
358	.	_	_	O

359	Overall	_	_	B-Premise
360	survival	_	_	I-Premise
361	remained	_	_	I-Premise
362	better	_	_	I-Premise
363	in	_	_	I-Premise
364	those	_	_	I-Premise
365	assigned	_	_	I-Premise
366	to	_	_	I-Premise
367	3B	_	_	I-Premise
368	(	_	_	I-Premise
369	90	_	_	I-Premise
370	)	_	_	I-Premise
371	E	_	_	I-Premise
372	(	_	_	I-Premise
373	500	_	_	I-Premise
374	)	_	_	I-Premise
375	P	_	_	I-Premise
376	than	_	_	I-Premise
377	in	_	_	I-Premise
378	those	_	_	I-Premise
379	assigned	_	_	I-Premise
380	to	_	_	I-Premise
381	4B	_	_	I-Premise
382	(	_	_	I-Premise
383	30	_	_	I-Premise
384	)	_	_	I-Premise
385	E	_	_	I-Premise
386	(	_	_	I-Premise
387	360	_	_	I-Premise
388	)	_	_	I-Premise
389	P	_	_	I-Premise
390	(	_	_	I-Premise
391	8	_	_	I-Premise
392	-	_	_	I-Premise
393	year	_	_	I-Premise
394	survival	_	_	I-Premise
395	:	_	_	I-Premise
396	92	_	_	I-Premise
397	%	_	_	I-Premise
398	vs	_	_	I-Premise
399	83	_	_	I-Premise
400	%	_	_	I-Premise
401	;	_	_	I-Premise
402	hazard	_	_	I-Premise
403	ratio	_	_	I-Premise
404	of	_	_	I-Premise
405	death	_	_	I-Premise
406	=	_	_	I-Premise
407	0	_	_	I-Premise
408	.	_	_	I-Premise

409	38	_	_	I-Premise
410	,	_	_	I-Premise
411	95	_	_	I-Premise
412	%	_	_	I-Premise
413	confidence	_	_	I-Premise
414	interval	_	_	I-Premise
415	=	_	_	I-Premise
416	0	_	_	I-Premise
417	.	_	_	I-Premise

418	15	_	_	I-Premise
419	to	_	_	I-Premise
420	0	_	_	I-Premise
421	.	_	_	I-Premise

422	97	_	_	I-Premise
423	,	_	_	I-Premise
424	P	_	_	I-Premise
425	=	_	_	I-Premise
426	.	_	_	I-Premise

427	037	_	_	I-Premise
428	)	_	_	I-Premise
429	.	_	_	I-Premise

430	Progression	_	_	B-Premise
431	-	_	_	I-Premise
432	free	_	_	I-Premise
433	survival	_	_	I-Premise
434	favored	_	_	I-Premise
435	3B	_	_	I-Premise
436	(	_	_	I-Premise
437	90	_	_	I-Premise
438	)	_	_	I-Premise
439	E	_	_	I-Premise
440	(	_	_	I-Premise
441	500	_	_	I-Premise
442	)	_	_	I-Premise
443	P	_	_	I-Premise
444	but	_	_	I-Premise
445	was	_	_	I-Premise
446	not	_	_	I-Premise
447	statistically	_	_	I-Premise
448	significantly	_	_	I-Premise
449	different	_	_	I-Premise
450	between	_	_	I-Premise
451	the	_	_	I-Premise
452	treatment	_	_	I-Premise
453	groups	_	_	I-Premise
454	(	_	_	I-Premise
455	8	_	_	I-Premise
456	-	_	_	I-Premise
457	year	_	_	I-Premise
458	progression	_	_	I-Premise
459	-	_	_	I-Premise
460	free	_	_	I-Premise
461	survival	_	_	I-Premise
462	,	_	_	I-Premise
463	3B	_	_	I-Premise
464	(	_	_	I-Premise
465	90	_	_	I-Premise
466	)	_	_	I-Premise
467	E	_	_	I-Premise
468	(	_	_	I-Premise
469	500	_	_	I-Premise
470	)	_	_	I-Premise
471	P	_	_	I-Premise
472	vs	_	_	I-Premise
473	4B	_	_	I-Premise
474	(	_	_	I-Premise
475	30	_	_	I-Premise
476	)	_	_	I-Premise
477	E	_	_	I-Premise
478	(	_	_	I-Premise
479	360	_	_	I-Premise
480	)	_	_	I-Premise
481	P	_	_	I-Premise
482	:	_	_	I-Premise
483	86	_	_	I-Premise
484	%	_	_	I-Premise
485	vs	_	_	I-Premise
486	79	_	_	I-Premise
487	%	_	_	I-Premise
488	;	_	_	I-Premise
489	hazard	_	_	I-Premise
490	ratio	_	_	I-Premise
491	of	_	_	I-Premise
492	progression	_	_	I-Premise
493	=	_	_	I-Premise
494	0	_	_	I-Premise
495	.	_	_	I-Premise

496	6	_	_	I-Premise
497	,	_	_	I-Premise
498	95	_	_	I-Premise
499	%	_	_	I-Premise
500	confidence	_	_	I-Premise
501	interval	_	_	I-Premise
502	=	_	_	I-Premise
503	0	_	_	I-Premise
504	.	_	_	I-Premise

505	3	_	_	I-Premise
506	to	_	_	I-Premise
507	1	_	_	I-Premise
508	.	_	_	I-Premise

509	1	_	_	I-Premise
510	,	_	_	I-Premise
511	P	_	_	I-Premise
512	=	_	_	I-Premise
513	.	_	_	I-Premise

514	15	_	_	I-Premise
515	)	_	_	I-Premise
516	.	_	_	I-Premise

517	At	_	_	B-Claim
518	the	_	_	I-Claim
519	end	_	_	I-Claim
520	of	_	_	I-Claim
521	treatment	_	_	I-Claim
522	,	_	_	I-Claim
523	average	_	_	I-Claim
524	scores	_	_	I-Claim
525	for	_	_	I-Claim
526	most	_	_	I-Claim
527	side	_	_	I-Claim
528	effect	_	_	I-Claim
529	scales	_	_	I-Claim
530	favored	_	_	I-Claim
531	3B	_	_	I-Claim
532	(	_	_	I-Claim
533	90	_	_	I-Claim
534	)	_	_	I-Claim
535	E	_	_	I-Claim
536	(	_	_	I-Claim
537	500	_	_	I-Claim
538	)	_	_	I-Claim
539	P	_	_	I-Claim
540	.	_	_	I-Claim

541	After	_	_	B-Premise
542	the	_	_	I-Premise
543	completion	_	_	I-Premise
544	of	_	_	I-Premise
545	treatment	_	_	I-Premise
546	,	_	_	I-Premise
547	average	_	_	I-Premise
548	GLQ	_	_	I-Premise
549	-	_	_	I-Premise
550	8	_	_	I-Premise
551	scores	_	_	I-Premise
552	for	_	_	I-Premise
553	numbness	_	_	I-Premise
554	(	_	_	I-Premise
555	P	_	_	I-Premise
556	=	_	_	I-Premise
557	.	_	_	I-Premise

558	003	_	_	I-Premise
559	)	_	_	I-Premise
560	and	_	_	I-Premise
561	hair	_	_	I-Premise
562	loss	_	_	I-Premise
563	(	_	_	I-Premise
564	P	_	_	I-Premise
565	=	_	_	I-Premise
566	.	_	_	I-Premise

567	04	_	_	I-Premise
568	)	_	_	I-Premise
569	and	_	_	I-Premise
570	the	_	_	I-Premise
571	Spitzer	_	_	I-Premise
572	Quality	_	_	I-Premise
573	of	_	_	I-Premise
574	Life	_	_	I-Premise
575	Index	_	_	I-Premise
576	(	_	_	I-Premise
577	P	_	_	I-Premise
578	=	_	_	I-Premise
579	.	_	_	I-Premise

580	05	_	_	I-Premise
581	)	_	_	I-Premise
582	favored	_	_	I-Premise
583	3B	_	_	I-Premise
584	(	_	_	I-Premise
585	90	_	_	I-Premise
586	)	_	_	I-Premise
587	E	_	_	I-Premise
588	(	_	_	I-Premise
589	500	_	_	I-Premise
590	)	_	_	I-Premise
591	P	_	_	I-Premise
592	.	_	_	I-Premise

593	The	_	_	B-Claim
594	survival	_	_	I-Claim
595	benefit	_	_	I-Claim
596	of	_	_	I-Claim
597	3B	_	_	I-Claim
598	(	_	_	I-Claim
599	90	_	_	I-Claim
600	)	_	_	I-Claim
601	E	_	_	I-Claim
602	(	_	_	I-Claim
603	500	_	_	I-Claim
604	)	_	_	I-Claim
605	P	_	_	I-Claim
606	over	_	_	I-Claim
607	4B	_	_	I-Claim
608	(	_	_	I-Claim
609	30	_	_	I-Claim
610	)	_	_	I-Claim
611	E	_	_	I-Claim
612	(	_	_	I-Claim
613	360	_	_	I-Claim
614	)	_	_	I-Claim
615	P	_	_	I-Claim
616	was	_	_	I-Claim
617	maintained	_	_	I-Claim
618	with	_	_	I-Claim
619	long	_	_	I-Claim
620	-	_	_	I-Claim
621	term	_	_	I-Claim
622	follow	_	_	I-Claim
623	-	_	_	I-Claim
624	up	_	_	I-Claim
625	.	_	_	I-Claim


0	There	_	_	O
1	is	_	_	O
2	a	_	_	O
3	paucity	_	_	O
4	of	_	_	O
5	methodologically	_	_	O
6	robust	_	_	O
7	vocational	_	_	O
8	rehabilitation	_	_	O
9	(	_	_	O
10	VR	_	_	O
11	)	_	_	O
12	intervention	_	_	O
13	trials	_	_	O
14	.	_	_	O

15	This	_	_	O
16	study	_	_	O
17	assessed	_	_	O
18	the	_	_	O
19	feasibility	_	_	O
20	and	_	_	O
21	acceptability	_	_	O
22	of	_	_	O
23	a	_	_	O
24	VR	_	_	O
25	trial	_	_	O
26	of	_	_	O
27	women	_	_	O
28	with	_	_	O
29	breast	_	_	O
30	cancer	_	_	O
31	to	_	_	O
32	inform	_	_	O
33	the	_	_	O
34	development	_	_	O
35	of	_	_	O
36	a	_	_	O
37	larger	_	_	O
38	interventional	_	_	O
39	study	_	_	O
40	.	_	_	O

41	Women	_	_	O
42	were	_	_	O
43	recruited	_	_	O
44	in	_	_	O
45	Scotland	_	_	O
46	and	_	_	O
47	randomised	_	_	O
48	to	_	_	O
49	either	_	_	O
50	a	_	_	O
51	case	_	_	O
52	management	_	_	O
53	VR	_	_	O
54	service	_	_	O
55	or	_	_	O
56	to	_	_	O
57	usual	_	_	O
58	care	_	_	O
59	.	_	_	O

60	Data	_	_	O
61	were	_	_	O
62	collected	_	_	O
63	on	_	_	O
64	eligibility	_	_	O
65	,	_	_	O
66	recruitment	_	_	O
67	and	_	_	O
68	attrition	_	_	O
69	rates	_	_	O
70	to	_	_	O
71	assess	_	_	O
72	trial	_	_	O
73	feasibility	_	_	O
74	,	_	_	O
75	and	_	_	O
76	interviews	_	_	O
77	conducted	_	_	O
78	to	_	_	O
79	determine	_	_	O
80	trial	_	_	O
81	acceptability	_	_	O
82	.	_	_	O

83	Sick	_	_	O
84	leave	_	_	O
85	days	_	_	O
86	(	_	_	O
87	primary	_	_	O
88	outcome	_	_	O
89	)	_	_	O
90	were	_	_	O
91	self	_	_	O
92	-	_	_	O
93	reported	_	_	O
94	via	_	_	O
95	postal	_	_	O
96	questionnaire	_	_	O
97	every	_	_	O
98	4	_	_	O
99	weeks	_	_	O
100	during	_	_	O
101	the	_	_	O
102	first	_	_	O
103	6	_	_	O
104	months	_	_	O
105	post	_	_	O
106	-	_	_	O
107	surgery	_	_	O
108	and	_	_	O
109	at	_	_	O
110	12	_	_	O
111	months	_	_	O
112	.	_	_	O

113	Secondary	_	_	O
114	outcome	_	_	O
115	measures	_	_	O
116	were	_	_	O
117	change	_	_	O
118	in	_	_	O
119	employment	_	_	O
120	pattern	_	_	O
121	,	_	_	O
122	quality	_	_	O
123	of	_	_	O
124	life	_	_	O
125	and	_	_	O
126	fatigue	_	_	O
127	.	_	_	O

128	Of	_	_	O
129	the	_	_	O
130	1	_	_	O
131	,	_	_	O
132	114	_	_	O
133	women	_	_	O
134	assessed	_	_	O
135	for	_	_	O
136	eligibility	_	_	O
137	,	_	_	O
138	163	_	_	O
139	(	_	_	O
140	15	_	_	O
141	%	_	_	O
142	)	_	_	O
143	were	_	_	O
144	eligible	_	_	O
145	.	_	_	O

146	The	_	_	O
147	main	_	_	O
148	reason	_	_	O
149	for	_	_	O
150	ineligibility	_	_	O
151	was	_	_	O
152	age	_	_	O
153	(	_	_	O
154	>	_	_	O
155	65	_	_	O
156	years	_	_	O
157	,	_	_	O
158	n	_	_	O
159	=	_	_	O
160	637	_	_	O
161	,	_	_	O
162	67	_	_	O
163	%	_	_	O
164	)	_	_	O
165	.	_	_	O

166	Of	_	_	O
167	those	_	_	O
168	eligible	_	_	O
169	,	_	_	O
170	111	_	_	O
171	(	_	_	O
172	68	_	_	O
173	%	_	_	O
174	)	_	_	O
175	received	_	_	O
176	study	_	_	O
177	information	_	_	O
178	,	_	_	O
179	of	_	_	O
180	which	_	_	O
181	23	_	_	O
182	(	_	_	O
183	21	_	_	O
184	%	_	_	O
185	)	_	_	O
186	consented	_	_	O
187	to	_	_	O
188	participate	_	_	O
189	in	_	_	O
190	the	_	_	O
191	study	_	_	O
192	.	_	_	O

193	Data	_	_	O
194	for	_	_	O
195	18	_	_	O
196	(	_	_	O
197	78	_	_	O
198	%	_	_	O
199	)	_	_	O
200	women	_	_	O
201	were	_	_	O
202	analysed	_	_	O
203	(	_	_	O
204	intervention	_	_	O
205	:	_	_	O
206	n	_	_	O
207	=	_	_	O
208	7	_	_	O
209	;	_	_	O
210	control	_	_	O
211	:	_	_	O
212	n	_	_	O
213	=	_	_	O
214	11	_	_	O
215	)	_	_	O
216	.	_	_	O

217	Participants	_	_	B-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	intervention	_	_	I-Premise
221	group	_	_	I-Premise
222	reported	_	_	I-Premise
223	,	_	_	I-Premise
224	on	_	_	I-Premise
225	average	_	_	I-Premise
226	,	_	_	I-Premise
227	53	_	_	I-Premise
228	fewer	_	_	I-Premise
229	days	_	_	I-Premise
230	of	_	_	I-Premise
231	sick	_	_	I-Premise
232	leave	_	_	I-Premise
233	over	_	_	I-Premise
234	the	_	_	I-Premise
235	first	_	_	I-Premise
236	6	_	_	I-Premise
237	months	_	_	I-Premise
238	post	_	_	I-Premise
239	-	_	_	I-Premise
240	surgery	_	_	I-Premise
241	than	_	_	I-Premise
242	those	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	control	_	_	I-Premise
246	group	_	_	I-Premise
247	;	_	_	I-Premise
248	however	_	_	B-Premise
249	,	_	_	I-Premise
250	this	_	_	I-Premise
251	difference	_	_	I-Premise
252	was	_	_	I-Premise
253	not	_	_	I-Premise
254	statistically	_	_	I-Premise
255	significant	_	_	I-Premise
256	(	_	_	I-Premise
257	p	_	_	I-Premise
258	=	_	_	I-Premise
259	0	_	_	I-Premise
260	.	_	_	I-Premise

261	122	_	_	I-Premise
262	;	_	_	I-Premise
263	95	_	_	I-Premise
264	%	_	_	I-Premise
265	confidence	_	_	I-Premise
266	interval	_	_	I-Premise
267	-	_	_	I-Premise
268	15	_	_	I-Premise
269	.	_	_	I-Premise

270	8	_	_	I-Premise
271	,	_	_	I-Premise
272	122	_	_	I-Premise
273	.	_	_	I-Premise

274	0	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	No	_	_	B-Premise
278	statistically	_	_	I-Premise
279	significant	_	_	I-Premise
280	differences	_	_	I-Premise
281	were	_	_	I-Premise
282	found	_	_	I-Premise
283	for	_	_	I-Premise
284	secondary	_	_	I-Premise
285	outcomes	_	_	I-Premise
286	.	_	_	I-Premise

287	Interviews	_	_	B-Premise
288	with	_	_	I-Premise
289	trial	_	_	I-Premise
290	participants	_	_	I-Premise
291	indicated	_	_	I-Premise
292	that	_	_	I-Premise
293	trial	_	_	I-Premise
294	procedures	_	_	I-Premise
295	,	_	_	I-Premise
296	including	_	_	I-Premise
297	recruitment	_	_	I-Premise
298	,	_	_	I-Premise
299	randomisation	_	_	I-Premise
300	and	_	_	I-Premise
301	research	_	_	I-Premise
302	instruments	_	_	I-Premise
303	,	_	_	I-Premise
304	were	_	_	I-Premise
305	acceptable	_	_	I-Premise
306	.	_	_	I-Premise

307	Conducting	_	_	B-Claim
308	a	_	_	I-Claim
309	pragmatic	_	_	I-Claim
310	trial	_	_	I-Claim
311	of	_	_	I-Claim
312	effectiveness	_	_	I-Claim
313	of	_	_	I-Claim
314	a	_	_	I-Claim
315	VR	_	_	I-Claim
316	intervention	_	_	I-Claim
317	among	_	_	I-Claim
318	cancer	_	_	I-Claim
319	survivors	_	_	I-Claim
320	is	_	_	I-Claim
321	both	_	_	I-Claim
322	feasible	_	_	I-Claim
323	and	_	_	I-Claim
324	acceptable	_	_	I-Claim
325	,	_	_	I-Claim
326	but	_	_	B-Claim
327	more	_	_	I-Claim
328	research	_	_	I-Claim
329	about	_	_	I-Claim
330	the	_	_	I-Claim
331	exact	_	_	I-Claim
332	components	_	_	I-Claim
333	of	_	_	I-Claim
334	a	_	_	I-Claim
335	VR	_	_	I-Claim
336	intervention	_	_	I-Claim
337	and	_	_	I-Claim
338	choice	_	_	I-Claim
339	of	_	_	I-Claim
340	outcomes	_	_	I-Claim
341	to	_	_	I-Claim
342	measure	_	_	I-Claim
343	effectiveness	_	_	I-Claim
344	is	_	_	I-Claim
345	required	_	_	I-Claim
346	.	_	_	I-Claim

347	VR	_	_	B-Claim
348	to	_	_	I-Claim
349	assist	_	_	I-Claim
350	breast	_	_	I-Claim
351	cancer	_	_	I-Claim
352	patients	_	_	I-Claim
353	in	_	_	I-Claim
354	the	_	_	I-Claim
355	return	_	_	I-Claim
356	to	_	_	I-Claim
357	work	_	_	I-Claim
358	process	_	_	I-Claim
359	is	_	_	I-Claim
360	an	_	_	I-Claim
361	important	_	_	I-Claim
362	component	_	_	I-Claim
363	of	_	_	I-Claim
364	cancer	_	_	I-Claim
365	survivorship	_	_	I-Claim
366	plans	_	_	I-Claim
367	.	_	_	I-Claim


0	Postcancer	_	_	B-Claim
1	fatigue	_	_	I-Claim
2	is	_	_	I-Claim
3	a	_	_	I-Claim
4	frequently	_	_	I-Claim
5	occurring	_	_	I-Claim
6	problem	_	_	I-Claim
7	,	_	_	I-Claim
8	impairing	_	_	I-Claim
9	quality	_	_	I-Claim
10	of	_	_	I-Claim
11	life	_	_	I-Claim
12	.	_	_	I-Claim

13	Until	_	_	O
14	now	_	_	O
15	,	_	_	O
16	little	_	_	O
17	is	_	_	O
18	known	_	_	O
19	about	_	_	O
20	(	_	_	O
21	neuro	_	_	O
22	)	_	_	O
23	physiological	_	_	O
24	factors	_	_	O
25	determining	_	_	O
26	postcancer	_	_	O
27	fatigue	_	_	O
28	.	_	_	O

29	For	_	_	O
30	non	_	_	O
31	-	_	_	O
32	cancer	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	chronic	_	_	O
36	fatigue	_	_	O
37	syndrome	_	_	O
38	,	_	_	O
39	certain	_	_	O
40	characteristics	_	_	O
41	of	_	_	O
42	brain	_	_	O
43	morphology	_	_	O
44	and	_	_	O
45	metabolism	_	_	O
46	have	_	_	O
47	been	_	_	O
48	identified	_	_	O
49	in	_	_	O
50	previous	_	_	O
51	studies	_	_	O
52	.	_	_	O

53	We	_	_	O
54	investigated	_	_	O
55	whether	_	_	O
56	these	_	_	O
57	volumetric	_	_	O
58	and	_	_	O
59	metabolic	_	_	O
60	traits	_	_	O
61	are	_	_	O
62	a	_	_	O
63	reflection	_	_	O
64	of	_	_	O
65	fatigue	_	_	O
66	in	_	_	O
67	general	_	_	O
68	and	_	_	O
69	thus	_	_	O
70	also	_	_	O
71	of	_	_	O
72	importance	_	_	O
73	for	_	_	O
74	postcancer	_	_	O
75	fatigue	_	_	O
76	.	_	_	O

77	Fatigued	_	_	O
78	patients	_	_	O
79	were	_	_	O
80	randomly	_	_	O
81	assigned	_	_	O
82	to	_	_	O
83	either	_	_	O
84	the	_	_	O
85	intervention	_	_	O
86	condition	_	_	O
87	(	_	_	O
88	cognitive	_	_	O
89	behavior	_	_	O
90	therapy	_	_	O
91	)	_	_	O
92	or	_	_	O
93	the	_	_	O
94	waiting	_	_	O
95	list	_	_	O
96	condition	_	_	O
97	.	_	_	O

98	Twenty	_	_	O
99	-	_	_	O
100	five	_	_	O
101	patients	_	_	O
102	in	_	_	O
103	the	_	_	O
104	intervention	_	_	O
105	condition	_	_	O
106	and	_	_	O
107	fourteen	_	_	O
108	patients	_	_	O
109	in	_	_	O
110	the	_	_	O
111	waiting	_	_	O
112	list	_	_	O
113	condition	_	_	O
114	were	_	_	O
115	assessed	_	_	O
116	twice	_	_	O
117	,	_	_	O
118	at	_	_	O
119	baseline	_	_	O
120	and	_	_	O
121	six	_	_	O
122	months	_	_	O
123	later	_	_	O
124	.	_	_	O

125	Baseline	_	_	O
126	measurements	_	_	O
127	of	_	_	O
128	20	_	_	O
129	fatigued	_	_	O
130	patients	_	_	O
131	were	_	_	O
132	compared	_	_	O
133	with	_	_	O
134	20	_	_	O
135	matched	_	_	O
136	non	_	_	O
137	-	_	_	O
138	fatigued	_	_	O
139	controls	_	_	O
140	.	_	_	O

141	All	_	_	O
142	participants	_	_	O
143	had	_	_	O
144	completed	_	_	O
145	treatment	_	_	O
146	of	_	_	O
147	a	_	_	O
148	malignant	_	_	O
149	,	_	_	O
150	solid	_	_	O
151	tumor	_	_	O
152	minimal	_	_	O
153	one	_	_	O
154	year	_	_	O
155	earlier	_	_	O
156	.	_	_	O

157	Global	_	_	O
158	brain	_	_	O
159	volumes	_	_	O
160	,	_	_	O
161	subcortical	_	_	O
162	brain	_	_	O
163	volumes	_	_	O
164	,	_	_	O
165	metabolite	_	_	O
166	tissue	_	_	O
167	concentrations	_	_	O
168	,	_	_	O
169	and	_	_	O
170	metabolite	_	_	O
171	ratios	_	_	O
172	were	_	_	O
173	primary	_	_	O
174	outcome	_	_	O
175	measures	_	_	O
176	.	_	_	O

177	Volumetric	_	_	O
178	and	_	_	O
179	metabolic	_	_	O
180	parameters	_	_	O
181	were	_	_	O
182	not	_	_	O
183	significantly	_	_	O
184	different	_	_	O
185	between	_	_	O
186	fatigued	_	_	O
187	and	_	_	O
188	non	_	_	O
189	-	_	_	O
190	fatigued	_	_	O
191	patients	_	_	O
192	.	_	_	O

193	Change	_	_	B-Premise
194	scores	_	_	I-Premise
195	of	_	_	I-Premise
196	volumetric	_	_	I-Premise
197	and	_	_	I-Premise
198	metabolic	_	_	I-Premise
199	parameters	_	_	I-Premise
200	from	_	_	I-Premise
201	baseline	_	_	I-Premise
202	to	_	_	I-Premise
203	follow	_	_	I-Premise
204	-	_	_	I-Premise
205	up	_	_	I-Premise
206	were	_	_	I-Premise
207	not	_	_	I-Premise
208	significantly	_	_	I-Premise
209	different	_	_	I-Premise
210	between	_	_	I-Premise
211	patients	_	_	I-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	therapy	_	_	I-Premise
215	and	_	_	I-Premise
216	the	_	_	I-Premise
217	waiting	_	_	I-Premise
218	list	_	_	I-Premise
219	group	_	_	I-Premise
220	.	_	_	I-Premise

221	Patients	_	_	B-Premise
222	in	_	_	I-Premise
223	the	_	_	I-Premise
224	therapy	_	_	I-Premise
225	group	_	_	I-Premise
226	reported	_	_	I-Premise
227	a	_	_	I-Premise
228	significant	_	_	I-Premise
229	larger	_	_	I-Premise
230	decrease	_	_	I-Premise
231	in	_	_	I-Premise
232	fatigue	_	_	I-Premise
233	scores	_	_	I-Premise
234	than	_	_	I-Premise
235	patients	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	waiting	_	_	I-Premise
239	list	_	_	I-Premise
240	group	_	_	I-Premise
241	.	_	_	I-Premise

242	No	_	_	B-Premise
243	relation	_	_	I-Premise
244	was	_	_	I-Premise
245	found	_	_	I-Premise
246	between	_	_	I-Premise
247	postcancer	_	_	I-Premise
248	fatigue	_	_	I-Premise
249	and	_	_	I-Premise
250	the	_	_	I-Premise
251	studied	_	_	I-Premise
252	volumetric	_	_	I-Premise
253	and	_	_	I-Premise
254	metabolic	_	_	I-Premise
255	markers	_	_	I-Premise
256	.	_	_	I-Premise

257	This	_	_	B-Claim
258	may	_	_	I-Claim
259	suggest	_	_	I-Claim
260	that	_	_	I-Claim
261	,	_	_	I-Claim
262	although	_	_	I-Claim
263	postcancer	_	_	I-Claim
264	fatigue	_	_	I-Claim
265	and	_	_	I-Claim
266	chronic	_	_	I-Claim
267	fatigue	_	_	I-Claim
268	syndrome	_	_	I-Claim
269	show	_	_	I-Claim
270	strong	_	_	I-Claim
271	resemblances	_	_	I-Claim
272	as	_	_	I-Claim
273	a	_	_	I-Claim
274	clinical	_	_	I-Claim
275	syndrome	_	_	I-Claim
276	,	_	_	I-Claim
277	the	_	_	I-Claim
278	underlying	_	_	I-Claim
279	physiology	_	_	I-Claim
280	is	_	_	I-Claim
281	different	_	_	I-Claim
282	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	cisplatin	_	_	O
4	plus	_	_	O
5	paclitaxel	_	_	O
6	(	_	_	O
7	C	_	_	O
8	+	_	_	O
9	P	_	_	O
10	)	_	_	O
11	improved	_	_	O
12	response	_	_	O
13	rate	_	_	O
14	,	_	_	O
15	progression	_	_	O
16	-	_	_	O
17	free	_	_	O
18	survival	_	_	O
19	(	_	_	O
20	PFS	_	_	O
21	)	_	_	O
22	,	_	_	O
23	or	_	_	O
24	survival	_	_	O
25	compared	_	_	O
26	with	_	_	O
27	cisplatin	_	_	O
28	alone	_	_	O
29	in	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	stage	_	_	O
33	IVB	_	_	O
34	,	_	_	O
35	recurrent	_	_	O
36	,	_	_	O
37	or	_	_	O
38	persistent	_	_	O
39	squamous	_	_	O
40	cell	_	_	O
41	carcinoma	_	_	O
42	of	_	_	O
43	the	_	_	O
44	cervix	_	_	O
45	.	_	_	O

46	PATIENTS	_	_	O
47	AND	_	_	O
48	METHODS	_	_	O
49	Eligible	_	_	O
50	:	_	_	O
51	patients	_	_	O
52	with	_	_	O
53	measurable	_	_	O
54	disease	_	_	O
55	,	_	_	O
56	performance	_	_	O
57	status	_	_	O
58	(	_	_	O
59	PS	_	_	O
60	)	_	_	O
61	0	_	_	O
62	to	_	_	O
63	2	_	_	O
64	,	_	_	O
65	and	_	_	O
66	adequate	_	_	O
67	hematologic	_	_	O
68	,	_	_	O
69	hepatic	_	_	O
70	,	_	_	O
71	and	_	_	O
72	renal	_	_	O
73	function	_	_	O
74	received	_	_	O
75	either	_	_	O
76	cisplatin	_	_	O
77	50	_	_	O
78	mg	_	_	O
79	/	_	_	O
80	m2	_	_	O
81	or	_	_	O
82	C	_	_	O
83	+	_	_	O
84	P	_	_	O
85	(	_	_	O
86	cisplatin	_	_	O
87	50	_	_	O
88	mg	_	_	O
89	/	_	_	O
90	m2	_	_	O
91	plus	_	_	O
92	paclitaxel	_	_	O
93	135	_	_	O
94	mg	_	_	O
95	/	_	_	O
96	m2	_	_	O
97	)	_	_	O
98	every	_	_	O
99	3	_	_	O
100	weeks	_	_	O
101	for	_	_	O
102	six	_	_	O
103	cycles	_	_	O
104	.	_	_	O

105	Tumor	_	_	O
106	measurements	_	_	O
107	and	_	_	O
108	quality	_	_	O
109	-	_	_	O
110	of	_	_	O
111	-	_	_	O
112	life	_	_	O
113	(	_	_	O
114	QOL	_	_	O
115	)	_	_	O
116	assessments	_	_	O
117	were	_	_	O
118	obtained	_	_	O
119	before	_	_	O
120	each	_	_	O
121	treatment	_	_	O
122	cycle	_	_	O
123	.	_	_	O

124	Of	_	_	O
125	280	_	_	O
126	patients	_	_	O
127	entered	_	_	O
128	,	_	_	O
129	6	_	_	O
130	%	_	_	O
131	were	_	_	O
132	ineligible	_	_	O
133	.	_	_	O

134	Among	_	_	O
135	264	_	_	O
136	eligible	_	_	O
137	patients	_	_	O
138	,	_	_	O
139	134	_	_	O
140	received	_	_	O
141	cisplatin	_	_	O
142	and	_	_	O
143	130	_	_	O
144	received	_	_	O
145	C	_	_	O
146	+	_	_	O
147	P	_	_	O
148	.	_	_	O

149	Groups	_	_	O
150	were	_	_	O
151	well	_	_	O
152	matched	_	_	O
153	with	_	_	O
154	respect	_	_	O
155	to	_	_	O
156	age	_	_	O
157	,	_	_	O
158	ethnicity	_	_	O
159	,	_	_	O
160	PS	_	_	O
161	,	_	_	O
162	tumor	_	_	O
163	grade	_	_	O
164	,	_	_	O
165	disease	_	_	O
166	site	_	_	O
167	,	_	_	O
168	and	_	_	O
169	number	_	_	O
170	of	_	_	O
171	cycles	_	_	O
172	received	_	_	O
173	.	_	_	O

174	The	_	_	O
175	majority	_	_	O
176	of	_	_	O
177	all	_	_	O
178	patients	_	_	O
179	had	_	_	O
180	prior	_	_	O
181	radiation	_	_	O
182	therapy	_	_	O
183	(	_	_	O
184	cisplatin	_	_	O
185	,	_	_	O
186	92	_	_	O
187	%	_	_	O
188	;	_	_	O
189	C	_	_	O
190	+	_	_	O
191	P	_	_	O
192	,	_	_	O
193	91	_	_	O
194	%	_	_	O
195	)	_	_	O
196	.	_	_	O

197	Objective	_	_	B-Premise
198	responses	_	_	I-Premise
199	occurred	_	_	I-Premise
200	in	_	_	I-Premise
201	19	_	_	I-Premise
202	%	_	_	I-Premise
203	(	_	_	I-Premise
204	6	_	_	I-Premise
205	%	_	_	I-Premise
206	complete	_	_	I-Premise
207	plus	_	_	I-Premise
208	13	_	_	I-Premise
209	%	_	_	I-Premise
210	partial	_	_	I-Premise
211	)	_	_	I-Premise
212	of	_	_	I-Premise
213	patients	_	_	I-Premise
214	receiving	_	_	I-Premise
215	cisplatin	_	_	I-Premise
216	versus	_	_	I-Premise
217	36	_	_	I-Premise
218	%	_	_	I-Premise
219	(	_	_	I-Premise
220	15	_	_	I-Premise
221	%	_	_	I-Premise
222	complete	_	_	I-Premise
223	plus	_	_	I-Premise
224	21	_	_	I-Premise
225	%	_	_	I-Premise
226	partial	_	_	I-Premise
227	)	_	_	I-Premise
228	receiving	_	_	I-Premise
229	C	_	_	I-Premise
230	+	_	_	I-Premise
231	P	_	_	I-Premise
232	(	_	_	I-Premise
233	P	_	_	I-Premise
234	=	_	_	I-Premise
235	.	_	_	I-Premise

236	002	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	The	_	_	B-Premise
240	median	_	_	I-Premise
241	PFS	_	_	I-Premise
242	was	_	_	I-Premise
243	2	_	_	I-Premise
244	.	_	_	I-Premise

245	8	_	_	I-Premise
246	and	_	_	I-Premise
247	4	_	_	I-Premise
248	.	_	_	I-Premise

249	8	_	_	I-Premise
250	months	_	_	I-Premise
251	,	_	_	I-Premise
252	respectively	_	_	I-Premise
253	,	_	_	I-Premise
254	for	_	_	I-Premise
255	cisplatin	_	_	I-Premise
256	versus	_	_	I-Premise
257	C	_	_	I-Premise
258	+	_	_	I-Premise
259	P	_	_	I-Premise
260	(	_	_	I-Premise
261	P	_	_	I-Premise
262	<	_	_	I-Premise
263	.	_	_	I-Premise

264	001	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	There	_	_	B-Premise
268	was	_	_	I-Premise
269	no	_	_	I-Premise
270	difference	_	_	I-Premise
271	in	_	_	I-Premise
272	median	_	_	I-Premise
273	survival	_	_	I-Premise
274	(	_	_	I-Premise
275	8	_	_	I-Premise
276	.	_	_	I-Premise

277	8	_	_	I-Premise
278	months	_	_	I-Premise
279	v	_	_	I-Premise
280	9	_	_	I-Premise
281	.	_	_	I-Premise

282	7	_	_	I-Premise
283	months	_	_	I-Premise
284	)	_	_	I-Premise
285	.	_	_	I-Premise

286	Grade	_	_	B-Premise
287	3	_	_	I-Premise
288	to	_	_	I-Premise
289	4	_	_	I-Premise
290	anemia	_	_	I-Premise
291	and	_	_	I-Premise
292	neutropenia	_	_	I-Premise
293	were	_	_	I-Premise
294	more	_	_	I-Premise
295	common	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	combination	_	_	I-Premise
299	arm	_	_	I-Premise
300	.	_	_	I-Premise

301	There	_	_	B-Premise
302	was	_	_	I-Premise
303	no	_	_	I-Premise
304	significant	_	_	I-Premise
305	difference	_	_	I-Premise
306	in	_	_	I-Premise
307	QOL	_	_	I-Premise
308	scores	_	_	I-Premise
309	,	_	_	I-Premise
310	although	_	_	B-Premise
311	a	_	_	I-Premise
312	disproportionate	_	_	I-Premise
313	number	_	_	I-Premise
314	of	_	_	I-Premise
315	patients	_	_	I-Premise
316	(	_	_	I-Premise
317	cisplatin	_	_	I-Premise
318	,	_	_	I-Premise
319	n	_	_	I-Premise
320	=	_	_	I-Premise
321	50	_	_	I-Premise
322	;	_	_	I-Premise
323	C	_	_	I-Premise
324	+	_	_	I-Premise
325	P	_	_	I-Premise
326	,	_	_	I-Premise
327	n	_	_	I-Premise
328	=	_	_	I-Premise
329	33	_	_	I-Premise
330	)	_	_	I-Premise
331	dropped	_	_	I-Premise
332	out	_	_	I-Premise
333	of	_	_	I-Premise
334	the	_	_	I-Premise
335	QOL	_	_	I-Premise
336	component	_	_	I-Premise
337	,	_	_	I-Premise
338	presumably	_	_	I-Premise
339	because	_	_	I-Premise
340	of	_	_	I-Premise
341	increasing	_	_	I-Premise
342	disease	_	_	I-Premise
343	,	_	_	I-Premise
344	deteriorating	_	_	I-Premise
345	health	_	_	I-Premise
346	status	_	_	I-Premise
347	,	_	_	I-Premise
348	or	_	_	I-Premise
349	early	_	_	I-Premise
350	death	_	_	I-Premise
351	.	_	_	I-Premise

352	C	_	_	B-Claim
353	+	_	_	I-Claim
354	P	_	_	I-Claim
355	is	_	_	I-Claim
356	superior	_	_	I-Claim
357	to	_	_	I-Claim
358	cisplatin	_	_	I-Claim
359	alone	_	_	I-Claim
360	with	_	_	I-Claim
361	respect	_	_	I-Claim
362	to	_	_	I-Claim
363	response	_	_	I-Claim
364	rate	_	_	I-Claim
365	and	_	_	I-Claim
366	PFS	_	_	I-Claim
367	with	_	_	I-Claim
368	sustained	_	_	I-Claim
369	QOL	_	_	I-Claim
370	.	_	_	I-Claim


0	Imatinib	_	_	B-Claim
1	(	_	_	I-Claim
2	Gleevec	_	_	I-Claim
3	)	_	_	I-Claim
4	,	_	_	I-Claim
5	a	_	_	I-Claim
6	highly	_	_	I-Claim
7	effective	_	_	I-Claim
8	specific	_	_	I-Claim
9	tyrosine	_	_	I-Claim
10	kinase	_	_	I-Claim
11	inhibitor	_	_	I-Claim
12	,	_	_	I-Claim
13	demonstrates	_	_	I-Claim
14	a	_	_	I-Claim
15	better	_	_	I-Claim
16	side	_	_	I-Claim
17	effect	_	_	I-Claim
18	profile	_	_	I-Claim
19	than	_	_	I-Claim
20	interferon	_	_	I-Claim
21	-	_	_	I-Claim
22	alpha	_	_	I-Claim
23	(	_	_	I-Claim
24	IFN	_	_	I-Claim
25	)	_	_	I-Claim
26	,	_	_	I-Claim
27	which	_	_	I-Claim
28	impairs	_	_	I-Claim
29	patients	_	_	I-Claim
30	'	_	_	I-Claim
31	quality	_	_	I-Claim
32	of	_	_	I-Claim
33	life	_	_	I-Claim
34	(	_	_	I-Claim
35	QoL	_	_	I-Claim
36	)	_	_	I-Claim
37	.	_	_	I-Claim

38	This	_	_	O
39	phase	_	_	O
40	III	_	_	O
41	international	_	_	O
42	study	_	_	O
43	evaluated	_	_	O
44	QoL	_	_	O
45	outcomes	_	_	O
46	in	_	_	O
47	1	_	_	O
48	,	_	_	O
49	106	_	_	O
50	newly	_	_	O
51	diagnosed	_	_	O
52	patients	_	_	O
53	with	_	_	O
54	chronic	_	_	O
55	-	_	_	O
56	phase	_	_	O
57	chronic	_	_	O
58	myeloid	_	_	O
59	leukemia	_	_	O
60	(	_	_	O
61	CML	_	_	O
62	)	_	_	O
63	who	_	_	O
64	were	_	_	O
65	randomized	_	_	O
66	to	_	_	O
67	receive	_	_	O
68	either	_	_	O
69	imatinib	_	_	O
70	400	_	_	O
71	mg	_	_	O
72	daily	_	_	O
73	or	_	_	O
74	IFN	_	_	O
75	up	_	_	O
76	to	_	_	O
77	5	_	_	O
78	MU	_	_	O
79	/	_	_	O
80	m	_	_	O
81	(	_	_	O
82	2	_	_	O
83	)	_	_	O
84	/	_	_	O
85	d	_	_	O
86	with	_	_	O
87	cytarabine	_	_	O
88	(	_	_	O
89	Ara	_	_	O
90	-	_	_	O
91	C	_	_	O
92	)	_	_	O
93	20	_	_	O
94	mg	_	_	O
95	/	_	_	O
96	m	_	_	O
97	(	_	_	O
98	2	_	_	O
99	)	_	_	O
100	/	_	_	O
101	d	_	_	O
102	added	_	_	O
103	for	_	_	O
104	10	_	_	O
105	days	_	_	O
106	every	_	_	O
107	month	_	_	O
108	(	_	_	O
109	IFN	_	_	O
110	+	_	_	O
111	LDAC	_	_	O
112	)	_	_	O
113	.	_	_	O

114	Crossover	_	_	O
115	to	_	_	O
116	the	_	_	O
117	other	_	_	O
118	treatment	_	_	O
119	arm	_	_	O
120	was	_	_	O
121	permitted	_	_	O
122	due	_	_	O
123	to	_	_	O
124	a	_	_	O
125	lack	_	_	O
126	of	_	_	O
127	efficacy	_	_	O
128	or	_	_	O
129	treatment	_	_	O
130	intolerance	_	_	O
131	.	_	_	O

132	QoL	_	_	O
133	was	_	_	O
134	assessed	_	_	O
135	with	_	_	O
136	the	_	_	O
137	Functional	_	_	O
138	Assessment	_	_	O
139	of	_	_	O
140	Cancer	_	_	O
141	Therapy	_	_	O
142	-	_	_	O
143	Biologic	_	_	O
144	Response	_	_	O
145	Modifiers	_	_	O
146	(	_	_	O
147	FACT	_	_	O
148	-	_	_	O
149	BRM	_	_	O
150	)	_	_	O
151	at	_	_	O
152	baseline	_	_	O
153	,	_	_	O
154	monthly	_	_	O
155	for	_	_	O
156	6	_	_	O
157	months	_	_	O
158	and	_	_	O
159	then	_	_	O
160	at	_	_	O
161	months	_	_	O
162	9	_	_	O
163	,	_	_	O
164	12	_	_	O
165	,	_	_	O
166	and	_	_	O
167	18	_	_	O
168	.	_	_	O

169	The	_	_	O
170	Trial	_	_	O
171	Outcome	_	_	O
172	Index	_	_	O
173	(	_	_	O
174	TOI	_	_	O
175	;	_	_	O
176	a	_	_	O
177	composite	_	_	O
178	endpoint	_	_	O
179	of	_	_	O
180	physical	_	_	O
181	/	_	_	O
182	functional	_	_	O
183	/	_	_	O
184	treatment	_	_	O
185	-	_	_	O
186	specific	_	_	O
187	subscales	_	_	O
188	)	_	_	O
189	was	_	_	O
190	the	_	_	O
191	primary	_	_	O
192	endpoint	_	_	O
193	.	_	_	O

194	Secondary	_	_	O
195	endpoints	_	_	O
196	measured	_	_	O
197	were	_	_	O
198	social	_	_	O
199	/	_	_	O
200	family	_	_	O
201	well	_	_	O
202	-	_	_	O
203	being	_	_	O
204	(	_	_	O
205	SFWB	_	_	O
206	)	_	_	O
207	and	_	_	O
208	emotional	_	_	O
209	well	_	_	O
210	-	_	_	O
211	being	_	_	O
212	(	_	_	O
213	EWB	_	_	O
214	)	_	_	O
215	.	_	_	O

216	QoL	_	_	O
217	was	_	_	O
218	analyzed	_	_	O
219	for	_	_	O
220	the	_	_	O
221	first	_	_	O
222	18	_	_	O
223	months	_	_	O
224	of	_	_	O
225	treatment	_	_	O
226	using	_	_	O
227	mixed	_	_	O
228	effects	_	_	O
229	growth	_	_	O
230	curve	_	_	O
231	models	_	_	O
232	.	_	_	O

233	The	_	_	O
234	primary	_	_	O
235	analyses	_	_	O
236	were	_	_	O
237	intention	_	_	O
238	-	_	_	O
239	to	_	_	O
240	-	_	_	O
241	treat	_	_	O
242	(	_	_	O
243	ITT	_	_	O
244	)	_	_	O
245	;	_	_	O
246	secondary	_	_	O
247	analyses	_	_	O
248	incorporated	_	_	O
249	crossover	_	_	O
250	as	_	_	O
251	a	_	_	O
252	time	_	_	O
253	-	_	_	O
254	dependent	_	_	O
255	covariate	_	_	O
256	.	_	_	O

257	A	_	_	O
258	total	_	_	O
259	of	_	_	O
260	1	_	_	O
261	,	_	_	O
262	049	_	_	O
263	patients	_	_	O
264	completed	_	_	O
265	at	_	_	O
266	least	_	_	O
267	one	_	_	O
268	QoL	_	_	O
269	assessment	_	_	O
270	.	_	_	O

271	Two	_	_	B-Premise
272	hundred	_	_	I-Premise
273	sixty	_	_	I-Premise
274	-	_	_	I-Premise
275	one	_	_	I-Premise
276	patients	_	_	I-Premise
277	(	_	_	I-Premise
278	50	_	_	I-Premise
279	%	_	_	I-Premise
280	)	_	_	I-Premise
281	crossed	_	_	I-Premise
282	over	_	_	I-Premise
283	from	_	_	I-Premise
284	IFN	_	_	I-Premise
285	to	_	_	I-Premise
286	imatinib	_	_	I-Premise
287	and	_	_	I-Premise
288	11	_	_	I-Premise
289	(	_	_	I-Premise
290	2	_	_	I-Premise
291	%	_	_	I-Premise
292	)	_	_	I-Premise
293	crossed	_	_	I-Premise
294	over	_	_	I-Premise
295	from	_	_	I-Premise
296	imatinib	_	_	I-Premise
297	to	_	_	I-Premise
298	IFN	_	_	I-Premise
299	.	_	_	I-Premise

300	There	_	_	B-Premise
301	was	_	_	I-Premise
302	a	_	_	I-Premise
303	significant	_	_	I-Premise
304	decline	_	_	I-Premise
305	in	_	_	I-Premise
306	TOI	_	_	I-Premise
307	scores	_	_	I-Premise
308	for	_	_	I-Premise
309	the	_	_	I-Premise
310	IFN	_	_	I-Premise
311	treatment	_	_	I-Premise
312	arm	_	_	I-Premise
313	compared	_	_	I-Premise
314	with	_	_	I-Premise
315	preservation	_	_	I-Premise
316	of	_	_	I-Premise
317	baseline	_	_	I-Premise
318	TOI	_	_	I-Premise
319	scores	_	_	I-Premise
320	in	_	_	I-Premise
321	the	_	_	I-Premise
322	imatinib	_	_	I-Premise
323	arm	_	_	I-Premise
324	(	_	_	I-Premise
325	P	_	_	I-Premise
326	<	_	_	I-Premise
327	.	_	_	I-Premise

328	001	_	_	I-Premise
329	,	_	_	I-Premise
330	ITT	_	_	I-Premise
331	)	_	_	I-Premise
332	.	_	_	I-Premise

333	Mean	_	_	B-Premise
334	social	_	_	I-Premise
335	/	_	_	I-Premise
336	family	_	_	I-Premise
337	and	_	_	I-Premise
338	EWB	_	_	I-Premise
339	scores	_	_	I-Premise
340	were	_	_	I-Premise
341	22	_	_	I-Premise
342	.	_	_	I-Premise

343	8	_	_	I-Premise
344	and	_	_	I-Premise
345	19	_	_	I-Premise
346	.	_	_	I-Premise

347	5	_	_	I-Premise
348	,	_	_	I-Premise
349	respectively	_	_	I-Premise
350	,	_	_	I-Premise
351	for	_	_	I-Premise
352	imatinib	_	_	I-Premise
353	and	_	_	I-Premise
354	21	_	_	I-Premise
355	.	_	_	I-Premise

356	6	_	_	I-Premise
357	and	_	_	I-Premise
358	17	_	_	I-Premise
359	.	_	_	I-Premise

360	6	_	_	I-Premise
361	,	_	_	I-Premise
362	respectively	_	_	I-Premise
363	,	_	_	I-Premise
364	for	_	_	I-Premise
365	IFN	_	_	I-Premise
366	(	_	_	I-Premise
367	P	_	_	I-Premise
368	<	_	_	I-Premise
369	.	_	_	I-Premise

370	001	_	_	I-Premise
371	,	_	_	I-Premise
372	ITT	_	_	I-Premise
373	)	_	_	I-Premise
374	.	_	_	I-Premise

375	After	_	_	B-Premise
376	crossing	_	_	I-Premise
377	over	_	_	I-Premise
378	from	_	_	I-Premise
379	IFN	_	_	I-Premise
380	to	_	_	I-Premise
381	imatinib	_	_	I-Premise
382	,	_	_	I-Premise
383	patients	_	_	I-Premise
384	experienced	_	_	I-Premise
385	a	_	_	I-Premise
386	significant	_	_	I-Premise
387	(	_	_	I-Premise
388	P	_	_	I-Premise
389	<	_	_	I-Premise
390	.	_	_	I-Premise

391	001	_	_	I-Premise
392	)	_	_	I-Premise
393	increase	_	_	I-Premise
394	in	_	_	I-Premise
395	TOI	_	_	I-Premise
396	scores	_	_	I-Premise
397	.	_	_	I-Premise

398	Imatinib	_	_	B-Claim
399	offers	_	_	I-Claim
400	clear	_	_	I-Claim
401	QoL	_	_	I-Claim
402	advantages	_	_	I-Claim
403	over	_	_	I-Claim
404	IFN	_	_	I-Claim
405	as	_	_	I-Claim
406	first	_	_	I-Claim
407	-	_	_	I-Claim
408	line	_	_	I-Claim
409	treatment	_	_	I-Claim
410	of	_	_	I-Claim
411	chronic	_	_	I-Claim
412	-	_	_	I-Claim
413	phase	_	_	I-Claim
414	CML	_	_	I-Claim
415	.	_	_	I-Claim

416	In	_	_	O
417	addition	_	_	O
418	,	_	_	O
419	patients	_	_	B-Claim
420	who	_	_	I-Claim
421	crossed	_	_	I-Claim
422	over	_	_	I-Claim
423	to	_	_	I-Claim
424	imatinib	_	_	I-Claim
425	reported	_	_	I-Claim
426	higher	_	_	I-Claim
427	QoL	_	_	I-Claim
428	than	_	_	I-Claim
429	those	_	_	I-Claim
430	who	_	_	I-Claim
431	remained	_	_	I-Claim
432	on	_	_	I-Claim
433	IFN	_	_	I-Claim
434	.	_	_	I-Claim


0	Both	_	_	O
1	Billroth	_	_	O
2	I	_	_	O
3	(	_	_	O
4	B	_	_	O
5	-	_	_	O
6	I	_	_	O
7	)	_	_	O
8	and	_	_	O
9	Roux	_	_	O
10	-	_	_	O
11	en	_	_	O
12	-	_	_	O
13	Y	_	_	O
14	(	_	_	O
15	R	_	_	O
16	-	_	_	O
17	Y	_	_	O
18	)	_	_	O
19	reconstructions	_	_	O
20	are	_	_	O
21	commonly	_	_	O
22	performed	_	_	O
23	as	_	_	O
24	standard	_	_	O
25	procedures	_	_	O
26	,	_	_	O
27	but	_	_	O
28	it	_	_	O
29	has	_	_	O
30	yet	_	_	O
31	to	_	_	O
32	be	_	_	O
33	determined	_	_	O
34	which	_	_	O
35	reconstruction	_	_	O
36	is	_	_	O
37	better	_	_	O
38	for	_	_	O
39	patients	_	_	O
40	.	_	_	O

41	A	_	_	O
42	randomized	_	_	O
43	prospective	_	_	O
44	phase	_	_	O
45	II	_	_	O
46	trial	_	_	O
47	with	_	_	O
48	body	_	_	O
49	weight	_	_	O
50	loss	_	_	O
51	at	_	_	O
52	1	_	_	O
53	year	_	_	O
54	after	_	_	O
55	surgery	_	_	O
56	as	_	_	O
57	a	_	_	O
58	primary	_	_	O
59	endpoint	_	_	O
60	was	_	_	O
61	performed	_	_	O
62	to	_	_	O
63	address	_	_	O
64	this	_	_	O
65	issue	_	_	O
66	.	_	_	O

67	The	_	_	O
68	current	_	_	O
69	report	_	_	O
70	delivers	_	_	O
71	data	_	_	O
72	on	_	_	O
73	the	_	_	O
74	quality	_	_	O
75	of	_	_	O
76	life	_	_	O
77	and	_	_	O
78	degree	_	_	O
79	of	_	_	O
80	postoperative	_	_	O
81	dysfunction	_	_	O
82	,	_	_	O
83	which	_	_	O
84	were	_	_	O
85	the	_	_	O
86	secondary	_	_	O
87	endpoints	_	_	O
88	of	_	_	O
89	this	_	_	O
90	study	_	_	O
91	.	_	_	O

92	Gastric	_	_	O
93	cancer	_	_	O
94	patients	_	_	O
95	who	_	_	O
96	underwent	_	_	O
97	distal	_	_	O
98	gastrectomy	_	_	O
99	were	_	_	O
100	intraoperatively	_	_	O
101	randomized	_	_	O
102	to	_	_	O
103	B	_	_	O
104	-	_	_	O
105	I	_	_	O
106	or	_	_	O
107	R	_	_	O
108	-	_	_	O
109	Y	_	_	O
110	.	_	_	O

111	Postsurgical	_	_	O
112	QOL	_	_	O
113	was	_	_	O
114	evaluated	_	_	O
115	using	_	_	O
116	the	_	_	O
117	EORTC	_	_	O
118	QLQ	_	_	O
119	-	_	_	O
120	C30	_	_	O
121	and	_	_	O
122	DAUGS	_	_	O
123	20	_	_	O
124	.	_	_	O

125	Between	_	_	O
126	August	_	_	O
127	2005	_	_	O
128	and	_	_	O
129	December	_	_	O
130	2008	_	_	O
131	,	_	_	O
132	332	_	_	O
133	patients	_	_	O
134	were	_	_	O
135	enrolled	_	_	O
136	in	_	_	O
137	a	_	_	O
138	randomized	_	_	O
139	trial	_	_	O
140	comparing	_	_	O
141	B	_	_	O
142	-	_	_	O
143	I	_	_	O
144	versus	_	_	O
145	R	_	_	O
146	-	_	_	O
147	Y	_	_	O
148	.	_	_	O

149	A	_	_	O
150	mail	_	_	O
151	survey	_	_	O
152	questionnaire	_	_	O
153	sent	_	_	O
154	to	_	_	O
155	327	_	_	O
156	patients	_	_	O
157	was	_	_	O
158	completed	_	_	O
159	by	_	_	O
160	268	_	_	O
161	(	_	_	O
162	86	_	_	O
163	.	_	_	O

164	2	_	_	O
165	%	_	_	O
166	)	_	_	O
167	of	_	_	O
168	them	_	_	O
169	.	_	_	O

170	EORTC	_	_	O
171	QLQ	_	_	O
172	-	_	_	O
173	C30	_	_	O
174	scores	_	_	O
175	were	_	_	O
176	as	_	_	O
177	follows	_	_	O
178	:	_	_	O
179	global	_	_	O
180	health	_	_	O
181	status	_	_	O
182	was	_	_	O
183	similar	_	_	O
184	in	_	_	O
185	each	_	_	O
186	group	_	_	O
187	(	_	_	O
188	B	_	_	O
189	-	_	_	O
190	I	_	_	O
191	73	_	_	O
192	.	_	_	O

193	5	_	_	O
194	±	_	_	O
195	18	_	_	O
196	.	_	_	O

197	8	_	_	O
198	,	_	_	O
199	R	_	_	O
200	-	_	_	O
201	Y	_	_	O
202	73	_	_	O
203	.	_	_	O

204	2	_	_	O
205	±	_	_	O
206	20	_	_	O
207	.	_	_	O

208	2	_	_	O
209	,	_	_	O
210	p	_	_	O
211	=	_	_	O
212	0	_	_	O
213	.	_	_	O

214	87	_	_	O
215	)	_	_	O
216	.	_	_	O

217	Scores	_	_	O
218	of	_	_	O
219	five	_	_	O
220	functional	_	_	O
221	scales	_	_	O
222	were	_	_	O
223	also	_	_	O
224	similar	_	_	O
225	.	_	_	O

226	Only	_	_	B-Premise
227	the	_	_	I-Premise
228	dyspnea	_	_	I-Premise
229	symptom	_	_	I-Premise
230	scale	_	_	I-Premise
231	showed	_	_	I-Premise
232	superior	_	_	I-Premise
233	results	_	_	I-Premise
234	for	_	_	I-Premise
235	R	_	_	I-Premise
236	-	_	_	I-Premise
237	Y	_	_	I-Premise
238	than	_	_	I-Premise
239	for	_	_	I-Premise
240	B	_	_	I-Premise
241	-	_	_	I-Premise
242	I	_	_	I-Premise
243	(	_	_	I-Premise
244	B	_	_	I-Premise
245	-	_	_	I-Premise
246	I	_	_	I-Premise
247	13	_	_	I-Premise
248	.	_	_	I-Premise

249	6	_	_	I-Premise
250	±	_	_	I-Premise
251	17	_	_	I-Premise
252	.	_	_	I-Premise

253	9	_	_	I-Premise
254	,	_	_	I-Premise
255	R	_	_	I-Premise
256	-	_	_	I-Premise
257	Y	_	_	I-Premise
258	8	_	_	I-Premise
259	.	_	_	I-Premise

260	6	_	_	I-Premise
261	±	_	_	I-Premise
262	16	_	_	I-Premise
263	.	_	_	I-Premise

264	3	_	_	I-Premise
265	,	_	_	I-Premise
266	p	_	_	I-Premise
267	=	_	_	I-Premise
268	0	_	_	I-Premise
269	.	_	_	I-Premise

270	02	_	_	I-Premise
271	)	_	_	I-Premise
272	.	_	_	I-Premise

273	With	_	_	B-Premise
274	respect	_	_	I-Premise
275	to	_	_	I-Premise
276	DAUGS	_	_	I-Premise
277	20	_	_	I-Premise
278	,	_	_	I-Premise
279	the	_	_	I-Premise
280	total	_	_	I-Premise
281	score	_	_	I-Premise
282	did	_	_	I-Premise
283	not	_	_	I-Premise
284	differ	_	_	I-Premise
285	significantly	_	_	I-Premise
286	between	_	_	I-Premise
287	the	_	_	I-Premise
288	R	_	_	I-Premise
289	-	_	_	I-Premise
290	Y	_	_	I-Premise
291	and	_	_	I-Premise
292	B	_	_	I-Premise
293	-	_	_	I-Premise
294	I	_	_	I-Premise
295	groups	_	_	I-Premise
296	(	_	_	I-Premise
297	24	_	_	I-Premise
298	.	_	_	I-Premise

299	8	_	_	I-Premise
300	vs	_	_	I-Premise
301	.	_	_	I-Premise

302	23	_	_	I-Premise
303	.	_	_	I-Premise

304	6	_	_	I-Premise
305	,	_	_	I-Premise
306	p	_	_	I-Premise
307	=	_	_	I-Premise
308	0	_	_	I-Premise
309	.	_	_	I-Premise

310	41	_	_	I-Premise
311	)	_	_	I-Premise
312	.	_	_	I-Premise

313	Only	_	_	B-Premise
314	reflux	_	_	I-Premise
315	symptoms	_	_	I-Premise
316	were	_	_	I-Premise
317	significantly	_	_	I-Premise
318	worse	_	_	I-Premise
319	for	_	_	I-Premise
320	B	_	_	I-Premise
321	-	_	_	I-Premise
322	I	_	_	I-Premise
323	than	_	_	I-Premise
324	for	_	_	I-Premise
325	R	_	_	I-Premise
326	-	_	_	I-Premise
327	Y	_	_	I-Premise
328	(	_	_	I-Premise
329	0	_	_	I-Premise
330	.	_	_	I-Premise

331	7	_	_	I-Premise
332	±	_	_	I-Premise
333	0	_	_	I-Premise
334	.	_	_	I-Premise

335	6	_	_	I-Premise
336	vs	_	_	I-Premise
337	.	_	_	I-Premise

338	0	_	_	I-Premise
339	.	_	_	I-Premise

340	5	_	_	I-Premise
341	±	_	_	I-Premise
342	0	_	_	I-Premise
343	.	_	_	I-Premise

344	6	_	_	I-Premise
345	,	_	_	I-Premise
346	p	_	_	I-Premise
347	=	_	_	I-Premise
348	0	_	_	I-Premise
349	.	_	_	I-Premise

350	01	_	_	I-Premise
351	)	_	_	I-Premise
352	.	_	_	I-Premise

353	The	_	_	B-Claim
354	B	_	_	I-Claim
355	-	_	_	I-Claim
356	I	_	_	I-Claim
357	and	_	_	I-Claim
358	R	_	_	I-Claim
359	-	_	_	I-Claim
360	Y	_	_	I-Claim
361	techniques	_	_	I-Claim
362	were	_	_	I-Claim
363	generally	_	_	I-Claim
364	equivalent	_	_	I-Claim
365	in	_	_	I-Claim
366	terms	_	_	I-Claim
367	of	_	_	I-Claim
368	postoperative	_	_	I-Claim
369	QOL	_	_	I-Claim
370	and	_	_	I-Claim
371	dysfunction	_	_	I-Claim
372	.	_	_	I-Claim

373	Both	_	_	B-Claim
374	procedures	_	_	I-Claim
375	seem	_	_	I-Claim
376	acceptable	_	_	I-Claim
377	as	_	_	I-Claim
378	standard	_	_	I-Claim
379	reconstructions	_	_	I-Claim
380	after	_	_	I-Claim
381	distal	_	_	I-Claim
382	gastrectomy	_	_	I-Claim
383	with	_	_	I-Claim
384	regard	_	_	I-Claim
385	to	_	_	I-Claim
386	postoperative	_	_	I-Claim
387	QOL	_	_	I-Claim
388	and	_	_	I-Claim
389	dysfunction	_	_	I-Claim
390	.	_	_	I-Claim


0	The	_	_	O
1	Medical	_	_	O
2	Research	_	_	O
3	Council	_	_	O
4	CR07	_	_	O
5	/	_	_	O
6	National	_	_	O
7	Cancer	_	_	O
8	Institute	_	_	O
9	of	_	_	O
10	Canada	_	_	O
11	Clinical	_	_	O
12	Trials	_	_	O
13	Group	_	_	O
14	C016	_	_	O
15	(	_	_	O
16	MRC	_	_	O
17	CR07	_	_	O
18	/	_	_	O
19	NCIC	_	_	O
20	CTG	_	_	O
21	C016	_	_	O
22	)	_	_	O
23	trial	_	_	O
24	showed	_	_	O
25	that	_	_	O
26	,	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	operable	_	_	O
31	rectal	_	_	O
32	cancer	_	_	O
33	,	_	_	O
34	short	_	_	O
35	-	_	_	O
36	course	_	_	O
37	preoperative	_	_	O
38	radiotherapy	_	_	O
39	(	_	_	O
40	PRE	_	_	O
41	)	_	_	O
42	reduced	_	_	O
43	the	_	_	O
44	rate	_	_	O
45	of	_	_	O
46	local	_	_	O
47	recurrence	_	_	O
48	compared	_	_	O
49	with	_	_	O
50	surgery	_	_	O
51	followed	_	_	O
52	by	_	_	O
53	selective	_	_	O
54	postoperative	_	_	O
55	chemoradiotherapy	_	_	O
56	for	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	a	_	_	O
60	positive	_	_	O
61	circumferential	_	_	O
62	resection	_	_	O
63	margin	_	_	O
64	.	_	_	O

65	However	_	_	O
66	,	_	_	O
67	the	_	_	O
68	advantages	_	_	O
69	of	_	_	O
70	giving	_	_	O
71	PRE	_	_	O
72	to	_	_	O
73	all	_	_	O
74	patients	_	_	O
75	needs	_	_	O
76	to	_	_	O
77	be	_	_	O
78	balanced	_	_	O
79	against	_	_	O
80	any	_	_	O
81	negative	_	_	O
82	impact	_	_	O
83	on	_	_	O
84	patients	_	_	O
85	'	_	_	O
86	quality	_	_	O
87	of	_	_	O
88	life	_	_	O
89	.	_	_	O

90	All	_	_	O
91	1	_	_	O
92	,	_	_	O
93	350	_	_	O
94	patients	_	_	O
95	were	_	_	O
96	asked	_	_	O
97	to	_	_	O
98	complete	_	_	O
99	the	_	_	O
100	Medical	_	_	O
101	Outcomes	_	_	O
102	Study	_	_	O
103	Short	_	_	O
104	-	_	_	O
105	Form	_	_	O
106	36	_	_	O
107	-	_	_	O
108	item	_	_	O
109	(	_	_	O
110	MOS	_	_	O
111	SF	_	_	O
112	-	_	_	O
113	36	_	_	O
114	)	_	_	O
115	and	_	_	O
116	the	_	_	O
117	European	_	_	O
118	Organisation	_	_	O
119	for	_	_	O
120	Research	_	_	O
121	and	_	_	O
122	Treatment	_	_	O
123	of	_	_	O
124	Cancer	_	_	O
125	Quality	_	_	O
126	of	_	_	O
127	Life	_	_	O
128	Questionnaire	_	_	O
129	Colorectal	_	_	O
130	38	_	_	O
131	-	_	_	O
132	item	_	_	O
133	(	_	_	O
134	EORTC	_	_	O
135	QLQ	_	_	O
136	-	_	_	O
137	CR38	_	_	O
138	)	_	_	O
139	questionnaires	_	_	O
140	.	_	_	O

141	A	_	_	O
142	priori	_	_	O
143	hypotheses	_	_	O
144	related	_	_	O
145	to	_	_	O
146	the	_	_	O
147	impact	_	_	O
148	of	_	_	O
149	treatment	_	_	O
150	on	_	_	O
151	sexual	_	_	O
152	,	_	_	O
153	bowel	_	_	O
154	,	_	_	O
155	and	_	_	O
156	physical	_	_	O
157	function	_	_	O
158	and	_	_	O
159	general	_	_	O
160	health	_	_	O
161	.	_	_	O

162	Male	_	_	B-Premise
163	sexual	_	_	I-Premise
164	dysfunction	_	_	I-Premise
165	was	_	_	I-Premise
166	significantly	_	_	I-Premise
167	increased	_	_	I-Premise
168	following	_	_	I-Premise
169	surgery	_	_	I-Premise
170	(	_	_	I-Premise
171	P	_	_	I-Premise
172	<	_	_	I-Premise
173	.	_	_	I-Premise

174	001	_	_	I-Premise
175	)	_	_	I-Premise
176	,	_	_	I-Premise
177	although	_	_	B-Premise
178	there	_	_	I-Premise
179	was	_	_	I-Premise
180	no	_	_	I-Premise
181	difference	_	_	I-Premise
182	between	_	_	I-Premise
183	treatment	_	_	I-Premise
184	arms	_	_	I-Premise
185	.	_	_	I-Premise

186	However	_	_	O
187	,	_	_	O
188	a	_	_	O
189	treatment	_	_	O
190	difference	_	_	O
191	had	_	_	O
192	emerged	_	_	O
193	at	_	_	O
194	6	_	_	O
195	months	_	_	O
196	(	_	_	O
197	PRE	_	_	O
198	patients	_	_	O
199	reporting	_	_	O
200	significantly	_	_	O
201	greater	_	_	O
202	dysfunction	_	_	O
203	;	_	_	O
204	P	_	_	O
205	=	_	_	O
206	.	_	_	O

207	004	_	_	O
208	)	_	_	O
209	,	_	_	O
210	which	_	_	O
211	persisted	_	_	O
212	out	_	_	O
213	to	_	_	O
214	at	_	_	O
215	least	_	_	O
216	2	_	_	O
217	years	_	_	O
218	(	_	_	O
219	an	_	_	O
220	insufficient	_	_	O
221	number	_	_	O
222	of	_	_	O
223	female	_	_	O
224	patients	_	_	O
225	completed	_	_	O
226	the	_	_	O
227	sexual	_	_	O
228	dysfunction	_	_	O
229	questions	_	_	O
230	to	_	_	O
231	draw	_	_	O
232	firm	_	_	O
233	conclusions	_	_	O
234	)	_	_	O
235	.	_	_	O

236	Both	_	_	B-Premise
237	treatment	_	_	I-Premise
238	groups	_	_	I-Premise
239	reported	_	_	I-Premise
240	similar	_	_	I-Premise
241	levels	_	_	I-Premise
242	of	_	_	I-Premise
243	decreased	_	_	I-Premise
244	physical	_	_	I-Premise
245	function	_	_	I-Premise
246	at	_	_	I-Premise
247	3	_	_	I-Premise
248	months	_	_	I-Premise
249	,	_	_	I-Premise
250	but	_	_	B-Premise
251	thereafter	_	_	I-Premise
252	it	_	_	I-Premise
253	returned	_	_	I-Premise
254	to	_	_	I-Premise
255	baseline	_	_	I-Premise
256	levels	_	_	I-Premise
257	.	_	_	I-Premise

258	There	_	_	B-Premise
259	was	_	_	I-Premise
260	no	_	_	I-Premise
261	evidence	_	_	I-Premise
262	of	_	_	I-Premise
263	any	_	_	I-Premise
264	major	_	_	I-Premise
265	changes	_	_	I-Premise
266	between	_	_	I-Premise
267	treatments	_	_	I-Premise
268	or	_	_	I-Premise
269	time	_	_	I-Premise
270	points	_	_	I-Premise
271	in	_	_	I-Premise
272	terms	_	_	I-Premise
273	of	_	_	I-Premise
274	general	_	_	I-Premise
275	health	_	_	I-Premise
276	or	_	_	I-Premise
277	bowel	_	_	I-Premise
278	function	_	_	I-Premise
279	,	_	_	I-Premise
280	but	_	_	B-Premise
281	exploratory	_	_	I-Premise
282	analysis	_	_	I-Premise
283	indicated	_	_	I-Premise
284	a	_	_	I-Premise
285	significant	_	_	I-Premise
286	(	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	.	_	_	I-Premise

290	006	_	_	I-Premise
291	at	_	_	I-Premise
292	2	_	_	I-Premise
293	years	_	_	I-Premise
294	)	_	_	I-Premise
295	increase	_	_	I-Premise
296	in	_	_	I-Premise
297	the	_	_	I-Premise
298	level	_	_	I-Premise
299	of	_	_	I-Premise
300	fecal	_	_	I-Premise
301	incontinence	_	_	I-Premise
302	with	_	_	I-Premise
303	PRE	_	_	I-Premise
304	.	_	_	I-Premise

305	These	_	_	B-Claim
306	results	_	_	I-Claim
307	from	_	_	I-Claim
308	a	_	_	I-Claim
309	large	_	_	I-Claim
310	randomized	_	_	I-Claim
311	trial	_	_	I-Claim
312	using	_	_	I-Claim
313	validated	_	_	I-Claim
314	patient	_	_	I-Claim
315	-	_	_	I-Claim
316	completed	_	_	I-Claim
317	questionnaires	_	_	I-Claim
318	show	_	_	I-Claim
319	that	_	_	I-Claim
320	,	_	_	I-Claim
321	for	_	_	I-Claim
322	males	_	_	I-Claim
323	,	_	_	I-Claim
324	the	_	_	I-Claim
325	main	_	_	I-Claim
326	adverse	_	_	I-Claim
327	effect	_	_	I-Claim
328	was	_	_	I-Claim
329	sexual	_	_	I-Claim
330	dysfunction	_	_	I-Claim
331	,	_	_	I-Claim
332	and	_	_	I-Claim
333	the	_	_	I-Claim
334	main	_	_	I-Claim
335	cause	_	_	I-Claim
336	of	_	_	I-Claim
337	this	_	_	I-Claim
338	was	_	_	I-Claim
339	surgery	_	_	I-Claim
340	,	_	_	I-Claim
341	but	_	_	O
342	that	_	_	O
343	PRE	_	_	B-Claim
344	also	_	_	I-Claim
345	affected	_	_	I-Claim
346	sexual	_	_	I-Claim
347	and	_	_	I-Claim
348	some	_	_	I-Claim
349	aspects	_	_	I-Claim
350	of	_	_	I-Claim
351	bowel	_	_	I-Claim
352	functioning	_	_	I-Claim
353	.	_	_	I-Claim


